<SEC-DOCUMENT>0000950170-23-008523.txt : 20230316
<SEC-HEADER>0000950170-23-008523.hdr.sgml : 20230316
<ACCEPTANCE-DATETIME>20230316170227
ACCESSION NUMBER:		0000950170-23-008523
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230316
DATE AS OF CHANGE:		20230316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nkarta, Inc.
		CENTRAL INDEX KEY:			0001787400
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474515206
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39370
		FILM NUMBER:		23739639

	BUSINESS ADDRESS:	
		STREET 1:		6000 SHORELINE COURT
		STREET 2:		SUITE 102
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-582-4923

	MAIL ADDRESS:	
		STREET 1:		6000 SHORELINE COURT
		STREET 2:		SUITE 102
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nktx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-16T16:12:20.9864+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:nktx="http://nkartatx.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_198285a3-afca-45fe-b559-b79c053dd8b8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_491c5e57-d09d-4f35-9266-28735ed2f748" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_d1fe8023-9b9c-459a-9183-c5748a0f5ae1">P3Y</ix:nonNumeric><ix:nonNumeric id="F_cd35d35f-e0f0-49de-af9e-1f263eba3ae9" name="dei:EntityCentralIndexKey" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb">0001787400</ix:nonNumeric><ix:nonNumeric id="F_7a3231a8-b815-4c18-aeab-3a8b512a8687" name="dei:CurrentFiscalYearEndDate" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb">--12-31</ix:nonNumeric><ix:nonFraction id="F_5658f9a6-0756-441f-93ac-997697fa2195" name="us-gaap:PreferredStockValue" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_863703a1-6d57-4227-9b1e-b47b16972aad" name="us-gaap:CommitmentsAndContingencies" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d097accb-afd7-473f-ba55-bdffd509663b" name="dei:DocumentFiscalPeriodFocus" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb">FY</ix:nonNumeric><ix:nonNumeric id="F_ba20813a-d918-4a71-9738-db3869415333" name="dei:AmendmentFlag" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb">false</ix:nonNumeric><ix:nonFraction id="F_039b0ac0-597a-43be-a936-17146b41c847" name="us-gaap:PreferredStockValue" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nktx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_31abcc35-68e1-488a-b26e-29817aecaa5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0abf9930-6b9d-43f1-bcde-e0a41387b2cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktx:NkCellProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac5b81a2-efd6-441c-b505-52b48bac16ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_328c18c4-b70f-49ff-8925-ad2743c6a99e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_187aafe4-a065-4b40-be67-1ac1dc3d08cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b79def7d-c6df-41a1-bf0c-919f674fb2ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktx:UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c9c944a-ceec-4d30-8fa4-840b650e3911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d014bbfe-ee80-4fc5-925e-c46b0ee01917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c1f1543-5dab-4779-b06e-a0d704393f4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5303a92-212e-4aad-9186-0d262371436b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8d0678a-6dba-4324-ac26-5b00dadee7ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dad82f88-3e0b-4f88-88f6-fb0cde6e2f5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a1834a9-94f0-4aab-abd5-ebb33501f4c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00c5bf6f-2fc6-4028-b703-d38c7fb1eb15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_176fb4da-b4be-4abb-b573-31f43872e49d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktx:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74c75d73-fb22-4295-b576-4cef5d2a18f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ad6f663-9c17-49d2-af22-eb2005f970e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_104df7f6-48a5-4dc9-8ed3-ca5b85d25ef3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_229b2864-98b4-4ede-83cb-94419b551487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:CarryForwardIndefinitelyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44eb9b84-6402-486d-8d17-eda195e16bed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e5762e7-f7e7-4ca0-95b2-9a9aca43a951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1eb2f144-5565-4350-a09a-b2ab343aade0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">nktx:KPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57e7b3dc-ab16-4aa2-987e-e194bd6384a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0bf228a-dcc8-47a6-9520-a9d355912f12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktx:FollowOnOfferingOfStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a8087e1-63e7-4651-bc43-c16820cff537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c452dd17-c870-489d-8326-cf1262b803dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c60f034b-7278-446d-9f32-ef360df72d1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43a91ef6-617a-4181-b769-aa8b7eeac784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea510978-78aa-41fd-bda5-9491f506aa24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3983a133-278f-4146-b005-921fbc2b18af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9766f258-dd51-4457-9526-56fe0bcb58d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_444f64e4-77b4-4f0d-a3be-c07ea1bd14aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ae365a0-6a87-4a4e-a567-430fbc72a73f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:ExpirationYearOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18a918ed-b24c-4a30-91c4-1883263c2b4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8ccfab3-765f-42cd-a915-348919b0824a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18f31adc-2623-483c-a5cc-71db7010cc81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1fc9433-2e3d-4914-a5c8-bc7a7bff7abf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bc72894-bc11-4b07-8e86-b0f46fc9cf6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3d36e67-6511-40e9-9266-1efc22df210e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ac1ee49-377e-467a-9ba3-17eff01ca117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fca8d672-8425-4bf2-a2fd-b3e697b44bd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96c15272-baf2-49fd-8372-c7699ec34602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56c70c9b-2181-46db-b6a8-a17ab68f0f6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktx:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed9f3140-e20c-40cc-acc9-33bafd2a727b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e103274a-366e-48fb-b799-052573c606d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4adcd202-22d8-4ab3-b561-2ff39d168d3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7932d5a-1ed2-47f6-8f53-4bf014a752e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-14</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddefd491-c663-47f5-b387-ddd0b74ee428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b32eb187-1110-42c8-a989-031bf9074bfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nktx:AfterYearTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46288b47-1afa-44f0-be59-d2f91c284d71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_740287c6-87bc-41cd-9f00-710fff88daae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f580e365-5516-4a7a-ab29-b585665fbce7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98fde113-4079-4ef0-aed0-57bc5371b89d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fec699f-ea28-4689-9337-687766f60d30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4a20bb1-0ddc-4e5d-9ac6-131ac886e0ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a024a1ed-5c61-4be8-a5a7-9e8fa9a97eff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f88de343-0a59-45f7-9df8-b09992f4929c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a03030f-25af-4ff1-945c-997f499c318d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d27112b2-cbb8-4700-a273-558f65b6fae8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88e987e9-14ae-4a55-adf7-c0657a837adb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_001b7558-daa1-49c1-8059-798879009ca2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d09d41d-b86f-424c-9448-32c8e1aee0c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26bd2db9-3e16-458f-8423-a038b4619fe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62587f67-7720-4862-8bc3-ad2de14109b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feea12d5-fa67-4f8d-a138-14014b003a98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9156c0d3-efa4-45e5-8f61-29564c2a7e1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementAndAdditionalLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6a22efc-c313-4977-a01d-0fa7148647f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4d8076e-e0bc-4c00-a7ca-5d44c39d9a6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b68d2390-4372-4de3-9b47-180a4a7b91f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktx:ThirdAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cee8cd7-5f97-41bd-add1-44d08b9bb04e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f5f41de-e22b-492e-9aab-31a2107d81dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c424608-d9ed-42fb-be8c-a8171cb6a5ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:ExpirationYearOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktx:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8f4b60d-ae7d-4ecd-ad6a-e4de3f34ea9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d89cf241-714f-47ac-b0fd-90fc206d8545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:AgreementWithFinancialInstitutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed03bf83-d13d-4a93-9a1b-a266f8faf400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_583fcba6-1ff0-489b-a59a-27d2cc6bc251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e258be6-92d4-4784-8087-1c605ecf79d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:MaxcyteLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e12e22c5-6319-489d-998a-5a9b9f8b965c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_737c89a5-e439-47b8-8aaf-76cfec47c0ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd5a17ec-15ba-48c4-a69b-663e0936c2fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f80d2293-58a8-4680-be9d-fb127ceff8c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b23572bd-0d8a-4cf9-afdc-816a5cbc484c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54a727df-02a6-4bb0-88ff-9fcf2ef7503f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:AgreementWithFinancialInstitutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_242f872b-1115-4f14-a73e-62ca3a640241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_981a3fe1-5a1b-4bea-9a27-e819dcdf253c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5494864e-30df-4f68-b4b1-cd4ad5b4ba91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c1cfa1c-67c5-4c85-a0df-ba0a03295212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:AgreementWithFinancialInstitutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc9d6414-7006-461a-ad35-be8368d5db4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f2f80b9-36c3-4ae7-b0df-62a4197809a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:SecondAmendmentOfAdditionalLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42e1761d-f976-4772-b948-69c953e4e0be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nktx:NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd275879-1ce5-41b8-bf9c-ea076c74e129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_141cfb9f-1119-4e34-b791-208f5def88e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_217c98a8-e1b0-496a-b167-e85ebc606b96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23b5530e-7d65-4f89-a655-72c856a9b438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d693d1f-0170-4af7-8991-dbab6eb94595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5727518-e2f1-4921-a234-816384299bb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e4795d5-2002-4904-a3ea-f02d9bec752b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:MaxcyteLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6595a8da-7252-4dae-89c8-5653af52ef0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de1b3fd2-437c-46d9-9d40-3096dc12b8c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ffabe62-fbe5-446e-b9de-8398a5aa0a92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c954c54-02fd-4743-8a11-058f3cf49640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6097964e-eb40-4699-9cf6-6a9b004fabb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7e114d6-1e43-4e3e-a721-90f9540d66a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c963d9bf-d21f-4940-8b1d-41239a955535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c494cf9e-deff-4d61-b7a3-4124b968194f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7611da9-a17b-4506-b7d2-762f752b122e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b8fd370-f133-4a2b-a2c1-752e3951322c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d26eec10-62b5-4c3b-988b-3b120717f7c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51775edc-1ac6-4de8-ae0e-dabb7398d898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59d64f92-ff2e-4690-bf99-cc3623e46e80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2914dfc3-b00d-4a26-95ed-1856d75544a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52762d64-2657-4a85-b085-9b43b6ef6b2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24c0aaae-b891-4b96-8392-e3514173d5c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7e0478f-dfc8-4a2e-bc04-3e92eb222605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0dbf8ba2-16eb-4d47-8a53-2bcd7625019d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99a492e6-fb70-4aea-a41e-5b84273ea158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_996ef9b2-0b0e-4010-a387-288c02df3d11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d61b13b8-5000-41ad-872b-a55642f66d70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c46e250-9967-4f2d-81f6-f41141108536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab31f486-dd4c-4921-9836-0c2daa665d2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8cd6f3e-33d2-431d-8c68-01cfb7d24237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktx:CommonStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e0afc55-bbb0-416e-a754-625e5f859147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6be6113f-92b4-4ee7-a950-89b44b4f6055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">nktx:KPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b01db192-8bff-49f9-aa8a-eb072e8e8931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdd7e725-4ef2-4276-b95f-8ec6ebdac396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktx:ThirdAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed817214-47bd-4dc1-80a6-cb7172f19a31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a853c5f-fc86-43fd-bf06-21c2b2e36b23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktx:UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71271a5b-183d-4f56-9d1b-7e8e195a7acb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d26a61da-14d4-4715-904f-6250145d2632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9997cb7c-7d06-42b6-b7a1-bf97634ec016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1fe8023-9b9c-459a-9183-c5748a0f5ae1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b847b099-3feb-4070-a061-cbb4d32913b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d56636f3-c58d-42fd-837d-0a0954658fe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6740d2cc-da91-46a2-ad58-636e6c3384c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d932bf8-0352-4715-adee-681c326862f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41f74bcf-d3f3-4e8a-b3f5-64d52ddf8089"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7e05b12-6998-4ee3-a819-f951b803d26c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9183cb74-8a77-407b-ac80-773ff92736bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e51d5a3b-deec-4d63-bc9d-87858ed3e409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e16f2952-c482-4fb5-b289-6a2484c1649e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:ExpirationYearTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e12b052-9715-41fd-bddf-9db4bb8a1947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8785059f-96d4-4f04-8c0f-0809aa5b503b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b77baa8f-96a7-406d-a97a-325fd5089207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5787b06-caba-4869-913a-d42e3e4d8626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktx:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81bfa481-ab6e-4a60-9e7f-38e17ed8e269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff496bec-fe97-479b-a5c4-6ec81afca185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:ExpirationYearTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d7aca5b-833d-4eaf-8d07-daf876c42502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8074f9cd-476b-4fa5-a455-4be53c9fdce6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1068e57e-6f93-49e0-ba99-d2c70b9915f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktx:NkCellProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59e66b2e-c33f-48fe-ad46-f3ff01344f2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f472547-d9cb-42a2-9d4b-f15637efe5f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:SecondAmendmentOfAdditionalLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6bef3a2-7f1b-4b5f-99b7-d7a3e86365c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktx:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cd10163-6e81-4530-a414-a8bef05e747e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_CrisprCas9"><xbrli:measure>nktx:CrisprCas9</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_SGD"><xbrli:measure>iso4217:SGD</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>nktx:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7efaeb9b-f3a8-43b7-95fd-16996ea57086" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b4f4896d-ea70-4f7b-902a-2b11d4ab7800" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_363ec7b3-275b-4fc2-ab59-1e0891c4e450" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fdd1647b-eff9-437a-b73c-8191080e46d4" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_046a9cbe-e7cf-4744-adaf-e9dc9d6d7b03" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_29622cfd-0e9e-4b5c-b7e7-dc1e5394c513" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81dd8a0f-77d4-40f5-b0d1-53a8eacd4c68" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e20d9fce-f32b-4633-ae2d-ae7471c4d2db" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c5ee00f-3b05-4d96-aec2-91eb1ab954e0" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47-4515206</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_734e44f5-0517-48fb-9cfe-1eedab0b258d" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6000 Shoreline Court</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ad35fc5e-fa84-4d6f-b5a9-5d3d27d623be" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 102</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3b116f0e-fc92-41d6-a2ab-1880ede90440" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_163d56f3-df06-45c7-ab62-5e4ce2799a83" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ec4bb150-2298-494a-b690-644b7da0acac" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94080</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b3046f48-c7f9-47eb-b275-84d3d3772bcc" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">925</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_29a419bd-2cc4-4c66-b274-085cd674f9b6" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">407-1049</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.806%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:20.398%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:38.759%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4cfe69d1-31cc-4434-ab09-942636c88e5e" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_43103304-b4ba-4e62-9abe-55117e94aa1f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKTX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d818f2dd-3a75-4792-82d9-a7c003ada568" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a5b03d0a-6677-468f-a604-80dbbc017894" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_455f6566-52ab-4ca7-b7f7-14c35de000f6" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a48c1d08-3a0a-4df1-998e-daebc06e68d9" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d531bec7-8b1f-4866-8bd3-36116e62d7e0" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.333%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.444%;"></td>
    <td style="width:47.824%;"></td>
    <td style="width:23.343%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.056%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d1f83016-c42c-471d-88c9-8b852416b019" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ddb2cb31-1e92-415c-adb0-3b744ddbf048" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cda045bf-6c82-4c6a-8622-8d823fcbc251" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a534669e-ee18-457f-b467-be9e6209ec99" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_adb78635-051c-45b1-92cb-5b4b074abcdf" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b)</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a925dd2-bf1c-43f4-81df-6df5202faf30" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the voting and non-voting equity held by non-affiliates of the registrant, based on the closing price of a share of common stock on June 30, 2022 as reported by The Nasdaq Stock Market on such date was approximately $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3d08270-791f-46de-ad37-e7599624030b" contextRef="C_ed9f3140-e20c-40cc-acc9-33bafd2a727b" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">345.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other  purpose.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 13, 2023, the number of outstanding shares of the registrant&#x2019;s common stock, par value $0.0001 per share, was </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06034b31-cba6-44ba-ad00-9a7d6f519383" contextRef="C_b23572bd-0d8a-4cf9-afdc-816a5cbc484c" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,928,670</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <div style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b9413a47-df93-4e0a-bfa0-f73ed6274473" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the registrant&#x2019;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.662%;"></td>
    <td style="width:82.543%;"></td>
    <td style="width:6.795%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K, and the information incorporated herein by reference, particularly in the sections captioned &#x201c;Business&#x201d; under Part I, Item 1, &#x201c;Risk Factors&#x201d; under Part I, Item 1A, and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; under Part II, Item 7, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;objective,&#x201d; &#x201c;ongoing,&#x201d; &#x201c;plan,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;potential,&#x201d; &#x201c;should,&#x201d; &#x201c;will,&#x201d; or &#x201c;would,&#x201d; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, these statements are based on our management&#x2019;s beliefs and assumptions and on information currently available to our management as of the date of this Annual Report on Form 10-K. While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. You should read the sections titled &#x201c;Risk Factor Summary&#x201d; below and &#x201c;Risk Factors&#x201d; set forth in Part I, Item 1A of this Annual Report on Form 10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements, which such factors may be updated or supplemented from time to time by subsequent reports we file with the Securities and Exchange Commission.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should read this Annual Report on Form 10-K, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISK FACTOR SUMMARY</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#x201c;Cautionary Note Regarding Forward-Looking Statements&#x201d; and Part I, Item 1A, &#x201c;Risk Factors&#x201d; in this Form 10-K. The below summary is qualified in its entirety by those more complete discussions of such risks and uncertainties. You should consider carefully the risks and uncertainties described under Part I, Item 1A, &#x201c;Risk Factors&#x201d; in this Form 10-K as part of your evaluation of an investment in our common stock.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history and do not have any products approved for sale</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception and we expect to continue to incur significant losses for the foreseeable future.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have never generated revenue from product sales and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require additional capital, which, if available, may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business and the business or operations of our research partners and other third parties with whom we conduct business have been and could continue to be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have business operations. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business depends upon the success of our CAR NK cell technology platform.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Utilizing CAR NK cells represents a novel approach to the treatment of cancer, and we must overcome significant challenges in order to develop, commercialize and manufacture our product candidates.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and we may encounter substantial delays due to a variety of reasons outside our control.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is highly dependent on the clinical success of our product candidates, and on the clinical success of NKX101 and NKX019 in particular, and we may fail to develop NKX101, NKX019 and/or our other product candidates successfully or be unable to obtain regulatory approval for them. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our preclinical pipeline programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The results of preclinical studies and early-stage clinical trials may not be predictive of future results. Interim, &#x201c;topline&#x201d; and preliminary data from our clinical trials may differ materially from the final data. Initial success in any clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our product candidates, or any competing product candidates, demonstrate relevant, serious adverse events, we may be required to halt or delay further clinical development.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have entered into a research collaboration with CRISPR Therapeutics regarding certain product candidates, and we may enter into additional collaborations with third parties to develop or commercialize other product candidates.  Our prospects with respect to those product candidates will depend in significant part on the success of those collaborations, and we may not realize the benefits of such collaborations.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to compete effectively with academic institutions and other biopharmaceutical companies that develop similar or alternatives to cellular immunotherapy product candidates, our business will be materially adversely affected.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our manufacturing process is novel and complex, and we may encounter difficulties in production, or difficulties with internal manufacturing, which would delay or prevent our ability to provide a sufficient supply of our product candidates for clinical trials or our products for patients, if approved.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to manufacture certain of our product candidates, or certain materials for use in the production of our product candidates, which increases the risk that we will not have sufficient quantities of such product candidates or materials, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are reliant on a sole supplier for certain steps of our manufacturing process.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delays in commissioning and receiving regulatory approvals for our manufacturing facilities could delay our development plans and thereby limit our ability to develop our product candidates and generate revenues.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our license agreement with National University of Singapore and St. Jude Children&#x2019;s Research Hospital, Inc. is terminated, we could lose our rights to key components enabling our NK cell engineering platform.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any patent protection we obtain is not sufficiently robust, our competitors could develop and commercialize products and technology similar or identical to ours. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our product candidates are approved for marketing and commercialization and we have not developed or secured marketing, sales and distribution capabilities, either internally or from third parties, we will be unable to successfully commercialize such products and may not be able to generate product revenue. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates, including NKX101 and NKX019, could be subject to regulatory limitations following approval, if and when such approval is granted.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market price for our common stock may be volatile, which could contribute to the loss of all or part of your investment.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of ownership of our shares of common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WEBSITE REFERENCES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In this Annual Report on Form 10-K, we make references to our website at www.nkartatx.com.  References to our website through this Form 10-K are provided for convenience only and the content on our website does not constitute a part of, and shall not be deemed incorporated by reference into, this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (&#34;NK&#34;) cell therapies to treat cancer. We currently have two lead product candidates, NKX101, a chimeric antigen receptor-natural killer (&#34;CAR NK&#34;) product candidate targeting cells that display NKG2D ligands, and NKX019, a CAR NK product candidate targeting the CD19 antigen, in ongoing Phase 1 clinical trials. Both product candidates incorporate proprietary technologies that enable us to generate an abundant supply of NK cells, improve the persistence of these cells for sustained activity in the body, engineer enhanced NK cell recognition of tumor targets, enhance cell fitness and tumor microenvironment evasion, and freeze, store and thaw our engineered NK cells for the treatment of cancer. Our product candidates are allogeneic, which means they are produced using cells from a different person than the patient(s) being treated, and they are produced in quantity, then frozen and therefore available off-the-shelf for treating patients without delay, unlike autologous cell therapies, which are derived from a patient&#x2019;s own cells and must be manufactured as needed for each patient. We believe that engineered NK cells have the potential to be an effective cancer therapy, be well tolerated, and avoid some of the toxicities observed with other cell therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our modular NK cell engineering platform allows us to generate new product candidates in a rapid and cost-efficient manner. Our process starts with differentiated, mature NK cells derived from healthy donors. We build on the intrinsic ability of these immune cells to identify and kill transformed cells with cell engineering to further enhance their activity. This engineering involves chimeric antigen receptors (&#34;CARs&#34;) on the surface of an NK cell to enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Our engineered CAR NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3&#x3b6;(zeta) signaling moiety, and a membrane-bound form of the cytokine IL(interleukin)15 (&#34;mbIL-15&#34;). We believe that the modular nature of our platform and the proprietary technologies we use for the multiplex engineering of NK cells, which include genome editing, are advantages that can support the rapid generation of new product candidates with enhanced properties and/or new targeting receptors for additional disease indications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Product Candidates and Discovery Programs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX101 is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells. The primary activating receptor for NK cells is known as NKG2D, which works through the detection of stress ligands displayed by cancerous cells. We have engineered NKX101 to increase the inherent cancer killing ability of our donor-derived NK cells by raising levels of NKG2D at least ten-fold as compared to non-engineered NK cells and by adding a costimulatory domain, which is an additional signaling element for white blood cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX101 is currently being studied in a multi-center Phase 1 clinical trial in the United States for the treatment of relapsed or refractory acute myeloid leukemia (&#34;r/r AML&#34;) or higher risk myelodysplastic syndromes (&#34;MDS&#34;). This ongoing first-in-human study evaluates the safety, pharmacology, and preliminary anti-tumor activity of NKX101. The clinical trial consists of dose-finding followed by dose-expansion and is designed to identify the recommended Phase 2 dose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our NKX019 program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells, where CD19-targeted engineered NK cells, T cells and monoclonal antibodies have demonstrated clinical activity. NKX019 is currently being studied in a Phase 1 clinical trial for the treatment of certain B-cell malignancies. This ongoing, first-in-human study evaluates the safety, pharmacology, and preliminary anti-tumor activity of NKX019, at multiple centers in the United States and Australia. The clinical trial consists of dose-finding followed by dose-expansion and is designed to identify the recommended Phase 2 dose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to our two lead product candidates, we are engaged in extensive discovery and preclinical stage activities directed to expansion of our pipeline of product candidates over time. As part of our collaboration with CRISPR Therapeutics AG (&#34;CRISPR&#34;), we are developing an allogeneic, off-the-shelf CAR NK product candidate targeting the CD70 tumor antigen (&#34;NKX070&#34;) for the treatment of solid and liquid tumors, and conducting discovery efforts for an allogeneic, off-the-shelf product candidate that comprises both engineered NK cells and engineered T cells (&#34;NK+T&#34;) to take advantage of both the innate and adaptive immune systems. This NK+T program is designed to harness multiple aspects of human immunology to treat a variety of cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have an intensive focus on manufacturing capabilities and technology. We are currently manufacturing NKX019 at our 2,700-square foot clinical current good manufacturing practice (&#34;cGMP&#34;) facility located in South San Francisco, California. We are also currently constructing a new facility in South San Francisco to support pivotal clinical trials and potential commercial supply of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing novel engineered, allogeneic, off-the-shelf cell therapies to improve the lives of cancer patients and their overall survival by leveraging our NK cell engineering platform. Key elements of our strategy to achieve this include:</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Next generation platform enlists natural, healthy human donor NK cells for optimal product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cell engineering platform utilizes healthy adult donors as our source for NK cells. By enlisting this natural source of NK cells, we start with bona fide NK cells already endowed with inherent cytotoxic and tumor-recognizing capabilities, as compared to other more complex cell sources where these basic therapeutic features must be painstakingly designed and synthetically added to the cells. Healthy donor-derived NK cells are also available in abundance, providing a large quantity of cells with which to begin each manufacturing run. Finally, healthy donor-derived adult cells consist of a diverse repertoire of NK cells. By utilizing a cell source that contains the full range of naturally occurring NK cells, we believe we can capitalize on the inherent diversity of the innate immune system and select for different NK cell sub-populations with desired characteristics.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Develop NKX101 for r/r AML and other cancers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have engineered NKX101 to overexpress the NKG2D receptor. Because NKG2D is the primary activating receptor responsible for innate immune surveillance for cancerous cells by NK cells, we believe that NKX101 presents an opportunity to potentially treat a variety of blood cancers and solid tumors, which represent approximately 90% of all cancer incidences in the United States. Therefore, upon clinical proof-of-concept from our ongoing NKX101 Phase 1 clinical trial for r/r AML, we may pursue a broad clinical development plan for multiple tumor types including solid tumors.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Develop NKX019 for B-cell malignancies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX019 is designed to treat a variety of B-cell malignancies by targeting the clinically and commercially validated CD19 antigen that is found in different B-cell malignancies. Because the targeting of CD19 has demonstrated clinical activity with both CAR T and CAR NK cell therapies as well as monoclonal antibodies, we believe that NKX019 presents an opportunity to treat a variety of B-cell malignancies while addressing the limitations of existing autologous CAR T cell therapies. NKX019 is currently being investigated in the dose-expansion portion of the ongoing Phase 1 clinical trial, as both a monotherapy and in combination with rituximab, an anti-CD20 antibody, in patients with large B-cell lymphoma (&#34;LBCL&#34;) following administration of LD. These expansion cohorts are being investigated in patients who have not previously been treated with an approved autologous CD19 CAR T therapy and also in patients who have failed autologous CD19 CAR T therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Apply our NK cell engineering platform to build a broad pipeline of product candidates incorporating engineered NK cells.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our proprietary NK cell engineering platform is based on a modular and generalizable approach that we believe enables us to generate new product candidates in a rapid and cost-efficient manner. Our engineered CAR NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3&#x3b6;(zeta) signaling moiety, and mbIL-15. We believe that the modular nature of our platform and the proprietary technologies we use for the multiplex engineering of NK cells are advantages that can support the rapid generation of new INDs for product candidates with enhanced properties and/or new targeting receptors for additional disease indications. With these attributes, we plan to continue to build out a pipeline with product candidates focused on novel targets as well as clinically and commercially validated targets. With our partner, CRISPR, we are also engaged in preclinical research for NKX070 and NK+T, which may provide advantages of both the innate and adaptive immune responses.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continue to build proprietary manufacturing capabilities to enable speed, control, flexibility, scalability, and cost efficiency.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that internal cGMP manufacturing capabilities will facilitate clinical product supply, lower the risk of manufacturing disruptions, and enable more cost-effective manufacturing for clinical and commercial supply of our product candidates. We are currently manufacturing NKX019 product for the Phase 1 clinical trial at our 2,700-square foot clinical cGMP facility on-site at our primary corporate location in South San Francisco, California. We intend to manufacture NKX101 at our cGMP facility in 2023, and in the future, we intend to manufacture our proprietary, engineered K562 stimulatory cells (&#34;NKSTIM&#34;) in house. We believe this clinical cGMP facility will supply our anticipated non-pivotal clinical trial needs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also currently constructing a separate, larger commercial cGMP facility for manufacturing. In July 2021, we entered a lease agreement for an 88,000 square foot facility in South San Francisco to support research and development and future manufacturing of Nkarta&#x2019;s cell therapy products and product candidates, including engineered NK cells for pivotal clinical trials and potential commercial supply. This new facility will also serve as our future headquarters with office space and research facilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continue to opportunistically evaluate enabling, adjacent or potential competing technologies, and where advantageous, seek licenses or collaborations regarding those technologies, to advance our platform.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will continue to evaluate technologies that may enable or enhance our various product candidates, and we will maintain awareness of those that may provide a broader cell therapy engineering or manufacturing platform for us. To facilitate the advancement of our engineering and manufacturing platforms, we routinely engage in partnering and licensing discussions with a range of biotechnology or pharmaceutical companies and academic institutions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Update on COVID-19, Macroeconomic Conditions, and Supply Disruptions</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic, as well as global and national economic and market conditions, have affected and may in the future affect our business and operations and those of third parties on which we rely, including by causing disruptions in the supply of our product candidates or other materials necessary to construct our new facility, conduct our preclinical or clinical studies, and conduct and enroll our current and future clinical trials. For a discussion regarding the impact of the COVID-19 pandemic, macroeconomic conditions, and supply disruptions on our business, see Part II, Item 7, &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations &#x2013; Overview&#x201d; in this Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Immune System and Cancer</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In recent decades there has been a significant level of innovation and improvement in the treatment of different cancers with the introduction of new therapeutic approaches and the approval of new therapies. Despite these advances, many of the most common cancers remain burdened with substantial unmet medical need. Immuno-oncology therapies seek to stimulate or supplement a person&#x2019;s own immune system to attack cancer cells selectively without affecting normal cells, or deliver certain immune system components in order to inhibit the spread of cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immuno-oncology therapy has emerged as an important mode of cancer treatment, alongside more established options such as surgery, chemotherapy, targeted therapy and radiation therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the immune system to recognize and destroy tumors has been known for decades. More recently, a growing understanding of molecular mechanisms underlying recognition of cancer cells by the immune system and their evasion of detection has allowed scientists to develop new classes of immuno-oncology therapies. These therapies either undermine the tumor&#x2019;s ability to resist immune attack or enhance immune targeting and killing of cancer cells.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cellular Immunotherapies</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cellular immunotherapy is a type of immuno-oncology therapy whereby human cells are engineered to recognize and destroy cancer cells in a more targeted manner. Most cellular immunotherapies are focused on modulating or enhancing the activity of different lymphocytes, a subtype of white blood cell that are responsible for defending the body against pathogens and other foreign material, as well as killing cancerous cells within the body. There are different classes of lymphocytes which differ in function. T cells are a type of lymphocyte that primarily serves to protect from infections such as bacteria, viruses, fungi and parasites. Every T cell recognizes a specific antigen, or substances found on of pathogens or other foreign material. This type of lymphocyte is activated and divides rapidly when it detects its specific antigen. Accordingly, T cells are the foundation of the adaptive immune system, selectively responding to different threats.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NK cells are the foundation of the innate immune system. While T cells are activated by unique antigens specific to each T cell, the activity of NK cells is tightly regulated by a common set of activating receptors on these cells that serve to improve recognition and killing of cancerous or virally infected cells, as well as a set of inhibitory receptors that help identify healthy cells. This balance of inhibition and activation spares healthy cells from the surveillance and killing effects of the innate immune system. The primary activating receptor for NK cells is known as NKG2D and functions by detecting eight known stress ligands, or signals that cancerous or virally infected cells typically produce in higher numbers. The detection of these stress ligands by NKG2D on the surface of the NK cells is the primary basis for tumor surveillance by NK cells and is the basis of the mechanism of action for our product candidate NKX101.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A frequently used approach for cellular immunotherapy involves CARs on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. The concept of a CAR builds upon and enhances the normal biology of T cells and NK cells, whereby naturally occurring receptors serve to activate these cells when a foreign pathogen or cancerous cell is detected. The key components of CARs used today often include the following elements:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Target binding domain. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At one end of the CAR is a binding domain that is specific to a target antigen or protein. This domain extends out from the surface of the engineered lymphocyte, where it can recognize the target antigen or antigens. The target binding domain may be based upon a naturally occurring receptor, such as the NKG2D receptor for NKX101, or a binder derived from a monoclonal antibody against a target antigen, such as the CD19 binder for NKX019.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transmembrane domain and hinge. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This middle portion of the CAR links the target binding domain to the activating elements inside the cell. This transmembrane domain anchors the CAR in the cell&#x2019;s membrane. In addition, the transmembrane domain may also interact with other transmembrane proteins that enhance CAR function. The hinge domain, which extends to the exterior of the cell, connects the </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">transmembrane domain to the binder and provides structural flexibility to facilitate binding to the target antigen on the surface of the cancer cell.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activating domains. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The other end of the CAR, inside the lymphocyte, includes domains responsible for activating the lymphocyte when the CAR binds to its target antigen. The first, found in almost all CAR constructs, is called CD3&#x3b6;(zeta) and is the natural basis for lymphocyte activation. The second is called a costimulatory domain, is found in the most recent generation of CARs under development today and provides an additional activating signal. Together, these signals trigger lymphocyte activation, resulting in proliferation of the CAR cells and killing of the cancer cell. In addition, activated CAR cells stimulate the secretion of cytokines and other molecules that can thereby recruit and activate additional immune cells to increase killing of the cancer cells.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States Food and Drug Administration (&#34;FDA&#34;) has approved six CAR-based T cell therapies for the treatment of certain types of cancer affecting B-cells since 2017. Each of these therapies is an autologous therapy, or derived from a patient&#x2019;s own cells, which necessitates a complex, individualized manufacturing process for every patient treated. The approvals of these patient-specific cell therapies were a landmark event for many reasons, including the ability to treat and provide long-term remission for otherwise deadly disease; achieving the run-to-run product consistency required by the FDA despite the complex manufacturing required; and achieving successful reimbursement in the United States and other countries of several hundred thousand dollars per treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Limitations of Current CAR T Therapies</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the ability of the approved autologous CAR T therapies to achieve anti-tumor responses and extend the survival of patients with advanced B-cell malignancies, accessibility of these autologous cell therapies remains limited. Only a minority of eligible patients who might benefit from currently approved cell therapies are able to receive them. These therapies have certain features that are believed to limit their accessibility and broader adoption. These features include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse events. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to the product labels for the three CAR T therapies approved for non-Hodgkin lymphoma (&#34;NHL&#34;), cytokine release syndrome (&#34;CRS&#34;) was observed in 46% to 94% of patients treated in the respective pivotal clinical trials. In addition, neurotoxicity was seen in 35% to 87% of patients treated in such trials. Because of the frequency and severity of these adverse events, patients treated with the approved CAR T therapies can require a lengthy stay in an intensive care unit and costly ancillary care.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Availability restricted to select centers. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a condition of FDA approval, treatment with approved CAR T therapies is currently limited to select centers due to safety, logistical and regulatory reasons under a Risk Evaluation and Mitigation Strategy (&#34;REMS&#34;) Program.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accessibility compromised by lengthy manufacturing time. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the individualized manufacturing process, patients must wait approximately two to four weeks to be treated with their engineered cells. In the registrational trials for the first four approved CAR T therapies, 7% to 34% of enrolled patients did not receive CAR T cells, for reasons including manufacturing failure as well as patient progression or death while waiting for manufacturing. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable potency. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In many cases, patients have T cells that have been damaged or weakened due to prior chemotherapy or hematopoietic stem-cell transplant (&#34;HSCT&#34;). Compromised T cells may not proliferate well during manufacturing or may produce engineered T cells with insufficient potency that cannot be used for patient treatment. This can result in outright manufacturing failures as well as cells with poor expansion and activity in a patient. The individualized nature of autologous manufacturing, together with the inconsistency in patients&#x2019; T cells, can cause variable and unpredictable treatment outcomes.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">High manufacturing complexity and cost. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacture of autologous T cell therapy is individualized and labor-intensive. The collection of T cells through leukapheresis from each individual patient is a time-consuming and costly step in the autologous manufacturing process. In contrast to traditional pharmaceutical manufacturing where a single manufacturing run generates product for hundreds or thousands of patients, a full manufacturing run of autologous T cell therapy generates product for a single patient. In addition, autologous T cell therapy requires specialized infrastructure to </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain a strict chain of custody and identity of patient cells throughout collection, manufacturing and delivery, adding significant cost to the process and limiting the ability to scale.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These limitations are difficult to address as many are inherent to fundamental aspects of T cell biology. CRS, which accounts for many of the adverse events which in part limit availability, is believed to be a consequence of the exponential expansion of T cells upon detection of a target antigen. Manufacturing time, product variability, and cost are due in great part to the autologous nature of approved CAR T therapies. These limitations might be mitigated by using donor-derived allogeneic T cells, but application of allogeneic T cells without additional gene edits, human leukocyte antigen (&#34;HLA&#34;), matching or modifications carries a high risk that donor T cells might recognize the recipient as &#x201c;non-self&#x201d; and cause Graft-versus-host disease (&#34;GvHD&#34;), a serious or life-threatening condition where the donor&#x2019;s T cells attack the recipient&#x2019;s body.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Allogeneic NK Cell Therapies</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of allogeneic, off-the-shelf cell therapies addresses certain limitations of autologous CAR T cells by offering these potential advantages:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tolerability. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In initial clinical data reported by us and others, patients who received allogeneic NK cell therapies did not experience the more severe adverse events that are commonly associated with approved autologous CAR T cell therapies. This emerging safety profile of allogeneic NK cell therapies may enable their use in outpatient settings and broader access to treatment.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Availability. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because an allogeneic NK cell therapy is produced in quantity then frozen in advance of patient need, it would be available for on-demand administration to patients in an outpatient setting.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consistency. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By using true NK cells from a healthy donor as starting material, and producing large numbers of doses per manufacturing run, an allogeneic NK cell therapy provides the opportunity for more rigorous quality control and release of consistent engineered cells.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of manufacturing. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An allogeneic NK cell therapy provides an opportunity to spread manufacturing costs across a large number of doses, thereby significantly lowering the cost per dose produced.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Opportunity for Engineered NK Cells in Treating Cancer</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of CAR NK therapies can capitalize on the knowledge and experience gained from decades of CAR T research. Furthermore, the biology of NK cells offers potential advantages as the starting cell type for allogeneic, off-the-shelf engineered cell therapy. These advantages include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inherent anticancer activity. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a systematic literature review of published clinical trial results of allogeneic NK cells in cancer, which identified a 34% composite response rate (&#34;Aggregate CR Rate&#34;) among 103 patients with r/r AML who were treated with non-engineered NK cells across six academic clinical studies. The Aggregate CR Rate includes complete remission with hematologic recovery (&#34;CR&#34;), complete remission with incomplete count (hematologic) recovery, and morphologic leukemia free state. These data demonstrate the anticancer activity of endogenous NK cells, and support the opportunity for increasing the activity of NK cells through engineering. In 2022, we reported initial data from our two lead programs demonstrating preliminary favorable safety and efficacy profiles.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Allogeneic and off-the-shelf without genome editing or other modifications. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because NK cells are not generally activated by &#x201c;non-self&#x201d; cells, further modification of NK cells is not necessary to avoid the risk of GvHD and thereby produce an allogeneic, off-the-shelf engineered NK cell therapy.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Modest clonal expansion and therefore potential for reduced CRS risk. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While T cells experience exponential growth when activated by a target antigen, NK cells expand only modestly upon activation. The explosive growth of T cells is believed to be the basis of the risk of CRS when CAR T cells are administered to patients. However, a significant incidence of CRS has not been reported in medical literature for NK cell therapy or by us in initial clinical data reported in 2022.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance of activation and inhibition. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The activity of NK cells is tightly regulated by a common set of activating receptors that serve to recognize and kill cancerous or virally infected cells, as well as a set of inhibitory receptors that identify healthy cells from the same individual. This balance of inhibition and activation spares healthy cells from the surveillance and killing effects of the innate immune system. Therefore, the fundamental biology of CAR NK cells drives their ability to discriminate between healthy and tumor cells.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ability to overcome tumor evasion of the immune system. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many solid tumors are able to evade the immune system by creating an immunosuppressive environment around the cancerous cells, which can dramatically reduce the normal tumor-killing ability of the immune system. This tumor microenvironment involves down-regulators of immune response, including regulatory T cells and myeloid-derived suppressor cells. However, these cell types also display NKG2D ligands, and preclinical models demonstrate that clearance of these cells can reduce immune suppression from the tumor microenvironment. Therefore, by acting through NKG2D, CAR NK cells may be able to reduce the immune suppression of the tumor microenvironment, and therefore uncover a broader opportunity for immuno-oncology cell therapy development for the treatment of solid tumors.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to re-dose to deepen or consolidate patient responses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NK cells provide a unique opportunity to optimize responses and manage potential toxicities through re-dosing and retreatment. The favorable safety profile of NK cells observed to date combined with their off-the-shelf availability allows patients who achieve a partial response to be treated again to potentially deepen their response, and for those patients who achieve a complete response, additional doses of cells can be administered to consolidate their response. Retreatment is also possible in patients who progress after clinical benefit.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Challenges with Developing NK Cell Therapies</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the emerging data from our clinical trials of NK cell products along with the prior academic experience with NK cells validate the opportunity for NK cells for the treatment of different cancers. To achieve a commercially viable engineered NK cell therapy, we believe that a number of challenges inherent with NK cells must be addressed. These include the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expansion. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One of the historical challenges in treating patients with NK cells has been the lack of robust techniques to grow these cells in large numbers without causing exhaustion, or the inability of the expanded NK cells to kill tumor cells with the same potency as native NK cells.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Engineering.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Primary NK cells have been reported to be difficult to engineer efficiently.  Poor efficiency of engineering could limit the potency and consistency of engineered NK cell therapies.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Persistence. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-engineered human NK cells turn over rapidly, with a half-life of seven to 10 days in the body. This short lifetime could limit the cancer-killing ability of these NK cells.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cryopreservation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Without cryopreservation, a truly off-the-shelf engineered NK cell therapy would be challenging to commercialize. However, freezing then thawing NK cells while maintaining cancer cell killing potency is difficult to achieve using standard techniques for T cell cryopreservation.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our NK Cell Engineering Platform</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cell engineering platform is designed to operationalize the full therapeutic potential of NK cells and address the limitations and challenges of current technologies for engineering T cells and NK cells. The platform is a result of our internal expertise and deep understanding of NK cell biology. It includes proprietary technologies for NK cell expansion, persistence, targeting, genome editing, and cryopreservation. This enables us to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, improve the persistence of these cells for sustained activity in the body, and to freeze, transport and store our engineered NK cells for off-the-shelf use for the treatment of cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have chosen to use healthy adult donors as our source for NK cells. We believe this offers a number of advantages including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Starting with differentiated, natural, and mature NK cells with inherent cytotoxic and tumor-recognizing capabilities, as compared to other cell sources such as stem cells, which must be artificially manipulated in an in vitro setting to reproduce these fundamental features;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A large number of NK cells as starting material for each manufacturing run, as compared to other potential sources of NK cells;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability to select donors with consistent and favorable NK cell characteristics, thereby avoiding challenges with patient-derived or other cell sources; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A diverse repertoire of NK cells. Different NK cell sub-populations have different characteristics, and by utilizing the entire natural gamut of NK cells as our cell source, we can capitalize on the inherent diversity of the innate immune system.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Below are the five core technologies that comprise our proprietary platform. Each of these technologies is part of an integrated approach to develop potent, scalable, and consistent NK cell products:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expansion.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The first pillar of our technology platform enables NK cell expansion without causing cell exhaustion. Our NKSTIM has been engineered with mbIL-15 as well as a protein named 4-1BB ligand (&#34;4-1BBL&#34;). IL-15 is a naturally occurring growth protein that induces cell proliferation in NK cells. 4-1BBL binds to 4-1BB, a receptor normally found on NK cells that stimulates NK cell division and expansion. Therefore, NKSTIM is selectively able to stimulate the expansion of NK cells as compared to other leukocytes, and thereby provide large numbers of NK cells. Based on our current process and early cGMP manufacturing experience, we believe that we can produce many hundreds of doses from a single manufacturing run. At the 2022 Annual Meeting of the Society for Immunotherapy of Cancer (&#34;SITC&#34;), we presented data demonstrating further optimization of our core process could allow the production of several thousand doses from a single manufacturing run.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Persistence.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Pharmacokinetics of allogeneic NK cells will be limited by both immune suppression of allogeneic cells following lymphodepleting conditioning (&#34;LD&#34;), and by the intrinsic half-life of the administered cells.  The second component of our technology platform is engineering NK cells with mbIL-15 to enhance persistence relative to non-engineered NK cells. We believe increased persistence could result in improved clinical activity. Because IL-15 is a selective driver of NK activation and expansion, tethering IL-15 to the surface of our engineered NK cells serves to stimulate the naturally occurring IL-15 receptor on these NKs, and thereby provide weeks of persistence in immune-deficient animal models. Because mbIL-15 selectively stimulates NK cells without elevating soluble IL-15 concentration, we believe that mbIL-15 provides meaningful advantages as compared to secreted IL-15 or the systemic administration of other cytokines such as IL-2 or IL-21. The first graph below shows data from a cell culture experiment which demonstrates the increase of the number and persistence of NK cells engineered with mbIL-15, as compared to unmodified NK cells or NK cells expressing soluble IL-15. The second graph below shows the increased number and persistence in mice of NK cells engineered with mbIL-15, as compared to unmodified NK cells, as a percentage of total peripheral blood mononuclear cells (&#34;PBMCs&#34;).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img183648649_0.jpg" alt="img183648649_0.jpg" style="width:621px;height:417px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Source: Imamura et al., Blood. 2014 Aug 14;124(7):1081-8</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img183648649_1.jpg" alt="img183648649_1.jpg" style="width:617px;height:431px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Targeting and Signaling.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The third element of our technology platform is CARs optimized for NK cells, based on extensive preclinical evaluation of different possible constructs. We have performed extensive optimization of the CARs that serve to target our engineered NK cells to cancer cells as well as provide signals that engage the cancer cell killing activity found naturally in NK cells. For both NKX101 and NKX019, we have found that using the OX40 costimulatory domain enhances the ability of the engineered NK cells to kill cancerous cells repeatedly in several </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> models, as compared to CAR NK cells that include other costimulatory domains commonly used for CAR T cells. We confirmed these findings in animal models for both product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Genome Editing. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fourth component of our platform is the ability to edit our NK cells using CRISPR-Cas9 technology. Through our collaboration with CRISPR, we have identified a number of genomic modifications that serve to further enhance the cytotoxicity and resistance to tumor-mediated immune suppression.  We have shown that knocking out certain genes can prolong the persistence and activity of CAR NK cells, and improve their resistance to suppression by the tumor microenvironment.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cryopreservation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The fifth constituent of our technology platform is cryopreservation of our engineered NK cells, the ability to freeze and store these cells for an extended time. The development of robust cryopreservation techniques is a result of our insight into the biology of engineered NK cells as well as extensive experimental optimization. Based on our preclinical data, we are able to freeze and subsequently thaw individual doses of engineered NK cells without significant loss of cancer cell killing potency of our engineered NK cells as shown in the graph below. Cryopreservation of our allogeneic CAR NK cells will enable their off-the-shelf use in medical centers around the world, for administration to a patient at any time. Therefore, we believe that our cryopreservation of CAR NK cells will enable us to achieve the attractive commercial profile of an off-the-shelf, allogeneic cell therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img183648649_2.jpg" alt="img183648649_2.jpg" style="width:620px;height:351px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that these key elements of our technology platform have the potential to grant us a key competitive advantage if our product candidates are approved. As illustrated in the image below, our engineered CAR NK cells generally consist of an NK cell engineered with a swappable targeting receptor, OX40 costimulatory domain, CD3&#x3b6;(zeta) signaling moiety, and mbIL-15.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img183648649_3.jpg" alt="img183648649_3.jpg" style="width:619px;height:358px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline of Product Candidates and Discovery Programs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of our product candidates and discovery programs incorporate each of the four components of our technology platform, which we believe provides the best opportunity for achieving clinically meaningful results in our development program. Our current pipeline of product candidates and discovery programs is shown below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img183648649_4.jpg" alt="img183648649_4.jpg" style="width:624px;height:327px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NKX101</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidate NKX101 consists of allogeneic, donor-derived and expanded NK cells that have been genetically engineered to express mbIL-15 along with a CAR containing an NKG2D activating receptor, an OX40 costimulatory domain and a CD3&#x3b6;(zeta) signaling moiety. We have designed NKX101 to increase longevity, potency and activity as compared to non-engineered NK cells.  NKG2D is a primary activating receptor for NK cells, triggered through binding to any of eight known stress ligands frequently expressed on cancerous or virally infected cells. The detection of these ligands by NKG2D is a primary basis for tumor surveillance by NK cells and contributes to the mechanism of action for NKX101. We believe that the activity of non-engineered NK cells in treating cancer, previously described by others, validates targeting NKG2D ligands through the NKG2D receptor as the mechanism of action for NKX101. NKX101 is currently being studied in a Phase 1 monotherapy clinical trial investigating NKX101 for the treatment of r/r AML and higher-risk MDS. This multi-center, first-in-human study evaluates the safety, pharmacology, and preliminary anti-tumor activity of NKX101 administered in a cycle of either three weekly infusions (Regimen A) or two weekly infusions (Regimen B) following LD. Based on tumor response and tolerability, multiple treatment cycles can be administered. The clinical trial consists of dose-finding followed by dose-expansion and is designed to identify the recommended Phase 2 dose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, FDA granted orphan drug designation to NKX101 for treatment of r/r AML. In February 2022, we filed a protocol amendment with the FDA for the ongoing Phase 1 clinical trial of NKX101 to optimize the study design for maximum benefit and flexibility. The amended protocol allows for a higher dose of cyclophosphamide for LD, enrollment of patients who have received as few as 1 to 2 prior lines of therapy, and increased dosing of NKX101.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img183648649_5.jpg" alt="img183648649_5.jpg" style="width:618px;height:409px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We engineered NKX101 based on our understanding of NK cell biology, including extensive comparison and optimization of different ways to enhance natural NKG2D signaling and targeting of cells which display NKG2D ligands. Based on our preclinical studies, we believe that levels of NKG2D are increased significantly in NKX101 as compared to non-engineered NK cells. Because NKG2D is the primary activating receptor for NK cells, through its detection of stress ligands displayed by cancerous cells, NKX101 is thereby designed to increase the natural cancer cell killing ability of NK cells. Although some cancer cells are able to evade detection and killing by NK cells through shedding of NKG2D ligands, thereby reducing ligand display on the cell surface, NKX101 can recognize tumor cells expressing even low levels of NKG2D ligands, and maintains the ability of NK cells to recognize tumor cells through an array of other activating receptors that are broadly expressed in NK cells. Furthermore, we found in preclinical studies that the addition of mbIL-15 and the OX40 costimulatory domain each increase the activity of engineered NK cells. Because NKG2D is the primary activating receptor responsible for innate immune surveillance of cancerous cells, we believe that NKX101 presents a broad opportunity to treat a variety of blood cancers, as well as, potentially, solid tumors, which collectively represent approximately 90% of all cancer incidences in the United States.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NKX101 for Blood Cancers</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX101 is currently being evaluated in a Phase 1 clinical trial for the treatment of r/r AML. This multi-center clinical trial is designed to evaluate safety, pharmacology, and preliminary anti-tumor activity of NKX101. According to the federal Surveillance, Epidemiology, and End Results Program database (&#34;SEER&#34;), the incidence of AML in the United States is approximately 20,000 cases per year, and newly-diagnosed patients have a five-year survival rate of approximately 30%. We believe there is a substantial unmet medical need for patients r/r AML and that this disease represents a significant market opportunity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ongoing Phase 1 clinical trial comprises standard dose-finding and dose-expansion phases. Patients are expected to receive LD prior to administration of NKX101 in order to allow our engineered NK cells the opportunity to kill cancerous cells without first being cleared by the patient&#x2019;s immune system. The LD regimen being used in the NKX101 clinical trial is based upon doses used by Rezvani Liu et al, New England Journal of Medicine 2020, similar to that used for the currently approved CAR T therapies, and generally lower than the most commonly used regiment found in our systematic literature review of allogeneic cells and is also similar to that used for the currently approved CAR T therapies. The trial also evaluated two separate dosing regimens. The three-dose regimen was designed to deliver three infusions of NKX101 at weekly intervals following LD. The two-dose regimen delivered the same number of CAR NK cells in two weekly infusions following LD.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The dosing schema is shown in the graphic below. Our starting dose of 100 million cells is based upon the established tolerability of non-engineered NK cells from academic literature.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img183648649_6.jpg" alt="img183648649_6.jpg" style="width:624px;height:354px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we expect that the initial subjects treated with NKX101 in clinical studies will be hospitalized for a minimum of 24 hours observation after infusion, a favorable tolerability profile may potentially allow for administration of NKX101 and observation in a fully outpatient setting. This could represent a significant competitive advantage for NKX101 and our engineered NK product candidates more generally, as compared to the approved CAR T therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we announced preliminary data from our Phase 1 clinical trial evaluating NKX101. As of data cut-off on April 21, 2022, 21 patients had been enrolled and dosed in this study. Three of five patients with r/r AML treated at the higher dose levels in a three-dose regimen achieved a complete response (60% CR) with hematologic recovery, with two of the three responses measurable residual disease negative. NKX101 was well tolerated, and no dose-limiting toxicities were observed. No CRS, GvHD, or immune effector cell-associated neurotoxicity syndrome (&#34;ICANS&#34;) was observed. The most common higher-grade adverse events were myelosuppression and infection, which are common in this patient population following LD.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NKX101 for Solid Tumors</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following clinical proof of concept with NKX101 in r/r AML, we may also evaluate NKX101 in patients with solid tumors. Our initial solid tumor clinical trial may include patients with liver cancer, a bile duct cancer known as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">intrahepatic cholangiocarcinoma, as well as patients with surgically removed colon cancer where only liver metastases remain. These tumors represent an attractive opportunity for the initial solid tumor indication for NKX101 for several reasons, including the overexpression of NKG2D ligands in many liver cancers and the substantial unmet medical need for the treatment of these cancers. According to the federal SEER database, the incidence of liver and intrahepatic cholangiocarcinoma in the United States is approximately 42,000 cases per year, and the five-year survival rate is approximately 20%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may file an Investigational New Drug application (&#34;IND&#34;) amendment for this clinical program after achieving clinical proof of concept with NKX101 in r/r AML. An NKX101 Phase 1 trial in solid tumors may also incorporate a dose-finding and dose-expansion component and potential combinations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If this program is successful, we believe that it would establish proof of concept for treating solid tumors with engineered NK cells and enable us to evaluate a broader solid tumor clinical development program.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NKX019</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidate NKX019 is for the treatment of various B-cell malignancies, including LBCL, ALL, and several other subtypes of NHL. NKX019 consists of allogeneic, donor-derived and expanded NK cells that have been genetically engineered to express mbIL-15 along with a CAR containing a CD19 binder, an OX40 costimulatory domain and a CD3&#x3b6;(zeta) signaling moiety. We chose to target CD19 based on the clinical validation provided by Kymriah</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Yescarta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Tecartus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Breyanzi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which have all shown to improve remission rates and overall survival in patients with various B-cell malignancies, as well as the significant unmet medical need that remains for treating B-cell malignancies despite these recent approvals.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img183648649_7.jpg" alt="img183648649_7.jpg" style="width:617px;height:394px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ongoing NKX019 clinical trial is a Phase 1 clinical trial that evaluates the safety, pharmacology, and preliminary anti-tumor activity of NKX019, administered in a cycle of three weekly infusions following LD in multiple centers in the United States and Australia. Based on tumor response and tolerability, multiple treatment cycles can be administered. The clinical trial consists of dose-finding followed by dose-expansion and is designed to identify the recommended Phase 2 dose.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we announced preliminary data from the NKX019 Phase 1 clinical trial in relapse/refractory B cell malignancies, in which three of six patients treated at the higher dose level in a three-dose regimen had a complete response (50% CR), including one patient with aggressive large B cell lymphoma (&#34;LBCL&#34;) and one patient with mantle cell lymphoma (&#34;MCL&#34;). No dose limiting toxicity was observed and there were no CAR T like adverse events of any grade.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We presented updated data from the ongoing NKX019 clinical trial in December 2022. In this update, seven of ten patients treated at the higher dose levels in a three-dose regimen had a complete response (70% CR), including two patients with aggressive LBCL, one patient with MCL, and one patient with marginal zone lymphoma. No dose limiting toxicity, neurotoxicity / ICANS, GvHD, or &gt;Gr3 CRS were observed in the study.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All patients in the NKX019 clinical trial have been treated with off-the-shelf material that has been manufactured at our in-house clinical cGMP facility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span><img src="img183648649_8.jpg" alt="img183648649_8.jpg" style="width:624px;height:273px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Efficacy based on: Lugano criteria for NHL; 2018 iwCLL guidelines for CLL; NCCN v1.2020 for B-ALL</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CAR: chimeric antigen receptor; CR: complete response; ECOG PS: Eastern Cooperative Oncology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Group performance status; EOT: end of therapy; r/r: relapsed/refractory; iwCLL: International</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Workshop on Chronic Lymphocytic Leukemia; NCCN: National Comprehensive Cancer Network.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Partnership with CRISPR Therapeutics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 5, 2021, we entered into a Research Collaboration Agreement with CRISPR (the &#34;CRISPR Agreement&#34;). Pursuant to the CRISPR Agreement, CRISPR and Nkarta will establish research plans for the purpose of collaboratively designing and advancing up to two (2) allogeneic, gene-edited NK cell therapies and one (1) allogeneic, gene-edited NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease up to the filing of an application to a regulatory authority to request the ability to start a clinical trial. The first allogeneic, gene-edited NK cell therapy being developed in partnership with CRISPR is targeting cancers expressing the CD70 antigen. Together with CRISPR, we may advance this product candidate for the treatment of solid tumors and blood cancers. The NK+T program combines CAR NK cells and CAR T cells, bringing together the advantages of the innate and adaptive immune systems. We expect the NK+T product will incorporate all of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">core elements of our NK cell engineering platform and CRISPR&#x2019;s experience developing gene-edited, allogeneic CAR T cells with reduced risk of GvHD and enhanced resistance to immunosuppression. We are also evaluating potential antigens and targets for this product candidate. The NK+T product candidate could incorporate two different targets into the CAR NK and CAR T cells, based on the differing pharmacokinetic and pharmacodynamic profile of these two cell types. Additionally, under the CRISPR Agreement, CRISPR will also grant non-exclusive licenses to us on up to five gene-editing targets to enable us to independently research, develop and commercialize NK cell therapies that have been gene-edited using CRISPR&#x2019;s gene-editing technology. On May 4, 2022, we amended the CRISPR Agreement to revise the transfer of materials and nomination provisions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our process for the generation of an allogeneic, off-the-shelf NK cell therapy requires multiple steps. To achieve a commercially viable product, we believe that each of these steps must be scalable, reproducible and cost-effective and must provide consistent cancer cell killing potency of our CAR NK cells once these cells are frozen and then thawed. Therefore, we have focused on developing a manufacturing process that incorporates the following elements:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">starting material consisting of differentiated, mature NK cells with inherent cytotoxic and tumor-recognizing capabilities, as compared to other cell sources such as stem cells, where these fundamental features must be engineered into the cells which must be artificially manipulated in an in vitro setting to reproduce these fundamental features;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a cell source which provides high numbers of easily characterized NK cells;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion technology which increases the number of NK cells by orders of magnitude, without inducing exhaustion;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">techniques for genetic engineering of NK cells which are cost-effective and which introduce a controlled and specified range of the number of copies of the gene into each cell;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">techniques for genome editing of NK cells to selectively knock-out or knock-in genetic targets in each cell; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cryopreservation techniques that permit bulk CAR NK cells to be frozen in individual doses; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">techniques for thawing the frozen NK cell product that are easy to adopt in different clinical settings, and that provide consistent CAR NK cell recovery, viability and potency.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our overall manufacturing scheme is shown in the diagram below.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img183648649_9.jpg" alt="img183648649_9.jpg" style="width:624px;height:189px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The source material for production of our off-the-shelf NK cell therapy product candidates is NK cells collected from healthy donors by leukapheresis, the selective collection of white blood cells from plasma. We then isolate the NK cells from the other cells in the leukapheresis product. Next, we selectively activate the NK cells by co-culture with NKSTIM. After initial expansion, we engineer the expanded NK cells using a gamma-retrovirus to express mbIL-15 and the CAR. We further expand the NK cells, followed by harvesting and cryopreservation to form the final cell product. For off-the-shelf administration, clinical sites will thaw the CAR NK product candidate for administration to patients at the clinical site.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that establishing our own internal cGMP manufacturing capabilities will facilitate clinical product supply, lower the risk of manufacturing disruptions, and enable more cost-effective manufacturing for clinical and commercial supply of our product candidates. In 2020, we completed the construction of a 2,700-square foot clinical cGMP facility within our primary corporate location in South San Francisco, California.  This facility is currently producing clinical supply of NKX019 for the Phase 1 clinical trial. We currently manufacture clinical supply of NKX101, NKSTIM, and the gamma-retrovirus at third-party contract manufacturing sites. We intend to manufacture NKX101 at our cGMP facility in 2023. We believe that this clinical cGMP facility will be capable of supplying our anticipated non-pivotal clinical trial needs. Also, in the future, we intend to manufacture NKSTIM in house.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also constructing a separate, larger commercial cGMP facility for manufacturing engineered NK cells for pivotal clinical trials as well as for eventual commercial supply. In July 2021, we announced that we leased the property in South San Francisco, CA where we are building the facility for the commercial-scale manufacture of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current process and early cGMP manufacturing experience, we believe that we can produce many hundreds of doses from a single manufacturing run. At the 2022 Annual Meeting of the SITC, we presented data demonstrating that further optimization of our core process could allow the production of several thousand doses from a single manufacturing run.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with government regulations related to the manufacture of our product candidates may require significant effort and financial resources. The design, construction, qualification and regulatory approvals for our cGMP manufacturing facilities require substantial capital and technical expertise. The facilities will be subject to inspection by the FDA and other regulatory agencies to ensure compliance with cGMP. Any delays in receiving regulatory approvals for our manufacturing facilities or any failure by us to comply with applicable regulations at our manufacturing facilities could delay our development and commercialization activities.  In addition, if our product candidates fail to meet the required specifications after manufacture or if we change the manufacturing process, we may need to obtain additional regulatory approvals. If we are not able to obtain the necessary additional regulatory approvals, we may need to perform additional clinical trials or manufacturing runs or further refine our manufacturing processes, which could delay development and commercialization of our product candidates and cost substantial additional capital.  Any delays in our development and commercialization activities could have a material effect on our business, financial position, results of operations and competitive position.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents, Trademarks and Proprietary Technology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We protect our intellectual property rights and proprietary technology with a combination of patent rights that we own or license in certain fields of use, trademark rights, confidentiality procedures and contractual provisions. We seek not only to protect our intellectual property rights and proprietary technology in select key global markets, but also to supplement our intellectual property portfolio with new filings and applications to enhance such protection and support commercialization of current and future product candidates. To that end, we continue to seek protection for our technological innovations and branding efforts by filing new patent and trademark applications when and where appropriate. Our patent portfolio consists of a combination of issued patents and pending patent applications licensed from third parties, jointly owned by us with third parties, and owned solely by us. The patents and applications in our portfolio can be categorized as related to our NK cell engineering platform (e.g., NK cell expansion and/or persistence), NKX101, NKX019, NKX070, or future pipeline product candidates and alternative technologies. Some of our issued patents and patent applications are exclusively licensed to us in therapeutic fields of use from the National University of Singapore (&#34;NUS&#34;), St. Jude Children&#x2019;s Research Hospital, Inc., or both (collectively, &#34;Licensors&#34;). As of December 31, 2022, our patent portfolio includes at least 20 issued utility patents and at least 130 pending utility patent applications, which are solely owned by us, jointly owned with others, or licensed to us.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At least 15 of the issued utility patents and at least 60 of the pending utility patent applications in our portfolio are related to our NKX101 product candidate, and include composition of matter, manufacturing process, and method of use claims (e.g., targeting NKG2D ligand-expressing tumors, including monotherapies and combination therapies). These issued utility patents include patents in the United States, Europe, Japan, and other jurisdictions outside the United States that are licensed from Licensors, including one patent in the United States that is co-owned by us with NUS. These pending utility patent applications include applications in the United States, Europe, Japan, the Patent Cooperation Treaty (&#34;PCT&#34;), and other jurisdictions outside the United States. Of these pending patent applications, at least 25 are solely owned or co-owned by us, with the remaining patent applications (and the co-owned applications) licensed from Licensors. The estimated expiration dates of the issued utility patents are between approximately 2024 and 2038 (with certain commercially relevant patents extending through approximately 2038), and the estimated expiration dates of these pending utility patent applications are between approximately 2024 and 2043 (with certain commercially relevant patent applications extending through approximately 2043).<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At least 13 of the issued utility patents and at least 50 of the pending utility patent applications in our portfolio are related to our NKX019 product candidate, and include composition of matter, manufacturing process, and method of use claims (e.g., targeting CD-19-expressing tumors, including monotherapies and combination therapies). These issued utility patents include patents in the United States, Europe, Japan, and other jurisdictions outside the United States and are solely owned by us or licensed from Licensors. These pending utility patent applications include applications in the United States, Europe, Japan, and other jurisdictions outside the United States. Of these pending patent applications, at least 17 are solely owned by us, with the remaining licensed from Licensors. The estimated expiration dates of the issued utility patents are between approximately 2024 and 2040 (with certain commercially relevant patents extending through approximately 2040), and the estimated expiration dates of these pending utility patent applications are between approximately 2024 and 2043 (with certain commercially relevant patent applications extending through approximately 2043).<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At least 10 of the issued utility patents and at least 50 of the pending utility patent applications in our portfolio are related to our NKX070 product candidate, and include composition of matter, manufacturing process, and method of use claims(e.g., targeting CD70-expressing tumors, including monotherapies and combination therapies). These issued utility patents include patents in the United States, Europe, Japan, and other jurisdictions outside the United States and are licensed from Licensors. These pending utility patent applications include applications in the United States, Europe, Japan, the PCT, and other jurisdictions outside the United States. Of these pending patent applications, at least 17 are solely owned by us or, in the case of one patent application, co-owned by us with our collaboration partner on the NKX070 program, CRISPR, with the remaining licensed from Licensors. The estimated expiration dates of the issued utility patents are between approximately 2024 and 2035 (with certain commercially relevant patents extending through approximately 2035), and the estimated expiration dates of these pending utility patent applications are between approximately 2024 and 2043 (with certain commercially relevant patent applications extending through approximately 2043).<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At least 10 of the issued utility patents and at least 30 of the pending utility patent applications in our portfolio are related to our NK cell engineering platform, and include manufacturing process, method of use and composition of matter claims relating to NK cell expansion and/or NK cell persistence. These issued utility patents include patents in the United States, Europe, Japan, and other jurisdictions outside the United States and are licensed from Licensors. These pending utility patent applications include applications in the United States, Europe, Japan, and other jurisdictions outside the United States. Of these pending patent applications, at least 10 are solely owned by us, with the remaining licensed from Licensors. The estimated expiration dates of the issued utility patents are between approximately 2024 and 2035 (with certain commercially relevant patents extending through approximately 2035), and the estimated expiration dates of these pending utility patent applications are between approximately 2024 and 2040 (with certain commercially relevant patent applications extending through approximately 2040). Composition of matter claims relating to our NKSTIM cell line are estimated to expire in Q4 2024.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2016, we entered into a license agreement with the Licensors. Pursuant to this license, the Licensors granted to us an exclusive, worldwide, royalty-bearing, sublicensable license under specified patents and patent applications related to NK cell technology in the field of therapeutics. Payments to the Licensors pursuant to the license agreement include single-digit royalty payments on commercial sales, a portion of any sublicensing revenue, patent expenses, license maintenance fees and milestone payments upon completion of certain regulatory and commercial milestones related to the clinical development and commercialization of our product candidates, in an aggregate amount of up to 5 million Singapore Dollars (&#34;SGD&#34;). The License Agreement also includes certain performance objectives which obligate us to meet various milestones related to the clinical development and commercialization of our product candidates over time for up to 120 months after the effective date of the License Agreement. The term of the license agreement extends until expiration of the last of the patent rights licensed to us by the Licensors, which is currently expected to occur in approximately 2039. We may terminate the license agreement at will upon 90 days&#x2019; prior written notice to the Licensors. The Licensors may terminate the license agreement for certain conditions such as uncured material breach by us, the cession of our business, or our insolvency, liquidation, or receivership.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. government has certain rights in some of our licensed patents (including U.S. Patent Nos. 7,435,596, 8,026,097 and certain related U.S. patent applications, which relate to our NK cell engineering platform) in accordance with the Bayh-Dole Act of 1980. These rights in certain technology developed under government-funded research include, for example, a license to use those inventions for governmental purposes and the right to require us to grant exclusive licenses to such inventions to a third party under certain circumstances. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States.  For further details about risks related to the government&#x2019;s rights in such inventions, see &#x201c;&#x2014;The U.S. government could choose to exercise certain rights in technology developed under government-funded research, which could eliminate our exclusive use of such technology or require us to commercialize our product candidates in a way we consider sub-optimal.&#x201d; in the section titled &#x201c;Risk Factors&#x201d; in Part I, Item 1A in this Annual Report on Form 10-K.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our continuing research and development activities, technical expertise and contractual arrangements supplement our existing intellectual property protection and help us maintain our competitive position, and we rely on trade secrets to protect our proprietary information and technologies, especially where we do not believe patent protection is appropriate or obtainable, or where such patents would be difficult to enforce. In order to maintain such trade secrets and other proprietary information, we rely in part on confidentiality agreements with our employees, consultants, contractors, outside scientific collaborators and other advisors.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also protect our brand through trademark rights. As of December 31, 2022, we are the listed owner of the U.S. registered trademark, NKARTA, and 15 related foreign registered trademarks. In order to supplement the protection of our brand, we also have a registered internet domain name.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA Approval Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates investigational drugs, including biological products, under the Federal Food, Drug, and Cosmetic Act (&#34;FDCA&#34;) and its implementing regulations. Marketing authorization of a biological product via a biologics license application (&#34;BLA&#34;) occurs under section 351 of the Public Health Service Act (&#34;PHSA&#34;). The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including imposition of a clinical hold, refusal by the FDA to approve applications, withdrawal of an approval, import/export delays, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal investigations and penalties brought by the FDA and the Department of Justice (&#34;DOJ&#34;) or other governmental entities. The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of our product candidates are governed by extensive regulation by governmental authorities in the United States and other countries. The FDA, under the FDCA and PHSA, regulates biopharmaceutical products in the United States. The steps required before a product candidate may be approved for marketing in the United States generally include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preclinical laboratory tests and animal tests conducted under Good Laboratory Practices (&#34;GLP&#34;);</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials commence;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an independent institutional review board (&#34;IRB&#34;) representing each clinical site before each clinical trial may be initiated;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the product for each indication and conducted in accordance with Good Clinical Practices (&#34;GCP&#34;);</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the preparation and submission to the FDA of a BLA;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA acceptance, review and approval of the BLA, which might include an advisory committee review; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facilities at which the product, or components thereof, are made to assess compliance with cGMPs and in the case of cell-based advanced therapy, additionally, current Good Tissue Practices.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The testing and approval process typically requires many years and substantial effort and financial resources, and the receipt and timing of any approval is uncertain. The actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. For example, the FDA has, at times, taken longer than its usual 30-day window to complete its review of certain first-of kind INDs. In addition, the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unreasonable and significant health risk.</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical and Human Clinical Trials in Support of a BLA</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical studies generally include laboratory evaluations of product chemistry, formulation, and toxicity, as well as animal studies to assess the potential safety and bioactivity of the product candidate. The conduct of preclinical trials is subject to federal regulations and requirements including GLP regulations. The results of the preclinical studies, together with manufacturing information and analytical data, among other things, are submitted to the FDA as part of the IND, which must become effective before clinical trials may be commenced. The IND will become effective automatically 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the trials as outlined in the IND prior to that time. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can proceed. If outstanding concerns cannot be resolved, the FDA will place the clinical trial, or a portion of it, on clinical hold. A partial clinical hold stops new patients from enrolling in a clinical trial. A complete clinical hold further requires all patients currently enrolled to discontinue treatment with the product candidate being evaluated. The FDA may also initiate a clinical hold after the 30 days if, for example, significant public health risks arise during the trial, if FDA believes the study is not being conducted in accordance with FDA regulations, or if results from additional preclinical studies are required by the FDA to evaluate the potential risk and benefit to patients for such a trial. Clinical holds may be temporary or permanent.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified investigators in accordance with federal regulations, in compliance with GCP requirements, and in accordance with a protocol submitted to FDA as part of the IND detailing the objectives of the trial, the parameters used to monitor safety, and the effectiveness criteria, if any, to be evaluated. Each clinical trial and informed consent information must also be reviewed and approved by an independent IRB at each of the sites at which the trial will be conducted. The IRB will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the institution. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#x2019;s requirements, or may impose other conditions if it believes that the patients are subject to unacceptable risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases prior to approval, but the phases may overlap or be combined. These phases generally include the following:</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Phase 1 clinical trials represent the initial introduction of a product candidate into human subjects. In Phase 1 trials of cellular therapies, the product candidate is tested for safety, including adverse effects.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2 clinical trials usually involve studies in a limited patient population to (i) evaluate the efficacy of the product candidate for specific indications, (ii) determine dosage tolerance and optimal dosage and (iii) identify possible adverse effects and safety risks.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product candidate is found to be potentially effective and to have an acceptable safety profile in Phase 2 clinical trials, the clinical trial program will be expanded to Phase 3 clinical trials to further demonstrate clinical efficacy, optimal dosage and safety within a larger number of patients, typically at geographically dispersed clinical trial sites.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 4. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 4 clinical trials may be conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">drugs approved under accelerated approval regulations, or when otherwise requested by the FDA (post-approval commitments) or required by the FDA (post-approval requirements). Failure to promptly conduct any required Phase 4 clinical trials could result in enforcement action or withdrawal of approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A Phase 2/3 trial design is often used in the development of pharmaceutical and biological products. The trial includes Phase 2 elements, such as an early interim analysis of safety or activity, and Phase 3 elements, such as larger patient populations with less restrictive enrollment criteria. With appropriate statistical restrictions, an early interim analysis of clinical or physiologic activity and/or safety may provide for the trial to be stopped, changed or continued before a large number of patients have been enrolled, while still allowing all data from enrolled patients to count in the analysis used to support approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A pivotal trial is a clinical trial that is designed to meet regulatory requirements to demonstrate a product candidate&#x2019;s safety and efficacy to support the approval of the drug or biologic. Generally, pivotal trials are Phase 3 trials, but the FDA may accept results from any phase clinical trial if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations in which there is an unmet medical need and the results are sufficiently robust.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA, the IRB or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, an independent group of qualified experts organized by the clinical trial sponsor, often known as a Data Safety Monitoring Board (&#34;DSMB&#34;) or committee, may oversee some clinical studies. Depending on the trial design, this group may provide authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and the competitive climate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials require substantial time, effort and financial resources. The costs associated with running clinical trials typically increase as a product candidate advances to later stage clinical trials, since the later stage clinical trials typically involve a larger number of patients than the early-stage clinical trials. If a clinical trial for one of our product candidates is put on clinical hold by the FDA (or another regulatory authority in a foreign country), further development and any eventual commercialization of that product candidate would be delayed or may not be possible at all.  Any delays in our clinical trials or termination of a program due to a clinical hold could materially adversely affect our business, financial conditions, results of operations, growth prospects and competitive position.</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Submission and Review of a BLA</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of preclinical studies and clinical trials, together with detailed information on the product&#x2019;s manufacture, composition, quality, controls and proposed labeling, among other things, are submitted to the FDA in the form of a BLA, requesting approval to market the product. The cost of preparing and submitting a BLA is substantial. The application must also be accompanied by a significant user fee payment, which typically increases annually, although waivers may be granted in limited cases. Under an approved BLA, the applicant is also subject to an annual program fee. The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the Agency&#x2019;s determination that it is adequately organized and sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has substantial discretion in the approval process and may refuse to accept an application or decide that the data are insufficient for approval and require additional preclinical, clinical or other studies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a BLA has been accepted for filing, the FDA sets a user fee goal date that informs the applicant of the specific date by which the FDA intends to complete its review. The FDA has agreed to certain performance goals to complete the review of BLAs. This is typically ten months from the date that the FDA accepts the BLA for filing for standard review BLAs. Applications classified as Priority Review are reviewed within six months of the date the FDA accepts the BLA for filing. A BLA can be classified for Priority Review when the FDA determines the biologic product has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review process can be extended by FDA requests for additional information or clarification. The FDA reviews BLAs to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#x2019;s identity, strength, quality and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">purity. The FDA may also refer applications for novel biologic products, or biologic products that present difficult questions of safety or efficacy, to be reviewed by an advisory committee&#x2014;typically a panel that includes clinicians, statisticians and other experts&#x2014;for review, evaluation, and a recommendation as to whether the BLA should be approved. The FDA is not bound by the recommendation of an advisory committee, but generally follows such recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facilities comply with cGMP. Additionally, the FDA will typically inspect the sponsor and one or more clinical trial sites for compliance with GCP and integrity of the data supporting safety and efficacy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA will provide a preliminary determination as to whether a REMS is necessary to assure the safe use of the product prior to the BLA, but a final decision will be made during the approval process. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS, and the FDA will not approve the application without an approved REMS, if required. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#x2019;s safe use (&#34;ETASU&#34;). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. A REMS can substantially increase the costs of obtaining approval. The FDA could also require a special warning, known as a boxed warning, to be included in the product labeling in order to highlight a particular safety risk. The FDA may delay approval of a BLA if applicable regulatory criteria are not satisfied and/or the FDA requires additional testing or information. The FDA may require substantial post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On the basis of the FDA&#x2019;s evaluation of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA will issue either an approval of the BLA or a Complete Response Letter, detailing the deficiencies in the submission and the additional testing or information required for reconsideration of the application. If, or when, those deficiencies have been addressed to the FDA&#x2019;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing and distribution of the biologic with specific prescribing information for specific indications. Even with submission of this additional information, the FDA may ultimately decide that the application does not satisfy the regulatory criteria for approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once granted, product approvals may need be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Changes to some of the conditions established in an approved BLA, including changes in indications, product labeling, manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs. BLA supplement review timelines are typically ten months from the date of submission to the FDA for standard review and six months from the date of submission to the FDA for Priority Review.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain a BLA for a product candidate accepted or approved, commercialization of that product candidate will be delayed or we may not be able to commercialize that product candidate at all.  This would have a material effect on our business, financial conditions, results of operations, growth prospects and competitive position.</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Programs, Accelerated Approval Programs, Breakthrough Therapy Designation, and Regenerative Medicine Advanced Therapies and Priority Medicine Designation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A sponsor may seek approval of its drug candidate under programs designed to accelerate FDA&#x2019;s review of INDs and BLA. For example, the FDA may grant Fast Track Designation to a drug intended for treatment of a serious or life-threatening disease or condition that has potential to address unmet medical needs for the disease or condition. The key benefits of fast track designation are the eligibility for priority review, rolling review (submission of portions of an application before the complete marketing application is submitted) and accelerated approval, if the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">application meets relevant criteria. Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The FDA generally requires post-marketing studies or completion of ongoing studies after marketing authorization to verify the drug&#x2019;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit to convert the accelerated approved to a full approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on results of the Phase 3 clinical trials or trials submitted in a BLA, upon the request of an applicant, the FDA may grant the BLA a priority review designation, which sets the target date for FDA action on the application at six months after the FDA accepts the application for filing. The FDA grants priority review where there is evidence that the proposed drug would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition. If the criteria for priority review are not met, the application is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a sponsor may seek a FDA IND designation of its drug candidate as a breakthrough therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if the drug can, alone or in combination with one or more other drugs, treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A breakthrough therapy designation (&#34;BTD&#34;) allows companies to work earlier, more closely, and frequently with the FDA, and they may be eligible for priority review and accelerated approval. The sponsor of a new biologic product candidate may request that the FDA designate the candidate for a specific indication as a Breakthrough Therapy concurrent with, or after, the submission of the IND for the biologic product candidate. The FDA must determine if the biological product qualifies for BTD within 60 days of receipt of the sponsor&#x2019;s request.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cell-based advanced therapies intended to treat, modify, reverse or cure a serious medical condition can receive Regenerative Medicine Advanced Therapy (&#34;RMAT&#34;) designation from the FDA once preliminary clinical evidence has been obtained demonstrating the therapy has the potential to address unmet medical needs for the condition. Similar to BTD, the RMAT allows companies developing regenerative medicine therapies to work earlier, more closely, and frequently with the FDA, and RMAT designated products may be eligible for priority review and accelerated approval. Interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The timing of a sponsor&#x2019;s request for designation and FDA response are the same as for the breakthrough therapy designation program. Like the other expedited development programs previously mentioned, RMAT designation does not change the scientific or medical standard for approval or the quality of evidence necessary to support approval. In Europe, the European Medicines Agency (&#34;EMA&#34;) can grant PRIority MEdicine (&#34;PRIME&#34;), designation to support development of product candidates that may address unmet needs and improve quality of life, based on the potential to benefit patients from early clinical data.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Special Protocol Assessment</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A company may reach an agreement with the FDA under the Special Protocol Assessment (&#34;SPA&#34;) process as to the required design and size of clinical trials intended to form the primary basis of an efficacy claim. Under the FDCA and FDA guidance implementing the statutory requirement, an SPA is generally binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the clinical trial begins, public health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and the FDA agree to the change in writing, or if the clinical trial sponsor fails to follow the protocol that was agreed upon with the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disclosure of Clinical Trial Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information on the website www.clintrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The U.S. National Institutes of Health&#x2019;s (&#34;NIH&#34;) Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both NIH and FDA have signaled the government&#x2019;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors.</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drugs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer than 200,000 individuals in the United States, or in other limited cases. Orphan drug designation must be requested before submitting a BLA. If the FDA grants orphan drug designation, the identity of the biological product and its potential orphan disease use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan drugs may be eligible for certain incentives, including tax credits for qualified clinical testing. In addition, a BLA for a product that has received orphan drug designation is not subject to a prescription drug user fee unless the application includes an indication other than the rare disease or condition for which the drug was designated. In December 2021, we announced that the FDA granted orphan drug designation to our product candidate NKX101 for treatment of AML.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same active moiety for the same indication for seven years, except in limited circumstances, such as another drug&#x2019;s showing of clinical superiority over the drug with orphan exclusivity. A product can be considered clinically superior if it is safer, more effective or makes a major contribution to patient care. Competitors, however, may receive approval of different active moieties for the same indication or obtain approval for the same active moiety for a different indication. In some cases, orphan drug status is contingent on a product with an orphan drug designation demonstrating that it is clinically superior to a previously approved product or products.</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Pediatric Research Equity Act (&#34;PREA&#34;), new drug applications (&#34;NDAs&#34;) or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by the FDA to be substantially relevant to the growth or progression of a pediatric cancer that is subject to an NDA or BLA submitted on or before August 18, 2020. If a BLA is submitted after August 18, 2020, the sponsor is subject to the requirements of Sections 504(a) and (b) of the FDA Reauthorization Act of 2017 (&#34;FDARA&#34;) which will require pediatric studies regardless of orphan designation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Additional Controls for Biologics</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend biologics licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases within the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the lot manufacturing history and the results of all of the manufacturer&#x2019;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before allowing the manufacturer to release the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of a BLA, biologics manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biosimilars</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009 (&#34;BPCIA&#34;) creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial or trials, unless the Secretary of Health and Human Services waives a required element. A biosimilar product may be deemed interchangeable with a previously approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. To date, a small number of biosimilar products and no interchangeable products have been approved under the BPCIA. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to biosimilar product implementation, which is still being evaluated by the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reference biologic is granted 12 years of exclusivity from the time of first licensure, or BLA approval, of the reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biologic product submitted under the biosimilar abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii) 18 months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar&#x2019;s application has been approved if a patent lawsuit is ongoing within the 42-month period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements or Commitments</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approved drugs and biologics that are manufactured or distributed in the United States pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, adverse event reporting, product sampling and distribution, advertising and promotion including standards and regulations for direct-to-consumer advertising, off label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling and reporting of adverse experiences with the product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may impose a number of post-approval requirements or commitments as a condition of approval of a BLA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance programs to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization or the FDA may place conditions on an approval that could restrict the distribution or use of the product. The FDA may also require a REMS, which could involve requirements for, among other things, medication guides, special trainings for prescribers and dispensers, patient registries and elements to assure safe use.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. The FDA has promulgated specific requirements for drug cGMP. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an approval is granted, the FDA may issue enforcement letters or product approvals may need to be withdrawn if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Corrective action could delay product distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve applications or supplements to approved applications, or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension or revocation of product approvals;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.173%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union and other geographies, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></p>
  <p style="text-indent:4.173%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage, Reimbursement and Pricing</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States and foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the availability of coverage and the adequacy of reimbursement from third-party payors. Third-party payors include government authorities and private entities, such as managed care organizations, private health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. Moreover, a third-party payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. For example, the payor&#x2019;s reimbursement payment rate may not be adequate or may require co-payments that patients find unacceptably high. Additionally, coverage and reimbursement for products can differ significantly from payor to payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Further, some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they provide reimbursement for use of such therapies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of products and services, in addition to their safety and efficacy. To obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of our product. These studies will be in addition to the studies required to obtain regulatory approvals. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Thus, obtaining and maintaining reimbursement status is time-consuming and costly.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. and foreign governments regularly consider reform measures that affect healthcare coverage and costs. For example, the U.S. and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#34;ACA&#34;) contains provisions that may reduce the profitability of products, including, for example, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#x2019; share of sales to federal health care programs. The Centers for Medicare and Medicaid Services (&#34;CMS&#34;) may develop new payment and delivery models, such as bundled payment models. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, the focus on cost containment measures, particularly in the United States, has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if we attain favorable coverage and reimbursement status for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">European Union Coverage Reimbursement and Pricing</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular drug candidate to currently available therapies, or so called health technology assessments, in order to obtain reimbursement or pricing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Laws and Regulations</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Physicians, other healthcare providers, and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors are and will be subject to various federal, state and foreign fraud and abuse laws and other healthcare laws and regulations. These laws and regulations may impact, among other things, our arrangements with third-party payors, healthcare professionals who participate in our clinical research programs, healthcare professionals and others who purchase, recommend or prescribe our approved products, and our proposed sales, marketing, distribution and education programs. The U.S. federal and state healthcare laws and regulations that may affect our ability to operate include, without limitation, the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute, which prohibits persons from, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federally funded healthcare programs, such as Medicare and Medicaid. The term &#x201c;remuneration&#x201d; has been broadly interpreted to include anything of value;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil and criminal false claims laws, including, without limitation, the federal civil monetary penalties law and the civil False Claims Act (which can be enforced by private citizens through qui tam actions), prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment of federal funds, and knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (&#34;HIPAA&#34;) which creates federal criminal laws that prohibit, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without the appropriate authorization by entities subject to the law, such as certain healthcare providers, health plans and healthcare clearinghouses and their respective business associates who use, disclose, store or otherwise process HIPAA-protected health information on their behalf;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal transparency requirements under the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (&#34;CHIP&#34;) to report to the Department of Health and Human Services (&#34;HHS&#34;) information related to payments and other transfers of value provided to physicians and teaching hospitals and physician ownership and investment interests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Analogous state laws and regulations, such as state anti-kickback and false claims laws, that impose similar restrictions and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other health care providers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State and local laws requiring the registration of pharmaceutical sales representatives;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State health information privacy and data breach notification laws, which govern the collection, use, disclosure and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State unfair and deceptive trade practices statutes, pursuant to which significant statutory fines and penalties can be imposed against pharmaceutical companies alleged to have engaged in consumer fraud.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Recent healthcare reform legislation has strengthened these federal and state healthcare laws. For example, the ACA amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes to clarify that liability under these statutes does not require a person or entity to have actual knowledge of the statutes or a specific intent to violate them. Moreover, the ACA provides that the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Government regulators have been very active in the last several years in revising existing regulations and promulgating new regulations. Government enforcement regulators have also become increasingly active in bringing enforcement actions based on these laws. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are found to be in violation of these laws, we may be subject to criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, and reputational harm, in which case we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. For example, in March 2010, the ACA was enacted, which includes measures that have significantly changed the way healthcare is financed by both governmental and private payors. The provisions of the ACA of importance to the pharmaceutical and biotechnology industry are, among others, the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drug agents or biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extension of manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, unless the drug is subject to discounts under the 340B drug discount program;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">new requirements under the federal Physician Payments Sunshine Act for drug manufacturers to report information related to payments and other transfers of value made to physicians and teaching hospitals as well as ownership or investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct, comparative clinical effectiveness research, along with funding for such research;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">creation of the Independent Payment Advisory Board, which, if and when impaneled, will have authority to recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been legislative, judicial, and executive challenges to certain aspects of the ACA, including efforts to repeal or replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of  the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandates,&#x201d; and the Bipartisan Budget Act of 2018 (the &#34;BBA&#34;) among other things, amends the ACA to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#x201c;donut hole.&#x201d; Further, the 2020 federal spending package eliminated, effective January 1, 2020, the ACA-mandated &#x201c;Cadillac&#x201d; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer. Congress could continue to consider other legislation to repeal or replace certain elements of the ACA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the Court of Appeals for the Fifth Circuit court affirmed the lower court&#x2019;s ruling that the individual mandate portion of the ACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA. Thereafter, on March 2, 2020, the U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November 10, 2020. On June 17, 2021, the U.S. Supreme Court dismissed the case without specifically ruling on the constitutionality of the ACA, finding that the plaintiffs lacked standing to bring the action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Supreme Court&#x2019;s decision, an executive order was issued to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is unclear how other efforts, if any, to challenge, repeal or replace the ACA, and other healthcare reform measures, will impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted. For example, as a result of the Budget Control Act of 2011, among other things, providers are subject to Medicare payment reductions of 2% per fiscal year which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 pursuant to the Coronavirus Aid, Relief and Economic Security Act (the &#34;CARES Act&#34;). Further, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment center, and increased the statute of limitations period for the government to recover overpayments from providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 also introduced a quality payment program under which certain individual Medicare providers will be subject to certain incentives or penalties based on new program quality standards. Payment adjustments for the Medicare quality payment began in 2019. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have also been a number of proposals in the United States to control the escalating cost of healthcare, including the cost of drug treatments, patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and we expect that coverage and reimbursement for new therapies will be increasingly restricted. Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. Most significantly, on August 16, 2022, the Inflation Reduction Act of 2022 (&#34;IRA&#34;) was signed into law. The IRA includes provisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that will, among others: (i) direct CMS to negotiate the price of certain single-source prescription drugs reimbursed under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law; (ii) impose requirements on drug manufacturers to provide rebates to CMS under Medicare Part B and Medicare Part D as a penalty for price increases that outpace inflation; (iii) cap Medicare Part D beneficiaries&#x2019; annual out-of-pocket drug expenses to $2,000 starting in 2025, effectively eliminating the &#x201c;donut hole&#x201d; for Medicare Part D; and (iv) delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. The IRA also extends enhanced subsidies for individuals purchasing coverage in a health insurance marketplace through plan year 2025. The effect of the IRA on our business and the healthcare industry in general is not yet known, but we continue to evaluate its potential impact. At the state level, individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#x2019; ability to regulate pharmaceutical benefit managers (&#34;PBMs&#34;) and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict what initiatives may be adopted in the future. Further federal, state, and regional developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. These changes may adversely impact the prices we or our future collaborators may charge for our products candidates, if commercialized.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Additional Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in foreign countries that impose similar obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-Corruption Laws</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Foreign Corrupt Practices Act (the &#34;FCPA&#34;) the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. These anti-corruption laws prohibit any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. This could become relevant in the conduct of international clinical trials where the sites for such trials may be a government-owned hospital. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight and debarment from government contracts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the U.S., we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to develop or sell any products outside of the U.S. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biopharmaceutical industry in general, and the cell therapy field in particular, is characterized by rapidly advancing and changing technologies, intense competition and a strong emphasis on intellectual property. We face substantial and increasing competition from many different sources, including large and specialty biopharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions. Competitors may compete with us in hiring scientific and management personnel, establishing clinical study sites, recruiting patients to participate in clinical trials and acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our known biopharmaceutical competitors developing allogeneic CAR-NK or CAR-T cell therapies include 2seventy Bio, Allogene, Artiva Biosciences, Bristol-Myers Squibb, Caribou, Cellectis, Celularity, Celyad, Century Therapeutics, CRISPR Therapeutics, Fate Therapeutics, Gamida Cell, Gilead, Glycostem, Gracell, ImmunityBio, Intellia, Legend Biotech, NKGen, Novartis, Precigen, Precision BioSciences, Sanofi, Takeda, and Vor Biopharma, each of which has clinical-stage allogeneic programs. Biopharmaceutical companies with potentially competitive cell therapies in preclinical development include Astellas, CytoImmune, Cytovia, Editas, Indapta Therapeutics, ONK Therapeutics, Senti, Shoreline Biosciences, Surface Oncology, and WuGen. The autologous CAR-T therapies Kymriah</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Yescarta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Tecartus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Breyanzi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which have been commercially approved, are direct competitors to our product candidate NKX019. Bispecific CD20-directed CD3 T-cell engaging antibodies such as mosunetuzumab-axgb (Lunsumio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), which has accelerated approval, and others that are currently in development and under BLA review at the FDA are also competitors to our product candidate NKX019. Furthermore, a number of companies are seeking to harness NK or T cell biology through engagers which seek to direct a patient&#x2019;s own NK or T cells to the site of a tumor. Such competitors include Affimed, Amgen, Dragonfly Therapeutics, GT Biopharma, Innate Pharma, and Servier. Several companies are investigating other types of immune cells, such as gamma delta and NKT. These companies include Acepodia, Adicet, Appia Bio, Athenex, Gadeta, In8Bio, Portage, and Takeda.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, numerous academic institutions are conducting preclinical and clinical research in these areas. Furthermore, a number of biopharmaceutical companies and academic groups are focused on engineering other white blood cell types including NKT cells and gamma-delta T cells, which may offer some of the same advantages as engineered NK cells. Finally, research in immuno-oncology is one of the most active areas for the discovery and clinical development of new anticancer therapies in the biopharmaceutical industry. New approaches, such as bispecific antibodies, as well as refinements of existing modalities, such as immune checkpoint inhibitors, are constantly emerging.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our current or potential competitors have significantly greater financial, technical and human resources, as well as more expertise in research and development, manufacturing, preclinical testing, conducting clinical studies and trials and commercializing and marketing approved products, than us. Mergers and acquisitions in the biopharmaceutical industry may result in even greater resource concentration among a smaller number of competitors. Smaller or early-stage companies may also prove to be significant competitors, either alone or through collaborative arrangements with large and established companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of all of our programs are likely to be their efficacy, safety, convenience, price and degree of reimbursement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our values &#x2013; patient first, data driven, intellectually honest, transparent, diverse, inclusive, work/life balance, respectful, humble, creative, and ethical &#x2013; are the foundations for our team and our behaviors for promoting creativity, innovation and productivity. As of December 31, 2022, we had 163 full-time employees, 39 of whom have Ph.D., M.D. or J.D. degrees. Of these full-time employees, 126 employees are engaged in research and development activities and 37 employees are engaged in finance, business development and other general and administrative functions. We have no collective bargaining agreements with our employees and we have not experienced any work stoppages. We consider our relations with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that a diverse and inclusive work environment is critical for driving innovation, workforce productivity and the development of new cell therapies. We embrace the principles of workplace development, diversity and inclusion set forth by the Biotechnology Innovation Organization. As part of comprehensive approach to diversity, equity and inclusion at Nkarta, we rely on data to identify gaps, set priorities and enable ongoing measurement of our progress. We publish these quarterly data on our website in the spirit of shared responsibility and accountability. Nothing on our website shall be deemed incorporated by reference into this Annual Report on Form 10-K.</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation, Benefits and Well-being</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to offer fair, market-competitive compensation and benefits that support our employees&#x2019; overall well-being. To ensure alignment with our short- and long-term objectives, our compensation programs for all employees include base pay, short-term incentives, and opportunities for long-term incentives. Our well-being and benefit programs focus on four key pillars: physical, emotional, financial and community. We offer a wide array of benefits including comprehensive health insurance, generous time-off and leave, and retirement and financial support.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the COVID-19 pandemic, we implemented significant changes that we determined were in the best interest of our employees as well as the communities in which we operate. This includes having many of our employees not in research or manufacturing work from home, while implementing additional safety measures for employees continuing critical on-site work. We also provide flexible work hours and paid time off for employees who cannot work due to circumstances related to COVID-19. We have actively encouraged employees to structure their days and work to best help address caregiving responsibilities they have with family members as well as taking care of themselves personally.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Risk Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as all of the other information contained in this Annual Report on Form 10-K, before making an investment decision. The risks described below are not the only ones facing us. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could significantly harm our business, financial condition, results of operations and growth prospects. In such case, the trading price of shares of our common stock could decline, and you may lose part or all of your investment. This Annual Report on Form 10-K also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Financial Position</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history and do not have any products approved for sale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a development-stage biopharmaceutical company without any products approved for commercial sale, and have not generated any revenue from product sales. We are focused on developing genetically-engineered human cells as therapeutics and our technologies are new and largely unproven. Since our inception in 2015, we have invested most of our resources in developing our product candidates, building our intellectual property portfolio, developing our supply chain and in-house manufacturing capability, conducting business planning, raising capital and providing general and administrative support for these operations. Consequently, we have no meaningful operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing drug products. We have not yet demonstrated an ability to overcome many of the risks and uncertainties frequently encountered by companies in the rapidly evolving biotechnology industry. If we do not address these risks, our business, financial condition, results of operations and growth prospects will be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception, and we expect to continue to incur significant losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception in 2015, we have incurred significant operating losses. Our net losses were $113.8 million and $86.1 million for the years ended December 31, 2022 and 2021, respectively. Our accumulated deficit was $317.9 million as of December 31, 2022. We expect to continue to incur increasing operating losses for the foreseeable future as we continue to develop our product candidates. In addition, we anticipate that our expenses will increase substantially if, and as, we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue the clinical development of NKX101 and NKX019; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance additional product candidates to clinical trials, including product candidates under the collaboration with CRISPR Therapeutics AG (&#34;CRISPR&#34;); </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">develop our current product candidates for additional disease indications;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek to discover and develop additional product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish and qualify our own clinical- and commercial-scale clinical current good manufacturing practice (&#34;cGMP&#34;) facilities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submit a biologics license application (&#34;BLA&#34;) or marketing authorization application, (&#34;MAA&#34;) for NKX101 and/or NKX019 and/or seek marketing approvals for any of our other product candidates that successfully complete clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approval of our product candidates in various jurisdictions for commercial sale;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire or in-license other product candidates and technologies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incur additional costs associated with operating as a public company; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">develop or secure marketing, sales and distribution capabilities, either internally or with third parties, to support commercialization; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increase our employee headcount and related expenses to support the foregoing activities.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have never generated revenue from product sales and may never achieve or maintain profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to incur significant research and development and other expenses related to ongoing operations and the development of our two lead product candidates, NKX101 and NKX019. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. Neither the United Sates Food and Drug Administration (&#34;FDA&#34;) nor any other regulatory authority has approved NKX101, NKX019 or any of our other product candidates, and we do not anticipate generating revenues from product sales unless and until such time as NKX101, NKX019 or another of our product candidates has been approved by the FDA or another regulatory authority, if ever, and we are able to successfully market and sell a product candidate. Our ability to generate revenues from product sales depends on our, or potential future collaborators&#x2019;, success in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completing clinical development of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seeking and obtaining regulatory approvals for product candidates for which we successfully complete positive clinical trials, if any; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launching and commercializing product candidates, by establishing a commercial infrastructure or, alternatively, collaborating with a commercialization partner; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">qualifying for adequate coverage and reimbursement by government and third-party payors for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing, maintaining and enhancing a sustainable, scalable, reproducible and transferable manufacturing process for each of our cell therapy product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate products and services, in both amount and quality, to support clinical development and the market demand for our product candidates, if approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining market acceptance of our product candidates as a viable treatment option; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing any competing technological and market developments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implementing additional internal systems and infrastructure, as needed; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, know-how, and trademarks; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">avoiding and defending against third-party interference or infringement claims; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">attracting, hiring and retaining qualified personnel. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond our current expectations if we are required by the FDA or other global regulatory authorities to perform clinical trials and/or other preclinical studies in addition to, or beyond the scope of, those that we currently anticipate being required to perform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we are able to generate revenues from the sale of any approved products, we may not become profitable or be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could decrease the value of our company and impair our ability to raise capital, thereby limiting our research and development programs and efforts to expand our business or continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require additional capital, which, if available, may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have financed our operations primarily through private placements of our preferred stock, proceeds from our previous collaboration with GlaxoSmithKline, proceeds from our IPO completed in July 2020, proceeds from our underwritten public offering of our common stock completed in April 2022 (the &#34;Secondary Offering&#34;), and our &#34;at the market&#34; equity offering program (the &#34;ATM Offering Program&#34;). We intend to continue to use the proceeds from our IPO and our Secondary Offering to, among other uses, advance NKX101 and NKX019 through clinical development. Developing pharmaceutical products and conducting preclinical studies and clinical trials is expensive. As of December 31, 2022, we had cash, cash equivalents, restricted cash and short-term investments of $354.9 million. Our research and development expenses increased from $63.4 million for the year ended December 31, 2021 to $90.9 million for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until and unless we can generate substantial product revenue, we expect to finance our cash needs through the proceeds from our IPO and Secondary Offering, a combination of equity offerings and debt financings, including pursuant to our ATM Offering Program, and potentially through additional license and development agreements or strategic partnerships with third parties. Financing may not be available in sufficient amounts or on reasonable terms. In addition, market volatility resulting from the ongoing conflict in Ukraine, rising inflation or other factors could adversely impact our ability to access capital as and when needed. We have no commitments for any additional financing and will likely be required to raise such financing through the sale of additional securities. If we sell equity or equity-linked securities, our current stockholders may be diluted, and the terms may include liquidation or other preferences that are senior to or otherwise adversely affect the rights of our stockholders. Moreover, if we issue debt, we may need to dedicate a substantial portion of our operating cash flow to paying principal and interest on such debt and we may need to comply with operating restrictions, such as limitations on incurring additional debt, which could impair our ability to acquire, sell or license intellectual property rights which could impede our ability to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attempting to secure additional financing may also divert our management from our day-to-day activities, which may impair or delay our ability to develop our product candidates. In addition, demands on our cash resources may change as a result of many factors currently unknown to us including, but not limited to, any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to the COVID-19 pandemic or other causes, and we may need to seek additional funds sooner than planned. Furthermore, if, in the future, one or more banks or financial institutions enter receivership or become insolvent in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened and could have a material impact on our business and financial condition. If we are unable to obtain funding on a timely basis or at all, we may be required to significantly curtail or stop one or more of our research or development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business and the business or operations of our research partners and other third parties with whom we conduct business have been and could continue to be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have business operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic and preventative measures taken to mitigate the impact of the pandemic disrupted economic activity and business operations worldwide, including the San Francisco Bay Area, where our primary operations are located. The emergence of another health epidemic, including future outbreaks of COVID-19 variants, could result in similar disruptions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, as well as the operations of some of our contract research organizations (&#34;CROs&#34;), contract development and manufacturing organizations (&#34;CDMOs&#34;), and clinical trial sites, were impacted by the COVID-19 pandemic and may in the future be similarly impacted by further outbreaks of COVID-19 variants or other health epidemics. For example, we experienced  some delays in construction of our cGMP manufacturing facilities and in our internal research efforts as a result of the COVID-19 pandemic. COVID-19 also caused global supply shortages of certain materials, such as certain raw materials, cell culture media, disposable plastics, and equipment, that we and our CDMOs use for research and cGMP manufacturing. Due to the COVID-19 pandemic, some of our CROs experienced employee turnover/attrition, delays, or disruptions and some of our clinical trial sites had to temporarily restrict enrollment into clinical protocols. Supply chain and operational disruptions due to COVID-19 contributed to certain enrollment delays in our NKX101 clinical trial. In addition, we had minor delays in setting up clinical sites in our NKX019 clinical trial due to COVID-19 restrictions due to repurposing of healthcare personnel and facilities to support local pandemic efforts. We will continue to monitor the impact of COVID-19 and any future waves of the COVID-19 pandemic or other health epidemics on our operations, including on continued enrollment in our NKX101 and NKX019 clinical trials, as well as on our collaboration partners, CROs, CDMOs, and clinical trial sites. The COVID-19 pandemic has also impacted, and may impact in the future, the regulatory authorities to which we are subject in our industry, which may, in turn, hamper or delay our clinical development efforts. We periodically interact with health authorities such as the FDA to obtain advice, or reach consensus, on our ongoing clinical trials, product development, and manufacturing activities. If FDA personnel prioritize pandemic related efforts, we may experience delays in obtaining periodic advice which may affect our ability to move our clinical programs forward into the next phase of development.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the potential future impacts of a further spread of COVID-19, including its variants, or the emergence of another health epidemic on us, our research partners, including CRISPR, and other third parties with whom we conduct business. As a result of the COVID-19 pandemic or other pandemic, epidemic or outbreak of an infectious disease, we have experienced and/or may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in enrolling patients in our clinical trials, including our ongoing NKX101 and NKX019 clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff and in training medical personnel on how to properly thaw and administer our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in recruitment of key personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines, including the review of Investigational New Drug (&#34;IND&#34;) or other regulatory submissions for our product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of, or delays in receiving, supplies of our product candidates, or materials necessary for production of our product candidates, from our vendors or contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery or supply systems; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of, or delays in manufacture of our product candidates, including at our in-house manufacturing facility and CDMOs, due to staffing shortages, production slowdowns and disruptions or inability to procure critical raw materials or other supplies in a timely fashion;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or disruptions in the planning, construction or qualification of our cGMP facility for commercial-scale manufacture of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruptions in preclinical studies due to restricted or limited operations at our laboratory facility;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruptions, or delays in receiving supplies and materials necessary for our business operations, and research and development activities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increases in the cost of services or supplies necessary for our research and development activities; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption or delays to our discovery and clinical activities. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 30, 2023, it was announced that the U.S. public health emergency declarations related to COVID-19 will end on May 11, 2023. On January 31, 2023, the FDA indicated that it would soon issue a Federal Register notice describing how the termination of the public health emergency will impact the agency&#x2019;s COVID-19 related guidances, including the clinical trial guidance and updates thereto. At this point, it is unclear how, if at all, these developments will impact our efforts to develop and commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain. The extent of any delays or impacts will depend on future developments that are highly uncertain and cannot be predicted with confidence, but these delays could have a material impact on our business, financial condition, and/or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business and Industry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business depends upon the success of our CAR NK cell technology platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends on our ability to utilize our chimeric antigen receptor-natural killer cell (&#34;CAR NK&#34;) technology platform to generate product candidates, to obtain regulatory approval for product candidates derived from it, and to then commercialize our product candidates addressing one or more indications. Phase 1 clinical trials to evaluate our first two CAR NK product candidates in humans is ongoing. All of our product candidates developed from our technology platform will require significant additional clinical and non-clinical development, review and approval by the FDA or other regulatory authorities in one or more jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before they can be successfully commercialized. If any of our product candidates encounter safety or efficacy problems, developmental delays or regulatory issues or other problems, such problems could impact the development plans for our other product candidates because all of our product candidates are based on the same core CAR NK engineering technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Utilizing CAR NK cells represents a novel approach to the treatment of cancer, and we must overcome significant challenges in order to develop, commercialize and manufacture our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have concentrated our research and development efforts on utilizing CAR NK cells as an immuno-oncology therapy. To date, the FDA has approved only a few cell-based therapies for commercialization and no natural killer (&#34;NK&#34;)-based cell therapy has been approved for commercial use by any regulatory authority. The processes and requirements imposed by the FDA or other applicable regulatory authorities may cause delays and additional costs in obtaining approvals for marketing authorization for our product candidates. Because our CAR NK platform product candidates are novel, and cell-based therapies are relatively new, regulatory agencies may lack precedents for evaluating product candidates like our CAR NK product candidates. As the cell therapy field develops further, the processes and requirements imposed by the regulatory agencies may evolve in a manner that adversely impacts us. The novelty of our product candidates may lengthen the regulatory review process, including the time it takes for the FDA to review our IND applications if and when submitted, increase our development costs and delay or prevent approval and commercialization of our CAR NK platform product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, advancing novel immuno-oncology therapies creates significant challenges for us, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enrolling sufficient numbers of patients in clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">training a sufficient number of medical personnel on how to properly thaw and administer our cells, especially in any solid tumor trial wherein the cells are given through a procedure by trained medical doctors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">training a sufficient number of medical and clinical laboratory personnel in the proper collection and handling of clinical samples in our clinical trials to enable a sufficient understanding of CAR NK pharmacokinetics and pharmacodynamics for the design of an optimal dosing regimen;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">educating medical personnel regarding the potential side-effect profile of our cells and, as the clinical program progresses, on observed side effects with the therapy;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing a reliable and safe and an effective means of genetically modifying our cells; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing and cryopreservation our cells on a large scale and in a cost-effective manner;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sourcing starting material suitable for clinical and commercial manufacturing; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing sales and marketing capabilities, as well as developing a manufacturing process and distribution network to support the commercialization of any approved products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We must be able to overcome these challenges in order for us to develop, commercialize and manufacture our product candidates utilizing CAR NK cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain aspects of the function and production of CAR NK cells are currently unknown or poorly understood, and may only become known through further preclinical testing and clinical trials. Any potential re-engineering required may result in delays and additional expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current clinical experience with NK cell therapy is predominantly based on cells from haplomatched donors, i.e., at least half of the major Human Leukocyte Antigen (&#34;HLA&#34;), types matched between donor and recipient. Our ongoing NKX101 Phase 1 clinical trial evaluated product manufactured from patient specific haplo-related donors and completely unrelated donors (used off the shelf). Based on preliminary clinical results, we have moved forward into expansion cohorts and further development of NKX101 using off the shelf product only. There is a risk that the early clinical results may not be reflective of future clinical trial results which may require us to re-evaluate HLA matching. If it becomes apparent through future preclinical testing or clinical trials that such matching is required, the production of NKX101, NKX019, and our other product candidates as standardized, off-the-shelf products for all patients will not be achievable. Instead, we would need to establish an alternative approach for each of our product candidates to achieve coverage of the addressable patient population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the killer immunoglobulin-like receptor (&#34;KIR&#34;), is found on the surface of NK cells and recognizes certain HLA types. If there is a match between KIR and the HLA type, KIR acts as a natural inhibitor of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NK activity, thereby serving to prevent immune reactions against an individual&#x2019;s own cells. In both NKX101 and NKX019 Phase 1 clinical trials, product is administered regardless of specific KIR phenotype. As we continue our clinical trials, we may discover that retaining a KIR mismatch is required to achieve clinically meaningful activity, and we may need to factor KIR mismatch into the donor and product selection process for patients enrolled in our clinical trials. We also continue to analyze for donor characteristics that correlate with clinical activity and we may decide to select for donors to enhance activity of our products in the clinic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, tumors are sometimes able to evade detection by naturally occurring NK cells by shedding the NKG2D ligands found on malignant cells. While NKX101 has been engineered to resist this shedding mechanism, there can be no guarantee that tumor cells will not retain or regain the ability to shed NKG2D ligand completely despite the presence of NKX101, which would give such tumors a degree of resistance against NKX101. If we discover that tumors develop a resistance to NKX101 as a result of such NKG2D ligand shedding, we will need to reengineer NKX101 to counteract this effect, or we may need to change or abandon our development efforts for NKX101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finally, there is limited history of CAR NK cells manufacturing for clinical use, and our understanding of NK cell biology is continuously expanding. If we find that our current manufacturing processes are inadequate, or should we identify opportunities for material improvement, adaptation of process improvements may require significant periods of time. Process improvements might also necessitate new pre-clinical studies and clinical protocols to establish product comparability. If we are unable to show comparability after a process change, further changes to our manufacturing process and/or clinical trials will be required. For example, if sufficient comparability is not shown, we may be required to repeat one or more clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing processes would require us to redesign the clinical protocols and clinical trials for our product candidates and could require significant additional time and resources to complete and the participation of a significant number of additional clinical trial participants and donors, any of which would delay the clinical development of our product candidates and their eventual commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and we may encounter substantial delays due to a variety of reasons outside our control.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials are expensive, time consuming and subject to substantial uncertainty. Failure can occur at any time during the clinical trial process, due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. We, the FDA, or other applicable regulatory authorities may suspend or terminate clinical trials of a product candidate at any time for various reasons, including, but not limited to, a belief that subjects participating in such trials are being exposed to unacceptable health risks or adverse side effects, or other adverse initial experiences or findings. The FDA, or other applicable regulatory authorities may also require us to conduct additional preclinical studies or clinical trials due to negative or inconclusive results or other reasons, fail to approve the raw materials, manufacturing processes or facilities of third-party manufacturers upon which we rely, find deficiencies in the manufacturing processes or facilities upon which we rely, and change their approval policies or regulations or their prior guidance to us during clinical development in a manner rendering our clinical data insufficient for approval. In addition, data collected from clinical trials may not be sufficient to support the submission of a BLA, MAA or other applicable regulatory filings. We cannot guarantee that any clinical trials that we may plan or initiate will be conducted as planned or completed on schedule, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A failure of one or more of our clinical trials could occur at any stage,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and any failure could prevent us from obtaining the FDA and other regulatory approvals necessary to commercialize our product candidates. Events that may prevent successful initiation, timely completion, or positive outcomes of our clinical development include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining regulatory approval to commence a clinical trial; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective clinical trial sites or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different trial sites and CROs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to recruit sufficient patients for our clinical trials in a timely manner or at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in achieving a sufficient number of clinical trial sites or obtaining the required institutional review board (&#34;IRB&#34;), approval at each clinical trial site; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a temporary or permanent clinical hold by us or by the FDA or other regulatory agencies based on emerging data; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to obtain long-term follow-up data due to patient drop out or in cases where patients elect to receive post-protocol treatment for their disease before it progresses;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension or termination of a clinical trial by the IRB of the institutions in which such trials are being conducted or by the Data Safety Monitoring Board (&#34;DSMB&#34;) (where applicable); </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials, or production delays, shutdowns or setbacks at any of our contract manufacturers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays due to additional regulatory, site and clinical trial participant approvals required if a product candidate, especially a product candidate custom manufactured for a specific patient, does not meet the required specifications;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulatory requirements or guidance that may require us to amend or submit new clinical protocols, or such requirements may not be as we anticipate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the standard of care or treatment landscape on which a clinical development plan was based, which may require new or additional trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">insufficient quantities or inadequate quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates, including potential limitations to the availability of agents such as fludarabine, cyclophosphamide, or other agents administered to patients prior to treatment or in combination with our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, or additional administrative burdens associated with foreign regulatory schemes; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of ourselves or any third-party manufacturers, contractors or suppliers to comply with regulatory requirements, maintain adequate quality controls, or be able to provide sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, disruptions caused by or related to the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing preclinical studies and clinical trials, as applicable. For example, we periodically interact with health authorities such as the FDA to obtain advice, or reach consensus, on our ongoing clinical trials, product development, and manufacturing activities. If these health authorities need to prioritize efforts related to futurewaves of the COVID-19 pandemic or other health epidemics, then we may experience delays in obtaining periodic advice which may affect our ability to move our clinical programs forward into the next phase of development. For instance, in 2020,  the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities and implemented various policies and systems to prioritize domestic inspections in response to the COVID-19 pandemic The FDA resumed conducting domestic surveillance inspections on February 7, 2022, but if the FDA or regulatory authorities outside the U.S. adopt similar restrictions or other policy measures in response to future waves of the COVID-19 pandemic or other health epidemics in the future, we may experience delays in their regulatory activities. If global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As regulatory expectations regarding the genome editing of cellular therapies continue to evolve with data emerging on chromosomal abnormalities from CAR T therapies or other sources, our pipeline programs that involve gene-edited cells, including an allogeneic, off-the-shelf CAR NK product candidate targeting the CD70 tumor antigen (&#34;NKX070&#34;) and an allogeneic, off-the-shelf product candidate that comprises both engineered NK cells and engineered T cells (&#34;NK+T&#34;) programs on which we are collaborating with CRISPR could be impacted. For example, the FDA may require additional or new release assays for manufactured lots of any product candidates that have been gene edited, which, as a result, could slow development of our gene-edited product candidates and increase expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience further delays in the initiation, enrollment or completion of any preclinical study or clinical trial of our product candidates, or if any preclinical studies or clinical trials of our product candidates are canceled, the commercial prospects of our product candidates may be materially adversely affected, and our ability to generate product revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs and slow down our product candidate development and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is highly dependent on the clinical success of our product candidates, and on the clinical success of NKX101 and NKX019 in particular, and we may fail to develop NKX101, NKX019 and/or our other product candidates successfully or be unable to obtain regulatory approval for them.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot guarantee that NKX101 and NKX019, or any of our other product candidates, will be safe and effective, or will be approved for commercialization, on a timely basis or at all. Although certain of our employees have prior experience with clinical trials, regulatory approvals, and cGMP manufacturing, we have not previously completed any clinical trials or submitted a BLA to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that NKX101 and NKX019, or any of our other product candidates, will be successful in clinical trials or receive regulatory approval. The FDA, and other comparable global regulatory authorities can delay, limit or deny approval of a product candidate for many reasons. For further details about such reasons, see &#x201c;&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and we may encounter substantial delays due to a variety of reasons outside our control.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; Any delay in obtaining, or inability to obtain, applicable regulatory approval will delay or harm our ability to successfully commercialize NKX101, NKX019, or any of our other product candidates, and could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX101 is in an early-stage clinical trial and is subject to the risks inherent in drug development. In April 2022, we announced preliminary data from our Phase 1 clinical trial of NKX101 for the treatment of relapsed or refractory acute myeloid leukemia (&#34;r/r AML&#34;) or higher risk myelodysplastic syndromes (&#34;MDS&#34;). If the ongoing Phase 1 or our later clinical trials of NKX101 encounter concerning safety signals, efficacy concerns, manufacturing problems, enrollment issues, development delays, regulatory issues, or other problems, our development plans for NKX101 could be significantly impaired, which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also develop NKX101 for additional indications if we are able to obtain clinical proof-of-concept from our NKX101 Phase 1 trials for blood cancers including r/r AML and MDS. We may not be able to advance any of these indications through the development process. Even if we receive regulatory approval to market NKX101 for the treatment of any of these additional indications, any such additional indications may not be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize NKX101 for these additional indications, our commercial opportunity will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the potential development of NKX101 for treating solid tumors is subject to a number of risks related to use of cell therapies in general including a hostile tumor microenvironment and trafficking to tumor site. Additional risks from direct liver delivery of a cell therapy using a catheter through the hepatic artery generally include potential damage to arteries from the catheter placement itself, from use of imaging contrast, radiation exposure, and differences between catheter models potentially introducing variability into the observed clinical effects. The development of treatments to treat solid tumors often requires larger and more expensive clinical trials than for treating blood cancers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we announced data from the dose escalation portion of the multi-center Phase 1 clinical trial of NKX019 for the treatment of B-cell malignancies. The dose-expansion portion of the Phase 1 study is ongoing.  NKX019 is being investigated in dose expansion cohorts as a combination therapy with rituximab, as well as a monotherapy, in both patients with large B-cell lymphoma (&#34;LBCL&#34;) who have previously received autologous CD19 CAR T-cell therapy and those who have not.  Due to the availability of multiple commercially available agents that target CD19, as well as others that are in various stages of commercialization, we have had increasing difficulty, and may continue to have increased difficulty, enrolling subjects into trials with NKX019 who have not previously been exposed to a CD19- directed cellular therapy. This could impact the ability to obtain data about NKX019 activity in certain patient populations and slow enrollment. If our ongoing Phase 1 or later clinical trials of NKX019 encounter safety, efficacy, manufacturing problems, enrollment issues, development delays, regulatory issues, or other problems, our development plans for NKX019 could be significantly impaired, which could materially adversely affect our business, financial condition, results of operations and growth prospects.  Furthermore, because NKX101 and NKX019 are our most advanced product candidates, and because our other product candidates are based on similar technology, if our clinical trials of NKX101 or NKX019 experience any of the foregoing issues, our development plans for our other product candidates in our pipeline could also be significantly impaired, which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to develop our product candidates both as monotherapy and potentially as combination therapy, a common form of cancer treatment, with one or more currently approved cancer therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the combination therapy used with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also evaluate our product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying and qualifying patients to participate in our clinical trials is critical to our success. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease that the product candidate is intended to treat and who meet other eligibility criteria. The rates of patient enrollment, a significant component in the timing of clinical trials, are affected by many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to open clinical trial sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design and eligibility criteria of the clinical trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of subjects to clinical sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changing medical practice patterns or guidelines related to the indications we are investigating; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competing clinical trials or approved therapies which present an attractive alternative to patients and their physicians; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perceived risks and benefits of the product candidate under study, including as a result of adverse effects observed in similar or competing therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patient consents due to various reasons; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that enrolled subjects will drop out or die before completion of the trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patients failing to complete a clinical trial or returning for post-treatment follow-up;  </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to manufacture the requisite supply of our product candidates for a patient and clinical trials; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any failure or any delay by us or by our clinical sites to obtain sufficient quantities of components and supplies necessary for the conduct of our clinical trials, including any inability to obtain agents such as cyclophosphamide, fludarabine, or other agents administered to patients prior to treatment or in combination with our product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we need to compete with many ongoing clinical trials to recruit patients into our expected clinical trials. Our clinical trials may also compete with other clinical trials of product candidates that are in a similar cellular immunotherapy area as our product candidates, and this competition could reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial site. If we are unable to enroll a sufficient number of patients in our clinical trials in a timely manner, our completion of clinical trials may be delayed or may not be achieved, which would prevent us from further developing or commercializing our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical development of our product candidates depends on our ability to manufacture and provide the requisite supply of our product candidates for our clinical trials. Any failure or delays by us to manufacture and provide our product candidates in sufficient quantity and quality for the conduct of our clinical trials, may delay our ability to enroll and treat patients in, or complete, our current or future clinical trials of our product candidates on time, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical development of our product candidates also depends on the availability of a sufficient supply of certain other materials and agents used in our clinical trials. For example, certain of our clinical trial protocols require the use of fludarabine and cyclophosphamide, agents which are routinely used in oncology studies, and which we use in certain of our clinical trial protocols to condition patients for treatment with our product candidates. Further, we may develop certain of our product candidates as a combination therapy with other cancer therapies, which would require the availability and use of those therapeutic agents in certain of our clinical trial protocols. Recently, the FDA reported a shortage of fludarabine and it is uncertain how long the fludarabine shortage may last. Certain of our clinical trial sites have reported that they are experiencing a shortage of fludarabine, which has resulted in some enrollment delays. We do not know how long the fludarabine shortage may last. Any failure or delays by us or by our clinical sites to obtain sufficient quantities of fludarabine or other components and agents necessary for the conduct of our clinical trials, may delay our ability to enroll and treat patients in, or complete, our current or future clinical trials of our product candidates on time, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to enroll a sufficient number of patients in our clinical trials in a timely manner, our completion of clinical trials may be delayed or may not be achieved, which would prevent us from further developing or commercializing our product candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our preclinical pipeline programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to obtain FDA or other regulatory authority approval to market a new biological product we must demonstrate proof of safety, purity, potency and efficacy in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned INDs in the United States. We began clinical development for our first product candidate, NKX101, in 2020 and our second product candidate, NKX019, in 2021, and the rest of our programs are in preclinical development. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Any delays in preclinical testing and studies conducted by us or potential future partners may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on acceptable clinical trial design or manufacturing process; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA not allowing us to rely on previous findings of safety and efficacy for other similar but approved products and published scientific literature. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, because standards for pre-clinical assessment are evolving and may change rapidly, even if we reach an agreement with the FDA on a pre-IND proposal, the FDA may not accept the IND submission as presented, in which case patient enrollment would be placed on partial or complete hold and treatment of enrolled patients could be discontinued while the product candidate is re-evaluated. Even if clinical trials do begin for our preclinical programs, our clinical trials or development efforts may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The results of preclinical studies and early-stage clinical trials may not be predictive of future results. Interim, &#x201c;topline&#x201d; and preliminary data from our clinical trials may differ materially from the final data. Initial success in any clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence may not be predictive of the results of the later-stage clinical trials. For example, preclinical models as applied to cell therapy in oncology do not adequately represent the clinical setting, and thus cannot predict clinical activity nor all potential risks, and may not provide adequate guidance as to appropriate dose or administration regimen of a given therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publicly disclose preliminary or &#x201c;topline&#x201d; data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial, including as patient enrollment continues and more data on existing patients becomes available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report, including the preliminary Phase 1 clinical data for NKX101 and NKX019 reported in April 2022 and updated Phase 1 clinical data for NKX019 reported in December 2022, may differ from, and may not be indicative of, future results of the same clinical trials, or different conclusions or considerations may qualify such topline results once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available and negative differences between preliminary or interim data and final data could materially adversely affect the prospects of any product candidate that is impacted by such data updates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically a summary of extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our product candidates, or any competing product candidates, demonstrate relevant, serious adverse events, we may be required to halt or delay further clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label than anticipated or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preliminary data from our NKX101 Phase 1 clinical trial were reported in April 2022, and updated data from the dose escalation portion of our NKX019 Phase 1 clinical trial were reported in December 2022.  The most common higher-grade adverse events in the early data for both trials were myelosuppression &#x2013; a condition resulting in fewer red blood cells, white blood cells and platelets, which is common in the treated patient populations post lymphodepleting conditioning (&#34;LD&#34;). The early data from the NKX101 clinical trial indicated that adverse events experienced by certain patients included infusion reactions, such as transient fever and fluid responsive hypotension. In the dose escalation phase of the NKX019 Phase 1 clinical trial, certain patients experienced adverse events including transient fevers and infusion-related reactions. Three patients in the NKX019 dose escalation study were assessed to have cytokine release syndrome (&#34;CRS&#34;), despite the rapid onset and rapid resolution, not consistent with previously described presentations of CRS with CAR T cell therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the preliminary data reported from our NKX101 and NKX019 Phase 1 clinical trials indicate that NK cell-based therapies may be better-tolerated as compared to T cell-based therapies due to biologic differences between these cell types, there can be no assurance that patients will not experience CRS, neurotoxicity, Graft-versus-host disease (&#34;GvHD&#34;), or other serious adverse events associated with our specific product candidates NKX101 or NKX019. NKX101 targets NKG2D ligands, which is not yet a well-characterized modality. NKG2D targets multiple ligands, and the extent and impact of ligand expression is currently not fully characterized. For example, there are risks that ligands may be expressed on either known or an as-yet-underappreciated population of healthy cells. Therefore, such cells may also be targeted by NKX101 and lead to adverse events of unknown frequency and severity as well as potentially decreased efficacy. Such adverse events may cause delays in completion of our clinical programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If unacceptable side effects arise in the development of our product candidates such that there is no longer a positive benefit-risk profile, we, the FDA, the IRBs at the institutions in which our trials are conducted, or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, and inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek special designations by the regulatory authorities to expedite regulatory approvals, but may not be successful in receiving such designations, and even if received, they may not benefit the development and regulatory approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek various expedited programs available through regulatory authority such as Regenerative Medicine Advanced Therapy (&#34;RMAT&#34;) designation, Breakthrough Therapy designation, Fast Track designation, or PRIority MEdicine (&#34;PRIME&#34;), from regulatory authorities, for any product candidate that we develop. A product candidate may receive RMAT designation from the FDA if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening condition, and preliminary clinical evidence on a clinically meaningful endpoint, indicates that the product candidate has the potential to address an unmet medical need for such condition. A breakthrough therapy is defined by the FDA as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation by the FDA. PRIME is a voluntary scheme launched by the European Medicines Agency (&#34;EMA&#34;), to strengthen support for the development of medicines that target an unmet medical need through enhanced interaction and early dialogue with developers of promising medicines in order to optimize development plans and speed up evaluation to help such medicines reach patients earlier.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Seeking and obtaining these designations is dependent upon results of our clinical program, and we cannot guarantee whether and when we may have the data from our clinical programs to support an application to obtain any such designation. The FDA and the EMA, as applicable, have broad discretion whether or not to grant any of these designations, so even if we believe a particular product candidate is eligible for one or more of these designations, we cannot assure you that the applicable regulatory authority would decide to grant it. Even if we do receive the designations we may apply for, we may not experience a faster development process, review or approval compared to conventional FDA or EMA procedures, as applicable. The FDA or EMA, as applicable, may rescind any granted designations if it believes that the designation is no longer supported by data from our clinical development program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek and obtain orphan drug designation for our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively low prevalence populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. On December 16, 2021, we announced that the FDA granted orphan drug designation to NKX101 for the treatment of AML.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, in Europe, the European Commission grants orphan drug designation after receiving the opinion of the EMA Committee for Orphan Medicinal Products on an orphan drug designation application. orphan drug designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances (&#x201c;sameness&#x201d;). The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable such that market exclusivity is no longer justified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain orphan drug exclusivity for our product candidates, that exclusivity may not effectively protect those product candidates from competition because different therapies can be approved for the same condition and the same therapies can be approved for different conditions but used off-label. Even after an orphan drug is approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for applicable indications for our product candidates, we may never</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Public opinion and scrutiny of cell-based immuno-oncology therapies for treating cancer may impact public perception of our company and product candidates, or impair our ability to conduct our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our platform utilizes a relatively novel technology involving the genetic modification of human NK cells derived from adult healthy donors, and utilization of those modified cells in other individuals, and no NK cell-based immunotherapy has been approved to date. Further, many other cell therapies are in development, including NK cells derived from induced pluripotent stem cells (iPSCs), and negative results from those therapies may affect perception of NK cell therapy derived from adult healthy donors. Public perception may be influenced by claims, such as claims that NK cell-based immunotherapy is ineffective, unsafe, unethical, or immoral and, consequently, our approach may not gain the acceptance of the public or the medical community. Negative public reaction to cell-based immunotherapy in general could result in greater government regulation and stricter labeling requirements of cell-based immunotherapy products, including any of our product candidates, and could cause a decrease in the demand for any products we may develop. Adverse public attitudes may adversely impact our ability to enroll clinical trials. More restrictive government regulations or negative public opinion could have an adverse effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business depends upon our ability to identify, develop and commercialize product candidates. A key element of our strategy is to discover and develop additional product candidates based upon our NK cell engineering platform. We are seeking to do so through our internal research programs and may also explore strategic collaborations for the discovery of new product candidates. Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. In addition, targets for different cancers may require changes to our NK manufacturing platform, which may slow down development or make it impossible to manufacture our product candidates. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the research methodology or technology platform used may not be successful in identifying potential product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competitors may develop alternatives that render our product candidates obsolete or less attractive; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may choose to cease development if we determine that clinical results do not show promise; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates we develop may nevertheless be covered by third parties&#x2019; patents or other exclusive rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have limited resources, we must choose to pursue and fund the development of specific types of treatment, or treatment for a specific type of cancer, and we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our estimates regarding the potential market for our product candidates could be inaccurate, and if we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of these events occur, we may be forced to abandon or delay our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If third parties that we rely on to conduct clinical trials do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have the ability to independently conduct clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs to conduct or otherwise support clinical trials for our product candidates. We rely heavily on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs and other third parties will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to untitled letters, warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and the third parties on which we rely for clinical trials are required to comply with regulations and requirements, including GCPs for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the competent authorities of the European Union member states, and comparable foreign regulatory authorities for any drugs in clinical development. The FDA enforces GCP requirements through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or these third parties fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials not deviate from GCP. In addition, our clinical trials must be conducted with product candidates produced under cGMP regulations. Our failure or the failure of these third parties to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process and could also subject us to enforcement action. The COVID-19 pandemic and government measures taken in response have also had a significant impact on our CROs, and we expect that they will face further disruption, which may affect our ability to initiate and complete our preclinical studies and clinical trials. We also are required to register certain ongoing clinical trials and provide certain information, including information relating to the trial&#x2019;s protocol, on a government-sponsored database, ClinicalTrials.gov, within specific timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we intend to design the clinical trials for our product candidates, we plan to rely on third parties to conduct our clinical trials. As a result, many important aspects of our clinical development, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future clinical trials will also result in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have staffing difficulties; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fail to comply with contractual obligations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience regulatory compliance issues; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undergo changes in priorities or become financially distressed; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">form relationships with other entities, some of which may be our competitors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If third parties do not perform our clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, we would be unable to rely on clinical data collected by these third parties and may be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct, which could significantly delay commercialization and require significantly greater expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms, or at all. If third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such third parties are associated with may be extended, delayed or terminated, and we may not be able to obtain marketing approval for or successfully commercialize our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are not able to establish pharmaceutical or biotechnology collaborations on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our programs, we may seek to collaborate with pharmaceutical and biotechnology companies to develop and commercialize such product candidates, such as our recent collaboration with CRISPR. Any of these relationships, including our relationship with CRISPR, may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, relinquish valuable rights to our product candidates, or disrupt our management and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for new collaborations will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view them as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development and commercialization of our product candidates, which would harm our business prospects, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have entered into a research collaboration with CRISPR Therapeutics regarding certain product candidates, and we may enter into additional collaborations with third parties to develop or commercialize other product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">candidates. Our prospects with respect to those product candidates will depend in significant part on the success of those collaborations, and we may not realize the benefits of such collaborations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may form strategic alliances or create joint ventures or collaborations with respect to our product candidates that we believe will complement or augment our existing business. We routinely engage, and are engaged, in partnering discussions with a range of pharmaceutical and biotechnology companies and could enter into new collaborations at any time. If we enter into a collaboration, strategic alliance or license arrangement, there is no guarantee that the collaboration will be successful, or that any future partner will commit sufficient resources to the development, regulatory approval, and commercialization effort for such products, or that such alliances will result in us achieving revenues that justify such transactions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, we entered into a Research Collaboration Agreement with CRISPR (as amended, the &#34;CRISPR Agreement&#34;) to establish research plans for the purpose of collaboratively designing and advancing allogeneic, gene-edited NK cell therapies and an allogeneic, gene-edited NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease up to the filing of an application to a regulatory authority to request the ability to start a clinical trial. See Item 1, Business for additional information. If CRISPR, or any potential future collaboration partner, does not perform in the manner that we expect or fulfill their responsibilities in a timely manner or at all, the research, clinical development, regulatory approval and commercialization efforts related to the product candidates that are the subject of the collaboration with CRISPR, or that potential future collaboration partner, could be delayed or terminated.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we terminate the CRISPR Agreement in its entirety or with respect to a particular product candidate under the research collaboration with CRISPR, due to a material breach by CRISPR or CRISPR&#x2019;s insolvency, then we have the right to negotiate a license from CRISPR to continue research, development, and commercialization of the terminated product candidate(s) on our own at our sole expense. We would need to pay CRISPR milestones and royalties for the terminated product candidate(s), and we may not be able to negotiate terms to the license that are favorable to us. Furthermore, assumption of sole responsibility for further development would greatly increase our expenditures and may mean we would need to limit the size and scope of one or more of our programs, seek additional funding and/or choose to stop work altogether on one or more of the affected product candidates. This could result in a limited potential to generate future revenue from such product candidates, and our business could be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whenever we enter into collaborations with third parties, we could face the following risks:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products and processes that compete directly or indirectly with our products or product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation, or other intellectual property proceedings; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaboration agreements may restrict our right to independently pursue new product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If conflicts arise between our collaborators and us, including CRISPR, our collaborators may act in a manner adverse to us and could limit our ability to implement our strategies. CRISPR or future collaborators may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our product candidates. Our collaborators may preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could harm our product development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result, we may not be able to realize the benefit of new or existing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaboration agreements and strategic partnerships if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to compete effectively with academic institutions and other biopharmaceutical companies that develop similar or alternatives to cellular immunotherapy product candidates, our business will be materially adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of new cellular immunotherapy products is highly competitive. We face competition from existing and future competitors with respect to each of our product candidates currently in development, and will face competition with respect to other product candidates that we may seek to develop or commercialize in the future. For example, the autologous cell therapies Kymriah</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Yescarta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Tecartus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Breyanzi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which have been commercially approved, are direct competitors to our product candidate NKX019. In addition, other competitors, including biopharmaceutical companies, have clinical-stage or earlier stage allogenic programs, and a number of other companies are seeking to harness NK biology through engagers that seek to direct a patient&#x2019;s own NK cells to the site of a tumor or are investigating other types of immune cells. Other biopharmaceutical companies are developing bi-specific antibodies, which are also direct competitors to NKX019. Numerous academic institutions are also conducting preclinical and clinical research in these areas, as well as with other white blood cell types including NKT cells and gamma-delta T cells. It is also possible that new competitors, including those developing similar or alternatives to cellular immunotherapy product candidates, may emerge and acquire significant market share. Such competitors may have an advantage over us due to their greater size, resources or institutional experience, or may develop product candidates that are safer, more effective, more widely accepted, more cost-effective or enable higher patient quality of life than ours. More established biopharmaceutical companies may also develop and commercialize their product candidates at a faster rate, which could render our product candidates obsolete or non-competitive before they are fully developed or commercialized. If we are not able to compete effectively against our existing and potential competitors, our business, financial condition, results of operations and growth prospects may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 163 full-time employees. We will need to continue to expand our managerial, operational, clinical, quality, human resources, legal, manufacturing, supply chain, finance, commercial and other resources in order to manage our operations and clinical trials, continue our development activities and eventually commercialize our product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">discover new product candidates, develop the process and analytical methods for IND-enabling studies and FDA submissions, complete the required IND-enabling studies for each, and receive approval from the FDA and other regulatory authorities to initiate clinical trials for such product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manage our clinical trials effectively; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identify, recruit, retain, incentivize and integrate additional employees; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expand into additional office and laboratory space as we grow our employee base;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complete the qualification of our in-house clinical GMP manufacturing facility and establish and validate a commercial GMP manufacturing facility; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to improve our operational, financial and management controls, reports systems and procedures. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to attract skilled employees, increase the size of our organization or manage our future growth effectively, it will impair our ability to execute our business strategy and our business, financial condition, results of operations and growth prospects will be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to attract and retain senior management, clinical, and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly our chief executive officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our future product candidates. We do not have employment agreements with our senior management team.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition for qualified personnel in the biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and manufacturing activities, or if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. If we are unable to hire and retain the qualified personnel we need to operate our business, our business, financial condition, results of operations and growth prospects would be materially adversely affected. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for any product candidate that we may develop; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant time and costs to defend the related litigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased insurance costs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any product candidate that we may develop; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation and significant negative media attention. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any such outcomes could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our insurance policies may be inadequate, may not cover all of our potential liabilities and may potentially expose us to unrecoverable risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not carry insurance for all categories of risk that our business may encounter. Although we maintain product liability insurance coverage that also covers our clinical trials, such insurance may not be adequate to cover all liabilities that we may incur, and we may be required to increase our product liability insurance coverage. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify. However, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. Any significant uninsured liability may require us to pay substantial amounts, which would materially adversely affect our business, financial condition, results of operations and growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, although we are dependent on certain key personnel, we do not have any key man life insurance policies on any such individuals. Therefore, if any of our chief executive officer or other executive officers die or become disabled, we will not receive any compensation to assist with such individual&#x2019;s absence. The loss of such person could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development and manufacturing activities and our third-party manufacturers&#x2019; and suppliers&#x2019; activities involve the controlled storage, use and disposal of hazardous materials owned by us. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#x2019; facilities pending their use and disposal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot eliminate the risk of contamination, which could cause an interruption of our research and development efforts and business operations, including drug supply and inventory, and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers and suppliers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. Any contamination by such hazardous materials could therefore materially adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business could be negatively impacted by the failure to address emerging environmental, social, and corporate governance matters.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is an increasing focus from investors, employees, business partners, and other stakeholders concerning environmental, social, and corporate governance (&#34;ESG&#34;) matters. The expectations related to ESG matters are rapidly evolving and, while we have internal efforts directed at ESG matters and preparations for any increased required future disclosures, we may be perceived to not be adequately addressing these matters, which could negatively impact our reputation and our business. Moreover, the SEC has recently proposed, and may continue to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">propose, certain mandated ESG reporting requirements, such as the SEC&#x2019;s proposed rules designed to enhance and standardize climate-related disclosures, which, if finally approved, would significantly increase our compliance and reporting costs and may also result in disclosures that could have a negative impact on investor perception. In addition, we currently do not report our environmental emissions, and our lack of reporting could result in certain investors declining to invest in our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our manufacturing process is novel and complex, and we may encounter difficulties in production, or difficulties with internal manufacturing, which would delay or prevent our ability to provide a sufficient supply of our product candidates for clinical trials or our products for patients, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are genetically engineered human cells, and the process of manufacturing such product candidates, as well as engineered K562 cells and viral vectors, is complex, highly regulated and subject to numerous risks. Manufacturing our product candidates involves harvesting white blood cells from a donor, isolating the NK cells, activating and expanding the NK cells, genome editing the NK cells (for certain product candidates with such edits), introducing a gamma-retrovirus with genes encoding the proteins we wish to express, cryopreservation, storage and eventually shipment. As a result of these complexities, the cost to manufacture our cellular product candidates, our proprietary, engineered K562 stimulatory cells (&#34;NKSTIM&#34;), and viral vector is generally higher than traditional small-molecule chemical compounds or biologics, and the manufacturing process is presently less reliable and more difficult to reproduce.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our manufacturing process will be susceptible to product loss or failure, or product variation that may negatively impact patient outcomes, due to logistical issues associated with the collection of starting material from the donor, shipping such material to the manufacturing site, shipping the final product to the clinical trial recipient, preparing the product for administration, manufacturing issues or different product characteristics resulting from the differences in donor starting materials, variations between reagent lots, interruptions in the manufacturing process, contamination, equipment or reagent failure, improper installation or operation of equipment, vendor or operator error, inconsistency in cell growth and variability in product characteristics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in any of the manufacturing facilities in which products or other materials are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any failure in the manufacturing processes could render a batch of product unusable, could impact supply and delay the progress of our clinical trials, could affect the regulatory approval of such product candidate, could cause us to incur fines or penalties or could harm our reputation and that of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our manufactured product candidates may fail to meet the required specifications for any of a variety of reasons, including variability in starting material, deviations from normal manufacturing process, or insufficient optimization of specific process steps. This failure to meet specifications could result in supply shortages, or delays related to obtaining additional regulatory, site and patient approvals to continue dosing patientsin the clinical trial. If the required additional approvals cannot be obtained, additional delays may occur as manufacturing would need to be restarted and/or the patient may be unable to remain in the study.  Any delay in the clinical development or commercialization of NKX101, NKX019, or our other product candidates could materially adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may make changes to our manufacturing process at various points during development, and even after commercialization, for various reasons, such as to control costs, achieve scale, decrease processing time, increase manufacturing success rate or for other reasons. Changes to our manufacturing process carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials, or the performance of the product once commercialized. Changes to our process made during the course of clinical development could require us to show the comparability of the product candidate used in earlier clinical phases or at earlier portions of a trial to the product candidate used in later clinical phases or later portions of the trial. It is difficult to establish comparability of cell therapy products, and this may complicate efforts to verify process changes during scale up. Other changes to our manufacturing process made before or after commercialization could require us to show the comparability of the resulting product to the product candidate used in the clinical trials using earlier processes. Such showings could require us to collect additional nonclinical or clinical data from any modified process prior to obtaining marketing approval for the product candidate produced with such modified process. If such data are not ultimately comparable to that seen in the earlier trials or earlier in the same trial in terms of safety or efficacy, or if regulatory authorities do not agree that comparability has been established, we may be required to make further changes to our process and/or undertake additional clinical testing, either of which could significantly delay the clinical development or commercialization of the associated product candidate, which would materially adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we are manufacturing NKX019 in our own internal manufacturing facility for the NKX019 Phase 1 clinical trial, and plan to manufacture other product candidates, including NKX101, in our internal manufacturing facilities in the future, we may encounter problems with the internal production of our product candidates. We believe our current clinical cGMP manufacturing facility will supply our anticipated non-pivotal clinical trial needs, but if the dose and number of cycles needed increases, our current manufacturing process may not be able to support the enrollment of trials which could lead to delays until we scale up the manufacturing. Although we have an internal cGMP manufacturing facility for the production of certain of our product candidates for our early-stage clinical trials has been completed, we do not yet have a cGMP facility for the commercial-scale manufacture of our product candidates. We have only recently begun building a commercial-scale cGMP manufacturing facility. Building a commercial-scale facility and manufacturing product candidates in our own facilities will require an increase in staff and significant internal resources. Our manufacturing facilities will be subject to compliance with regulatory requirements, which we may struggle to meet. We may encounter problems with properly staffing our internal manufacturing facilities due to hiring challenges or other issues. For example, factors such as potential future outbreaks of COVID-19 variants and related restrictions could impact our ability to properly staff production of our product candidates. We experienced delays in the construction of our cGMP manufacturing facilities due to the COVID-19 pandemic and current macroeconomic conditions and may in the future experience similar delays due to future COVID-19 outbreaks. Current inflationary pressures are negatively affecting and could continue to negatively affect the costs of constructing our commercial-scale manufacturing facility. Global supply chain disruptions, including procurement delays and long lead times on certain materials, have adversely impacted and could continue to adversely impact the scheduled completion and/or costs of constructing our commercial-scale manufacturing facility. We may also encounter problems with training the staff we have to effectively manage and control the complex manufacturing process required to produce our product candidates and comply with all necessary regulations. We may also find it difficult to properly manage supply chain issues critical to the manufacturing process. If we are unable to build, maintain, and properly staff our manufacturing facilities, manage and control the manufacturing process, and comply with regulations, the clinical development or commercialization of our product candidates could be significantly delayed, which would materially adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to manufacture certain of our product candidates, or certain materials for use in the production of our product candidates, which increases the risk that we will not have sufficient quantities of such</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">product candidates or materials, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we are building a commercial-scale manufacturing facility, we do not yet operate our own cGMP facility for the production of commercial supplies of the product candidates that we are developing or evaluating in our development programs or supplies of such product candidates for pivotal clinical trials. We have limited personnel with experience in drug manufacturing and currently lack the resources and the capabilities to manufacture any of our product candidates on a commercial scale. If we are unable to successfully build, maintain and staff our own commercial-scale cGMP facility, we will need to rely on third parties for commercial-scale manufacture of our product candidates. Although we intend to manufacture NKX101 at our cGMP facility in 2023, we currently rely on a third-party manufacturer for our clinical supply of NKX101. We compete with other companies for access to third party cGMP facilities and cannot assure continued access.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we currently outsource manufacturing of certain critical materials necessary for production of our product candidates, including NKSTIM and viral vectors. Even though we have established our own internal cGMP facility for clinical supply of certain product candidates, and even if we successfully establish our own cGMP manufacturing facility for manufacture of our product candidates on a commercial scale, we will continue to outsource manufacturing of certain materials necessary for production of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to conduct clinical trials of product candidates, we will need to have them manufactured in potentially large quantities. Our third-party manufacturers may be unable to increase the manufacturing capacity for any of our product candidates or other necessary materials in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and at any other time. If these third-party manufacturers are unable to, or do not, scale up the manufacture of our product candidates or other necessary materials in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently have any agreements with third-party manufacturers for long-term commercial supply. We may be unable to enter into agreements with third-party manufacturers for commercial supplies of any product candidate or any material necessary for production of a product candidate that we develop, or may be unable to do so on acceptable terms. Even if we establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers for either clinical or commercial supply entails risks, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reliance on the third-party for regulatory compliance and quality assurance; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible breach of the manufacturing agreement by the third-party; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP requirements or similar regulatory requirements outside the United States. The failure of our third-party manufacturers to comply with applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and/or criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the third parties that we engage to supply any materials or to manufacture any products for our preclinical tests and clinical trials should cease to continue to do so for any reason, including due to the effects of the COVID-19 pandemic and the actions undertaken by governments and private enterprises to contain COVID-19, we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively. At some of our contract manufacturing sites, COVID-19-related restrictions, including temporary shutdowns, and instances of COVID-19 cases impacting personnel have resulted in some delays.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and anticipated dependence upon others for the manufacture of our product candidates and materials necessary for production of our product candidates may adversely affect our profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are reliant on a sole supplier for certain steps of our manufacturing process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our manufacturing process for NKX101 and for NKX019 depends on the use of the Miltenyi CliniMACS Plus system, and related reagents, all of which are only available from Miltenyi as the sole supplier. In addition, some of these reagents, at the time of procurement, typically expire after approximately four to six months. This short expiration period means that stocking the reagents in large quantities for future needs would not be an effective strategy to mitigate against the risk of shortage due to disruption of the supply chain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, while many of the reagents and consumables used in our manufacturing process are available from more than one commercial supplier, we have not confirmed the suitability of the use of all such reagents and consumables in our manufacturing process. Even if we are able to replace any raw materials or consumables with an alternative, such alternatives may cost more, result in lower yields or not be as suitable for our purposes. In addition, some of the raw materials that we use are complex materials, which may be more difficult to substitute. Therefore, supply disruptions could result in delays and additional regulatory submissions and prevent us from being able to manufacture our product candidates due to the unsuitability of the substituted reagent or consumable that we are able to procure. Substitution of some or all of these reagents and materials may require substantial changes to our manufacturing process, which may require us to establish product comparability. If we are unable to show comparability after a process change, further changes to our manufacturing process and/or clinical trials will be required. For example, if sufficient comparability is not shown, we may be required to repeat one or more clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any disruption in supply of these instruments and reagents could also result in delays in our clinical trials, which would materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delays in commissioning and receiving regulatory approvals for our manufacturing facilities could delay our development plans and thereby limit our ability to develop our product candidates and generate revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that internal cGMP manufacturing is important to facilitate clinical product supply, lower the risk of manufacturing disruptions and enable more cost-effective manufacturing. We have a cGMP facility in South San Francisco, California that allows us to supply the product candidates needed for our early-stage clinical trials. We have also leased a property where we are building a facility for the commercial-scale manufacture of our product candidates. The design, construction, qualification, regulatory approvals and maintenance for such facilities require substantial capital and technical expertise and any delay would limit our development activities and our opportunities for growth.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our manufacturing facilities will be subject to ongoing, periodic inspection by the FDA and other comparable regulatory agencies to ensure compliance with cGMP. Our failure to follow and document our adherence to these regulations or other regulatory requirements may lead to significant delays in the availability of product candidates for clinical use or may result in the termination of or a hold on a clinical study. Failure to comply</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with applicable regulations could also result in sanctions being imposed on us, including fines, injunctions, civil penalties, a requirement to suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant marketing approval of our drug candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates, operating restrictions and criminal prosecutions, any of which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also may encounter problems with the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complying with regulations regarding evolving donor infectious disease testing, traceability, manufacturing, release of product candidates and other requirements from regulatory authorities outside the United States; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achieving adequate or clinical-grade materials that meet regulatory agency standards or specifications with consistent and acceptable production yield and costs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bacterial, fungal or viral contamination in our manufacturing facilities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disruptions due to natural disasters or supply chain interruptions; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shortages of qualified personnel, raw materials or key contractors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates, if approved by applicable regulatory authorities, may require significant commercial supply to meet market demand. In these cases, we may need to increase, or &#x201c;scale up,&#x201d; the production process by a significant factor over the initial level of production. If we fail to develop sufficient manufacturing capacity and experience, whether internally or with a third party, are delayed in doing so, or fail to manufacture our product candidates economically or on reasonable scale or volumes, or in accordance with cGMP, or if the cost of this scale-up is not economically feasible, our development programs and commercialization of any approved products will be materially adversely affected and we may not be able to produce our product candidates in a sufficient quantity to meet future demand and our business, financial condition, results of operations and growth prospects may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The optimal donor and manufacturing parameters for our product candidates have not been definitively established, which may hinder our ability to optimize our product candidates or to address any safety or efficacy issues that may arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our clinical trials reveal issues with the safety or efficacy of any of our product candidates, modification of the donor selection criteria or the manufacturing process may be necessary to address such issues. Alternatively, we may choose to modify the manufacturing process in an effort to improve the efficiency of the process or efficacy of the product candidates. However, we have not, at present, fully characterized or identified how donor characteristics and manufacturing process parameters affect the optimal cancer cell killing ability for our engineered NK cell product candidates for in vitro and animal efficacy studies or how such potency differences may translate into efficacy to be seen in human clinical trials, including both the proportion of patients who achieve a meaningful clinical response, and the duration of any such clinical responses. As a result, our ability to improve our manufacturing process or product potency, safety, or efficacy according to such parameters is limited and may require significant trial and error, which may cause us to incur significant costs or could result in significant delays to the clinical development and eventual commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are dependent on third parties to store our CAR NK cells, viral vector, master and working cell banks of NKSTIM, and any damage or loss would cause delays in replacement, and our business could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CAR NK cells, the viral vector, and the master and working cell banks of NKSTIM are stored in freezers at third-party biorepositories and will also be stored in our freezers at our production facility. If these materials are damaged at these facilities, including by the loss or malfunction of these freezers or our back-up power systems, as well as by damage from fire, power loss or other natural disasters, we would need to establish replacement CAR NK cells, viral vector, and master and working cell banks of NKSTIM, which would impact clinical supply and delay our patients&#x2019; treatments. If we are unable to establish replacement materials, we could incur significant additional expenses and liability to patients whose treatment is delayed, and our business could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have not yet developed a validated methodology for freezing and thawing commercial-scale quantities of CAR NK cells, which we believe will be required for the storage and distribution of our CAR NK product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not yet demonstrated that CAR NK cells, which can be frozen and thawed in smaller quantities, can also be frozen and thawed in commercial scale quantities without damage, in a cost-efficient manner and without degradation over time. We may encounter difficulties not only in developing freezing and thawing methodologies for large scale use, but also in obtaining the necessary regulatory approvals for using such methodologies in treatment. If we are unable to freeze CAR NK cells for shipping purposes, our ability to promote adoption and standardization of our product candidates, as well as achieve economies of scale by centralizing our production facility, will be limited. Even if we are able to successfully freeze and thaw CAR NK cells in large quantities, we will still need to develop a cost-effective and reliable distribution and logistics network, which we may be unable to accomplish.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, we have not yet demonstrated long-term stability of cryopreserved CAR NK cells and therefore do not know if we will be able to store the cryopreserved cells for extended periods of time. If we are unable to demonstrate long-term stability, we will need to reduce the manufacturing batch size to ensure that the material we produce will be used before it expires. In that case, the scaling of our production processes will not deliver the efficiencies we expect, and the cost per dose of our product candidates will be substantially higher.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For these and other reasons, we have not yet established the long-term stability of our cryopreserved CAR NK cells and we may not be able to commercialize CAR NK cells on a large scale or in a cost-effective manner. If such product candidate is found to be instable, we would be required to conduct more frequent manufacturing runs, which could cause us to incur significant additional expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our license agreement with National University of Singapore and St. Jude Children&#x2019;s Research Hospital, Inc. is terminated, we could lose our rights to key components enabling our NK cell engineering platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2016, we entered into a license agreement with the National University of Singapore and St. Jude Children&#x2019;s Research Hospital, Inc. (the &#34;Licensors&#34;). Pursuant to this license, the Licensors granted to us an exclusive, worldwide, royalty-bearing, sublicensable license under specified patents and patent applications related to NK cell technology in the field of therapeutics. We are reliant upon certain rights and proprietary technology provided to us under this license for the production and development of certain of our product candidates, such as NKX101, NKX019 and NKX070. We make single-digit royalty payments, patent expenses, license maintenance fees and milestone payments to the Licensors. The term of the license agreement extends until expiration of the last of the patent rights licensed to us by the Licensors, which is currently expected to occur in approximately 2039. The Licensors may terminate the license agreement upon the occurrence of certain events, such as an uncured material breach by us, the cessation of our business or our insolvency, liquidation or receivership. If the Licensors terminate or narrow the license agreement, we could lose the use of intellectual property rights that may be material or necessary to the development or production of our product candidates, including NKX101, NKX019 and NKX070, which could impede or prevent our successful commercialization of such product candidates and materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our patent license agreement with the Licensors is field-specific and has been granted to us in the field of therapeutics. This license agreement permits the Licensors to practice the licensed rights, and to allow non-profit academic third parties to practice the licensed rights for certain academic purposes. As such, certain patents in a patent family that is licensed to us by the Licensors have been licensed to at least one other third party. Although these patents should not be overlapping with our licensed patents, there is a risk that inadvertent overlap may occur, and thus resources may have to be expended to resolve any such overlap and to prevent other licensees from practicing under our licensed patents rights. If any of the foregoing were to occur, it could delay our development and commercialization of our product candidates, which in turn could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our development and commercialization rights to our current and future product candidates and technology are subject, in part, to the terms and conditions of licenses granted to us by others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a party to a variety of intellectual property license agreements with third parties and expect to enter into additional license agreements in the future. These license agreements provide us with access to certain rights and proprietary technology from third parties for the production and development of our current and future product candidates, including NKX101, NKX019 and NKX070. However, these licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we choose to develop or commercialize our technology and product candidates in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also engage in collaborations with scientists at academic and non-profit institutions to access technologies and materials that are not otherwise available to us. Although the agreements that govern these collaborations may include an option to negotiate an exclusive license to the institution&#x2019;s rights in any inventions that are created in the course of these collaborations, we may not be able to come to a final agreement for an exclusive license with the institution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have entered, and may in the future enter, into collaboration or license agreements with commercial entities to access technologies and materials that are not otherwise available to us. Our agreements with such entities may provide licenses to technology useful for the discovery, development, or commercialization of our product candidates. These licenses may in some instances, be non-exclusive. For example, we have entered into an agreement with CRISPR, which grants us a non-exclusive license on up to five gene-editing targets to enable us to independently research, develop and commercialize NK cell therapies that have been gene-edited using CRISPR&#x2019;s gene-editing technology.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such licenses and other contracts may be the subject of disagreements with the grantors and/or various third parties regarding the interpretation of such licenses and contracts. The resolution of any such disagreements that may arise could affect the scope of our rights to the relevant technology, or affect financial or other obligations under the relevant agreement, either of which could inhibit our ability to utilize the underlying technology in a cost-effective manner to develop and commercialize our product candidates, which in turn could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, milestone payment, royalty, insurance, indemnification and other obligations on us. Under certain circumstances such as a material breach of terms, our licensors could terminate our license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors could have the freedom to seek regulatory approval of, and to market, products identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications directed to the technology that we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with our best interests. For example, if we do not have the right to control patent prosecution and maintenance of patents and patent applications directed to the technology that we license from licensors, such licensors could file terminal disclaimers and/or take other actions that could shorten the term of the patents or patent applications. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be impaired. Additionally, we may be required to reimburse our licensors for all of their expenses related to the prosecution, maintenance, enforcement and defense of patents and patent applications that we in-license from them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could harm our competitive position, and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Duration of patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time, and the expiration of our patents may subject us to increased competition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the patent portfolio that is assigned to us, jointly owned with others or licensed to us includes issued patents in the United States, Europe, Japan, and other jurisdictions outside the United States, and pending patent applications in the United States, Europe, Japan, and other jurisdictions outside the United States across our platform, NKX101, NKX019, and NKX070 patent families. Our portfolio of issued patents, excluding pending patent applications, has estimated expiration dates between 2024 and 2040. Our portfolio, including issued patents, and including pending applications if they issue, has estimated expiration dates between 2024 and 2043. For instance, composition of matter claims in our licensed patent portfolio that relate to our engineered K562 cells are estimated to expire in Q4 2024. We plan to file additional patent applications that could potentially allow for further increase of the exclusive market protection for use of NKX101, NKX019, and NKX070 product candidates. However, we can provide no assurance that we will be able to file or receive additional patent protection for these or other product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent expiration dates may be shortened or lengthened by a number of factors, including terminal disclaimers, patent term adjustments, supplemental protection certificates and patent term extensions. Patent term extensions and supplemental protection certificates, and the like, may be impacted by the regulatory process and may not significantly lengthen patent term. Our patent protection could also be reduced or eliminated for noncompliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies. In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we have or will obtain patent rights. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent; provided that the patent is not enforceable for more than 14 years from the date of drug approval, which is limited to the approved indication (or any additional indications approved during the period of extension). Furthermore, only one patent per approved product can be extended and only those claims directed to the approved product, a method for using it or a method for manufacturing it may be extended. However, the applicable authorities, including the FDA and the United States Patent and Trademark Office (the &#34;USPTO&#34;) in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If we are responsible for patent prosecution and maintenance of patent rights in-licensed to us, we could be exposed to liability to the applicable patent owner. If we or our licensors fail to maintain the patents and patent applications covering our product candidates and technologies, we may not be able to prevent a competitor from marketing products that are the same as or similar to our product candidates. Further, others commercializing products similar or identical to ours, and our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, which could increase competition for our product candidates and materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any patent protection we obtain is not sufficiently robust, our competitors could develop and commercialize products and technology similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market for cell therapy is highly competitive and subject to rapid technological change. Our success depends, in large part, on our ability to maintain a competitive position in the development and protection of technologies and products for use in these fields and to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and our technology. We have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and our technology that are important to our business. If we are unable to protect our intellectual property, our competitive position could be materially adversely affected, as third parties may be able to make, use or sell products and technologies that are substantially the same as ours without incurring the sizeable development and licensing costs that we have incurred. This, in turn, would materially adversely affect our ability to compete in the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates or effectively prevent others from commercializing competitive technologies and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. We also may fail to identify patentable aspects of our research and development output, or may identify patentable aspects of our research and development output once it is too late to obtain patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Claim scope in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even after issuance, our owned and in-licensed patents may be subject to challenge, which if successful could require us to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the use of the underlying technology, which could materially adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents, even after issuance, may be challenged in the courts or patent offices in the United States and abroad. Third-party challenges may result in a loss of exclusivity or in our patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to prevent others from using or commercializing similar or identical technology and products, or could limit the duration of the patent protection of our technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our patents are determined to be valid and enforceable, they may not be interpreted sufficiently broadly to prevent others from marketing products similar to ours or designing around our patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ex parte reexaminations have been filed by one or more third parties against certain licensed patents in our portfolio. Ex parte reexaminations of U.S. Patent Nos. 9,511,092 (the &#34;&#x2019;092 Patent&#34;), 10,774,309 (the &#34;&#x2019;309 Patent&#34;), and 10,829,737 (the &#34;&#x2019;737 Patent&#34;) were recently concluded, resulting in the claims of each Patent being maintained in amended form. None of the claims of the &#x2019;092, &#x2019;309, and &#x2019;737 Patents as maintained in amended form relate to any of our current product candidates. Additional ex parte reexaminations could be filed in the future and although we plan to vigorously protect our intellectual property rights, as with all legal proceedings, there can be no guarantee as to the outcome, and, regardless of the merits of third-party challenges, such proceedings are time-consuming and costly. As a result of such reexaminations, our rights under the relevant patents could be narrowed or lost, and in the course of such proceedings, we may incur substantial costs, and the time and attention of our management may be diverted from the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which could materially adversely affect our ability to develop, manufacture and market our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are many patents issued or applied for in the biotechnology industry, and we may not be aware of patents or patent applications held by others that relate to our business. We cannot guarantee that any of our or our licensors&#x2019; patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and elsewhere that is relevant to or necessary for the development and commercialization of our product candidates in any jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, patent applications in the United States and many international jurisdictions are typically not published until 18 months after the filing of certain priority documents (or, in some cases, are not published until they issue as patents) and publications in the scientific literature often lag behind actual discoveries. Thus, we cannot be certain that others have not filed patent applications or made public disclosures relating to our technology or our contemplated technology. A third party may have filed, and may in the future file, patent applications directed to our product candidates or technology similar to ours or that of our licensors. Any such patent application may have an earlier priority date than our patent applications or patents, or those of our licensors, which could further require us to obtain rights to patents directed to such technologies. Under certain circumstances, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by any such third party, or by the USPTO itself, to determine who was the first to invent any of the subject matter recited by the patent claims of our applications or issued patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, after issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, and we may incorrectly determine that our product candidates or technology are not covered by a third party's patent or may incorrectly predict whether a third party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or elsewhere that we consider relevant may also be incorrect. If we fail to correctly identify or interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We may also be forced to attempt to redesign our product candidates or technology in a manner that no longer infringes third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Claims brought against us for infringing, misappropriating or otherwise violating intellectual property rights of third parties or engaging in unfair competition, would be costly and time-consuming and could prevent or delay us from successfully developing or commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our ability to develop, manufacture and market our technology and use our technology without infringing the proprietary rights of third parties. We or our collaborators may be subject to third-party claims that could cause us to incur substantial expenses to defend and these claims, if successful, could require us to pay substantial damages and/or limit our ability to commercialize our product candidates if we or our collaborators are found to be infringing a third party&#x2019;s intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are aware of third-party patents and patent applications that may relate to the areas in which we are developing product candidates. Additionally, as  our industry expands and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our product candidates and technology of which we are not aware or that we may need to challenge to continue our operations as currently contemplated. As a result, our technology and any future products that we commercialize could be alleged to infringe patent rights or other proprietary rights of third parties, which may require costly litigation and, if we are not successful in defending against such litigation, could cause us to pay substantial damages and/or limit our ability to commercialize our product candidates. Issued patents are entitled to a presumption of validity in many countries, including the United States and many European countries, and issued patents held by others that claim our technology or any of our product candidates may limit our freedom to operate, including our ability to commercialize our product candidates, unless and until these patents expire or are declared invalid or unenforceable in a court of applicable jurisdiction, if we do not obtain a license or other right to practice the claimed inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Accordingly, we may be subject to claims that these employees, or we, have used or disclosed trade secrets or other proprietary information of their former employers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties could threaten or initiate litigation or other legal proceedings alleging that we have infringed their patents, trade secrets, trademarks or other intellectual property rights. Litigation may make it necessary to defend ourselves by determining the scope, enforceability and validity of third-party proprietary rights, or to establish our proprietary rights. Regardless of whether any such claims that we are infringing patents or other intellectual property rights have merit, such claims can be time consuming, divert management attention and financial resources and are costly to evaluate and defend.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of any such litigation are difficult to predict and may require us to stop treating certain conditions, obtain licenses or modify our product candidates or technology while we develop non-infringing substitutes, or may result in significant settlement costs. Litigation can involve substantial damages for infringement (and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#x2019;s attorneys&#x2019; fees), and the court could prohibit us from selling our product candidates or require us to take a license from a third party, which the third party is not required to do at a commercially reasonable price or at all. If a license is available from a third party, we may have to pay substantial royalties, upfront fees, or milestone fees, or grant cross-licenses to intellectual property rights for our product candidates or technology. We may also have to redesign our product candidates or technology so they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our product candidates may not be available for manufacture, use, or sale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to effectively monitor unauthorized use of our intellectual property and enforce our intellectual property rights against infringement, and may incur substantial costs as a result of bringing litigation or other proceedings relating to our intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we review our competitors&#x2019; products for potential infringement of our rights. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully monitor unauthorized use of our intellectual property could result in competitors offering products that incorporate our product candidates or service features, which could in turn reduce demand for our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also, from time to time, seek to enforce our intellectual property rights against infringers when we determine that a successful outcome is probable and may lead to an increase in the value of the intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we choose to enforce our patent rights against a party, that party could counterclaim that our patent is invalid and/or unenforceable. The defendant may challenge our patents through proceedings before the Patent Trial and Appeal Board (&#34;PTAB&#34;), including inter partes and post-grant review. Proceedings to challenge patents are also available internationally, including, for example, opposition proceedings and nullity actions. In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability and PTAB challenges are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before the PTAB, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, such lawsuits and proceedings are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. Litigation is inherently unpredictable, and there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions. Furthermore, some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party&#x2019;s activities do not infringe our intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could materially adversely affect the price of our common stock. Finally, any uncertainties resulting from the initiation and continuation of any litigation could materially adversely affect our ability to raise the funds necessary to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a number of international patents and patent applications and expect to continue to pursue patent protection in many of the significant markets in which we intend to do business. However, filing, prosecuting and defending patents relating to our product candidates and technology, including all of our in-licensed patent rights, in all countries throughout the world would be prohibitively expensive. We must ultimately seek patent protection on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the protection offered by intellectual property rights in certain countries outside of the United States may be less extensive than those in the United States. Consequently, we may not be able to prevent third parties from utilizing proprietary technology in all countries outside of the United States, even if we pursue and obtain issued patents in particular foreign jurisdictions, or from selling or importing products made using our proprietary technology in and into the United States or other jurisdictions. Such products may compete with our products, and our patent rights or other intellectual property rights may not be effective or sufficient to prevent them from competing. If such competing products arise in jurisdictions where we are unable to exercise intellectual property rights to combat them, our business, financial condition, results of operations and growth prospects could be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law or the patent law of other jurisdictions could decrease the certainty of our ability to obtain patents and diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. Supreme Court and the Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. For example, in recent years the U.S. Supreme Court modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of a challenge of any patents we obtain or license. Similarly, international courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. Those changes may materially adversely affect our patent rights and our ability to obtain issued patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For instance, the Leahy-Smith America Invents Act (the &#34;America Invents Act&#34;), enacted in 2011, included a number of significant changes to patent law in the United States. Many of the substantive changes to patent law under the America Invents Act came into effect in March 2013. For example, in March 2013, the United States transitioned from a &#x201c;first-to-invent&#x201d; patent system to a patent system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also included a number of significant changes that affect the way patent applications are prosecuted and how issued patents may be challenged, such as allowing third-party submission of prior art to the USPTO during patent prosecution and  new post-grant administrative proceedings which can be used by third parties to attack the validity of an issued patent, including post-grant review, inter partes review and derivation proceedings. The America Invents Act and its implementation could increase the uncertainties and/or costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we own, have licensed or might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future, which in turn could materially adversely affect our business, financial condition, results of operations and growth prospects. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system will take effect on June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European patent applications will have the option, upon grant of a patent, of becoming a Unitary Patent, which will be subject to the jurisdiction of the Unitary Patent Court (the &#34;UPC&#34;). As the UPC is a new court system, there is no precedent for the court or any decisions that it may take, increasing the uncertainty of any litigation. Existing European patents that have not lapsed as of June 1, 2023 and for which no action has been filed before the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries that have ratified the UPC agreement. We cannot predict with certainty the long-term effects of any potential changes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may fail to obtain or enforce assignments of intellectual property rights from our employees and contractors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing an enforceable agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Furthermore, our assignment agreements may not be self-executing or may be breached, and we may be forced to bring or defend claims to determine the ownership of what we regard as our intellectual property, and we may not be successful in such claims. If we fail in bringing or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could materially adversely affect our business, financial condition, results of operations and growth prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product candidates could be materially diminished.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trade secrets are difficult to protect. We rely on trade secrets to protect our proprietary information and technologies, especially where we do not believe patent protection is appropriate or obtainable, or where such patents would be difficult to enforce. We rely in part on confidentiality agreements with our employees, consultants, contractors, collaboration partners, scientific collaborators, and other advisors to protect our trade secrets and other proprietary information. We cannot guarantee that we have entered into such agreements with each party that may have had access to our proprietary information or technologies, or that such agreements, even if in place, will not be circumvented. These agreements may not effectively prevent disclosure of proprietary information or technology and may not provide an adequate remedy in the event of unauthorized disclosure of such information or technology. In addition, others may independently discover our trade secrets and proprietary information, in which case we may have no right to prevent them from using such trade secrets or proprietary information to compete with us. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The U.S. government could choose to exercise certain rights in technology developed under government-funded research, which could eliminate our exclusive use of such technology or require us to commercialize our product candidates in a way we consider sub-optimal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. government has certain rights in some of our licensed patents (including U.S. Patent Nos. 7,435,596, 8,026,097 and certain related U.S. patent applications) in accordance with the Bayh-Dole Act of 1980. These rights in certain technology developed under government-funded research include, for example, a nonexclusive, nontransferable, irrevocable, paid-up license to use those inventions for governmental purposes. In addition, the U.S. government has the right to require us to grant exclusive licenses to such inventions to a third party if the U.S. government determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. government also has the right to take title to such technology if we fail to disclose the invention of such technology to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title to patent rights in any country in which a patent application is not filed within specified time limits. To the extent any of our owned or in-licensed intellectual property, now or in the future, is generated through the use of U.S. government funding, these provisions of the Bayh-Dole Act may apply.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property generated under a government-funded program is also subject to certain reporting requirements. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. If we are unable to obtain a waiver from the government agency that provided the underlying research funding, we may be limited in our ability to contract with non-U.S. product manufacturers for products related to such intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The exercise of any of the foregoing rights of the U.S. government over technology that we own or use in the development and commercialization of our product candidates could prevent us from enjoying the exclusive use of such technology, or could cause us to incur additional expenses in the commercialization of our product candidates. Any of the foregoing could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our product candidates are approved for marketing and commercialization and we have not developed or secured marketing, sales and distribution capabilities, either internally or from third parties, we will be unable to successfully commercialize such products and may not be able to generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have limited sales, marketing or distribution expertise. We will need to develop internal sales, marketing and distribution capabilities and infrastructure to commercialize any product candidate that gains FDA or other regulatory authority approval, which would be expensive and time-consuming, or enter into partnerships with third parties to perform these services. If we decide to market any approved products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties to market products or decide to co-promote products with partners, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any product revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for any approved product. If we are not successful in commercializing any product approved in the future, if any, either on our own or through third parties, our business, financial condition, results of operations and growth prospects could be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates, including NKX101 and NKX019, could be subject to regulatory limitations following approval, if and when such approval is granted.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following approval of a product candidate, if any, we must comply with comprehensive government regulations regarding the manufacture, labeling, marketing, distribution and promotion of biologic products. We must comply with the FDA&#x2019;s labeling protocols, which prohibits promoting &#x201c;off-label uses.&#x201d; We may not be able to obtain the labeling claims necessary or desirable to successfully commercialize our products, including NKX101 and NKX019 or other product candidates in development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and foreign regulatory authorities could impose significant restrictions on use of an approved product including potentially restricting its use to limited clinical centers as well as through the product label, as well as on advertising, promotional and distribution activities associated with such approved product. The FDA or a foreign regulatory authority could also condition their approval on the performance of post-approval clinical trials, patient monitoring or testing, which could be time-consuming and expensive. If the results of such post-marketing trials are not satisfactory, the FDA or such foreign regulatory authority could withdraw marketing authorization or may condition continued marketing on commitments from us or our partners that may be expensive and/or time-consuming to fulfill.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we or others identify side-effects after any of our products are on the market, if our products fail to maintain a continued acceptable safety profile after approval, if manufacturing problems occur subsequent to regulatory approval, or if we, our manufacturers or our partners fail to comply with regulatory requirements, including those mentioned above, we or our partners could be subject to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on such products&#x2019; manufacturing processes; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes to the product label; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing of a product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on product distribution; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to conduct post-marketing clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Untitled or Warning Letters from the FDA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of the product from the market; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recall of products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, restitution or disgorgement of profits or revenue; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension or withdrawal of regulatory approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any one or a combination of these penalties could prevent us from achieving or maintaining market acceptance of the affected product, or could substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating any revenue or profit from the sale of such product and could materially adversely affect our business, financial condition, results of operations and growth prospects. In addition, third-party payors may impose limitations on centers and personnel that may administer our products, including but not limited to requiring third-party accreditation to be obtained before the use of our products is reimbursed in such a center, which could materially adversely affect our potential commercial success and lead to slower market acceptance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates, if and when approved, may be limited, and if such market opportunities are smaller than we expect, our revenues could be materially adversely affected and our business could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial clinical trials evaluate NKX101 and NKX019 in relapsed/refractory patients who have been previously treated with other anti-cancer therapies. We do not know at this time whether either NKX101 or NKX019 or any of our product candidates will be safe for use in humans or whether they will demonstrate any anti-cancer activity. If the activity is sufficient, we may initially seek approval of any product candidates we develop as a therapy for patients who have received one or more prior treatments. Depending on the activity we note in the initial clinical trials, we plan to conduct additional clinical trials in less heavily pretreated populations in order to expand use of our product candidates in a broader group of patients and increase market opportunities. However, there is no guarantee that product candidates we develop, even if approved for later lines of therapy, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of patients who have the cancers we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited. Potentially addressable patient populations for of our product candidates are only estimates. These estimates could prove to be incorrect, and the estimated number of potential patients in the United States and elsewhere could be lower than expected. It may also be that such patients may not be otherwise amenable to treatment with our product candidates, or patients could become increasingly difficult to identify and access for a variety of reasons including other drugs being approved, any of which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The commercial success of any of our product candidates will depend upon such product candidate&#x2019;s degree of market acceptance by physicians, patients, third-party payors and others in the medical community.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may not be commercially successful. Even if requisite approvals are obtained from the FDA in the United States and other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on the acceptance by physicians, patients and healthcare payors of cell therapy products in general, and our product candidates in particular, as medically necessary, cost-effective and safe. Physicians, patients, healthcare payors and others in the medical community may not accept any product that we commercialize. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of cell therapy products and, in particular, our product candidates, if approved for commercial sale, will depend on several factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and safety of such product candidates as demonstrated in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential and perceived advantages of product candidates over alternative treatments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment relative to alternative treatments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications for which the product candidate is approved by the FDA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of physicians to refer patients and prescribe new therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the nature, prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product labeling or product insert requirements imposed by the FDA or other regulatory authorities, including any limitations or warnings contained in a product&#x2019;s approved labeling; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relative convenience and ease of administration; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse publicity concerning our product candidates or favorable publicity about competing products and treatments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sufficient third-party payor coverage, any limitations in terms of center or personnel training requirement imposed by third parties and adequate reimbursement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the FDA-approved labeling for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any FDA requirement to undertake a REMS; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of our sales, marketing and distribution efforts; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product liability claims. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a product candidate displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after such product is launched. Our product candidates may not achieve broad market acceptance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market such products and to generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the cost of a single administration of one of our cell therapy product candidates to be substantial, when and if they achieve regulatory approval. We expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of our products, if approved, will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be reimbursed by government authorities, private health coverage insurers and other third- party payors. Coverage and reimbursement by a third-party payor could depend upon several factors, including the third-party payor&#x2019;s determination that use of a product is (i) a covered benefit under its health plan, (ii) safe, effective and medically necessary, (iii) appropriate for the specific patient, (iv) cost-effective and (v) neither experimental nor investigational.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be adequate to realize a sufficient return on our investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is significant uncertainty related to third-party coverage and reimbursement of newly approved drug products. In the United States, third-party payors, including government payors such as Medicare and Medicaid, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. Medicare and Medicaid are increasingly used as models for the development of private payors&#x2019; and government payors&#x2019; coverage and reimbursement policies. Currently, few cell therapy products have been approved for coverage and reimbursement by the Centers for Medicare and Medicaid Services (&#34;CMS&#34;), the agency responsible for administering Medicare. It is difficult to predict what third payors, including CMS, will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, since there is no body of established protocols and precedents for these types of drug products. Moreover, reimbursement agencies in other countries, such as those in Europe, may be more conservative than CMS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside the United States, international operations vary significantly by country and are subject to extensive government price controls and other market regulations, and increasing emphasis on cost-containment initiatives in the European countries, Canada and other countries could place pricing pressure on us. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. It can also take a significant amount of time after approval of a product to secure pricing and reimbursement for such product in many counties outside the United States. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable product revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, increasing efforts by government and third-party payors in the United States and abroad to cap or reduce healthcare costs could limit coverage and the level of reimbursement for our product candidates. Payors are increasingly considering new metrics as the basis for reimbursement rates, such as average sales price, average manufacturer price, and Actual Acquisition Cost. The existing data for reimbursement based on some of these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates, and CMS has begun making pharmacy National Average Drug Acquisition Cost and National Average Retail Price data publicly available on at least a monthly basis. Therefore, it may be difficult to project the impact of these evolving reimbursement metrics on the willingness of payors to cover candidate products that we or our partners are able to commercialize. Furthermore, most third-party payors currently require additional accreditation for approved cell therapy drugs, which limits the centers that can administer the drugs, and similar limitations may also be imposed on the product candidates that we are developing. We expect to experience pricing pressures in connection with the sale of our product candidates, if any, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, and on prescription drugs and surgical procedures in particular, has become intense. As a result, increasingly high barriers to entry are developing for new drug products such as ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare reform initiatives and other administrative and legislative proposals may harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. Furthermore, future price controls or other changes in pricing regulation or negative publicity related to the pricing of pharmaceutical drugs could restrict the amount that we are able to charge for our drug products, which could render our product candidates, if approved, commercially unviable and materially adversely affect our ability to raise additional capital on acceptable terms. For further details on how healthcare reform may impact our business, see &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; in the section titled &#x201c;Government Regulation&#x201d; in Part I, Item 1 in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining marketing approval or commercialization of our product candidates in one jurisdiction does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we market approved products outside the United States, we expect that we will be subject to additional risks in commercialization, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">different regulatory requirements for approval of therapies in foreign countries; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced protection for intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods and fires, and other public health crises, illnesses, epidemics or pandemics, such as the potential impact of the COVID-19 outbreak. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in which we may operate, with which we will need to comply. Any of the foregoing difficulties, if encountered, could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business operations and relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable fraud and abuse and other healthcare laws and regulations, which could expose us to penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act, the Health Information Technology for Economic and Clinical Health Act, the U.S. Physician Payments Sunshine Act and its implementing regulations, U.S. state laws and regulations, including, state anti-kickback and false claims laws, laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources, laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, laws requiring the registration of pharmaceutical sales representatives, laws governing the privacy and security of health information in certain circumstances, and similar healthcare laws and regulations in other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will also involve substantial costs. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Any of the foregoing could significantly harm our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may fail to comply with evolving global privacy laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we conduct clinical trials in the European Economic Area (&#34;EEA&#34;), we may be subject to additional privacy laws. The General Data Protection Regulation, (EU) 2016/679 (&#34;GDPR&#34;) imposes a broad range of strict requirements on companies subject to the GDPR, including requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the EEA, including to the United States, providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#x2019; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing privacy and data protection officers, conducting data protection impact assessments, and record-keeping. The GDPR increases substantially the penalties to which we could be subject in the event of any non-compliance, including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious offenses. Given the limited enforcement of the GDPR to date, we face uncertainty as to the exact interpretation of the new requirements on our trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, national laws of member states of the European Union are in the process of being adapted to the requirements under the GDPR, thereby implementing national laws which may partially deviate from the GDPR and impose different obligations from country to country, so we do not expect to operate in a uniform legal landscape in the EU. Also, as it relates to processing and transfer of genetic data, the GDPR specifically allows national laws to impose additional and more specific requirements or restrictions, and European laws have historically differed quite substantially in this field, leading to additional uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event we conduct clinical trials in the EEA, we must also ensure that we implement and maintain adequate safeguards to enable the transfer of personal data outside of the EEA, in particular to the United States, in compliance with European data protection laws. We expect that we will continue to face uncertainty as to whether our efforts to comply with our obligations under European privacy laws will be sufficient. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or pharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national clients or pharmaceutical partners to continue to use our products and solutions due to the potential risk exposure as a result of the current and, in particular, future data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the GDPR. Such clients or pharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the foregoing could materially harm our business, prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act (the &#34;CCPA&#34;), which went into effect on January 1, 2020, is creating similar risks and obligations as those created by the GDPR, though the California Consumer Privacy Act does exempt certain clinical trial data. Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market price for our common stock may be volatile, which could contribute to the loss of all or part of your investment.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Factors affecting the trading price of our common stock may include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our decision to initiate a clinical study, not to initiate a clinical study or to terminate an existing clinical study; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in the announcement of initial data or clinical results from our clinical trials or expectations that such delays may occur;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval for our products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">success or failure of competitive products, immunotherapy drugs or cellular therapies more generally; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse developments concerning our manufacturers or our strategic partnerships; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse safety or other clinical results, such as those that have occurred in the past or that may occur in the future, related to cellular therapies being developed by other companies that are or may be perceived to be similar to our cellular therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating and stock price performance of other companies that investors deem comparable to us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of substantial amounts of common stock by our directors, executive officers or significant stockholders or the perception that such sales could occur; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic and political conditions such as recessions, inflationary pressures, interest rates, fuel prices, elections, drug pricing policies, international currency fluctuations, acts of war or terrorism, and other public health crises, illnesses, epidemics or pandemics, such as the potential impact of the COVID-19 outbreak; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other factors discussed in these risk factors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the factors listed above could materially adversely affect your investment in our common stock, and our common stock may trade at prices significantly below the initial public offering price or the price at which you purchased the stock, which could contribute to a loss of all or part of your investment. In such circumstances the trading price of our common stock may not recover and may experience a further decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, broad market and industry factors could materially adversely affect the market price of our common stock, irrespective of our operating performance. The stock market in general, and Nasdaq and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of ours, may not be predictable. For instance, technical factors in the public trading market for our common stock may produce price movements that may or may not comport with macro, industry or company-specific fundamentals, including, without limitation, the sentiment of retail investors (including as may be expressed on financial trading and other social media sites), the amount and status of short interest in our common stock, access to margin debt, and trading in options and other derivatives on our common stock. In addition, the trading prices for common stock of other biopharmaceutical and biotechnology companies have been highly volatile as a result of the COVID-19 pandemic. The COVID-19 outbreak continues to rapidly evolve. The full extent to which the outbreak may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. A loss of investor confidence in the market for biotechnology or pharmaceutical stocks or the stocks of other companies which investors perceive to be similar to us, the opportunities in the biotechnology and pharmaceutical market or the stock market in general, could depress our stock price regardless of our business, financial condition, results of operations or growth prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of ownership of our shares of common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 13, 2023, our directors and executive officers, and entities affiliated with them, as well as holders of more than 5% of our outstanding shares of common stock, in the aggregate beneficially own 63% of our common stock. These stockholders, acting together, are able to control or significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of these persons or entities may have interests different from yours. For example, because many of these stockholders purchased their shares at prices substantially below the price at which shares were sold in the IPO and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A significant portion of our total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop significantly.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of stockholders intend to sell shares of our common stock, could reduce the market price of our common stock. As of March 13, 2023, we had 48,928,670 shares of common stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of an aggregate of 13,200,076 shares of common stock, including with respect to shares of our convertible preferred stock that converted into shares of our common stock upon the completion of the IPO, have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, until such shares can otherwise be sold without restriction under Rule 144 under the Securities Act, or until the rights terminate pursuant to the terms of the stockholders agreement between us and such holders. We have also registered all shares of common stock subject to equity awards issued or reserved for future issuance under our equity compensation plans on registration statements on Form S-8, and these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates under Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a negative impact on the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; under the JOBS Act and a &#x201c;smaller reporting company&#x201d; and we rely on exemptions from certain disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, as a result of which our common stock may be less attractive to investors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We take advantage and may continue to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including: not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier to occur of (1) the last day of the fiscal year (a) following the fifth anniversary of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a &#x201c;large accelerated filer&#x201d; under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30; and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; as defined by applicable rules of the SEC. Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company and would be permitted to continue to take advantage of many of the same reporting exemptions, including exemption from compliance with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act as long as we do not otherwise also qualify as an &#x201c;accelerated filer&#x201d; or &#x201c;large accelerated filer&#x201d; for SEC reporting purposes and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive if we rely on emerging growth company or smaller reporting company exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our severance and change in control agreements with our executive officers may require us to pay severance benefits to any of those persons who are terminated, which could materially adversely affect our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our executive officers are parties to agreements that contain certain change in control and severance provisions. The agreements provide for cash payments for severance and other benefits in the event of a termination of employment that is not in connection with a change in control of us. They also provide for cash payments for severance and other benefits and acceleration of stock options vesting in the event of a termination of employment in connection with a change in control of us. The accelerated vesting of options could result in dilution to our existing stockholders and could materially adversely affect the market price of our common stock. The payment of these severance benefits could materially adversely affect our financial condition and results of operations. In addition, these potential severance payments may discourage or prevent third parties from seeking a business combination with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryovers and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As described above under &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception, and we expect to continue to incur significant losses for the foreseeable future</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; we have incurred net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. Under the Internal Revenue Code of 1986 (the &#34;Code&#34;), a corporation is generally allowed a deduction for net operating losses (&#34;NOLs&#34;) carried over from a prior taxable year. Under that provision, we can carry forward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire, in the case of NOLs generated prior to 2018. The same is true of other unused tax attributes, such as tax credits. The amounts of our unused carryovers of NOLs and tax credits as of December 31, 2017, and a description of the valuation allowance we have recorded with respect to those items, are set forth below under &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&#x201d; In addition, under the Tax Act, the amount of post-2017 NOLs that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. The Tax Act generally eliminates the ability to carry back any NOL to prior taxable years, while allowing post-2017 unused NOLs to be carried forward indefinitely. Recently enacted legislation, the Coronavirus Aid, Relief and Economic Security Act (the &#34;CARES Act&#34;) temporarily reverses the limitations imposed by the Tax Act by suspending the 80% taxable income limitation to permit a corporation to offset without limitation its taxable income in 2019 or 2020 with NOL carryforwards generated in prior years. The CARES Act also allows NOLs generated in tax years 2018-2020 to be carried back up to five years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, if a corporation undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, Sections 382 and 383 of the Code limit the corporation&#x2019;s ability to use carryovers of its pre-change NOLs, credits and certain other tax attributes to reduce its tax liability for periods after the ownership change. Our issuance of common stock pursuant to our IPO may result in a limitation under Sections 382 and 383 of the Code, either separately or in combination with certain prior or subsequent shifts in the ownership of our common stock. As a result, our ability to use carryovers of our pre-change NOLs and credits to reduce our future U.S. federal income tax liability may be subject to limitations. This could result in increased U.S. federal income tax liability for us if we generate taxable income in a future period. Limitations on the use of NOLs and other tax attributes could also increase our state tax liability. The use of our tax attributes will also be limited to the extent that we do not generate positive taxable income in future tax periods. To the extent our ability to utilize our NOLs and other tax assets going forward is limited, in part or altogether, our tax liability for future periods may be greater than expected, and our business, financial condition, results of operations and growth prospects may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Tax Act&#x2019;s amendment to Section 174 of the Code, beginning with tax years that start after December 31, 2021, research and development expenses must be capitalized and amortized over five or fifteen years, as applicable. This tax law change has increased our effective tax rate and our cash tax payable in the taxable year 2022. If the requirement to capitalize Section 174 expenditures is not repealed or otherwise modified, it may also impact our effective tax rate and our cash tax liability in future years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not expect to pay any cash dividends to the holders of our common stock for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently intend to invest our future earnings, if any, to fund our growth. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. There is no guarantee that our common stock will appreciate in value or even maintain the price at which our stockholders have purchased our common stock. Investors seeking cash dividends should not purchase our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions in our certificate of incorporation, our bylaws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our certificate of incorporation, bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our certificate of incorporation and bylaws include provisions that:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorize &#x201c;blank check&#x201d; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a classified board of directors such that not all members of the board are elected at one time, which may delay the ability of our stockholders to change the membership of a majority of our board of directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">specify that only our board of directors, the Chairperson of our board of directors, our Chief Executive Officer or the President, or holders of greater than 10% of our common stock can call special meetings of our stockholders;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that a majority of directors then in office, even though less than a quorum, may fill vacancies on our board of directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">specify that no stockholder is permitted to cumulate votes at any election of directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expressly authorize our board of directors to modify, alter or repeal our bylaws; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require supermajority votes of the holders of our common stock to amend specified provisions of our Certificate of Incorporation and bylaws. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any provision of our certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit your opportunity to receive a premium for your shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our certificate of incorporation includes a forum selection clause, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Certificate of Incorporation provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) will be the exclusive forum for any:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other action asserting a claim against us that is governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This exclusive forum provision is intended to apply to claims arising under Delaware state law and is not intended to apply to claims brought pursuant to the Exchange Act or the Securities Act, or any other claim for which the federal courts have exclusive jurisdiction. This exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. The Delaware Supreme Court recently determined that the exclusive forum provision of federal district courts of the United States of America for resolving any complaint asserting a cause of action arising under the Securities Act is permissible and enforceable under Delaware law, reversing an earlier decision from the Court of Chancery of the State of Delaware that had ruled that such provisions were not enforceable. Nevertheless, there is uncertainty as to whether a federal district court would enforce any exclusive forum provision with respect to claims under the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our bylaws described above. This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our Certificate of Incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially adversely affect our business, financial condition, results of operation and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Various macroeconomic factors could adversely affect our business, results of operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties, such as those resulting from the current and future conditions in the banking system aand the global financial markets. For instance, inflation has negatively impacted us and could continue to negatively impact us by increasing our cost of labor (through higher wages), commercial support, construction, manufacturing and clinical supply expenditures. See above under &#x201c;&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Our manufacturing process is novel and complex, and we may encounter difficulties in production, or difficulties with internal manufacturing, which would delay or prevent our ability to provide a sufficient supply of our product candidates for clinical trials or our products for patients, if approved</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; for the risks related to the impact of inflation on the construction of our commercial-scale manufacturing facility. Current inflationary pressures, if sustained, could have a negative impact on our operations. In addition, interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect our ability to raise capital in order to fund our operations, if needed. Financial conditions affecting the banking system and financial markets may threaten our ability to access our cash, as well as our access to letters of credit or other funding necessary to support our business, which may require us to find additional sources of cash or funding on short notice. Similarly, these macroeconomic factors could affect the ability of our third-party manufacturers, contractors or suppliers to manufacture materials required for our product candidates on a cost effective basis, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any acquisitions or strategic collaborations may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities or subject us to other risks.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary drugs, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including, but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased operating expenses and cash requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the assumption of indebtedness or contingent or unknown liabilities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assimilation of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adequately prosecuting and maintaining protection of any acquired intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the diversion of our management&#x2019;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">retention of key employees, the loss of key personnel, and uncertainties about our ability to maintain key business relationships; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or product candidates and regulatory approvals; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to generate revenue from acquired drugs, intellectual property rights, technologies, and/or businesses sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we engage in acquisitions or strategic partnerships, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses or acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our growth or limit access to technology or drugs that may be important to the development of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a period of volatility or decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could materially adversely affect our business, financial condition, results of operation and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities analysts do not publish research or reports about our business or if they publish negative reports or downgrade our stock, the price of our common stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us, our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock, the lack of research coverage may materially adversely affect the market price of our common stock. Furthermore, if one or more of the analysts who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline and may also impair our ability to expand our business with existing customers and attract new customers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules of the SEC and those of Nasdaq have imposed various requirements on public companies including that we establish and maintain effective disclosure and financial controls. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures following an initial transition period available to public companies. In particular, we must evaluate our systems and procedures, and test our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. In addition, we will be required to have our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting in the later of our second Annual Report on Form 10-K or the first Annual Report on Form 10-K following the date on which we are no longer an emerging growth company unless we are a smaller reporting company and do not otherwise also qualify as an &#x201c;accelerated filer&#x201d; or &#x201c;large accelerated filer&#x201d; for SEC reporting purposes. Our compliance with Section 404 of the Sarbanes-Oxley Act will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. If we do not comply with the requirements of Section 404 in a timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which would require additional financial and management resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To successfully implement our business plan and comply with Section 404, we must prepare timely and accurate financial statements. We expect that we will need to continue to improve existing procedures and controls, and implement new operational and financial systems, to manage our business effectively. Any delay in the implementation of, or disruption in the transition to, new or enhanced systems, procedures or controls, may cause our operations to suffer, and we may be unable to conclude that our internal control over financial reporting is effective and to obtain an unqualified report on internal controls from our auditors as required under Section 404 of the Sarbanes-Oxley Act. This, in turn, could materially adversely affect the trading prices for our common stock and our ability to access the capital markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would materially adversely affect our business and the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status both as an emerging growth company and a smaller reporting company, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. Any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inadequate internal controls could also cause investors to lose confidence in our reported financial information, which could materially adversely affect the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes to, or interpretations of, financial accounting standards may affect our results of operations and could cause us to change our business practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We prepare our financial statements in accordance with U.S. GAAP. These accounting principles are subject to interpretation by the Financial Accounting Standards Board, the SEC and various bodies formed to interpret and create accounting rules and regulations. Changes in accounting rules can have a significant effect on our reported financial results and may affect our reporting of transactions completed before a change is announced. Changes to those rules or the questioning of current practices may materially adversely affect our financial results, including those contained in this filing, or the way we conduct our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Computer system interruptions or security breaches could significantly disrupt our product development programs and our ability to operate our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our internal computer systems, cloud-based computing services and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, ransomware, malware, data corruption, cyber-based attacks, phishing attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have taken steps to protect the security of our information systems and the data maintained in those systems, we have, from time to time, experienced cyber incidents of varying degrees, although none of these cyber incidents have had a material adverse impact on our business, financial condition or results of operations. It is possible that in the future our safety and security measures will not prevent the improper functioning or damaging of our systems, or the improper access or disclosure of personally identifiable information, and any such event could materially and adversely impact our business, financial condition or results of operations. In addition, if a significant system failure, accident, security breach or other cyber incident were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information, the disclosure of protected personally identifiable patient information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, federal, state and international laws and regulations, such as the GDPR, which took effect in May 2018, and the CCPA which took effect on January 1, 2020, as well as the California Consumer Privacy Act, which was passed in November 2020 and makes a number of significant amendments to the CCPA, can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts fail or if our privacy practices do not meet the requirements of such laws. Other states are considering similar laws that could impact our use of research data with respect to individuals in those states. There are extensive documentation obligations and transparency requirements, which may impose significant costs on us. In addition, our software systems include cloud-based applications that are hosted by third-party service providers with security and information technology systems subject to similar risks. To the extent that any disruption, security breach or other cyber incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed, any of which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Staff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our facilities are located at two adjacent leased sites. The first site, located at 6000 Shoreline Court, Suites 102, 104, 201, 203, 204 and 325, South San Francisco, California, consists of approximately 42,145 square feet of office and laboratory space and is primarily used for research, clinical, manufacturing and corporate activities. Our lease covering Suites 102, 104, 204, and 325 expires in July 2030. Our lease covering Suites 201 and 203 expires in March 2024. The second site, located at 7000 Shoreline Court, South San Francisco, California, consists of 340 square feet of vivarium space and an additional 215 square feet of shared laboratory space, and is primarily used for preclinical research. Our agreement that provides for our use of these vivarium and laboratory spaces expires in June 2023. Our lease for an 88,000 square foot facility in South San Francisco to support research and development and future manufacturing of Nkarta&#x2019;s cell therapy products and product candidates commenced in 2022 and expires in 2034. This new facility will also serve as our future headquarters with office space and research facilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that these facilities are sufficient to meet our current needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. There are currently no claims or actions pending against us that, in the opinion of our management, are likely to have a material adverse effect on our business, results of operations, financial condition or growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ex parte reexaminations have been filed by one or more third parties against certain licensed patents in our portfolio. Ex parte reexaminations of U.S. Patent Nos. 9,511,092 (the &#34;&#x2019;092 Patent&#34;), 10,774,309 (the &#34;&#x2019;309 Patent&#34;), and 10,829,737 (the &#34;&#x2019;737 Patent&#34;) were recently concluded, resulting in the claims of each Patent being maintained in amended form.  None of the claims of the &#x2019;092, &#x2019;309, and &#x2019;737 Patents as maintained in amended form relate to any of our current product candidates. Additional ex parte reexaminations could be filed in the future and although we plan to vigorously protect our intellectual property rights, as with all legal proceedings, there can be no guarantee as to the outcome, and, regardless of the merits of third-party challenges, such proceedings are time-consuming and costly. As a result of such reexaminations, our rights under the relevant patents could be narrowed or lost, and in the course of such proceedings, we may incur substantial costs and the time and attention of our management may be diverted from the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock has been listed on The Nasdaq Global Select Market under the symbol &#x201c;NKTX&#x201d; and has been publicly traded since July 10, 2020. Prior to that date, there was no public trading market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 13, 2023, there were approximately 15 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, we may enter into agreements in the future that could contain restrictions on payments of cash dividends.</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 14, 2020, we completed our IPO. Our registration statement on Form S-1 (File No. 333-239301) relating to the IPO was declared effective by the SEC on July 9, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on July 13, 2020 pursuant to Rule 424(b)(4) under the Securities Act. As of December 31, 2022, we estimate that we have used $167.6 million from the net proceeds from the IPO primarily to advance our product candidates through preclinical studies and clinical trial programs, the construction of our manufacturing facility, and for working capital and general corporate purposes. We invested the remaining funds received in cash equivalents and other marketable securities in accordance with our investment policy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no unregistered sales of equity securities during the period covered by this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in Part III, Item 12 of this Annual Report on Form 10 K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. [Reserved]</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled &#x201c;Risk Factors&#x201d; included under Part I, Item 1A and elsewhere in this Annual Report. See &#x201c;Cautionary Note Regarding Forward-Looking Statements&#x201d; in this Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered NK cell therapies to treat cancer. We currently have two lead product candidates, NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, and NKX019, a CAR NK product candidate targeting the CD19 antigen, in ongoing Phase 1 clinical trials. Both product candidates incorporate proprietary technologies that enable us to generate an abundant supply of NK cells, improve the persistence of these cells for sustained activity in the body, engineer enhanced NK cell recognition of tumor targets, enhance cell fitness and tumor microenvironment evasion, and freeze, store and thaw our engineered NK cells for the treatment of cancer. Our product candidates are designed to be allogeneic and off-the-shelf, which means they are produced using cells from a different person than the patient(s) being treated, and they are produced in quantity, then frozen and therefore available for treating patients without delay, unlike autologous cell therapies, which are derived from a patient&#x2019;s own cells. We believe that engineered NK cells have the potential to be an effective cancer therapy, be well tolerated, and avoid some of the toxicities observed with other cell therapies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our modular NK cell engineering platform is designed to address the limitations and challenges of current technologies for engineering T cells and NK cells and is a result of our internal expertise and deep understanding of NK cell biology. Our platform includes proprietary technologies for NK cell expansion, persistence, targeting and cryopreservation. All of our product candidates incorporate each of the four components of our technology platform, which we believe provides the best opportunity for achieving clinically meaningful results in our development program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX101 is currently being studied in a multi-center Phase 1 clinical trial in the U.S. for the treatment of r/r AML and MDS. This ongoing first-in-human study evaluates the safety, pharmacology, and preliminary anti-tumor activity of NKX101. The clinical trial consists of dose-finding followed by dose-expansion and is designed to identify the recommended Phase 2 dose.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX019 is currently being studied in a multi-center Phase 1 clinical trial in the U.S. and Australia for the treatment of a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells and where CD19-targeted engineered NK cells, T cells and monoclonal antibodies have demonstrated clinical activity. This ongoing first-in-human study evaluates the safety, pharmacology, and preliminary anti-tumor activity of NKX019. The clinical trial consists of dose-finding followed by dose-expansion and is designed to identify the recommended Phase 2 dose.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the CRISPR Agreement entered into in May 2021, we are collaboratively designing and advancing up to two allogeneic, gene-edited NK cell therapies, one of which is the engineered CAR NK product candidate targeting the CD70 tumor antigen, and one allogeneic, gene-edited NK+T cell therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since the commencement of our operations in 2015, we have devoted substantially all of our resources in support of our product development efforts, hiring personnel, raising capital to support and expand such activities and providing general and administrative support for these operations. We have not generated any revenue from product sales and have funded our operations primarily from our initial public offering completed in July 2020, the issuance of convertible promissory notes, private placements of our preferred stock, the secondary offering of our common stock completed in April 2022, the proceeds from the sale of our common stock pursuant to the ATM Offering Program, and with proceeds from our previous collaboration. We have incurred a net loss of $113.8 million and $86.1 million during the years ended December 31, 2022 and 2021, respectively, and we expect to continue to incur significant losses for the foreseeable future. As of December 31, 2022, we had an accumulated deficit of $317.9 million. At December 31, 2022, we had cash, cash equivalents, restricted cash and short-term investments of $354.9 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our operating expenses to significantly increase as we continue to develop and seek regulatory approvals for our product candidates, engage in other research and development activities to expand our pipeline of product candidates, maintain and expand our intellectual property portfolio, and ultimately establish a commercial organization. We have also incurred increased operating expenses since becoming a public company, which we expect will further increase when we are no longer able to rely on certain &#x201c;emerging growth company&#x201d; exemptions we are afforded under the Jumpstart Our Business Startups Act (the &#34;JOBS Act&#34;) as further described under &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x2014;JOBS Act</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; below. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials, and our expenditures on other research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we issued and sold 15,333,334 shares of our common stock in an underwritten public offering, including 2,000,000 shares associated with the full exercise of the underwriters&#x2019; option to purchase additional shares, at a price to the public of $15.00 per share. The total net proceeds from the offering were approximately $215.3 million, after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the third quarter of 2022, we issued and sold 113,213 shares of our common stock pursuant to the ATM Offering Program, resulting in net proceeds of approximately $1.6 million, after deducting offering expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need substantial additional funding to support our continuing operations and pursue our long-term development strategy. We may seek additional funding through the issuance of our common stock, including through our ATM Offering Program, other equity or debt financing or collaborations or partnerships with other companies. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts for our product candidates and other research, development and manufacturing activities. We may not be able to raise additional capital on terms acceptable to us, or at all. Any failure to raise capital as and when needed would compromise our ability to execute on our business plan and may cause us to significantly delay, scale back or discontinue the development of some of our programs or curtail any efforts to expand our product pipeline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Update on COVID-19, Macroeconomic Conditions, and Supply Disruptions</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations have been and may in the future be impacted by the COVID-19 pandemic, as well as by global and national economic and market conditions generally.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic has caused and may in the future cause disruptions in the conduct and enrollment of current and future clinical trials due to, among other things, bed shortages and staffing challenges at our treating hospitals. Hospitals may experience staffing challenges as a result of employee turnover and attrition, the current labor shortage, and/or personnel being pulled off clinical trials to care for patients with COVID-19. In addition, the COVID-19 pandemic has resulted in a significant increase in FDA workload, as well as the need to reprioritize the projects under review, and may do so again in the future. As a result, we may experience delays in FDA timelines along the course of the regulatory process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The continuing disruptions in the global supply chain due to COVID-19 outbreaks or other factors have also resulted in limited disruptions in the supply of our product candidates, as well as global supply shortages of certain materials that we and our CDMO partners use for research and cGMP manufacturing, such as certain raw materials, cell culture media, disposable plastics, and equipment. To the extent there is a subsequent outbreak of COVID-19, or if such an outbreak begins to significantly impact essential distribution systems or our third-party manufacturers, contractors or suppliers, we may experience further disruptions in our supply chain and operations with associated delays in the manufacturing and supply of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we could experience delays in the construction of our commercial-scale cGMP manufacturing facility and future headquarters due to the COVID-19 pandemic or current macroeconomic conditions. We saw significant inflation in construction costs in 2022, which has negatively affected the costs of constructing our new facility, and inflation may continue to impact our future construction and maintenance costs. In addition, global supply chain disruptions, including procurement delays and long lead times on certain materials, have impacted and could in the future further adversely impact the scheduled completion and/or costs of constructing our new facility.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A shortage of fludarabine, an agent commonly used in oncology, including in LD, was initially reported in 2022 and is ongoing. Fludarabine is used in our NKX101 and NKX019 clinical trials prior to treatment with our product candidates. Certain of our clinical trial sites have indicated that they are experiencing a shortage of fludarabine. Although we and our clinical sites are taking steps to try to mitigate any impact of the shortage on our clinical trials, enrollment has been delayed at certain of our clinical trial sites, and we could continue to experience enrollment delays due to the fludarabine shortage in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continuously monitor the effects of domestic and global events, including but not limited to the current and expected impact of the COVID-19 pandemic, inflation, labor shortages, and supply chain matters on our operations, including continued enrollment in the NKX101 and NKX019 clinical trials, as well as on our CROs, CDMOs, and clinical trial sites, to ensure that we remain responsive and adaptable to the dynamic changes in our operating environment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Operations Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs consist primarily of costs incurred for the discovery and clinical development of our drug candidates, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employee-related expenses, including salaries, related benefits, travel and share-based compensation expenses for employees engaged in research and development functions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred in connection with research, laboratory consumables, sponsored research, and preclinical studies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred in connection with conducting clinical trials including investigator grants and site payments for time and pass-through expenses and expenses incurred under agreements with CROs, other vendors or central laboratories and service providers engaged to conduct our trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of consultants engaged in research and development related services;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost to manufacture drug product candidates for use in our preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facilities, depreciation and other expenses, which include allocated expenses for rent and maintenance of facilities, insurance and supplies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to regulatory compliance; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of annual license fees. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We typically have various early-stage research and drug discovery projects as well as various product candidates undergoing clinical trials. Our internal resources, employees and infrastructure are not directly tied to any one research or drug discovery project and are typically deployed across multiple projects. As such, we do not maintain information regarding the costs incurred for these early-stage research and drug discovery programs on a project-specific basis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expense research and development costs as they are incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2022 and 2021. The direct external development program expenses reflect external costs attributable to our clinical development candidates and preclinical candidates selected for further development. Such expenses include third-party contract costs relating to manufacturing, clinical trial activities, translational medicine and toxicology activities. The partner cost sharing represents reimbursable research and development expenses from the CRISPR Agreement. The unallocated internal research and development costs include personnel, facility costs, laboratory consumables and discovery and research related activities associated with our pipeline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.599%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.049%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.123%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct external development program expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX101</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,708</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,456</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKX019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,527</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,466</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CD70</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,839</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">645</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NK+T</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">520</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Program 5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">241</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Partner cost sharing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,163</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,310</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unallocated internal research and development costs:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel related (including share-based compensation)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,637</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,919</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Others</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,929</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,716</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,897</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,412</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development activities are central to our business model. There are numerous factors associated with the successful commercialization of any of our drug candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. In addition, future regulatory factors beyond our control may impact our clinical development programs. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our drug candidates. However, we expect that our research and development expenses will increase substantially in connection with our planned preclinical and clinical development activities in the near term and in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The successful development of our drug candidates is highly uncertain. A change in the outcome of any of a number of variables with respect to the development of our drug candidates may significantly impact the costs and timing associated with the development of our drug candidates. A discussion of the risks and uncertainties that we face in the development and commercialization of our drug candidates can be found under Part I, Item 1A, &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K. We may never succeed in obtaining regulatory approval for any of our drug candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of salaries and employee-related costs, including share-based compensation, for personnel in executive, finance and other administrative functions. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services and facility-related costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our general and administrative expenses will increase for the foreseeable future to support our increased research and development activities and to reflect increased costs associated with operating as a public company. These increased costs will likely include increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income consists of interest earned on our cash, cash equivalents and short-term investments and adjustments related to amortization of purchase premiums and accretion of discounts of short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to corporate U.S. federal and state income taxation. As of December 31, 2022, we had federal and state net operating loss carryforwards of approximately $153.3 million and $65.1 million, respectively. Of the $153.3 million federal net operating loss carryforwards, $3.2 million will begin expiring in 2035, if not utilized, while $150.1 million can be carried forward indefinitely. The state tax loss carryforwards will begin expiring in 2036, if not utilized. As of December 31, 2022, we had federal and state research and development tax credits of approximately $9.9 million and $5.6 million, respectively. If not utilized, the federal research tax credit will begin to expire in 2035. The California research tax credit can be carried forward indefinitely.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of net operating losses and credits before utilization. We have not performed an analysis to determine the limitation of our net operating loss carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimate our income tax provision, including deferred tax assets and liabilities, based on management&#x2019;s judgment. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We record liabilities related to uncertain tax positions in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2022 and 2021, we had gross unrecognized tax benefits of $2.3 million and $1.4 million, respectively, all of which would affect our income tax expense if recognized, before consideration of our valuation allowance. As of December 31, 2022, we do not expect our unrecognized tax benefits will significantly change over the next 12 months.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.154%;"></td>
    <td style="width:1.567%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.666%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.567%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.74%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.567%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.74%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,897</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,412</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,485</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,058</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,017</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,041</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,955</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,429</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,526</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(118,955</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(86,429</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(32,526</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,588</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">370</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,218</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(470</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(454</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,118</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">354</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,764</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(113,837</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(86,075</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(27,762</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were $90.9 million and $63.4 million for the years ended December 31, 2022 and 2021, respectively. The increase of $27.5 million was primarily due to increases of $4.7 million in personnel costs, including an increase in share-based compensation expense of $0.6 million as a result of continued growth in headcount, and increases of $13.4 million in our external program costs primarily related to NKX101 and NKX019, and $11.2 million in other internal research costs, primarily consisting of research and laboratory supplies and facilities expenses, offset by an increase of $1.9 million in partner cost sharing reimbursable expenses. The increase in program costs relating to NKX101 and NKX019 is primarily due to additional clinical development activities compared to the prior year period. We expect our research and development expenses will continue to increase in future periods as we progress our product candidates and conduct our clinical trials and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and administrative expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses were $28.1 million and $23.0 million for the years ended December 31, 2022 and 2021, respectively. The increase of $5.1 million was primarily due to an increase in personnel costs of $3.4 million, including an increase of $1.8 million in share-based compensation expense as a result of continued growth in headcount. The increases in general and administrative expense were also due to a $1.0 million increase in professional services related to accounting services, corporate legal fees, other consulting and patent legal fees, and a $0.7 million increase in other general and administrative expenses that included insurance, rent, depreciation expense and other facilities expense. We have incurred and expect to continue to incur additional expenses as a result of being a public company following the completion of our IPO in July 2020, which we expect will further increase when we no longer qualify as an &#x201c;emerging growth company&#x201d; under the JOBS Act. In addition, we have incurred and expect to continue to incur increased expenses related to additional insurance, investor relations and other increases related to needs for additional human resources and professional services associated with being a public company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest income</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income was $5.6 million and $0.4 million for the years ended December 31, 2022 and 2021, respectively. The increase in interest income was due to higher interest earned from short-term investments, partially offset by amortization of purchase premiums and accretion of discounts of short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents, restricted cash and short-term investments of $354.9 million. In connection with our IPO which closed on July 14, 2020, we received $265.1 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2021, we filed a Registration Statement on Form S-3 (the &#34;Shelf Registration Statement&#34;), covering the offer and sale from time to time, pursuant to Rule 415 of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), of up to $500.0 million in aggregate offering price of shares of our common stock, shares of our preferred stock, debt securities, warrants, and rights and units. The Shelf Registration Statement was declared effective by the SEC on September 2, 2021. The Shelf Registration Statement included a prospectus covering the offer and sale from time to time of up to $150.0 million in aggregate offering price of shares of the Company&#x2019;s common stock through an &#x201c;at-the-market&#x201d; equity offering program under the Securities Act (the &#34;ATM Offering Program&#34;) with Cowen and Company, LLC, as sales agent. In 2022, we issued and sold 113,213 shares of our common stock pursuant to the ATM Offering Program, resulting in net proceeds of approximately $1.6 million, after deducting offering expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 28, 2022, we issued and sold 15,333,334 shares of our common stock in an underwritten public offering, including 2,000,000 shares associated with the full exercise of the underwriters&#x2019; option to purchase additional shares, at a price to the public of $15.00 per share. The total net proceeds from the offering were approximately $215.3 million, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred net losses and negative cash flows from operations since our inception and anticipate that we will continue to incur net losses for the foreseeable future. We expect to incur substantial expenditures as we develop our product pipeline and advance our drug candidates through clinical development, undergo the regulatory approval process and, if approved, launch commercial activities. Specifically, in the near term we expect to incur substantial expenses relating to initiating and completing our clinical trials, the development and validation of our manufacturing processes, and other development activities. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need substantial additional funding to support our continuing operations and pursue our long-term development strategy. Until such time as we can generate significant revenue from sales of our drug candidates, if ever, we may seek additional funding through the issuance of our common stock, including through our ATM Offering Program, other equity or debt financing or collaborations or partnerships with other companies. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts for our product candidates and other research, development and manufacturing activities. We may not be able to raise additional capital on terms acceptable to us, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of our drug candidates or delay our efforts to expand our product pipeline. We may also be required to sell or license to other parties&#x2019; rights to develop or commercialize our drug candidates that we would prefer to retain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our current cash, cash equivalents, restricted cash and short-term investments as of December 31, 2022 will be sufficient to meet our cash needs for at least 12 months following the issuance date of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth a summary of our cash flows for the periods indicated (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.809%;"></td>
    <td style="width:1.513%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.013%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.534%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.131%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(57,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(67,927</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(184,689</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,534</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">219,012</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,202</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(22,677</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(34,191</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net cash used in operating activities for the year ended December 31, 2022 of $57.0 million was primarily due to our net loss of $113.8 million, adjusted for net non-cash charges of $23.1 million and a change in operating assets and liabilities of $33.7 million. The net non-cash charges of $23.1 million consisted primarily of share-based compensation of $16.9 million, depreciation and amortization of $2.6 million, investment accretion and amortization of $0.8 million and non-cash lease expense of $3.9 million.  The net change in operating assets and liabilities of $33.7 million was related to the increase in prepaid and other current assets of $1.5 million, offset by an increase in accounts payable and accrued and other liabilities of $2.8 million as we continued to increase our research and development related activities and an increase in operating lease liabilities of $32.5 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net cash used in operating activities for the year ended December 31, 2021 of $67.9 million was primarily due to our net loss of $86.1 million, adjusted for net non-cash charges of $19.8 million and a change in operating assets and liabilities of $1.6 million. The net non-cash charges of $19.8 million consisted primarily of share-based compensation of $14.5 million, depreciation and amortization of $1.8 million, investment accretion and amortization of $3.2 million and non-cash lease expense of $0.4 million.  The net change in operating assets and liabilities of $1.6 million was related to the increase in prepaid and other current assets of $4.4 million primarily due to the cost sharing receivable, higher manufacturing and clinical deposits and other current assets, offset by an increase in accounts payable and accrued and other liabilities of $2.8 million as we continued to increase our research and development related activities.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net cash used in investing activities for the year ended December 31, 2022 of $184.7 million was comprised of purchases of property and equipment of $47.1 million primarily related to the construction of our manufacturing facility and purchases of short-term investments of $385.9 million, partially offset by proceeds from maturities of short-term investments of $248.3 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net cash provided by investing activities for the year ended December 31, 2021 of $32.5 million was comprised of proceeds from maturities of short-term investments of $264.8 million, partially offset by purchases of property and equipment of $5.0 million primarily related to the construction of our manufacturing facility and purchases of short-term investments of $227.3 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2022 of $219.0 million was mainly due to the net proceeds of $215.6 million from the secondary offering, after deducting underwriting discounts and commissions and other offering costs, net proceeds of $1.6 million from the ATM Offering Program after deducting issuance costs, proceeds from ESPP purchases of $0.4 million, and proceeds of $1.4 million from the exercise of stock options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2021 of $1.2 million was mainly due to proceeds from the exercise of stock options, partially offset by payment of deferred offering costs of $0.3</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million associated with the filing of our Shelf Registration Statement and the establishment of our ATM Offering Program.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based upon our current operating plans, we believe that our existing cash, cash equivalents, restricted cash and short-term investments will be sufficient to fund our operations for at least the next 12 months from the date of issuing this Annual Report on Form 10-K. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing therapeutic product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the type, number, scope, progress, expansions, results, costs and timing of, our clinical trials and preclinical studies for our product candidates or other potential product candidates or indications which we are pursuing or may choose to pursue in the future; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the outcome, timing and costs of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of manufacturing for our product candidates, including commercial manufacturing and the costs associated with building our manufacturing facility; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patients&#x2019; willingness or ability to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements, including payments required for meeting regulatory and commercial milestones or sales based royalties; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of obtaining, maintaining and enforcing our patent and other intellectual property rights; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs associated with any product candidates, products or technologies that we may in-license or acquire.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time as we can generate significant revenue from sales of our therapeutic product candidates, if ever, we expect to finance our cash needs through public or private equity, including pursuant to the ATM Offering Program, or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. We may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. There may also be instances where our ability to access a portion of our existing cash, cash equivalents and investments may be threatened due to financial conditions affecting the banking system and financial markets. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams or research programs or may have to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">grant licenses on terms that may not be favorable to us and may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2018, we entered into a lease agreement for our corporate office and laboratory space located in South San Francisco, California with an expiration date in May 2025 (the &#34;Initial Lease Agreement&#34;). In April 2019, we executed the first amendment to the Initial Lease Agreement for additional corporate space, laboratory space and manufacturing capabilities and an extension to the lease term through April 2026. The terms of the lease amendment contain a rent abatement for the first month and rent escalation provisions. In addition to the base rent payments, we will be obligated to pay certain customary amounts for our share of operating expenses and tax obligations related to the facilities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, we executed the second amendment to the Initial Lease Agreement for an eight-year non-cancelable lease for additional office and laboratory space in the same building. The lease amendment for the additional space provided for abatement of rent during the first three months of the lease and contained rent escalations during the term of the lease. The lease amendment for this additional space commenced in January 2021 and expires in January 2029. The lease amendment also included an extension of the lease term of our existing office and laboratory space through January 2029, with an option to extend the lease for an additional seven-year term.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, we executed the third amendment to the Initial Lease Agreement for a three-year non-cancelable lease for additional office space in the same building. The lease amendment for this additional space commenced in the second quarter of 2021 and expires in March 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, we executed the fourth amendment to the Initial Lease Agreement for a seven-year non-cancelable lease for additional office and laboratory space in the same building. The lease amendment for additional space provided for abatement of rent during the first two months of the lease and contained rent escalations during the term of the lease. The lease amendment for this additional space is anticipated to commence in April 2022 and expires in January 2029. The Company expects to pay base rent of approximately $4.6 million over the lease term. The lease amendment also includes this additional space in our option to extend the lease for an additional seven-year term.  The other terms of the Initial Lease Agreement, as amended, remain unchanged.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, we entered into a lease agreement for corporate office, manufacturing and laboratory space located in South San Francisco, California with an expiration date approximately twelve years after the lease's legal commencement date (the &#34;Additional Lease Agreement&#34;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will become responsible for paying rent on the lease's legal commencement date. The Company expects to pay base rent of approximately $99.6 million over the lease term. In addition to the base rent payments, we will be obligated to pay certain customary amounts for our share of operating expenses and tax obligations related to the facilities. The Additional Lease Agreement also provides for certain tenant improvement allowances for tenant improvements and certain infrastructure upgrades in connection with the initial buildout of the premises, a portion of which, if utilized, would need to be repaid by us over the lease term.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> executed the first amendment to the Additional Lease Agreement for our corporate office, manufacturing and laboratory space. The amendment expressly includes manufacturing as a permitted use at the facility, clarifies that Silicon Valley Bank is an acceptable bank for purposes of issuing a letter of credit under the lease, revises the letter of credit transferability terms and replaces the form of letter of credit attached to the lease. The other terms of the Additional Lease Agreement remain unchanged.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, we executed the fifth amendment to the Initial Lease Agreement and the second amendment to the Additional Lease Agreement. The amendments provide for approximately $15 million of additional tenant improvement allowances for the future facility, increase the rent for the future facility, and increase the rent and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">term of the lease for some of our existing facilities. These allowances are in addition to the tenant improvement allowances of $25.2 million included in the original lease agreement for the future facility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules and regulations of the SEC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, including those related to preclinical studies and clinical trial accruals, and share-based compensation. We base our estimates and assumptions on historical experience, known trends and events, and various other factors that are believed to be reasonable and appropriate under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. See Note 2 to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for a summary of significant accounting policies and the effect on our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Recent Accounting Pronouncements in Note 2 to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As permitted under Delaware law and in accordance with our bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also a party to indemnification agreements with our officers and directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of December 31, 2022 and 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have one business activity and operate in one reportable segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JOBS Act</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; as described under the JOBS Act, and we could have taken advantage of an extended transition period for complying with new or revised accounting standards. This would have allowed us to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have chosen irrevocably to &#x201c;opt out&#x201d; of such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of The Sarbanes-Oxley Act of 2002 (the &#34;Sarbanes-Oxley Act&#34;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of the consummation of our IPO, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (iii) the last day of the fiscal year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;Exchange Act&#34;), which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company or a non-accelerated filer, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our prospectuses and in our periodic reports and proxy statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We hold certain financial instruments for which a change in prevailing interest rates may cause the principal amount of the marketable securities to fluctuate. Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We invest our excess cash primarily in money market funds, commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our marketable securities without significantly increasing risk. Additionally, we established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity. For marketable investment securities with short-term maturities, we do not believe that an increase or decrease in market rates would have a significant impact on the realized values or the statements of operations and comprehensive loss. As such, we believe that if a 10.0% change in interest rates were to have occurred on December 31, 2022, this change would not have had a material effect on the fair value of our investment portfolio as of that date.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to market risk related to changes in foreign currency exchange rates. We contract with vendors that are located outside the United States and certain invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with such arrangements. We do not currently hedge our foreign currency exchange risk. Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not believe that inflation, interest rate changes, or exchange rate fluctuations had a significant impact on our results of operations for any periods presented herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Index to Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:89.925%;"></td>
    <td style="width:10.075%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_962285eb-20f8-4f4a-baea-ebb6b265cf57" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audited Financial Statements</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:18.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,204,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:18.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,204,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operation and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:18.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,204,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Stockholders' Equity</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:18.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,204,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:18.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,204,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Regist</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and Board of Directors of Nkarta, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying balance sheets of Nkarta, Inc. (the &#34;Company&#34;) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, stockholders&#x2019; equity and cash flows, for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#34;financial statements&#34;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:18.0pt;margin-right:16.667%;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_479c7b92-ce03-4a16-9d01-3adcb1e649a1" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_12cfa57e-57e4-4744-a033-25c6ce8ab73f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.599%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.049%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.123%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_111e0ab1-c95e-40eb-a2bc-007290248d15" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55d2631e-f25f-496d-ba20-17bd42f4297a" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments, available-for-sale</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_511cac85-8410-455f-acd9-ab5d7b87e4fe" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">314,649</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b0ee423-394a-448c-ab6f-c7a853f90058" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,272</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43e245bd-353a-4834-a73e-c7e1bc253dfc" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,545</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6dd11b7-103b-43e4-934a-acc54545d0bc" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93a24b35-eb5c-43ae-8e31-fb5b723bdcfc" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">360,688</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0016913e-e79d-418b-8a1e-f12f994547e9" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">245,780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f973d1b-88bb-4db2-8806-95182fd51a42" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,743</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8652cb6a-3280-4406-8d1d-02bee7b39105" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5263469-a984-46fb-8abf-254c23c1dfff" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,908</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84cd5b3b-bba5-432b-ac33-58ff98f8164e" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57d8a6dc-e12b-4657-9af8-681409f831fb" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,749</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53d29299-7394-4bc6-a79b-5aa91bfa3648" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e1e6dd7-f42c-4cb8-87ed-7d20b2a4c2f4" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7613e14c-63c0-4a1a-9714-8452bbe3b2a3" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,491</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69bfc2a4-701c-4c75-9541-b93a71834913" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">472,938</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_414bf7b1-e968-4e65-ade3-9285ad807079" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273,903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59b584d4-f351-4b66-a703-51db0da67be2" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a59d38c6-a80f-46f5-b81c-9131db42f713" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea9919ea-81ee-4926-85f9-abb46e8229ef" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,249</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f89f0487-30af-4794-970c-737bfc6dde40" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1de04a01-177a-4c92-8450-5845f4fa5964" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_288ca8c4-dedb-4893-b173-431f1f7aaa73" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69d7af77-52cb-4ba3-a8a2-ea0d24b749fb" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,046</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2da773ef-060a-4319-9c40-58a51f61e8cc" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab9206f7-eeb3-41dc-a3d0-1d0f117c1b17" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,685</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8fd4783-6364-4ad8-a858-5bdf47986351" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e93b5ed3-1875-4b4f-9845-d3e8851bf188" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d2fc66f-538f-4381-9a06-a5bf6dcb57f3" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73e45353-0106-4c74-9003-1639922e46b4" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,936</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_863703a1-6d57-4227-9b1e-b47b16972aad;"><span style="-sec-ix-hidden:F_198285a3-afca-45fe-b559-b79c053dd8b8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 7)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c6a0b1b-c163-49c0-bca7-ed40c82f6c93" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_e15bd7a7-9fa0-4ee2-b6b2-53c30ebd4372" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0d337cd-02a6-4d1c-9e9b-5b367837e3e8" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_9c5f5530-0664-44b6-8430-519168e1ebfb" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">54,350,179</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares<br />&#160;&#160;&#160;authorized at December 31, 2022; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_376f47c3-b51d-4839-8383-ac609fe1306e" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6f7bf634-9868-4e25-b03f-600691126f96" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_55a1d0c1-70de-4ce7-b6ef-fc2f2dde194e" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fb2c3656-cf93-44ae-bfe9-8d578179673f" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;issued and outstanding at December 31, 2022 and 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_039b0ac0-597a-43be-a936-17146b41c847;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_5658f9a6-0756-441f-93ac-997697fa2195;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10c9d330-7985-42d8-aa9b-41159dd1c862" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_c8c18be9-0ac0-4330-adb7-f149f2344771" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_854bcd68-f6dd-40a3-b94f-7bc8d6ecadb5" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_3678723a-bd9e-4c4d-81e8-22f2a9f2dfcd" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;authorized at December 31, 2022; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5524e24b-6f91-4e9f-98d2-6510acbb423c" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_5b8eb859-5888-4390-8e92-34ee07415eed" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,877,806</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />&#160;&#160;&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8af12453-5356-4c57-9f61-fce3ef225b7d" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_38af41ba-dc70-4250-ac12-f6075a2f9d9c" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,971,107</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022 <br />&#160;&#160;&#160;and 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da546fcf-979e-4408-a56d-d5c635321b2d" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcdcb700-45c8-47d8-b88d-4795dde730fd" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02fdc582-c17b-4e5c-a6a8-ce66518bd22e" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">690,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e913ec2-5396-472d-af7f-77d9e59387b8" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">455,210</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3028601-b665-41d2-af74-ca07561ac183" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">679</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f6195cd-3e3b-4e3c-83e0-445db5e4c72a" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f07b295a-ef52-4198-ad01-0f6926266287" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">317,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66c6084b-ce03-40bf-ad15-2f03f0d25cc1" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">204,096</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_472125a9-e02c-42c3-b8a7-bce6340ab8bf" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">372,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf8e818f-0bc6-4bfa-8046-7da000c30a2c" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">250,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b7ea332-ec2b-45d9-b17a-5b1ca7d4e7ea" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">472,938</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0126fce-6bc2-448c-903f-dcd3ed0ebc22" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273,903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.162%;"></td>
    <td style="width:1.89%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.491999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.89%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.565999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a6496b9-e661-4e60-aa81-4df1f697eb08" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,897</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_669cdd70-fe7b-4faf-8c85-58bc7b01cadd" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,412</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb814061-4e8a-4eac-a55f-93f6142c8ad3" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e684570-8149-4900-87af-23c93bb149dd" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a1d6820-bbab-43f8-8f66-2128904689da" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98de15be-5b15-42b4-9acd-0cfb57a2ec6d" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,429</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43111545-39a2-4b56-a8d0-9a5f25fe96ff" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">118,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aab2b4e9-36ce-4480-844e-7f783a3b0c72" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,429</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_026f615d-dd89-4c1e-b8e3-e7407224c017" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,588</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ff4066e-da72-4886-ad88-1f941bd83e0d" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2d06ffd-7efb-4761-aace-9528e52682a7" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1edec751-a3c2-40c1-b1c0-e63ab0a6f96b" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29b54b1c-2c17-4071-9084-b46ffd886f2a" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53e3eceb-62bd-4ad4-9375-a1aad2e3e680" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">354</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2848cfb9-f223-4bf2-baeb-980397437541" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">113,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86efb2b0-02e2-487c-bd42-339a089c84e3" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f26d2e2a-d63c-4b63-8670-3834eb06c7b0" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">113,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59e52909-6cae-4748-8aa2-78bfb5217063" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cffd6df9-437f-4e2f-8b73-871086f1f378" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42ca0519-47f9-40aa-8d79-7e364844d031" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a995be3-69d2-44fd-89d0-9238b3dccafb" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">114,366</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9de13ff1-6011-4991-93fb-7d8fddaeb11e" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ce0ad60-2ac2-49e6-b545-a31da174b0d6" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_f25ea6cc-0c1d-4a39-90ee-9c492b19bfb5" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.61</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ef81ae9-dfcc-4c0a-a11f-433b8c63ed09" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_0cb4a1c2-5e7d-4408-9caa-94b7252e1312" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.62</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of common shares used in<br />&#160;&#160;&#160;net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07ea61a1-5fe3-4a0b-a268-136fc5129688" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_37bfbcfc-25ee-435f-8df3-31f46764d864" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">43,631,722</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9dde344-7b2b-41a2-af12-df2094feda04" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_15220682-179b-400d-877f-8d14b2c76c03" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,856,883</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.136%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.144%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.291%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.826%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.291%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.84%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.305%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.854%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.305%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.854%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.305%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.854%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paid-In<br />Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive<br />Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders'<br />Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84d220d1-5e9a-4ab8-a389-0a91fafc8311" contextRef="C_a4a20bb1-0ddc-4e5d-9ac6-131ac886e0ba" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,627,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d647aee1-a5b0-403e-a586-813cf6ed36b1" contextRef="C_a4a20bb1-0ddc-4e5d-9ac6-131ac886e0ba" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c7268a9-8008-4664-94e6-0fd4acb03020" contextRef="C_0f5f41de-e22b-492e-9aab-31a2107d81dc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">439,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bee9e481-5a97-4579-b137-d135c72859e0" contextRef="C_5ac1ee49-377e-467a-9ba3-17eff01ca117" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">118,021</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d9d4c01-727a-4b3a-903a-d206233851c5" contextRef="C_3c46e250-9967-4f2d-81f6-f41141108536" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb6f32e4-eeb4-4858-a8f9-e779a8b137fa" contextRef="C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">321,220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of shares of common stock<br />&#160;&#160;&#160;subject to repurchase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9213aa3-1332-4959-b5fc-dc08bcc07239" contextRef="C_ea510978-78aa-41fd-bda5-9491f506aa24" name="nktx:StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">62,045</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfd4b668-f921-4c1a-b6b0-5e0693e31e84" contextRef="C_6740d2cc-da91-46a2-ad58-636e6c3384c2" name="nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66b23e1e-0851-4144-bdd0-864720157fb4" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock<br />&#160;&#160;&#160;upon exercise of stock option</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0df4c60e-6079-4094-908a-a5b5fb32b89f" contextRef="C_ea510978-78aa-41fd-bda5-9491f506aa24" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">281,099</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad718b2e-3319-4ca4-9b7e-b0b02fe312da" contextRef="C_6740d2cc-da91-46a2-ad58-636e6c3384c2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d28a488b-ec4d-4cae-86c1-e15922d72873" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7bde141-c9d2-4ffd-bd89-84bae6322c30" contextRef="C_6740d2cc-da91-46a2-ad58-636e6c3384c2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d9efb70-3e2c-4d3c-92f6-2dc47656ff41" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on short-term<br />&#160;&#160;&#160;investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5ba6296-1307-430b-a19b-952af0296d8f" contextRef="C_d56636f3-c58d-42fd-837d-0a0954658fe0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15577549-80b7-4794-b9b6-1d2925caf538" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d520d38-4892-49f4-bc12-73b9ffe608b7" contextRef="C_51775edc-1ac6-4de8-ae0e-dabb7398d898" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_790063c2-1aca-40ec-8ba8-501a42bf4bec" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36a00aa6-a8d5-4a64-aed7-7d29a2240d22" contextRef="C_8074f9cd-476b-4fa5-a455-4be53c9fdce6" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,971,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c8da132-ab66-4701-ac0c-68835373900d" contextRef="C_8074f9cd-476b-4fa5-a455-4be53c9fdce6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26edfcc1-b7a4-4ab8-a2b9-9ec8582024e2" contextRef="C_e103274a-366e-48fb-b799-052573c606d1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">455,210</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6af22231-fafa-4874-9222-93c1dedef7e9" contextRef="C_fca8d672-8425-4bf2-a2fd-b3e697b44bd8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">204,096</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40fd5da4-4811-45e0-802a-e1667e2cb299" contextRef="C_31abcc35-68e1-488a-b26e-29817aecaa5c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_412e417f-326b-4b14-8b56-1da8055c266b" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">250,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of shares of common stock<br />&#160;&#160;&#160;subject to repurchase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c91d9ace-c11c-45b9-a7f6-c9fe15cb3202" contextRef="C_1cd10163-6e81-4530-a414-a8bef05e747e" name="nktx:StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a226d55b-a6e3-4d4f-a643-f9298d0d69e7" contextRef="C_996ef9b2-0b0e-4010-a387-288c02df3d11" name="nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_128fef68-52c0-41d5-8698-27981e129ad5" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock<br />&#160;&#160;&#160;upon exercise of stock option, net of repurchase</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd713bf5-3319-4213-83f6-3b699d942cbb" contextRef="C_1cd10163-6e81-4530-a414-a8bef05e747e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">383,120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2f80c04-0e04-46fc-8154-7db78851ea8e" contextRef="C_996ef9b2-0b0e-4010-a387-288c02df3d11" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,397</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1cfb938-53dd-4692-9faf-76c94eb4d124" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,397</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock<br />&#160;&#160;&#160;upon employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46f7b78b-dfbb-497f-be29-b8f1fdbec112" contextRef="C_1cd10163-6e81-4530-a414-a8bef05e747e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">61,754</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bfbccf2-9090-4a2e-a4a2-1b379b561640" contextRef="C_996ef9b2-0b0e-4010-a387-288c02df3d11" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">445</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a53c795-c460-4743-9087-eb7d64c236e6" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">445</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock<br />&#160;&#160;&#160;upon secondary offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5333a9a-09b6-4fc0-b887-e59ecbbbebbd" contextRef="C_1d7aca5b-833d-4eaf-8d07-daf876c42502" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,333,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f9eeb14-dc5c-424c-9670-47c20bff5f92" contextRef="C_1d7aca5b-833d-4eaf-8d07-daf876c42502" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4b39b7f-6f26-4a17-98c0-95230cafcddb" contextRef="C_217c98a8-e1b0-496a-b167-e85ebc606b96" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">215,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f708fd3f-c5e3-4efb-8d97-9fb6b3fa1520" contextRef="C_187aafe4-a065-4b40-be67-1ac1dc3d08cc" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">215,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock<br />&#160;&#160;&#160;upon at-the-market offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27f1231c-f461-4742-a3af-2cfc14bab7e3" contextRef="C_dd275879-1ce5-41b8-bf9c-ea076c74e129" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">113,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0d01c9b-f97b-4d24-b489-2840abe4d888" contextRef="C_e51d5a3b-deec-4d63-bc9d-87858ed3e409" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,559</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f04f876-53ce-4af3-9fde-1e9ef23f1e72" contextRef="C_328c18c4-b70f-49ff-8925-ad2743c6a99e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,559</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7b769f2-34e7-4b4c-b5bc-0fe8970dcac8" contextRef="C_996ef9b2-0b0e-4010-a387-288c02df3d11" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b4d1d88-0d87-43f1-a3c7-d78a51adcedd" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on short-term<br />&#160;&#160;&#160;investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de15f746-7d5a-4e81-87f6-735122863761" contextRef="C_ddefd491-c663-47f5-b387-ddd0b74ee428" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d260072d-073b-4955-b10e-817bfbbddb43" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88de4f2e-4ed5-4d12-929e-8105bf912477" contextRef="C_41f74bcf-d3f3-4e8a-b3f5-64d52ddf8089" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">113,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb1e5473-fef6-45fd-a227-93718e6727f9" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">113,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77557ec3-52b4-4d84-9b60-47c3b8a0c865" contextRef="C_3d09d41d-b86f-424c-9448-32c8e1aee0c0" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">48,877,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c445998-0c05-4248-b05a-aa2b756613d9" contextRef="C_3d09d41d-b86f-424c-9448-32c8e1aee0c0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd1fb674-0348-463c-b6e5-55dc722f9390" contextRef="C_104df7f6-48a5-4dc9-8ed3-ca5b85d25ef3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">690,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8f07987-d4a9-4e18-ba13-5f2c7d89dd1d" contextRef="C_242f872b-1115-4f14-a73e-62ca3a640241" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">317,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbe289e2-b2ad-4b66-9be2-75e46307c592" contextRef="C_d3d36e67-6511-40e9-9266-1efc22df210e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">679</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6033e8ad-62b0-4ad4-b0f0-e7344d79c94d" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">372,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.603%;"></td>
    <td style="width:1.604%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.052%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.615%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.127%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30432ea6-cb81-4dbc-a07a-e23e8c9242dd" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">113,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a67ee0e-015c-42e1-a90a-c819051c7521" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65eba554-eb14-401a-8bce-5b61a10e52b3" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b509e95-3260-47d4-b471-54f8c41e800b" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89d7fb50-d5c6-43a1-8713-8e6295d25184" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,637</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e93ff60f-c7bc-47bb-8ef4-b840a76337da" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,756</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accretion of discount and amortization of premium on investments, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a99ecb9e-e7fd-4bcf-98f8-103f08ac33be" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9569aac-b109-478b-b7f4-934d1cded489" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa7f33b4-2d89-4847-b488-f52505676918" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,935</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79f67574-c83b-41ae-8711-7fbc4742441d" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized loss on investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe58089a-1bdd-4a39-aeac-68000d89cf32" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Others</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a61fcb09-1448-4545-896d-08a46a66a3fb" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45f7d157-d395-489a-92da-1b0fd91553fc" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,489</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21768bc4-844f-42f4-9aca-2524f5364d2d" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9af8cf50-a507-4249-8930-f5d6807c7c1d" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,469</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable and accrued and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_565bef13-615d-49be-bc70-df50235354d8" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,757</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_694f928b-6567-4f6a-80ab-d743150c25a7" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="nktx:IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,792</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1da03a9-18ca-4082-a677-9a90c97767fe" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c734b83f-2a6e-44f5-a0a2-b04349de4b75" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">67,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of available-for-sale securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dc3b7da-fe04-426e-b8ae-524c4daeab7b" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">385,887</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf87267b-800b-4062-9a51-636095206f11" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,282</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from maturities of available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a3c3408-57df-4e93-aa9a-167ded76156d" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">248,309</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74f81f12-b31f-427c-9c70-00a1b4ec230f" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264,841</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_500b1649-49f5-40f9-920f-2b81d487e706" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3ae322f-bfe9-4cc0-9fb7-95d1ab9f0b4b" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_444663d3-607f-4ecc-a9eb-c8dcabcb1459" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">184,689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc940210-19ff-4618-a59f-ec6471bacb91" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from secondary offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6059c82-0c29-47f2-b6f3-2c7c72765851" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:ProceedsFromSecondaryOfferingNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">215,611</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from ATM offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15ad6665-6195-40e9-a6bd-0448300beedd" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,559</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from ESPP purchases</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e51026f-8ee9-4524-aa43-05800e93c71f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">445</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from stock option exercises</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b99f856-20dc-42f1-94c8-430253a78331" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,397</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cdf00a9-60f0-4148-b249-a4197e17fc39" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments of deferred offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6953e061-7d7b-40e9-95bd-f332e1e1a443" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="nktx:PaymentsOfDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b6b8008-8359-4d99-84f3-29d772c29782" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">219,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2a1d00e-2b11-40c0-a792-2066c3692c42" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,202</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76770806-2c88-45b8-a9d3-40887e4e46bc" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22,677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fa2ed0a-4805-4c2e-91c9-5b3b1cd1fc25" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,191</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66ecd308-2c0b-4fce-9fd3-c43c31df4288" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6302a8e8-527f-4d6b-a5db-6b9e151e4c44" contextRef="C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,105</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1cd3a72-fa84-42a6-b917-91014622862f" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6d33090-d430-48ba-81f7-8327ad52d9f9" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reconciliation of cash, cash equivalents and restricted cash <br />&#160;&#160;&#160;to the balance sheets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0e9bb48-097f-4801-96e9-e8ebd1101c47" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cde583e-c70b-46c3-a459-92bddf0f02ba" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25ce0740-dca6-4804-81fe-4bfc00b873a2" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,743</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e714165-011e-4887-974e-e4cde818f000" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e27b0bf4-ae18-425d-9b39-80cd7461c065" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2892f732-b90b-4081-8587-2f4cfed44233" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of non-cash investing and <br />&#160;&#160;&#160;financing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisitions of property and equipment in accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d46c164d-6865-47cb-bb38-b7659dce4fae" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,579</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2f6de27-c374-4c98-a761-d26d8b1c2830" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="nktx:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to the Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6c039e17-25c0-4b1e-9155-47bea22d4b07" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of the Business</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc. (&#34;Nkarta&#34; or the &#34;Company&#34;) was incorporated in the State of Delaware in July 2015. The Company is a biopharmaceutical company developing engineered natural killer (&#34;NK&#34;) cells to treat cancer. The Company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta&#x2019;s goal is to develop off-the-shelf NK cell therapy product candidates to improve outcomes for patients. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s operations are based in South San Francisco, California, and it operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35f05915-3d2c-4813-81a1-73e8c44a28d1" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Management Plans</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, conducting preclinical studies and initiating clinical studies, and has not realized substantial revenues from its planned principal operations. In addition, the Company has a limited operating history, has incurred operating losses since inception and expects that it will continue to incur net losses into the foreseeable future as it continues its research and development activities. As of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a39650c-8465-4288-b1a4-6ea767aa3d1d" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">317.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and cash, cash equivalents, restricted cash and short-term investments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0146ffb-b91c-4354-bd53-18ae656a3c2a" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:CashCashEquivalentsRestrictedCashAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">354.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ebt or equity financings or other arrangements to fund operations. Management believes that the Company&#x2019;s current cash, cash equivalents, restricted cash and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3972a55d-07a7-4e47-b9cb-08b6a689e738" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df2a1773-6154-41e7-a67f-56678eccc25a" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principle (&#34;U.S. GAAP&#34;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df6b93c0-6fe1-45de-95ae-6da9cda8ad64" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:UnusualOrInfrequentItemsDisclosurePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19 Pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic has caused disruptions in the global economy and has affected and may in the future affect the Company&#x2019;s business and operations in the future. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (the &#34;CARES Act&#34;) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act had no impact on the Company&#x2019;s income tax provision for the year ended December 31, 2022. The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_836bf1b3-de33-4e4a-b52b-08f0d9b437ed" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#x2019;s financial statements and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accompanying </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">notes. On an ongoing basis, management evaluates its estimates, including those related to preclinical studies, fair value of assets and liabilities, share-based compensation and income taxes. Management bases its estimates on historical experience, knowledge of current events and actions it may undertake in the future that management believes to be reasonable under the circumstances. Actual results may differ from these estimates and assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d19048d-3be3-4f0d-8f33-b142ae41af9b" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality and are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bce4e0bc-2cf3-4238-8e4a-9b55c3dad0fe" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_be0a0722-8e9b-4d87-aba5-b864814b4906" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable inputs such as quoted prices in active markets;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_34434d35-5ee2-4d8d-9706-50cb8f50954b" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, Short-term Investments and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with insignificant interest rate risk and an original maturity of three months or less at the date of purchase to be cash equivalents. Cash includes demand deposits held in readily available checking accounts at a federally insured financial institution. Cash equivalents consist of money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-term Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments consist of commercial debt securities, commercial paper and Government securities, classified as available-for-sale securities and have maturities of greater than three months but less than one year. The Company has classified most of its available-for-sale investment securities as current assets on the balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carries these securities at fair value, and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to maintain letters of credit related to its office and lab space lease and the additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing. This cash is the collateral for those letters of credit and per the terms of the leases, must remain in place until one to two months after the termination of the leases. As the remaining terms of the leases as of December 31, 2022 is greater than one year, the related restricted cash has been classified as non-current.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_637a5edd-d044-4b45-be2b-333162293ba1" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and software and construction-in-progress are stated at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_491c5e57-d09d-4f35-9266-28735ed2f748;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ebe639a5-7164-4337-9890-5f1265501394" contextRef="C_9b8fd370-f133-4a2b-a2c1-752e3951322c" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_44c0a79a-5c25-4829-96ec-813dcabbcb9c" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December 31, 2022, there has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8181722c-4c81-437e-a3e3-573885011fef" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairment losses recorded by the Company.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_98944738-a7ef-40e5-9948-94add03bd96c" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_298f6a2e-f2b0-466b-801c-530e3840027f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. There has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bf45f04-6b46-4205-9457-84bfc9e1902a" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such liabilities recorded by the Company as of December 31, 2022.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db44f29d-44b5-42ac-9390-e87293b468be" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets (&#34;ROU assets&#34;) which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the balance sheets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize lease liabilities and ROU assets for short-term leases with terms of twelve months or less.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_79eee969-f337-4128-96dc-0158ccae566b" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option, employee stock purchase plan, and restricted stock unit grants, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options, employee stock purchase plan rights and restricted stock units and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options and employee stock purchase plan rights are estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. Options granted during the year have a maximum contractual term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_34ef2807-349d-42f9-a2e4-6446a4a1c0c2" contextRef="C_9b8fd370-f133-4a2b-a2c1-752e3951322c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected term of the employee stock purchase plan rights equals the</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1079385b-d11b-4e89-aa96-58d9c7441f7f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:EmployeeStockPurchasePlanLookBackPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> six-month </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">look-back period. The expected volatility is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury (&#34;U.S. Treasury&#34;) yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options. The fair value of restricted stock units is based on the closing price of the Company's common stock as reported on The Nasdaq Global Market on the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c1aff36c-c801-4653-86fb-0db8a8dae94b" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_edc14200-435d-40f1-a460-1290b399e651" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s chief operating decision maker, its President and Chief Executive Officer, manages its operations and business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbce195d-343b-452b-ae7b-c207dda70ef6" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">segment for the purposes of allocating resources, makes operating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decisions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and evaluates financial performance. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61c4df49-7b53-44c8-aa6b-3e6185f84e63" contextRef="C_a7932d5a-1ed2-47f6-8f53-4bf014a752e3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> product revenue has been generated since inception and all assets are held in the United States.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fb3e24e5-e2ca-4ea6-8394-d032dbc41caa" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities, which include unvested common stock, unvested restricted stock options, and outstanding stock options under the Company&#x2019;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aac70c5f-6d0e-401c-99fb-72787301fa0f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2ddca2f2-495d-4c6a-bee9-8b2ac6b974db" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Net Loss Per Share</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52d38d83-34a6-4f6c-969d-c3ff087a7fd0" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the computation of the basic and diluted net loss per share (in thousands except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.162%;"></td>
        <td style="width:1.89%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.491999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.89%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.565999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e368d5b-7663-4ef3-b1ec-80b85963871a" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">113,837</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_498a3610-d3ac-4284-9ee0-3722d374b60d" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,075</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee963da6-9966-42a1-9b3f-31b40d77577f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">43,635,044</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60901f20-caf4-429c-b355-8f8f9aeb48b4" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,901,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: weighted average unvested common stock <br />&#160;&#160;&#160;issued upon early exercise of common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50b8346b-bfe0-4385-8e38-593960517af4" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions" unitRef="U_shares" decimals="0" sign="-" format="ixt:numdotdecimal">3,322</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4db75677-9b47-40b5-ba2d-7559c75e06b5" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="nktx:WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions" unitRef="U_shares" decimals="0" sign="-" format="ixt:numdotdecimal">44,119</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average shares used to compute net loss<br />&#160;&#160;&#160;per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8e81621-45a6-4bfa-8ada-8a26e9adb31e" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_128f5e54-7df0-4847-b59a-f0e96aeb4cce" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">43,631,722</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_028f0fbd-bfed-4571-83a8-df870b714482" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_33147547-584e-44b1-898e-617cdad6474d" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,856,883</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b8334b4-494e-483b-b09a-fbfdd980148a" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_066524d9-687c-48e4-95f1-b5f3b4aca2ff" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.61</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fb78351-957b-4b80-849b-6610c4532919" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_c6275885-280a-48c3-896f-fa0474791270" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.62</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_626c7975-143c-4592-b226-dd297e5b4da8" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.573%;"></td>
        <td style="width:1.175%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.882%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.175%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.195%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91e9e08c-c728-46cc-a8ed-edc9be2da6d5" contextRef="C_56c70c9b-2181-46db-b6a8-a17ab68f0f6e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,519,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_928e8996-6ece-499f-8d0c-379c953b55c5" contextRef="C_f5787b06-caba-4869-913a-d42e3e4d8626" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,204,686</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16ec8046-41d5-4712-87dc-7cc18468df64" contextRef="C_0c9c944a-ceec-4d30-8fa4-840b650e3911" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">356,728</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested common stock upon early exercise of common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d05b1327-8b6e-413b-8e48-6dfce4e55ab5" contextRef="C_6a853c5f-fc86-43fd-bf06-21c2b2e36b23" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">508</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ebb90df-f9f1-4074-898e-5742d29bbb27" contextRef="C_b79def7d-c6df-41a1-bf0c-919f674fb2ff" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">16,181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2cf122b-8819-4140-9fef-8e2868f8082c" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,876,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87bd7a3c-dacb-479a-9916-570ec7e9d133" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,220,867</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fb19b8b9-162e-4f61-b5e0-f6fd6ea85928" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Fair Value of Financial Instruments</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cd8995a7-b65b-42df-bccc-4cc6cf6775dc" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the fair value of the Company&#x2019;s financial instruments (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:39.51%;"></td>
        <td style="width:1.219%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.957%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.219%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.85%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.219%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.85%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.219%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.957%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br />in Active Markets for<br />Identical Assets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br />Observable Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant <br />Unobservable Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cc17ce6-8210-401d-9b4c-bc42958173af" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fadf217-bb91-4b51-9c66-639eeded3c14" contextRef="C_5d932bf8-0352-4715-adee-681c326862f1" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa88c07d-12f3-4776-aa72-c255de88e54b" contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_459eba88-90a5-4298-a74a-a5ee2dc6a4e8" contextRef="C_d61b13b8-5000-41ad-872b-a55642f66d70" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a606f5fa-5792-4724-9375-1ca4c913a7c0" contextRef="C_e8f4b60d-ae7d-4ecd-ad6a-e4de3f34ea9b" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6015a657-cb31-4d8f-8860-22f759b1e0e2" contextRef="C_62587f67-7720-4862-8bc3-ad2de14109b8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d53efb2-7bde-4eb6-908b-bcabe3aa9996" contextRef="C_ed817214-47bd-4dc1-80a6-cb7172f19a31" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c08fcb8c-8ef4-4bde-a53e-add5cfb5ca86" contextRef="C_7e5762e7-f7e7-4ca0-95b2-9a9aca43a951" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_847594c2-47db-46c3-bc7c-e76e723d0c41" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">314,649</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d363366-d7f5-42cd-a6a3-b1bed7f4e1f5" contextRef="C_d27112b2-cbb8-4700-a273-558f65b6fae8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">314,649</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_333d58b7-7f86-4410-a670-7260ae276e21" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">351,143</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_875a129d-80f1-49fd-b2e0-0e2277c141c2" contextRef="C_5d932bf8-0352-4715-adee-681c326862f1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10b343f9-200f-469c-9f6d-fee5f21c405c" contextRef="C_d27112b2-cbb8-4700-a273-558f65b6fae8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">314,649</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:42.916%;"></td>
        <td style="width:0.437%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.493%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.437%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.168%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.437%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.168%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.437%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.506%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br />in Active Markets for<br />Identical Assets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br />Observable Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant <br />Unobservable Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2a63fa8-e11b-4495-bbd2-4ebb6317e861" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,018</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8f7d061-5841-48d6-a603-9917433f0fd5" contextRef="C_e12e22c5-6319-489d-998a-5a9b9f8b965c" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,018</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ce1fb2f-6ec1-413a-8807-b72cbe1c39d3" contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e1d5e01-b557-4121-a7a2-1206529f0e53" contextRef="C_9e12b052-9715-41fd-bddf-9db4bb8a1947" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e022a817-8aaa-4a3e-bca9-09d184e823f3" contextRef="C_23b5530e-7d65-4f89-a655-72c856a9b438" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae86f00f-b062-4a4e-af5b-b7da871f6247" contextRef="C_71271a5b-183d-4f56-9d1b-7e8e195a7acb" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_761961bd-1d70-44d7-8660-8f6e3aa2ccf4" contextRef="C_c494cf9e-deff-4d61-b7a3-4124b968194f" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,534</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c52d3f8d-fe31-4b06-8806-483a9e8849c1" contextRef="C_9997cb7c-7d06-42b6-b7a1-bf97634ec016" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,534</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93e8a60f-8413-4f88-b8dd-ea211b8f1a56" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b638d9f3-3c8a-4037-865f-d9a9615963d8" contextRef="C_b8ccfab3-765f-42cd-a915-348919b0824a" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08e4956d-e1bf-4987-824a-4dfcdd039492" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">234,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_257b6845-4100-4dc6-931f-e67437e5daa9" contextRef="C_e12e22c5-6319-489d-998a-5a9b9f8b965c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,018</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3da0b11-0d59-45db-9de1-570107eaecb8" contextRef="C_b8ccfab3-765f-42cd-a915-348919b0824a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents and Short-Term Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets measured at fair value on a recurring basis consist of the Company&#x2019;s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and short-term investments consisted of commercial paper, corporate debt securities and Government securities. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments are classified as Level 1 within the fair value hierarchy if their quoted prices are available in active markets for identical securities. Investments in money market funds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca648bbf-e73b-476f-8d86-dd5e8ec445c6" contextRef="C_24c0aaae-b891-4b96-8392-e3514173d5c6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_486fad1c-3e30-4659-a202-a055b6848568" contextRef="C_ac5b81a2-efd6-441c-b505-52b48bac16ee" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">57.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million included in cash equivalents as of December 31, 2022 and 2021, respectively, were classified as Level 1 instruments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments in corporate debt securities, commercial paper and Government securities included in short-term investments are valued using Level 2 inputs. Level 2 securities are initially valued at the transaction price and subsequently valued and reported upon utilizing inputs other than quoted prices that are observable either directly or indirectly, such as quotes from third-party pricing vendors. Fair values determined by Level 2 inputs, which utilize data points that are observable such as quoted prices, interest rates and yield curves, require the exercise of judgment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and use of estimates, that if changed, could significantly affect the Company&#x2019;s financial position and results of operations.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d1f0539-509c-4892-9f7b-d1f5c67ba822" contextRef="C_88e987e9-14ae-4a55-adf7-c0657a837adb" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#x2019;s short-term investments as of December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.958%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:14.279%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.109%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.369%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.171%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.097%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.171%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.297999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity<br />(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated<br />Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_95a1e782-7f2a-4820-8d5d-e3d6d2ed14a9" contextRef="C_d26a61da-14d4-4715-904f-6250145d2632" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cfe24f4-a2a5-4ef8-8e8b-09b86c301c81" contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_409e61c4-41b3-43bb-8f86-5430d551f820" contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c893b841-e117-4e5d-8514-03246797365b" contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_758b4a28-43a4-485d-9588-5033507da8fd" contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_75528e76-e668-4a5f-a23f-ae22edb55c8c" contextRef="C_81bfa481-ab6e-4a60-9e7f-38e17ed8e269" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e774a02-9fb1-4398-85f3-fd06ca6ff029" contextRef="C_737c89a5-e439-47b8-8aaf-76cfec47c0ae" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5dfdc04-e313-4544-8215-7b726e556fa1" contextRef="C_737c89a5-e439-47b8-8aaf-76cfec47c0ae" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6aa6962e-af8b-435d-9bbd-1546079e5575" contextRef="C_737c89a5-e439-47b8-8aaf-76cfec47c0ae" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a174b3ab-d944-41b4-8a54-0b6d57e70cf5" contextRef="C_583fcba6-1ff0-489b-a59a-27d2cc6bc251" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbf1cde9-7d76-4a70-8116-d236c0f81a52" contextRef="C_18f31adc-2623-483c-a5cc-71db7010cc81" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc2754b4-0206-4ecb-9fba-ef5fe417dc2f" contextRef="C_18f31adc-2623-483c-a5cc-71db7010cc81" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">319</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92c2e7e7-d703-4de5-a737-6510c3300baa" contextRef="C_18f31adc-2623-483c-a5cc-71db7010cc81" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9df1d7ea-e72d-48b3-9744-77eb43a5383a" contextRef="C_18f31adc-2623-483c-a5cc-71db7010cc81" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8452c17-2b4c-47bc-874d-18c984ed7ff2" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">315,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a979b4b6-5490-4119-9736-2a8837521a9b" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">762</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4089727b-f90d-4c8c-9144-007a715aa517" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ebbab00-18de-49ee-b0b5-7827b460536c" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">314,649</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.958%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:14.279%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.109%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.183%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.369%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.171%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.097%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.171%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.297999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity<br />(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated<br />Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_27371710-9f86-4918-9844-ac6f87531dd9" contextRef="C_1bc72894-bc11-4b07-8e86-b0f46fc9cf6c" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35e625a7-1ae8-4737-8a3a-83cb27d711a3" contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,548</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d71d707c-4a0d-4da0-8360-7518fc470fdd" contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4f5210d-627c-43f6-b891-e80ba6de01c1" contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a10fddcf-e1f8-4a59-9eee-a980d8bd1f1c" contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c69f2cc1-041c-4d6c-bafb-3c7db0bca99a" contextRef="C_3fec699f-ea28-4689-9337-687766f60d30" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26a13b20-3f67-4302-b9df-e165c675cdf8" contextRef="C_3ad6f663-9c17-49d2-af22-eb2005f970e2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d77e6040-0970-404b-84bd-5e874abc4489" contextRef="C_3ad6f663-9c17-49d2-af22-eb2005f970e2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d608220-d0e0-4323-8681-11b9894d022c" contextRef="C_c7e114d6-1e43-4e3e-a721-90f9540d66a2" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf175a11-dd9c-4a86-a214-2186d3e75049" contextRef="C_d014bbfe-ee80-4fc5-925e-c46b0ee01917" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,602</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e05a6be-b9ff-4242-9fab-5d68150ad4e4" contextRef="C_d014bbfe-ee80-4fc5-925e-c46b0ee01917" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f905ed52-6da8-453b-ba8d-6aa036fa817c" contextRef="C_d014bbfe-ee80-4fc5-925e-c46b0ee01917" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,534</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34b2bbb5-a6ff-4353-ad39-a6101efafa48" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27dd4ab8-2cd8-40ee-9932-b73ebf706945" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">157</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68d22c4b-c99b-4fef-9aa6-2324c28394e6" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01a8ff62-7041-4ac3-8a5d-09737c3493aa" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#x2019;s available-for-sale securities as of December 31, 2022 and 2021 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December 31, 2022 and 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> It is neither management&#x2019;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value, except for investments totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15b8373d-e294-4e79-a30f-8ddaf9e099fc" contextRef="C_bd5a17ec-15ba-48c4-a69b-663e0936c2fc" name="us-gaap:AvailableforsaleSecuritiesSoldAtPar" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">67.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that were sold with a realized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32e03d96-f330-4305-8aa9-712e3c12d199" contextRef="C_bd5a17ec-15ba-48c4-a69b-663e0936c2fc" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in January 2023. The Company recorded this $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a8d47ca-d413-4904-b510-16921c75df3f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:Impairments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as an impairment loss for the year ended December 31, 2022. Unrealized gains and losses are included in accumulated other comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excludes accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment and to not measure an allowance for expected credit losses for accrued interest receivables. Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. It is the Company's policy to present the accrued interest receivable balance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as part of prepaid expenses and other current assets in the balance sheets. Accrued interest receivable related to short-term investments was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb25c1a2-f5d4-4810-8f8e-6e35bd181549" contextRef="C_3a8087e1-63e7-4651-bc43-c16820cff537" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_529b2aac-3c85-4dc9-ba40-3be03aa552f9" contextRef="C_de1b3fd2-437c-46d9-9d40-3096dc12b8c7" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_a4518eba-914a-48c2-9957-3a57176cb0e5" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Balance Sheet Components</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e58e0066-e339-4b8c-bec1-29301170e3d5" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets are comprised of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.853%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.161999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71184a43-e06d-410b-a99c-fd6729b9f2dc" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,616</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b477b7e3-4eaa-488d-8978-b6ec123b783a" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,538</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09476528-0121-4c9f-a2ad-1e951d706a7d" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,929</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_307d2114-cff3-4ab9-a25a-5423b4004d6d" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af0a1dd9-e0f8-46fa-99a0-109ac55243e8" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,545</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f315b8c2-a262-4a27-ba94-229e276388f5" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,692</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5147a44a-044a-401f-90c4-45403c911787" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" continuedAt="F_5147a44a-044a-401f-90c4-45403c911787_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">roperty and equipment, net is comprised of the following (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_5147a44a-044a-401f-90c4-45403c911787_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.049%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.123%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa598145-21aa-49c9-aedb-753b5730f958" contextRef="C_ed03bf83-d13d-4a93-9a1b-a266f8faf400" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_965b38cc-d561-45a9-9c10-2ea3e92f8314" contextRef="C_d8d0678a-6dba-4324-ac26-5b00dadee7ad" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,462</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e282a62-8f88-4574-86ac-7ed1ed879034" contextRef="C_a6a22efc-c313-4977-a01d-0fa7148647f3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">645</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5dfa4af-fdc8-41aa-8b43-9db6a3b99466" contextRef="C_2c954c54-02fd-4743-8a11-058f3cf49640" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_850d7279-5e43-4220-99b5-78709dd50106" contextRef="C_6595a8da-7252-4dae-89c8-5653af52ef0a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea877f48-6112-4020-bf76-ece3cbec9d67" contextRef="C_26bd2db9-3e16-458f-8423-a038b4619fe9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f4d483-24a9-466a-8607-cf1ce7db245d" contextRef="C_3983a133-278f-4146-b005-921fbc2b18af" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">130</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8ad5cda-9452-423c-8367-9f972fcce8ec" contextRef="C_43a91ef6-617a-4181-b769-aa8b7eeac784" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">130</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d07d84e4-7075-40a1-b13e-a51522f085c6" contextRef="C_46288b47-1afa-44f0-be59-d2f91c284d71" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,655</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30d45e90-d908-4e18-9b76-bc0e6b79e290" contextRef="C_2914dfc3-b00d-4a26-95ed-1856d75544a6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33cb961d-c9c4-4a29-bda5-c4026eacaaa1" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,732</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02be0ed0-44c3-4be4-81cb-dcd5cf222ed3" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,043</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97d5cbbd-7dc2-4444-9f93-856c6b71bb5c" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,824</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38bcff42-157f-4afa-94fe-66a49cc69b87" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,187</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_873c9fbe-9da6-4283-9fa1-b74d8ed46aea" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,908</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b3c4a43-542e-4a1f-809e-9e075b8bf04d" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,856</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40bc969e-be4e-434e-bec8-bb63cd3796f1" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f11c2930-877d-4f58-92bd-90ac62421b1f" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued and Other Current Liabilities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_684c883b-b83d-4cac-919d-e6c1fcd3d6c0" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other current liabilities are comprised of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.853%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.161999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_249f42e7-6a5a-4caf-9bbf-1703e0a817bc" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,691</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91701ce7-f2ef-4d48-a6d8-f68a2b6b014e" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9621b491-b1fd-4161-ad8d-47fbdc06c7f3" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,486</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db498929-0dd8-4125-8a56-c2680ea12981" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="nktx:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b0cc00d-9c16-436b-91d6-f93d684f3861" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:AccruedPropertyAndEquipmentLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,001</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80d8dac8-26e2-4fa6-b2a2-bc8f34cf6378" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="nktx:AccruedPropertyAndEquipmentLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued and current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c92c84e3-196b-4bdb-b963-3e30c83e9bb2" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f6a2169-29b5-430f-9e14-8edd55fa28a1" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,518</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f48ffe0-abfc-48e0-b267-0b0f23f61045" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_730e9d91-2c3a-453c-ac95-adce6c9db1a3" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,347</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ad4e1e74-6218-43c5-94ff-b688e7846b07" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has operating leases for its current corporate offices, laboratory space, manufacturing facility, and dedicated space in a vivarium in South San Francisco, California, as well as for an additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a206aa47-2052-42a7-b2e9-c055f9889792" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.851%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.16%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a42334d-59bd-4dda-8fd4-5dbc1bb29fc0" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,220</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f6f1a49-7fed-477e-8f7e-7f663c3768ee" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease expense </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b0d020a-59d2-4e8d-9636-bb7167ae0f37" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">462</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4912a96-9a5c-4368-9c1e-8c2bfb3d4802" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71ca7e2e-0b57-4751-a787-901d5f52b68f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f716a81-fbd5-42d9-81a0-1dbced75a17e" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0d8201d-6310-432f-9ad6-4a90d1854662" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,727</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88c9f0dd-92c5-4022-a537-e14e88610038" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-2.557%;padding-left:2.507%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Variable lease expense for the periods presented primarily included common area maintenance charges.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2938ad9-e594-4cc5-889a-51cd44b4fc27" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental information related to operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.851%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.16%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7523c3c-b727-4818-a654-ed59be001dbc" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,887</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7e1819e-093a-403a-9f3c-43e78bc78790" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average remaining lease term was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bdff1599-c311-4683-9e5e-87dfd7646350" contextRef="C_2ffabe62-fbe5-446e-b9de-8398a5aa0a92" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years for the corporate office and laboratory space leases as of December 31, 2022. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The corporate office lease includes an option to renew for an additional seven years. However, the renewal option was not included in the lease term for calculating the lease liability, as the renewal option allows the Company to maintain operational flexibility, and the Company was not reasonably certain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that it would exercise the renewal option at the time of the lease commencement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average discount rate was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5092ee0-07b2-421f-b21e-02a1e102bb9d" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_390cc75c-5722-4972-b11a-fdbb93f67669" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">59.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95719281-092f-4f31-8382-e02185750673" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases and from modifications of existing leases, respectively, for the year ended December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_05cfb7e8-6c93-467c-bbe3-2ae22d05ba63" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of operating lease liabilities under existing operating leases as of December 31, 2022 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.968%;"></td>
        <td style="width:1.938%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.093%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_226af516-437e-441d-bedf-34b035474231" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,206</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e928ab24-3511-42ec-a337-502ab25f31a8" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,671</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_046ccf90-9eed-4093-9ac0-f8647a9f0300" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a2b7bee-3120-495f-94d6-abc610321e31" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,467</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c88a0f74-021d-43dd-89f5-b9b35d64d0a8" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,917</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_204c3623-c497-45e9-beef-f8f66c2dc0ff" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f869702-61c1-4956-8753-c41ae5f63990" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151,584</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6466930d-b6e7-4fbc-8370-560c576ed1b0" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less tenant improvement receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63c73621-0ea3-4cf3-bbc6-b4dfa14333f3" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:TenantImprovementReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,837</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6778643e-7887-4a0b-ac50-7fb98bcb3a7c" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3fdd34b-8485-44bc-b2a3-28dd56cdcded" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,249</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_910f78ac-17f2-4ced-9be0-a03c63549a24" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,685</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_287f88d0-b51a-4f4b-9b0a-0aa643468e8c" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2018, the Company entered into a lease agreement for its corporate office and laboratory space located in South San Francisco, California with an expiration date in May </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ac46f93b-84da-49c6-8839-40338f138aa2" contextRef="C_d1fc9433-2e3d-4914-a5c8-bc7a7bff7abf" name="nktx:LeaseExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;Initial Lease Agreement&#34;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f6d54e9a-8d69-48de-b20a-b7798b13721b" contextRef="C_52762d64-2657-4a85-b085-9b43b6ef6b2d" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2019, the Company executed the first amendment to the Initial Lease Agreement for additional corporate space, laboratory space and manufacturing capabilities and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81164e46-cac2-4ba7-9a76-01b9fe1381e6" contextRef="C_e7e05b12-6998-4ee3-a819-f951b803d26c" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an extension</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to the lease term through April 2026. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, the Company signed a second amendment to the Initial Lease Agreement. The amended lease provides for an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e69a77e3-93c9-47b6-9f16-c5689b49ad8c" contextRef="C_0dbf8ba2-16eb-4d47-8a53-2bcd7625019d" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eight-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> non-cancelable lease of additional office and laboratory space in the same building. The lease amendment for additional office and laboratory space provided for abatement of rent during the first three months of the lease and contains rent escalations during the term of the lease. The lease for this additional space commenced in January 2021 and expires in January </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4ae5b06e-4516-4307-8402-acd40c03110f" contextRef="C_59d64f92-ff2e-4690-bf99-cc3623e46e80" name="nktx:LeaseExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fa665cec-2f27-42c3-813f-dca68be4e396" contextRef="C_99a492e6-fb70-4aea-a41e-5b84273ea158" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease amendment also includes an extension of the lease term for the existing office and laboratory space beginning on May 1, 2020 and expiring in January 2029. The amendment to the Initial Lease Agreement also includes an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_157afab4-63a6-4442-bcb4-f8284012cee5" contextRef="C_59d64f92-ff2e-4690-bf99-cc3623e46e80" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to extend</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the lease for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99fceea9-17e4-4870-bf3e-c0e154facb15" contextRef="C_9766f258-dd51-4457-9526-56fe0bcb58d8" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, the Company signed a third amendment to the Initial Lease Agreement which provides for the lease of additional space in the same building. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_266e6344-0fcf-4c98-ad9b-5ddfa1090a6d" contextRef="C_b68d2390-4372-4de3-9b47-180a4a7b91f9" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease amendment for this additional space commenced in April 2021 and expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f426bc54-ee18-4909-b808-6e5b96ecb629" contextRef="C_bdd7e725-4ef2-4276-b95f-8ec6ebdac396" name="nktx:LeaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the Company signed a fourth amendment to the Initial Lease Agreement which provides for the lease of additional space in the same building. The lease for additional office and laboratory space provides for abatement of rent during the first two months of the lease and contains rent escalations during the term of the lease. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9b0ea8b8-ec1d-4711-960e-c38a825f7f6b" contextRef="C_c452dd17-c870-489d-8326-cf1262b803dc" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease amendment of this additional space commenced in April 2022 and expires in January </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a80154c7-3820-4f59-863a-17febdadfd19" contextRef="C_c452dd17-c870-489d-8326-cf1262b803dc" name="nktx:LeaseExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The lease amendment also includes this additional space in the Company&#x2019;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_26347c69-9a91-47bc-90ef-e57714ac764f" contextRef="C_c452dd17-c870-489d-8326-cf1262b803dc" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to extend</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the amended Initial Lease Agreement for an additional seven-year term.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The other terms of the Initial Lease Agreement, as amended, remain unchanged.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company entered into a lease agreement for corporate office, manufacturing and laboratory space located in South San Francisco, California with an expiration date approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e0e1895f-b3c0-4a9b-a559-44626e12679b" contextRef="C_00c5bf6f-2fc6-4028-b703-d38c7fb1eb15" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">twelve years </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after the lease's legal commencement date (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;Additional Lease Agreement&#34;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease for this additional space and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obligation to pay rent commenced in January 2022. In addition to base rent, the Company is responsible for payment of direct expenses, which include operating, insurance and tax expenses. The lease also provides for certain tenant improvement allowances of up to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a7062c7-e4b2-48db-bcb8-f9079f5e62ab" contextRef="C_b77baa8f-96a7-406d-a97a-325fd5089207" name="nktx:TenantImprovementsYetToReceiveFromLessor" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for tenant improvements and certain infrastructure upgrades in connection with the initial buildout of the premises, approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4ebb1ef-6999-4922-a11a-0dcb300f10c7" contextRef="C_d5727518-e2f1-4921-a234-816384299bb5" name="nktx:CashReceivedForTenantImprovementAllowancesToBeRepaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of which, if utilized, would need to be repaid by the Company over the lease term. In 2021, the Company delivered a security deposit in the form of a letter of credit o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22bae3a6-8f8a-45e7-9272-ddc526a4a6a4" contextRef="C_4adcd202-22d8-4ab3-b561-2ff39d168d3f" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">llion to the Landlord in connection with the Additional Lease Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company entered into an amendment to the Additional Lease Agreement. The lease amendment expressly includes manufacturing as a permitted use at the facility, clarifies that Silicon Valley Bank is an acceptable bank for purposes of issuing a letter of credit under the lease, revises the letter of credit transferability terms and replaces the form of letter of credit attached to the lease.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, the Company entered into fifth amendment to the Initial Lease Agreement and a second amendment to the Additional Lease Agreement for its existing facilities in South San Francisco, California. The fifth amendment to the Initial Lease Agreement includes an extension of the lease term for certain of the Company's existing facilities through July 31, 2030. The second amendment to the Additional Lease Agreement provides for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b49ef2d-467f-4902-ac0d-dfee29bac743" contextRef="C_6f2f80b9-36c3-4ae7-b0df-62a4197809a3" name="nktx:AdditionalTenantImprovementAllowances" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of additional tenant improvement allowances, in addition to the tenant improvement allowances of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c911700a-681c-49cf-97e0-6af99cf8769d" contextRef="C_0f472547-d9cb-42a2-9d4b-f15637efe5f6" name="nktx:TenantImprovementsYetToReceiveFromLessor" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million included in the original Additional Lease Agreement, and increases the base rent payments over the existing term of the lease.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a7722cb4-5edd-41a8-b891-bf5a59f90fea" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Guarantee Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#x2019;s request in such capacity. The term of the indemnification period is for the officer&#x2019;s or director&#x2019;s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts under certain circumstances and subject to deductibles and exclusions. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c27ff41-7840-4fcd-8257-82edc0ba9910" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bb29f82f-f580-4160-bde6-5c8750f26e62" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> liabilities recorded for these agreements as of December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Letters of Credit</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fac4dc5d-b181-4949-8c0e-0b6f1e7b6535" contextRef="C_d89cf241-714f-47ac-b0fd-90fc206d8545" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in letter of credit agreements with a financial institution that are used as collateral for the Company&#x2019;s corporate headquarters&#x2019; operating lease and the additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing. The letters of credit automatically renew annually without amendment unless cancelled by the financial institutions within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_499bfcfa-fbbf-4dee-ba16-cda4e2927270" contextRef="C_2c1cfa1c-67c5-4c85-a0df-ba0a03295212" name="nktx:LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8f3dc299-8e5b-4fe1-b2be-a714782ae1f1" contextRef="C_54a727df-02a6-4bb0-88ff-9fcf2ef7503f" name="nktx:LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the annual expiration date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0e58d3da-5b22-4f23-afc6-9dd5f7a0a03b" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Collaboration and License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRISPR Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 5, 2021, the Company entered into the CRISPR Agreement with CRISPR to co-develop and co-commercialize an engineered CAR NK product candidate targeting the CD70 tumor antigen and a second novel NK plus T cell product candidate. In addition, the Company has received licenses from CRISPR for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b15f81bf-119e-4530-b430-ab7514b4c520" contextRef="C_1068e57e-6f93-49e0-ba99-d2c70b9915f6" name="nktx:NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" unitRef="U_CrisprCas9" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> CRISPR-Cas9 gene editing targets and will receive a license from CRISPR for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9657f305-2365-4bda-bea5-b6295105cac3" contextRef="C_0abf9930-6b9d-43f1-bcde-e0a41387b2cd" name="nktx:NumberOfNonExclusiveRightsToGeneEditingTargets" unitRef="U_CrisprCas9" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> more CRISPR-Cas9 gene editing targets that can be engineered into an unlimited number of its own NK cell products. CRISPR also has an option to co-develop and co-commercialize a future CAR NK program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms of the CRISPR Agreement, the Company and CRISPR share equally in all research and development costs and potential profits worldwide related to the NKX070 product candidate, NK+T product candidate, and the potential future CAR NK program. For the NK+T program, CRISPR is responsible for gene-editing activities and T cell related activities, and Nkarta is responsible for NK cell related activities. The related impact of the cost sharing associated with the research and development activities is included in research and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expense on the condensed statements of operations. Expenses related to services performed by the Company are classified as research and development expense. Payments received from CRISPR for partial reimbursement of expenses are recorded as a reduction of research and development expense. Reduction of research and development expense resulting from partial reimbursement from CRISPR was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b6a8793-f608-4434-94d2-b59c4494c4eb" contextRef="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9" name="nktx:ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_780a552b-2be3-459b-a825-295ec19ef044" contextRef="C_a6bef3a2-7f1b-4b5f-99b7-d7a3e86365c0" name="nktx:ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the Company had a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_330856b4-2624-4770-8e54-d20718b0d3e0" contextRef="C_176fb4da-b4be-4abb-b573-31f43872e49d" name="nktx:ReceivableUnderResearchCostSharingProvision" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million receivable under the research cost sharing provision, which is included as part of prepaid expenses and other current assets in the condensed balance sheet.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ea</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ch non-collaboration product candidate incorporating a genome editing target licensed from CRISPR (a &#34;CRISPR-licensed product candidate&#34;), the Co</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mpany</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> would retain worldwide rights and may be required to make potential future payments based on the achievement of development and regulatory approval milestones </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_34e547d7-c9a5-4f65-8b29-477886556173" contextRef="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9" name="nktx:PotentialFuturePaymentsBasedOnAchievementOfMilestones"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">totaling less than mid-twenty million dollars</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for each CRISPR-licensed product candidate, as well as tiered royalties up to the mid-single digits on net product sales of such product. Further, for each CRISPR-licensed product candidate targeting a specified tumor antigen, the Company may be required to make potential future payments based on the achievement of development and regulatory approval milestones totaling less than high-forty million dollars</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for each CRISPR-licensed product candidate targeting the specified tumor antigen, as well as tiered royalties up to the mid-single digits on net product sales of such product. As of December 31, 2022, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5336f99-81c7-4c60-bc79-3dfc9f97da7a" contextRef="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9" name="nktx:PaymentsMadeUnderCollaborativeArrangement" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t paid any amounts </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55cb52a2-e963-43fe-a9b0-3b8efba75891" contextRef="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9" name="nktx:AmountsOwedUnderAgreement" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">r are any amounts owed by the Company under the CRISPR Agreement, and no milestones have been achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MaxCyte License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 26, 2021, the Company entered into a license agreement (the &#34;MaxCyte Agreement&#34;) with MaxCyte, Inc. (&#34;MaxCyte&#34;) to obtain non-exclusive clinical and commercial rights to use MaxCyte's cell loading technology to develop and commercialize in up to ten licensed products.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the MaxCyte Agreement, the Company must pay to MaxCyte annual research license fees and commercialization license fees, ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_600fe0ca-c92a-4b9d-aca6-dfe6c6d8027b" contextRef="C_5e4795d5-2002-4904-a3ea-f02d9bec752b" name="nktx:AnnualResearchLicenseFeesAndCommercializationLicenseFees" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03dda348-5866-4295-ae7c-0eb32b81cfc6" contextRef="C_7e258be6-92d4-4784-8087-1c605ecf79d1" name="nktx:AnnualResearchLicenseFeesAndCommercializationLicenseFees" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, for each instrument licensed by the Company. Further, the Company could be required to make milestone payments to MaxCyte upon completion of certain regulatory and commercial milestones related to the clinical development and commercialization of certain of the Company&#x2019;s licensed products. The aggregate potential milestone payments range from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c64d96e1-fd11-4355-8102-ac1780f60834" contextRef="C_5e4795d5-2002-4904-a3ea-f02d9bec752b" name="nktx:PotentialMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6d91e6a-f2a6-4ceb-8d4f-dc40773039ab" contextRef="C_7e258be6-92d4-4784-8087-1c605ecf79d1" name="nktx:PotentialMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">13</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per licensed product. Additionally, the Company may be required to make net sales milestone payments totaling between $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3142c0e8-5dc4-47fb-97a2-4947273d4c9d" contextRef="C_5e4795d5-2002-4904-a3ea-f02d9bec752b" name="nktx:NetSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">61.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d363f75e-2327-483d-a38a-490d90c4304f" contextRef="C_7e258be6-92d4-4784-8087-1c605ecf79d1" name="nktx:NetSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">116.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per licensed product. As of December 31, 2022, no milestones have been achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">University of Singapore and St. Jude Children&#x2019;s License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2016, the National University of Singapore (&#34;NUS&#34;) and St. Jude Children&#x2019;s Research Hospital (&#34;St. Jude&#34;) and the Company entered into a license agreement under which NUS and St. Jude (the &#34;Licensors&#34;) granted the Company an exclusive, royalty-bearing, worldwide license to its patent rights related to a method for expanding natural killer cells; a chimeric receptor with NKG2D specificity; and a method for supporting autonomous natural killer cell function (&#34;NUS and St. Jude License Agreement&#34;). The NUS and St. Jude License Agreement provides the Company with the rights to grant and authorize sublicenses to make, have made, use, sell, offer for sale and import products and otherwise exploit the patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license, the Company made an upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d76be6bb-0436-4765-942f-60903402e48d" contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931" name="nktx:LicenseAgreementUpfrontPayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">31,800</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and issued NUS </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45a3c760-82ad-4438-90f7-2996bb714500" contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931" name="nktx:StockIssuedDuringPeriodSharesIssuedUpfrontPayments" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock. The Company determined that the upfront payment (SGD </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12bb6b9a-f00a-4e6e-a799-a40834513033" contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931" name="nktx:LicenseAgreementUpfrontPayment" unitRef="U_SGD" decimals="0" format="ixt:numdotdecimal">42,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and value of the common stock issued ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7a2f483-903f-49b8-8c24-cfd617b15f39" contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931" name="nktx:FairValueOfCommonStockIssued" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> based on fair value at time of issuance) as part of the license agreement would be expensed upon execution of the contract as the license was acquired for research and development purposes which does not have alternative future uses, and the underlying technology has not reached technological feasibility, hence the Company expensed these costs during 2016.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company is required to pay an annual license maintenance fee of SGD </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d65d3074-269c-40c1-9dd3-4f6aa21fb4bc" contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931" name="nktx:AnnualLicenseMaintenanceFee" unitRef="U_SGD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, increasing to SGD </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d435a8fe-403f-4bd6-b86d-4f49e9b421cb" contextRef="C_b32eb187-1110-42c8-a989-031bf9074bfb" name="nktx:AnnualLicenseMaintenanceFee" unitRef="U_SGD" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year two of the agreement. Further, the Company could be required to make milestone payments to the Licensors upon completion of certain regulatory and commercial milestones related to the clinical development and commercialization of certain of the Company&#x2019;s product candidates. The aggregate potential</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">milestone </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payments are approximately SGD </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca77a2f8-6482-4fa0-a923-0466dac340e2" contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931" name="nktx:PotentialMilestonePayments" unitRef="U_SGD" scale="6" decimals="-6" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company has also agreed to pay the Licensors royalties of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e9c350d-37f4-4e4f-a6e3-ee90830476e4" contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931" name="nktx:PercentageOfLicensorsRoyalties" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net sales of products sold by the Company or through a sublicense. Additionally, the Company agreed to pay the Licensors a tiered percentage of sublicensing income (ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80b03ed5-e103-49ec-aa25-0a43f1a9e169" contextRef="C_98fde113-4079-4ef0-aed0-57bc5371b89d" name="nktx:PercentageOfSublicensingIncome" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83b2bc1b-18dd-4239-b60f-2118b3e6f9b9" contextRef="C_96c15272-baf2-49fd-8372-c7699ec34602" name="nktx:PercentageOfSublicensingIncome" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%) based on the timing of capital raised and stage of clinical trials. The NUS and St. Jude License Agreement also includes certain performance objectives which obligate the Company to meet various milestones related to the clinical development and commercialization of certain of the Company&#x2019;s product candidates over time for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3dd3509b-26df-43a3-afb0-36f35f45e441" contextRef="C_96c15272-baf2-49fd-8372-c7699ec34602" name="nktx:LicenseAgreementTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after the effective date of the NUS and St. Jude License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c1e2ffc-3e34-4a3f-8360-8e42ebd314a2" contextRef="C_740287c6-87bc-41cd-9f00-710fff88daae" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_8bab6f7d-5e91-4df7-b4ca-62392bc89830" contextRef="C_3a1834a9-94f0-4aab-abd5-ebb33501f4c8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">37,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> license maintenance fees included as part of research and development expenses for each of the years ended December 31, 2022 and 2021.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_23e019b8-6d97-48f3-88a7-24fb44711fa8" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Employee Benefits</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_78b340ce-6095-45c5-8620-f0fc40c1c5a2" contextRef="C_1eb2f144-5565-4350-a09a-b2ab343aade0" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2018, the Company adopted a defined contribution 401(k) plan that is available to eligible employees. </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. As part of the plan, the Company elected to make non-matching contributions via mandatory </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8bc000e-4504-47ca-b748-6aaa07343fe5" contextRef="C_1eb2f144-5565-4350-a09a-b2ab343aade0" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of compensation safe harbor nonelective contributions. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5dca5679-3b39-465e-9624-9e3853667ef3" contextRef="C_1eb2f144-5565-4350-a09a-b2ab343aade0" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc4c08f4-6cf9-49a2-9563-1b530eda1d6f" contextRef="C_6be6113f-92b4-4ee7-a950-89b44b4f6055" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for expense related to the nonelective 401(k) contributions for the years ended December 31, 2022 and 2021, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a70de548-e6cd-45f3-ae9c-68b5fa63a6c5" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Amended and Restated Certificate of Incorporation dated July 14, 2020, the Company had a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88764f72-7c4f-4e62-bfce-514671613d2d" contextRef="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> authorized shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27593d56-435a-4ef6-bada-69633b9254bf" contextRef="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81e4b9fd-6f25-44b6-8c25-3553f8ceb809" contextRef="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">54,350,179</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> authorized shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3d9db06-481d-4b07-b12d-38666049ac1a" contextRef="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2021, the Company filed a Registration Statement on Form S-3 (the &#34;Shelf Registration Statement&#34;), covering the offer and sale from time to time, pursuant to Rule 415 of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddadaa16-ef67-4071-92a2-216fd97bff63" contextRef="C_e5303a92-212e-4aad-9186-0d262371436b" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">500.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate offering price of shares of the Company&#x2019;s common stock, shares of the Company&#x2019;s preferred stock, debt securities, warrants, and rights and units. The Shelf Registration Statement was declared effective by the Securities and Exchange Commission (the &#34;SEC&#34;) on September 2, 2021. The Shelf Registration Statement included a prospectus covering the offer and sale from time to time of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9358c3d-b072-4fda-aa11-0128a61f422a" contextRef="C_e5303a92-212e-4aad-9186-0d262371436b" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">150.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate offering price of shares of the Company&#x2019;s common stock through an &#x201c;at-the-market&#x201d; equity offering program (the &#34;ATM Offering Program&#34;) with Cowen and Company, LLC, as sales agent. As of December 31, 2022, the Company has issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be3652b9-998d-49a8-8d05-030f44e91fcc" contextRef="C_1cd10163-6e81-4530-a414-a8bef05e747e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">113,213</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock pursuant to the ATM Offering Program, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_020191a0-a631-4f7a-8253-94904a6952b0" contextRef="C_a0bf228a-dcc8-47a6-9520-a9d355912f12" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting offering expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 28, 2022, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76f4fc27-1e37-4bc6-929e-eaedd0e438df" contextRef="C_981a3fe1-5a1b-4bea-9a27-e819dcdf253c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,333,334</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock in an underwritten public offering, including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62dff67b-23af-407c-92db-3f06cc96cefa" contextRef="C_001b7558-daa1-49c1-8059-798879009ca2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares associated with the full exercise of the underwriters&#x2019; option to purchase additional shares, at a price to the public of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6195d4b3-8319-4ec8-b550-b10c59a65323" contextRef="C_141cfb9f-1119-4e34-b791-208f5def88e6" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">15.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The total net proceeds to the Company from the offering were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d9491c6-a6d7-42f6-ad35-004f834fa2b5" contextRef="C_981a3fe1-5a1b-4bea-9a27-e819dcdf253c" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">215.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares were issued pursuant to the Company&#x2019;s Shelf Registration Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82c80976-ca74-4007-8024-612a9fed69ab" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Share-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2015 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company granted options under its 2015 Equity Incentive Plan (the &#34;2015 Plan&#34;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2015 Plan allowed for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock unit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">awards </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and other stock awards, although only stock options were awarded under the 2015 Plan. Awards could be made to officers, directors, employees, non-employee directors, and consultants of the Company. In connection with the Board of Directors&#x2019; and stockholders&#x2019; approval of the 2020 Plan, the 2015 Plan was terminated as to future awards and any options then outstanding under the 2015 Plan remained outstanding and effective. As of December 31, 2022, there were an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_297ccb12-166c-4fc5-ac3e-3b7153b8e5f3" contextRef="C_3c1f1543-5dab-4779-b06e-a0d704393f4c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,344,048</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of outstanding options issued under the 2015 Plan.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Performance Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s 2020 Performance Incentive Plan (the &#34;2020 Plan&#34;) which was adopted by the Company&#x2019;s board of directors in June 2020 and approved by the Company&#x2019;s stockholders in July 2020, became effective upon the consummation of the IPO in July 2020. The 2020 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of December 31, 2022, a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db72fc13-2875-4ef1-9145-ef02dbbb3585" contextRef="C_5494864e-30df-4f68-b4b1-cd4ad5b4ba91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,945,002</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock were authorized for issuance with respect to awards granted under the 2020 Plan (this number of shares gives effect to the annual increases in the 2020 Plan share limit, as described in the next sentence). The share limit will automatically increase on the first trading day in January of each year by an amount equal to the lesser of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b196c8d1-9a11-4353-8511-bd584fc5a014" contextRef="C_44eb9b84-6402-486d-8d17-eda195e16bed" name="nktx:IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of outstanding shares of the Company&#x2019;s common stock on the last trading day in December in the prior year, or (2) such lesser number as determined by the Company&#x2019;s board of directors. Any shares subject to awards granted under the 2020 Plan or the 2015 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2020 Plan. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da856218-6016-4adf-bb1c-c7d8285b94e6" contextRef="C_5494864e-30df-4f68-b4b1-cd4ad5b4ba91" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,775,102</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares was available for issuance under the 2020 Plan as of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_10f042d7-9df3-4582-96a5-1f360396b9d6" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the stock option activity during the year ended December 31, 2022 (in thousands, except number of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares, exercise prices and contractual term):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.154%;"></td>
        <td style="width:0.513%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.425%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.655%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.298%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.526%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.091%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.988%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.349%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br />exercise price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br />remaining contractual<br />term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate <br />Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d79a6fa4-faff-4f39-87c0-54224d0722e7" contextRef="C_c963d9bf-d21f-4940-8b1d-41239a955535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,204,686</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aea1dc9a-6d26-4e68-8f3c-7b9c28bee938" contextRef="C_c963d9bf-d21f-4940-8b1d-41239a955535" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">19.19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0398cdf0-24d1-484f-b521-d685526ee09e" contextRef="C_a7e0478f-dfc8-4a2e-bc04-3e92eb222605" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_810bcab9-30a8-4fe6-aee1-e3b6d7d05bfe" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,327,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8331564e-7309-41f4-8f25-fd64843fb059" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.61</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09e7f906-4841-498b-bfac-491da20c693e" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">383,120</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96b3a53c-5819-4bb3-8ade-abc518116f9e" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ea081b5-d925-4ae5-8d96-b2abd9b3e690" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">630,111</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1fc338f-afe3-4299-8e49-8cc96256ff29" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">21.99</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20443572-a301-472a-aea8-d314fb0c31c5" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,519,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a95c94b9-f177-4a64-9339-1cce20653ba7" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">17.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c697c62b-ad33-4697-81c8-4a1195c9962f" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4a14960-dcc1-4115-9406-6e44b3df2a78" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,915</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70a5cfa1-b780-4c73-b096-f2f9cfc11b2a" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,337,753</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3d342fd-41ff-45b1-b5ea-4da5eddafb43" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">17.49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7e54a44d-1aad-4884-9ce6-fd8715a6686e" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43e1d9eb-6359-4ead-82c5-216de7344a80" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,957</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at <br />&#160;&#160;&#160;December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42d33993-84d3-4c73-b057-f4ab37a59c3c" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,519,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa026a6e-5e1c-49bb-b114-2ce322a5b8dd" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">17.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1ea6cf96-6370-4726-a88e-079ea402c21c" contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_314d90ba-d998-42fa-a9c9-f54bc11bedec" contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,915</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value represents the difference between the exercise price of stock options and the quoted closing market price of the Company&#x2019;s common stock on the applicable date for all in-the-money stock options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f77b0f7f-9bbe-4282-9f39-41cd896e11b9" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional information related to the Company&#x2019;s stock options is summarized below (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.324%;"></td>
        <td style="width:1.554%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.129000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.554%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.438%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average grant-date fair value of stock option grants per share</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a9193ea-84a2-4ace-ae25-ae46f5cf835c" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70ece0cd-74ea-480f-a8c7-15141bdfe7e0" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">30.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic value of options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d216ac2-ca28-492b-926e-180f24aa1cf2" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b8576d9-f25c-4be2-b2bd-313e04172d4c" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ee4ace3c-4d7f-430b-a214-f509e96f9a98" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the restricted stock unit activity during the year ended December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.384%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.030000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.187000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.99%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.006%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br />grant date fair value per share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />average<br />remaining<br />contractual<br />term<br />(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eecc094b-913e-42d5-a4ee-a89fc08f6740" contextRef="C_0a03030f-25af-4ff1-945c-997f499c318d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4493adc2-6e98-45e6-8649-3a9bf550f1c0" contextRef="C_0a03030f-25af-4ff1-945c-997f499c318d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3091255-c975-4664-a31e-00e9fa290e9c" contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">389,388</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f20c2f51-e115-497f-b74c-494814a4479e" contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e92acbf8-6125-475e-a1be-0bb000d8747f" contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,660</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4892dd1-2611-409e-b704-75ef1aaa3b91" contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc520ff2-cdcf-44ce-8864-46923c72a799" contextRef="C_dad82f88-3e0b-4f88-88f6-fb0cde6e2f5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">356,728</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5176ab0-21fb-49f2-a35e-1d2fdd8a44ad" contextRef="C_dad82f88-3e0b-4f88-88f6-fb0cde6e2f5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">12.66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2926f36a-eb28-40ce-afb8-e356102e9ab1" contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s 2020 Employee Stock Purchase Plan (the &#34;ESPP&#34;), which was adopted by the Company&#x2019;s board of directors in June 2020 and approved by the Company&#x2019;s stockholders in July 2020, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">became effective upon the consummation of the IPO. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_142410ab-5272-4682-b730-b44d274f8712" contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">952,524</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock were authorized for issuance under the ESPP. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb6a1c6f-bcbc-42d6-aee0-4bf6d76a43c1" contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation, subject to any plan limitations. The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP provides for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f6587cd3-d337-485d-8db4-cb34ada62636" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> offering periods, and at the end of each offering period, employees are able to purchase shares at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1d72d0e-0345-4e37-b599-ce3c7db5551d" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. During 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_185c0779-ad26-470b-ab12-9f8d83f61f61" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,754</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were issued under the ESPP resulting in aggregate cash proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af72d8be-a8a8-4933-aae3-ee053959701a" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_545cb9d3-3f4d-4a90-a34c-327a5f2b1663" contextRef="C_ab31f486-dd4c-4921-9836-0c2daa665d2d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ESPP purchases in 2021. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a67948f9-10f6-4669-8070-7c401836f6cb" contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">890,770</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remained available for issuance under the ESPP (after giving effect to share purchases made under the ESPP through and including the ESPP offering period that ended on November 30, 2022).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liability for Early Exercise of Restricted Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain individuals were granted the ability to early exercise their stock options. The shares of common stock issued from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. Shares subject to repurchase by the Company were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18728d4b-a367-4832-92f6-62ee0d019faa" contextRef="C_a024a1ed-5c61-4be8-a5a7-9e8fa9a97eff" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">508</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ee04480-a723-4152-bd6e-0fb99b633477" contextRef="C_f580e365-5516-4a7a-ab29-b585665fbce7" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,181</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, as of December 31, 2022 and 2021, respectively, and in each case the related liability recorded under other accrued and other current liabilities in the condensed balance sheets was insignificant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d596e03-a051-4fff-955e-ba1d85dbc531" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had reserved the following shares of common stock for future issuance:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.426%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.094%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options and restricted stock units granted and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59dd0b18-a87f-4d4e-8fd2-a3b659c53f58" contextRef="C_a8cd6f3e-33d2-431d-8c68-01cfb7d24237" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,876,003</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved for future equity award grants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad8fdb28-b9fd-40ab-a8c5-286c14b12076" contextRef="C_5494864e-30df-4f68-b4b1-cd4ad5b4ba91" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,775,102</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved for future ESPP issuances</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab973b92-9bf3-4e16-841a-44311faf3c93" contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">890,770</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa07ec18-bb45-4fa3-b7cb-3b1902af6ae1" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,541,875</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_464ee3b6-5738-4427-b6dc-0a866f8b1041" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense for the years ended December 31, 2022 and 2021 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64.324%;"></td>
        <td style="width:1.554%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.129000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.554%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.438%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6593086b-cfab-4856-be9e-2be1af8dab7d" contextRef="C_5cee8cd7-5f97-41bd-add1-44d08b9bb04e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,326</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16e68958-e639-4946-9674-8cc0892dc945" contextRef="C_18a918ed-b24c-4a30-91c4-1883263c2b4d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee05a677-bbc7-4785-a8ec-6316769123ba" contextRef="C_d26eec10-62b5-4c3b-988b-3b120717f7c4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31d7dfc4-94ca-4d0f-b349-a1282e6e0784" contextRef="C_f80d2293-58a8-4680-be9d-fb127ceff8c4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,742</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b71c5cb-14c3-467d-a35c-e659b8ed367e" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,856</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f88e04a-d5cc-4ffa-80c8-4262c9e11ff5" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total unrecognized compensation cost related to stock options was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5de5e07b-6fb1-491b-bdc4-55b3683c4d38" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c4fb24e-b03c-4933-abc7-e945886c7988" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years as of December 31, 2022. The total unrecognized compensation cost related to restricted stock units was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_062b4c06-6401-4afe-89dc-3b3b6e668407" contextRef="C_dad82f88-3e0b-4f88-88f6-fb0cde6e2f5d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e9d71cd7-fcbc-4ccf-9226-7e06b24fb75e" contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years as of December 31, 2022. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c85a5b2a-c838-402e-82d1-22279de82167" contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized compensation cost related to ESPP, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which is expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1e4ac48d-fca3-434b-97e8-e13aee77289a" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Disclosures</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fa1ff00a-1a9f-4584-a51c-4a5254e6a169" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options was estimated on the date of grant using the Black-Scholes option pricing model with the following range of assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64.551%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:16.165%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:16.165%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc9b9c81-94f7-4b90-b5cd-1799d95ee155" contextRef="C_f4d8076e-e0bc-4c00-a7ca-5d44c39d9a6f" name="nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d058ff30-1962-4a0a-bc9b-4f86f38f6313" contextRef="C_8785059f-96d4-4f04-8c0f-0809aa5b503b" name="nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.44</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f032ffd-6495-419e-a88d-4b764b0adb97" contextRef="C_a7611da9-a17b-4506-b7d2-762f752b122e" name="nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d5a8483-b785-4346-9f43-3086442bd13c" contextRef="C_74c75d73-fb22-4295-b576-4cef5d2a18f0" name="nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">54.89</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81322160-d283-451c-9c50-a350ccaf9b72" contextRef="C_9183cb74-8a77-407b-ac80-773ff92736bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d0526b0-3d19-46cf-853d-82e7cfe985b0" contextRef="C_9183cb74-8a77-407b-ac80-773ff92736bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_858cedce-b912-45d7-90f9-677a61193a17" contextRef="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_524f3d06-8f31-4d4c-bb14-67e91be671e0" contextRef="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6907dce4-fd9e-41ea-80d8-17f30601ac74" contextRef="C_9183cb74-8a77-407b-ac80-773ff92736bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">75.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a063032-f288-4fb5-8972-c2df98b49c0a" contextRef="C_9183cb74-8a77-407b-ac80-773ff92736bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">78.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcb43e1e-27ba-46bc-b973-8127f17a0ddd" contextRef="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a364093-2093-4468-b660-254f36d56f39" contextRef="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">79.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ec605cf7-becd-4c39-ae31-9a9e0f6deafe" contextRef="C_f4d8076e-e0bc-4c00-a7ca-5d44c39d9a6f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8300a31d-fdb6-4a49-9803-043a9ffac951" contextRef="C_8785059f-96d4-4f04-8c0f-0809aa5b503b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7ca5bb5c-9a69-409f-aabb-a22d77e0e435" contextRef="C_a7611da9-a17b-4506-b7d2-762f752b122e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_78f45160-ce84-4c0c-8134-ef0a2772e729" contextRef="C_74c75d73-fb22-4295-b576-4cef5d2a18f0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d55db3f-6f65-40ac-bb6f-2ba89094f735" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2d6327f-181e-4e3f-b021-d5e949e68919" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4faa6aa-b8cf-4258-b5fc-de19221313fe" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">63.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3097612-e6d5-4c75-bd04-232566584a7d" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">151.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_873a237e-b0e7-4daf-ada9-c1390d9f0271" contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value of the awards on the date of grant, net of forfeitures. The Company generally recognizes grant-date fair value of stock options granted to employees and non-employee service providers on a straight-line basis over the requisite service period, which is generally the vesting term of the respective awards. The Company determines the fair value of stock options with a service and performance condition, or performance-based options, based on the fair value of the Company&#x2019;s common stock on the date of grant. The Company accounts for the impact of forfeitures as they occur. For purposes of calculating share-based compensation, the Company estimates the fair value of stock options issued using a Black-Scholes option-pricing model. The determination of the fair value of share-based payment awards utilizing the Black-Scholes option-pricing model is affected by the Company&#x2019;s stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company opted to use the &#x201c;simplified method&#x201d; for estimating the expected term of employee options, whereby the expected term equals the average of the vesting term and the original contractual term of the option (generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_609cff8a-8ca4-4195-8e62-a3fc54ca4868" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company based its estimate of expected volatility on the historical volatilities of the common stock of comparable publicly traded biopharmaceutical companies over a period equal to the expected term</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle, and financial leverage to the Company.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected dividend yield. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc9c3a56-53c1-4d97-8977-9309d9e4fc35" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:DividendsShareBasedCompensation" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t issued any dividends and do </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef58ef22-f66d-4324-8d2d-d67ce5d1c53f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t expect to issue dividends over the life of the options, as a result the estimated dividend yield is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac3bd990-8b25-48a1-8547-8ffd5196bf7f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_51b990df-e72d-4c03-8420-c61c50cea7f1" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the Company&#x2019;s net losses for the years ended December 31, 2022 and 2021, and since the Company has a full valuation allowance against deferred tax assets, there was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9cdc3fa-0e8d-4adc-abc6-228929ba32f6" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_08368f86-0e1c-40e9-bb50-6cfa6b157cc2" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> tax provision or benefit for income taxes recorded in the years presented other than minimum amounts required for state tax purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ce0660f4-ec08-437b-8f47-8f6e3d5588a3" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation on income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.158%;"></td>
        <td style="width:1.891%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.494%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.891%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.568%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at statutory rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_876c97b0-3f97-49a8-bbac-19a05032c7c1" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,906</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eddd498-c043-4e6b-85e7-6751c2429ec1" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">18,076</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b67ce320-67b8-4ca1-9913-5037a7052ffe" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,566</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bb7078d-b52f-4308-ad69-dd32b47895b3" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,005</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4f6d158-6820-42dc-8b8b-784fdc1a0b8f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1629246d-cb0d-464d-9811-88aa48af5e19" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="nktx:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">592</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b14337ed-47b0-4495-b649-109d327f4a9d" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b42969f4-4a00-4944-9db1-971370ae8fce" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,661</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fecdebf9-6755-42ae-85ff-6cbd9f72ec52" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc423002-d2bd-487d-a056-27d4200a015b" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">515</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff1cd822-c10b-4529-977b-ebc069291022" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae2267cf-6924-4d89-b475-6aca581f99fe" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93804940-6431-41d5-870d-06488aef792e" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c25a586-1576-4e48-bef3-e9ed2d46974f" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_67c4ad4d-3eba-4b96-bb50-034a6c6b9a84" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of the Company&#x2019;s deferred tax assets are shown below (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.148%;"></td>
        <td style="width:1.795%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.6%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.784%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.674%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ae0f5f9-5fdd-49eb-9102-3791dfe816d8" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,732</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9352f3fb-ae32-4de9-92e2-af2e286cf101" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,767</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_557e0e69-b9a7-49bf-ba82-ee7e37c33d28" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:DeferredTaxAssetsDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">316</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bd1b0be-c4bb-4671-af99-ebedd443df56" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="nktx:DeferredTaxAssetsDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04d1d24e-8b72-405e-a4d9-95eba6371d7f" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d94a95c-45a8-48f3-8f13-de5113603cab" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d909e2db-4624-40f6-83e9-caa21d413d3b" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,552</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_111a9d54-b5ce-4ceb-913c-44ad12b87042" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,245</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74bda772-902f-4f8f-bde6-111e205a7548" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfe6d7a9-187d-4a25-bbab-1284071fec21" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec334b6d-4a9a-452f-87b0-7222cc53d86b" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,062</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be526e7d-0a13-490f-9e63-f0d8edc6c2f4" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="nktx:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,616</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86072953-28a1-440d-80be-9942a097a670" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_393f42f6-56e8-4c8a-ab2d-2042f8f9e742" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 Capitalized R&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ace75c6e-ee2e-4737-b645-319ecd3c7206" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,352</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7659b5c6-240c-40f3-9b51-e9f7e00be45f" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="nktx:DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce7d0e46-23cb-48ce-bbb0-766c78c555f6" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90057401-5d84-49a9-8c91-440ff8b2cf07" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance for deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_456b0f50-3118-42c7-b0f2-7336226a243c" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,368</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72f25a6b-e2d1-4231-9320-e6e072f7f2cc" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,361</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2338aeed-62f6-4b1f-b217-d1a4af66120f" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_398b7995-0ed0-4105-b1dd-493cf24e950c" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,742</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cc5d1c9-afa3-40c8-a550-3587aa4d9ffd" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e6c3c60-211c-437d-8a37-80e75e1242ee" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="nktx:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f60bcee7-1412-4470-b815-d4be81a4f4bc" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="nktx:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9160cbe3-01d9-4674-be8a-1da1004a7b65" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="nktx:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_286befca-81bf-4bb7-835e-1ffeffa8c147" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62cb9ebf-4185-4c5f-b143-db4612837c2c" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#x2019;s ability to realize these assets. The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ced0b91e-5fd3-4e6b-aeb8-c40900a1bfa4" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">27.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_693361f4-8df1-4bc2-8287-500aa9a28511" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">representing net future deductible amounts become deductible. Due to the Company&#x2019;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are substantially offset by a valuation allowance at December 31, 2022 and 2021. The deferred tax assets were primarily comprised of federal and state tax net operating losses and tax credit carryforwards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had net operating loss (&#34;NOL&#34;) carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c52fd815-855e-4376-b7b2-38f0f587106e" contextRef="C_c60f034b-7278-446d-9f32-ef360df72d1f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">153.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_597d61e8-54e7-4905-b1b9-d0dfc9443a11" contextRef="C_feea12d5-fa67-4f8d-a138-14014b003a98" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">65.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. Of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cd11126-6fdc-4c44-a298-28d4189d6206" contextRef="C_c60f034b-7278-446d-9f32-ef360df72d1f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">153.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million federal NOL carryforwards, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_890af32f-dfe7-4b99-bfdc-412cecc99f40" contextRef="C_3ae365a0-6a87-4a4e-a567-430fbc72a73f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75ac444a-961b-4f23-a484-12b8408e99dd" contextRef="C_e16f2952-c482-4fb5-b289-6a2484c1649e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d2cbc3c-9072-4663-8701-1757a55c93be" contextRef="C_5c424608-d9ed-42fb-be8c-a8171cb6a5ea" name="nktx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_90ac06a0-6fdd-45bb-8309-9bb8a0a44dc8" contextRef="C_ff496bec-fe97-479b-a5c4-6ec81afca185" name="nktx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, if not utilized, while $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9731ffc3-e125-4c4b-a0e6-c81244dc5fd3" contextRef="C_229b2864-98b4-4ede-83cb-94419b551487" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">150.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million can be carried forward indefinitely. The state NOL carryforwards will begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c75e2da1-9c64-454c-af53-353ff2a72a5e" contextRef="C_59e66b2e-c33f-48fe-ad46-f3ff01344f2e" name="nktx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if not utilized.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also had federal and state research and development credit carry forwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71125502-0325-4082-af36-7f5c80b18978" contextRef="C_444f64e4-77b4-4f0d-a3be-c07ea1bd14aa" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4eedbbc-16bc-43d9-b1dc-0a6dc6c1269d" contextRef="C_6097964e-eb40-4699-9cf6-6a9b004fabb9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, at December 31, 2022. The federal credits will begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8dfc5c7-3c9e-47cd-81dc-f28f105bd9b5" contextRef="C_57e7b3dc-ab16-4aa2-987e-e194bd6384a0" name="nktx:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> if not utilized. The California credits have no expiration date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the &#34;Code&#34;), as well as similar state provisions. The future utilization of the Company&#x2019;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21707fe8-4690-4f9f-a192-2e5e2f4beef8" contextRef="C_42e1761d-f976-4772-b948-69c953e4e0be" name="nktx:ChangesInOwnershipByStockholdersHoldingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or more of the Company&#x2019;s common stock. An assessment of such ownership changes under Section 382 was not completed through December 31, 2019. To the extent that an assessment is completed in the future, the Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2022, its federal and state returns for the years ended 2015 through the current period are still open to examination. In addition, all of the net operating losses and research and development credit carryforwards that may be used in future years are still subject to inquiry given that the statute of limitation for these items would begin in the year of the utilization. The balance of gross unrecognized tax benefits as of December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a769682-44f4-46e8-a45f-1332a5cdaede" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69136d3e-eddc-4a28-a953-cd9d4dd1e5cf" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, all of which would affect the Company&#x2019;s income tax expense if recognized, before consideration of the Company&#x2019;s valuation allowance. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01d20a1f-4278-4f36-9e4f-ce99b10181bc" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_77ab1134-18db-47e5-8628-6ef8cfd31d6e" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest and penalties for the years ended December 31, 2022 and 2021. The Company files income tax returns in the United States federal jurisdiction and the State of California and is not currently under examination by any taxing authority for any open tax year. Due to net operating loss carryforwards, all years remain open for income tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c44a8a3b-a126-4e06-939c-392a0ceccaaa" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the changes in the Company&#x2019;s gross unrecognized tax benefits (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.049%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.123%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f4f8d23-bf9b-4acc-a8a1-9f2274d7745a" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,359</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c150de49-f889-4c61-b4a1-587d8d6e495f" contextRef="C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">777</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases (decreases) related to tax positions taken in prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_729b3af3-27c1-444c-a870-9b0d6606f91f" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="nktx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87506651-c05b-40e1-af76-e618d6c0d957" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="nktx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f86442-37f2-4420-8aef-bf2fb4810841" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,023</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b59b50a-2bcf-46f4-a4dc-58dcc9400d8a" contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">863</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42c773bb-4995-4e11-aa00-679b2dfdaa21" contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,339</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb48939a-bee2-4747-94fe-0f0a0c72fe9b" contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,359</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_053360a8-c5ed-4625-b7c2-6d87c2dafdab" contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 10, 2023, Silicon Valley Bank (&#34;SVB&#34;) in the United States was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#34;FDIC&#34;) as receiver. On March 12, 2023, the U.S. Department of the Treasury, Federal Reserve, and FDIC jointly announced that the FDIC will complete its resolution of SVB in a manner that fully protects all depositors. As of March 10, 2023, we held $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70ebbca6-127c-4355-bc9a-744cb80d9224" contextRef="C_9156c0d3-efa4-45e5-8f61-29564c2a7e1d" name="nktx:AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in collateral money market accounts supporting letters of credit issued by SVB to the Landlord in connection with the Initial Lease Agreement and Additional Lease Agreement. We are working with the Landlord to replace the letters of credit issued by SVB with letters of credit from a different financial institution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial and Business Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. Based on this evaluation, our Chief Executive Officer and Chief Financial and Business Officer concluded that, as of December 31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that the transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial and Business Officer, regarding the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no changes in our internal control over financial reporting during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inherent Limitations on Effectiveness of Controls</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, including our Chief Executive Officer and our Chief Financial and Business Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Di</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have adopted a written code of business ethics that applies to our Chief Executive Officer and senior financial officers and a code of business conduct and ethics that applies to directors, executive officers, and employees. A current copy of each code is posted under &#x201c;Corporate Governance&#x201d; on our website at https://ir.nkartatx.com/. To the extent required by rules adopted by the Securities and Exchange Commission and The Nasdaq Stock Market LLC, we intend to promptly disclose future amendments to certain provisions of the code, or waivers of such provisions granted to executive officers and directors, on our website at www.nkartatx.com/.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The remaining information required by this Item will be set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tant Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item will be set forth in the Company&#x2019;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#x2019;s fiscal year end and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits and Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	The following documents are filed as part of this Annual Report on Form 10-K:</span></p>
  <div style="margin-left:9.074%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989771902426148%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Statements.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.</span></div></div>
  <div style="margin-left:9.074%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989771902426148%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Statement Schedules</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. None. All financial statement schedules are omitted because they are not applicable, not required under the instructions or the requested information is included in the financial statements or notes thereto.</span></div></div>
  <div style="margin-left:9.074%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989771902426148%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exhibits</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The following is a list of exhibits filed with this report or incorporated herein by reference:</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="exhibit_index"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.278%;"></td>
    <td style="width:0.983%;"></td>
    <td style="width:38.6%;"></td>
    <td style="width:0.983%;"></td>
    <td style="width:6.635%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:11.635%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:7.778%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:10.566%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:8.568%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File No.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520192614/d62111dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of Nkarta, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/14/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520192614/d62111dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of Nkarta, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/14/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520186953/d884708dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Common Stock Certificate of the Registrant.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/2/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520173939/d884708dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Investors&#x2019; Rights Agreement, dated as of August 27, 2019, by and among Nkarta, Inc. and certain of its stockholders.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/19/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;4.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021015517/nktx-ex43_989.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Capital Stock</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/25/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520186953/d884708dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement between Nkarta, Inc. and each of its directors and executive officers.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/2/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.2(A)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520173939/d884708dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2015 Equity Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/19/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.2(B)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520173939/d884708dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Agreement for 2015 Equity Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/19/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.3(A)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520186953/d884708dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Performance Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/2/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.3(B)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459020040819/nktx-ex105_289.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Director Option Agreement between Nkarta, Inc. and certain of its directors.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.3(C)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="nktx-ex10_3c.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Director Option Agreement between Nkarta, Inc. and certain of its directors.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.3(D)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459020040819/nktx-ex106_290.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of non-qualified Stock Option Agreement between Nkarta, Inc. and certain of its officers and employees.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3(E)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="nktx-ex10_3e.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of non-qualified Stock Option Agreement between Nkarta, Inc. and certain of its officers and employees.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3(F)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="nktx-ex10_3f.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Unit Agreement between Nkarta, Inc. and certain of its officers and employees.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520186953/d884708dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Stock Purchase Plan.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/2/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000095017022004095/nktx-ex10_5.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc. Non-Employee Director Compensation Policy, as amended on March 16, 2022.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/17/2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.6(A)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001787400/000119312520173939/d884708dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Offer Letter between Nkarta, Inc. and Paul Hastings.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/19/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.278%;"></td>
    <td style="width:0.983%;"></td>
    <td style="width:38.6%;"></td>
    <td style="width:0.983%;"></td>
    <td style="width:6.635%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:11.635%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:7.778%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:10.566%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:8.568%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.6(B)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021027591/nktx-ex102_204.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Offer Letter between Nkarta, Inc. and Dr. Nadir Mahmood</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/13/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.6(C)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021027591/nktx-ex103_205.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Employment Offer Letter between Nkarta, Inc. and Dr. Nadir Mahmood</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/13/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.6(D)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021027591/nktx-ex104_206.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Offer Letter between Nkarta, Inc. and Dr. Alicia Hager</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/13/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021001077/nktx-ex101_8.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Severance Agreement</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">01/13/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520173939/d884708dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exclusive License Agreement between Nkarta, Inc., National University of Singapore and St. Jude Research Hospital, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/19/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.10(A)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520173939/d884708dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement, dated May 29, 2018, by and between Nkarta, Inc. and HCP Life Science REIT, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/19/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.10(B)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520173939/d884708dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Lease Agreement, dated April 24, 2019, by and between Nkarta, Inc. and HCP Life Science REIT, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/19/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.10(C)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000119312520173939/d884708dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Lease Agreement, dated May 5, 2020, by and between Nkarta, Inc. and HCP Life Science REIT, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-239301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/19/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.10(D)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021015517/nktx-ex1010d_137.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Lease Agreement, dated January 14, 2021, by and between Nkarta, Inc. and HCP Life Science REIT, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10(D)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/25/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.10(E)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001787400/000156459021051572/nktx-ex101_8.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Amendment to Lease Agreement, dated October 19, 2021, by and between the Registrant and HCP Life Science REIT, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/22/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10(F)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000095017022016892/nktx-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment to Lease Agreement, dated August 11, 2022, by and between Nkarta, Inc. and HCP Life Science REIT, Inc.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8/11/2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.11(A)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021036496/nktx-ex101_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease, dated July 9, 2021, by and between Nkarta, Inc. and HCP BTC, LLC</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/14/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.11(B)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021056233/nktx-ex102_80.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Lease, dated November 5, 2021, by and between Nkarta, Inc. and HCP BTC, LLC</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/10/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11(C)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000095017022016892/nktx-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Lease, dated August 11, 2022, by and between Nkarta, Inc. and HCP BTC, LLC</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/11/2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10.12(A)**</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000156459021044018/nktx-ex101_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research Collaboration Agreement, dated May 5, 2021, by and between Nkarta, Inc. and CRISPR Therapeutics AG</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8/12/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12(B)**</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000095017022009693/nktx-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to the Research Collaboration Agreement, dated May 4,</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39370</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/12/2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.278%;"></td>
    <td style="width:0.983%;"></td>
    <td style="width:38.6%;"></td>
    <td style="width:0.983%;"></td>
    <td style="width:6.635%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:11.635%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:7.778%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:10.566%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:8.568%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1787400/000095017022009693/nktx-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, by and between Nkarta, Inc. and CRISPR Therapeutics AG</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;23.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="nktx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;31.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="nktx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;31.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="nktx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;32+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="nktx-ex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">_________________</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># Indicates management contract or compensatory plan</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ This certification is being furnished solely to accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">** Portions of this exhibit have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The Company undertakes to provide to the Securities and Exchange Commission or its staff, if requested and on a supplemental basis, an unredacted copy of this exhibit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.385%;"></td>
    <td style="width:3.002%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:47.618%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc.</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 16, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Paul J. Hastings</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paul J. Hastings</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.002%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:43.301%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:21.624%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Paul J. Hastings</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paul J. Hastings</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Nadir Mahmood</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial and Business Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nadir Mahmood, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Fouad Azzam</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fouad Azzam, Ph.D., MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ali Behbahani</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ali Behbahani, M.D., MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael Dybbs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Dybbs, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Simeon George</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Simeon George, M.D., MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Leone Patterson</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leone Patterson, MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Zachary Scheiner</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Zachary Scheiner, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Laura Shawver</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laura Shawver, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.002%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:43.301%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:21.624%;"></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Angela Thedinga</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Angela Thedinga</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>nktx-ex10_3c.htm
<DESCRIPTION>EX-10.3(C)
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 10.3(C)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 PERFORMANCE INCENTIVE PLAN</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>NOTICE OF GRANT OF STOCK OPTION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc., a Delaware corporation, (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Corporation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), pursuant to its 2020 Performance Incentive Plan, as may be amended from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), granted on the Date of Grant set forth below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Award Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to the award recipient listed below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grantee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), a nonqualified stock option (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to purchase the number of shares of the Corporation&#x2019;s Common Stock set forth below at a price per share equal to the Exercise Price per Share set forth below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  The Option is subject to all of the terms and conditions set forth in this Notice of Grant of Stock Option (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), as well as in the Plan and the Terms and Conditions of Director Stock Option attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), each of which is incorporated herein by this reference.  Unless otherwise defined in this Grant Notice or in the Terms, capitalized terms used in this Grant Notice or in the Terms are used as defined in the Plan.</font></p>
  <table style="margin-left:0.167%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.096%;"></td>
    <td style="width:61.904%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grantee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Award Number:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Grant:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price per Share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Number of Shares Subject to the Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1,2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[100% of the shares will vest on the first to occur of (i) the first anniversary of the date of grant of the award, or (ii) on the day immediately preceding the first annual meeting of the Company's stockholders to occur after the date of grant of the award]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By accepting the Option (by clicking &#x201c;sign&#x201d;, &#x201c;accept&#x201d; or similar acknowledgement of acceptance through the Company&#x2019;s stock plan recordkeeping system which may be administered by the Company or through a third party on behalf of the Company), the Grantee (1) signs this Grant Notice electronically, which acceptance shall be valid and effective to bind the Grantee to this Grant Notice and shall be treated, for purposes of validity, enforceability and admissibility, the same as Grantee&#x2019;s hand-written signature to this Grant Notice, (2) agrees to be bound by the terms and conditions of the Plan, the Terms, and this Grant Notice and accepts the Option on and subject to such terms and conditions, (3) acknowledges having received and having reviewed in their entirety the Plan, the Terms, this Grant Notice, and the Prospectus for the Plan, (4) acknowledges having had an opportunity to obtain the advice of counsel (to the extent Grantee believed it was appropriate to consult with counsel) prior to executing this Grant Notice, (5) represents that he or she fully understands all provisions of the Plan, the Terms, and this Grant Notice, and (6) agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Terms, and this Grant Notice.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <table style="margin-left:1.102%;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.:</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Address:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 PERFORMANCE INCENTIVE PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERMS AND CONDITIONS OF DIRECTOR STOCK OPTION</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These Terms and Conditions of Director Stock Option (these &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) apply to a particular stock option (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) if incorporated by reference in the Notice of Grant of Stock Option (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) corresponding to that particular grant.  The recipient of the Option identified in the Grant Notice is referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;  The per share exercise price of the Option as set forth in the Grant Notice is referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;  The effective date of grant of the Option as set forth in the Grant Notice is referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Award Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;  The exercise price and the number of shares covered by the Option are subject to adjustment under Section 7.1 of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option was granted under and subject to the Nkarta, Inc. 2020 Performance Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Capitalized terms are defined in the Plan if not defined herein.  The Option has been granted to the Director in addition to, and not in lieu of, any other form of compensation otherwise payable or to be paid to the Director.  The Grant Notice and these Terms are collectively referred to as the &#x201c;Option Agreement&#x201d; applicable to the Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting; Limits on Exercise; Incentive Stock Option Status</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1	Vesting in General. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Subject to Sections 2.2 and 5 below, the Option shall vest and become exercisable in percentage installments of the aggregate number of shares subject to the Option as set forth on the cover page of this Option Agreement.  The Option may be exercised only to the extent the Option is vested and exercisable.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2	Change in Control Event.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Notwithstanding any other provision to the contrary contained herein or in the Plan, upon the occurrence of a Change in Control Event, the Option, to the extent then outstanding and unvested, shall accelerate and become fully vested and exercisable as of (or, as may be necessary to effectuate the purposes of this acceleration, immediately prior to) the date of the Change in Control Event.  For purposes of the Option, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in Control Event</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall be deemed to have occurred as of the first day, after the Award Date, that any one or more of the following conditions shall have been satisfied:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)) (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 30% or more of either (1) the then-outstanding shares of Common Stock of the Corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding Corporation Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) or (2) the combined voting power of the then-outstanding voting securities of the Corporation entitled to vote generally in the election of directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding Corporation Voting Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); provided, however, that, for purposes of this definition, the following acquisitions shall not constitute a Change in Control Event; (A) any acquisition directly from the Corporation, (B) any acquisition by the Corporation, (C) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Corporation or any affiliate of the Corporation or a successor, or (D) any acquisition by any entity pursuant to a transaction that complies with Sections (c)(1), (2) and (3) below;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Individuals who, as of the Award Date, constitute the Board (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incumbent Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Award Date whose election, or nomination for election by the Corporation&#x2019;s stockholders, was approved by a vote of at least two-thirds of the directors then comprising the Incumbent Board (including for these purposes, the new members whose election or nomination was so approved, without counting the member and his predecessor twice) shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)	Consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Corporation or any of its Subsidiaries, a sale or other disposition of all or substantially all of the assets of the Corporation, or the acquisition of assets or stock of another entity by the Corporation or any of its Subsidiaries (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business Combination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), in each case unless, following such Business Combination, (1) all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding Corporation Common Stock and the Outstanding Corporation Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the entity resulting from such Business Combination (including, without limitation, a Parent, as defined above) in substantially the same proportions as their ownership immediately prior to such Business Combination of the Outstanding Corporation Common Stock and the Outstanding Corporation Voting Securities, as the case may be, (2) no Person (excluding any entity resulting from such Business Combination or a Parent or any employee benefit plan (or related trust) of the Corporation or such entity resulting from such Business Combination or Parent) beneficially owns, directly or indirectly, 30% or more of, respectively, the then-outstanding shares of common stock of the entity resulting from such Business Combination or the combined voting power of the then-outstanding voting securities of such entity, except to the extent that the ownership in excess of 30% existed prior to the Business Combination, and (3) at least a majority of the members of the board of directors or trustees of the entity resulting from such Business Combination or a Parent were members of the Incumbent Board at the time of the execution of the initial agreement or of the action of the Board providing for such Business Combination; or</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d)	Approval by the stockholders of the Corporation of a complete liquidation or dissolution of the Corporation other than in the context of a transaction that does not constitute a Change in Control Event under clause (c) above.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3	Limits on Exercise; Incentive Stock Option Status.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The following limits shall apply with respect to the Option:</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cumulative Exercisability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  To the extent that the Option is vested and exercisable, the Director has the right to exercise the Option (to the extent not previously exercised), and such right shall continue, until the expiration or earlier termination of the Option.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Fractional Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Fractional share interests shall be disregarded, but may be cumulated.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Minimum Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No fewer than 100 shares of Common Stock (subject to adjustment under Section 7.1 of the Plan) may be purchased at any one time, unless the number purchased is the total number at the time exercisable under the Option.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nonqualified Stock Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Option is a nonqualified stock option and is not, and shall not be, an incentive stock option within the meaning of Section 422 of the Code.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continuance of Board Service Required; No Service Commitment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	The vesting schedule requires the Director&#x2019;s continued service on the Board through each applicable vesting date as a condition to the vesting of the applicable installment of the Option and the rights and benefits under this Option Agreement.  Service for only a portion of the vesting period, even if a substantial portion, will not entitle the Director to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a termination of services as provided in Section 5 below or under the Plan.  Nothing contained in this Option Agreement or the Plan constitutes a continued service commitment by the Corporation or interferes with the right of the Corporation to increase or decrease the compensation of the Director from the rate in existence at any time.</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Method of Exercise of Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option shall be exercisable by the delivery to the Secretary of the Corporation (or such other person as the Administrator may require pursuant to such administrative exercise procedures as the Administrator may implement from time to time) of:</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a written notice stating the number of shares of Common Stock to be purchased pursuant to the Option or by the completion of such other administrative exercise procedures as the Administrator may require from time to time;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payment in full for the Exercise Price of the shares to be purchased in cash, check or by electronic funds transfer to the Corporation;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any written statements or agreements required pursuant to Section 8.1 of the Plan; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfaction of the tax withholding provisions of Section 8.5 of the Plan.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Administrator also may, but is not required to, authorize a non-cash payment alternative by one or more of the following methods (subject in each case to compliance with all applicable laws, rules, regulations and listing requirements and further subject to such rules as the Administrator may adopt as to any such payment method):</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">notice and third party payment in such manner as may be authorized by the Administrator;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in shares of Common Stock already owned by the Director, valued at their fair market value (as determined under the Plan) on the exercise date;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a reduction in the number of shares of Common Stock otherwise deliverable to the Director (valued at their fair market value on the exercise date, as determined under the Plan) pursuant to the exercise of the Option; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a &#x201c;cashless exercise&#x201d; with a third party who provides simultaneous financing for the purposes of (or who otherwise facilitates) the exercise of the Option.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Early Termination of Option; Acceleration on Death/Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Subject to earlier termination as provided below in this Section 5, the Option will terminate on the &#x201c;Expiration Date&#x201d; set forth in the Grant Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Possible Termination of Option upon Certain Corporate Events.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Option is subject to termination in connection with certain corporate events as provided in Section 7.2 of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination of Option upon a Termination of Director&#x2019;s Services.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Subject to earlier termination on the Expiration Date of the Option or pursuant to Section 5.2 above, if the Director ceases to be a member of the Board, the following rules shall apply (the last day that the Director is serving as a member of the Board is referred to as the Director&#x2019;s &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;):  </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other than as expressly provided below in this Section 5.3, (a) the Director will have until the date that is 3 months after his or her Severance Date to exercise the Option (or portion thereof) to the extent that it was vested on the Severance Date, (b) the Option, to the extent not vested on the Severance Date, shall terminate on the Severance Date, and (c) the Option, to the extent exercisable for the 3-month period following the Severance Date and not exercised during such period, shall terminate at the close of business on the last day of the 3-month period; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if the Director ceases to be a member of the Board due to the Director&#x2019;s death or Total Disability (as defined below), (a) the Option, to the extent then outstanding and unvested, shall accelerate and be fully vested on the Director&#x2019;s Severance Date, (b) the Director (or his or her beneficiary or personal representative, as the case may be) will have until the date that is 12 months after the Director&#x2019;s Severance Date to exercise the Option, and (c) the Option, to the extent not exercised during the 12-month period following the Severance Date, shall terminate at the close of business on the last day of the 12-month period.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of the Option, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a &#x201c;permanent and total disability&#x201d; (within the meaning of Section 22(e)(3) of the Code or as otherwise determined by the Administrator).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In all events the Option is subject to earlier termination on the Expiration Date of the Option or as contemplated by Section 5.2.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option and any other rights of the Director under this Option Agreement or the Plan are nontransferable and exercisable only by the Director, except as set forth in Section 5.7 of the Plan.</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any notice to be given under the terms of this Option Agreement shall be in writing and addressed to the Corporation at its principal office to the attention of the Secretary, and to the Director at the address last reflected on the Corporation&#x2019;s payroll records, or at such other address as either party may hereafter designate in writing to the other.  Any such notice shall be delivered in person or shall be enclosed in a properly sealed envelope addressed as aforesaid, registered or certified, and deposited (postage and registry or certification fee prepaid) in a post office or branch post office regularly maintained by the United States Government.  Any such notice shall be given only when received, but if the Director is no longer employed</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">by the Corporation or a Subsidiary, shall be deemed to have been duly given five business days after the date mailed in accordance with the foregoing provisions of this Section 7.</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option and all rights of the Director under this Option Agreement are subject to the terms and conditions of the Plan, incorporated herein by this reference.  The Director agrees to be bound by the terms of the Plan and this Option Agreement.  The Director acknowledges having read and understanding the Plan, the Prospectus for the Plan, and this Option Agreement.  Unless otherwise expressly provided in other sections of this Option Agreement, provisions of the Plan that confer discretionary authority on the Board or the Administrator do not and shall not be deemed to create any rights in the Director unless such rights are expressly set forth herein or are otherwise in the sole discretion of the Board or the Administrator so conferred by appropriate action of the Board or the Administrator under the Plan </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the date hereof.</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Option Agreement and the Plan together constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof.  The Plan and this Option Agreement may be amended pursuant to Section 8.6 of the Plan.  Such amendment must be in writing and signed by the Corporation.  The Corporation may, however, unilaterally waive any provision hereof in writing to the extent such waiver does not adversely affect the interests of the Director hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof.</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Option Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without regard to conflict of law principles thereunder.</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of this Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the Corporation&#x2019;s right to terminate the Option pursuant to Section 7.2 of the Plan, this Option Agreement shall be assumed by, be binding upon and inure to the benefit of any successor or successors to the Corporation.</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Electronic Signatures and Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Grant Notice may be signed and/or transmitted in one or more counterparts by facsimile, e-mail of a .PDF, .TIF, .GIF, .JPG or similar attachment or using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), all of which will be considered one and the same agreement and will become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart, and that any such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party&#x2019;s hand-written signature.  To the extent a party signs the Grant Notice using electronic signature technology, by clicking &#x201c;sign&#x201d; (or similar acknowledgement of acceptance), such party is signing the Grant Notice electronically.  Electronic signatures appearing on the Grant Notice shall be treated, for purposes of validity, enforceability and admissibility, the same as hand-written signatures.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The section headings of this Option Agreement are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clawback Policy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option is subject to the terms of the Corporation&#x2019;s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require forfeiture of the Option and repayment or forfeiture of any shares of Common Stock or other cash or property received with respect to the Option (including any value received from a disposition of the shares acquired upon exercise of the Option).</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Advice Regarding Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Director is hereby advised to consult with his or her own tax, legal and/or investment advisors with respect to any advice the Director may determine is needed or appropriate with respect to the Option (including, without limitation, to determine the foreign, state, local, estate and/or gift tax consequences with respect to the Option and any shares that may be acquired upon exercise of the Option).  Neither the Corporation nor any of its officers, directors, affiliates or advisors makes any representation (except for the terms and conditions expressly set forth in this Option Agreement) or recommendation with respect to the Option.  Except for the withholding rights contemplated by Section 4 above and Section 8.5 of the Plan, the Director is solely responsible for any and all tax liability that may arise with respect to the Option and any shares that may be acquired upon exercise of the Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>nktx-ex10_3e.htm
<DESCRIPTION>EX-10.3(E)
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 10.3(E)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 PERFORMANCE INCENTIVE PLAN</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>NOTICE OF GRANT OF STOCK OPTION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc., a Delaware corporation, (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Corporation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), pursuant to its 2020 Performance Incentive Plan, as may be amended from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), granted on the Date of Grant set forth below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Award Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to the award recipient listed below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grantee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), a nonqualified stock option (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to purchase the number of shares of the Corporation&#x2019;s Common Stock set forth below at a price per share equal to the Exercise Price per Share set forth below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  The Option is subject to all of the terms and conditions set forth in this Notice of Grant of Stock Option (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), as well as in the Plan and the Terms and Conditions of Nonqualified Stock Option attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), each of which is incorporated herein by this reference.  Unless otherwise defined in this Grant Notice or in the Terms, capitalized terms used in this Grant Notice or in the Terms are used as defined in the Plan.</font></p>
  <table style="margin-left:0.167%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:45.521%;"></td>
    <td style="width:54.479%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grantee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Award Number:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Grant:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price per Share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:9.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Number of Shares Subject to the Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:37.45pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1,2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[25% of the shares will vest on the one-year anniversary of the Vesting Commencement Date above and then 1/48th monthly thereafter for the remaining 36 months]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By accepting the Option (by clicking &#x201c;sign&#x201d;, &#x201c;accept&#x201d; or similar acknowledgement of acceptance through the Company&#x2019;s stock plan recordkeeping system which may be administered by the Company or through a third party on behalf of the Company), the Grantee (1) signs this Grant Notice electronically, which acceptance shall be valid and effective to bind the Grantee to this Grant Notice and shall be treated, for purposes of validity, enforceability and admissibility, the same as Grantee&#x2019;s hand-written signature to this Grant Notice, (2) agrees to be bound by the terms and conditions of the Plan, the Terms, and this Grant Notice and accepts the Option on and subject to such terms and conditions, (3) acknowledges having received and having reviewed in their entirety the Plan, the Terms, this Grant Notice, and the Prospectus for the Plan, (4) acknowledges having had an opportunity to obtain the advice of counsel (to the extent Grantee believed it was appropriate to consult with counsel) prior to executing this Grant Notice, (5) represents that he or she fully understands all provisions of the Plan, the Terms, and this Grant Notice, and (6) agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Terms, and this Grant Notice.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <table style="margin-left:1.102%;border-spacing:0;table-layout:fixed;width:51.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.:</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Address:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 PERFORMANCE INCENTIVE PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STOCK OPTION AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERMS AND CONDITIONS OF NONQUALIFIED STOCK OPTION</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These Terms and Conditions of Nonqualified Stock Option (these &#x201c;Terms&#x201d;) apply to a particular stock option (the &#x201c;Option&#x201d;) if incorporated by reference in the Notice of Grant of Stock Option (the &#x201c;Grant Notice&#x201d;) corresponding to that particular grant. The recipient of the Option identified in the Grant Notice is referred to as the &#x201c;Grantee.&#x201d; The per share exercise price of the Option as set forth in the Grant Notice is referred to as the &#x201c;Exercise Price.&#x201d; The effective date of grant of the Option as set forth in the Grant Notice is referred to as the &#x201c;Award Date.&#x201d; The exercise price and the number of shares covered by the Option are subject to adjustment under Section 7.1 of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option was granted under and subject to the Nkarta, Inc. 2020 Performance Incentive Plan (the &#x201c;Plan&#x201d;). Capitalized terms are defined in the Plan if not defined herein. The Option has been granted to the Grantee in addition to, and not in lieu of, any other form of compensation otherwise payable or to be paid to the Grantee. The Grant Notice and these Terms are collectively referred to as the &#x201c;Option Agreement&#x201d; applicable to the Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting; Limits on Exercise; Incentive Stock Option Status. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option shall vest and become exercisable in percentage installments of the aggregate number of shares subject to the Option as set forth on the Grant Notice. The Option may be exercised only to the extent the Option is vested and exercisable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Cumulative Exercisability. To the extent that the Option is vested and exercisable, the Grantee has the right to exercise the Option (to the extent not previously exercised), and such right shall continue, until the expiration or earlier termination of the Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; No Fractional Shares. Fractional share interests shall be disregarded, but may be cumulated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Minimum Exercise. No fewer than 100 shares of Common Stock (subject to adjustment under Section 7.1 of the Plan) may be purchased at any one time, unless the number purchased is the total number at the time exercisable under the Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Nonqualified Stock Option. The Option is a nonqualified stock option and is not, and shall not be, an incentive stock option within the meaning of Section 422 of the Code.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continuance of Employment/Service Required; No Employment/Service Commitment. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The vesting schedule applicable to the Option requires continued employment or service through each applicable vesting date as a condition to the vesting of the applicable installment of the Option and the rights and benefits under this Option Agreement. Employment or service for only a portion of the vesting period, even if a substantial portion, will not entitle the Grantee to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a termination of employment or services as provided in Section 5 below or under the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nothing contained in this Option Agreement or the Plan constitutes a continued employment or service commitment by the Corporation or any of its Subsidiaries, affects the Grantee&#x2019;s status, if he or she is an employee, as an employee at will who is subject to termination without cause, confers upon the Grantee any right to remain employed by or in service to the Corporation or any Subsidiary, interferes in any way with the right of the Corporation or any Subsidiary at any time to terminate such employment or service, or affects the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">right of the Corporation or any Subsidiary to increase or decrease the Grantee&#x2019;s other compensation. Nothing in this paragraph, however, is intended to adversely affect any independent contractual right of the Grantee without his/her consent thereto.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Method of Exercise of Option. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option shall be exercisable by the delivery to the Secretary of the Corporation (or such other person as the Administrator may require pursuant to such administrative exercise procedures as the Administrator may implement from time to time) of:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; a written notice stating the number of shares of Common Stock to be purchased pursuant to the Option or by the completion of such other administrative exercise procedures as the Administrator may require from time to time;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; payment in full for the Exercise Price of the shares to be purchased in cash, check or by electronic funds transfer to the Corporation;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; any written statements or agreements required pursuant to Section 8.1 of the Plan; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; satisfaction of the tax withholding provisions of Section 8.5 of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Administrator also may, but is not required to, authorize a non-cash payment alternative by one or more of the following methods (subject in each case to compliance with all applicable laws, rules, regulations and listing requirements and further subject to such rules as the Administrator may adopt as to any such payment method):</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; notice and third party payment in such manner as may be authorized by the Administrator;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; in shares of Common Stock already owned by the Grantee, valued at their fair market value (as determined under the Plan) on the exercise date;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; a reduction in the number of shares of Common Stock otherwise deliverable to the Grantee (valued at their fair market value on the exercise date, as determined under the Plan) pursuant to the exercise of the Option; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; a &#x201c;cashless exercise&#x201d; with a third party who provides simultaneous financing for the purposes of (or who otherwise facilitates) the exercise of the Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Early Termination of Option. </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1 	Expiration Date. Subject to earlier termination as provided below in this Section 5, the Option will terminate on the &#x201c;Expiration Date&#x201d; set forth in the Grant Notice (the &#x201c;Expiration Date&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2 	Possible Termination of Option upon Certain Corporate Events. The Option is subject to termination in connection with certain corporate events as provided in Section 7.2 of the Plan. 5.3 Termination of Option upon a Termination of Grantee&#x2019;s Employment or Services. Subject to earlier termination on the Expiration Date of the Option or pursuant to Section 5.2 above, if the Grantee ceases to be employed by or ceases to provide services to the Corporation or a Subsidiary, the following rules shall apply (the last day that the Grantee is employed by or provides services to the Corporation or a Subsidiary is referred to as the Grantee&#x2019;s &#x201c;Severance Date&#x201d;):</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; other than as expressly provided below in this Section 5.3, (a) the Grantee will have until the date that is 3 months after his or her Severance Date to exercise the Option (or portion thereof) to the extent that it was vested on the Severance Date, (b) the Option, to the extent not vested on the Severance Date, shall terminate on the Severance Date, and (c) the Option, to the extent exercisable for the 3-month period following the Severance Date and not exercised during such period, shall terminate at the close of business on the last day of the 3-month period;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; if the termination of the Grantee&#x2019;s employment or services is the result of the Grantee&#x2019;s death or Total Disability (as defined below), (a) the Grantee (or his beneficiary or personal representative, as the case may be) will have until the date that is 12 months after the Grantee&#x2019;s Severance Date to exercise the Option (or portion thereof) to the extent that it was vested on the Severance Date, (b) the Option, to the extent not vested on the Severance Date, shall terminate on the Severance Date, and (c) the Option, to the extent exercisable for the 12-month period following the Severance Date and not exercised during such period, shall terminate at the close of business on the last day of the 12-month period;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; if the Grantee&#x2019;s employment or services are terminated by the Corporation or a Subsidiary for Cause (as defined below), the Option (whether vested or not) shall terminate on the Severance Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of the Option, &#x201c;Total Disability&#x201d; means a &#x201c;permanent and total disability&#x201d; (within the meaning of Section 22(e)(3) of the Code or as otherwise determined by the Administrator).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of the Option, &#x201c;Cause&#x201d; means that the Grantee:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) has been negligent in the discharge of his or her duties to the Corporation or any of its Subsidiaries, has refused to perform stated or assigned duties or is incompetent in or (other than by reason of a disability or analogous condition) incapable of performing those duties;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2) has been dishonest or committed or engaged in an act of theft, embezzlement or fraud, a breach of confidentiality, an unauthorized disclosure or use of inside information, customer lists, trade secrets or other confidential information; has breached a fiduciary duty, or willfully and materially violated any other duty, law, rule, regulation or policy of the Corporation, any of its Subsidiaries or any affiliate of the Corporation or any of its Subsidiaries; or has been convicted of a felony or misdemeanor (other than minor traffic violations or similar offenses);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3) has materially breached any of the provisions of any agreement with the Corporation, any of its Subsidiaries or any affiliate of the Corporation or any of its Subsidiaries; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4) has engaged in unfair competition with, or otherwise acted intentionally in a manner injurious to the reputation, business or assets of, the Corporation, any of its Subsidiaries or any affiliate of the Corporation or any of its Subsidiaries; has improperly induced a vendor or customer to break or terminate any contract with the Corporation, any of its Subsidiaries or any affiliate of the Corporation or any of its Subsidiaries; or has induced a principal for whom the Corporation, any of its Subsidiaries or any affiliate of the Corporation or any of its Subsidiaries acts as agent to terminate such agency relationship.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In all events the Option is subject to earlier termination on the Expiration Date of the Option or as contemplated by Section 5.2. The Administrator shall be the sole judge of whether the Grantee continues to render employment or services for purposes of this Option Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Transferability. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option and any other rights of the Grantee under this Option Agreement or the Plan are nontransferable and exercisable only by the Grantee, except as set forth in Section 5.7 of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notices. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any notice to be given under the terms of this Option Agreement shall be in writing and addressed to the Corporation at its principal office to the attention of the Secretary, and to the Grantee at the address last reflected on the Corporation&#x2019;s payroll records, or at such other address as either party may hereafter designate in writing to the other. Any such notice shall be delivered in person or shall be enclosed in a properly sealed envelope addressed as aforesaid, registered or certified, and deposited (postage and registry or certification fee prepaid) in a post office or branch post office regularly maintained by the United States Government. Any such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">notice shall be given only when received, but if the Grantee is no longer employed by the Corporation or a Subsidiary, shall be deemed to have been duly given five business days after the date mailed in accordance with the foregoing provisions of this Section 7.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option and all rights of the Grantee under this Option Agreement are subject to the terms and conditions of the Plan, incorporated herein by this reference. The Grantee agrees to be bound by the terms of the Plan and this Option Agreement. The Grantee acknowledges having read and understanding the Plan, the Prospectus for the Plan, and this Option Agreement. Unless otherwise expressly provided in other sections of this Option Agreement, provisions of the Plan that confer discretionary authority on the Board or the Administrator do not and shall not be deemed to create any rights in the Grantee unless such rights are expressly set forth herein or are otherwise in the sole discretion of the Board or the Administrator so conferred by appropriate action of the Board or the Administrator under the Plan after the date hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Option Agreement and the Plan together constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof. The Plan and this Option Agreement may be amended pursuant to Section 8.6 of the Plan. Such amendment must be in writing and signed by the Corporation. The Corporation may, however, unilaterally waive any provision hereof in writing to the extent such waiver does not adversely affect the interests of the Grantee hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Option Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without regard to conflict of law principles thereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of this Agreement. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the Corporation&#x2019;s right to terminate the Option pursuant to Section 7.2 of the Plan, this Option Agreement shall be assumed by, be binding upon and inure to the benefit of any successor or successors to the Corporation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counterparts. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Option Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section Headings. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The section headings of this Option Agreement are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clawback Policy. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Option is subject to the terms of the Corporation&#x2019;s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require forfeiture of the Option and repayment or forfeiture of any shares of Common Stock or other cash or property received with respect to the Option (including any value received from a disposition of the shares acquired upon exercise of the Option).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Advice Regarding Grant. </font></div></div>
  <hr style="page-break-after:always;">
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Grantee is hereby advised to consult with his or her own tax, legal and/or investment advisors with respect to any advice the Grantee may determine is needed or appropriate with respect to the Option (including, without limitation, to determine the foreign, state, local, estate and/or gift tax consequences with respect to the Option and any shares that may be acquired upon exercise of the Option). Neither the Corporation nor any of its officers, directors, affiliates or advisors makes any representation (except for the terms and conditions expressly set forth in this Option Agreement) or recommendation with respect to the Option. Except for the withholding rights contemplated by Section 4 above and Section 8.5 of the Plan, the Grantee is solely responsible for any and all tax liability that may arise with respect to the Option and any shares that may be acquired upon exercise of the Option.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>nktx-ex10_3f.htm
<DESCRIPTION>EX-10.3(F)
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 10.3(F)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>2020 PERFORMANCE INCENTIVE PLAN</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>NOTICE OF GRANT OF RESTRICTED STOCK UNITS</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc., a Delaware corporation, (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Corporation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), pursuant to its 2020 Performance Incentive Plan, as may be amended from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), granted on the Date of Grant set forth below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Award Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to the award recipient listed below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grantee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), an award of restricted stock units (each, an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RSU</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  The Award is subject to all of the terms and conditions set forth in this Notice of Grant of Restricted Stock Units (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), as well as in the Plan and the Terms and Conditions of Restricted Stock Units attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), each of which is incorporated herein by this reference.  Unless otherwise defined in this Grant Notice or in the Terms, capitalized terms used in this Grant Notice or in the Terms are used as defined in the Plan.</font></p>
  <table style="margin-left:0.167%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.096%;"></td>
    <td style="width:61.904%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grantee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Award Number:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Grant:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Number of RSUs Subject to the Award:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[______________________________]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[One quarter (1/4) of the Award will vest on each of the one (1) year, two (2) year, three (3) year, and four (4) year anniversaries of the Vesting Commencement Date, such that all of the Award shall be vested on the four (4) year anniversary of the Vesting Commencement Date, subject in each case to the Grantee continuing to be an Eligible Person through each such date]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By accepting the Award (by clicking &#x201c;sign&#x201d;, &#x201c;accept&#x201d; or similar acknowledgement of acceptance through the Company&#x2019;s stock plan recordkeeping system which may be administered by the Company or through a third party on behalf of the Company), the Grantee (1) signs this Grant Notice electronically, which acceptance shall be valid and effective to bind the Grantee to this Grant Notice and shall be treated, for purposes of validity, enforceability and admissibility, the same as Grantee&#x2019;s hand-written signature to this Grant Notice, (2) agrees to be bound by the terms and conditions of the Plan, the Terms (including, without limitation, the tax withholding provisions of Section 8 of the Terms), and this Grant Notice and accepts the Award on and subject to such terms and conditions, (3) acknowledges having received and having reviewed in their entirety the Plan, the Terms, this Grant Notice, and the Prospectus for the Plan, (4) acknowledges having had an opportunity to obtain the advice of counsel (to the extent Grantee believed it was appropriate to consult with counsel) prior to executing this Grant Notice, (5) represents that he or she fully understands all provisions of the Plan, the Terms, and this Grant Notice, and (6) agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Terms, and this Grant Notice.</font></p>
  <table style="margin-left:1.102%;border-spacing:0;table-layout:fixed;width:51.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.:</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Address:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 PERFORMANCE INCENTIVE PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERMS AND CONDITIONS OF RESTRICTED STOCK UNITS</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These Terms and Conditions of Restricted Stock Units (these &#x201c;Terms&#x201d;) apply to a particular award of restricted stock units (each, an &#x201c;RSU,&#x201d; and collectively, the &#x201c;Award&#x201d;) if incorporated by reference in the Notice of Grant of Restricted Stock Units (the &#x201c;Grant Notice&#x201d;) corresponding to that particular grant. The recipient of the Award identified in the Grant Notice is referred to as the &#x201c;Grantee.&#x201d; The effective date of the Award as set forth in the Grant Notice is referred to as the &#x201c;Award Date.&#x201d; The RSUs covered by the Award are subject to adjustment under Section 7.1 of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Award was granted under and subject to the Nkarta, Inc. 2020 Performance Incentive Plan (the &#x201c;Plan&#x201d;). Capitalized terms are defined in the Plan if not defined herein. The Award has been granted to the Grantee in addition to, and not in lieu of, any other form of compensation otherwise payable or to be paid to the Grantee. The Grant Notice and these Terms are collectively referred to as the &#x201c;RSU Agreement&#x201d; applicable to the Award.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Award shall vest and become nonforfeitable in percentage installments of the aggregate number of RSUs subject to the Award as set forth on the Grant Notice.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend and Voting Rights.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1 	Limitations on Rights Associated with RSUs. The Grantee shall have no rights as a stockholder of the Corporation, no dividend rights (except as expressly provided in Section 3.2 with respect to Dividend Equivalent Rights) and no voting rights, with respect to the RSUs and any shares of Common Stock underlying or issuable in respect of such RSUs until such shares of Common Stock are actually issued to and held of record by the Grantee.  No adjustments will be made for dividends or other rights of a holder for which the record date is prior to the date of issuance of such shares.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2	Dividend Equivalent Rights Distributions. As of any date that the Corporation pays an ordinary cash dividend on its Common Stock, the Corporation shall credit the Grantee with an additional number of RSUs equal to (i) the per share cash dividend paid by the Corporation on its Common Stock on such date, multiplied by (ii) the total number of RSUs (including any dividend equivalents previously credited hereunder) (with such total number adjusted pursuant to Section 7.1 of the Plan) subject to the Award as of the related dividend payment record date, divided by (iii) the fair market value of a share of Common Stock on the date of payment of such dividend.  Any RSUs credited pursuant to the foregoing provisions of this Section 3.2 shall be subject to the same vesting, payment and other terms, conditions and restrictions as the original RSUs to which they relate.  No crediting of RSUs shall be made pursuant to this Section 3.2 with respect to (i) any RSUs which, as of such record date, have either been paid pursuant to Section 5 or terminated pursuant to Section 6 or (ii) any cash dividend or distribution as to which an adjustment is made pursuant to Section 7.2 of the Plan.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continuance of Employment/Service Required; No Employment/Service Commitment. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The vesting schedule applicable to the Award requires continued employment or service through each applicable vesting date as a condition to the vesting of the applicable installment of the Award and the rights and benefits under this RSU Agreement. Employment or service for only a portion of the vesting period, even if a substantial portion, will not entitle the Grantee to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a termination of employment or services as provided in Section 6 below or under the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nothing contained in this RSU Agreement or the Plan constitutes a continued employment or service commitment by the Corporation or any of its Subsidiaries, affects the Grantee&#x2019;s status, if he or she is an employee, as an employee at will who is subject to termination without cause, confers upon the Grantee any right to remain employed by or in service to the Corporation or any Subsidiary, interferes in any way with the right of the Corporation or any Subsidiary at any time to terminate such employment or service, or affects the right of the Corporation or any Subsidiary to increase or decrease the Grantee&#x2019;s other compensation. Nothing in this paragraph, however, is intended to adversely affect any independent contractual right of the Grantee without his/her consent thereto.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Timing and Manner of Payment of RSUs. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On or as soon as administratively practical following each vesting of the applicable portion of the total Award pursuant to Section 2 hereof or Section 7 of the Plan (and in all events not later than two and one-half months after the applicable vesting date) and subject to Sections 6 and 8, the Corporation shall deliver to the Grantee a number of shares of Common Stock (either by delivering one or more certificates for such shares or by entering such shares in book entry form, as determined by the Corporation in its discretion)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">equal to the number of RSUs subject to this Award that vested on that vesting date.  The Corporation&#x2019;s obligation to deliver shares of Common Stock or otherwise make payment with respect to vested RSUs is subject to the condition precedent that the Grantee or other person entitled under the Plan to receive any shares with respect to the vested RSUs deliver to the Corporation any representations or other documents or assurances required pursuant to Section 8.1 of the Plan.  The Grantee shall have no further rights with respect to any RSUs that are paid or that terminate pursuant to Section 6.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination of Award. </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1 	Possible Termination of Award upon Certain Corporate Events. The Award is subject to termination in connection with certain corporate events as provided in Section 7.2 of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2 	Termination of Award upon a Termination of Grantee&#x2019;s Employment or Services. On the date the Grantee ceases to be employed by or ceases to provide services to the Corporation or a Subsidiary (the last day that the Grantee is employed by or provides services to the Corporation or a Subsidiary is referred to as the Grantee&#x2019;s &#x201c;Severance Date&#x201d;), the RSUs subject to the Award will terminate to the extent such RSUs have not become vested by such Severance Date. If any unvested RSUs are terminated hereunder, such RSUs shall automatically terminate and be cancelled as of the Severance Date without payment of any consideration by the Corporation and without any other action by the Grantee, or the Grantees&#x2019;s beneficiary or personal representative, as the case may be. The Administrator shall be the sole judge of whether the Grantee continues to render employment or services for purposes of this RSU Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Transferability. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Award and any other rights of the Grantee under this RSU Agreement or the Plan are nontransferable, except as set forth in Section 5.6 of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Withholding.</font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Grantee agrees that, in connection with any distribution of shares of Common Stock in respect of the RSUs, the withholding obligations of the Corporation or its Subsidiaries with respect to such distribution of shares shall be satisfied as follows:</font></p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation will determine the amount of any federal, state, local or other income, employment, or other taxes which the Corporation or any of its Subsidiaries may be obligated to withhold with respect to such distribution of shares of Common Stock in respect of the RSUs (such withholding obligations, the &#x201c;Withholding Obligation&#x201d;).</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Grantee hereby irrevocably instructs the Corporation (and any third-party broker designated by the Corporation) to sell in one or more transactions on the open market, for and on the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:10.0%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grantee&#x2019;s behalf, from the shares of Common Stock otherwise deliverable to the Grantee in payment of such RSUs, a number of such shares of Common Stock (valued at the applicable sale prices applying the applicable broker&#x2019;s customary methodology) to satisfy the Withholding Obligation and any brokerage fees and commissions arising in connection with such sale (rounded up to the nearest whole share).  Such sale shall occur in connection with the delivery of the shares of Common Stock in payment of the RSUs as to which such Withholding Obligation relates.  The proceeds of such sale, in an amount equal to the Withholding Obligation, shall be promptly remitted to the Corporation to satisfy the Withholding Obligation.  Any brokerage fees and commissions arising in connection with such sale shall also be satisfied from the proceeds of such sale.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any such sale of shares of Common Stock for and on the Grantee&#x2019;s behalf will be conducted through a broker designated by the Corporation.  The Grantee agrees to execute any and all such other documents as may be requested by the Corporation or such broker, as applicable, in order to implement and consummate the transactions contemplated by this Section 8.  The Grantee agrees to comply with any administrative rules and procedures established by the Corporation with respect to such transactions.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For clarity, should any tax withholding event arise in connection with the RSUs other than in connection with the delivery of shares of Common Stock in payment of the RSUs, the Corporation (or a Subsidiary) shall be entitled to require a cash payment by or on behalf of the Grantee and/or to deduct from other compensation payable to the Grantee any sums required by federal, state or local tax law to be withheld with respect to such distribution or payment.  In such circumstances, the Corporation shall not be obligated to deliver any shares to the Grantee unless and until the amount of all federal, state and local taxes applicable to the taxable income of the Grantee resulting from the grant or vesting of the RSUs, or other applicable withholding event, has been satisfied in full by or on behalf of the Grantee.</font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation reserves the right, by action of the Administrator and subject to Section 8.5 of the Plan, to provide that the Withholding Obligation arising in connection with any distribution of shares of Common Stock in respect of the RSUs will be satisfied by the Corporation reducing the number of shares to be delivered by (or otherwise reacquiring) the appropriate number of whole shares, valued at their then fair market value, to satisfy such Withholding Obligation with respect to such distribution of shares.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notices. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any notice to be given under the terms of this RSU Agreement shall be in writing and addressed to the Corporation at its principal office to the attention of the Secretary, and to the Grantee at the address last reflected on the Corporation&#x2019;s payroll records, or at such other address as either party may hereafter designate in writing to the other. Any such notice shall be delivered in person or shall be enclosed in a properly sealed envelope addressed as aforesaid, registered or certified, and deposited (postage and registry or certification fee prepaid) in a post office or branch post office regularly maintained by the United States Government. Any such notice shall be given only when received, but if the Grantee is no longer employed by the Corporation or a Subsidiary, shall be deemed to have been duly given five business days after the date mailed in accordance with the foregoing provisions of this Section 9.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Award and all rights of the Grantee under this RSU Agreement are subject to the terms and conditions of the Plan, incorporated herein by this reference. The Grantee agrees to be bound by the terms of the Plan and this RSU Agreement. The Grantee acknowledges having read and understanding the Plan, the Prospectus for the Plan, and this RSU Agreement. Unless otherwise expressly provided in other sections of this RSU Agreement, provisions of the Plan that confer discretionary authority on the Board or the Administrator do not and shall not be deemed to create any rights in the Grantee unless such rights are expressly set forth herein or are otherwise in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sole discretion of the Board or the Administrator so conferred by appropriate action of the Board or the Administrator under the Plan after the date hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This RSU Agreement and the Plan together constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof. The Plan and this RSU Agreement may be amended pursuant to Section 8.6 of the Plan. Such amendment must be in writing and signed by the Corporation. The Corporation may, however, unilaterally waive any provision hereof in writing to the extent such waiver does not adversely affect the interests of the Grantee hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This RSU Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without regard to conflict of law principles thereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of this Agreement. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the Corporation&#x2019;s right to terminate the Award pursuant to Section 7.2 of the Plan, this RSU Agreement shall be assumed by, be binding upon and inure to the benefit of any successor or successors to the Corporation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Electronic Signatures and Counterparts. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Grant Notice may be signed and/or transmitted in one or more counterparts by facsimile, e-mail of a .PDF, .TIF, .GIF, .JPG or similar attachment or using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), all of which will be considered one and the same agreement and will become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart, and that any such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party&#x2019;s hand-written signature.  To the extent a party signs the Grant Notice using electronic signature technology, by clicking &#x201c;sign&#x201d; (or similar acknowledgement of acceptance), such party is signing the Grant Notice electronically.  Electronic signatures appearing on the Grant Notice shall be treated, for purposes of validity, enforceability and admissibility, the same as hand-written signatures.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section Headings. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The section headings of this RSU Agreement are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clawback Policy. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Award is subject to the terms of the Corporation&#x2019;s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require forfeiture of the Award and repayment or forfeiture of any shares of Common Stock or other cash or property received with respect to the Award (including any value received from a disposition of the shares acquired pursuant to the Award).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Advice Regarding Grant. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Grantee is hereby advised to consult with his or her own tax, legal and/or investment advisors with respect to any advice the Grantee may determine is needed or appropriate with respect to the Award (including, without limitation, to determine the foreign, state, local, estate and/or gift tax consequences with respect to the Award and any shares that may be acquired pursuant to the Award). Neither the Corporation nor any of its officers, directors, affiliates or advisors makes any representation (except for the terms and conditions expressly</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">set forth in this RSU Agreement) or recommendation with respect to the Award. Except for the withholding rights contemplated by Section 8 above and Section 8.5 of the Plan, the Grantee is solely responsible for any and all tax liability that may arise with respect to the Award and any shares that may be acquired pursuant to the Award.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction. </font></div></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is intended that the terms of the Award will not result in the imposition of any tax liability pursuant to Section 409A of the Code. This Agreement shall be construed and interpreted consistent with that intent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>nktx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-252134) pertaining to the Nkarta, Inc. 2020 Performance Incentive Plan and the Nkarta, Inc. Employee Stock Purchase Plan of Nkarta, Inc.;  </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-240309) pertaining to the Nkarta, Inc. 2020 Performance Incentive Plan, the Nkarta, Inc. Employee Stock Purchase Plan, and the Nkarta, Inc. 2015 Equity Incentive Plan of Nkarta, Inc.; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-3 No. 333-258766) of Nkarta, Inc. pertaining to the offer, issuance, and sale of a maximum aggregate offering of up to $500,000,000 of common stock, preferred stock, debt securities, warrants, rights and unit and at-the-market offering of common stock.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(4)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263650) pertaining to the Nkarta, Inc. 2020 Performance Incentive Plan and the Nkarta, Inc. Employee Stock Purchase Plan</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(5)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-269164) pertaining to the Nkarta, Inc. 2020 Performance Incentive Plan and the Nkarta, Inc. Employee Stock Purchase Plan</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated March 16, 2023, with respect to the financial statements of Nkarta, Inc. included in this Annual Report (Form 10-K) of Nkarta, Inc. for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                                                                                                                    /s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 16, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>nktx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Paul J. Hastings, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K (the &#x201c;report&#x201d;) of Nkarta, Inc. (the &#x201c;registrant&#x201d;);</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.353%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:4.295%;"></td>
    <td style="width:46.357%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 16, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Paul J. Hastings</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paul J. Hastings</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>7
<FILENAME>nktx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Nadir Mahmood, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K (the &#x201c;report&#x201d;) of Nkarta, Inc. (the &#x201c;registrant&#x201d;);</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.353%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:4.295%;"></td>
    <td style="width:46.357%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 16, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Nadir Mahmood</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nadir Mahmood</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial and Business Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>nktx-ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NKARTA, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K for the year ended December 31, 2022 of Nkarta, Inc. (the &#x201c;Company&#x201d;) as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), we, Paul J. Hastings, Chief Executive Officer of the Company, and Nadir Mahmood, Chief Financial and Business Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.406%;"></td>
    <td style="width:4.957%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:45.641%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 16, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Paul J. Hastings</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paul J. Hastings</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.395%;"></td>
    <td style="width:4.968%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:45.641%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 16, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Nadir Mahmood</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nadir Mahmood</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial and Business Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">This is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350. This certification shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img183648649_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,M!+L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-F+;"-A'Z,1GO@4;I+K:_P" 2T;:[_J:WPK\6ZYXDM=??5K[[0UHZB$^4B;
M0W]T#/0=:L?!_P 4:SXIT?4I]9O/M4L-P$C;RD3"[<X^4"N=^!__ !Y>*O\
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MDAF49\MQD X[C!((KHJ*'JK#3L[GDTOP\\=:Q81:)KGBNV;18BH(@C)EE4=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ ILDB0Q/+(X2- 69F.  .I-.JAK>DQ:YH]SIL\LL45PH5GB(#
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MUUUO:WS_ ,M1NB>)O%7B.QFETZPTR,P3/$\URSA'(/ 55R>F,DGJ>E;WA7Q
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M1U+2M:MH+:^L%61W@8F*1&&=PSR/QJG9^(/$VOPOJ&AZ?IT>FAF$)O9'$EP
M<9&WA1G/7-5?LSWGC[Q5:QG$DVEQQJ?0E2!6%X7MM&_L%(-1\4ZOI5[: QW-
MHVIF 1D'^%3V/MZT*,6N;R0W)IV\W^G]?([>Q\7VD_AJ[U>[A>U:Q9X[N G+
M1R+U4'OG(Q]:STUKQC)IXU=='TX693S19&9_M)3KUQMSCMBN??1X-4^'.O-H
M<>IR_:9_-5[Q][W.Q@2R]R"!WY.*?"_AEM!&H/XTUM%$>6MSJQ$@;'*;.N>U
M/EBKM+^K!S-V7K^9OZ]XU^Q>%M,UW38EGAN[B-"CJ2VUL[@ "/F&,>F:D_X2
M+6='TB^U3Q)8VL$,84VT-K(7D8L<!&SQG..1QS[5SFK6=O9> _#<5K;W=O V
MJ0.L5V09%#,QYQ]<_C6_\2K">]\*;H$E?[-<1W$BPG#E%/.WW&<_A2<8IV[N
MWRT&G)J_E?U>HV?6_%^GV!U:^TG3FLD7S);6"9_M$2=2<D;6('8>E7]9\5)9
MZ=ILNFP"]NM495LXBVT-D9W,>P ZUREY_P (N-#:\_X3+6[J.1,+;)JI:24G
M^#9UR<XP15G4[:/0#X.U?R;F+3=/#13+-\SP+(N 7QZ=#3Y(MI-=?Z7Y?>)2
ME:Z?0K>-;OQ"FG:=;:U:6)26_A9+BQ=]J,&^ZP;GIW'I7IU>>>/O$6E7NFV%
ME8WD-Y-)>P2'[.X<1J&'+$=,\ ?6O0ZB5^175M7^A4?C>M]%^;/,?%VB2:[\
M1D@MYFAO(=*^T6L@.-LJR?+_ (?C71:=X@_X2#P3J$DR>5?V\$L-W">#'(%.
M>/0]14#_ /)88O\ L#G_ -&5G>.+2?PY=7/B33XR]M>0-;:E"O?((23Z@G'_
M .LTW[T%!]M/6[_,:TJ.:Z-7]++\O\S.U;_D@MK_ -<H?_1@JYJ/B9?%.K6O
MA32K\6MK*I6YO0>9=H&Z.(]"?4_Y-/5O^2"VO_7*'_T8*ZC6/!UKJ'A.ULM-
M1;.YLU66RD3@QR#GK[]S^-:R<4VY?S/]#&*DU%1_E7]?\$Z+3-,L]'T^*QL8
M%AMXAA57^9]3[U%KFL6V@Z-<ZE=9,4"YVKU8G@ ?4XK+\&^)3X@TQX[I/)U2
MS;R;R \%7'&<>AQ_.H?B)8W%]X.N1;1F5X9(YS&!DNJL"1^7\JP<7SVD^O\
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M71X<_P"?+5?^_4?_ ,75?57_ "F/M*7='<_V1IG_ $#K3_OPO^%']D:9_P!
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M_K-[!>&$126=H74[4YYX'?M4QU5O[K_]**GHV_-?D>C.Z11M)(ZHB@LS,<
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MUU]74^)D4_A04445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC/R[/1,>G^%7K2RNE^*]_>M;3"U;3419S&=A;<. W3/M47C#1[ZSU*V\5:#
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MT.6,;!;0++)$_<,A/S ^HK.\*:,\?BV\UBSTB;1M+DMA"+:4!&FDW9W[ 3M
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M;Q$G'RDYP"1GOQQ5#Q!#'XET^2UB\$7L.LR *+F2W6-(FS][S0?F IJW,_\
M@?\ #"=^5?/N;^OWEW#XV\*VZ7$L<4[3^=%'(0DF$R,CO@^M9=A#JNN>,_$M
MBVM7UKIUM+'A(),/DK]U6.=B\$G &2:NZEIM\OBCP:3'-<BT25;BX5"5!\L#
M+'MD^M3^&;.Z@\8^*YYK::.&>:$Q2.A"R (<[2>OX5*LH_)_^E#E=M>J_)E?
M0+^]TGQ!KNC7VH37UI8P)<PS7!!D52,D,W>H="T_5O%6F+KMYKVH63W)9[6W
MLW"1PIG"[A@[SQW]:MVVFSS?$'7WFMIEL[FQBB$I0A&XP0#T)JIH6H:MX5TQ
M="O-!U&]>V+);7%F@>.9,Y7<<C8>>_I1>ZNM[+];_H/9VZ7?Z6^6Y9\ W.J3
MOKT6K7;W%Q;WYBR2=H 4?=!^Z#UP/6M#QOJ-_I?AF:YT\ND@=%DEC3>T49/S
M.!W(%9'PXDNIG\1RWJ*ERVIOYBJVX*V!D ]\=*Z3Q#)J\.EF;18HIKJ-U9H9
M/^6J9^903T..]3/2:^7ILBH?"[>?KNSDM+:*[N+6?PWXVFO9_,#3VNHW&\2)
M_%A-H93]!6EK%YJ.L>+T\.6-]+86\-M]IN[B$#S&R<*BD_=]<U@Z]8Q^*(XX
M-,\(WNGZJ948W\]NL @P02V\'Y^/3-;NK66I:-XMB\165G+J%O+:BUO((<>:
M,'(=0<9^E6[73?GV[:&>MFEY=^^OS(9VU#P?KNDQG5+O4-*U"?[*Z7KB22*0
MCY2KX!(/H:BL7:/QKXW=&*LMM 0P."#Y9J6X34/&&NZ3(=+N]/TK3Y_M3O>H
M(Y)9!]T*F20/<U+INFW3^-/%K2031P74,"13,A"O\A!VGH<9[5+^%WWL_P T
M6OBTVNC0\"7,]YX(TNXN9Y)YGB):25RS,=QZD\FN(O+NZO?@YJTMU<2W$HO&
M4/*Y8X$RX&3VK:\,ZEK&@Z##H$WAO49+^V#1QRQJOV=QN)#&0G '//>LE='U
M9?A!J-A)8W!OVNV/DK"VYOWH.0N,D=\XZ5I9>T;Z77YD0;4(Q>Z6OW&U>:'K
MUCX??5X_$5\=5@A\YH"5^S' R4$>.F!C/6H-?U,:S:>!]15=GVG489"O]TD<
MC\ZMW^M:]?:++HT7AV]359HO(>9@!;+D8+B3/(QDXQFH]9T&>QL_!MA:0RW"
M6%]#YKQQDA0!RYQT&?6E%^\K]_Z_04E[EEV=_P!/U&:WKHU#Q?/HDOB!-%T^
MRB5II%G2*6>1AD*K-T '7%+H^N)IWBVUT:W\0IK6GWT;F-GG2:6"11G!9>H(
MSC/I2ZII$FD^,+O67T/^V-.OXT$J1Q+)+!(HQD*W4$>E6]%2>^\01W5KX:@T
MK2X8SF2ZM4CN)'/ V@<J![TER\J]/Q_X?8J5^9^NG]?F=C7$>"_^1F\8_P#7
M\O\ (UV]<?X1LKJV\1>*Y9[::*.>\#1/)&5$@P>5)ZCZ5C'X9>GZHTGO'U_1
MD7PM_P"1._[>YO\ T*NMO+ZSTZ#S[VZ@MH<[?,GD"+GTR:\V\'Z_>^&M$;3K
MKPMXAED$\C[X;$E2">.N*Z^PO;3QA:SP:CX?OH(8F4^7J=KL#GGE0<YQ_6M:
ML7S.70F$EMUU-:QU;3=3+C3]0M+LQXWBWF63;GIG!.*X+Q7X;T[1%T:>VC=[
MJXUJ!IKF9M\C\G@L>WL*[K3M$TO2#(=.L+>U,F YAC"[L=,X^M87CNSN;R'0
MQ;6TTYCU6"1_*0MM49RQQT ]:FFTJBY=M!S3<'S=G^1/X^MK^]\'7MIIUN\]
MQ/M0(G7;N!/Z"LVZUCQ;X?L!?7FD::^EP(OF06T[F>)!P220%.!Z5O\ B6/6
MGTAGT&94OHW5PCA2)5'5,D<9]>/K7/ZMK>L:]H\^D6/AO4K>\NH_)EENT"0P
MAN&._/S<9Q@?X40O:R2W"=KW;>QV-E>0ZA8P7ENVZ&>-9$/J",BIZI:/IR:1
MHUGIR,76VA6+<?XL#&:NUG*UW;8J-^57W"BBBD4%%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!R'@+_F9_^P_=?^RUU]<AX"_YF?\ [#]U_P"RUU]74^)D4_A04445!844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '(?%#_DG6J_]L?\ T<E?.=?1GQ0_Y)UJO_;'_P!')7SG7HX3
MX'ZGG8OXUZ!11174<I]=T445XA[84444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK_VQ_P#1R5\YUZ.$^!^IYV+^->@4445U'*?7=%%%>(>V%%%% !1110 4444
M%%%<%\6]0O=-\*6LUA>7%K*U\BEX)61BNR0XR#TX'Y54(\TE$F<N6+D=[17R
MW_PE?B/_ *#^J_\ @9)_C1_PE?B/_H/ZK_X&2?XUU?4Y=SE^N1['U)17SAX9
M\3:_<>*]'AFUO4I(I+Z%71[N0JREP""">17T?6%6DZ;LS>E551704445D:A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%>2>L%%%% !1110 4444 <A\4/^2=:K_P!L?_1R5\YU]&?%#_DG6J_]L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /(OCC_S ?\ MX_]IUY#7KWQQ_Y@/_;Q_P"TZ\AKU,-_"1Y>)_BL*]&^"_\
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M_80G_P#1C5V8/XF<>,^%&11117><![K\%_\ D3KO_L(/_P"BXZ]&KSGX+_\
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M10 4444 %%%% !1110 4444 %>%?&C_D<;3_ +!Z?^C)*]UKPKXT?\CC:?\
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M]@^#_P!%K7'C/A1V8/XF:]%%%<!WA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7A7QH_Y'&T_[!Z?^C)*]UKPKXT?\CC:?]@]/_1DE=&%
M_B'/BOX9YS1117IGF'HWP7_Y'&[_ .P>_P#Z,CKW6O"O@O\ \CC=_P#8/?\
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M;<Q";_=/K['!KH:3BUN-23V"BBBD,Y#P%_S,_P#V'[K_ -EKKZY#P%_S,_\
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M_P!%R5Z-7G/QH_Y$ZT_[""?^BY*UH?Q$95_X;/"J***]8\DU_"G_ "..A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >+_$;7=:UCQ@/#&E2
M3*B;4\J)MIE=AD[CZ 'Z<$UD0Q>*/ACJME<7;,+*9_GC27?%(/X@1V;'?_Z]
M;-K_ ,G O_UV?_T0:W/C4!_PC%B<<_;!_P"@-7;&7(H1MHTK_,XIQYW.3>VW
MR.>\:?$N^U2]?2/#C.EN6\LS0@F2<^BXZ#Z<FNJ^%WA34_#MG>W6IA8Y;W81
M#G+J%W<M[G=TJW\._!^G:+HEIJ7E++J%U"LK3,,E PSM7T&#^-=M6=2<8)TX
M+U9I3A*;52;]$%%%%<QTA1110 4444 %1SPK<6\L#E@LB%"5.#@C'!J2J]_>
MPZ;I]Q>W!(AMXVD<CT S0",R672?!/AE0[>38VJ;44G+,>N!ZDFN$N[:]TGX
M0WQG1K>74;KS/)_YXI+(/E]N.WO532_&'AW5=4&M^*-1)GC<_8]/$$C16PSP
MQPN&?W_R.RU>6S\?>!]031)_..<1L49/WB$,!\P'L,^]=/*X.\UU5_O.=2C/
M2#[V];&Y?Z=;OX9N-.,:_9_LC1!<< !<"O/-.NGU6P^'EI<9:-I)'8'^(P@A
M<_E6Y<^.8;KP^]G;VMX=?EA\G[#]G<.DA&,DD8V@\YSTJ"_\/W>@Z!X9N[:!
MKF?1'#7$4(RSHPQ)M'?DTH7B_>[K]?\ -!+WDN7L_P!/^":/Q,4+X-EO%XFL
MYXIX6[JP<#(_,UUT3^9$C_WE!K@?$.LVWC:TM]!T03S_ &B=&NY3"Z+!$I#'
M<6 YXZ5WX 50!T P*S::@D][O\D:)ISNNW^97O=0LM-A$U_>6]K$S;0\\JHI
M;DXR3UX/Y51_X2OPY_T']*_\#(_\:O7NGV6I0B&_L[>ZB5MP2>)74-R,X(Z\
MG\ZH_P#"*>'/^@!I7_@''_A4KEZE/FOH8GP\ECN(?$<T,B212:[<LCHP*LIV
M$$$=1795QOP\BCMX?$<,,:1Q1Z[<JB(H"JHV   =!79557XV32^!!11169H%
M%%% !1110 5\M^*_^1QUS_L(3_\ HQJ^I*^6_%?_ "..N?\ 80G_ /1C5V8/
MXF<>,^%&11117><![K\%_P#D3KO_ +"#_P#HN.O1J\Y^"_\ R)UW_P!A!_\
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MU]&?%#_DG6J_]L?_ $<E?.=>CA/@?J>=B_C7H%%%%=1RGUW1117B'MA1110
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M.OHSXH?\DZU7_MC_ .CDKYSKT<)\#]3SL7\:] HHHKJ.4^NZ***\0]L****
M"BBB@ HHHH *\Y^-'_(G6G_803_T7)7HU><_&C_D3K3_ +""?^BY*UH?Q$95
M_P"&SPJBBBO6/)-?PI_R..A_]A"#_P!&+7U)7RWX4_Y''0_^PA!_Z,6OJ2N#
M&?$COP?PL****XSL"BBB@ HHHH **** /D2BBBO;/$"OJ3PI_P B=H?_ &#X
M/_1:U\MU]2>%/^1.T/\ [!\'_HM:X\9\*.S!_$S7HHHK@.\**** "BBB@ HH
MHH *^1*^NZ^1*[<']KY'%C/L_,****[CA/J3PI_R)VA_]@^#_P!%K6O61X4_
MY$[0_P#L'P?^BUK7KQI?$SV8_"@HHHJ2@HHHH **** "O"OC1_R.-I_V#T_]
M&25[K7A7QH_Y'&T_[!Z?^C)*Z,+_ !#GQ7\,\YHHHKTSS#T;X+_\CC=_]@]_
M_1D=>ZUX5\%_^1QN_P#L'O\ ^C(Z]UKS,5_$/3PO\,****YSH"BBB@ HHHH
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M_P#,!_[>/_:=>0UZF&_A(\O$_P 5A7HWP7_Y'&[_ .P>_P#Z,CKSFO1O@O\
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M* "BBB@ HHHH **** "BBB@ HHHH Y#P%_S,_P#V'[K_ -EKKZY#P%_S,_\
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M@HHHJ2@HHHH **** "O"OC1_R.-I_P!@]/\ T9)7NM>%?&C_ )'&T_[!Z?\
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M+_\ (XW?_8/?_P!&1U5?^&R:'\1'NM%%%>2>L%%%% !1110 4444 <A\4/\
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MT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*X,9\2._!_"PHHHKC.P**** "BBB@ HHHH ^1****]L\0*^I/"G_ ")VA_\
M8/@_]%K7RW7U)X4_Y$[0_P#L'P?^BUKCQGPH[,'\3->BBBN [PHHHH ****
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M !6%==\/_P#C^U;_ +!__M>&N1KKOA__ ,?VK?\ 8/\ _:\-;K=>J_,Y:O\
M#EZ/\CKJ***[SYD*]?KR"O7Z\K,_L_/]#Z+(/^7GR_4****\H^B"BBB@#D/B
MA_R3K5?^V/\ Z.2OG.OHSXH?\DZU7_MC_P"CDKYSKT<)\#]3SL7\:] HHHKJ
M.4^NZ***\0]L**** "BBB@ HHHH *\Y^-'_(G6G_ &$$_P#1<E>C5YS\:/\
MD3K3_L()_P"BY*UH?Q$95_X;/"J***]8\DU_"G_(XZ'_ -A"#_T8M?4E?+?A
M3_D<=#_["$'_ *,6OJ2N#&?$COP?PL****XSL"BBB@ HHHH **** /D2BBBO
M;/$"OJ3PI_R)VA_]@^#_ -%K7RW7U)X4_P"1.T/_ +!\'_HM:X\9\*.S!_$S
M7HHHK@.\**** "BBB@ HHHH *^1*^NZ^1*[<']KY'%C/L_,****[CA/J3PI_
MR)VA_P#8/@_]%K6O61X4_P"1.T/_ +!\'_HM:UZ\:7Q,]F/PH****DH****
M"BBB@ KPKXT?\CC:?]@]/_1DE>ZUX5\:/^1QM/\ L'I_Z,DKHPO\0Y\5_#/.
M:***],\P]&^"_P#R.-W_ -@]_P#T9'7NM>%?!?\ Y'&[_P"P>_\ Z,CKW6O,
MQ7\0]/"_PPHHHKG.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M '^7_&O&Y)=CU_:T_P"9?>7**I_VMIO_ $$+3_O\O^-68IHYXQ)#(DD9Z,C
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M_8/@_P#1:UKUD>%/^1.T/_L'P?\ HM:UZ\:7Q,]F/PH****DH**** "BBB@
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MK3_L()_Z+DK6A_$1E7_AL\*HHHKUCR37\*?\CCH?_80@_P#1BU]25\M^%/\
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M0G_]&-7U)7RWXK_Y''7/^PA/_P"C&KLP?Q,X\9\*,BBBBN\X#T7PA_R)T?\
MV$)__1<-:]9'A#_D3H_^PA/_ .BX:UZZ:'P??^9X6/\ ]XE\OR05L>%O^1CM
M/^!_^@-6/6QX6_Y&.T_X'_Z U.O_  I>C_(C!_[Q3_Q+\ST>BBBOFC[L****
M /(OCC_S ?\ MX_]IUY#7KWQQ_Y@/_;Q_P"TZ\AKU,-_"1Y>)_BL*Z[X?_\
M']JW_8/_ /:\-<C77?#_ /X_M6_[!_\ [7AK=;KU7YG+5_AR]'^1UU%%%=Y\
MR%>OUY!7K]>5F?V?G^A]%D'_ "\^7ZA1117E'T04444 <A\4/^2=:K_VQ_\
M1R5\YU]&?%#_ ))UJO\ VQ_]')7SG7HX3X'ZGG8OXUZ!11174<I[1JW_ "&;
M[_KXD_\ 0C5.KFK?\AF^_P"OB3_T(U3KLI_ CYNM_$EZL*]'\+?\BY:?\#_]
M#:O.*]'\+?\ (N6G_ __ $-JXLR_A+U_1GJY'_O$O\/ZHV****\4^J"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#D/ 7_,S_ /8?NO\ V6NOKD/ 7_,S_P#8?NO_ &6NOJZG
MQ,BG\*"BBBH+"BBB@ HHHH *^6_%?_(XZY_V$)__ $8U?4E?+?BO_D<=<_["
M$_\ Z,:NS!_$SCQGPHR****[S@/1?"'_ ")T?_80G_\ 1<-:]9'A#_D3H_\
ML(3_ /HN&M>NFA\'W_F>%C_]XE\OR05L>%O^1CM/^!_^@-6/6QX6_P"1CM/^
M!_\ H#4Z_P#"EZ/\B,'_ +Q3_P 2_,]'HHHKYH^["BBB@#R+XX_\P'_MX_\
M:=>0UZ]\<?\ F _]O'_M.O(:]3#?PD>7B?XK"NN^'_\ Q_:M_P!@_P#]KPUR
M-==\/_\ C^U;_L'_ /M>&MUNO5?F<M7^'+T?Y'74445WGS(5Z_7D%>OUY69_
M9^?Z'T60?\O/E^H4445Y1]$%%%% '(?%#_DG6J_]L?\ T<E?.=?1GQ0_Y)UJ
MO_;'_P!')7SG7HX3X'ZGG8OXUZ!11174<I[1JW_(9OO^OB3_ -"-4ZN:M_R&
M;[_KXD_]"-4Z[*?P(^;K?Q)>K"O1_"W_ "+EI_P/_P!#:O.*]'\+?\BY:?\
M _\ T-JXLR_A+U_1GJY'_O$O\/ZHV****\4^J"BBB@ KSGXT?\B=:?\ 803_
M -%R5Z-7G/QH_P"1.M/^P@G_ *+DK6A_$1E7_AL\*HHHKUCR37\*?\CCH?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!O'_M.O(:]3#?PD>7B?XK"NN^'_P#Q_:M_V#__ &O#7(UUWP__ ./[5O\
ML'_^UX:W6Z]5^9RU?X<O1_D==1117>?,A7K]>05Z_7E9G]GY_H?19!_R\^7Z
MA1117E'T04444 <A\4/^2=:K_P!L?_1R5\YU]&?%#_DG6J_]L?\ T<E?.=>C
MA/@?J>=B_C7H%%%%=1RGM&K?\AF^_P"OB3_T(U3JYJW_ "&;[_KXD_\ 0C5.
MNRG\"/FZW\27JPKT?PM_R+EI_P #_P#0VKSBO1_"W_(N6G_ _P#T-JXLR_A+
MU_1GJY'_ +Q+_#^J-BBBBO%/J@HHHH *\Y^-'_(G6G_803_T7)7HU><_&C_D
M3K3_ +""?^BY*UH?Q$95_P"&SPJBBBO6/)-?PI_R..A_]A"#_P!&+7U)7RWX
M4_Y''0_^PA!_Z,6O=?\ A.?^H=_Y'_\ L:Y:]"I5E[BO8WIXNCAX_O7:_K^A
MU]%<A_PG/_4._P#(_P#]C1_PG/\ U#O_ "/_ /8UA]2K_P OXHO^UL'_ #_@
M_P#(Z^BH;2?[59P7&W;YL:OMSG&1G%35S-6=F>@FI*Z"BBBD,**** /D2BBB
MO;/$"OJ3PI_R)VA_]@^#_P!%K7RW7U)X4_Y$[0_^P?!_Z+6N/&?"CLP?Q,UZ
M***X#O"BBB@ HHHH **** "OD2OKNOD2NW!_:^1Q8S[/S"BBBNXX3ZD\*?\
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MWQQ_Y@/_ &\?^TZ\AKU,-_"1Y>)_BL*Z[X?_ /']JW_8/_\ :\-<C77?#_\
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MEZ/\B,'_ +Q3_P 2_,]'HHHKYH^["BBB@#R+XX_\P'_MX_\ :=>0UZ]\<?\
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M7XQT*>[D_P"$?\_[1;^1C[;"NWYT?/WCG[F/QKW6BJ^MS[(AX.FTT[ZGD/\
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M\CD/^$A\8_\ 0B_^5>'_  H_X2'QC_T(O_E7A_PKKZ*.=?RK\?\ ,.1_S/\
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MZ)IQBN;B>Z2*Y?EEA4G&,@_>_EBJ4).7*MR7.*CS/8[*BBBH+"BBB@ HHHH
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M.Q3W8X_SSA?&B :AH%GI*/\ V[$Y>RQC8B 8?S,_PX].:BTJ[\4Z+I\5C8>
M8X8(QP!JD62>Y)[D^M:NNZ/JD^HZ9X@TM(1J5I&4EM9GPLB,.5W#H0>AZ5MI
M%I=/U_K\#&[DF^O]?B8=\VL6_BG1;SQ>MJ+..79:MIQ8Q).PP#)O^;Z8X%>B
MUQ=W8>(/%=S8Q:IIL.E:=;3K<2I]I$TDS+T VC 7]:[2HF]$BX+5L****S-
MHHHH **** "BBB@"K?"[6SF;3DMS>E0(_/)"$_[1'..M<7X:DNK3QU>Q>(T
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MC0>@ P*FJ*U>:6TADN(?)F9 9(MP;8V.1D=<'O4M9.]]3:-K:!1112&%%%%
M!1110 5Q?C#7+:6_A\,G4H+$7"^9>W$LJQ[(?[JDD?,W3V&37:5FWOA[1M2N
M#<7VE65S,0!YDT"LV!VR151:3NR9)M61Q6EZGH=O\3Y!::A8+9C2H[> I.FP
ML'&$4YP3[=:MWMZOA#QWJ&JZC#-_96IP1C[5'&7$+H,;6 Y -2VW@NU@\?RW
MHT6S32A9J(B(TVK.'SD+U!QWQ6KJW_"26.LB^TR*/4;!XMDEB\JQ,C@_?1B,
M=.Q-;.2NK=C*,6E*_=?H<O<ZR=9^)?AFZLX)EL0LZ1S2H8_.^0EB%.#M'')'
M7->E5RVEZ3JE_P")!K^MQ0VSPPF&TLXI/,\L-]YF; !8]..U=36=1JR2Z?YL
MN"=VWU_R"BBBLS0**** "BBB@ HHHH X2S\-^*X]4UNY@U6TTQ+VZ,J.+<7$
MC*!A0<D #'U/6HI/$6J-I'BC1=66(ZGI]F\BSP A9HV4X;'8]/SJ_#%XK\/W
ME[';VW]NV,\QE@:6\\N6'/\  2^<J.V/_K5-HGAJZ:XU;4]>,37NJ)Y3PPDE
M(8@,! 3U/J:V;O'6UK?/I_78R2M+2][_ -?UN8WAFU\5ZAX2TV;3]3M=*MXX
M%6&W-J)3, ,;G8GY<G)X'0UTOA+7IM>TN5KR%8;ZTG>VN43[N]>I'L<UD:;!
MXL\,Z>-'MM,MM4MXLK:W1NA$43L)%(R<>U;/A30I="TJ2.ZF6:]NIWN;F1!\
MID;J![#@4ZC3YG]W]?YDTTURKKU[&[1116!N%%%% !1110 4444 <1\4KAK?
MPO;L(C*AOH=\8_C )./Q(%+J"^-K&PDUD:G8R&&,RR:6+7"!1R0),[B<?2M_
MQ-H2>(]!GTYI/*=L/%*!G8ZG(-8-VWC74=*?1Y-+LH)98_)EU(709-I&"RQX
MW9(SQ6L'[ME:]^OR,Y+W[O:W3U?^9T^DZA#K6D6>HQIA)XUE56Y*DCI^%</X
MFDU>VUG3M0\2Q6[:!;78>,6+$E'SA'EW#D#_ &:W=0\.7]IH^D1:!>&.?2MN
MV*5RL=PH&"KX]?7M5#5=/\2>,((M,U#3(-)T[S%>Y;[2)I)0ISM3:,#GN:J'
M*IW6U_P)ES.%GO;\3N 00".0:*15"J% P , 4M8&P4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;4+V/3=.N;Z97:*
MWB:5P@!) &3C/>K-9'BK_D4M8_Z\Y?\ T$T#6YR'_"Z/#G_/EJO_ 'ZC_P#B
MZM6/Q=\+WDPCD-Y:9. T\(V_^.EJXKX1Z)IFM3ZJ-2L8;H1+$4$JYVY+9Q^0
MKK_&'PVT.XT&[N=,LEM+V"-I$,1(#X&=I7IS774C1A+E:9QTY5IQYDT=_#-%
M<P)-!(LD4BAD=#D,#T(-/KR?X+ZW+-;WVBS.62$": $_=!.&'TS@_B:VO$?Q
M5TO1-1DT^VM9;^YB.U]C!4#?W<\DG\*RG1DI\BU-85HRASO0[ZBO-M(^,6F7
MM[':ZAI\]@SMLW^8)$4_[7 ('X5O>-O&4W@^WM+@:7]M@G8H7$_E[& R!]TY
MR,_E4NE--)K<I58--I['5T5G:%J\6NZ'9ZG"NQ;B,,4W9VGH5SWP<BN63XC&
MY\<GPU9Z3YV)S$;G[3@  98[=IZ8/?G%)4Y.3BEJANI%14KZ,[JBN UWXK:=
MI>I2:=86,^I7,;%&\MMJ;AU ."3CZ5!I'Q=TZ[OTL]4TZ?3)'8+O=]ZJ3TW<
M CZXJE1FU=(3K03LV>C44=:*R- HKCO%7Q'TCPO<FS9)+N] RT,1 ">FYCT^
MG-86E_&C3+JY6+4=.FLD8X\U)/-5?<\ _D#6D:,Y*Z1G*K"+LV>G5QVM_$WP
M[H>H/8S/<7$\;;9!;QA@A]"20./;-:7B;Q/%H'AEM;AA6]BRFQ5EVAPQ !#8
M/KZ5X%H_B&UT_P 33:O?:3%J*2-(XMYG& S'.<E3G'TK2A1YVV]E^9%:MR))
M;O\ (^C-$UFT\0:5%J5EYGV>4D+YB[3P<'CZBM"LSP]/!=^'K"ZMK..SAGA6
M5;>(#:F[D@8 [GTK/\=:Z_A[PG=WL)Q<$"*$^C-QG\!D_A6,H^]RI&L7>-V,
MU[Q]X>\.SFVO+LR7*_>A@7>R_7L/H369IWQ:\+W\ZQ227-F6. US$ OYJ3C\
M:XWX:^![/Q%!<:UK2O<1^:4CB9R [=69B.3U_G73>+?A9I=]IC2:%:+:Z@F"
MBJY"2#N#DX'UK=PI0?)*]S!3JS7-&UCT..1)8UDC=71AE64Y!'J#3JY3P!HF
ML^'M!;3]7F@D"ON@$3EBBGJIR!WY[]:HZ+\1/[8\9S>'O[*\GRWE3S_M&[.S
M/.W:.N/6LG3;DU'6QJJB44YZ7.YJKJ5_%I6F75_.KM%;Q-*X0 L0!DXR1S61
MXR\4?\(EHJ:C]C^U[IEB\OS?+Z@G.<'TK-N==_X23X5ZAJOV;[/Y]G/^ZW[]
MN-R]<#T]*E0?+S="N9*7+U-/PMXPT_Q=#<RV$-U&MNRJ_P!H5023GIACZ5?U
M'7=-TJXMK>\NT2XN9%CABSEW+' X],GKTKSCX*OY>E:T^,[9(SC_ ("U<#JW
MBS^T_'$7B/[%Y?ERQ2?9_-SG9CC=COCTKI^KIUG!;*QS+$-45-[N_P"9]+45
MQ,?Q"\SP#+XH_LO&R7R_LWVCK\P7.[;[^E:_@_Q-_P )9H?]I?9/LO[UH_+\
MS?TQSG ]?2N=TY)-M;&ZJQ;23W-^BN&U7XB_V9XWB\-_V5YOF2Q1_:/M&W&_
M'.W;VSZU/XW\>_\ "&W%G%_9OVS[2K-GS_+VX(']TYZTU2D[66^PW4BKW>VY
MV5%>=M\6["37X=,L=.GNUDD6(3)(!EB0/E&.1[Y%=%XJ\9Z7X2@C:\+R7$HS
M';Q8W,/4^@]Z3IS5KK<%4@[V>QT5%>86/QHT^6Y5+_2;BUA<\2K()./4C _3
M->EV]Q#=VT=Q;R+)#*H='4Y# ]"*)TY0^)!&I&?PLDHHHJ"PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA/7,^.->UOQ9X<%Z^D-IVDVTJD&9B6F<\#' X&3_ (UTV@?\D*G_ .O.Y_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.>,]5US1])BN=
M!L!?7!F"O$87DPN#SA2#U KHZ*:=G<3U1XMH/A+Q'XI\81ZYXDM)+>!'61Q,
MFPMM^ZBH>0.G7MGO7M-%%74J.=ELD13IJ%WNV%%%%9F@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?A**]-H^N6WF!MA8;C&&]#(!M!_&CQMXNL_"OAZ>Z>?;=2PO]C C9P\@'&2
M0!DCDX%)NRN-*[L=-17#?#=/MFF#5F\1:MJD\J!+F*[W+%%+@%O+5E! &<<9
M%,^)'C6/P[:0:=:WK6^IW4L8W+ S^7$6(9@=I&< \=?:J:L[,2U5T=Y17 ^+
M]>%P/"<.FZC-;0:A>K,\P=H2UO&I9]V<$ C&<UT.F>,_#NLZB=/T_58)[H L
M(QD;P.ZDC##Z9I6 W:*Q]:\4Z)X=,:ZKJ$5O)(,I%@O(P]0B@L?RJSI.M:;K
MMG]KTN\BNH,[2R'[I]"#R#[&C<"_117.:AX\\+Z5?-97FL0I<(<2*JLXC/\
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MZV#H>C453TS5;#6K%+W3;N*YMG^[)&<C/I['VK&N?B#X4M+YK.;6[<2JVQR
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M&\0Z3XAMWGTJ]CN40[7"Y5D/HRD C\10!IT444 %%%% !1110 4444 %%%%
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MMX8TG3=,BM#%Y4E^964$;0-HCP6R1WZ]ZBUNTDC^'7@WPTP+2:A<6D,JG^X
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M_%K7KRUVI;6^B"6_V]#*&RI/^UM_2L4K/8? 1$!S>ZRX'^\T\O\ \2:[3_A
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MGOULH67C!7$9<>_S$YKTSPSH*>&O#-GHT,WF_9HROF[-NYB22V,GN?6L[2?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img183648649_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -$!*P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L;Q7X@C\+>&KS69(?/%NH(BW[=Y)  S@XY/I6S7E?QW
MU P>$+/3T/SWEVN5'=5!/\]M3*]M"HI-ZG=>$]=D\3>&K/6)++[&;D%A#YGF
M8 8@'.!UQGIWK:KQ?XBWFJ>'M#\'>&=#N[FVO'54/V>9HRY 50"5(."S'\JB
M\>R>+_"+:/JS^*[BXOKF?8UE$NR =\!<_,!TRW/.:T=G+3:]B%>ROO:Y[;13
M4)**6&&(&1Z&O,O%FIZCH_QB\,D:C=)IM\ODO;"9A$SY*Y*YQGYE_*I7Q*/<
M?V7+L>GUS.O^*+[2/$.DZ59Z%<7Z7K 2W*,52W!8#)(4@]SU'2N.\1:OJGB_
MXE6WA?0M0N[.QT_]YJ-Q:S-&2>,KE2.G"_4GTIVFZIJ.K?'>\L8M1O!I>FVV
M#;B=_+9@H7YES@G<_4^E$=6OG]R"6B?]:L]5HKRKP!KUWI_B+QI8:WJ=S-!I
MTIF1KJ9I/+B!;.-Q.!C;53PIK^JZI<:_X_U2\OH]$M%D^QV"SLL;[1_=SM/&
M!_O$^E%]+]+7&UJUYV/8**\;\/6'C3XC6$FOS^*KK1K:21A:6]F"%P#CG##(
MSQSDG%;WPL\5:KJ[ZQHFMS"YO=*F\O[0 !YBY9><=<%>OO3L]GN)]SK/%FO_
M /"+^&;W6?LWVG[,%/D^9LW98+UP<=?2O/(/C/K%Q:+>1^ -0DLR-WGQS.R;
M1U(/E8_6NJ^+'_),M9_W(_\ T8M>>>#?C!I'A[P?8:,^FZA<7MNC+B-4V.2Q
M(P=V>_I4KJ4UHOG^AZCX+\;:=XVTR2ZL4DAEA8)-!+C<A/0\=0?7VKI:\:^&
M-M?>'=&\4>+M4L9+2"<-/%;,NTE5W,< ]N0!6-INKZSXGTVYU^[^)%MH]Z&<
MVNF_:4C3 Z!E+#@]!D'UYJI:/Y79*7YV1[]17DL'C?4/$/P2U753</!JEHIA
MDG@8QMN!4A@1TR#V]Z=\/M/\5Z_I^C>(K[Q/=+:1 J+ !CYZJ2,NY;DDCN#Q
MZ46LVGT_4.E_7\#UBJFJWDFG:3>7L5LUS)!"\BP(<&0@9"C@\GIT->$6?BVY
MU[5-03Q%XWU'P[>QSLEO:PQE84QV8CK@\8;'3K7HMG=:U%\*]5N;_7+34;J.
MTF>"_P!/D/0(<?,,?,#W&/SJ7\#EY%)>^H^9T7A37;KQ%H2:A>:5-IDS.RFV
MF)+  ]>57K]*VZ\D\,>)-<M_@==ZU%//?:G$TFV2X<RL!O SSDG:"3^%<WI&
MN3ZM8075K\3KFUUYMIDMM1S'; D\@9!7^>?0=J?Q6]"%M?U/9_$WB;3O">CO
MJ>INXA#!%6-=S.QSA1^1Z\5HV5TM[86]VJE5GB60*>H# ''ZUX_\;-/OY/".
ME:C=:D6:-TAFMX"?(E<J3Y@&?;CCH>M6]0U34?AO\*X9X]6N-1OM0:,6TEUE
MOLX:,' !)X4*<#ID]*2>DF^CL5;6*75'KE%> WNKZSX9TFW\06OQ'MM7OBR-
M=:6;E)%(/4*NX].AP!Z\8K?^*'BO4(]"\*:OHUW<VPO)!,8XIF02 JI"MM(R
M.<4[?G82U^ZYZ_17B/CD>-/!4%CXD?Q9/<RS3B.:T";8$)!; 7)!'!&<9KI?
MB-XRU/3[#0].T1U@U+6F4+*0#Y2G:.,]R6'/L:7IO>P?EN>DT5YA#X3^('A[
M4[&ZT_Q1+K43O_IEO?.50#OMR6P/3&,52\>>+;^[\=0>$K+7HM!M$C#WE^\@
M0@E=V Q(QQC&",DT=K >N45X]X6\47VA_$&V\-3>*(O$FEWT>8;H2K(\3\X!
M8$G/&,$]P>*]@9@BEF. !DFA[7#K86BO%]+N?%GQ5U'4KJP\13:%H]K+Y4"V
MRG<YZC.UE)XP3SCGI6EX4USQ /$>L^ =?U)I;M;=C::C&,. 5&#Q@DX8,.X(
M/-"N_7<;T-+4?BC+'XJN="T7PU>:O):-MN9(9-NSD X&TYP3CDCFO0U)*@D8
M..E?/G@3PS?7/Q-UNU3Q%?PR:?,6FG1FW7863D2?-R#WSFOH2FO@3[B?QM=C
MRJ_^,-_!XCU'1M/\'W.HR64SQLUO<,Q(5L;BHC.!5G2_B;X@O]6M+.?X?ZG:
MQ3S)&\[M)MB!."QS$.!UZBN#TSQ#J?ASXL>*;G2]!N=9EDFF1H;?=E!YF=QV
MJW'&/QKT3P_\0/$FKZ[:V%[X$U'3[>9B'NI1)MC&"<G,8';'7O2IZJ+W'4TE
M)=CT2BO'->U/Q)-\:WT/2-7FMH[BU50'=GBA&S<SB/.TM@''N:33[WQ)X/\
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MRAU*L,@C!%+10]58.MSQ;2[;Q9\*]1U.UL?#DVNZ/=2^9 ULQW*>@SM5B.,
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M#@Y'8<U=^&OA?5[35=8\3Z_ +:_U1R5M\Y,:%MQS^G'M7H]%$=/R"6H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *Y#Q[_S+'_8?M?_ &:NOKD/'O\ S+'_
M &'[7_V:KI_$B*GPLZ^BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK
MA]0O?B%INFW5_,OAAHK:%YG""X+%5!)QGOQ1I][\0M2TVUOX5\,+%<PI,@<7
M 8*P!&<=^:T]F[7NC/VBO:S.XHHHK,T"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KD/'O\ S+'_ &'[7_V:NOKD/'O_ #+'_8?M?_9JNG\2
M(J?"SKZ***@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,CQ7_R)VN?]@^?_
M -%M1X4_Y$[0_P#L'P?^BUH\5_\ (G:Y_P!@^?\ ]%M1X4_Y$[0_^P?!_P"B
MUJ_L?,C[?R->BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-8T^XG?.V**Y1V; R< ')X!-5ROL3S+N:5%%%24%%%% !1110 4444 %%%%
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MX4_Y$[0_^P?!_P"BUJ_L?,C[?R->BBBH+"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\+GA34_CL8KL?)]M!PQZ[$!
M4?\ CHKW2O&OBCX6O['6_P#A*=+$GEL5>9HOO0R+T?Z<#GL?K71AVN9KNC#$
M)\J?9GLM4-<ABN- U&&?'DR6TBODXX*G->06'QJU6"W2.]TVWNG48,BN8RWN
M1@C/TQ67XB^*&M^([-].B@BM+>8;'2'+/(#_  Y/8^@%..&J7)>)IV.A^!\K
M^=K4.3LVPMCL#\X_S]*]AK@OA9X6N/#VAS75]&8KR^96,;=41<[0?0\D_B*[
MVHKR4JC:+H1<::3"BBBL38**** "BBB@#@OBG;06W@"\$$,<0>Y21]B@;F+Y
M)..I)[UUNN6+:IH5]8).(#<P-%YK#(4,,$X^AK,\<:!=>)O#$NFV4D,<SR(P
M:9B%P#D] 3^E:>MZ3!KNBW>F7)(BN$VE@,E3U!'T(!_"M.9<JUZ_Y&?*^9^G
M^9QB?#9[700L?B/51J$,7[J6.<K$I X 0=%_'-:_@O7-2\0>!([W,+:F$DC5
MY00CR+D*6QV/&<>^*RX=$\>PZ1_8:ZCI7V4)Y*WI#^<L>,8 QC../Z]ZZ[0=
M%MO#VBVVF6I)CA7&YNK,3DD_4DU4Y::N[N3".NBLC"_XN-_U*O\ Y,5A>(_^
M$L^V>&_[=_L7[+_;=KM^P^;OWY.,[^,8S^E>F5R'CW_F6/\ L/VO_LU%.=Y;
M(*D+1W9U]%%%8FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <AX]_P"98_[#]K_[
M-77UR'CW_F6/^P_:_P#LU=?5R^%$1^)A1114%A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!D>*_^1.US_L'S_P#HMJ/"G_(G:'_V
M#X/_ $6M'BO_ )$[7/\ L'S_ /HMJ/"G_(G:'_V#X/\ T6M7]CYD?;^1KT44
M5!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Y#Q[_S+'_8?M?\ V:NOKD/'O_,L?]A^U_\ 9JZ^KE\*(C\3"BBBH+"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(\5_\B=K
MG_8/G_\ 1;4>%/\ D3M#_P"P?!_Z+6CQ7_R)VN?]@^?_ -%M1X4_Y$[0_P#L
M'P?^BUJ_L?,C[?R->BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *BN+:"[A:&YACFB;JDBAE/X&I:\?\>?$K7-
M*\0WFCZ=Y%O' 57SMF]SE0>_ Z^E:4Z<INT2*E2,%>1T^N_#'PI>Q27!C_LQ
M@,F6"0(@^JGY0/IBO)=30^#]0'_"/^*UNLGDVA9<?[V,HP_$_2GI;3^(9EF\
M0^+K:%3\V)IFG9?HJ_*/ID5U>DZ)\,+#:]YK?]H2C!/FED3/^ZH'Y$FNR-Z:
MM)M^5CCE:H[Q27G<Z/X6^+=6\30:E'JDL<K6GE;)%0*S;M^<XX_A':O0JPO#
M6H>&[N":#PXUIY4.WS%MH]@&<XSP,YP:W:XJC3DVE8[*::BDW<****@L****
M "BBB@ HHHH **** "N0\>_\RQ_V'[7_ -FKKZY#Q[_S+'_8?M?_ &:KI_$B
M*GPLZ^BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D/'O_,L?]A^U_\ 9JZ^
MN0\>_P#,L?\ 8?M?_9JZ^KE\*(C\3"BBBH+"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#(\5_P#(G:Y_V#Y__1;4>%/^1.T/_L'P
M?^BUH\5_\B=KG_8/G_\ 1;4>%/\ D3M#_P"P?!_Z+6K^Q\R/M_(UZ***@L**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KA==^%NDZ_K5SJES>WL<UP066,IM&% XRI]*[JO'_BCXWU2SUK^P]*NI+58
MD4SR0G#LS#( /4  CIZUK14W*T'8RK."C>:N:O\ PI30O^@CJ/\ WTG_ ,31
M_P *4T+_ *".H_\ ?2?_ !-</IOC_P 5>&_M%KJ,EW*986\L7H8O&Y'RN"W)
M&>QXK.<>-7T_^WFFU<VI._[3YSXZ]>O ]^E=7)5ZS.7GI=('M_A+P58^#_MG
MV*XN9OM6S?YQ4XV[L8P!_>-=+7&?#7Q1<>)O#KF^;=>6DGE228_U@QE6/OU'
MX5V=<=3FYGS;G93Y>5<NP4445!84444 %%%% !1110 4444 %<AX]_YEC_L/
MVO\ [-77UR'CW_F6/^P_:_\ LU73^)$5/A9U]%%%06%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '(>/?^98_[#]K_P"S5U]<AX]_YEC_ +#]K_[-77U<OA1$?B84
M445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9'
MBO\ Y$[7/^P?/_Z+:CPI_P B=H?_ &#X/_1:T>*_^1.US_L'S_\ HMJ/"G_(
MG:'_ -@^#_T6M7]CYD?;^1KT445!84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7A6LW5I9?'%[J_D5+:*YC=W<9"XB
M7!_/%>ZUYMXE^$__  D/B&[U7^VOL_V@J?*^R[]N%"]=XST]*WH2C%OF>Z,*
M\922Y5LSEOBUK^D:\VD-I=Y'<M$)A*4!^7.S;G(]C78_\)EX5_X0?^S?[4M]
M_P#9OD>3M;KY>W;T_"L+_A1O_4Q?^27_ -LH_P"%&_\ 4Q?^27_VRMFZ+BH\
MVQBE64G+EW#X&_\ ,>_[=_\ VI7KU<AX&\#?\(9]O_XF/VS[7Y?_ "P\O9LW
M?[1SG=^E=?7/7DI5&T=%"+C3284445D:A1110 4444 %%%% !1110 5R'CW_
M )EC_L/VO_LU=?7(>/?^98_[#]K_ .S5=/XD14^%G7T445!84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 <AX]_YEC_L/VO\ [-77UR'CW_F6/^P_:_\ LU=?5R^%
M$1^)A1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!D>*_^1.US_L'S_\ HMJ/"G_(G:'_ -@^#_T6M'BO_D3M<_[!\_\ Z+:C
MPI_R)VA_]@^#_P!%K5_8^9'V_D:]%%%06%%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Y#Q[_P RQ_V'[7_V:NOKD/'O_,L?
M]A^U_P#9JZ^KE\*(C\3"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#(\5_\B=KG_8/G_P#1;4>%/^1.T/\ [!\'_HM:/%?_
M ")VN?\ 8/G_ /1;4>%/^1.T/_L'P?\ HM:O['S(^W\C7HHHJ"PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSQD<5KROV=[=3+F7M+7Z'4T445D:A1110 4444 %%%% !1110 4444 %%%%
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M?W]O);BZV)%'("K$+DEB/3D8^AKTZN.O;VCL=="_LU<****R-0HHHH ****
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1%3X6=?1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%>>^.OB*FCLVD:)BYU:0["R#<(2>,8[O[?GZ5
M4(.;LB9S4%=FCXW\?6?A2W,$6VXU21<QP9X3T9_;VZG]:Y;PIX#O?$-__P )
M)XO,DK2D/%:R<%QV+#LOHOY\<'0\$_#IX+@:]XES<ZG(WFI#(=PC)YW-ZO\
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MY3$]_(N)KDCD_P"ROHO\^]=153J)+DAM^9$*;;YY[_D%%%%8FP4444 %%%%
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M>QT&W?@=A]/[[GUZ#/YZTZ?-J]$95*G+HM6.U/6M;^*6KG2=&1[;1HV!E=^
M1_>DQ].%'_UQZAX:\+Z=X6TX6MC'EVP99V'SRGU)]/0=JMZ/HUCH.G1V&G0"
M&!/Q+'N2>YJ_1.I=<L=$$*=GS2U84445D:A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]035M3EB26$F'S78Q[\Y/'0$^OU]>?=Z\RUOX-V6I:G->6.J/9+,Y=HFA\P
MGGY?F&![<UO1E"SC/J85HSNI0Z%'X>?$*6>74/\ A)];C"A8_(\X*G/S;L8
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MS/\ ]A^Z_P#9:N/PLB7Q(Z^BBBH+"BBB@ HHHH **** "BBB@ HHHH ****
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M7/E;\X^]P<XQQ]36O133:=T)I-69YG_PCES_ ,)[_87_  E/B7[+_9?VS?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^98_P"P_:_^S5U]<AX]_P"98_[#]K_[-3I_$A5/A9U]%%%06%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7(>,?A]IOBJ-IU M=2 ^6X4</Z!QW'OU_E77T549.+NB914E9
MGCFC>,M<\!7ZZ'XK@EFLQQ%.#N9%]5/\:^W4?I7K5C?VFIV<=Y97"3V\@RLB
M'(/_ -?VJ#6-$T_7K![+4K99H6Y&>"I]5/8UY->:/XE^%M\^H:3*U[HKMF56
M&0!_TT4=#_M#_P"M6UHU=M)?@S&\J6^L?Q1[37(> O\ F9_^P_=?^RTW3?B;
MX:O='-_<7JV;I@26\F2X/L!RP]Q^.*Q_A]XLT1KS6;1KY(Y[[5Y[FV20%?,1
M]NW!(QDXZ=:E4Y*,KHISBY1LSTFBBBL38**** "BBB@ HHHH **** "BBB@
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M.>H9_P"B]!^E>I]!@53DJ:Y8;]_\B5%U'S3V[?YC(88K>%(88TCB10J(@P%
MZ #M3Z**YS<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I&574JRAE(P01D$4M% 'S-X\LK;3_&VIVMG;+;0(Z[8EZ#*@G'H"23BN<K
MWGQ_\-V\370U/3)8XK_:%D27A90.AR.A X]^.E<=H_P=UNYO4_M62&TM5;YR
MCAW8>B@<?B?R->G3KPY%=GF5*$^=V1ZOX,O[C4_!VEW=V29Y(!O9NK$<9/UQ
MG\:W:AM+6&RLX;6W0)#"@CC4=E P!4U>;)W=T>DE9684444AA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7(>/?\ F6/^P_:_^S5U]<AX]_YEC_L/VO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCR#<?HO4_E7%ZI\9="M=RZ?;7-\X'#8\I#^)Y_2HM,^#&E0$2:I?W-[)G)5
M(E/UZG]17::7X4T'10#8:7;1..!(4W/_ -]')_6C]U'N_P  _>R[+\3SC_A+
MOB)XFR-&T?[% V-LHBQQ_OR?*?P%.3X7>)-<D$OB3Q"2-V[RU9IB/IG 7\,U
MZ[11[=KX$D'L4_C;9Q.E_"KPOINUI;:2^D'\5R^1_P!\C _,&NOM+*TL(1#9
MVT-O$.B1(%'Y"IZ*RE.4MV:1A&.R"BBBI*"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N0\>_\RQ_V'[7_P!FKKZY
M#Q[_ ,RQ_P!A^U_]FJZ?Q(BI\+.OHHHJ"PHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5$48"J, 4ZBLG)RW9JHJ.R"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N0\>_\RQ_V'[7_ -FKKZY#Q[_S+'_8?M?_ &:KI_$B*GPLZ^BB
MBH+"BBB@ HHHH **** "N$^('P]'BLQWUC*D.HQ+L/F9V2KZ''0C)P?P^G=T
M54)N#NB9P4U9G@^F_!WQ!<786^DMK2W#?-('WL1_L@?U(KVW3--MM(TRWT^T
M39! @1!W^I]R>?QJW15U*TJGQ$4Z4:?PA11161J%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML&R0.WEW#GS /X#N)X/M@^A%*/(G>[^[_@CESM6LOO\ ^ =K17(?\*O\&_\
M0'_\F9O_ (NC_A5_@W_H#_\ DS-_\74VAW?W?\$J\^R^_P#X!U]%<A_PJ_P;
M_P! ?_R9F_\ BZ/^%7^#?^@/_P"3,W_Q=%H=W]W_  0O/LOO_P" =?17(?\
M"K_!O_0'_P#)F;_XNC_A5_@W_H#_ /DS-_\ %T6AW?W?\$+S[+[_ /@'7T5R
M'_"K_!O_ $!__)F;_P"+H_X5?X-_Z __ ),S?_%T6AW?W?\ !"\^R^__ (!U
M]<GXJ\13V,PL;-MDFT-))W&>@%,_X5?X-_Z _P#Y,S?_ !=8FO\ AJWT!HET
MZW,6GD?*H9F"-GD$DD\]>:X\?)PHWIM_\#[S&O*HH;?U]Q!:^(M5M9A(+R63
MGE)6+J?S_I7=VOB/3;BSCFDNX8G9<M&SC*GN*\R1&D=412S,<!0,DFNYL/!E
MF;*%KWS?M!&757P ?2O/P52NVU'5>9AAYU'=+4USXATA1DW\/X'-1MXGT91D
MWR_@C'^E0#P?HX.3%(?8R&GCPEHH/-JQ]C*W^-=]\5VC^)U?OO(5O%FBCI=D
M_2)_\*8WC#1QTFD;Z1FGGPGHAZV1_"9Q_P"S4T^#]";K9O\ A<2#_P!FHMBN
MO+^(OWWE^)$WC/20>#.WN(__ *]1MXWTL' BNF]PB_\ Q53-X+T%CS:2_A=S
M#_V:HV\"^'F.3:W/X7TX_P#9Z?+B']I?<*U?NB(^.=/SQ;7./HO^-,/CJTSQ
M9S_F*E/@#PV3DV=P3_U_3_\ Q=-/P[\,$Y-A-_X&S_\ Q=/V=;^?\/\ @BY:
M_=$!\>18XL'S_P!=!_A3/^$[9N%TS+'I^^S_ .RU.?AKX3.<Z8YS_P!/<W_Q
M=1_\*O\ !O\ T!__ "9F_P#BZ?L:G6K_ .2K_,7+B.Z_KY#?^$SO&X323N_W
MB?Z4?\)7JS\1Z0<_[KFG?\*O\&_] ?\ \F9O_BZ/^%7^#?\ H#_^3,W_ ,73
M]A+K5?\ X"O\PY*_?^ON&'Q)XA?_ %>CGCK^XD/]:!KGBB3E=*"X_P"G=Q_,
MT_\ X5?X-_Z _P#Y,S?_ !='_"K_  ;_ - ?_P F9O\ XNE]6[U9?<O\P]G6
M[_C_ , ;_:?BQ^18!1Z>5C^9H^U>,&^86X /;:G]33O^%7^#?^@/_P"3,W_Q
M='_"K_!O_0'_ /)F;_XNG]5C_P _)?@'LJG?\?\ @#,^-6Y P#V_<TOV?QB>
MLX&?]I/\*=_PJ_P;_P! ?_R9F_\ BZ/^%7^#?^@/_P"3,W_Q=+ZI3_Y^2_KY
MA[*??\?^ -_L[Q:W!O@ >_F#_"D.B^*7&TZH #W\]A_(4_\ X5?X-_Z _P#Y
M,S?_ !='_"K_  ;_ - ?_P F9O\ XNCZG1ZSE_7S#V,OZ;_R&#PYXC;B36/E
M_P"OB0_TK+UW1-2L+:.>[NC<QAMN=S-LS]?6M?\ X5?X-_Z _P#Y,S?_ !=6
M[+P#X9T[?]ETSR_,QN_?R'.,XZM[FLZV!I.#4&[^?_#O\A2H-JUOQ?\ D>?5
MOZ%H>HW]J]S:W1MDW;<[F7?CZ5:_LBQ_X6-_8_D?Z%_97VO9O;/F>;LZYSC%
M;%[X!\,ZCL^U:9YGEYV_OY!C.,]&]A7-1RZ49IU7IY&5/#RO=E$^&M?7F/6#
MN_Z[2"@:!XG3YAJV3Z?:)#_,4_\ X5?X-_Z _P#Y,S?_ !='_"K_  ;_ - ?
M_P F9O\ XNNWZE0Z2E_7S-O8OM^+_P AO]D^*UY&H@D=O./]11]@\7+R+P$C
MMO'^%._X5?X-_P"@/_Y,S?\ Q='_  J_P;_T!_\ R9F_^+I_5*7\\OZ^8>QE
M_3?^0WR/&0Y$P..VZ/\ PI/^*U_SY-/_ .%7^#?^@/\ ^3,W_P 71_PJ_P &
M_P#0'_\ )F;_ .+I?5*?_/R7]?,/93[_ (_\ ;]H\8_\\!_WRG^-']H>+O\
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M/^"/EK]T"^-]+8X,5TON47_XJI!XSTDG!\\>YC_^O35\"^'E.1:W/XWTY_\
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M/^%0?\(CHW_/LW_?UO\ &C_A$=&_Y]F_[^M_C1?%=H_B'[[R_$G_ .$ET?\
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M_P##_P!]52_X0[2/^><O_?PT?\(=I'_/.7_OX:+XGLOQ"];LB[_PD&D_\_\
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MC_"C_A"]*];C_OL?X4<V)[+[PO5[(T_[;TO_ *"%M_W\%.&L:81G^T;3_O\
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MB?Y5]X<U7LC9_M?3/^@C:?\ ?]?\:/[7TS_H(VG_ '_7_&L;_A!],_Y[W?\
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M7T5R'_"K_!O_ $!__)F;_P"+H_X5?X-_Z __ ),S?_%U5H=W]W_!'>?9??\
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MUIJUM42XWDF34444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2JVP..A_O<_X9[;G@CPS/H%C<W6HR"75M0D\^[<'(!Y(4?3)_$_2E^($:1^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'XQM;
M^^\(ZE::9!YUW/%Y21[PF0Q ;DD#[I)K<HIIV=Q-75C*\,Z<^D^&-,L)4"2P
M6R+(H(.'Q\W(Z\YK5HHH;N[@E96"BBBD,**** "BBB@ HHHH **** "BBB@
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MG\3Q7?44_:6>B%R76K.#M=%\0>(_%5AK7B"TBTVUT[<UM9I*)'9SW9AQV!_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8>)?%>DL^DZ38V]U!(\-S/>2L8-ZG&(PHW-V)Y &>IH_X<=COZ*XG3_B#&?
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MU<\9.?I6YX7\0'Q!I\SS6WV6]M)WMKNWW;@DB]<'N"""#[T ]#<HK)\3ZN=
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M6WM[<6\$$44 &!&B!5 ],#BDM+.UL+5+:SMH;:W3[D4*!$7OP!P*%I_7G?\
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M3I^H!C<>&;":&8D'F3?Y8//JFTYK7\&:59:_X]\3^*+J!9I+>^^R6C-R$V*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img183648649_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +)!.D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^3M*G?R,]<CKFAZ-KM_6@HZI/N?2Q( R3Q6?%KNCSW?V2'5;&2YZ>2EPA?\
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M*95&,Y*9ST([4/JVFQ:DFFR:A:)?R#<EJTRB5ASR$SD]#V[5Y7IG_)R6J?\
M7K_[22C6O^3C]%_Z]1_Z!)1'7E\_^#_D.6G-Y?\  /5K[4[#3(Q)?WUM:(>C
M3RK&/S)J2VN[:]A$UK<13Q'H\3AE/XBO%/'&E:KIGQ$N]>U'PP_B/2)HU6%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+1CXIA/AYHHVVR0_OPN 0IP/F ]V'05M^-?AY/K'@73/#FARV\*V,J,&NG8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDF]08Y&0X8@9!VYZ#K5ZDU;0$[JZ"BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!1TK2K;1[5X+;>1)*\TCR'+.['))-7J**&[@E;1!1110!D^
M'/\ D&3?]?\ >?\ I3)6M63X<_Y!DW_7_>?^E,E:U5+XF3#X4%%%%24%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D^'/\ D&3?]?\
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MR1D JRD@#(Y!%=1X6_Y%'1?^O"#_ -%K0XVC<49WE8UJ***@T"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3)6M6-X7,AT9S,JI*;V[WJC;E!^T29 ) R/? ^E;-.7Q,4/A04445)04444
M%%%% !5/^UM-_P"@A:?]_E_QJS-$D\,D,B[HY%*L,XR#P:Y[_A"M-_Y[W?\
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MG2,@:.12 %V^7N&#W].]"A%JX.I).QVFJ^*+#2KP631W=U=E/,,-I TK*O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRA,=E*PR#@\A<=15*+>PG)+=G1!5!)"@$]2!UHVKNW;1N'&<<TB.)(U=<X8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEY>+*DDDA*QR@AHT_A7'; Q75_#_ $'4O$UE=6[ZU?V>F6S "*!R [-DD#G
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^%!1114E!1110 4444 -D4O&Z*[1LP(#KC*^XR",_45QW_"&:U_T.%_^3_\
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MVD]N#771J4C5"[.5 !9L9;W..*4J&&& (]Z.;74.330\MU>_CU*U\=W4"O\
M9VMK,1.RE?,4;AN&>Q.<'OUKJ_%BK_8>E_*/EO[3;QT_>*.*ZBBFY[:;$JGH
M[O?_ ((5S>K_ /(]>&O^N5Y_Z#'7245"=C22NCE_&9\PZ%:IGSI=6@9<=0$)
M9F_ "NHK/ET>WGUR#5I6D>:WB:*%"1LCW?>8#&=Q''7I6A3;T2$D[ML****D
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO$<@'S1G#(P.0RGL00#5VBA.VHFKZ,;&I2-4+LY4 %FQEO<XXIU%% PHHHH
M**** *$FD6\VN0ZM*TCSP1-%"C$;(]WWF QG<1QG/2K]%%%Q)6"BBB@84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%9VJZ]I6B0^;J5]#;C&0K-EF^BCD_@*Y!_'NJZ
M[(T'A+0YK@9VF\NAMC7]<?F<^U7&$I:HB52,='N=[--%;Q-+/*D4:C+.[!0!
M[DUX=\2/%[ZQJQL=.OB^F1( ?*)"ROW)]<=/2NTA^'^H:S,MUXNUJ:\(Y%I
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M@ HHHH **** "BBB@ HHHH **** "N?\6:A]DL[6W.D+JJWDWDM;$@9 5G)
M(P3A>!705SFIZEI\K6][-!J;'3[YD58;5R6<(RDXVY*88\COCFJAN1/8R;0^
M%M.TQ]<T+3+;[3%-%"Z.I62%GD5""#RI&X_6NYK@=4;P_KVHV]PVGZU;7?F)
MF:*QD3S &!"R?+@KD \],5WU5,FGUM:WD%%%%9FH4444 ,>*.1T=XT9HSE&*
M@E3TX]*?110 4444 9/AS_D&3?\ 7_>?^E,E:U9/AS_D&3?]?]Y_Z4R5K54O
MB9,/A04445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5E=2QP&=<*3]?\:RM5TO7I=-E-Q?K<*,,88TQNQ] /K7(Q0R3S+#$A>1CA5
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MC?8X/_A%_%OB?#>(]7%A:-ULK+J1Z$]/S+5U&B>$=#\/@&PL4$PZSR?/(?\
M@1Z?ABMNBLG4DU;H:QI13ONPHHHJ#0**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN7\1^(Y]/NQ:6@4.%#.
M[#.,]@*K:;XPG*M'=6S3R_P>2O)^H_PKJ6#JRASI'GRS/#QJNE)ZK[CL:*YW
M^T/$-[_Q[:;':H?XISR/PX_E0-#U:[YO]8<#ND P/Z?RJ?8)?')+\?R-/K;E
M_#@W^"_&WY&W/>VMJ,W%Q%%_ON!6%JWBJTCLY4L)]]R>%(4X7WR:LV_A32H3
MEXWG;KF1S_3%7FTG3VMGMQ:0K&XPP5 #^=.+H0DF[O\  F:QE2+2M&_JW^AY
MS#JU_!<"=+N8N#GYG)!^H[UV"7OB6Z17BL;6&-@"&=LGG\?Z4V'P791W =YY
M9(P<B,@#/U-=*    , =JZ,3B:4FN2*?JCBP& Q,%+VLVEY/_ASG?LOBB4_-
M?VL(]%7/_LM*=$UF4?O==D7_ '$Q_(BNAHKE^L26R2^2._ZE!_%*3_[>?^9S
MW_"+M)_Q\:M>R?\  _\ '-8&N^')M/F5[1)IK=A][&Y@WO@5Z!16E/&582N]
M3*OE="K#E2L^_P#PYQ'A;1)9+MKF\M1Y"J0JS)]YO8'T]:[5$2-=J*JCT48I
MU%95Z\JTN9F^$PD,-3Y(Z^84445B=04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6+J/ABQU&Y-PQDBD;[QC(PWOR*VJ*N%25-WB[&56C3K1Y:B
MNBII^G6^F6P@ME(7.22<ECZFK=%%3*3D[LN,(PBHQ5D@HHHI%!3%BC5RZQH&
M/4@<FGT4!8**** "BBB@ HHHH **** "L;Q#I=W?+9W6G21+?6,WG1";.Q\J
M593CD9!/-;-<GX@TKPY8"74M5NKN$RN3M2\E!=CV1%;D^P%5#<B>PZ6W\1:\
MT5IJ-A9Z?8K,DLS)<&9Y=C!@JX  R0.3VKJJ\YTKPG>:KJ4&HG[?I&FQL'CM
MI+J1YYL'.7#,0@Z<=>M>C54[+1"IW>K"BBBLS0*9+#'/$T4T:21N,,CJ""/0
M@T^B@"C9Z+I6GRF6RTRSMI",%X8%0X^H%7J**&[[B22V"BBB@9D^'/\ D&3?
M]?\ >?\ I3)6M63X<_Y!DW_7_>?^E,E:U5+XF3#X4%%%%24%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAJU147;=S1125DBK8Z;9:7!Y%A:0VT6<E8D"@GU..M6J**0TK!1110 4444
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M12K8B=:W-T'A<%2PU_9]0HHHK ZPHHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !12,P52S$ #DD]JYK6_'>@:1;S#^TX);I5;9%$?,RV.
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MS-,BMF8,XR7(Z9-7Z**Y92<I.3W9WTX1IQ4([(****DL**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \3VE])_
M9NH6%O\ :I;"Y\YK;<%,BE64X)XW#=D5OU3O=3M["YLH)RP:\E\F(@<;L$X)
M[9P:<6T]"9)-:G+ZA?W_ (H2WTV#0-1M(_M,4D]Q>HL:QJC!CMY)8G&/QKM*
M**;=] C&VK84445)04444 %%%% !1110!D^'/^09-_U_WG_I3)6M63X<_P"0
M9-_U_P!Y_P"E,E:U5+XF3#X4%%%%24%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 445#)=V\4RPR7$22M]U&<!C]!0!-115
M>[OK2PB,MY=0V\8_BED"C]: +%%<?J'Q-\,V+&.*ZDO9>@2UC+9/L3@'\#6?
M_P )?XMU?(T/PJ\*$X6>^;:,>N#M_0FM%2EUT,G6ALG?TU.H\1^)+#PQIOVR
M^+G<VR..,99V]!_C7-:-\5]$U&Y,%Y')I_!*R2D,AQV)'0_A7->,/"GC74].
M34-3N(;YX&.VTM$YC4XR0,#/0>IKF_"?@_4]6U^U2;3YDLXY%>X>:(JNP')7
MGJ3TQ[UO"E3Y+MG-.M5]HE%:'IUU\4='$WV?2K:]U2<YPMO$0#^?/Y U7_M/
MXA:YQ9Z7::-"PXDN6W./P.?_ $&NYM+&TL(A%9VT-O&/X(D"C\A4]8<\5LOO
M.GDF_BE]QP ^'%WJC!_$GB.^ON0?)B.Q!^>1^0%=#IG@SP]I&UK72H/,7D22
MCS&!]06SC\*WJ*3J2>EQQI03O8XJ\^%GAJ\U W?EW,(9MS0PR 1D_3!(_ BN
MNL[.WL+2*TM(EB@B7:B+T J>BDYREHV5&$8NZ04445)0445A:]XC729$@BB$
ML[#<=QP%%73IRJ2Y8K4RK5X48<]1V1NT5SNC>*8M0D:&Z5+>0#<&W?*1^/0U
MI2:YI<7WK^ _[K;OY5<Z%2,N5K4SIXNA4ASQDK?<:%%8<GBW2$^[-))_NQG^
MN*B'BM)1FVTV]E]/D_PS36&JO[)+QV&6G.GZ:_D=#4#WEK',(9+F%)3T1I &
M/X5AOK6MRQ,8=$>/CK(W3\"!7"N[2.SNQ9F.23U)KHH8%U+\SM^)Q8O-HT;<
MD6[]TU^:/7:*Y#2+36]0TR*1=5:"'!5%V9.!QUJ]_P (Q-(/])UF\E]<$C^9
M-8RH0@VI37W,ZH8JK4BI0I.S[M+]3>>6.(9DD5!_M'%5)-9TV+(>^M\CL) ?
MY5G1^$-+4Y?SY3W+R=?RQ5N+P[I,7W;*,_[Y+?S-3:@NK?R_X)7-BY;1BOFW
M^A@Z]XI<RK#I<X$8&7E"\D^@S4.D>*[N-VBO%DN@1E-BC<#_ %%:VK^%8+W8
M]GY=M(HP5"85A^'?WI^A>&QI4S7$THEF(VKM& H[UV>TPJH6MK^/WGF^PS!X
MKF<K+OTMZ#?^$COI/^/?0KIAZMD#^5!U'Q%+_JM(B3_KI(/\170T5Q^U@MH+
M\?\ ,]+ZO5?Q57\DE^ASV/%,P^]90?KC^=-?1]<N8V2YUD!6&&$:<$?ABNCH
MI_6)+X4E\@^I1?Q2D_\ MY_I8\PFT/4X;@P&SF9LX#(I*GWS77:7X5LX;.,W
ML EN3RV6.![8Z5T-%:U<=4J12V]#GP^4T*,W)^]Z]"O!86=M_J;6&,^JH :L
M445QMMZL].,5%62L%! (P1D444A@  , 8%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !6%XMLK&]T4C4=2?3[:*19#,A4$$=,%@<'/3'-;M<WXMAD_P")5??9
M)+RULKOSKB"--[%=C ,%[[20<54/B)G\+,;1KK3;Z]@M;3QOJLTO#)%.H3S0
M/0O&"W ['-=[7$ZKK%IXJ%E8:3;7$]P+N*5IWMGC%LJ.&9MS 8.!C ZYKMJJ
M9-/J%%%%9F@4444 %%%% !1110!D^'/^09-_U_WG_I3)6M63X<_Y!DW_ %_W
MG_I3)6M52^)DP^%!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%<MXY\7CPEI<4D42S7EPQ6%'^Z,8RQQU R./>G&+D[(F4E%<S.IHKQ
M[0OB_>+>[-<MXGM6!^>W0AT/;@G!'Y5T7_"?ZQJA"Z!X4O9U896:Y^1/\/\
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M&HBQHJ(H5%& H& !3J**DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+#^:5Q_A";5;?6&ETFT6ZF$3!XV.!MX[Y'?%=W_PD?B>'_7>%G?_ *YR_P"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVC_QY*[1UO'!\_1[:3CGA3_C522PM7.9?"]JQZDK$N3^0J_[3I+=27_;LO\
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M1110!"UI;O)YCP1L_P#>*C-3445*C&-VEN-ML****H050U#2H[\J^\QR 8W
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MVVY<SVR ,ISQCYB?;IWKB*U@E;0\_%3J\ZYY-M>5CTJ'XH6^U1-ILN['S%)
M>:L)\3M+.-]E>#UP%/\ 6LN))/(B+> DD!0?,KGYACKTXJ-A8%")_ -]'@_P
M-+_/ K+EAV_$[_;XA?;7SB_\C?3XDZ&X^:.\3GHT8_HQJPOQ \/-G-S*OUA;
M^@KE''AI2?-\*ZK$ .<,_P#5J@:7P2&VRZ=JT!89RQ''_CU')'LQ_6JZWE'\
M2_K/Q'NOMK)I"1"V7@22(2S^^.PK=\/^.K&_L2=3FAM+I#@@G"N/49_E7E-S
MY/VJ;[-N\C>WE[NNW/&??%:6AV^AW!F_MF]GML;?*\I-V>N<\'VK25./*<M+
M'5_:ZM?/8]?7Q'HC' U:R_&=1_6IDUC2Y%W)J5FR^JSJ?ZUY@-(\'.=J>(YP
MQZ%K=L?^@BD/ASPW(0(O%4:^N^W/^(K+V<?/[CN6,K=HO_MY'JZW=LQPMQ$3
MZ!Q45_J=KINGS7MQ(/)B&6*\D^@'N37EG_"+:*S83Q99X]6CQ_[-5'5- L["
MR:X@UVRO&4@>5$?F()Z]:%3C??\  )XZJHM\B_\  D=C:_$ZTEO%CN-/DA@9
ML>:)-Q ]2N!_,UW0(900<@\@BOG>NO@T/6A;QM#XCLT5U!""_92O'0C%5.E%
M;:&&%Q]:5U)<QZU17EXTCQ;$_P GB!&X_P"@@2/R-3+9>.5&$U-77LPN4.?S
MK/V:[G:L7+K39Z55.]U73].95O+V"!F^Z)' )_"N$5?B)O/ER;\<9#P$?K7$
M:I<7MSJ=P^HNSW8<K*6QP1QCCCMVJHTKO<QKYBX1T@T_-6/>XI8YXEEAD62-
MAE70Y!'L:?7C_A?5?$EM:SPZ-!]IA1@SH4W;2?3GOC]*W6\2^-XOF;0PPZ8%
MJY_DU)TFG:YI3Q\904G%_<>AT5YV/&/BV-OWWA_MP!:RK_,F@>/-=3=YN@GC
M_8<8_2E[.1?UZEUO]S/1**\PU#XAZI+I\L2Z?]DDD&U9PQ^7Z9'7&:Y&TU6^
ML;X7D%U*L^<EMQ.[_>]1]:I46]S&IF=*+2BK_@>^T5!97'VNQM[G;M\Z)9,>
MF1FIZQ/13NKA1110,**** "BBB@ HHHH **** "BBB@ HHHH **@BO;6>9H8
MKF&25/O(D@++]14] !1110!D^'/^09-_U_WG_I3)6M63X<_Y!DW_ %_WG_I3
M)6M52^)DP^%!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]S-<1L/FB8G!&?KVZ_A7%0>%;-;E6S++S\L9(P3^7->K5$MO C[TAC5_[P4
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M"VC<@LL2J<=,@"IZ:B".-4'10 *=7>KVU.RUM$%%%%, HHHH **** "BBB@
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M#VE_^!D?^-:U%'NA:7?^OO,G_A*?#W_0>TO_ ,#(_P#&C_A*?#W_ $'M+_\
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M]I?_ (&1_P"-'_"4^'O^@]I?_@9'_C6M11[H6EW_ *^\R?\ A*?#W_0>TO\
M\#(_\:/^$I\/?]![2_\ P,C_ ,:?X;BD@\+Z1#-&T<L=E"KHXPRD( 00>AK3
MH?*G82YFKF3_ ,)3X>_Z#VE_^!D?^-'_  E/A[_H/:7_ .!D?^-:U%'NCM+O
M_7WF3_PE/A[_ *#VE_\ @9'_ (T?\)3X>_Z#VE_^!D?^-:U%'NA:7?\ K[S)
M_P"$I\/?]![2_P#P,C_QH_X2GP]_T'M+_P# R/\ QK6HH]T+2[_U]YD_\)3X
M>_Z#VE_^!D?^-'_"4^'O^@]I?_@9'_C6M11[H6EW_K[S)_X2GP]_T'M+_P#
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M-:U9GB2*2?POJ\,,;22R64RHB#+,2A   ZFA<K=A/F2N,_X2GP]_T'M+_P#
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M*?#W_0>TO_P,C_QK6HH]T+2[_P!?>9/_  E/A[_H/:7_ .!D?^-'_"4^'O\
MH/:7_P"!D?\ C6M11[H6EW_K[S)_X2GP]_T'M+_\#(_\:/\ A*?#W_0>TO\
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M>2YM(YI;>2V=AS%(067ZX)'ZT--*X)INQ/1112&%%%% !1110 4444 %%%%
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MH;"RB$5O",(N<^Y)]23S1.2:LA0C)2NRW11169J%%%% !1110 4444 %%%%
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M\:ZB*-(8DBC4*B*%4#L!TKE+/P%#I\;I:>(-=A61S(^RX3YF/4GY.3[UU%K
M;:UB@,TLQC4+YDIR[X[D\<TY6M9$PYKWDB6BBBH- HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBJ6IOJ4=LITN"VFGW@,MQ(44+@\Y /.<4(&[%VB
MN0T[7O$VHWMY;)IFF*;.80S$W+]2 ?E^7G@^U;D&I;#J,E]<6,5O;3;%=)A\
MBX!_>9X5LGI[BJ<6B5-,TZ*HKK6EM>R6:ZE:&ZC!+PB9=RXZY&>U.L=6T[4F
MD6QO[:Y,?WQ#*K[?K@TK,=T7**HS:UI=O?+8S:C:1W;8Q"\RASGIQG-7J5@N
MF%%<C?\ BN[&@:]JEE!$(+&0Q6TDF6\YE(#DCCY<D@<\XK?M]9TV>Y6S74+1
MKS'S0+,I<''/RYS5.+0E-,OT53O]5T_2T5K^^M[4.<*9I N[Z9ZU(U_9K9?;
M6NX!:;=WGF0>7CUW=,4K,=T6**BFN(+8(9YHXA(XC3>P7<QZ*,]2?2H+K5M.
ML5D:[O[: 1D!_,E5=I(R <GC(Z46872+E%9]YKND:?(D=YJ=G;NXW*LLRJ2/
M7D]/>J\VM&WU^RL9$0VM_$QM[A&SF1>2I[<KR#[4<K#F1L4444AA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 <QX7_Y#WBC_K_7_P!%K7/ZS_R+/CK_ *_?_9(J[^WL;:TFN)H(
M0DER_F3,"?G;&,_E4$NBZ=/;WD$EJC17C[[A23^\;@9/Y#\JT4TG?T,G3;C;
MU.0\7Z-IL5CX6B2R@5#JEM;MA -T; [E)[@XYK4FL;6Q^(.DM:6\4'FV,Z.(
MD"A@I3 X],UT%UIUI>K;+<P+(+:59X<Y^1U^ZP^F:>]E;R7L5X\0-Q"K)&_=
M0V,C\<"CGTMZA[/5OT/,]!T;4-?\)WD<D.C&XN))ENI;A6,\<NYN6(Z$<$>V
M*]'LH;BVT6VAFE$US';JCRK_ !N% )'U/-4;WPEH.H7;W5UID+S2<NPRN_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]=TO7[4W.E7L=S$K;6*9!0^C \@^Q%4=3\;>&]'U#[#?ZO;PW/&Y.6V9_OD
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MIBZ-KK%LPM4\R8N2FQ?[WS 97D<CCFI=&\6Z#XAN)K?2M2BN)H1N>,!E;'J
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M<\*,4:I+NE^+7_!'HV_-_@G_ , Y[X::7;WUOJGBBXC$T^I7T\D+2#.R+=C
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M)94ECSD!D;J0>AJ?P]X9@T%KJY>YFOM1O&#7-[<8WR8Z  <*H[ 41Z>7]?\
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MY_:'@R7P[;77V57MEMA-Y>_:H !^7(Z@8Z]Z37N-+>R7^?XE:<ROM?\ R2_
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M "$!@00"#P0:KV6G6.F0>186=O:19SY<$2QKGZ 59HH **** "BBB@ HHHH
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img183648649_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *B!(T# 2(  A$! Q$!_\0
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MW:ZJMN]NTHQ)$_\ "PZX/<=P?0T6 W**\4^)OQ(U_2?%;Z;X=NO+AL85>[Q
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M:E;6K21A\G:5._D9ZY'7->G^!? FMZ#H^I^']=N+&\T6Z5A&L,CET+<'@J
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M!\#M+;F\@C23:2CH'?##U!P2*Z&+P1X\U.ZM(M>\7JMA:N"/[/+1RRC_ &F
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M>Q@:2.$8Z9##!Y&!V %>H^%OA[JEMXG/B?Q7JT>IZJ(_+B$28CCXQGH.Q(P
M.IJC_P *[\4^'-4OIO!>OVMI97K[WMKN/(C/^S\K9QVZ<=<T;/7M^H7TT,[X
M>'5;3PGXKTN\L=2MM/AADDL?MT#1L$97RO/'8$@=R:H>"_\ DW[Q'];C_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*3!S0 >7'_SRC_[X%(4C&?W49_X *?WIO>@!NR/_ )Y1_P#? I1''G_5Q_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MC:G$FH9'VYIH3$8\XJ L%4MW!IKS\$D].E5+J;;'/S@E,BJ1DV06CM>:F\A7
MY(AQZ9K3*E7W#OUJOI$0BL$;'S.2Q/KS5N1]HXI@MK@<;"#58@]JD=L 5$6(
M'UH$*K9Z@U*KCG/_ .JH]I*Y7DU$684AD5W96]V"'3!_O*<$50ET8LH$=SD
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MD<>OM[ 8_*N'&8E4UR1?O,UIPN[L?#;)!;1Q0JS!!RWJ?4^] ED20GJG /\
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M:2;;&$XQE!3G8OTH>X)Z%P%)%Z<BHI#M /!YJ*-RO'?O4Z!7)],4AW$#'D=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTBC:WWOE7.T8Z'WJ8#Y>>3Z^M27N5<\@Y(]C4%[&;BW*+GS$.X#%7GV@#+
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M3TI"7\R\'_;T_P#C2+.D\R/^^O\ WT*<)(O[Z?\ ?0KF(_"NE\$2WA^MR_\
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MJA&=[+5B;25V/\1ZDC:=-:D@2S ;(QR57(RS?Y]*=I%U##%&)0S2= Y7"X[
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MO4=:THY&<?("$ ZDUB(E]%I["..*VCY8&5SD]]QP/TJWH8OFBDDNIEDA?A,
MC/O3A55U#=E<EM2.W0CQO<<Y_P! 0<]?O&N@''XU@P@CQO<>GV%/_0C6\![U
MLR4.HHHI%!1110 4444 %<GXF7/B;P[_ -=F_E765R?B<9\3>'3S_KVZ?2FA
M,WC24IZT51 4444A" 8J&\N/L=A<W6,B&)Y2/7:"?Z5-FF31I/;R0R E)%*,
M/4$8-,#CM&T*/Q%I%MK.K7E^U[>1B7]S=/$D0/(5%4@  8ZYI]@=1U?2]1T]
M+MO[2TF^,=M<.3^]V@%/,QUR&VM^?6K.E6VMZ!IT>E1:?#J$-OE+>X^U"(E,
M_*'4J>0..,]*:GA^^BT*XLUG5;W4[DRW]S&V/+#GY]G?A0%'US6K>N_H1830
M+^3Q1?+JVZ2&VLAY"VZMPTY4>86]0N0%_$U2UF[NM1U*RN89C'IMKJD$$?EN
M1]HD+X<GU5>5'J=WI6L=$EM-446"JFEW5K]ENXD;:R;5*I(I]<':?P/.*R+_
M ,"0);6<&GWNJ".&XB)1[YMJ1@\E1CA@.E-.-[@[V+<MI%XB\2ZE:WDMRMMI
MZ0I$D-PT67=2S,=I&2. .P_&IO#%Y<W6FW$%W,)'LKN6T\Y^KJAX)]3@CFAK
M*\TK59[O3[5;V*ZAB259+@(X>,$!B2#D%2,]\BCP_I<VFZ:\=W(LD\]Q)<3>
M63M#.<X&>P&!2=N4-4S7RN,CA<9]#67>ZG;6\AA+IOQ@KG) ]<=S1-<S7^Z.
MR.Q2V'G8<#_=[T^UM(+3*P($S]XC[Q_'O7F5\:HOE@M3:-*ZNR""ZLI)-D<P
M\P_WFP1CZU7U251(H5@TRL)!SRI%;4]I%=1A)D#H1T[K6%%I@AU!X)LLB+Y@
M]9!_D5C+$5JD?9)*[ZC]FHOFZ&U8WL5[%OA))'#J>H/TJ:[=HK=GCV@]F?[J
M^YK'E2.90_V?+1C DC;:1_C6=>F3<IF,SQD_)&[[L_45K]2G;E3ND0\1#XF/
M>\FNYF6R?S/X9KML<CN%["HH;:$"1@?W-NIX+$@OVY/6DENY)MD2A44<!8TQ
MBF;A%&9)7*8)VPKSEJ[:&%C1CYG/4J>T>@1720[I41)+MQS_ +(_I3$@N-0+
M3R.-IX+$\''I_P#KI#Y0MHH99MC3/F7:#E1UJ6[$URZP1[?+VX2,K@D>^.E=
M*T9FUI8=I]_<6"EQ&&0D9.<$?XUUEG,)E68-L+ ?>'45Q-S%<:8JQ3/'EC\H
M!SA:T]*U%KEA R !4PAZC\:4U?4J$[>Z=<LHR0K?UHV]"6))-06\F$0EE!/&
M ,5,3(S@_E63.@E+;1U)]J41Y&23351E )/-.)?'R@?C0,?@*,]Z-VX=\4S<
MYP%&2.I-.R<\CK4@*% ]>:48IIW%@ #3EQ@YZB@!>.]!P*C.2>*<%/>@!00>
M12T< 8I* %HI*7K0 AHHHI@**4]*2EH YKQ<@/\ 8^2>+],?D:[(5QGC '_B
M3$=3J$?\C79TI%Q"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD/2@!:#3:,T["N!J
M-ESUJ3--8B@3&[@!Q^E9VJ2^7;,[/VX [5<,B[L XK$U8-<7UO K?*6RWN*N
M*(E*R':39B)!<%B9'^89Z"KS[2,=><DTF#'\H^Z.,4H&X9QD4$I65B)HV[<4
MH"J,'I4QY49. *B:, ELDT7&-*MC /%((SGWHB?>2.@S3V<H0*!6(@660COW
MJR&^3@\=Z9L#\GO33&RGKQ0!*J[VY/%,DC&<+VI5W(*"P//>A ,+?+C%*JMM
M')_"AL,"1UILMU':P--(/E4=/4TP&R7JVX5/]8[\)&/YU$MI+<[FOY/,5^D.
M<(OL?7\:6SA)'VN5,3R#)!_@7T%70H/4TK@0I&(XUCB41H!PJ@ #\!3B"#U_
M&G'"\?K2A!(N0<4!8CQDY'#>N:EVL5]:B/[OK3T;*[@32 22([<KVIL?R]2-
MU2+E^_6FO$.M-#&7,^T!>C'O5*2.(_.55O>I;F&23;(IR%XQ56>< A0, ]JJ
MQFU<FLIV6X,+'<C#@FKVP,WH:I6*%VWE<*@_,UI#:#[4BX)]1F-A'.:"Q;YJ
M?(JD?+UJ,!@.:0V-/(SCBC:5& >*E*\9'3TI!M/'0TA7$7 7 /6DDE6",NYX
M[4A0H<@YS63=W!GN=O\  O0>]4D#=A[L9Y6D/#51)VS$#I_%[U8E9P%09![X
M[TJVRNO)P?6K,FKNY*EPA10,8I642N<D<=/>HUMAFG,WDJVX<]O:@=RO<KTQ
MU!Z4Z)V,"A1D@GBF*^X[CRU2*Y*# P<]J!- ("3N9\^PIT*;20:='(H4@]:C
M</N&#Q2 G9<\ U%Y)=B?\BIX4)')^GM0XV*0?E/>BX[%1E5),N3G/%7K6Y$@
MVY/XU60+*6&<X/>J=U(8F"*Q&#VH$O=9N$8<!CG-<[I1_P"*QUU2.=D6 1Q_
M'6C;W!>W&68L!UJCH8\SQ=K9SR4B_P#9Z6Q:=S5&GFV<SV1VN?O(#P:L6M]%
M>2-"QVS@$/&1U-63%L.<\?RJK/8173;P3'*.1(G!S[TGJ.UBGJ>GBWC>:W^7
M_P!E_P#K57L;X3Q[/NOT8$],5HV]XWF_8[Q0LA^ZQZ./\:Q=<LIK9Q/9 %V.
M%7.T'V_#K^&*I/H0]-2QJ;HD*.KA9"0% /)Y[5%IK6EQ>22ZA*LEQ%C8LDFX
M \\@=S64R.LT+WEVNZ4<X3YE8#) YZ5O645M)\YC53U7:O3ZUR<JKZQZ=36,
MG%:[E_[.=0G6>[=H[8?=M\_?]"W^%;4178 !A>@ '2LN&UVR#YG)/<UJ1 H/
M6KC3C!:%J39D1#_BM[AO^G%/_0C6ZO'%8,)_XK>Y'_3BG;_:-;HYJAHDHI!2
MTB@HHHH **** "N4\3#/B;P[Z><W\JZNN3\3?\C+X=_Z[-_*FA,WJ*#2=LU1
MF+FD[TF.0.:/K2 **0FH9;F"W ,TL<8)P"[ 9_.F!/3":C2XBG3?#(DBYQE6
MR*"U(!^:C8X..]*&J*>41Q[SSUQZU0F-DDCB0O,P1 >78X K,D$NJC%OO@M0
M3ND4X:3V'M_2HGSJ.JRB9<VUN,>7V9B>_P"57@)(BI ^0< =,>U>5BL6U+D6
MW4WIPNKCO)%O MO& BCH@Z"H]FT@@9-2.PE. WS>M/RGDF24A57DMG&*X7!2
ME:)J$<V0>.!UK,N9D76(F5\@0$E?J>*9>Z@8YT)B,DDO^HMT_B]&;^=.L=.:
MW+W%PPEN)?O$]%]A7=A*<I33>R,:TET'K%^\9CP.R*W7WJO<PQW4;!F.2.#_
M '#TJ^(2V0#@#KZTV6)(QMVA<],]37KHY+:6.::UDM;WR?M+2F,#/RXQDT]+
M>:]NG*J&<8_>'''X>M:5U8(YEN"\D91/^69^\/>LF$2V\#/'.Y+=<'AO85JK
M&5K,N>5:Q3K DB-.2#)(>2B@\U)YA-S/);N&/:8#"J*@BTIF(N[J3RD89\H=
M>F>34BO#-!*P(6)FVK&O7CO^M245XM/DU5?,8G8#C[0_7'T-.M!]CNY?LMR&
MV?*#L&#Q27@NG9$=O+$O"6R=QZFB72TMK,)Y["Y?[J9"J.?UIW):ZG2Z8\D]
MLLLI!E8_>XP?PK10A>ARW<CBN*TO4[BSU!-/=O-A;JPX*FNP0;0/FZ'I6<D;
M4Y<RN6!N8C]XP/TI)"RCA\_\!I!DGOQZ4X(3_$1^%0:7$B,A7/?TP*D^;&6.
M/84UFV?,>I/0#M3-SN<@G'88HL,EW-V;\#2X/KS2[=B[@!N[9HPQ&20,T@'@
M!1FBDZ#UI: #-%)10 4M)2T %)2T4  I:04M,#G/%N"='R0/]/3^1KL*XOQC
M_P P;_L(1_R:NTJ67$****104444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F<T$TT<4"%/6DH)
MYII-4(":AD; ZU(2/6JTS4A29%M#@]FK+*,VNH!]U$))].*O-.(0SMT7O573
MB97GN7!'F$!1Z 5HM-3%ZNQJ&/N3G([TARHPG% <&G9!'H:19 PYR>M2( R'
M!YIK@?6@,.=O!'6@")P WH:<$8J,@$4A)-2JVU<8HN(9G P*=P12.0>@IJJ>
MAH8Q9'V\'FHR#UJ1DYYYIFXY Q0B6T/78BEF[=:H^2U]=++C-I&<JIZLWK44
MTTFH3-:6Y*PJ?WLP]NPK8A")&L8&$7A0.U,:U$"[L\\GM4<@"<_I5AV"C..:
MKLX=LD<=ZD;$'[P<U)L,:@YI!M) '%.D(4!2>/4TQ#9"&7D5'%EOE4GCUI[$
M#C(S[4Q?E8GUH&/Z9]:!D]:0D'MBFY)-%@'C*DXJ$V\+DR%$X_B(Z58 /KS5
M"=C?3&WMVQ$HS(XZ,?2FA,:NH*6,5O"97'' PHHE759%W(\*$?P[:LQHD**L
M2!0., =:>N6[<CUI"2=C/1M8B^9Q#(.ZKQ5C^TD"KY\;1,??-7$ ZC@]\4DZ
M03)MD17)&.1S3#E: .",H=RX^\*0IDYS62WVC2SN&Z2USRIZQU=@O[>=<K*H
M?NC'%&X)EB5BL+;?O,,"L*6-D8-DCU^M:-W<@R?(RE5ZX-4'8S>P_6J2(D]2
MQ&NZ-03SZTDH[#I3$?80"#3)6+#"YH$3QW "[<U!<ONPO/-26UBS#<SXJ62W
M"DGJ10/U*\<6T ;0 .M3!4 .T@9]*@E+?=!IT2,R]S0(;)$0<]O45/#$67=G
MGT-,ED$(VL?F/0"GQ2[1N/!]* 3)&/E@[0"3U'I4# S8WDGZTLLA W $#N:5
M7#ID8H'<9&%1ROK27%J6C9N]+D%AQ@@]:661BN!0)D-FKYQG[O8]Z@T1P?%N
MN84JVV+/M]^KT*D*6)R?;M63H=QM\8ZT2#M98P?_ !^ACBSKE/O03MS@TW:=
MWW<4K1\=:DU*L]O%=Q%&4-_=..5-1V:&XB>SOD#21@ \Y#CLWUZ5; V@X'/K
M4<D'F[9(V*2(>,=_447$E8YC4-*6#53<G@-\C=\>F/PQ^.:V+6-T"JRJK=1W
M!'^>U:EU:)=1@$ /[UAQ236)>"X5V53]X]1[T*UK$<MF=#;Q@')SFKX&*H64
MP,(^=7'9ZO;LU+-HV,2''_";7)[_ &%/_0C6X*P82?\ A.+D?].2?^A&M\"D
M4API:8&P:=NJ1BT444#"BBB@ KD_$X/_  DWASG_ );M_*NLKE/$YQXE\.CU
MG;^5-"9NGK7(V>GVGBG5M4OM4C-Q%:73V5M;.Q\M @&YBO0L23R>P%=>>]<\
M=.U32]3O;C2ELIK:]D$SP7$C1E), ,58*V0< D$=:TB]^YDS.UO0].MDT#2X
MK;%E)J9+PEV8',<AQR<XR.E1ZIIT'A2]T[4=)WV\,UW':W5LKLR2(YP" 3PP
M/.16IJ5CJU]'I=QLL1=V=WY[1^<_EL-K* &V9S\P[4VXTG4=5O[&?5'M8;:S
MF$Z6ULS/YD@^Z79@O ] *M2VNR;;V,CQ/;>'K"6Y>_TN]O+FY4N)E1Y!&>G#
MYQ& >>V*LW4D[:'H^G;+.]U*YB5$GF02QKM0%Y1D'=@=/4D5IW,^N+.ZPVFG
MM'N/ER/<NO';<NP\_0UEIH=WI]EI"Z?/#)/IL;Q_Z0"$E#@;NF2O(&.M">BN
M)^1LZ9I]IHU@EG:HPC!+%CC<['JS$=2:M[@>]9NC:E-J5O,9[40303M;R(LF
M]=RXY#8&1SZ47.H(D_V>!?,N>Z9X4>I/:LJDU!<TF5%-[%YIU1PF&+GHO>CR
MSR[MEOSQ]*RQ!J#3[TNX8V(Y 7=G\:EFN[JS51/"ISPLRMA,^]<JQE)W:9I[
M.0W3Y-FH7T.,,2)0.[ Y_P *N2.J#)/!SCVK"B2[DNC/;2#>O5WX#>PJU+?3
M(WSZ=.6;LJ[@:\N7M*D7)1=GY&UXQT;+$C0Q%6.=QZ(HY8U0>2>XO9(]L=U.
M%^5-V8HO=F/WC[8J)(M1ORRQ0S6ZDX:Y<_,!Z =JW;:TBM(A';PJH/7&#D^I
MK7"8.4O>DK(52HOLLKV%BFGJ69O/NYA^\F(ZG_"K8MB[9D(..@ Z5*$"G.W)
MJ1>>HQ7LQ2BK)6.75[D9C/(7K4!@VY9B">Y/:KS%54XP6[ 5'Y98<J/<9IW"
MQF@22NR@ C^\16+J%A#:SQ[3L+<D X''IZ5TLK%&*HZ ?W1UJI-8QWA(N@I.
MWA<<J?K5Q>I$HZ'-(D]U?&)9=\6W[LA) ^O7/TK0,<6GQ-%D37T@ZYX0>I-9
MSJ+1I664Q.&(.&P5QP/TJ_;V"RVJ7%U(L4;'.[=G/N3W-6^YG'L,66-)6,#-
M+<"'#W$A.U< 9Q4,%D;E!<R2GRBV6D<\GW44MR]M(S%28;-%(P"5\P]JBV23
M);J';,JGRXUR0BCOBIZBZB2+:-J!^S2/E>-^2.?4>W3]:Z+1))IK<_:6#LA(
M#@]1G^=85U86EC9.S/YMWCY40G^E2Z+<SV\Z*7WQOPROW)[T25RH.TM3L@4Q
MD$_C29=P?+P/]INE1[5#9?D=E!J3S,@Y0CWK,Z!1&J]6W'U-.!)."0!3%88H
MP#[^](=R<[20,CBC<@."!N]JB" GL .V.M*0H(PHSZXH DW#M_.E616'# _A
M34V]P/RIPP.@'Y4@ YI0<CFCJ.E+0 E+24M !12=** %%+2"E-,#F/&(^;1?
M^PBG3Z-7:"N.\7*,Z/CMJ"']#78BI9<0HHHI%!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "&F
MFGTPTT)B$U&YXIYZTQJ"2 ,3&#4,K#:2Q  ZU8C V+GUK#U2::XD-G;L 2Q#
M'%4M29.VI"\HU&?R8I#LZM@=![_6M>WA2-%1!@+P :@M+9+.!8UR#T+GO5A6
MV< <?RJF^A$59$C[5Y YI@.3G/-!<]134)!*L>1S2*%)YYI,#.>A'ZT'FG8W
M+D4@$RN,_G4H4%"?055FGCM8_,D; Z8QG-9ZMJ%]N-N?L]N/NY/+?E56%<U>
M^>V:<6XR*QUCU&WYBN3<8^_'(3R/8GI2_P!JSLVP:=+NZ<D8S]:+"YT:VY5!
M9CP/6LN=IM2D$-LYB@!_>2=#]!3H;6\N9T:\F"[3GRX^F/?I6K(JH/E7CVH"
MS9';PPP0^5&H51V[F@-F;@D#L*C1V#[3SCC-2' .1UI,988#;\WZ56E0/TX%
M.$A(P<TPL=WM0,5> !4A"D9/-(0-O%(F#P6 ^II ,PJ]N/6G+AL\CBADR<9X
MJ%UX.T_TIH"8CD"C@$#.,]/>F,=CC/I2.[!<H,L>@[?C3$R&\N9(V2U@&9YA
MP?[J]S5F*..",11KA5[^IJI;6WD;Y&):60[I'/4_3T'M5]&'ED<8ZC- #@$Q
MG I'==N,8/M4$KE2-M/4[AD\>](8JH<9!Q0>.0.?6@MS@4K [>.] 7&[!M/0
MJ>Q[U5GLK2127A48YRO%6XV &&_A_6JU\Z^0R#(+'%"8K+J99M(F&5W@_6H?
M*FA??&^Y?1JTT51&&XJ&8#L0 3FK3,FD,CFCF3Y1ANA%+"58G@$"J%M$1?S;
M"=NW)J=7*L53IWH$:2R@*>@%-$@<?*<CVJD_F2<*-H'7FGP,(Y"R\8^^*0)C
M]IWY(Z&I6GC1=O%$PW1\'#'D&L[:P?Y^<4P8XAIKK/3'3O6@BIL[%JK@!3N7
M'2B)R<XSF@$/D&[@\+Z4HBVK@8_"H)0^_+-A3Q3UF8QB)!R.-WK3&/*X'/.>
M_I33Q\O6GP*>0_6GE.:0#8G51S7/6)7_ (2_6<G@B/'/^]6U.!GY3@GC K L
M&*>*-6W [@L>,?\  J=A([:UF$T0(.2.#4AZ\FLRQDD2;&#AA^M:&6SD^M1+
M<UB[H>XQSCBGQ%%&>I[4]CF+I51B58 9Q4C)YI,,N.GKZ4LMO'<0CS%&?7N*
M8!NQD=J [JV!GCVIC,N83:8X:/)A/7T)_I6M9WR7: J><X(/8TC[CD;?O=<]
M*Q;BTDTR1;F+<8<_,B]J=KZ$MVU+D)!\;W./^?%/_0C6^#QFN7TVX$WC*XD!
MX-BG_H1KI^N<5#-8NZ#O3A3,4X4ADE%(*6D4%%%% !7(^*2?^$H\. 9_U[?R
MKKJY/Q.&/B;PYCIY[Y_*FA,WR:C/-/-1MTIF8A/%(<D=:8'YP:-V#30#' S@
MCFHS@=/QI#* ['D#/)-84^H#5)3! S16P?#3=W]0/:LJU>%&/-((P<G9%F6>
M23S;33(U0 G?*HP$)Y./4TD-ND$0BP1(1EG/WG/N:GMEBBC$4/RHO)"_SHG,
M0?=(V 1D8.<5XM>M*O[S^XZX04-AMNC1,"6)!/*YJU<1+<6DD$@&'4A?;T-1
MH!'%S@@]6)Z54GU1;:%V$9= =J$'F1CQ@#T]ZRH^[[KZCEKJ6].V-I4&X#*K
MA\^M/V/-]QV$0/0GD_2H],M'AL88IN611N&<Y/>KX4+V_P#K5]%"ZBN8XI:N
MXB#Y=N H^E2!<J0H ]\4I4,.:524PK<CM5786&B/:/O$T $YP?SJ0CUII8*N
M!UHN%@X"Y.,U%*)),J@*KCEAU-/V$<DT\AB/3WH K&&-#\TC9QW'-12!W?<&
M 0'YO5A5M<*Q!()QP2*B*$XW-Q_.FF)HYWQ!9P/9&>.(!RV&=>N*Q;;SI98;
M5)"R$$$2'(^M=O-&CGRW",A'*D#%<5=_+J5PL$>Q$. HXSQ_]>M8:G/4TU-.
MYM['3(2]PYGG_@B/(SVXJDKJFT2W)BG;+O@?-&.R _YZT[3=+FOK6.:2Y6&+
M<?GZL?K3YE@646UJ0+:(DS7$@SO/H.Y%#&M5?H):V/VN(W4\OEVX."3]YC[F
MH;NXC^UQPV:E(S@;SW]ZF6'[3/';Q3&=BI*OM*J@^AI;B"PTV!E)^T7&  ?[
MISUS0A.-UH:6D7ES<"2&X8GRC@/W:M<R\8RS >IKD;:6ZMY]T<N\/@D'HU=-
M:*K O*@12.>,U,E;4N$KHM8+' )'M4D2\D9Z4D9 ?]V05 YSR?SI%((^89YZ
M;N:S-BR-H&,@FG*"",G\*:F,' %28R,X IC0N% Y- 8&F#:IRQ_"GC:QR*3
M<",44UEW# I44J.:0"TM)2T )1113&+0>G- H/2A".:\8D_\2;;_ -!"//Y&
MNS%<=XLR3H_3_C^3K]#78U++B%%%%(H**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8:?3#30F
M,---.:H7?!YZ4(ENQ!</Y4$K>G-4;*/]RTQ&)9,D-[4:M<%8&C7I)\N?2KD
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M6:Q.;TZST/4D(L_$5[(W]U;SYOR/2K#^$X4.[^T=5P/^GDG-:TVB:;<9#V4
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M>+\#^QN,_P"GI_(UV(J67$****104444 %%%% !1110 4444 %%%% !1110
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M&AW)@#CVI(P4&TD'WH$121^8WO\ 6EB3RGZ'/N<BK"IDG:?TI7B'ED*3]10
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MT'?;H,<YZY'2K$1#-]WBEGE61#&.W>@0VW)GDS_".]/FCR20.?:JRLT8RJD
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MZ44 .R?4T!CZFFYI<4 +N/J:3)]324O:@ W'U-+N/J?SIM% "Y/J:,GU-%%
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M]Z4J488&1V]JLHH$6">:8Z D@GIU%%BASR9@PW)/<U0VI'(=M7F4O'DXJ Q
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M6EN4O=17DD\R1G2UGM&/+!0"I_ 'I3I-0MKB$B[@53T5XAG/U'%/@O9;21D
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M2BD2*BXV@=?04\KCGTI$ZU)VYJ#1!10O%/%!0RG#FEHHN%A,5R?B?(\3^'<
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MTQ&*=2?K6@\B2*2!M/<&J)0/,!CCO2"VI*A,ARH)!Z5,B^6"H//>G *J!5&
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MA4$;W7C%. Q6(NAWZ_\ ,?O/^^(__B:4Z'?EPW]OWOTV1_\ Q-06;RGBE)K
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MXR 6&!Q5R)QTYZ5#-8DPR6SGBGH^330P(P*50!T-0625@^,6*^')2.OFQ?\
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MF)9X'\R-^AW<&KT4JMTS^-0=$7?4EQ2\T @TG>I*%%.'6FBE'6@!U I*3/-
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MN*.-<X04QH2 QK%DDAO<8I& '*@$XS3I0A8*0F*CF@\R,F%RI%2-E?S))#N
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M8U%]1D%JBR!Y!E^WM5S:,$@TR10X!4XQ28)Z<9& :DT2)8R"<-CV/K275U'
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M$S;4&2N/J.]-TC2Y;2Z>[NI5GNYR%; P%7L/YU*[FDM7RDMKI-N/+W>;-(G
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M' EJ+L;HKN)ALD0?,?8^HJ35]>M-+BPQ+3'A47G(]^PKF3>W.N:@K>63G C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1]3!9ND2@8'3FK@KR.7$S<*=T06&C#68O,F!6'=]6//J>:ZFQTVUL(A#;Q!
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MI:+@- P:>!D4F*=C H 3% !YI12T <SXO+*-&4=/[00$^V#79BN,\7_\P?\
M["$?\C79BI9<0HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ*YN(;.VEN;B01PQ*7D=NBJ.IKD;#Q+XEU4W-G9Z381WUC*8KN2XF;R0W;8
M-QR.>>GXT3ZW-KGP^\0-=VRVUY:QSVUQ$K;E#J.H/IS5>S=]1<ZZ'812QSPI
M+$P>.10ZL.A!&0:))HH=GF2(GF,$3<P&YCT ]3QTKB+/6?%5MX=M=0AT>Q?3
MH;5&\IIF%PT:J/F_N@D#.*TM:O8M2L_"M]!GR;C5;:5,]0"CGG\Z3@TQJ29T
MAGA%P+?S8_/*[Q'N&[;TSCKC/>I*Y:3_ )*I#_V!V_\ 1PKJ>M)JU@3N(>:C
M2:&222..9'>(@2*K E">F1VJ+4;:>\L)K>VO'LYI%VK<1J"R>X!KG_"VEV^C
MZYX@LK4-Y:&U)9V+,[&,EF)/4DDDT)*S8[ZF_<ZC8V3JEW>VUNS#(6654)'K
MR:=;7MI>JS6EU!<*IPQAD#X^N#7&ZVEHWC_?JNESWEFNFA8@+-IUWF0DG@'M
M6[X:N?#]Q;W']@Q00A7 N(XX#$RMCC<I /K^M4XVC<E2N[&TP.#S52:$\LHR
M<&KF*8X^7 '-0G8IJYP6M-]DU&42\>8%= >Y _\ K5V5FXFMHI%P044_2L?Q
M5H$NJV:2VO\ Q\Q$D+_>4]1^59.AZI/I,2P71+P*, ?Q1^V.]:OWHHX4_856
MI;,[8C&,]QUJ.:58H))&90$3<6)QTK*E\6:*EON:[S_L[#G-8.I:[)JT?D0H
M\=JW##&6D_#M4J+;U-IXFFHZ.[&>'5EN=4,ASLC!&"N.O_ZJ[N)?F+'G/3V%
M8F@64L5NTDH*N^"%[ >E;RH5 SZ5,WJ&%I\L$GU'< 8 Q0!2<YIPJ3H"BEH%
M,8=*6DHH *6DI:0@%+24O2F@.8\8Y_XDN/\ H()G\C7:5QGC#(&C8&?^)A'_
M "-=G4LN(4444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH .U<#\7)73P.RJ3A[J-6^G)_F!7?5SOC?
M0I/$7A2[L( OV@@20Y./G4YQ^/(_&KIM*:;(J)N#2,7X1PHG@6-UQNDN)6?Z
M@X_D!7=8KPOPAXZG\#07&CZOIEP4$A=5^X\9/48;&0<9_/KFNW\/_$ZV\0ZR
M;2+3I;>V2)Y9+B60?*%&>0!_6M:M*?,Y6T,J52/*H]3F_C#JTESJ>GZ!!*@5
M0)I 6P [':NX]L#)_&J'Q(L]-ALM"N=*U&TG:SA6T<03*S#:,JV ?7=S[BLS
M1[)?B)\1+E[AIDM[@R3.4(W(@&$&2"/[HKL-9^$.E6FBWMS975\UU#"TD:R,
MI#$#.#A0><5NG&GRQ;U7ZF-I5%*26_Z'<V.JQZWX-748V!$]F6;'9MIW#\#D
M5X)X,\5W/A.[N+JVLDNFFA"$,Q4*,YSP/:NY^%.MB;P[K&BR'YH(WGB_W6!#
M#\#@_P# JSO@LJOK6I(X#*;, @\@_,*F,534TUH5*3FX-/N5]#T[4_B3XQ.M
M7(B@M8)(S,8R/E"C*H 3DDXZ_7Z5ZKK'C;0-!O\ [%J5\8;C8'V>4[<'IR ?
M2O++PW?PO\?&:!"=*N3N$>>'B)Y7_>7/'X>M>G7_ (1\,^*IX]5NK4732Q*$
MF2=U#)U'W6 [U-7ENF_AZ6*I7LTOBZW(=8UW3_$/P^UN\TR?SH%MI8RVPK\P
M3)&"!ZBO)]'\.#7/AKJ-W#&6O=.NVD3:.6C*)O7WX&1]/>O5]9T+3O#WP_UN
MSTR P0-;2R%2[-\Q3&<DD]A7/_!7GP[J/_7W_P"R+1"7+3<H]PG'FJ*,NQBZ
M7XJ;6_A7K.DW3EKVQMAM)_CA! !]R.A_"NJ^$'_(D?\ ;U)_2O/?'N@3>#_$
M$TNGJ8].U")E7N &^_'_ %'X>E>A?" _\4/_ -O4G]*=51]ES1V;)I-^TY9;
MI'CFGZI?:3K5Y/IH?[5(LL*,@)9=QY( [X!^G6O0O@S'I3O?ROAM74C!<\B(
M]U_'.3]*Q/A@ ?B0_3(CG_G4OB_3;GX?>-H-7TA&BM)CYB#&5!/WXS['J/8^
MU;5&I-T^K1G33BE4Z)GNM>6_&R1QI&E1 G8UP[$>I"\?S->BZ5J=KK&FP7]G
M*)()D#*0<X]0?<=#7/?$7PS+XE\--':KNO+9_.A7/WR!@K^()_'%<5)\M17.
MRJN:FTA/AC;0V_@'3C$.9M\CGU8L1_0#\*ZX],UX=X1^(<G@W3GT75M.N6$4
MA:,#"O'GDJ5;'?)_&N]\)?$"+Q=JL]I!ITL$44)D,DD@)/(&, 8'4]^U55I3
MYG+H12J1<5'J>53:OIOB?QI<7OB>]GATY2_E)&"Q"@X5!@''')/>DFU+1_#O
MB^QU'PG=W$MJN#*DP88YPR<@9!%6+C3HO _C*?\ MO1A?Z3(SB(R(#N0G(92
M>-PX!'UKH[/Q#X!U+5[+3]/\)+))<3)&7D@1 F3C/!)..M=;:6R;5OD<R3;U
M:3O\Q_QNYBT,_P#7?_VG6AX__P"21Z;_ +MK_P"@5G?&_ BT/_MO_P"TZT/'
M_P#R233?]VU_]!K&'PT_4UEO4]#H?AI_R3[2O]V7_P!&M76UR7PT_P"2?:5_
MNR?^C6KK:YJGQOU.B'PH****@L**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ JM=6L-["]O<PI-"PP4=0P/X&K-% '*/9:KX;P=-S>Z:O+VTAS(@
M]5)Z_2M?2=9LM70M;2_O%XDB;AT/H1UK3-8=]X=AFEDO;!C9:@1Q-'T)_P!I
M>AIBL;AKDO$X)\2^'<?\]F_E5FS\036+I9>(%6WN6;$<PXCE'UZ ^U5?$;(?
M$WAWG.97Q@^U"$SH:2E/MS2<U1 4M)S1SZ4AA11SZ4<T""BCGTHY]*8!2TG/
MI1SZ4@%S12<T<T +7*>&XW3QGXM=D8*TUMM)'#?NSTKJN:,G&.U4G9- T<OX
M4C=-;\4ED90VHY4D$9&P=*R((9?^$9\=H8I-TEY<E!M.6!4=/6O0,DT9;/?B
MGSZW]"7&YP0\6QVOA9-)DL;S^VUM!;"R%NYW/LV@[L8*]\YJY-IT^G:#X.LI
M%+2VU_:K+MYVD(^[IV![UV.6QCMZ4G-/G71!R]SB=;U6#1/B)!?7<=P8#I9B
MW0PL_P QESC@>@-:<.H:3XVL[FP3[:D:;&D)1X&Z\8/'I72 L!P2/I02QZDG
MZFES*WF-1,W1M#M-"MI8+-IRDC[V\Z5I#G&."?I572U8>*_$3%2%;[+M)'!Q
M$<XK;YI<FE=ZW'8PM4\7:;HU^UG?"[B8*&$@MG:-LC. R@Y-4/#;OJOB;5==
MBLYK6RFAB@B,T91KAER2^#]0 :ZP,PZ$BDYHYDE9(5KL0]:0@DT[GTI#FI'I
MU$Z8/O63J&@6&HR W,11AGYXFVG\<=:UNO7I367)[YJD["DE+1HY8>!=,2;>
MK3L/]J0\5I66@6U@VY(S)SU?DULJ".HI<&FY-[D*C33ND11D'HI [9J3G-&T
M#K2X&>*DT"BEY]*.?2@ [4M)SZ4<T@%HI.?2CF@!:2CFCGTH 44IZ4T9I>:8
M'->,3@Z/_P!A"/\ D:[.N-\7#']C9[WZ=?H:[*I9<0HHHI%!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4A&:6B@"M=:?97NW[7:07&WIYL8?'YBG0V5K;0F&"WBBB/5(T"J?P%3T47"
MQ#%:6\#;H8(XR1C*H!Q4Q&:** (([.VB),=O$A(P2J 9'I2Q6MO 2888XR>"
M40#^5344 12V\,X FB20#IO4'%.CB2)0L:A5' 51@"GT4 -=%D4JZAE(P01D
M&FQ010 B&)(P3DA% 'Z5)10!'+!%. LT:2*#D!U!'ZT1PQPKMB147KA0 *DH
MH ACM+:%]\<$2/\ WE0 TZ6&*==LL:NO7# $5)10 R*&.!=L4:HOHH %/HHH
M JW.FV-Z5-W9V\Y48!EB5\?F*E@MH+:,1P1)%&.B1J% _ 5+11<".:WAN(FB
MFB26-NJ.H(/X&H;;3;&R)-K9V\!/4Q1*N?R%6J* (I;:"?'G0QR8Z;U!Q2O;
MQ21B-XT9!C"LH(X]JDHH 9'$D2!(T5$'15& *?110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 (1FC%+10!4O\ 3K34[1[:\A6:
M%Q@JXR*XO4O#.LV.I6$^F,+^WLR3'%<RX9<_[6#_ "KOZ3% FKG&K?>,\G.A
M6.,\?Z8?_B:47OC(DYT.Q [8NS_\378XI<4^87*CC_MOB_K_ &'9?3[4?_B:
M:+WQD3_R [+'_7V?_B:[*BCF#E..^V^,>VAV/_@6?_B::;WQE@_\2.Q/_;V?
M_B:[.BCF#E.-%[XRV#.AV(;O_I9_^)I3>^,>VA67_@6?_B:[&BBX<IQWVWQC
M_P! .Q_\"S_\32&]\9=M#LO_  +/_P 37944^8.4XT7OC+OH=C_X%G_XFC[;
MXR_Z =C_ .!9_P#B:[*BES!RG&B^\9'_ )@5D/\ M[/_ ,32B]\8]]#LO_ L
M_P#Q-=B!13Y@Y3COMOC'_H!V7_@6?_B:!>^,>AT.R^OVL_\ Q-=C11S!RG&?
M;?&8./["L3_V]G_XFC[=XR_Z 5C_ .!9_P#B:[/%)@4<P<IQXO?&/?0[+_P+
M/_Q-'VWQAD_\2.RQC_GZ_P#L:[&BCF#E..%[XPR,Z'9_^!7_ -C2->^,@3C0
M[+V_TH__ !-=E12Y@Y3C3>^,N<:%9=./]+/7_OFD2]\9?\M-#LA_NW6?_9:[
M/%%/F#E./-[XOW#;HEGCWNO_ +&FF\\9;^-$L<>]U_\ 8UV5%+F#E.--YXRS
M_P @2Q(_Z^S_ /$TGVSQB3_R K+_ ,"O_L:[+%&*+ARG&&\\9G_F!6/_ (%G
M_P")H^U^,>IT.RS_ -?9_P#B:[/%+BBX<IQ@O/&/_0#LO_ K_P"QH-[XQ XT
M*RS_ -??_P!C798HQ1<.5'&K>^,B/FT.QS_U]G_XFAK[QD,XT.R/I_I9_P#B
M:[.BCF#E.-2^\8E26T.R![?Z6?\ XF@7OC+:,Z'9;O:[/_Q-=E11<.4X[[;X
MQQSH=E_X%G_XFFB^\9EO^0'8@?\ 7V?_ (FNSI,4^8.5''&]\9=M"L?_  +/
M_P 30M[XR_BT.R!]KL__ !-=EBBCF#E.-^W>,@/^0%99_P"OL_\ Q-+]M\8;
M3_Q([+/I]K/_ ,378T4<P<IP-Y:^*=8NM/6\TJU@BM[I)2\=R6. #VVBN^%%
M%)NXTK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 48HHH ,4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8%%%% !111
M0 48HHH ,4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img183648649_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +7!6P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHS244 +FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS244 +FC-)10
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M ""[7_KDO\J!]"WFC-)10(7-&:2B@!<T9I** %S1FDHH 7-&:2B@!<T9I**
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MN/FBKW.SVU7^VV9OC9?:X/M87=Y'F#S,>NWKBN6T#XA+JNO_ -BZAI,^F7C
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M.4CVT;:DHHN'*1[:-M2447#E*MVO^AS_ /7-OY5'IB_\2JT_ZXK_ "JQ=_\
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M%"3FHRTN3*:Y6UT/3]M0W:_Z'/\ ]<V_E5JH;O\ X\I_^N;?RKGN:<I%I?\
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M+1'3;/<#[1+ZY;H/P7'ZUOWFGV6HQK'?6=O=1J=RK/$K@'U (JP %    '
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MV6G6ELYX+0P*A/Y"I+S3[+4$5+VSM[E%Y"S1*X'YBG]97->W3YA[%VM<\_\
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MAB.V8^/Y5Z&NA:0EJ]JNE6*V\A!>(6Z!&(Z$C&#5J2UMYK4VLMO$]N5"^4R
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M35#=_P#'E/\ ]<V_E7&=!%I?_()M/^N*_P JMU4TO_D$VG_7%?Y5;H ****
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M_?2_X4?8IO\ H(WG_?2_X4 :]%9'V.;_ *"-Y_WTO^%'V*;_ *"-Y_WTO^%
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M@#4J&[_X\I_^N;?RJC]@E_Z"5Y_WTO\ A3);"3R7SJ-V1M.067G]* +FE_\
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M)7G_ 'TO^%']GR_]!*\_[Z7_  H TZ*S/[/E_P"@E>?]]+_A1_9\O_02O/\
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M-I_UQ7^56ZK6"^7I]L@Y C4<_2K&: %HI,T9H 6BBB@ HHHH **** "BBB@
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MM:,::;LAU%%%2,**** "BBB@ HHHH XG4#_Q.;O_ *Z?TI\1YJ/4?^0S=_\
M73^E/AZTQ&C">*L"JL)XJ2:XAMH_,FD5%]332;=D2Y**NWH34M84WB:U0XBB
MDD]_NBH/^$J]+/\ \B__ %JZ%@Z[5U$X99IA(NSG^;_(Z44M<S_PE9_Y\O\
MR+_]:E_X2L_\^7_D7_ZU5]1K_P OXHG^UL'_ #_@_P#(Z:E%<Q_PEA_Y\O\
MR+_]:E_X2T_\^7_D7_ZU'U&O_+^*#^UL'_/^#_R.GI:Y?_A+3_SY?^1?_K4O
M_"7'_GQ_\B__ %J/J-?^7\4']K8/^?\ !_Y'4"EKEO\ A+C_ ,^/_D7_ .M2
M_P#"7G_GQ_\ (O\ ]:CZC7_E_%!_:V#_ )_P?^1U5%<K_P )@?\ GQ_\B_\
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M)_OK7-?\)B?^?#_R-_\ 8TR3Q<9 H^PXPP/^M_\ K4?4:_\ +^*#^UL'_/\
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M#_A91_Z!/_DS_P#8T?\ "RC_ - G_P F?_L:/J-?^7\4']K8/^?\'_D=_17
M?\+*/_0)_P#)G_[&C_A91_Z!/_DS_P#8T?4:_P#+^*#^UL)_/^#_ ,CO^]%<
M!_PLH_\ 0)_\F?\ [&C_ (64?^@3_P"3/_V-'U&O_+^*#^UL)_/^#_R._HK@
M/^%E'_H$_P#DS_\ 8T?\+*/_ $"?_)G_ .QH^HU_Y?Q0?VMA/Y_P?^1W]+7G
M_P#PLH_] G_R9_\ L:/^%EG_ *!/_DS_ /8T?4:_\OXH/[6PG\_X/_(] H%>
M?_\ "RC_ - G_P F?_L:>GQ*0G]YI;*/]F?/_LHH^I5_Y?R#^U<)_/\ @_\
M([VCM7-:?XWTB^<(TK6TAZ"88!_$<?G71+(KJ"I!!&01WK"=.4':2L=E*O3J
MJ].5Q]%(#1FH-1112 T9H 6EIM% "TO:FTO:@!:9-_J7_P!TTM-E_P!2_P#N
MF@!+7_CUB_W!_*I34-M_Q[1?[@_E4IH 6BDHH 6BDHH 6@FDHH 7-&:3-&:!
M"@T9I :,T .S29HS29H =FD!HS2 T .S1FDS1F@!<T9I,T9H 7/%&:2B@!2:
M :0T"@!LW^I?_=--M3_HD/\ N#^5+-_J7_W33;7_ (](?]P?RI#)L\TN:;WH
MIB'9HS3:* '9HS3:6@!<T9XIM+VH"XN:":2@T!<4&@FD%!H =FDSS24=Z %S
M1FDHH 7-&:2B@!<T9I** '9XI,T=J2@!V>*CF/[B3_=/\J?VJ.;_ %$G^Z?Y
M4 .L_P#CR@_ZYK_*IQ4%G_QY0?\ 7-?Y5.*DL2EI*6@!:*** "BBB@ HHHH
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M^N2_R%88F;G0IREYFE**C4DEY$]%%%<!TA1110 4444 %%%% '$:C_R&;O\
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M ,\D_P"^15/S:/-HY&3[1%S]S_SR3_OD4?N?^>2?]\BHK2"XOK@06T9DD()
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MW/\ SR3_ +Y%-O+2:QCMGE9"+B(2IM)X!]>.M5?-I17,KIE2DX.TEJ7/W/\
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M<;K<SERO8BJ)X(F)8Q1EO4J#FI:*MJYFFT[HJ VX)!@B!'7Y!3O]'_YX1?\
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MW7A^\\L 10W@AC _NJH_KFI+J**P>]UZ+&V>!3!T^^_4_P!?Q-9$/_(D3_\
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MNG^52=JCF_U$G^Z?Y4 ,L_\ CR@_ZYK_ "J<5!9_\>4'_7-?Y5.* $I:2EH
M6BBB@ HHHH **** "BBB@ HHHH XSQIIW]K:[H-CYAC>5;K9(#]Q@BLI_,"M
M#1]8DU/0[RWO%V:E9HT5S'[@'##V/^-)K7_([>&/^WO_ -%BJOBRSFTZ?_A(
M;!"S+&8;V-?^6D1XS]1_AZ5VJTH0IOMIZW?YG.])2DOZT1GS?\D<'_7!?_1H
MJ>.\_P"$NN$T>UN!'IMK&GVQE;#SG^XO?;D<G_)@F_Y(X/\ K@O_ *-%:.HZ
M-);V6GZSHL*)?6<*[HD&!/%C+(0._<?_ *JTO%7OOS.WKH39Z=K(=XF60-H_
MAZQ)MH;V1D<P\%8D + >G!_2KLNC^%])M$AN;738(F^53<A 6_X$W)-9NK32
M:U8Z1XCT>,W$EE*7-NOWBIP'7ZC%2R>+O"M_"GV]DWK_ ,L;FU9F0_3:?TK+
MEGRQ4;];VWO<N\;MOY>AK1:=HVH:&MC;"&;3<X"P297ALXR#ZU@^,-+TZUTN
MVBT^SA@U*2XC6S,"!7W C)X[8_I4/AW58O#O@(WMU%( )GV1[2"Y+<#V'O4>
MD>(=!6Z;5M6U:*74Y!@!8W*6Z?W$X_,]_P"=1IU(3<E=I/[W_6Y+E&44G9-H
MTO%,4<_B3PU%-&DD;3RAD=00?E'4&K>L^%-,O;"3[-90V]VBEH)H$$;*XY'(
MQGFLWQ3J-I!J_AC4))@MIYDDGF8/W2JX..O>IM0\86M[:R6FA+-J%[,I1!'&
MP5">-S$@8 ZTE&KRP<+_ *;O<;<+RYOZT-3PMJ,NK>&;&\G.970JY]2K%<_C
MC-;%9OA_3#HV@VFGLP9HD^8CIN))./Q)K2KEJ<O.^7:YM"_*K[A1114%!111
M0 4444 %%%% !1110!P^I?\ (:N_]_\ I0JAT*L,@C!%)J7_ "&;O_?_ *4^
M'K0#5]#F+B%K>=XFZJ?S%1UTVHZ;]LBWQX$R]/<>E<VZ-&Y1U*L."#VKZ+"X
MA5H>?4^(Q^"EA:C7V7LQM%%%=1P!1110 5/=7MQ>O&]Q)O:-!&IP!A1T''UJ
M"BE97N-2:32>C+#WMP]E'9M)_H\;%U3:.OKGJ>M-M;J:SN4N+=]DJ?=; ..,
M=ZAHI<JM:P^>5U*^J_0=)(TLC2.<NY+,?4FGV]Q):W"3PL%D0Y4D X/T-144
M[*UA*33YD]22::2XG>:5R\CDLS'N:DL[ZYL)6DMI-C,I1OE!R#VP:KT4G%-6
M:T&IR4N9/7N6&O;A[%+-I,VZ-O5-HX/UZ]Z5;^Z6P>Q$I^S.VYDP.3QWZ]A5
M:BCDCV'[2?=[6^7;T)X;VXM[>>"*3;%. )%P#NQT^G6IK'5[[34=+2?RU<Y8
M;%.?S%4J*3A%W36XXU:D6G&35MM=C5F\2:M/#)#)=[HY%*L/+09!&#VK*HHH
MC",/A5@J5:E1WG)OU=S4B\1ZM#"L27K;%&!E5)Q]2,U3N+ZYNXXHYYFD6+=L
MW=1DY//4\^M5Z*2IPB[I(<J]62Y92;7J6+N]N+^59+F3>ZJ$!V@<#Z4AO;AK
M%;(R?Z.K^8$P/O=,YZ]Z@HJN6-DK;$NI-MMO5[EZRUG4-/C,=K<LB$YVD!A^
M1!Q1/K%_=1S1SW+.DV-X('..1CCC\*HT5/LX7YK*Y7MZO+R<SMVN%3S7MQ<6
M\$$LFZ* $1K@#;GK]>E045;2>K,U)I-)[D\-[<6]O/!%)MBG $BX!W8Z?3K3
MA>3/:)8O+BV$F_;M'!Z9]>]5J*7+'>Q2J32M?R^78[#49]6TR2.UT>&1;%4!
MC>./S-^1DDD@]\U#J<ES-X:,NL1JMYYH%N60*Y'&<@?C7/0ZA>VZ;(;NXC0?
MPI(0/T-0RS2SOOFE>1^FYV)/ZURQPS35[:=>K_KJ=]3'*2DE>S5K7]U>B\NA
M)<7MQ=I"D\F]84$<8P!A1VXI5O;A+%[-9,6[MO9-HY/UZ]JKT5U<L;6L<'M)
MW;OJRY9:I>Z=N^R7#1ANHX(/X'BG7VL7^HQK'=W!D13N"[0!GUX%4:*7LX<W
M-97'[:KR<G,[=KZ$\U[<7%O!!+)NB@!$:X VYZ_7I4%%%4DEHB)2<G=NY8@O
M;BUAGAADVQSKMD&T'</QZ=:ACD:*19$.'0AE/H13:*7*M?,?-+17VV+@U6^%
M^U\+@BY;AG  SQCIC':I[CQ#JMU"T4MXQ1A@A55<CZ@5F45+I4VTW%:>1:Q%
M9)I3>N^K)X[VXBLYK1),03$%UP.<<CGK3K;4+JTAFA@EVQS#$B%0P;\Q5:BJ
M<(O=$JI----Z!5B>]N+J&"&:3=' NV,;0-H_#KTJO13:3U9*DTFD]RS)?W4M
ME%9R2EK>(Y1,#@\]^O<TT7MPMBUD)/\ 1V?S"F!][IG/7M4%%+DCV*]I/>[[
M?+L:%GKFHZ?!Y%K<>7'DG;L4\_B*6ZU[5+R(QSWCE#U50%S]< 5G45/LJ=^;
ME5_0OZQ6Y>3G=NUW8FM;J>RG$]O(8Y!T85H/XFUAT*F]8 \<(H/Y@5DT42IP
MD[R28H5ZM-<L)-+R;%9BS%F)+$Y))Y)I***LR"BBBF 4444 %%%5KR]CLX\L
M<N?NKZT@2N4M:N (TMU/S,=S?2LR,<4QG>>9I9#EF.34RC%2M7<MZ*PM%%%6
M2%%%% !1110 4444 %%%% !1110 445I:/HMSJ]R$C4K"I_>2D<*/ZFIG.,%
MS2>A=.G*I)0@KMFWX(TYI+R2_=3LC&Q#ZL>OY#^=>EVZX6LS3-/BL[:.WA3;
M&@P!_6MA%VK7SF(K>VJ.1]O@L,L-15/KU]1XHH%%8'6%%%% !2]J2E[4 )39
MO]2_^Z?Y4ZFS?ZE_]T_RH 9:_P#'K%_N#^53&H;7_CUB_P!P?RJ8T %%%% !
M1110 4444 %%%% "BDI124 +24M)0 M HH% !1110 4444 +VI*7M24 *:!0
M:!0!'/\ ZB3_ '3_ "IMI_QYP_[@_E3I_P#42?[I_E3;3_CSA_W!_*@";O11
MWHH **** "BBB@ H[44=J "E-)2F@ %!H%!H *.]%'>@ HHHH **** "BBB@
M [44=J* %[5'-_J)/]T_RJ3M4<W^HD_W3_*@!EG_ ,>4'_7-?Y5.*@L_^/*#
M_KFO\JG% "4M)2T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PVI_\ (:N_]^G0]:9J
M?_(:N_\ ?I\- &A$,BH[S3(+Q?WB?-V8<$5)#TJX!D549.+O%V9$X1J1Y9JZ
M.4F\.NI_=3 CT857_L*Z_OQ?F?\ "NR* ]J3R1Z5U+'UTMSSI9/A)._+;YG'
M_P!A7?\ ?B_,_P"%']@W?]^+\S_A78"!?2E\A?2J_M"L3_8N%[/[SCO[!N_[
M\7YG_"C^P+O^_%^9_P *[+R%]*40+Z4?VA6#^Q<+V?WG&_V!=_WXOS/^%'_"
M/W?]^'\S_A79^0/2E\@4?VA6#^Q<+V?WG%_\(_=_WX?S/^%+_P (]>?WX?S/
M^%=H(!2^0/2C^T*P?V+A>S^\XK_A'KS^_#^9_P */^$>O/[\/YG_  KMO('I
M2^0/2C^T*P?V+A>S^\X=- NW7<'BQ[D_X4O_  CMY_?A_,_X5V5M /)''<_S
MJ7R!Z4?VA6#^Q<+V?WG$_P#".WG]^'\S_A2?\([>?WX?S/\ A7<>0/2D\@9Z
M4?VA6#^Q<+V?WG$_\([>?WX?S/\ A1_PCMY_?A_,_P"%=OY ]*/(7TH_M"L'
M]BX7L_O.(_X1V\_OP_F?\*/^$=O/[\/YG_"NW\A?2@P+Z4?VA6#^Q<+V?WG$
M?\(Y>?WX?^^C_A1_PCEY_?A_[Z/^%=N(%]*# OI1_:%8/[%PO9_><1_PCEY_
M?A_[Z/\ A1_PCEY_?A_[Z/\ A7<" >E(8!Z4?VA6#^Q<+V?WG$?\(Y>?WX?S
M/^%'_".7G]^'\S_A7<>0/2CR!Z4?VA6#^Q<+V?WG#_\ ".7G]^'\S_A37\/W
M: $O%R0."?\ "NZ\A?2HKB!=B<?QK1_:%8/[%PO9_><9_P (Y>?WX?S/^%'_
M  CE[_?A_,_X5W'D+Z4OD+Z4?VA6#^Q<+V?WG#?\(Y>?WX?S/^%'_".7O]^'
M\S_A7<B!?2CR%]*/[0K!_8N%[/[SA3X=O!_%%^9_PIAT.[7J8_S/^%=YY"^E
M(;5#VH_M"L']BX7L_O.!_L>Z]4_,_P"%']CW7JGYG_"N[-DGI1]B3TH_M"L'
M]BX7L_O.$_L>Y]4_,_X4?V/=>J?F?\*[K[$GI2_8D]*/[0K!_8N%[/[SA/['
MN?5/S/\ A1_8]UZI^9_PKNOL2>E+]B3TH_M"L']BX7L_O.$_L>Y]4_,_X4?V
M/<^J?F?\*[L62?W:/L2?W:/[0K!_8N%[/[SA/['NO5/S/^%-&E7+.R#9E<9Y
M/^%=[]B3^[4,=DGVJ;Y>R_UH_M"L']BX7L_O.*_L>Z]4_,_X4?V/=>J?F?\
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M([>)8HHUCC48"J, 5H"$#M4@4 5SU*U2K\;N=M#"T:"M3C8CBB"U-2"EK(Z
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MHVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HP/04M% ";1Z"C ]!2T4
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MT)Y)A7D_2K=5-+_Y!-I_UQ7^56Z "BBB@ HHHH **** "BBB@ HHHH ****
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M_P EHB_W?_:!JGXJ=8_B?IKNP55DMR6)P -_6JWA_53K7Q)L+YUVR21D./\
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M\\ACC@S]Q1R>!P!TX_&O1+W4)-+^'27<)VRI8Q*C>A8*H/X9K#^*O_'CIO\
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M_H*K_P#"3WO_ #R@_P"^3_C74L#7:V/.EG&$B[<U_D=<**Y'_A*+W_GE;_\
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MVJ.;_42?[I_E0 RS_P"/*#_KFO\ *IQ4%G_QY0?]<U_E4XH 2EI*6@!:***
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M!0O^F[W!J%Y.7]:%[P]J;:SH%G?NH5Y4^<#IN!*G]0:TZR/#&FRZ1X;LK*;
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M"J?[BG\\G^M>=F=O9KU/<R&_MY=K?JCI!TIU-7I3J\4^J$[TM)WI: "BBB@
MHHHH *44E** $I:2EH .]%'>B@!DO^J?_=--M_\ CVB_W13I?]4_^Z:;;_\
M'M%_NB@"6@44"@ I:2EH 3O2TG>EH **** "BBB@ I124HH 2E[4E+VH 2EI
M*6@ %% HH **** "E[4E+VH 2FS?ZE_]T_RIU-F_U+_[I_E0 RU_X]8O]P?R
MJ8U#:_\ 'K%_N#^53&@ HHHH **** "BBB@ HHHH 44E**2@!:2EI* %H%%
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M?_(MCI3J2EKC/3$[TM)WI: "BBB@ HHHH *44E** $I:2EH .]%'>B@!DO\
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MXO\ S.4_X1UO^?C_ ,A__7H_X1QO^?C_ ,A__7KK/*'I2B(>E'U[$?S?@O\
M(/[(P?\ )^+_ ,SDO^$<;_GX_P#(?_UZ7_A&V_Y^?_(?_P!>NM\H>E+Y0]*/
MKV(_F_!?Y!_9&#_D_%_YG(_\(TW_ #\_^0__ *]+_P (TW_/S_Y#_P#KUUPB
M'I2^4/2CZ]B/YOP7^0?V1@_Y/Q?^9R'_  C+?\_/_D/_ .O2_P#",M_S\_\
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M4?7L1_-^"_R#^R,'_)^+_P SC?\ A%V_Y^O_ "'_ /7H_P"$7;_GZ_\ (?\
M]>NR\I?2CREQTH^O8C^;\%_D']D8/^3\7_F<;_PB[?\ /U_Y#_\ KTO_  BS
M?\_7_D/_ .O78^4OI2^4OI1]>Q'\WX+_ "#^R,'_ "?B_P#,XS_A%V_Y^O\
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M-S1FBP<P[\:/QIN:,T6#F&W#;;>5CT"$_I3+%P]A;N.AC4C/TI+H_P"AS?\
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M4N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0!!=?\>DW_7-OY5'IO_(+M?\
MKDO\JENA_H<W_7-OY5'IH_XE=K_UR7^5 ^A9HI<48H$)12XHQ0 E%+BC% "4
M4N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0
ME0W7_'I-_P!<V_E4^*ANA_H<W_7-OY4 +I?_ "";3_KBO\JMU4TO_D$VG_7%
M?Y5;J#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY9=@YEW+ %!%5_[0L_\ G[@_[^"@ZA9_\_<'_?P4<LNP<R[EG%&*K?VA9_\
M/W!_W\%']H6?_/W!_P!_!1RR[!S+N6<5#<#Y$_WUIG]H6?\ S]P?]_!45Q?V
MC*F+J$_.#Q(*.678.9=R]BC%5O[0L_\ G[@_[^"E_M"S_P"?N#_OX*.678+Q
M[E@"C%5_[0L_^?N#_OX*/[0L_P#G[@_[^"CEEV"\>Y8Q2XJM_:%G_P _<'_?
MP4?VA9?\_<'_ '\%'++L%X]RQBEQ5;^T+/\ Y^X/^_@H_M"R_P"?N#_OX*.6
M78+Q[EC%+BJW]H6?_/W!_P!_!2_VA9?\_<'_ '\%'++L%X]RQBC%5O[0LO\
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MTK/_ "$K/_O^O^-+_;6E?]!*S_[_ *_XT<DNP<T>Y=Q1BJ/]M:5_T$K/_O\
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M@!*;-_J7_P!T_P J=39O]2_^Z?Y4 ,M?^/6+_<'\JF-0VO\ QZQ?[@_E4QH
M**** "BBB@ HHHH **** %%)2BDH 6DI:2@!:!10* "BBB@ HHHH 7M24O:D
MH 4T"@T"@".?_42?[I_E3;3_ (\X?]P?RIT_^HD_W3_*FVG_ !YP_P"X/Y4
M3=Z*.]% !1110 4444 %':BCM0 4II*4T  H- H- !1WHH[T %%%% !1110
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MOS1Y(JR%&G9\S=V%%%%8&H4444 %%%% !1110!R5Q_R%+W_KK_04].M,N/\
MD*7O_77^@IZT 9&I',]4JN:A_KC]:IUZM+X$>95^-A1116AG8**** L%%%%
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MBTTR6[@,_G00Q!MNZ:3:,U<@)/A.Y!Y"W Q[=*C_ +.M+2S@GOYIMTZ[DCA
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M* (Y_P#42?[I_E3;3_CSA_W!_*G3_P"HD_W3_*FVG_'G#_N#^5 $W>BCO10
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MT72]_,CG:EJ^NQV=%%%<AN%%%% !1110 4444 %%%% !1110 4444 <C<_\
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MI** %HI** %HI** %S1FDHH"XH-&:044!<=FDS124!<=FD!HI!0%QV:,TE%
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M>E,EHL1NPZ&K4<\H'#_H*J)5A*+A8G^T2_W_ -!1]HE_O_H*BI:+A8E$\O\
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M(8W4-/&IPPY'!(_&H_\ A6\/_0V>+_\ P<R4GQ;_ .2:ZC_UVM/_ $IBKMJ
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MGW- ^(]<_P"@SJ/_ (%/_C33XCUS_H-:C_X%/_C6>:8:?*NPN9]S0/B37?\
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MI<<4 -ILW^I?_=-28IDP_<O_ +IH CM?^/6+_<'\JF-1VO\ QZQ?[@_E4I%
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MWF.0^9&!GKSU_#O5&;Q7XA\S69[:VTU[33+AHW#AQ(5#$ ]<=!_]:KY*_/\
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MBB@ I124HH 2E[4E+VH 2EI*6@ %% HH **** "E[4E+VH 2FS?ZE_\ =/\
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M ,[4E244 ,- I]% $$_^HD_W3_*FVG_'G#_N#^5/N_\ CRG_ .N;?RJ+2_\
MD$VG_7%?Y4 6.]%/HH 913Z* &44^B@!E':GT4 ,I33J* &B@TZB@!M'>G44
M -HIU% #:*=10 VBG44 -[44ZB@!.U1S?ZB3_=/\JEJ&[_X\I_\ KFW\J &V
M?_'E!_US7^53BJNE_P#()M/^N*_RJW0 VEI:* "BBB@ HHHH **** "BBB@
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M ,AR_P#]R+^1K1K.M?\ D.7_ /N1?R- &C1110 4444 %%%% !1110 4444
M%%%% !1110!#=_\ 'E/_ -<V_E46E_\ ()M/^N*_RJ6[_P"/*?\ ZYM_*HM+
M_P"03:?]<5_E0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "H;O_CRG_ZYM_*IJAN_^/*?_KFW\J (M+_Y!-I_UQ7^56ZJ
M:7_R";3_ *XK_*K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3S![T>8/>HZ* )/,'O1Y@]#4=% $GF#WI?,'O45** '^8/>EWCWJ*E[4 /\
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M#T>BN*_X5%X"_P"A;MO^_DG_ ,51_P *B\!?]"W;?]_)/_BJ .UHKBO^%1>
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M0.N8_P"7?_Q__P"M3#XAQ_RZ_P#D3_ZU9;]:@>J443SR-@^)L?\ +I_Y$_\
MK4P^*\?\N7_D7_ZU835 ]5R1%[21T)\8;?\ EQ_\C?\ V-1GQKM_YA__ )&_
M^QKFWZ57>J5./8GVDNYTL7CGRXL?V=GD_P#+?_[&D;Q_C_F&?^1__L:Y$?<J
M%^]-4H=A>UGW.Q/Q$Q_S"_\ R8_^QJ,_$?!_Y!7_ ),?_8UQ3]ZA/6J]C#L+
MVL^YW1^)6/\ F$_^3/\ ]C33\3,?\PC_ ,F?_L*X1JC:G[&'87MI]SO3\3L?
M\PC_ ,F?_L*0_%'_ *@__DS_ /85P!J,T_8P["]M/N>@_P#"T\?\P;_R:_\
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M%%% !1110 4HI*44 )2TE+0 =Z*.]% #)?\ 5/\ [IIMO_Q[1?[HITO^J?\
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M4!<;9_\ 'E!_US7^53BJ]L0+6$#IL'\JF#4!<6EIN:-U 7'T444#.?\ '?\
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M>$]+616VJJH^ =P7 ._'5@/J:!\;/'C%I%\*Z<Q4A"RI(<Y8J /GY^8'IZ4
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MI9/]4_T--M_^/>/_ '12 ES0#24"F%Q<TN:;2T!<,\TN:;WI: N&:7--I<T
M+FC-)FC- "YH!I,T T +FESQ3<T9XH 7-+FFYHS0 H-+FF@T9H =FC--I: %
MS2YXIE+VH 7--F/[E_\ =-%-E_U+_P"Z:0"6I_T6+_<'\JE)J&V_X]HO]P?R
MJ4T .S1FFT4P'9HS3:* 'BCZ4T''6EW =!2&*M [TU6P:7< >E "KWH[&FJV
M*-V 10%QXX&:3.12!AC!I-PQC% 7%H%)FD!H$.HI,T9H =24F:,T .[4E)GB
MC- #B: ::30#0 V8_N9/]TTVU/\ HD/^X/Y4LQ_<O_NFFVO_ !Z0_P"X/Y4
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MY0?]<U_E4XJMIS&33;5SU,2GCZ59Q0 E+1BEQ0 4444 %%%% !1110 4444
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M:?\ 7%?Y5+=_\>4__7-OY5%I?_()M/\ KBO\J +=%%% !1110 4444 %%%%
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M?^OJ/^=:-9VL?ZFU_P"OJ/\ G0!HT444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "H;O_ (\I_P#KFW\JFJ&[_P"/*?\ ZYM_*@"+2_\
MD$VG_7%?Y5;JII?_ "";3_KBO\JMT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!R4W_(8O?^NG]*NP=J@EM;@ZK>.()2K2<'8<'BK<,$PQF*0?\!- %V#M5X=!
M52%''56'X5;'2@!:*** "BBB@ HHHH **** "BBB@ HHHH SM#_Y!:?[[_\
MH9K1JAHT;QZ:JR(RMO?AA@_>-7Z "BBB@ HHHH **** "BBB@ HHHH ****
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MC!'% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *AN_P#CRG_ZYM_*IJBN@6M)E4$DQL !WXH ATO_ )!-I_UQ7^56ZJZ:
MK)IEJK*581*"",$<5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img183648649_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,3!*8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQJ?VF*17%Z;@-,V!PI+*0%[X %4VN?F\[BM[G+Y6.?\ B<0/BEX().!YZ?\
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M;#QC+XFL;B]MKN8DRP1.@A?/7*E<\GGKUHC:/N]/U'+WM>OZ&5\:/^2:7O\
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MD"1QHZB,@%CR"N?XCW%=)4K2-O4J6LK^2"BBB@04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(210 M% HH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;NH =13"^#3
M@<T"N+1124#%HI"<4$XH 6BFACFC=18+CJ*0'-+0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!HHH *;D4M&*8
MA:*!P**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F-WI
MYJ,\TT)D:@E\GI4F[;28Q3"23022>93@V14-.W '% [CBQQ0&S02-M(!P#3
M5C@9%(IR>:4TJ@4 .%+3<TZI&@HHHH&%%'>B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $HI">:!3$+FDS1FDH ?FD)YIN:*+!<7-+FFT4 .H-)FC
M-( S2YI*44 ***!10,**** "BB@'- !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4TFE
M/2FTT)B9[FH_,R^.U2$ TC*  <<T"#@]#3=N,\TN0>0*C9P""2,4)!H/S4+,
M58$'\#0\R 9SWJK),"P!R1G&:JS)<D77)P!T+4Z)OE(]*K1.SG)P?[OTIY?R
MT)_*BP7+&<\4_%58W+X/3U^M62W( J6- .:=2!N*,DT#' TA--R: 2.:+#N2
M"BF;LTI8BBP7'44@.1032&+1BDSS2T %(,'I031T% "T4F:6@ Q1BBB@ Q1B
MC-&: "BDR*,T +124A- #J*;DTFXT["N+GFG5#O^;!HW%C@46%<D!R33J8#P
M:%HL.X^BD!I:0PHQ1FB@ HHS1F@ HHHH **,T4 %%%&: "BBDS0 M%)F@&@!
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &D<
MT=*"::3Q3$!/%)FHV:F[O>F3<GW4A.*C8^E1/+B@+EC<*4&JJRY.*G0\4!<E
M%+FHRV*3=2'<ES1FFJ>*": 'YXHW"F9I:+#N.W"C--HHL%QV11Q3<FG"BP7%
MS1FDHH 6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!#R*0C%.I#[T"&9]J9(X0%C@ =23@42RQ
MPQ-+(X5%!9B3P *XV:>]\97306;FVT6,[)9P?FG/<+Z#WIB;,SQ+XFNKR%FT
MB26"RBF"276.&)[+GKWK!@TG7YKD[O$%P@E.\D '"^M=GXKL+:S\/V-I;1K'
M%'=1A4'3OUJM'=0V8U21\>8K;%C/L.!6L3">C.7O;75(K@Q_\)%<M&BCD*.#
MS36MM?@5 =9N5#IP70#BMFWM&N;]1/%D >8X'<GH/R'ZTR^U W-XJJ&*0DHJ
MM_$3Q6BMU,&V0:=9:Y+,D3^()5&-RG:.WK6FFC:Q*/E\3RL%[!1G-1744ENE
MN&D"R$G('4#%0VEZ+.^AD=B5)/R^M2X7V*C6MHS0.C:P(_E\1W"\CG8M2)H.
MM8&?$MQD]_+6IXM9AGN8U96C#GY2W )]*WD=L$,N .G-0T;1=^ISO]@:TJ;?
M^$FN-WKY8_PH70]97_F9IS]8Q_A71J[$<J,GMFHI)&5MNT<TBKF NBZRTG_(
MRSX_ZYBE?0-:D3:OB:<8/7RQ_A6\C'D +D5*C-W"T6"YA?V!K('_ ",<^<=X
MQ_A0N@ZQ@ >)+@X_Z9#_  K?9CCL33HR<?7VI#N<_P#V#K2#<?$D_!YS&/\
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M-9?BC_D6K_C/[H\5H^'_ /D7[' Q^Y7C\*3'$TZ***DL**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ H-)3"<4(3%-)BF%N:-V1G&<4Q7&2<
M<U 6YITDRJI(.23Z]*P[O4)I)!':1>8XZYY/_P!:K1G)JYKRW"HOWL&JINHS
MRK@YZYK.?3;ZY4--.L9/)7)/_P!:I8M(E52/-C/J&R*JR(YI=BVEW$6(#CZ5
M;CN4('S5S]Q:75N,K%D#H4^;'X&DMM7 <1R1;6Z$"BPO:6W.E:=<?*V:>D@8
MYS6?"Z3 %0#C^=68U53RJ_E4&B=RYO J-ICG@TW<A'"C\*3(]*15R1)P5^8@
M&I@X(ZU5W +CK[&I$D'J/H*+#3)]U+G-1QMN9@>U/I##-.!XIAIPZT !-***
M,T#'44@HI +10**!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !112'Z4 !Z55O]0M=,MFN+R811+U)_H*9JFIVNE6
M,EU=R!(U'_?1]!7.6&FW?B6[AU76$:.U0[K:Q;^$_P!YO?C]:8@FAU'Q1?()
M$:WT'&[!.&N/3CJ!]:Z>"&&U@6&"-4C085%&!4X  V@8 I"M CD/B 2-&MV&
M<BZ0\?C7.2V$\0@NYP&\^X4LF>=N1U]ZZ;QV0NEV9;H+R/\ K67JURCZA'M_
MU=KB0_[;GH/SQ6L=CGJBW5TL.J7,EOEAY #;1PK8.,U2M;#[-J$0EP&1#-*2
M>/\ /-71$;/0[F6XVLUUG(QU/0"H;U7U.XCM8'\M8H29I,<L!CY?TJD9VU*]
MU--J5PKHNY'RD"]-W;\N]2W5K;V5C';B/=>-\Y<]1Z_A5Z*2*&*SNQ"5@@B9
M2<_=QG^=5/)DO/*>7[U[*2/]F,?P_K1=H&D5)TNOL2W"0AD!!); '4?C4D?B
M*_CGC+;3$"-RCL*O:_<)*B6,7RQQC=(1V Z+_*L^33]FB27-P^W<C%$QV[9J
MKHAIK;8ZI]4LNBW:ENPS2K,C[G\PX/2O/WB^0,B[NXV]O<5LP>(46VBC\IRF
M &?/6DX=C2-5/?0ZF";S@2202<#W%6=P,A8L<8Z9JE!(7A5HTRF 0<U-',[E
MODY[<UF:(L @[L&E)(  //?VIOF,L8XY-("S948SZTBB5'$G Z#I[TXD$X!^
MHJ(!Q@)C)[T]\HN."!U^M [EA0 HQTH+ 5 CLPVJ,GU]JE&3C<!Q28QU+2CG
MDFF]Z0#J*;10,=3>]%(3@>] A:0FE!XII.33 -U-W4I-,8T@%9^!1NXS43$X
MH+?_ %_I3L@31'=WUO8VLES<S+%%&,LYZ"N&U'4$U)Y]3N8\Z;"A^RI(.7)_
MC([=L9]35J]W>*M3\O;C1[1P5STGD'_LH_J:B\3(&L[:Q'#WDXC [# )_+BL
MI2;=D>A1IJDN:6]C8\(PR6_AZR5AEW4NV>V23C\!73)C:.,U3MH1;0QP+T5=
MM6=W2M3S^:[;9,>G2F=Z W%+NQ18!QZ4S?2[Z0$8Q18!ZMFG U"SD=*D5MPY
MHL ^BFT4ACJ*** "BBB@ HII.*=0 4=Z*!U% &3XH_Y%K4/^N1_G6CX>Y\/V
M!YYA7^59OB@@>%]0)_YY'^=:?A\@Z!8D?\\5_E2D.)I4444BPHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHS0 449HS0 AJ-N1Q3V-1$\4T2R(MC@]C
M^=-))&<\=<4,<2COD8_&J5_="W@)'7H*M(B3LKE>]DDN9UM8N.[$=O>K=K;1
MPJ1&,GNQZM4.EP,UMY\F1)(2<GTS@?RJX@,9P.!3N2EW$E4@>U,5R1R<U:."
MG-5'^4X J2MA2N:KRV,$X8E%60\AP.<U,&P<&I00"*+LFR9A20R6<X!)",.&
M7@$_TJU'J)9."K#UZ'\JTY?*="KJ&![$9K'ET>)I_,B<H?[IY%7ON2TUL3K?
MH3PV#4XN00"6_$5BW6DW(;*%"#W!/^--&FWH4#>#CT8T61/-+L;JS*[ ;^*M
MQ[0I]<=2*YV.TOHB"%)_$5:%_/!\LD9!QT/^-*R*4K;FZ&Y#_@:GR:Q(=6C<
MB-B$8\X;-:=O-YHQP2!G@\&I:-8NY/FE!H!]J0FI*'9H!IFZ@-DTP),TN33?
MQH_&D X&G4P?6ES0,=12;A1D4ABT4F11D4 +11FDR* %HHHH **** "BBB@
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M2QFM[6,>9DY8BJVFPW$]PKOQ% PSN_B?.2?U%2R[]C2$#VUO9VK@?/(9"/3
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M[TACD6Y^_P"W4?H:Z:/ F&.F*Q-,T]=.M$52'N7.Z:0GF1N_X5LV[*6#N1M
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MY\/V./\ GBO\JECB:=%%%(L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M -;M/"+Z>QI9WCFNEFMB%CMT/EN>2YX!IL4%N)K&W&&CD/VB9VZN<$Y/^>U
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MI"/XA^5*XR3!I10#[T4 %%%% PHHHH *.]% ZTP,CQ23_P (O?X[1&M/0/\
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M3<)^!I'M;1^!!'^*TBVL"=((A_P&E<-0&H6S-A6>0GNJU/OR >1]:<"JKC:
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M.U*&#+G!IK8VG;0!#@@8ZBG+P033@!L#'O2A"W09IB2)<AN1UI-X!P:4*0O
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M)1YE8X)[B87$_P!GD?RW;&.^!6GH5I)=*QN6C-I;DED[LW7)/XU?CT*290R
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M_P"N1_G6GX=X\.V&?^>*_P J3'$TZ***184444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4&B@T )TH!S0>E(.#0(=1110,#24&DH$+3:4TE
M- !; I5;BF4=*!#RU,9Z:6[5$SCGGIU-.PFPE?@]E Y-9%Q.9E98VVQD<GU
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M#YCUIA#21Y8#V H$4I%VEG=2Q'W0:Q=8AM4M)I5MXQ(QXPO7WKHY6*)DQEF
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M5O(3MN+=26Z#?C^0-:N[(VMQZ9I1 &'S!2/H*=T"BRJ-2BVCSDDC!^C#]*M
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M3W3Z=:KZEIPSYJCY5& 3_#[-_L^_&,TT*2;6A5MUE"G*$E>2 0!_.M..)F4
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ML]*,DEQ<K]PR,NU55NA_"KUV>UOT)T^=_P!2?6/#>G.MWJ.HZAJ;;0T@<7+
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MA/())\9(3T![U*;AI3LQC/>FQP!7.1D>IIB9.D3<<\=,4KIY<9W?,>V*D64
M;0!FHY9 ,&@I%>$."6SU/0U.X+'!&!3X"DH88P5[TC2+D9Z>M AFTIP1D>M,
M*JIR3D]A4Q4D<YP:CVY.,?0T 2Q#<,&N:@_=^/=3VY+?9HR*WUE*,1W%<_;.
M6\<WSD8S;QTF%SMX666-6_.I1@ YZUG6,H5S&Q^5CQ5]SSZY%0S2.P'D<=:C
M*Y(;GCM4T:[A364JV304/C0'G%.,FU@,;B1@9/2F+)@X'>F,27!Q@@T!<H7V
MC(Q,EN"4;DHO8^WI45O<RVZK',F]%XWC@UMI(HCP2015:YM8I@2-RL?XE/\
M3I3N)QZQ)H)Q(@*/OSZ&I+QLV,X&>8V_D:YPR7.DW #*7A/(QPI_PK9^V1W6
MG3/&VX>4WUZ?G4N(XRZ,H>"\CPS #U$LO_HQJZ($$5S_ (+R_A> D8/FS?\
MHQJWN ?6DRUL/[TX'FF T\4AH?12 YI:104444 %%%% '+>.SC2[/_K\C_K6
MWCY5^E87CSG2[+'_ #^Q_P!:W00%4>U4MB&(2.]4ETS3XYA,EC;+*#G>(E!S
M]<5;(SWII%!)7FL;*YD\R>TMY9.FYXE8_F14NQ(HPD:JJJ, *, 4O(-#'Y::
M$R@^FZ>\QE>QMFD)SO:)2<_7%3. <@CC&*7.<G-03SQP1/-*ZQQJ,EV. !WR
M>U4^[$E=V,-= CA\3QZO$MO;Q16[1E8UVM(Q/5N,8 J"_P!7N=4E>RTI_*C
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MQ]3ZFK'E;>16T58\^K/GEIL*6VG:.:>H[TBJ.IZU(!5$)6%!(P *7 /WLYH
M[T[&:0"  =J">>M+R*"-W H 82.F,GUS3 @8Y+ X[4KH5'%*B$ FF <#C&/I
M3&QU!R*E*X7)J!F ;Y!N;U["@1"Q"Y+ ;>Q)[UG:BDMQ8SPQLHD9>,=#5\H2
MS;B&S^E0SQ89.Q'3WIHF2NCB'@,%G^\_=D (RL,8_.M33K;3;>S%S*XDD49
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MPO%/4'LP'UI#0\.J]F]C3@Q/8TU>OS?-3L\T#%ZCI249HR*0"Y]Z6FXIPZ4
M%%%% PHHHH *.XHH'6F!D^* #X9O\G \L\UI:!_R+]CC_GBO\JS/%7_(K7__
M %R/\ZTO#W_(OV'_ %Q7^52QQ-.BBBD6%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 'I49J2F4T)C&J-VVCGI4C5&^-ISTIHED%Q)LB#=T/Z5FZ
M81+<7%P>K<?U_K4TLAQ)$W+ =:KZ5P9T)Y&,CVP*O9&;=Y&H!N7I4+_+_A5F
M,\8%5YD)E]J0R-3U.*1?FZU(HV\$<4NS'(Z&BX#20G;--1E9LK^(J4C*_,.*
MA"A&W*.:!#YY$M;9YWQM49JGI=J-IN)/OG('Y\_K3M3E L@&P0S?,#Z5<MD\
MNUBC[A1GZ]Z?06EQ'58^!TJ)<[L=JFD Z>M(O'4=*$,7&>*=GRQ@=:B$GSXJ
M55WCKS2L,7?N&".:&'(([4Q1M8ANM/ SR* L+P.?6F-@L<\8[T[<5/(IDBDK
MD4(!APS8QGWIQ'(Z?2D1=HY)J1OG'H:=P&[!CFHF=<[/ND5("4/(S045R#BB
MX%"2RWRF11NSRW%"0N[X"E0/6KY&,#I_6G!<X'0T.3)Y5</)5(E05&5YZU*>
MI)IB^M(H-IIT:88FC..>U21#.#VH!#'E"]14.5*EAWJ>5!N]JB6->:!-"I]W
MFE/(YI'R.E-5]W%.X#6(6E094G'6FE?WF3TJ>)AC@<47&1*/7BG%UCYQ4CQE
M>5J-R%B8OC"]:0=#,OYA-=(O\(&X_6C8(P,<U7))=V/\1S5B,YP3SP,U1DGW
M+"@;1N-(\:>H_.G!@ /3M4<[@+DF@&5?*:1FSP<\4AA.X;JD20CW]Z664DX7
MMUJB;DL>V-<9J&:X_AQ0,LOK]*AD7GD&@;9-&^]@>E/?'0#D]Z1$X!%.48)W
M4 B%P!@-Z=:HS'SFVG<K9P&!K5DC$D)/ITJI%$ Q]:!6N5@TT!$4QX)X<#OZ
M&KL<*CJ WH/3_&G21B5=I&?:JJM+:ML(+P=I#U7VI!9$T[J%VCY6IT$(?#G'
MK4<C)-M=6#8'/%/AD!. <#&13&B50#,RG YXI7C0@XQFI=AR&QAJ1N%Y% -&
M?.<X*<D=:D@CQ&IQU)--VEI,C[IJTK@*HQTH%8='"JMG/X59M[C;=8/1ABJ
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M(TJSQ_S^1_UK<&=J^XK%\<C.F60_Z?(_ZUL $8)-4B&/IFW'>G9IK<T$D;L
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MUJ3 D=L?A2@4S?(.Q(IX<DX(J#0=@FEY'>DP<]*4[^PH *7\#3?WGI2X?WH
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MZ(CLWI]*O;0Q^M4M4O1:V$LIQA130GHKDD+>=!'.!\LB*^/J*4IE.3Q3-/\
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M(Y/_ (0:/_H-:M_W_'^%*G@B)1C^VM5/UF'^%=711=A9'*'P-%N!76=6&/\
MIN/\*3_A!HAG_B=:MDG/^O'^%=911<+(Y"3P%;2QM'+J^J2(W!5I@0?TKIK.
MU6SM(;:,DI$H52W7BK-%(+!1110,**** "BBB@ HHHH **** "BBB@ HHHH
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M5&,]"*9YAW9-2/TIB+UQ0 ]7=NBC%.VYZC%-C!5N>AJR"""I[T ,3'<T\H&
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MP4Y&0:8R@ $#IVJL[LY CX4'F@39+)<&-\+\U+%<,W+C]:8D0QS39%VD =*
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MK4@J#9#^U)WHI12*%I:3%&<4@%HJO<7MO:)ON)XXEZ9=@!5;^W-+[ZA:\_\
M344687-&BL_^W-*_Z"-K_P!_5_QH_MO2]V/[0ML_]=1_C18+FA16?_;FEG_F
M(6O_ ']%']N:5_T$+7_OZM.P7-"DJA_;FE_]!"U_[^K_ (TAUO3, G4+;!_Z
M:BBP7+Y&:2J/]MZ9_P!!&V_[^C_&D&MZ9GC4;4_]M5HLQ71>;[II@  JFVM:
M9U.H6W_?U:C&NZ7DC^T;4@=29EIA=&AMR<T[/%9YUS3%&?[0M0/4RKBHWUO2
MV&#J-KSV\Y?\:+"NC35N*8TF#68->TP9QJ=F1V_>K_C3?[>TL\-J-ID=?WH_
MQIV8N9&PCAA3@V>/2LB'7=) P=0M@?>4?XU(==T@G(U*T_[_ "_XTFF--&EG
M% ;-9AUS2@.-1M,G_ILM)'KFE-G.HVO'_39?\:-0YD:PI1Q68NMZ6"?^)E:G
MV\U:?_;FEX_Y"%K_ -_5I:CNC1Q0.M9_]N:7U_M&V_[^K_C2_P!N:5_T$+7_
M +^K_C2L,T*.U9QUW2@/^0C:_P#?U?\ &E.N:4.NH6O_ ']6G8+HOXHJA_;N
ME<?\3"UYZ?O5_P :3^W=+P#_ &A:X_ZZB@#0Q0*H#6]+//\ :%M_W]6C^W-+
MQG^T+7_OZO\ C18"_BEK/&N:5CC4;;_OZO\ C0-=THC/]H6O_?U?\: T-"BL
M_P#MS2O^@C:_]_5_QH_MS2O^@A;?]_5_QI6"YH45G_VYI7?4+;G_ *:K_C1_
M;FE]M0MO^_J_XT687-"BLXZ[I0!)U"VX_P"FJ_XTO]NZ5_T$;7_OZO\ C19A
M<T**SQKFE'IJ-K_W]7_&@ZYI7_00M?\ OZO^-&H7-"BL_P#MO2_^?^V_[^K_
M (T?VYI77^T;7'_75?\ &BS"YH45G?V]I.,_VC:XSC_6K_C2_P!NZ2/^8C:_
M]_5_QHLPN:%%9PU[22<#4;7U_P!:O^-+_;FE8S_:%MC_ *ZK_C1J%S0HK/\
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MX?!S_9-O_P!\BMRBBX&*/".@#II5N/\ @-*?"FA$$?V9!S_LULT4[@8A\(:
M00=)M\'_ &13O^$3T'_H%P?]\BMFDQ[T7 Q_^$3T$'/]E0?]\TT^$?#['/\
M9-OG_=%;=% C%/A'0&/.E6Y/^[2?\(?X?QC^R;?_ +Y%;=%%QF)_PB&@8V_V
M5;XSG&V@^$- /72K<_\  :VZ*+B,/_A#?#V<_P!D6W_?(I1X/\/@8&E6X_X#
M6W10!C?\(GH0Z:7!_P!\BF_\(AX?SG^RK?/^[6WWS11<9B-X0\/OC=I5N<?[
M-*/".@@C&E6X_P" BMJCO1<#DO$7AG1K70+RX@TZ".5(R5<+R#74>'0!X>L
M.T*_RK-\5#_BE[\_],JTO#W_ "+]C_UQ7^5*0XFG1114EA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2$4M% #<4 4[%%,0TGK3#TJ0CK
M3.U"!D+K5>1005[-UJRQZU4E;!JD9LP[&3RM8B5NCH8R<]\9_F*T+*5'O;R1
M2#\X3/T45BW<X348U_NR,>/J:U-"B)LY')YDE9N?KBKD90>IJ!B_(IQC+1D'
MK48;RC@TXN<[L\>E9HT(S&56HF),1/7FIY'+4P !,&J @$H?H:<T@S@<T[R4
M!S3]G' !IDD0W$C.<5-@%.E-9 RD'.:J&::T;?(/.M^[CJH^GI0!9<E.G(JM
M/=*X\N,G)ZYI+RZ4(OE."9!D$>E4$!+ @DA>*:0FRTL8C&<9/7/K2+/NDV\X
M[CTJ&2<J#S[8J.VD\QB>F#S3L1<M3R'9A<U!#(%P7;Y6' I\\R)_%BJD!#S$
M@9SGBFA-ETLV,!:41EUW#K2RE8U&#BH_-=N(S@>M ["&V0@]QW]JIK!-:.3$
MV]&_2M &0#.1[U#UE#9^4=10)Q(GGD155H7 ')I1=NV<0.?0FK,Q67@\#UIB
MJJC;GI1<5F5)9[U^%MAM[C>*=:2RQR_-$QCZ$ @D5=PH7=@^F<5!*%C.Y?O=
M,=,T7'8LDQ.Q,;?,.H(((_.JTLKDX;H>A%/V;H@'^5A]UAU'^-5W;?D@_2@+
MV+$<:LH.<TXN(\*.M5T?8HZ@U&UR=X!Y]Z!EXGC/>JI5F=EZ9Y%654>7\_I5
M9Y5+J <]CB@191QM4+R:<@9V.\8%);%&7Y.2*8]PBL3GGT% [D_E MM(Y[5#
M<6V%^4X-/BF^7>[@#M5"[N7N3Y"9!/<=Z!7*K,]Q+M0;E4DDU?CG51M!R![4
M^VMTM[;9P6/+$4+'&.<GK38*/4<9]J97J>U0J)'?.2I]:L(JL3@9%*R H0:0
M)LGB=)(MC9##VJK<F6),+R*6'>9MX7@#'7K1,Y#8(S[4BBG&#(Q+G%6M@10W
M3%0<A^1\N:623@X/'I3))8Y-[GDD4Z1W X%0VAW<@=*GGD5/FR,^E TQ8IE3
M.\_>&0*5KAF.%3I[U4@!E9B.N.<U==4BC#9 ^M%A)DJ)N4,/RIIA^?<N,=ZB
M6X9SMC8#%2-*R*6SD=Q2&RA>DHAPV>:CB8) @?(P2?UI]P,ON;[N2,>E6/(5
MDC!]!39+0V*?!SV/2I;9GEN]X'RHN?QIFU4&% W>E:%G&%B+;<;C29<46(\-
MC/UI74#I32=K_6GMRM2:(9&V[AJF"*2>X%0#Y#BI-V/8]J0R7S0HQVHWJ>:K
M-( PSR>]2@Y4X':@!&;<V*"J@=13'QN )_*G(!G!&?2@ (R>*38<\BG XSQS
M3ADC- #3'M]JP=-/F:@Q'((X/_ C6IJVHPZ;ITDUQ,D?& 6..M<AI^JZC?MY
M.B6>=S_/=3#"J#@?+_/\::^$E_$=U=ZA9Z;#YE[<QP)ZR-C-94FOWFH1'^P=
M-FG+?=N9U\J+Z\X)'T%-T_PG#%)]IU.=]1NCT:;E5^@KHXT5%"*H51P *DT.
M9M/"US?S?:O$5W]JDR"L$?RQ)_4_G740V\<$8CBC5$'0*,"GJ,4\5+*2#% I
M:04BCE_'(SIMF!_S^1_UK;'3\*Q?''_(-L@.IO(_ZUM<@"J1F]PHHHH 0]:3
M%*:*!"#K2,*#[5&2:8",2!S43MA>:>7R<=ZAD;)P,>],38QV8=.15&[*6\3S
MLX0KU'6IY),$#HS'N?Y5SVI:S'YLEI#$96Z2%CTJXKN92E9&1JM]+-/&WV8H
MR<9+=15RWTN[>)9S"9$/.(Y "?IFGVEO+J-JQ$*"5/E8,>AJ2TENK'Y$=<@\
MPN?Y5;=M$8)7=V36^H7,,GE[T+=HYOD8?GUIU^&,GG30FV/!\Z(Y4$'N!FHK
MN?4;I'6;2U,8'!)^8CVXJ*&TDG0+:ZE* V1Y3KR/;KVI&C)H5N]11IO-AN$Z
M*H&"!^)J.*[O+.<0*6BP.0_/Y5#<)/9EVF4C;T>,<'ZU1N;N6XPTD_S \87F
MFEU)<N78U8(XKB^$3OM63+94=#C-=-%!&D2I&GR#H=IK/T;2X884N QE9E!#
M,,D9'I6XJ!<;3CVK.3U-HQLKC4+*, ;A[GFI0W&,8I0 W7.:>%P.@J#1# ":
M>$P<TN,4ZD,4=*6D%+0,**** "BBB@ HHHH **** "BBB@ HHHH ****8!11
M12 **** "BBBF 4444@"CO10.HH R/%//A;4/^N9K2\/?\B]8?\ 7%?Y5F^*
M>/"^H?\ 7(UI>'?^1>L/^N*_RHD.)IT445)84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !4;#%24QJ:$RNU59QGC./>K;CF
MJT@'?I5HS:.3O+-[C4[ED< @C /TKH-.S!8Q1D= 3GZFLFZ/EW=US\W&./7%
M:L2M&J(QX  JI&,-V6 "QP:D R#35=2??M3\DC..G6I-2/&#S2;L\=Q3V8,*
M15'7O0!&02<"IXR%3!IAP#2-D#(H ?)@KP<5"&$0R!\HZTX#<.:@NCMC*?WJ
M:$S-:!HYFN(QF-CN,8[>X]*ECQ*@DC<%6&2/>GAAD>PJK*C6Y:X1<1-PX';W
MJS*Y'<H,DYZ=:;&/+CX/+<U(L7G.6+Y! (J62,*0 !P*"60) TAR_2IC&MNN
M]>U*LG:HKD$E<="*!C4!DD+'OS5N, , 3FJ\(\OMQZU81<-G.5H8(FD3C*]*
MIRD1,,#&[KFM#S,+CM525?,D"X!%(9 I<#YONTZ*-MX[J>]60B*N"<_6F*RA
MBHI@/;:J 5!N4NV>HZ4L@)!'K44*$M0!*P+C(XQ2&)6X J<J(T(:H0-I..]
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M,_\ /%?Y5F^*CCPOJ!_Z9'^=:7AXY\/6'_7%?Y42'$TZ***DL**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***#0 9HS249IB$S244G:F(
M8XJNZ\&K)J%Q\M")9S%PCRZK,!S\Z@?EG^E;/5MIK.3G6G'HQ8_AQ_6M)1ND
MSZ5I(R@*B^O%2,V!BHI7(' /X5&'8CGI4EBM)AP*E4AAG/-,\K*@GJ:13M.*
M8 V0X]*EW_+C(J%_F7WI%4A=H[T$CSDMQ4-T=SHG?!J6-BIVFJEP^+@!NN*
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ME%:#"F#P*C,84<?E5D$$TC(&I%6(FD#*!WJ!D8\YZ5,8U!.2*3>!\OK1<"
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M=F ..PH0C2,Y _G5&6Z9G^0\U)EFYQ^&*3R5 RHY]Z&!/!(S+NDQTYI)&##
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M*** "D)Q2T&@"+>#0:-@'2C%,DADROS ?A5624"$[CU/S5>?D8'6J<\6_P!
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MZS9T)CP*=FD6EI##-&<TE*!0 X4M(*6F,,T4W)W&G"D(****!A1110 4444
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MTH?)Q36XIH- R<&EJ)6J0'- "=S3J:>M%(!U%-S10,=1110 4444 %-IU-H
M*44E':F(4\"HV/RM2L<5%(W% "EL"HV8D4CMQ@9SVJO+<Q6Z;I940>KMBFD2
MVENR9,@<G-29K)_MW20P3[?%GOU%7+6^M;L$P3QR ?W6!IM,E2B]F7>I%.!J
M+?@9IP<GK4FB)@<T[^(5&OS5)CFA@8_BH9\+:@/^F1_G6IX>7;X>L%](5'Z5
ME^*FQX:O_P#KD?YUJ>'SGP_8'J/)7^5)[%1W9IT445)84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4AI:*8AM(>:<>E)0
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M45Q;E?N# IL2'&>0:;$237"\*#R>_I2P.6<(_P I'<=#3!;C<V[H:,>4-N>
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MZYN"\6+4Y;&%&N48ESL'W#Z&I_%FHB#2I3!)Y<S8V@=6^E7],TZ*RT^'R8@
MR*9&!Y+8Y)IK1$27/*RZ%6TL[J;4([NXA\F*(GRX^Y]SZ56\6X6^\/Y')O3U
M_P!TUU$<626/?BN>\81JM[H&<D_;3@_\ -0W=FT(J*T.M"X-28IO>GU+-4-[
MTHZ444@"DS0>E)3 #ZTT].*?UIA&SGJ* .1\>R,ND6N[ 'VM#^AKG+BZN-2U
M=-EN=VP J.<@=Q71^/V/]CVK+SFZ08/T-<Y;R3Z9K(E9 KH"?+8<N".Q^E;0
MV.6MK(MVUW):7)(BWI%Q,&ZJ#WQ4U]I^V,WMH%82#)C P'!JS/;+JT O[%PL
MZ_+@]#[$=_\ Z]9D,1D@E^R7;6P0Y>&49VG/8^F:=R-=BQ8">2(/I]T1M/SP
MN,[#_A35#B_,-Q+]CN6YQ$?DE]\>M0O;&"=9;N1)HYL?OHA@K]:?<Z9=*H;S
MOM-IV_OQ^X-/<-A=2CN86269PKA@([M.Y_NL/0U%/J<%W;R)<E4N%!78$SSC
MKFI4U5I[)[2<>=A<!U'WO3.>]94:HT2E%8XX*!>I%-+JR)/HA\3I.ZPK&,XS
MY8ZD?2NKLK*1(D=#&KHH4Y3O56PT]EL8E9 )%'*@\X]C6O$F(5\O(('.XY-3
M*71&D*=MQ6SL.%4-_='>DB VY?.[W'2GJ"V"P&_U'%3)DC!'/K4&NI&&8MQ\
MP]*F!^7Y@,>E 12W'6G%.*D>I6=MOS*6Q_*L_4;"VU2V*3#*]1(O#1GL0:U]
MF.U56@*R%X^G=3WJDR6KJS.9W7&FQ?9-8/VFRSB.Z/4?[W^-6HY)=*VB<M+9
MG 2XSDKGLWM[UM2P)/&R.H92.5(ZUSDZW7AYY"D1N]'88:$?>A'<C/4=>.*N
MYS3I<KNS=*)( <Y!'''6G(J1]0,UDV3"&#[7:RFXTUQD(/OPCV'<#TX_&M55
MCN(A)'(&0]"*&*W4E#@L,<&E,:S(8G (8;6![BHTC(.T]:FF9+>UDFD8!8QN
M)]A04O,RO#1(L9H Q#6\S1@YZBN@20;?2N8\-[UTR2Y;A9Y6DS[5O[MRC/4
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M#V*CN:=%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 F*,4M% "$4W'M3Z*=Q6$ I"*=24 -Q24_%)BBX#:C93FI32'K
M3$1;..U1-& ><>U3L*:0?3(HN38S;NS$L9&WV.._O61I\SV-XT$K,8W?"YZ
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MGV&2*U3.":47RMZFM!"'!]?4U4O'AL0&E+/N. JXW9^E$>KZ<8MOVPJ#TPK
MG]*KRWD#3!M/TR6[N^@E96R/^!-S0-)->8RXGDTV"2^NE5KN7]W D9R$&>.N
M#]:G\,::T%HUV[#S)23D]<U+I^@W=U<"[UAE+KG;$O 0?A6^856,(B@*. HZ
M"I;1TTJ=O>9(I  4#'%2;CTJO NU0.3CC)J<KG'-9O8Z;F3XF?/AR_&,_NJU
MO#V5\/V!_P"F*\?A61XF4_\ "-WY'7RC6OX?S_PC]AW_ '*_RH>PXFHK9%.I
MHZBG5!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC9!WH0F-P'7&*<K$* 1P*>@48(IP !/O3$&[>!CI2*I7!IPR%(%*JGC-(H0
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M#)X\HUI>'N?#UAC_ )XK_*A[#B:=%%%26%%%% !1110 4444 %%%% !1110
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M_P"S@4D?AR.,Y;<_^RSDC\L5T&:":.9C5.)GI96\("QQK@<$%1BE:.-<!8U
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M?RH6ZYM[@]G;L/\ 'O\ R)FF?]?5O_(UW5</X]BF;P9I_EP2R-'<0.R1H6;
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M "8]Z,>]+10 F/>@+[TM% "8HQ2T4 )BC%+10 F*,4M% !BC%%% !BDQ2T4
M)@48%+10 FWWH(S]*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img183648649_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .I!G4# 2(  A$! Q$!_\0
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M/10!!]BM/^?6'_OV*/L5I_SZP_\ ?L5/10!!]BM/^?6'_OV*/L5I_P ^L/\
MW[%3T4 0?8K3_GUA_P"_8H^Q6G_/K#_W[%3T4 0?8K3_ )]8?^_8H^Q6G_/K
M#_W[%3T4 0?8K3_GUA_[]BC[%:?\^L/_ '[%3T4 0?8K3_GUA_[]BC[%:?\
M/K#_ -^Q4]% $'V*T_Y]8?\ OV*/L5I_SZP_]^Q4]% $'V*T_P"?6'_OV*/L
M5I_SZP_]^Q4]% $'V*T_Y]8?^_8H^Q6G_/K#_P!^Q4]% $'V*T_Y]8?^_8HJ
M>B@#Y%HHHKVCQPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#V/X(RYL]9B_NR1-^88?TKU
M>O&_@C+B^UB'^]'$WY%A_6O9*\O$?Q&>EA_X:"BBBL38**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#Y%HHHKVCQPHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TKX+2X\
M47T7]ZR+?DZ?XU[A7@7P@E\OQP%S_K+61?Y'^E>^UYN*_B'H8;X HHHKG.@*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#Y%HHHKVCQPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#L/A=+Y?Q"TT9P'$JG_OVQ_I7T57S3X E\GQYH[9QF?;^8(_K7TM7
MGXM>^COPOP,****Y3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^1:***]
MH\<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH U_"LOD^+]&DS@"]AS]-XS7U'7RAI<OD:O
M93#^"=&_)@:^KZX<7NCMPFS"BBBN,ZPHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /D6BBBO:/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** %!*D$=1S7UM$XEB20=&4,
M/QKY(KZKT27SM TZ7^_:Q-Q[J#7%C-D=>$W9?HHHKB.T**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/'*VU#YJ-DXST4FMN:.US+E>]C=M/A5XCO-'CU&/[(HDB\U+=Y&$I!&0,;<
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M2*2M6D>#^)?^1JU?_K]F_P#0S676IXE_Y&K5_P#K]F_]#-9==D=D<<MV>N_
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M-A'>W2N-T;Y.$YR0H(+'IP#WKSG_ (7'?Q6EU:ZAI @U 1LJ/&2H23'&Y&Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2?Q4M-_CH =1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?(M%%%>T>.%%%% !1110 5[=\+==T?3_!JP7N
MJV-M-]HD/ES7"(V..<$UXC16=2FJD;,TIU'!W1TWQ!NK>]\=:G<6L\4\#LFV
M2)PRM^[4<$<'FNE^#^J:?IE[JK7]]:VBO'&$,\RQ[L%LXR>:\THHE33AR JC
M4^<]&^+VI6&IZQISV%[;7:);D,T$JR!3NZ'!KSFBBG"/)%1)G+FES'T7X?\
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MK2ITH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,)^<T^HF/[PT 2T4#I
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?(M%%%>T>.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 :ND>)-9T$M_9FHS6ZMR44Y4GUVG(S[
MXK8;XF^,&7!U@X]K>(?^RUR5%2X1>K12G):)EW4M7U'6+@3ZC>SW4@Z&5R0O
MT'0?A5*BBFE;8EN^X4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "I[&7R+^VFSCRY5;/T(-044 ?75%16LOGVD,W]]%;\QFI:\4]@
M**** "BBB@ ILG^K-.IDO^K- #8S4M0QFIJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@".7[H^M$9XHF^X/K21F@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *A8
M_O34U0/_ *TT 3+TI::G2G4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'R+1117M'CA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!]4>'I?/\-:5-_STLX6_- :TJP?!,OF^"=&;TM(U_(8_I6]7CRTDSUHZQ044
M45)04444 %,F_P!4U/J.;_5-0!'&:L#I56.K(Z4 +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!%/]P?6FQFG7'^K'UID= %BBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *K2?ZXU9JK+_KFH GCI]1QU)0 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_-M&?4  >W2K/P?_ .1W/_7I)_-:NWNL:GH?Q<UF^TS3WOV5<3P(I),1"9/
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M S$J.>3S67MX^U=-]">=<SB:=%(K!E#*001D$=ZKS:A96\GES7EO&_\ =>4
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M=9139)(X4+R.J(.K,< 5%#?6ERVV"ZAE;TCD#']*RY6U<W<HIV;U)Z*9+-%
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MD?'\78?UK$OCI!LXQIUK?1W2$$R2#AO_ !XX/TKLO$F@G6;>-X7"7,.=F>C
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M73@Y*-:+D[+_ (!P9G"4\+.,5=Z?FC,UNWDT#7HM3ME_<RMEE'3/\2_B.?\
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M_E3%EGO_ (%2RZN[R2&V8J\OWFQ(?+)/X+SWJ8U9V4GLW8J5*%W%=%<\XN_
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MZ_&C5HU=A&;F[)4'@X9L<5/M)M279#]G!.+[E?QQ\-;JPFU+6;$V,&E1!72
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K!UK0);^\BOK.X6&ZC 'S#@XZ'ZUO45=.I*G+FB95J$*T.2>QS$^C:
M]J*>1?:E ("?F$2]?T&:Z"SM(K&SBMH<^7&,#/4^]3T552M*:Y7HO(BCA84I
M.:NV^K=V%%%%9'0<I<>&M3U"\S?:@K6P<E5#$D#/I@"NHAA2WA2&)0L:*%4#
ML!3Z*UJ5IU$D]D<]#"TZ+<H[OJ]0HHHK(Z HHHH **** "BBB@ HHHH ****
M "LVY_X^W_#^5:59=U_Q^/\ A_*@":*K<?2J4578^E #Z*** "BBB@ HHHH
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M7/+3R+FK7W]IZQ?:AY?E?:KB2;R]V[;N8MC/&<9JG115)6(>H4444P"BBB@
MHHHH **** "BBB@ HHHH **** .J^&TOD_$'26SC+NOYQL/ZU](5\Q^"I?)\
M;:*WK=QK^9Q_6OIRO/Q:]Y'=A?A84445RG4%%%% !4%[_P >C_A_.IZKWO\
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MTK2;VUE26WNX+Y=T94]#B-201QR:]2H J:A_Q[K_ +X_D:J1&K>H_P#'NO\
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M%>A?#"TN+#QW=6EU$T4\5I*KHW53\M<;I&B:EKMTUMIMJT\JJ78 A0H'<L2
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M(=B1M.<]^X%0H.RB]D_PL7SK62[?J=A_PBUO;_%6:\DVC2(8CK&_^'9U'/\
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M5G'W@F0=V.F>!FH+3_DL^H?]@:/_ -&5RG@[3]*MK.[TG6?$>I:7JEE=2I+
M-4:V1P6R'5<@$'/4?UH ]-\/:];>(])2_MDDC^=HY891AXI%.&5O<5J5S_A#
M3]$T_3+@:%>&\MYKIY99S/YV^4@!CN[]!704 %%%% !1110 4444 %%%% !1
M110 5C7I_P!.D_#^0K9K&O?^/^3\/Y"@!\1J]%5"*KT1H LT4#I10 444A(
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M--3T][>;7O#,VFZ?<2+$+H7:3&-F^[YB  J/?G%7=8\475IK8T71]'?5-06
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MU0Q5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6#?\ _(1D_#^0K>K!U#_D(R_A_(4 /BJ[%5&*KT1H N)TIU-3
MI3J "BBB@ HHHH Q?^$?_P"*W_X23[5_S#?L'V?R_P#IIOW[L_AC'XUM444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MD:]IVK:C#%'I>M_V7C(E86RRLX/H21M(YY]ZUZ* ,W0=$M/#NC6^F60;RH@<
MNYRSL3DLQ[DDUI444 %%%% !1110 4444 %%%% !1110!\BT445[1XX4444
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MF*MU4U/_ )!\OX?S% &-#5Z*J$57HNU %^*K%4&NX;8?O7P?[HY-59-=YQ%
M2/5S_2@#9HK .N777RX0/<'_ !K.N/&A@)55BD;T13C\\UG4JPI*\W8F4HQU
M;.PHK@7\=WQ/R6MN!_M;C_6F?\)SJ?\ SPM/^^&_^*KC>:89=?P,OK-,]!HK
MSW_A.=3_ .>%I_WPW_Q5'_"<ZG_SPM/^^&_^*I?VIA^[^X7UFF>A45Y[_P )
MSJ?_ #PM/^^&_P#BJ/\ A.=3_P">%I_WPW_Q5']J8?N_N#ZS3/0J*X!?'6H
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M_?#?_%4?V?6#^VL+W?W'>T5P7_":ZE_SQM?^^&_^*H_X374O^>-K_P!\-_\
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M.D,C0Q8$DBJ2J9Z9/09P<5%3LF[BNTK&K'X@NX_"\OA\1P_9);G[2SE3OW8
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M_=].]"48:+J#YI:LP:***LD**** "BBB@ HHHH **** "BBB@ KM/A5+Y?Q
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M\BJOF4>91RL/:(M8A_YY1_\ ?(HQ#_SRC_[Y%5?,H\RCE8>T1:Q#_P \H_\
MOD48A_YY1_\ ?(JKYE'F4<K#VB+6(?\ GE'_ -\BC$/_ #RC_P"^157S*/,H
MY6'M$6L0_P#/*/\ [Y%&(?\ GE'_ -\BJOF4>91RL/:(M8A_YY1_]\BC$/\
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M*.;0C^ZY']: +M%%% !1110 4444 %%%% !1110 4444 ?(M%%%>T>.%%%%
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M[=WSH]W=37#1H(T,LA<JHZ*,]!R>*@HIDFA::[J]A (+/5;ZVB'/EPW#HOY
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M[L*U%\2:ZD(A76M16(# 073@8^F:RZ*&D]P3:V%)+$DDDGDD]Z2BBF(****
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M:QH;V[M/;*6B/)0=5_\ K5AU]%2JQJQYHGQ&(PU3#SY*B_X(4445J8!1110
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M\J#W]_:O:_#V@6NB6"6MLN>[R'J[>IKGKUE!66YO1HN;N]C7M(51555"JHP
M!P!5\# J.)-HJ6O-/1"BBB@ HHHH *0F@FGQ0M.>.%[F@ MH?.EW'[J\_4UI
M4U$6- JC %.H **** "BBB@ HHHH **** "BBB@ HHHH ^1:***]H\<****
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M^?7_ ,B+_C1_PCVJ_P#/K_Y$7_&O3/LP]*/LP]*7]D4.[_#_ "#ZK#NSS/\
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MT*_\J^Y_YA_8N$_G?WK_ "//_P"P=3_Y]O\ Q]?\:/[!U/\ Y]O_ !]?\:]
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MO0-UK_SWB_[[%&ZU_P">\7_?8H_M"O\ RK[G_F']BX3^=_>O\CS_ /L'4_\
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MWV*/[0K_ ,J^Y_YA_8N$_G?WK_(\_P#[!U/_ )]O_'U_QH_L'4_^?;_Q]?\
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MO[GZBM"B@#/^SS?W/U%*+64]0!]35^B@"LEF@.7.[V[59  & ,"BB@ HHHH
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M!*UC(HK3L5.D:]"NIZ0]PT38>QG#1LY(^4$8SU(.,<_C7HWAZ.7Q%J@TS5O
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M("]!UR,4S5%N(-2NI]0EU-;$X,,UE*0L0 YWJO/7G."*T8O#MNCP^;=WMQ#
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MT/8=<XZ\>E;6I7#:=HMU<1AG>"!F7/)) XS_ %I8M.AAU2XU!6<RSHJ,"1M
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M=8RZ_H12TE'I^IZ?1117 =P4444 %%%% !1110 4444 %%%% !1110 4444
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M:W@D2:*XD+KC8QX!X'([=J)3DKV6PE"+M=[G 06\UU.L%O#)-*YPL<:EF;Z
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MY)J*MC$****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP3CJ*[&BCZUY!_9_][\/^"<=178T4?6O(/[/_O?A_P $XZBNQHH^M>0?V?\
MWOP_X)QU%=C11]:\@_L_^]^'_!..HKL:*/K7D']G_P![\/\ @G'45V-%'UKR
M#^S_ .]^'_!..HKL:*/K7D']G_WOP_X)QU%=C11]:\@_L_\ O?A_P3CJ*[&B
MCZUY!_9_][\/^"<=178T4?6O(/[/_O?A_P $XZBNQHH^M>0?V?\ WOP_X)QU
M%=C11]:\@_L_^]^'_!..HKL:*/K7D']G_P![\/\ @G'45V-%'UKR#^S_ .]^
M'_!..HKL:*/K7D']G_WOP_X)QU%=C11]:\@_L_\ O?A_P3CJ*[&BCZUY!_9_
M][\/^"<=178T4?6O(/[/_O?A_P $Y:TM)+J9553MS\S=@*ZFBBL:E1S9U4*"
MHIZWN%<[J7_(3E_#^0KHJYW4O^0I+^'\A61N+#5Z&J,-7X: +T7W:DID7W:?
M0 4444 %%%% !1110 4444 %>,^(_!WC!_'MWK>C6&1YPD@F\Z'LH&=K-_,5
M[-16E.HX.Z(G34U9GC5SX1^(OBIHX->O%AM@<D/)'M'OLCX)^M>E:'X7L-"\
M.G1[<,T3JPFD/#2,PP6/]/0 5MT43JRDK;(4:48N^[/%M*\'>/?".JW)T2&W
MFCE&PSEX]K*#D'#$$&K:^ _%$?CK2M:O&6_9I8Y[V=751&P;E0"02 H7&!7K
MU%6\1+>R)5"*TNS \:Z9#JW@_4K:9E0+"94=N K+\P.>W3'T->5_"'1VU'Q-
M+JDR[HK"(!"1QO8;5_)0WZ5UGB[P3XI\1:W=&#6XXM'G*8MGFD^7"@'Y ,'D
M$]>]=9X5\,VGA31EL+9C*Q8O+,PP9&/?'8>@JE-0I.*>K)<'.HFUHC;KB/B5
MIGB/6-*MK'08VDBD9OM:K*B;EXV@EB..O _&NWHK"$N5W-I1YE8\0T;0/B=X
M?MFM]*LTMHW;<V#:L6/NQ))_.NMT[0_%7B/PSJ^E^,'\MYO+^RR8A.P@DY_=
M^X7KVS7H5%:2KN6ME<SC12ZNQX]IFB?$SPO;/INEQV\UH'+*P>(@$]2-Y!YZ
MX(K?\ ^!=0T74[G7-;G634;@,-BMNP6.69CW)([<<_EZ%11*M)IJVXXT8IIW
MV"BBBL34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^1:*
M**]H\<**** "BBB@ HHHH **** "BBB@ HHHH [_ ,4ZAX:\66T6L-K,MEJ<
M=GY;6+6CR"1US@!QP 2<9Y[=*RM6UBPN?AYX?TJ&?=>VDL[3Q;&&P,[$<D8/
M!'0URM%9JFE9=BW4;N^YV?A+7-)C\.:QX=UBYELH+XJZ7<49?:P(X(')' _6
MMCPSJ/@SPG=SM%K$]_<7-N\1NC:O''$N,[=O))) YZ<=N_FE%*5).^NXU4:M
MIL=5X;UBPT_PEXHL;J?R[F^BA6W38QWE2V>0,#J.N*J^!]2M-'\8Z??W\WDV
ML+.7?:6QE& X )ZD5S]%5R+7S)YWIY'2V\?AW5=9U>35-5GL5EG9[6>. R*0
M68G<H&>F/3O6U#JGA[POX9UBQTW6I]8N-2B\D(+9H(X@006(;J>>WL/>N HI
M.%]V-3MT/4;,:/+\(=,M];DF@MY;V01W,2[S#("Y!*]QC<#]?Q&;::KX;\':
M1J)T75)=5U>]A-ND_P!F:%($/4X;G/?OR!TK%N_$-I<?#[3] 2.<7=O=M.[E
M1L*G=P#G.?F':N:J8T[WOW+E4M:W8ZS3=9T^W^&FLZ1+<;;ZYNHY(HMC'<H*
M9.<8'0]36K=ZCX9\4^&]$MM1UJ72;O3(/LY4VCS+(  ,C;TSM'^>:\^HJG35
M[DJH[6.Y\0ZUX>?P%!H.C33.UKJ(D#3(0TR[&S)TP!N; '7 %4/$FL6&H>$O
M"]C:S^9<V,4RW";&&PL5QR1@]#TS7*T4*FD)U&SJO#>L6&G^$O%%C=3^7<WT
M4*VZ;&.\J6SR!@=1UQ5KPWJNAS^#;_PWK-[)8"6Y%U#=+"TH#848*KS_  _K
M7%T4W33N"FU8M:E!:6VH2PV-[]MME(V7'E&/?P,_*>1SD?A56BBJ1 4444P"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#I/ $OD^/-';.,S[?S!']:^EJ^7?"DOD^+]&?. +Z'/TWC-?45<&
M+7O([L+\+"BBBN0Z@JGJO_(-E_#^8JY5/5/^0=+^'\Q0!APU?AJA#5^+M0!>
MAZBK=58>U6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,W6_^/-/^N@_D:RX:U-:_P"/-/\
MKH/Y&LN'M0!?AJ]#UJC%VJ_#0 S4[I[+3+BYC"EXT+ -TKE;?Q3KMVK-;V$,
MH7[WEQ.V/R:NDU__ ) -[_UR-8G@;_CVO/\ ?7^1KNH*"H2J2C=IGD8N566,
MA1A-Q33V^9+IGBY9[D6VH0"WD)VAQT!]"#TKIZXOQQ;QI-:7"C$CAE;WQC'\
MZZ*))+[PY$OG-'++;*?,!P02H.<U->G3<(U(:)EX2O652I0J/F<=4]KFE17
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M[0K75[N>T>WN71$6)V+@LI89!4#H#WI^A?#_ %?7M&DU:.:SM+),_O+N1D#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN?U#_D)2_A_(4 +#5^&J,-7HJ +L?2GTV/[M.H **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !7TG\.Y?.\ :0V<XB9?R=A_2OFROH;X52^9\/[)?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%NOX?E4PJ:)OJ5*&K2Z'"T5V.H^%--T;7],%Q=7-UHFI()+:>W55D8'& 0W
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M4H:O14 78JGJ&*IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+96V'.IS7=]SJ/BO_P C)8?]@V'^;U)8V>G:!\.[3Q&=)@U.^O)VBS= M%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HK0T?0]1U^\:TTNV-Q.J&0H'5<*"
M3EB!W%4&4HQ5@0P."".0:5UL.SW$HHHIB"BBM;1O#UWKEOJ,]M);HMA;FXE$
MK[25&>%XZ\=\#WI-I:L:3>B,FG1R/#*DL3LDB,&5U."I'0@]C3:*8BW>ZIJ&
MIE3?W]U=%/NF>9I-OTR:J444DK!N%%%%, HHHH **** "BBB@ HHHH ****
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M?R-8%=^'^ \?&_Q0HHHK8Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_D&P_C_,US5=+I7_ "#8?Q_F:Y\3\!VX#^(_3_(N5B7W_(0D_#^0K;K%O?\
MC_D_#^0KB/6'15>AJE%5V*@"R.E+0.E% !1110 4444 %%%% !1110 4444
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M5C>)O#.FV6B:?KVAW<\^F7;&+;<@"2.09X.  >A_+OFKOQ!_Y!7A#_L#P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** /D6BBBO:/'"BBB@ HHHH
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M7F]3W=[=ZA/Y][=37,V,>9-(7;'U-04H1Y;WW8YROMT"BBBK("BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K4\,R>3XJT>7LE["QS_OBLNK%C+Y&H6TQ
M./+E5OR(-)JZ&M&?65%%%>,>N%5[[_CSD_#^8JQ5>]_X\Y/P_F* ,V*KL54X
MA5V(4 6DZ4ZD7I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ]>LY0A-ZQNM;ZW]%\UJ/UGQ ;'3+2YM51Y+G!57!(QC)Z$<\BMFV,S6T37
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M.4P21GGITI>TCO<?LY'(45W5GX"TG59Y+'2O%UK=ZFB$BW^S.J.1U"R$X/U
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M[HVF+I.G);!@SY+.P[L:OT5JZK</9VLOS.>.&BJKK-MOSZ>@4445D= 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %95T/]-?\/Y5JUEW7_'X_P"'\J 'Q5<BZ54B%7(^E $E%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R+1117M'CA1110
M4444 %%%% !6E/>Z7) Z1:1Y4A&%?[2S;3ZX[UFT4T[$R@I6;_-A1112*"BB
MB@#UKQYXI;1-:L8$T71KQOL,4@GO+7S)%.6X#9' QG\Z\]\0>)]4\2W$<NHS
M*5B!$4,:[4C!ZX'X=Z;XA\0W?B2^AN[R.".2*!8%$*D#:I."<D\\UDUE3IJ*
M5UJ:5*CDW;8[KX@L3I'A!<G:-'B('OM7_ 4NF_\ )%M9'IJ2?RCKF=8\07>M
MV^G0W,<*+I]LMM$8U(+*HP"V2>>.V*6#Q#=V_ABYT!(X#:7$XG=RIWAAC@'.
M,?*.U+D?*EYC<US-^1T]]H_A[PAI&ER:KIT^K:A?PB<I]H,,42G' *\D\X_P
MJ[XIEMI_A-H\UGIITZW>_9DM_-:3 Q)SN;DYZU@6?C[4+?2[;3[K3M)U**U7
M; U]:^8T:]@#D>WY55UKQGJVOZ;]AOS"T0N?M"%4VE/EVA%YP% [8SGO24)7
M5_S*<XV=C<\<N_\ PA?@N/<=ALW8KGC.$YIGP\=H]-\6NC%772)2K*<$'!YK
MF]5\0W>L:;I=C<1P+%IL1BA,:D,P./O9)R?E'3%)H_B"[T2WU&&VCA==0MFM
MI3(I)56&"5P1SSWS3Y'R<O\ 6Y/.N?F_K8UOAK_R4+2?]Z3_ -%M6?>$GQQ<
M$DDG4FR3_P!=*J:'K%QH&LV^J6J1// 2564$J<J1S@@]#ZU#)?RRZH^H,J><
MTYG*@';N+;ORS5\KYF_(GF7*EYGHVM^&T\4_&74[&:=H8$BCFE9/O;1%&,+G
MODBJ7AW4?"]QXMTVUTOPG*S_ &J/RKF6^DWKA@=Y0<< 9QTXKG9/&>K/XN?Q
M+&88+Y\;EC4^60%"X().00!WZUH'XD:G'(9;+3-'L)W8-+-:6FQY.<D,V2<'
MO67).R7EW-.>-[^?8ZWP^P'QD\1H"!*\$ZQ<\ELH>/P!KR-T>*1HY$9'4E65
MA@@CJ"*TKG7[^X\12:['(+>^>7S@T.0%;VR3Q['-;[_$K4I)#.^D:&;PK@W9
ML_WI]]V>M5&,HZKLB7*,M&6KK]_\$['[-EA;ZDWVK;_"2&P6_P"^D_,4GPD6
M0>+I9^EM%:2&X8_="\=3]?Y5SF@>*-2\./+]B>-X)QB:WG3?'(/<?CVJ_J'C
MO4[W2Y=-MK33M,M)O]='I]OY7F#T/)_2DX2LXKJ-3C=2?0W?AS-9V_AGQ9/J
M$+S6D:6SR1+C+@,YV\]CT/M4/Q%MI-46R\46,SW&D742QHAQ_HK 8,>!P!P?
MQS[9Y73?$%WI>D:IIL$<+0ZDB),SJ2RA22-N" /O'J#4ND>)[S1],OM-6&WN
M;&]7$L%RK,H/]Y<$$-TY]AZ"GR-3<T'.G!19T.I?\D7T;_L)/_*2E\<D_P#"
M'>"UR<?8W./P2N9G\0W=QX8MM >. 6EO.9T<*=Y8YX)SC'S'M1JOB&[UC3=+
ML;B.!8M-B,4)C4AF!Q][).3\HZ8H4'=/S8G-6:\D='H1/_"I/%0SP)[8@?\
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M 6XA4]0QU-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %9ES_Q]O^'\JTZS;C_C
M[?\ #^5 #XJN1]*JQ"K:=* '4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?(M%%%>T>.%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?0?PGE\SP%;+G_5S2K_X]G^M=O7G?P:EW^#KA,\I>N,>Q1#_C
M7HE>36_B,]2E\""H;K_CV?\ #^=35#=?\>[_ (?SK,T*<0JY$*J1BKD8XH E
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH K7O^I7_ 'O\:KQ"K-Y_J5_WJ@C'2@"U&.*E
MJ.,<5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9UP/\ 2G_#^5:-4)_^/IOP
M_E0 ^,5:7I5:(5:7I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'R+1117M'CA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'M7P3ESHFJ0Y^[<*V/JN/Z5ZA7D7P0EYUN(G_GBP'_ 'V#_2O7:\O$
M?Q&>E0_AH*BN?^/=OP_G4M(RAU*L,@UB;%&,5<CZ4"&,=%_6G  =* %HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH KW?^J'^]448Z5;=%<889'6D$2#HOZT *G2G4@ '2
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J,__'RWX?RJ]3&AC9BQ7D^] $,0
MJR.E-$:CH*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?(M%%%>T>.%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>H?!.7&M:I%_>MU;\F_^O7M5>$_!J79XQN$/\=DX'UWH?Z5[M7FXG^(>CAOX
M84445SFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'R+1117M'CA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% ';_">7R_'MLO_/2&5?\ QW/]*^@Z^;_AM+Y/Q!TEB>KN
MOYQL/ZU](5Y^+7OG?A?@"BBBN4Z0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D6BBBO:/'"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** -[P5+Y/C;16SUNXU_P"^CC^M
M?3E?*WA^7R/$FES9QY=Y$WY.#7U37!BU[R.["_"PHHHKD.H**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Y%HHHKVCQPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6VE\
MB[AF'\#JWY'-?6M?(M?65C+Y^GVTO]^)6_, UQ8Q;'9A.I8HHHKB.P**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#Y%HHHKVCQPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KZF\,R>=X5TB3^_90G_QP5\LU],^!)?.\#:,V<XME7\N/Z5R8M>ZCJPOQ
M,Z&BBBN [@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /D6BBBO:/'"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OHSX92^;\/=+)/*B13^$C?TQ7SG7T!\(Y?,\"QKG_
M %=Q(OZ@_P!:YL4O<.G"_&=U1117G'>%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\BT44AKVCQ
MPS1FBBF(,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9
MHHH ,T9HHH ,T9HHH ,TM)2TAA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7N?P7DW>$KR/NE\Q_ HG_UZ\,KV?X)29TO5HO[LR-^:G_"N?$_PV;X;^(>
MIT445YIZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'R+2&EI#7M'CA1113$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2TE+2 ****!A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>M?!"3$^MQ?WEA;\B_^->2UZ;\%)<>(=1AS]ZT
MW8^C@?UK'$+]VS6A_$1[;1117EGIA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?(M(:6D->T>.%
M%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %+
M24M( HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z#\')?+\:R)_STLY%_
M\>4_TKSZNT^%4OE_$"R7_GI'*O\ XX3_ $K.JKTV:4OC1]#4445Y)Z@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'R+2&EI#7M'CA1113$%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !2TE+2 ****!A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %=1\.I?)\?Z0WK*R_FC#^M<O6WX/E\KQGHK?]/L2_FP']:F:O%E0T
MDCZ?HHHKQSU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /D6D-+17M'CB44M% "44M% "44M% "
M44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "4M%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !5[19?)U[3I?[EU&W/LP-4:?$YBE20=
M58,/PI/5#6Y];T4BL&4,.A&12UXQZX4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R+1117M'CA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]7Z7+Y^D64W]^!&_
M-0:MUD>%)?.\(:-)G)-E#GZ[!FM>O&DK-GKQU04444AA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\BT
M445[1XX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?2WP_E\W
MP'H[>D&W\B1_2NDKD_AI_P D]TG_ '9/_1C5UE>14^-GJT_@04445!84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img183648649_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +3!&P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2R>5"\A!(12V!U.*\.\
M/7'BSXHW%_>1^,6T6.";$5E:DA@N,C(5E)'N2<D&O;KNYCL[.>ZFW>5#&TC[
M5+' &3@#K7D$?P^\(>/_ +1KOA74[G3I1*0X1/E63KG8<,N<]B!26_\ 6@^A
MT?@2;QM8ZY?:+XFCDO+*,$V^I%0 Q&.,]2"#WY!'6NCUWQMX;\-3"'5M6AMY
MB ?* 9W /<JH) KSOP1K'B'PY\2)/!.K:H=5MS&6CE9BS1G;O')Y''!!SVQ4
M7PPT^P\1>+O%E_K=I#=WZ7.U4N4#^6I9P< _0#Z"JWM;M?\ 06U[]_S/4K?7
M-.UK0[F]TB^BN8A&^)(6Y5MO?N#7F/PO\>VFG>#;N\\5:_*SF]9(FNI7FD("
M)PHY;'/;UKK=%T7PGH=QK\.@740O)(W-U:)<!O*QG_EG_" 3CIWQ7%_!#PYH
M^I>&M3N[_3K:ZF:X,&Z>(/A BG STY)I1^TUV7YC>ROW_0]>TK6-.URQ6]TR
M\BNK9C@/&<X/H>X/L:Q;[XB^$=-U(Z?=ZY;)<ABK* S!2.H9@"JGZFO+?AS=
MW&E^#/'ILBRM:AFA _A.UQD?D/RJEX'L[N?P1,D/P]@UF.Z:02:A)?11OGIP
M&4E=OU]Z'OIV3^\+=^[7W'NU_KNF:9HKZQ=7:+IR*KF= 9%VD@ C:"2#D=*Q
MKGXC^$;1;0SZW GVI%DB!1\[6Y!88RN?]K%><+IFMZ-\!-<T_6[<PM%*IMP9
M5?\ =ET/!4D==U.7PYI$?[/CWW]GV[7CV_GFX:,&3?YF!\W7IQ]*):7?16_$
M(J]EU=_PL>EZGX^\*Z//#!?:W;1R3*K(%R_RGD$E0< ^IQ6S)J-E%IQU&2[A
M6R$?F?:"XV;?7/3%>-6'AO2!^S]/?MI]N]Z]N\YN&C!D#!R!ANHP!C%6]/U+
M0K;X":6WB:&>[M'9HT@BD96D82/M&01P ,\\<4Y*W,NJM^(HZV?<[BT^)O@R
M]O19P:] 9BVT;T=%)]F90I_.N<^+/Q"G\,16^F:3=)%J,V'E)B):.(YPRDC;
MDD$=S7"?$&VO#X+L;D^#=.T*Q69%AD657N&!4XSM X(&3GG(%;/Q?AB?P=X4
MNVB0W,GEJ\I4;F'E@X)ZXS1;;U2&MUYILZCQGXBTO7/ ]GJ6G>+Y]'M6NP@O
M889]SL%;*84!O?GCBNX.HV>F:%#>W]_&ELD*%KF9MH;@<\\Y/YUYI\;;2VLO
MA_I\-K;Q01?;T.R) JYV/V%4?BA(;A_ NEW+%=,N&0S\X#?ZM>?H&/YT+5M+
MJTOP%TBWV;_$]%TCX@>%==OA9:=K,$MR3M6-E:,N?]G<!N_#-=+7#^(O"'@6
M!M-N=22STC[/(!;RQ2+;;F'(!88SC&:[=2"H(.01P?6C2P&9K?B31O#ENLVK
MZA#:(V=H<Y9L>BCD_@*AT+Q;H/B56.CZG#=,@RR#*N!ZE6 ./PKS""RM?$WQ
M^U2VUZ)+B&S@_P!%MIAE#@)C@\$89FQ2>---LO"WQ3\)W'AZVBL[BZD"3V]L
MH164N%^Z.!D%A^%*.O+?[02TO;H5/B!X_P#M_C6VT:Q\37.E:1!E+RZM8Y%=
M)0S!AP QQ@#CCGO7L'AM GAO3\:C-J2M"KK>3 AYE;D,0>1P1UKROQ)IUB?V
M@=#MS9V_DS6X>2/REVNQ\S)(Q@GZU[/%%'#$D42+'&@"JBC 4#H .U$?@^82
M^/Y'A/Q*\8ZWX9^*44EE?W7V2"**1K/SF\EQSN!7..1WQ7<^.O$?VSX1W.NZ
M+>S0^:D3Q30R%'3,B@C(Y!Z@_C7.:Q8V^I_M!1V-W$);>?36CD0]P8VKB->G
MO?!&E^(O M]ODM+@I/82GTWJ<_0@'/NOO4_8L_7\=BU\=^UK_<=]XHUC4[?X
M$Z7J,.HWD=\\=N6N4G82-GKE@<G-6M1^(H\,?#G0SYC7NO7UC$88W8NQ8J,R
M/W//XD_C61XN_P"3>-(_ZYVU<F/A[KEOX%M_&JWTCW\ BN((5.XQVZCY3GU
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MU+2O&NE_#:^TJ?4M&D\/6T+%;R%B\LJAN(QSCEL#IQZFKJ:2D_N)I:PBOO\
MP/6_"6O+XF\+:?JX4(UQ'F11T5P<,![9!K:KA?@_!)!\--,\P$;VE=0?0N<5
MW5.:M)V)CL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$!E*L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
MK4ZD- ,04AHS3&;BF2.S2YJ+=2[L4PN/)HS432 4@D!H"Y-FE!J,'-/SBD Z
MBF[J4'-(8X4M,SBES3L%QU%-)-)D^M%@N/H--S1FD%Q12T@I:!A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !2'I2T&@!M)3L<4G0?YYH$-.X=!FL37/$UIH:I]H#,[G C3D_7
M%+KGB&/2_+MH5,^H3Y\BV7J_O^%<5K^B7-GI$-Y?7/FZG=7:!G/2($_='\JI
M(B3TT-(?$VR9F5=/O"=VQ=L1Y-+-\1+6.;:UE>A^"5,)XZ^U2Z=IJ0WS2R;
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MGKB@!><T9-)DYYZGM2C@$=:0 **.@YH'-, I#2TE( S11BD- "%L4H/%,(-
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M&H774F&+DCU-4D0WT(#:RZG+YCL5MST/<U=CTRUMXP!$&/JW)JW#C)!   P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***3- "TPFE)R*BD;;3%<"<"J\I&58] :;)-R1G&*@DF#(R@X!'>J1#
M97U:8QQ8#8R#^56-,MOLUE'D?._S-]3UK+U)A// G7< OYG%= "!D?ACTJF9
MPUDV1L@7FG@X6F/*!COFFR$XXS4EC&7<>M1G*G(Z"EP^#ZTY%RI!ZT"%#Y -
M#2-CK4;JP&.A%,7><Y-- *2#PP!7T-5Y+&TG S;IN'M4V<D*>:E2,ENW%-BL
MF45TRT''V:,?08J0:;:D?ZH@_P"\:O.AR.GX4W/KS2N+E1GRZ83S!(0>X/\
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M(QQD8YJ0+.2QY'O6)J6FL-TUN !G/ ^X?45LY$?4DT@D'3)'O30I*YFZ=?\
MGQB*4D2J/^^O>K^>?:LK4K;[-FYA "@C..J>H_W<U);ZG'+;J[$C/!%.Q-[;
MF@S CUIT489N/E/M67-K-M&.6(/Y4MMK$<A+*HP.Y<468U-&N"Z$C.[ZT)."
M</E?K63+K2J3^Z)^C5"-=C;[\61[XI6'SQ.C!!Y'2E! K!M];@=Q&DFPC^%C
MD?\ UJU8;N.8#YN?8\4N5K<I23V+:R9X%2#D57#8Y[>M3H^14EH4L!Q2 T%<
MG-!XH 7=2AJB+<TH- 7)LTF13,\4 T#N29I":;FE'-%@N.!S12"EI#"BBB@
MHHHH **** "BBF.ZHI9F 4<DD]* %=U1"S'  R2:X^_U"Y\43RZ5I#R16B-M
MNKL\#'=4[GC(S2'4+OQE+);Z8[6VF1OMFN",&49P53U!YYS746-C!IMJEM;1
M+'&@QA1C\?K0(33M-M]+LH[6V0*B#''<^IJX***!A1110 4VG4TT" ]*X[X@
MY72K# S_ *=%_.NPKD?'Y(TRQQ_S_1?SJD)FPJ<ECW %1.I=NG //TJ9B4^I
MH )S[U1F5+AML9(/S \#%006S(-TB!OXB3U/M5P1!YL'HO<]Z)B6RHSTZBB[
M):74Y>?1;Q9W6TE00L2V&ZK[5G01-/Y\%Q*V Q7VQFNVX101SQU/%9TFD6UQ
M+YQS&X^9MAZUJF9RAV,/3EM]/2:Y9_,EY0+U.!V!IMLU_J-RQ#GSGX8CI&OI
MFFSP"RU"6(1A8\[E9N_XFK6FZFL F2&%@6(((P ?QIVOL0GK9ENYO((I8+.+
M:L=J-TK$<* /YU1DF6X^S2M&L%B9,1)MY<YY/XTRSL6U+4C"Z%<N9+IS_%ST
M!_*M/5(X3J%E;  1P-O;/ 0#'6I;L7K\16N4GNG%Y*C*\[>5;1G_ )9YZL?P
M%69)UTFW^PP%3*%RTC#A/5C^M12W$LJMJDN\Q@XMHB<>V356YMV6.,W,BM<7
MDJLQS_#D<?3%%[B9%#I$UVK2(P2(DLIDY/N:IP)(I4&=L#H%/ K=U.X\PBPM
MG\N*- UQ,IQM']T>_7BH+72@UM+=W),2$%DB'&T=N:?-W(<;;&A870_L^$RR
M*9.0,GD\D5=BG99" &/&2>PKCY9+=;9=HW$YVXY*\^M:]IKUM;V4$<F\S;1G
M"\?B?6I<2H33-\W+$L !QWI\4R[3G.1UXJK"R3KE2V&YSBK,<ID78F[;G&[Z
M5-C9.Y+YHD^16(]>*D0JBX!)^HHC(48 W>]!8 993UI%B&3..O6E=OE]*;P3
MN&<4.V[  S[T - )-/;BF[R.HIDDHZ &D)@[@@@$5FZEJ,=A I92\CG;&@ZL
M?\*G>=8P6(..AS619#[?>R:A(ORH3' K<X X+?CS65:HH1TW(;;T)+"Q>)I+
MR[;S+R7[Q'\([**LR*NWC@^M2YXP3W_.E*Y!]*\YJ^H6*J0O@DG()_*H9[KR
M&2)%\R5S\J X_$^U6I94MH&>3)4=AW/H*YN_:4SO;P_\A*Y ,CC_ )81=AG_
M #UJ5!R:427HM!LB-JTGV1)";9'WW,HX\YO[H]A_2N@4Q1K&L2850 (Q^F*S
M+&V%G;+$!L11\J],^_UJ+[;-=3F&Q_UJC!E(^6,]R?4UZJ4</"[)3L:TFKPV
MDWD*LD]TW)CB&<?7L*CCUZ&UG"7-O+"SG[[8.?RJ#3+>+3E94RSN<R2,?F<^
MYK1DMH;N,QSQK)&?X6&:XOK<I2O'8I7Z$MWK%NBE+<AY",Y["N;73+C4KQY6
ME!7^.5^-OLM7'\.*JE;>Y:*,'.TC(QZ5;328Q$([J>290.$R47'T'%0Y^TE>
MIMVZ$.,I?$-A31M-C"HZ,XZN1N)K(OKF.XU!/(C.V1U [9YZXK8GCTS3+8S&
M"")%'&U!D^P]346AZ<U[?G4[F#RXO^6$+=0/4BM?>K222LD.46W8W;=9)(44
MH8TQR.YJ^A"@#:0!T&*:O QTJ15R>M=US=(D5@12YIN,4M(H6B@=**8!1110
M 4444 *.U9'BD%O"^H '!,9YK7%8_BH[?"VH'K^[- &GX>_Y%ZPYS^Y7^5:=
M9GAW_D7=/[?N5_E6G4&B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ H/2D-)DT &:3-!--)IDL<33:3<!32X
MIA<?VIA(J-Y@!3$DR>:+";)VY%5+@ <^U3L_'/%9NHWT4"Y=AN(^4'BFE<F3
M211DVMK\.WTW$_0"M7RE<$CC':LK3K=I;EKV3=R-JYXW'Z>G2M/<0<+UZ$5;
M,X;#3'SG/2ATP.*<1LC+CD=Z:I,G7@4BF.@?:,D\^E6"RD$@_P#UJK&':<J<
MFGHI ]SVI#)BB[0Q/!JNY"MC\JESA"#TJ$X?)]*: 89"JXIX&X<C(Q49&\>]
M21/CY30 &-5Q@4X#=UJ8J",FH2QW;3Q2N!(B=V/3I3MP.:1!O')Z4C$#IB@
M.'7KTIRA63I^-1^6'.0U([&),4 (\:.K1R#*D$$>M0+I5DJX\DL#TRW2I%/F
M-D$Y'2ID?)V@8/>BX63*7V"U1OEMQ^(JTD< 7:%7CVJ<QEN<U$\'/O1=BY4N
M@H1>@VX^E*8XAP$!--4,GO2LYSG%%V/Y%22QMKA\RQ*^/PQ^-59]-=2#;28
MZ*W;\:TR0#U%([X(/6G<EQ3,F"^FMKC%QNW8PQ88P/?U_2MZUN!,H9'W*1D?
M2J=Q;)>)R=KX^5QU'M]*QOM%QI$ZAD'EYYP>"!W'^%%DP4N4[#?QS3'<=C6?
M!J$=U&&C;ZC'0^E2-)Z\#UK,TYKEH<T[.!4$<F13V.5'-,"4<BG#@5#&3@9]
M*F[4AH0M2K2 #-+0,=3A46X#K3E8'H: 3)**:#2YI%"T4F:6@ HI#G'%13W$
M=M"\TTJQQH-S,QP * "XFBMX9)IG"1H-S,QP !WKD&-WXTNF$<A@T!#M?CYK
MD]\'L.U$D]YXQO!#;B2'0$;]]*?D:YQ_"O?:3WXZ5UUI:V]E:QV]M&L<,8PJ
MJ, "F(6VMXK6!(((UCC10JJHX %34  =!12&%%%% !1110 4VE)Q2=:!"$X^
ME<EX^7.EV/K]MB/ZUUV-Q^E<GX]5FTZP"]?ML?\ .FA,VE7<H)';K3'8 ;1U
MJ<@JGMCFH(UR6<]_TJC,11@#UI53')/)YH49DHDP3@'FF%B!D\UC@?+CBE>(
M#Y5'4<U(B[/E!IP0[_4T E8J-"DK'S=C*HP 17-ZC:W,>I--#$9(Y,;2@Y'U
M%=3<+O&W\:CD#(I8*"S<8/>J4VB)04CD+>:\L)[D1R+'(< L1R 0./KTJ[HU
MO->Q2)*P"1N'E;J9"<X^@XI^IZ3=F]:X@"RB7!9"V"#C&<UGJVHV,\L ?R$<
M -MP=W7O^-79,Q3<79[&CJ^HQS3F&-<P6S ROV=NR#_/:JMU'=+ ^H2,JWD@
M MU*Y$()QT]:CTNR+R[9Y-\$+>;M(Y=O4^M&JZE'-?H0S+#;88E?XVZ@ >QQ
M2M8HGEM4A^QV;L TC>=,V>7QCFDO-0?4</AQ;!ML28P9V['Z5"\%Y_9\^H7;
M?Z1*-B GE%/8>E2ZG&MK?Z?O81Q0@O@#[N!Z#O0(<]E:6D+SW8\V[=<[1P W
M0 #Z8K.S"RG"<@X=>^:L3S75W/',\7SS'_1$88)_VF'ZU;E-M9V1MU1GNY<@
M87+,W<_RIKS)DKZH33]6@AMH[4&3Y5Y?''-='#+'%$ O((&TCOFN#6WG6.1K
M=3M'RN ,J/QKH++6[>*VMHIE<%5VE]HP32DATYOJ;OVC+<#)I_F-G##BJ\:K
MDOQAON\]JDC#/N;'M6=C=:CQ-U / I5:0G/&VHVA!'3 ]*2)I$0^8!CM@T6
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MQQ6G;S":%7 (!]^E<Q)<7"KM(W =.]6K35&B(#Q +W^8_P"%2XE*9O[L<&I
MV166NJ0N>N![U.E_"_ )Q_>QQ4\K*4DRQ,<+D4V&1B<8IC3Q-QN!H1D#9\P8
MH'?4MJW)%/X-0)(N?O"I :12']Z7.!2"J]]?6^G6DES=2K'%&,LQ- R6>>.W
MA>69U2-1EF8X %<=&UUXWN&+A[?08V!0 ;7N3[^@ZTZ*TN/&%TMY<EX-'0XB
MMB,--ZEO:NOBA2&-8XU"JHP * $M[:&UMXX(4"11J%55Z 5,!@444AA1110
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M/4&I,JZ4AE8J1AEJ5'XP2::.#@TJ*,_-0 V3GBB,80\Y-221_+Q4*@J<'M0
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M^T@$]ZC=MXP.N/RH0K7.$U."XANYX&C9PSE@57(Q5;3-1-A;FWCB9G+%M^[
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MQ_>)W_X%4[>--$2,/]L3!])$S_Z%6C!HNFHD:'3[8X ZQCTJR-$TK_H&VO\
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MD 4444QBXS1BDI>U !D'BDZ48%% @HHHH&+1244 %%%% "CM63XI_P"17O\
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M7Z5*O!!!S[5&_P O6D#\\'FI M[1)W_"F.I48)YHA.#NSS4Y*MU H&4FW;,
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MH'0/R<U*DHD'O2LI( Z&@$BL0%4C)P33K1Y8RV6(Y[U)+D# ' ZBH-C,1M)
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M.E%,W-_=HW'TI /I:;2YP* %HIN3G%+P*8"XI*0R#MG\*6@ HHHH&%%%+VH
M2BBEH !UK*\3#/AJ_'_3,UJBLCQ2Q7PSJ!'41'K]: -/0,?V!8X_YXK_ "K2
MK-\/G/A^Q/'^I7I]*TJ@M!1110,**** "BBB@ HHHH ***0G H 6DYS2"E-
MA":2@TW-,0I-0R.RCBGL>,U4F;)IHEL'G*)DKDD]JQF83ZY&A'"_,1^!']:V
M$.1@],UCZ:OFZK<W&> ./Q/_ -:K6QF]6C5:/'_UZ5%R1GH*FPK8/I2-R.!B
MD6,<A6]?I3 Q9L8IS*%&[/--7[V:!#9(BWW3S4<1*G!JTV-N>]5B/FS30@9<
MMN7D>E2HWRYQ2B/ RI^M-.1GC%)@+MW#/>D"#&3Q2JW;-!:@!C-@_P"%!<L>
M,"F+\Q)Z4H7:<XXIB'%21D@^M4;VYD\P65N?WK_>8=$7_&K5U?+:1#'S._"+
MZFDM-/\ (W3/S/)RYHV#<D@MU@MDA7D ?>[L?4U(#M&>]21C P:;)A>!S2*!
MF#C'0CN:B60ANE(H)ZBIT4'([T !"N,XYJNZLC#GK4P!5R#3)1GB@!?O@*3@
M^M*,CJ*CB&[(:I22.^:0"L0>U1% 6^89&*=WSVIQ' YYIB*4UJRJ3$1@]JJV
M]G.Q(;8O/5L@_P JU6 /&.*IWET(W\J)/,G[#THN2TMRU&OV=0N0><DGUI6N
MH(R,SQ#ZN*S$L)[H[KJ;:3_"!FI)-%M9!AVD)'N*=@N[:&@+F"; 6:(GOAQ2
ME5.2O3U]:R%T.W'"N_T89J86=Y:KF(ML'. <C\J+(:;-*-@H((-(^$.5.:HV
M>HB[+1OA)EYQGJ*NJ5"9_#-*P[W0*^<YJ*Y<10[@?F[5-MP<XXJI=@2/M[*<
MBFA2V,F-OWYW<EN6J:2'< X.Y,]/2F2(JR9'+9YJU" $]/459DAJ+Y:$'FG(
MJ.PXQZTDA&,BJ[3!6P#0-:%M@@7ITXK/FE<RJOWJLF3>F14$*$R9/% FQ0C,
M, 8%2^60 6)R!3B5C(!/K3C(.!D<B@9"9FC]"/:E+!R!@DGFAH 2& QZU/;(
M$&&/7H:!"1+M8#''K4TC*% /![$TK_*, <'O5<(6)R<@=*2&1,[N_'!'ZU83
M(0]L]:8PXY'(I\0W'#&F!2GC8-N8Y':K-M<X01,>#TIUR@QM'-06\7S?-^%
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MH*;5)M.Z,VK[F%;Z?X@CE03:Y!)"I!/^A8=QZ$[\#ZXJ.3P_?1:]?ZK8ZK'
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M:@*OHOY5("E@>] //%!V_P"S2# ..%% #LT$ G.*3GL,#UI:8 "2.1@T444
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M?F.:O7=P)" >%7]:H',T^.WK5(RD[LFB3:JD]_\ &I/.51M)Y[5'<.1$%49
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M_"M:2W5@01D'J#7+103:5K>=Q6WWET&>-I'S#\,D_A6E]#!W3.J56QTQ0W.
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M(-275X\PPA*J/P-9N'=\,3MJDC.4NQ+&6E7+#Y>U.VX' Q07V  X I6F&!R
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MN]/\:!XGU386_P"$7ONO3>O^-=KBFXYXHN'*<8?$VJ8S_P (O??]]K_C2_\
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M/C_BF+[_ +[7_&NS"GUH(]Z5RK'%CQ/JA//A>^'_  -/\:4^)=3!&/#%\?\
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M?C^+%)E1)+%C]D6.8XEB^1B?8X!_'^M6@%/6H=F!R,^OO5E%5@*AF@BD"G[
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M8^]/MYFN(3%<1-?1,H9)$'3K_P#6I60^9]S+37_';'FW@P.^T_X4DWB/Q:,
M/9[NZ$'/_H-:5O>7%C+L@D>0?Q0S<.![4W5=2AGMO-BMW691G.WMW_K1;78;
MD[;E&TU_Q;)<I#YEF!(<!L'C_P =K=4^,V;FYL0 .^?_ (FJ&C6-Q>S07?\
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ME@985#&7D?Y@-OI3(T,YS@Y[FK* K\I!_*AC6XK+A<  'L:I3\L%Q^\X(/\
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MM.LWP_QX?L,?\\5_E6E4&B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI":6FF@!#4+CFIJ8W2J)*D@KGM4)2YDV$9,8!_,UTKC(-<_=Q+-JI4]PJ_J?
M_K5I!F-0O+$(U4+T Q4RLV<]J0\. .E/P$Y-2-$@&%Z_2H]^.":'E##Y:@?<
M6R.E RPI"C'6D9QG%-C?C!ILN!SZ46$3%<IG(IB_*>::L@9?3%"XD.1TH"Y%
M=_<7!^\:J;L'/;%6;DCS(U'0 _TJM<.HC( QQ5(AC7MA<PELD2+]QO>JL+*9
M2L@ D4?,*O0MF$@'G%9U^Q1Q.JG*\-3(:L6V(<\=,5%E@V*CCN!(@<#@@59C
M(*Y-.P$<R^8JX[4V, 8 )!]*M.F5R*9;Q[V)/2E<:0](\X.,'M4K,0O7!IDD
MBH,?A49D+#'Y4#$8K))GKCKBI2V!P*A12"2O#>E3APR8(P:8B#S#YF.U#XY_
M6H9!M8C)QVI$D(RI/S$<&@5Q\2#<?0U:8A!A>XJM ZJP#=?7UJT67;FD!7SE
M@.YZTRYCVX)Z4A/^EDBEN')&11<4B6 JL?"C%1O\C<'K4 F9 !ZFI58;P!3N
M.X]9#CDC%-"DN21QV-380_,>*8V%)"]Z!HFB4D[E.>,'Z5, %&.U1!A;QACZ
M5 UZ#DC\10%R>:0;"F><5#$W3UJM)+YHZ<'^*EBD9,!_N_PD4 6KB?' ZXS4
M8DWH":CG;+!@,N.OTJ$EB2RY ]*";D\A5L9.,5.F OI5([F8'' ZU=1@0,=.
MWM18:!Y6X-1^4906/:BZ("8/%3HRBWP6  '4G%"'N58DC20^HJR07(XQ6?)?
MPKDY9EZ953_.I8+R.481P6]^":+"T+6XCBJURWF<9YJV#E-QP#4%PJC)'6DD
M-D,1(P 2#Z>M7(U8G[Q)[$U3M$\R8,QQCUIUSJ4<;>5&,N>I'04["5D27,A9
MQ$G7^(TF0" .,=<561RJD'F0]Z!NY9>#Z4P+ZR#;5C3U#RM*>W S5*-Q*-B@
M[CUK2A"P*$QD5#>A<5U)70AN#P*4$,<4QG'*]SWIZA54<@'U-38NXI!'2ID;
M(JI<WT-J0G,DQ&/+09/X^E5DM[^\DWW,WD1]HX^M%@N:$H3)_>)^=(LD00C>
MA'U%49M'AW99Y2.A-<CJ6LV=IJ;Z9:B6[N P58H5W'.,G]::1+DT]CJ[S58;
M:)E1E9QGYA]U?J:Y5]>CFNC%$DE[<-PD48X)_P!L] /SJ6+PIJFM21OJ=Q]D
MM.UM >3_ +Q'?\:Z[3]'LM+@6&S@2).Y4<M]31=(+.6YREMX?U?5?GUN9;>W
MYVV=LW4=@S<<>V*Z?3-/M=.@$5M!'$.^T=?QK1V<8-"0X8T.5RE&Q)&,8_PJ
M=14:KA:E4FH9JAS(#TH'I2]Z3&#FD,*444HHN 8I<444AB 8KDO'V#IUAE2W
M^FQ]/K775R?CIMNG6!_Z?8_YTT3+8W>=HSC&!BDS3LY44TU1 9IN:4]*C)H
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M,"!_6H]Q'&*8$3$*<CI07R<>M2>5N!..*8$QVIB8?*"!3))$@&\MA<X/%/\
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M!&C;8"&QE30#[A)<LI*E3GZ5#YC22<9Y]J6(BXB#,3N'6I I48)X]:+")D7
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M@T@%Q1THH/6D =:*04M PHHHI@+2444""BBB@84444""BBB@84444 %%%+0
ME'%%% A<48I,XHS0 N,4F103Q2"@!<T=:2E'2D,45D>*N/"^H'_ID?YUKBLC
MQ5G_ (1:_P ?\\S30C3T#']@6.!QY*_RK2K-T#_D 6.?^>*_RK2J#5!1110
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MH@6\WI041DB&ZX^56XJ63'ED <^E+=QB6$'HZC(JC'=&4@ 8?.&H(O8D0OG
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ML\#$G_@)K0M]2MY\?O-I]&%+4:G%ELPG/!&/2AX\**<DJL,JRL/4'-)(X9<
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M;I 6;W[4P;$:^1R50.I_VA4L7EC[Y!S4<[$,&DC!)^[TH!23K&#GOTI"U+)
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M&*8GJ5I$R.>E1(%R>#^56G7-,*?+BBY+,RZABF;$D:^VX<U1;2G_ .6+'/\
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MW,TMY)L4[( <$_X^M.*)D['->'8%U/4=652PB:\.2.PP./\ /M7<&/RU$<8
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MZ?+IFHI(H8I( 4G[H3Z_C6HMQ:W]H;?5%$,H.<D$#Z@U)#?Q&Q^RZHFY2O\
MKL9!%5H)UM]UG*([I67=;/(.&]16MSFLD5OD8RV]U MW*J[XY%ZLO;GO2,8K
M>1)K. P-P7A/W7^@]:FOW<P+YEL+&>,?(Z]#_LU:MS!JUH89AY-X@X]5/J*8
M:="%+.SU-?M5FOES X;;QGV(K,BDN%\ZUW;5RRE,9 /3BI[4RP7$A5_**_(X
M3^(^IIUEITUU+<,L_/F<Y'KS5+35D.[=D5[:RN)[<LSHFTE2V.:Z:UL5@MHX
M2'PB\..3^-);6201B$N#ALD'O6E'$5^4G"GMVK.4KLUA'E1$N'0)(<X'4U)'
M%A=H(Q[&GD8R"H([&E10%/&,^E(TL*J;1UXIR@D\]*7 (Q0N5/7BDQI#B!BF
M%?2GDTE(>A6DMQ(<GANQ'6FE0#M8<]CZU:/I3&0-P>::8D<QJND,;@WVG2&V
MOP.9!T<?W6'>H["=;V0[L6>L*,.O19,=..X_6ND,9;A@#[U2U+18;^/@M%<
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M2 OALC\:+DN!GP6X )?EL=:52$<]:T5M(EP,M^=2&T@;'R$_C1<:@S-,F]2
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M7_=-=;Z5P6HW6IZ[JVC_ /$ENH([:[\QW<< 8(_K7>CUI,:W%HHHI%!1110
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M&=>WFDJWY@&I8-2B>8PLLD,H'*2@?H1Q2"Y9? /'3N*3S"1M[42.)!\H/X5
MRE1C-,!6W'D&HB7!+#FG%B%P>M$:EN*9),DF8P1^-/X"?6H%C.[ ZU*H)&6/
M2DQH8IR<'IVI)(Q*.>HI^ >G>G GN.E"!E0;P,,/I4L)8]:>XRW/2HF)'/IZ
M4Q$Y8]*=&=\F#VJNI=NM6(1L?FD-"W!X'ITJ%1N. ,^E69%YR/Q^E59YX+*
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MMV4Y-4EJ1+5&R)5#''4TA92"<U6+?-]TTJ=&)_*AK4=V3X7&0*@GA6=?W@!
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M&>A1@%RV#QP,U, ,"H+1B]I$['YF4$U,>*R9Z6EKD@ I=M1[J7=Q2#J-DY7
MJ 1D'.:G/( J(DC)SC%,3(;N7R+2:0\;4)KB-'E:34(0K=$R1^A_G6CXGUC=
M:R6=L=V1^]<= /3\:I^#;&6Y#W<T13<-J$C!*YZ_F!^%:K2)PN2J8A)=#KHC
ME=JA@".215R/C  P/6HPI4G/0"K"BL;G:M1Q49SBG?2EHHN58:>E*M&*44@#
M%':EHH 1>@K(\4D#PQ?[LX\L]*V!U%9/BH9\+:@/^F1_G0@-+P\"/#]@#_SQ
M7^5:=9OA_P#Y%^P_ZXK_ "K2J31!1110,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% $9%,9/2I2.::
M13)9"4?U% WCHJ_G4V/>D*9.<F@5C,N[?SE8&W8CJ1GG/J*P5LI+:9GA=QDY
M"MP1_.NN:-6&&&1_*H&B ! '%4F1.%SFS<ZD&VEBH/3OG\:B>&^G !DV\\Y8
MG/Z5T7D@."R@CZ4IC!X_*JYD9^S,6'1;B1<O,&'ILS_6KR>'XUY>1OH#BKL3
M-&0N!]:M;CT-)MEQA#J9,VC02)L"*1[BJ1T=(CA3CZ' KHL ]A360 9P*.9C
M<(]#GFTJ7:620)COC^M$=MJ4 .)PX]CFMGS#OPHS_N\U)LEEY(55]QDT<Q')
MJ9"7&H)C<C'_ ("*;<:M=Q=(E)]C6\D$8'(+'/?BI5AB'.SKVI\Z[%>S?<Y*
M.[U:>3 5@#WV@ ?C5J'3;B7#7$BD]^2?UKHC!%VC4?A36!YZ8["ES#5/N9,>
MGO#'L5HASG"BG&WF+$^;_P".UHLA;'/- C ]:+CM;1%%8)<X$H^FVH[K3FN8
MMC[#VYK4"@'.*0@YR.![4A<JZG+&SO+"1I[=L[CDCV]ZN0ZMN&V6W)<=2AK8
M\LDE6.5(S^-4;F&*8\1^81QC:#C\ZI-/<GEDMF5WUM(U&(&_WF( J#^W7N'$
M=NH#D=%^9ORX'ZU:32(R<R*F?[JKP?QK1BM88HPB1JH Z#@?ETHND%I/=F))
M;W=X1YC;?4$;B?P[5<ATBW0A]B[O[S<FM+8=N!T]!Q3T3:, "DY=AJ'<JA O
MJ?>GI&A)P@SZU,T8/UHC3!HN5806^58 8J,(%8#%7!P*CESM)7K4E-*PHC4G
MW[4H0%\XZ#BH%9]XR#BK,9.[F@$*5&/>A02>M/I I!I# IZ\BG* .@I>M %
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MC)Z==_\ 2DO/B=H-EJSZ>ZW+LC[#-&(S'G_>W]*/B59VZ> K@)$B"!XC$%&
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MH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-&CW#=N4]C4F11D4 -W>U.'(HXHH 7&:,&E6EICT$Q1BEI*06044N1ZTF>*
MT#%&*,BBBX608HQ2TE 608K(\5#/AB_ Z^4:U\UD>*3CPSJ!_P"F1IB9I>'N
M/#U@#U$*_P JTZS?#_\ R +'G_EBO\JTJ@T04444#"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!C*I!# $'L:Y35_ MK?3K/8W#6#JV_
M:B!D)SG.W(Y_&NNHHN)HY(>'-?\ ,!/B4XQC MCR?^^Z4^'->)'_ !4I&/\
MIU//_C]=913N+E1RI\.Z[CCQ&W_@/_\ 9TW_ (1S7O\ H96_\!O_ +.NLHHN
M'*CD_P#A'->X_P"*E;_P&_\ LZ/^$<UW_H96Z_\ /M_]G76447#E1RG_  CF
MN\_\5*W_ (#?_9TB>&M> 8-XF9L]/]&/'_C]=91BBX^5'*'PYKVS \2G/_7L
M?_BZ0>'-?QSXE;/_ %['_P"+KK**+L7*CE/^$<U[_H96_P# ;_[.D_X1O7_^
MAF;_ ,!C_P#%UUE%',PY4<D/#>O]_$SY_P"O;_[.G?\ ".:[C_D97S_U[_\
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MZ&\-ZZQ_Y&-U&/\ GW_^SKK,447#D1R8\-ZX!SXC<_\ ;N?_ (ND_P"$;UW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img183648649_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" + !D<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGIZ5QWBCXJ?\(WXBNM)_L;[1]GV?O?M6S=N16Z;#C[V.M;OPX_Y)_I/^X_\
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MP'7G/Y9_2KE3A.#E#2Q,9SA-1GK<]RHHKCOB%XO?PII<*PVHGFO-\:,S85,
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M _WB<8P<G]*F-*4H\R*E4C%V9ZE17EO@_P")FK>)?%MOILMG90VDH=CL#EP
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#S[XQ?\B5'_ -?D?_H+5@_"[2[77O!>NZ3= ^7-,,MC[IVC##W!&:WO
MC%_R)4?_ %^1_P#H+5F_!+_D%:M_UW3_ -!-=<7:A==SE:O7MY'G>EWM_P"
M_&>Z52);24Q3Q@\21GJ/Q&"/P-=9\8KN"^ET*[MI!)!-;NZ..A!*XK8^+_A?
M[39Q^(+6/][ !'<@=T[-^!X^A]J\EN=3GNM,L[&4EDM#)Y3$]%;!V_0$$_\
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M=C.,_F:XCX+_ /(G7?\ V$'_ /1<=>C5S5YR<VKG30BE!.P5YS\:/^1.M/\
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M1UF_["+?^C*]A^,4TT7@J-8F95EO$27'==KG!_$+55X\THKN*A+EC)D#>._
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MICYF  4<>I//XU[A>:>VD_"Z[T]SE[?2)(W/^T(CG]<T5OAA?<*7Q3ML>)>
M=)M]:\::?9W:![<EI'0]&"J6 /MD"O:/&WAG3+WP?J 2QMXY;>W::%XX@I4J
M"V 1V."/QKP_P=K<?A[Q58ZE,"8(V*RA1D[64J3^&<_A7K/C+XB: _A2]M].
MOUNKJ[A:%$C4_*&&"3D<8!/OFJK*;J+E)HN"INYP'PGO)+;QY;0JQ"W,4D;C
MU 4O_-:L?%^_DN?&?V5F_=VL"*J^[?,3^H_*F_"+3I+OQJMV%_=V<+NS=@6!
M0#]3^1JS\8M)FM?%$6I;28+R%1N[!UX(_+::JZ]O\B;/V'S-#P?\1?#/ACP]
M;V/]GW_VG&ZXECBC/F/GKDN"0.@KA/%>HZ7J?B.>_P!&MY;6VEP_ENH4J^.2
M I(&3S^-=_X,?X?ZCH=O%JMO86^HQ+LF-R_EA\=&!) .1^M:]V/A;:2+'Y5A
M/*[!52V+29)..H./UJ5*,)MJ+N4XN4$FU8T/%5T]]\'9+N0DR3V-O*Q/<L4)
M_G7EWPST.VUWQA'%>1++;V\37#QMT;!  ([C+#BO7/']O%:?#74;:!!'###'
M'&@Z*H=0!^5><_!?_D<;O_L'O_Z,CJ*;M2DT545ZL4SN/B9H.FMX'N[F.S@B
MFM-CQ/'&%(^8 CCM@GCZ5Q/P6D8>*[V('Y&L68CW#IC^9KTGXC_\D_U;_<3_
M -#6O-/@O_R.-W_V#W_]&1TJ;;H2N.HK5HV.]UGXI:'H>KW.FW-KJ#S6[;7:
M*-"I. >,N#W]*E\/_$O1O$FL1:99VU^D\H8JTT:!> 2>C$]O2GZK\-?#^LZI
M/J-VMR9YVW/LEP,XQTQ[5)HGP\T'P_JL6HV*W N(PP7?+N'(P>,>]9_N>7K<
MU_>\W2QY=\7_ /D>/^W6/^;5ZQ\/_P#D0]'_ .N']37D_P 7_P#D>/\ MUC_
M )M7?Z9-/;_!436S,LR:=(59>H^]R/PK6HKTH(RINU63':[XK\"Z9K4ES=I!
M=ZFH$;M%#YK+CMD_*#^.:X_QUX]\.>*- >SMK*\%XCJT$TL* +@\C(8D#&>W
MI7'>#H-'N?%%K'KTJQV'S%B[;5+8X#'L,UW?Q!OO!=KX;>PT2WTJ2^F90LMI
M&C-&H8$G>/7&.O<U:IQA-+5LAU)3@WHD5_@FS#6=43)VFW4D>X;_ .N:D^-O
M_(1TC_KE)_,5%\$_^0WJ?_7LO_H52_&W_D(Z1_URD_F*7_,1_78?_,/_ %W-
M;X1:!I[^'9=3GM89KF6=D#R(&V*H' STYS^E<S\7=!L])UNSN[*W2!+R-MZ1
MKA=ZD9(';AA6I\+O&VDZ1HLVE:K<BV99C+%(X.UE(&1D#J"#^=<]\3O%%GXD
MUR!=/?S+6TC*"7& [$Y)&>W IQ4_;MO84G#V*74[CP5K4UM\(+RZWGS+!)TB
M/H0-R_JPKR7PY>Z;8^(;6]UB"6YLXG+O&BABYP<9#$ C.,YKV+P5X>DE^$\M
MA(NV348IG4-QC>,(?R"FO(=!DL=*\31+K]EYMI&[17,+@Y7J,X]0>?PIT[7G
M852]H7/0O$_Q)\*^(?#UUISZ=J'F-&?L[/#&!')CY3G?P,XSCMFL3X/7DD'C
M&2V4GR[BV<,O;*D$'^?YUW"V7PN:W$X?1MA&<&XPW_?.<_I6AX3B\%W>IW,W
MANUB\^S50\\:,!\^[@9Z_=-9.<5!Q29HH2<U)M'GGQH_Y'&T_P"P>G_HR2O2
M_AQ_R3_2?]Q__0VKS3XT?\CC:?\ 8/3_ -&25Z7\./\ DG^D_P"X_P#Z&U%7
M^!$=/^-(ZFBLS_A)-"^T?9_[:T[S]^SR_M2;MV<8QG.<\8K3KE::W.E-/8**
M**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_&/AC_A+=$73OMGV7;,
MLOF>5OZ C&,CUJMX)\&_\(=:7<'V_P"V?:'5]WD^7MP,?WCFNIHJ^>7+R]">
M2/-S=2.>"*YMY()D#Q2H4=#T92,$5Y3+\$(VF=HM?*1EB54VFXJ.PSO&?K7K
M5%$*DH?"Q3IQG\2,KPWHW_"/^'[32OM'VC[.I'F[-F[+$],G'7UKCO%'PK_X
M23Q%=:M_;/V?[1L_=?9=^W:BKUWC/W<]*]&HHC4E&7,GJ$J<9+E>Q6TZT^P:
M9:6>_P S[/"D6_&-VU0,X[=*XSQA\,K;Q3JRZC#?_89F0+-B#S!(1T/WA@XX
M_ 5WE%*,Y1=T.4(R5F< ?AYJ9\(CPY_PDW^B"7?N^Q_-MZ[/]9]W/-6O!?PZ
MMO"-Y/>/>?;;EUV1N8=@C7O@9/)XYKM:*IU9M-7W)5*":=M@(!&#R*\NU+X,
MP76J3W=EK!LX9)"Z0BVW>7GG .\<9Z<5ZC12A4E#X6.<(S^)%&VL'.C)8:G*
ME^WE>7-(T6T2CIDKD]>_->>ZE\%=/N+EI-/U2:TC8Y\J2(2A?8'(./KFO4**
M(U)1=XL)4XRT:.#\-?"O2=!O8[VXGDO[J(AHRZA$0CN%R>?J:[RBBE*<I.\F
M.,(Q5D1SQ>?;RQ9V[T*YQG&1BO-]"^$?]B:[9ZG_ &YYWV:02>7]DV[L=L[S
MC\J],HIQJ2BFEU%*$9--] KS/7OA&-;UV\U,:V8/M,AD,9M=VW/OO'\J],HH
MA.4'>(YPC-6D><Z1\'=$LIEEO[F>_*G(C($:'Z@9)_.O0XHHX(DBAC6.- %5
M$& H'0 #I3Z*)3E/XF$81C\*"HYXO/MY8L[=Z%<XSC(Q4E%04>9Z%\(_[$UV
MSU/^W/.^S2"3R_LFW=CMG><?E7IE%%7.<IN\B80C!6B<?XI^'.C^)YVNV+VE
MZ1S/"!\_^\IZ_7@URT7P0@64&;7I'CSRJ6H4X^I8_P J]9HJHUJD59,F5&$G
M=HR= \.:9X:L/LFFP;%8[G=CEY#ZL?\ (K)\;^"O^$RBLD_M#[']F9SGR?,W
M;L?[0QTKK**A3DI<U]2G"+CR]#G/!?A7_A$-'FT_[;]K\RX:;S/*\O&55<8R
M?[OZUT=%%*4G)W8TE%605SGC3PK_ ,)?H\.G_;?LGEW"S>9Y7F9PK+C&1_>_
M2NCHHC)Q=T$DI*S/(O\ A1__ %,7_DE_]LJQ:?!*T24&\UN:://*Q0",G\2S
M?RKU6BM?K%3N9>PI]BAH^BV&@Z>ECIUNL,*\GN6/<D]S5^BBLF[ZLU2MH@KD
M_%7P_P!(\52?:9O,MKT#'VB+'S =-P/7]#[UUE%.,G%W02BI*S/)5^"$8DRW
MB!BF>@M,''UW_P!*]"\->'+3POI"Z=9O*Z;S(SRD$LQQD\=.@K8HJIU9S5I,
MB-*$'>*.3\4?#W1O%$OVF826U[C!GAQEO3<#P?Y^]<A_PH]-^?\ A(&V>GV/
MG\]]>MT4XUIQ5DPE1A)W:.7\(>!['P@)WMKB>>:< 2/)@# Z8 Z=?>L_QK\/
M/^$PU.WO/[4^R>3#Y6S[/YF?F)SG</6NXHJ54DI<U]1NG'EY;:&1X7T/_A&_
M#MKI/VC[1]GW_O=FS=N=FZ9./O8ZUP^H_"#[?KUWJ?\ ;OE_:+E[CR_LF=NY
MBV,[^>O7%>GT4XU91;:>X.G&22:V"BBBLRSSSQ5\+O\ A)O$$^J_VQ]F\U4'
ME?9=^-J@==X]/2NWTFQ_LS1['3_,\W[+;QP^9MV[MJA<XYQG%7**N4Y223Z$
M*$8MM=3S/7?A'_;>NWFI_P!N>3]ID,GE_9-VW/;.\9_*O2((O(MXHL[MB!<X
MQG Q4E%$JDI))] C",6VNIY?+\'O,UM]1_MW&ZX,_E_9.F6W8SO_ %KT/5])
ML]<TR;3[^+S+>48(S@@]B#V(-7:*)5)2M=[!&G&-[+<\GE^"$!G)BUV1(<\*
M]L&;'UW#^5;4OPHTC_A&)-)MIFCN7D64WLD8=\CMC(XP2,9[]Z[ZBJ=>H^I*
MHTUT.?\ !WAC_A$M$;3OMGVK=,TOF>5LZ@#&,GTKF?%'PK_X23Q%=:M_;/V?
M[1L_=?9=^W:BKUWC/W<]*]&HI*K)2YD]2G3BX\K6A2MM/^SZ)#IOF[O+ME@\
MS;C.%VYQG],UP&A?"/\ L37;/4_[<\[[-()/+^R;=V.V=YQ^5>F44HU)1O9[
MA*G&5K]#Q_XJ^,)VOI?"]K;Q&-0GGO(@9BQ 8!<\#@CGKSVJ.S^"5S+:H]YK
M<<$Y&6CCM_,"^V[<,_E5OXD?#[4]3UA]<TA/M#2JHF@! <%0%!7/7@#CKQ67
M!XF^)]K$EN=-OY2@VAY-/9B?JV.?K77%OD7LVEW.627._:)OL<_XT\"7'@[[
M,[WL=U#<%E5@A1@1CJ,GU]:]5\&-<^)OA<+6ZN")9X)K3SF&X@?,H)YYP"._
M:N#'@[QOXVU..XUPR6\2\>9<@*$7N%C'?\![FO9M&TJWT32+73;4'R;=-H)Z
MD]23[DDG\:BM/W4F[LJC#WFTK(XKPK\+O^$9\00:K_;'VGRE<>5]EV9W*1UW
MGU]*[?5K'^T]'OM/\SROM5O)#YFW=MW*5SCC.,U<HKGE4E)W9T1A&*LCSSPK
M\+O^$9\00:K_ &Q]I\I7'E?9=F=RD==Y]?2ND\5>$=.\6V*07N^.6(DPS1_>
M0GK]0>./:M^BAU).7,WJ"IQ4>5+0\GA^"$"S S:[(\6>52V"MCZEC_*M?7_A
M/IFJ6NGP:=<#3A:(R,WD^8903G+'<.<YY]Z]!HJO;U+WN3[&G:UBGI-C_9FC
MV.G^9YOV6WCA\S;MW;5"YQSC.*\\T7X0?V1K=EJ/]N^;]FF67R_LFW=@YQG>
M<5Z?14QJ2C>SW*E3C*U^@5YAHOP@_LC6[+4?[=\W[-,LOE_9-N[!SC.\XKT^
MBB-24;I=0E",K-]"*YMH;RVEMKB)9895*.C#(8'J#7FNI?!;3;BX:33]3FLT
M8Y\MXA*%^AR#^>:]/HHA4E#X6$J<9_$CS31?@[8Z=J$%W=ZI-=&%Q(J)$(@2
M#D9Y)KJ/&GA7_A+]'AT_[;]D\NX6;S/*\S.%9<8R/[WZ5T=%-U9MJ3>HE2@E
MRI')^"/!7_"&Q7J?VA]L^TLASY/E[=N?]HYZUJ>(?#&E^)[(6VI0%MIS'*AV
MO&?8_P!#Q6Q14N<G+FOJ4H14>6VAY-/\$(6D)@UZ1$[+):AS^88?RK;\-?"O
M3_#^J0ZD^H7%U<0',8VA$!QCD<D]?6N^HJW7J-6;(5&FG=(Y7QAX&LO&'V=Y
M[J>WFMPRHT8!&#UR#UZ>HKCO^%'KOR?$!VYZ?8^<?7?7K=%$:TXJR8Y482=V
MCE_"O@32?"9::V\R>\==K7$N,@>B@=!5+QG\.K;Q=?0WPOFL[E(_+9A$'#J"
M2.,CGD\YKM:*E5)*7-?4;IQY>6VAD>&O#]OX9T2'3+:1Y%0EFD?JS'J?:M>B
MBI;;=V4DDK(\RUWX2RZ[KEYJ<WB#8]Q(7"?8\[1T"YW\X&!7HFG646FZ;:V,
M/^KMXEB7C&0!BK-%5*I*22;V)C3C%W0R:%+B"2"5=T<BE&'J",&O,-/^#LFF
M:K;7]MXB(DMY5E0&S]#G!^>O4J*(U)0T3"5.,MPJMJ-I]OTR[L]_E_:(7BWX
MSMW*1G'?K5FBH+/.?"_PK_X1OQ%:ZM_;/VC[/O\ W7V79NW(R]=YQ][/2NT\
M0:3_ &[H-YIGG^1]I39YFS=MY!Z9&>GK6E15RJ2D^9O4B-.,5RK8X'P?\-/^
M$4US^TO[7^U?NFC\O[-LZXYSN/IZ5T?BSP]_PE&@2Z7]J^S>8ZMYGE[\8.>F
M1_.MNBAU).7,WJ"IQ4>5;'%>"?A__P (=?75S_:?VOSXQ'M^S^7MP<YSN.:W
MO$7AS3_$^F&QU!&V@[HY$.'C;U!K7HH<Y.7,WJ-0BH\J6AY-_P *0A\_/]O2
M>3G[OV4;L?7=_2M74_A'I5SH]I8V%TUI)!(SO</%YKRY !SRN.@KT2BJ=>H^
MI'L*?8R/"^A_\(WX=M=)^T?:/L^_][LV;MSLW3)Q]['6N'UKX0?VOK=[J/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]PH_+GV[5V5%:3KSDK-D1HPB[HY[QAX4MO%VCBTED,,\;;X)@,[6QCD=P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !114;2JO'4^U $E%5C,QZ8%-\Q_P"\
M: +=%5-[?WC^=&]O[Q_.@"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O'\Z
M+=%5-[?WC^=&]O[Q_.@"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O'\Z +=
M%5-[?WC^=&]O[Q_.@"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O'\Z +=%5
M-[?WC^=&]O[Q_.@"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O'\Z +=%5-[
M?WC^=&]O[Q_.@"W153>W]X_G1O;^\?SH MT54WM_>/YT;V_O'\Z +=%5-[?W
MC^=*)7'\1H M45 LY_B'Y5*KJPX- #J*** "BBB@ HHI!U- "T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !2'K2TT_>% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *"<#)HJO-
M)D[1T'6@ DE+<+P*BHHH ***9+((87E8$JBECCKQ0 ^BN>\,^,=-\4Z;<W]H
MEQ!!;.4D-R%7&!DGACQBF>&_&EAXJN[N+3;6],-L<-=21JL3'/ 4[LDGKTZ=
M<4 =)1110 4444 %%<]:>,=.O/%]UX:CANA>VREW=E7RR  >#NS_ !#M70T
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M;U]\(;=K^6XTC6KC38Y2<PK&7 ![ A@<?7-='X0\#Z=X0BE:W=[BZF 62>0
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MB[PG:^+M+2TN)7@DB??%,@R5/0Y'<$?TK,\'^ Y?"U^]U+K<U\# 8$B:,HJ
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M5;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTS6=.UBS-WI]Y%<6ZDAG0_=(&<'/3@]ZQI_B)X3M[HV[ZU"9 <$HCNO_ 'T
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MQ[UL4FFG9C33U04444AA1110 4444 %%%% !1110!7G^^/I452S_ 'Q]*BH
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M)?#FJ1VN?M+6DJQ8Z[RAQ^N*Q_AU<6DOP^T<VK)LCMPD@!'RR#[^?0YR?QH
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M>16&D?V1JTD&)%C8E2H/)7L""1Q@=NN*XH:)J7@.^N9-8\-V^KZ>^%,[KN4
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M9U*D@'(R.WK4JJN5<SZE.F^9V70\RT>)I/" LT^'TU\\\;8U)2=Q8YPRG8<
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MB1U] 0/PJ*TE))IETHN+::-.BBBL#<**** (9#5<']\G^\*FE-5U/[Y/]X4
M:%%%% !1110 4444 %%%% $%Y9VVH6DEK=PI-;R##QN,AN<\_E7B?PWT;3=4
M\8ZO;7UE#<011N4CD7(4B0#C\*]SK@/!/@?4_#?B74=2O)[22&Y1E1878L"7
M#<Y4#H/6MJ<^6$E<QJ0O*+L<EJUI#KOQIATC4%*V$)6&.$D@!%BWA1TP&/\
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M#Q8L-MO9PO\ 9J,1N.3R6/K6SH/ABVT2:XNVN)[W4;G'G7=P<NP'\(]%]O\
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M7=5\0:AI_A^+3DM].*QW%S>AVWR$9**%(Q@$9)[]JI>!);N2Y\622VZ1WO\
M:3;HM^4\P1KT;'W2>AQG!Z4 =U17'7.M>)]$OM,;6(M(ELKZ\CLR+/S!)$[\
M*<L<,,^PK1T'79[V]UNPU(0176F7)4E 55H&7=&YR3U&<]N* .@HK"\):Q=Z
M_H?]J7,444=Q-(;544@^0&(0MDG+$#.>!R.*P(],BUKQ;X]TR;_5W5K9Q$_W
M28Y,'\#@_A0!WE%<3HWBHVOPRDU2^P+O2X7M[E#U\Z+Y #[L=O\ WU6MX*TB
M31O"=C;W&3=R*9[ECU,KG<V?H3C\* .@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *P=8\&>']>O!>:CIRRW(4+YJ2O&Q [$H1FMZB@#*T7PUHWAY9!I
M5A%;F3[[@EG;ZLQ)/YUJT44 <U-\/O"L^H/>R:/$9G?>X#N(V;KDH#M/XBM?
M3='L-(M)+6PMEA@DD>5DR6!9CENI/Y=*O44 <Q_PKOPD;O[3_8L.[=NV;W\O
M/_7/.S]*U=7T#2]=M([74;430QG<BAV3:<8X*D$<5I44 8ND>$]#T*Y>YTZP
M6.X<;6F>1Y'(]-SDG%1:OX*\.Z[>?:]0TQ)+G&#-'(\3L/<H03^-;]% &/%X
M5T2#0Y-%BT^--/D;>\(9OF;(.2<YSD#G/:JVF^!_#FDWL=Y:::/M,7^KDEFD
ME*?[N]CC\*Z&B@ KR_P1X1T+Q#X>N)M3T]9IEU"Y02+(\;;=_0E2"1[&O4**
M *FFZ99:/8QV6GVT=M;1_=CC&!]?<^]8=W\//"E]=R74VD()93F3RI9(U<^Z
MJP!_*NGHH S)O#VE7%II]I)9KY&G31W%K&K,HB=,[2,$9QD\'(K3HHH RM=\
M-Z3XEMHK?5K4W$44GF(HE=,-C&<J0>]8W_"L?"/_ $#9O_ ZX_\ BZZZB@#*
MUGPUH_B#RCJ=BD[P_P"KD#,CI]&4@C\Z31O#.C: TKZ98I#)-_K)2S.[_5F)
M)_.M:B@ KG]4\#^&]9OS?7VF(]RV-\B2/&7Q_>VD;OQS7044 9FF^'M)TA[I
MM/L8K?[4$$RIG:P1=JC;T''H.>]9D'P^\*VUT+B+1X@X8NJ&1VC5O4(6V@_0
M5TU% ',ZAK?A[P%I=KI[%H56)A9VB*\CR8_A4\\Y(ZGO4'PY\/R:!X647-LM
MO>7DK74\0'^K+?=3\% &.QS76T4 %<S>?#WPK?WLEW<:1&9I6W2;)717/J55
M@I_*NFHH \\\<ZM8Z]8R^"]('VK5)YHX9(UB;;:JK!C(QQ@  <<UWEC9PZ=8
M6]E;+M@MXUBC7T4# J>B@#F+GX=^$[N\DNYM'C,LC;W"2.B,?4H&"G\JVO[)
ML?[;_MGR/^)A]F^R^=O;_5;MVW&<?>YSC-7:* ,#5_!7AW7;S[7J&F))<XP9
MHY'B=A[E""?QK1TG1M/T*R^QZ9:I;6^XOL4DY8]22>2>*O44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %(>E+2-TH K2&JZG]^G^\*GD-5T_P"/B/\
MWA_.@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N/\)^!?^$7UC4-0_M'[3]K!'E^1LV?-NZ[CFNPHJE)I-+J2XIM-] H
MHHJ2@HHHH **** "BBB@ HHHH **** *\_WQ]*BJ6?[X^E14 %%%% !1110
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M HHHH **** "BBB@ HHHH *:_2G4R3I0!5EJNA_TB/\ WA_.IY35=#_I$?\
MO#^= &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>?[X^E15+/]\?2HJ
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MN/2GT %%%% !1110 4444 %%%% !1110 4444 6H?]4*?3(?]4*?0 5C2?\
M'U+_ +Y_G6S6)(?]*E_WS_.@"W%5R/I5&(]*O1=* )**** "BBB@ I&4,I5@
M"I&""."*6FNZ1QM)(RJB@EF8X  [DT 4=%T>WT+3_L-I),ULLC/&DK ^6&.=
MB\#Y1DXSD^]:%8O_  F/AC_H8](_\#HO_BJOV^J6=UJ5YI\,VZZLQ&9X]I&P
M."5Y(P<@'IF@"W1110 453EU2R@U6WTR2;;>7*/)%'M)W*N-QSC QD=35R@
MHHHH ***J:7JEGK.FPZAI\WG6LX)CDVE=P!(Z$ ]0: +=%4M1U6TTLV@NW9?
MM=REK#M0MF1LX!QT'!Y/%7: "BBB@#F)M)UNP\1:CJFD'3KA-0$?F1WC/&T9
M1=HVLJMD'K@CKFK&B:-?6^K7^L:I/;O>W:)%Y=LI$<:)G R>2<DY-;]% &)J
MFCW%]XFT'4HGB$.GM.958G<V^/:-O&.O7)%;=%% !1110 4444 %5-3L%U33
M+BQ>::%)T,;/"0'"GK@D'&1Q^-6Z* (+.T@L+*&TM8Q'!"@CC0=  ,"IZ**
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M7?[8U/\ Z"-Y_P!_V_QH_MC4_P#H(WG_ '_;_&J5%'M9_P S#F?<N_VQJ?\
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MVQOV[=^?FZ'.,=* -66*.>%X9HTDB<%71UR&!Z@@]14:V5HEF+-+6%;4+M$
MC 0#TV],57FU"6+6K:P%A</%-&SM=*/W<9'\+'U/:K] %&TT72M/E\VRTRRM
MI/[\,"H?S J2]TVPU)%6^LK:Z5>@GB5P/S%6J* (;>TMK2W%O;6\4,(Z1QH%
M4?@.*J1:!HUO<?:(=)L(Y\Y\Q+9 V?J!FM&B@"$VELUVMV;>(W*IY:S%!O"]
M=H;KCVIL]A9W5Q#/<6D$LT!S#))&&:,^JD\CH.E6** $(!!! (/4&L^+0-&M
M[C[1#I-A'/G/F);(&S]0,U>EE2"%Y9&VQHI9CZ <FN?T'Q%J.NO%<)H;0:5,
M&:*Z>Y4L0.A,>,C./6@#;O+"SU"'RKVT@N8LYV31AQGZ&F0Z7I]N8#!86L1M
M]WD[(57R]W#;<#C.!G'6G7^H6NF6INKR810AE7<03RQ  P.>I%4?$^N?\(YX
M=NM6^S_:/(V?NM^S=N=5ZX./O9Z4 :-TMR]NZVDL44YQM>6,R*.><J&4GC/<
M5G?9_$7_ $%=+_\ !;)_\?K7HH S%TV:\@D@UPZ=J$)(*1BR*J",\D.[Y[8Z
M8J/_ (17P[_T -+_ / ./_"M>B@!L<:0Q)%$BI&@"JJC 4#H .PKDH=+-S\0
M]8DO+ RV,UC"@::'=$Y!Y&2,$UU]% %>SL+/3HC%96D%M&3DI!&$!/T IT%I
M;6S2M;V\433/YDIC0*7;^\V.I]S4U% $)M+9KM;LV\1N53RUF*#>%Z[0W7'M
M45[I>GZD%%]8VMT%^Z)X5?'TR*MT4 ,AABMX5A@B2*)1A410H ]@*9;6EM90
MB&TMXH(@2=D2!5R>2<"IJ* "BBB@ HHHH **** "BBB@ HHHH M0_P"J%/ID
M/^J%/H *P9?^/N;_ 'S_ #K>K E/^F3?[[?SH LQ=JOQ5GQ=JOPT 6**** "
MBBB@ HHJ&\MEO;.:V=Y465"A>)RCKD=01R#0!-17E>NZ=X8L_L\'A&1'\3+=
M1B(V5PTL@PX\SSB"?EV[L[JW=1LH/%/Q GTK4@TVF:;8I+]E+D))-(Q^9@,9
MPHX!]: .WHKC?"Z#1?%NM>'(&?\ L^.*&[M(F8MY(?(=03_#D @=LFKOBSQ!
M?Z'+H\=A:17,E_>?9BDA(ZJ2"".G(&3@\9XH Z6BN(G\0>*]-UZTT:[L]*N+
MC4D=K.: R)'&4P7\P,22 ISD8R<# JYINOZO;:W?:3K\%HTD%D+Z.>Q5@KQY
M*D%6)(8$>M '5T5YU>>+/%B>#T\4P+HR64FR06[0RR2)&S!1\P=0S<C@ 5L^
M,[N^@\*1Z:)8VU7572P1X5*KN?AV )) "[CU.* .LHKC)M3U33?$UOX1T&SL
M_)BTJ.>.:XW;8@'9/FVGYN%7 &.23FHK+Q!XLO\ 4]0T)+32H]1T\JT]VWF&
M!D<93:@.[<?FSDX&WO0!V=Q<P6EN\]S-'#"@R\DC!54>Y/ IEE?V>I6XN+&[
M@NH"<"2"0.N?3(XKG-+\2)=Z%?W'B*WMX)M,O6M9U0%T>1=I4Q@\DG<N!US5
M_0+6>)M1U:]A6TEU"193 2,Q(J!5WGIN(&3Z=.<9H W*AN;NVLT5[JXB@1G"
M*TKA06/  SW/I7 :;K7]G:!K/C22W,]SJUV$LH2<%XP?+A7VSRQ]C4'C"3Q,
MNFZ8-:BTQX9=3M<&RW@PMY@.&W$[AC(R,<XXYH ],HK(U?\ X2%IHUT4Z8D>
MW+R7HD8YST"KCC'?/X5S7_";:G#H3:A=6MJC:=JW]GZH$W,H3(!DC.1C[ZGG
M/>@#O**P=9UNYM->T/2;!(7FOI6>8R G9 BY8C!&"20 3Q[&JOQ&_P"2>:W_
M ->Y_F* .HHKA9O^))XWT'4N%MM7M!I\Y["51OB/U/S+5B]_XGGQ-LK,?-:Z
M';F[F';SY/EC!]PH+"@#LJ*** "BBB@ HHHH **** "BBB@ HI&.!7(:Z=3M
M)&FL[Z8P]3&3DK]/45I2IJI+EO8PQ%9T8<_*WZ&OK_\ R#Y_]P_RKS>KLVKZ
MA.A26[D=2,$$U2KW,)AY4$U)[GR>98Z&+E%P35NX4445V'F&CH?_ "%H?Q_E
M7I<'^K%>312R02"2)BKCH16C!K&KRR+%%=S%CT ->;B\)*K/G325CW,MS*&'
MI^R<6VWT^1Z;161HJ7$4&;J[DN)6ZY/RK["M>O'DDG9.Y]/3DY14FK>04445
M)84444 %%%% !1110 445#<?-"R[F7(QN4X(^E ,E/2N-\8?ZF/_ *Z?T-4M
M4NM9T^8C[?+)"3\K@_H?0UC7-]=78 N)WD .1NKU,-@WS1J*2:/G\?F<73G0
ME!J3[V*]%%%>P?,A77>#_P#4R?\ 70_R%<C5BVOKJT!%O.\8)R=M<^*HNM3Y
M$=N Q,<-6]I)71ZP.E+7GVEW>LZA.!]OE2$'YG)_E[UW=M\L*KN9\#&YCDGZ
MUX5>C[)\K:;/KL)BOK,>=1:7GU)J***P.L**** "BBB@ HHHH ***:YPIYQQ
MU':@!U<OXL_Y!TGU7^8JIJNLZWIDY4R1/"3\L@CZ_7T-85[KE[J$1CG9"IZX
M7%>AA\'-RC4335T>+C<SI*$Z,DU)IK;NO4SJ***]P^3"NC\)?\?,_P#P'^M<
MY5NQU&XT]V:W*@MC.1GI7/B:;JTG".[.O 5XT,1&I/97_)GJB?=%.K@;7Q)K
M=U,L,!C9C_L<#ZUVMD9OLZBXE$LO\3*N!^ KPJV'E1TDU<^OPN-AB;NFG;NR
MS1116!V!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "'I566K3=*JRT 4I>]00G_3(?]]?YU-+W
MJO#_ ,?D/^^O\Z .AHHHH \<N9#-=32GJ[EC^)J*BBOB6[NYXX4444@"M/0=
M.CU35%@F8B)5+OMZD#L*S*FM;J:RN4N+>0I*ARK"KIN,9IR5T.+2:;--[[0V
M$B#1I$&#LD%RQ;/;(/%9JV5PUBUZ(\VZOY9?(X;TQUK?LYK/Q+<?9+FR2"]D
M5BES;\ D#/S+^'_ZJKP?\B1<_P#7XO\ Z"*ZI4^?WKIJSM96V[Z?UW-7&^ID
M16D\UK/<QIF&#;YC9'R[C@<=^:W/[)DOO#6FFSM%>X9Y-[@ $@'C+'^M0::C
M#PKK;D':3  ?4A^?YBIKQY%\#Z:JDB-IGW8[G+8_K3I4XQBW+K&__DUOT",4
ME=]OU,B^TR]TUE%W T>_[IR"#^(XJ;4XV2WL"UBMMN@!#JX;SA_>('2KT.7\
M#W/FDD1W2^5GL<#./S-7Y4B>_P##"S8V&"/KW/;]<4*A%I\KW2_%V_K8.1=.
MMC%7PYJ[0><+)]I&[&X;L?[N<_I5"&VFN+A8(8F>5C@(!SFNCO+O2[;Q!+<S
M#5/M<4Y8_.F,@]!QG;_2GZ?=1W,WB"_M$,4A@+1C/S*#]X\>XS0\/2<E&+ZO
MSV^2#V<;V3,B;P[JMNJM+:[0S! ?,4\GH.O%6=5\-7-A%'+&N^-8%>9C*O#=
MP!G)%8>3SR>>:W?%7_'[9_\ 7G'_ %K.*I.G*2B]+=?^ )<O*W8JP^'-6N(5
MECLVV,,KN=5)'T)S6;)&\,KQ2+M=&*L/0CK70O<:=XAGB,\LMEJ#!8PP&^-C
MT'N/Y5A7=O+:7DUO-@RQN58@YR?6IK4X12E#5=[_ *6T%.*2NAUQ97%I'#)-
M'M6=-\9R#N7\*=>:==V"Q&ZA,8F7<F2#D?A6_8VG]MZ-I<9!8VUT89,G_EF?
MF/Z#%3W3#Q-;RJF-UO?*J%1R(7(4'\QG\*V^JQ<;I[I6^Z[^XKV2:T^7ZF/I
MVGW5OJ<*3::MRTD)E6!Y%7*D<'V^AYIVG>'I[_2;F[53N&WR!YB@,=V&SGI@
M9]*V;.Z%UX[N&4_)&CQ(/0*,?SS6-IO_ "+.N?\ ;O\ ^AFK5*FG;=>_^"]/
MZ_-\L5^/Y%G2-+;[/K-O/;))=1PKL& Y5CG&",\].E9USX?U2TMVGFM&$:\L
M0RMCZ@'BM#PW(\.FZU)&Q5UMQ@CJ.M1^%B6NK]"<HUG)N4]#TZU*A3G&G&SN
M[_F]]-?P"T6HHP:***X# **** "NK\!RD:G<Q=FAW?DP_P :Y2NG\"_\AN;_
M *]F_P#0EKKP+MB(>IK1_B(]!HHHKZP],**** *\_P!\?2HJEG^^/I45 !11
M10 4444 %<?\1/\ D%Z3_P!A:W_F:["N;\9Z7>ZM8:=%90^:\.HPSN-P7"*3
MD\D4 0W]W<I\2M)M5N)5MI+*9GA#D(Q!X)'0FLG3+34M?\2>([:?6]0M["UN
M\1I;3%7R5Z;N2JC'08Y-;E[I=[+X_P!,U-(<V<%I+%))N'RL3P,9S^E'AO2[
MVPUKQ%<7,/EQ7EV)8&W [UVXSP>/QH I^&;F[L/$>N:'=:A/>VUDD4T,URVZ
M15922&;O]:YFRU^TUZ&74M4\1ZU8S2R-Y%M813+'"@)"YVH0Y[DYKLM.TJ\A
M\<ZYJ,T %G=00)$Y93O*KAAC.1^(K+TFU\1^$()-*L]'35M.65GM9$NDB>-&
M).U@W7DGD4 58=<\07_PYEN8!</?PW'DR2QPXEDB##+HA'WMI]/6K_AB/2KR
M]CNM,\5ZK>M'DRVEU=;R>,?,C $8/I6V+[6UT87+Z-&]^7YLTN@-JYX^<C!.
M*P3INKZWXGTO4I]"BTC[%(7EG:X2268%<;/D[?4__7 .PN[A+.SGN9/N0QM(
MWT S7%Z)I&H^)]'AUK4-?U6VN+L&2*&SG\J*%<_*-N/FXQUZUVT\*7%O)!(,
MI(I1AZ@C!KC=+C\4>&=/71[?18M4@@W+;W:W:1?(22 ZD9R,]J &V%U=Z]X/
MU>SU*[F6]TV:>VFEMV\LS;%."<=B#^.*N?#_ $M+7PSI]X+N]D,]JF8I;AGC
M3_=4\+^%3:+X?NM+\,:C;W#I-J5^TUQ.8^%,L@Z#/;H*O^%[*XT[PMIEG=Q^
M7<0VZI(FX'! Y&1Q0!SOQ.LA/HUI.;BY3;=PQ[(Y2J'+=2!W'8]J9XZTM-*^
M&NL1)=WMR':%MUW<-*P_>IP">@K;\::/=ZUX?,%B$:ZBFCGC1S@.5;.,]JSO
M$D&N>)O FI6;:(UI?2-$(K=KJ-]X#HQ.X' Z'J>U %77=%U33/#MUK9\1ZK_
M &G;P^>RB8>06')41XQM[5-XG\3W%MX?T3R[@V<VK;/,GCC,C0H5#.54 DGG
M XK?\465QJ/A;4[.TC\RXFMV2--P&21P,GBLC4_#E_=^'-#:T:.'5M*$4D:R
MG*,RJ R$C/!QU'I0!SZZU#I>JZ;)HVMZWJ2S7*PW=M?1RN/+;C>I= %(..A[
M_6M.Y&JZI\0]2TF'5+FTL!:12RF*0[U]H\\*23R<9XK8L]6\3W%U!%<>&$M(
MBX$T[WZ. O<JJ\G\<4EEI=[%X_U/4WAQ9SVD44<FX?,P/(QG/Z4 1ZU!8Z5H
MEG9WGB74+*)9#^^,^ZXGZG;NP6/4=.P%8OA[5TB\;QZ9I^KZCJ&GW%J[LM^)
M"T<BG^%G4$C'UK5U[3-4B\76&OZ?8)J*0VS6[VQF6-D).=ZEN,\XJO:Z?X@O
M?'-AKFH6,5K;);2P^2DRR&+TW'N22>@(&* *FF6FI:_XD\1VT^MZC;V%K=@1
MI;3E&R1TW<D* .@QR:=;QZJ-0UWPD=6NYC]C%S8WCRD31Y.-K.,$_-CGTSZU
M6T:YUJR\5^*9]-T]-1@:\"R0>>(G5MO# MP1S@CV%;WA[2M4?7]0\0ZS#':W
M%S&L$-K'('\J->?F8<$D^E %1/%CK\,GUB0L+^.$V[*?O?: =G3UW8/TKH]
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M PP1D'GV-,\3:1%IOAJZLO#>D0VUUJ;QVC-96H3:K'!=]HX"J6Y/3/O7744
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M_P!=&_G715SDW_'[/_UT;^= %F'M5^(UGP]JT(J +8Z44#I10 4444 %%%%
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M;'3+?S]0O+>TA+!?,N)5C7)[9)QFJ]GJ^DZN673]2LKPK]X6\ZR8^N":P?B
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MUE9=D>?.M.74N_VQJ9_YB-W_ -_F_P :/[7U/_H(W?\ W_;_ !JE17/[6?\
M,R.9]R[_ &OJ?_01N_\ O^W^-']KZG_T$;O_ +_M_C5*BCVL_P"9BYGW+O\
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MN_2/_OG_ .O1_;=WZ1_]\_\ UZ .BHKGO[;N_2/_ +Y_^O1_;=UZ1_\ ?/\
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MX+MQN'7(84M_X9U"'5+35=+EL[FYCLUL[F/4%.V=5.5?<H)#9)YP<Y]JY?\
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M(77_ '^;_&C^S)_S!_;]/^1GJM%>5?VMJ7_00NO^_P W^-']K:E_T$+K_O\
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MZ#1117UIZ@4444 5Y_OCZ5%4L_WQ]*BH **** "BBB@ KG_&.BWFO:(EK8/
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MDC0KK4M-&FE!#)=1H_VB2(<8VGY02."<UV]% $5M;Q6EK#;0KMBA18T7T4#
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M+0 4444 5[^Z%E87%R?^649;'J<5Y#([2R-(Y)=B68GN37IOBHD>&[S'HO\
MZ$*\PKY_.)OVD8^1PXI^\D%%%%>0<H4444 %%%% !1110 4444 %%%% %K3Y
M3'= =FX-='&V17+0?\?$?^\*Z6W.17T643;I.+Z,[\*[Q:+%+24M>J=(4M)2
MT %+24M !2BDI10 4"B@4 +1110 M%%% "T44R9_+A=_[JDTTKNPFTE=F%JU
MX9IS"I_=H<'W-9U!)))/4T5]/2IJG!01\!B*\J]1U)=0HHHK0Q"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME@/D?D?X52KZBG-5(J2ZGY_6HRHU'3EN@HHHJS(**** "BBB@ HHHH ****
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M<V<TZ EK>*;,@QUXQVJE0J-M);#Y)=C&HJ_IVCW.J13R6YCQ"5WAVQPV>?3
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M^S2V*VRH"=^X-G)&,8_&LV/0/$&@WUXWAVYTZ2QNYC.;:^#CR7/785SP?0T
M9,?]IQ_#3Q';:C!>11PB9;0WG^L,&,J&Y/(Z=:V/#'AJQ2PTW7+_ '7.J?9U
ME^TRR'$8*?=5<[0H!QT]ZNWFF:UJGA+4=/OY[(W]TCHAA#+$@(P!SD^O-:-K
MIQ3P[!I=PPRMHMO(R'C[FTD4 <%?P^&-62^O;30]9U-Y&D(OXMQ56YY1F<<
M^@Q4.IWEWJ'PBT2X>=OM37$*B9CDY#E0Q]3P*W=/\/\ BJRT9- %]I::>J&(
M72(YG\LGLI^4-@D9R:R?$>B3Z1\+M-T>YE0S1W<2-)"21S(3D9 ]: +WB;P?
MIND>'KO5]--Q;ZK9Q^>MYY[L[LO)W9.#GFG_ &AK'Q9H6O, D&NVJ6MR!T$V
MT-&?J?N_A5C4=#\6ZU9'2;_4-+33Y"%FN($<3RH#TVGY03WYJYXUL;5/ MVF
M\0+91++;O_<>/&P#ZD!?QH K60_MKXD7MZ>;;1H!:Q'L9GY<CZ#Y3785SW@K
M3Y;'PU!)<_\ 'Y>,UY<$]2\AW?H,#\*Z&@ HHHH **** "BBB@ HHHH M0_Z
MH4^F0_ZH4^@ KF)_^/Z?_KHW\ZZ>N8F_X_Y_^NC?SH LPU?AJA#VJ_#0!>7I
M2TB]*6@ HHHH *BG@2>)HY%#(PP5(R"*EHHW X'5?!\L3M)IYW)_SR8\CZ'O
M^-<Y/9W-LV)H)(_]Y2*]>9 U0/; ]J\NME5*;O!\OY'-/#1>JT/(:*]9-I1]
MDKG_ +&_O_A_P2/JGF>345ZS]DH^R4?V-_?_  _X(?5/,\FHKUG[)1]DH_L;
M^_\ A_P0^J>9Y-2@%C@ D^U>L?9*/LE/^QO[_P"'_!#ZIYGF=KI%]=L!';N%
M/\3C:*WK7PHZ89IU+_[O KL%M!4Z0!>U=F'RZE1?-NS6G0C!WW.>A\,N.?M"
M_P#?'_UZLCP\P_Y>%_[X_P#KUN@8I:[S<PO^$>?_ )^%_P"^/_KT?\(^_P#S
M\+_WS_\ 7K=HH PO^$??_GX7_OG_ .O2_P!@/_S\+_WS_P#7K<HH P_[ ?\
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M_P![&?UK7$3IN4H2ONG^!4W&[3.A#1K\1YM^-Q0"//\ >\L?TS65#JEMIVI
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MK#TKQ3::G?\ V"2TOK"]*>8D%]#Y;2+W*\D''UK:DD2*-I)&"H@+,QZ #J:
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MN53\/ZAJM[K$T-Q=I-! "'*HH!/08. ?_P!5:WB'4?[-TB5U.)9/W<?U/?\
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MKF?#'AJ'PUX#UF[\2[HQJ$>ZYC7[R)@A5_WB6/T) K3E@X7M;]3/FDI6O?\
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ML74O!0[7_&W^1+EHD%%%%9DA1110 5T_@7_D-S?]>S?^A+7,5T_@7_D-S?\
M7LW_ *$M=6!_WB'J:4?XB/0:***^M/4"BBB@"O/]\?2HJEG^^/I45 !5<V<1
M).Z?GTG?_&K%% %?[%%_?G_\"'_QH^Q1?WY__ A_\:L44 5_L47]^?\ \"'_
M ,:/L47]^?\ \"'_ ,:L44 5_L47]^?_ ,"'_P :/L47]^?_ ,"'_P :L44
M5_L47]^?_P "'_QH^Q1?WY__  (?_&K%% %?[%%_?G_\"'_QH^Q1?WY__ A_
M\:L44 5_L47]^?\ \"'_ ,:/L47]^?\ \"'_ ,:L44 5_L47]^?_ ,"'_P :
M/L47]^?_ ,"'_P :L44 5_L47]^?_P "'_QH^Q1?WY__  (?_&K%% %?[%%_
M?G_\"'_QH^Q1?WY__ A_\:L44 5_L47]^?\ \"'_ ,:/L47]^?\ \"'_ ,:L
M44 5_L47]^?_ ,"'_P :/L47]^?_ ,"'_P :L44 5_L47]^?_P "'_QH^Q1?
MWY__  (?_&K%% %?[%%_?G_\"'_QH^Q1?WY__ A_\:L44 5_L47]^?\ \"'_
M ,:/L47]^?\ \"'_ ,:L44 5_L47]^?_ ,"'_P :/L47]^?_ ,"'_P :L44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:Z?/]0Y$[6,>BNNU$37'AB2YNKVWN[F"=3'- >5!P,$X'U_*J>L6[:M+IM_
MOS7RB)\#@2 X/^?:G/"N.SOL_D]._<;IVV.=HK9\2W"2:H+6$_N+-! F#Z=?
MUX_"KFB7"VGAG4KAHEE,<L917&1NZ GZ=?PJ503JNGS;7U]!*"YG&YS5%=/H
MLLVL7MQ?7\L4KV=N3'YP 16[$@#H.>U6TG-S!<0ZQK&G7,#1GR]A&Y'[$?**
MTAA5*/,I;[?\'73\1JG=7N<;1716TK:/X9BO[95%W=3%/-*@E%'89Z<BF:9-
M/XBU^SCU%Q,B9)^4#( )P<#GG%1[!7C&_O.W337SO^@N39=68%6K:.T>VN6N
M)VCF5085"Y#GN#Z5UD-Y*]YMO=5TE]/;(:V5N O8#Y1TX[UF:<D<>F>(DA;=
M$JJ$;U&YL&M/JR4E9WWW\E?HRO9I/[SG**W]6#:GI.FZB@WS?\>LN#DEA]W\
MQD_C6BUK#<>(-,T0@-;V4>90.C/C<WUR<?F:A85MV3[6\[B]G=_=^)Q]%=M#
M>2O>;;W5=)?3VR&ME;@+V ^4=..]<==)''=S)"VZ)78(WJ,\&IK4%32:=_Z]
M63.'*KW(J***YR HHHH *Z?P+_R&YO\ KV;_ -"6N8KI_ O_ "&YO^O9O_0E
MKJP/^\0]32C_ !$>@T445]:>H%%%% %>?[X^E15+/]\?2HJ "BN<\??\B)K'
M_7#^HKS#POX1\&ZKX?M+K5/$!M;^7>)(!>0IMPY ^5E)&0 ?QH ]RHKD/%'C
M6W\&WFEV4]F\UO<+AYA)@QJI SMQ\W7/45D_\+5^SZC;PZGX=O;"TN#^ZN)F
M()7^]M*CCGG!- 'HM5;K4]/L9HH;N^MK>68XB26549STX!//4=*PO&'C6U\)
M16ZM;27=W<$^5 C;<@=R<''/'0UYMXH\0S:_XF\-M<Z5=:9<PSJ&@N%(R"ZX
M8$@9'![=J /<**X[Q5X^B\*ZY9Z?/8//%/%YC2QR?,O)& N.>GJ.M4]/^)@E
MU^#2]5T.[THW) A>=NN>!D%1@$\9&: .]HKD?%'CVW\/ZE%I=M83ZEJ4@#"W
MA.,9Z#@$Y/H!3/#7C^#6]6;2+[3KC2]2 RL$YSNXSCD @XYP10!U*:A92WLE
MG'=V[W48R\"R NH]2N<BK%>=:'>:5)\6M5@ATEXKX(X>Z-T65L;<X3;QGCN:
MDD^* 75M3TN'0KJYO;6X:""*W<N9MK,&8X7Y0,#UZ^U 'H-%<=X4\?P^)+RZ
ML)M.FL;^V0NT#-N) ."!P#D''&*Y&V\?>()/'6H-!HM]=1) 8UTOS"IAP5^=
M@ >?P_BZT >OT5Q>O>/QHTVGV,>D3W>JWD*2FS1\&/=_"3@DG(/&.U7=!\5W
MNK1W_P!L\/WFG2V<>\I*<[\@D!<@$GCTH Z>BN;\'>*_^$MT^>Z_L^2S\F7R
M]K/O#<9X.!^(KI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH M0_ZH4^F0_P"J%/H *YB;_C^G_P"NC?SKIZYF;_C^G_ZZ
M-_.@"Q#VK0BJA#5^&@"ZOW:6D7I2T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7O;
MH6=N92NXY  SC-16VJ6]QA=WEO\ W6_QJEKAE9HP$;RE&2V.,UCT =E17.V6
MJ26Y"2DO%[]1]*WXI4FC$D;!E/0B@!]%%% !1110 4444 %%%% #)/NU1EJ]
M)]VJ4M %"6H(/^/Z#_KHO\ZL2]ZKP?\ ']!_UT7^= '34444 >+T445\0>.%
M%%% !1110!IZ)J,.FW%Q),KL)+=XAL /)QZGIQ2Z%J,.EWSSSJ[*T3( @!.3
M]2*RZ*UC6E'EMTV*4VK>1IZ%J,.EZF+F=79 C+A ">1[D5+IVI6::3/IM_'/
MY4D@E5X,;@<8Z'Z5CT40KRBDEMK^.X*;6ANSZKIRZ'<:99P7"AW5UDD()8YY
MSCIT&,5<\-7@MM(OIIHPT=HPFA)Z"0@KC\>*Y=3M8-@'!S@]#6A>ZS/>6JVP
MAM[:W#;C';IL#'U//-;T\2U+VDMTK)6_K8N-37F?0SV9G<NQ)9CDD]S6E;:C
M##H-[8,KF6=T92 -HP<G/-9E%<T9N+;7]7,TVB_I&I?V9=L[1":&5#'+&3]Y
M34\S>'Q'*T$>HF4J=BR% JMCC..2!63151K-1Y;)H:DTK&O8ZG:G3&TW4HI7
MMP_F1/"1O1N_7C%,%]9Z=J-M=:4MP3$26^T%<MVQQTXS^=9=%/V\K+NMGU#G
M9N2S^'9YFG:#4(V8[FA0IL![@'KBJ]CJ,%KI^IV[))FZ55CQ@A<$]>?>LNBC
MV\K\R23UZ=Q\[O<V]!UFWTY9H;R*26%F65 F#M=3D'DC_(JE;ZI/!K U(8,W
MF&0@]#GJ/R)%4:*7MY\L8W^'87.[)=C<EG\.SS-.T&H1LQW-"A38#W /7%8C
M%2[%1A<\ ]A244IU'/=)>@.5PHHHK,D**** "NG\"_\ (;F_Z]F_]"6N8KI_
M O\ R&YO^O9O_0EKJP/^\0]32C_$1Z#1117UIZ@4444 5Y_OCZ5%4L_WQ]*B
MH YSQ]_R(FL?]</ZBO,?"K?#A- LWUTXU52QE/\ I']\[?N?+]W;TKVVXMX+
MN!X+F&.:%QAXY%#*P]P>#69_PBOAW_H :7_X!Q_X4 >=_%=DF\0>&F&&C?)Y
M'4%UJU\:P/[*THXY\]^?^ BO1;G2=-O7A>[T^TG:'_5&6%6*?[N1QT'2G7NF
M6&IHB7]C;72H<J)XE<*?;(XH \Q^)3'3/'GA[6[F-GL8M@;"Y *2%C^."#^%
M4?&OB32_$7BGPTVER&>."X >?RV4$LZ87D#IC/\ P*O8+JSMKZ P7=O#<0GK
M',@=3^!JM_8FD^5#%_9=EY<#;X4^SIB-O51C@\#D4 >7_$ZZ2R^(6@7<L;21
MP)%*Z*,EE64DC\A4'B_7;#QGXL\.VVA,UP\4OSR>6R]64XY . %)S[UM^-M+
MU"[^)/ANZMK&ZFMHGA\V6.%F1 )LG<0,#CGGM7?6ND:98S--9Z=:6\K_ 'GA
M@5&/U(% 'F&JW,?A;XR-J^K"1;&YCS'/L+!1Y87MZ$8XYP:9'?0^+OC#8W^C
M!Y+2UC4RS[&4$*&R3GD9R%[5ZQ=V5I?P^3>6L-Q%UV31AU_(TEGI]EIT1BLK
M2WMHR<E8(P@)^@% 'E_AO_DM^L_[LO\ [+2^ E4_%;Q2Q R'N,''3]^*],CT
MO3X;Y[Z*PM8[M\[YUA42-GKEL9-%OI>GVEW+=6UC:PW,V3+-'"JN^3D[B!DY
M//- 'FVA #XYZQ@8_=/_ "2J=CK-CX9^,&NW&KRM;0RQNBN4+<DHPZ G! ->
MK)IFGQ7SWT=C;)>.,/<+$HD8>[8R>@IEYH^F:A*LM[IUG<R*,*\T"N1]"10!
MY]XRD\&Z_>6DEYJLVFWYM8Y[:[6-L-&WS+D8]R>QI/AMXDU.>XU>TOKY]1TZ
MQC+QWC DG!]3R<@$X//%>@W.BZ5>JBW>F6<ZQJ%02P*VT#H!D<"I[:QM+*#R
M+6U@@A_YYQ1A5_(4 97AGQ5I_BNTFN=/6=%A?8ZS(%.<9!X)&*W*KV=A9Z?$
M8K*T@MHR=Q2&,("?7 [U8H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"U#_JA3Z9#_ *H4^@ KFIO^/Z?_ *Z-_.NEKFIO
M^/V?_KHW\Z +$/:M"*J$/:K\- %Q>@I:1>E+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZM1W;D]?,;E)[LN'5;TZ:-.,W^B Y$>T>N>N,]:ELM=U/3H/)M;IDCSG:5#
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M7[5=_:UE!0$$A% SDX[XK4U72;J;Q?X8O+:#-G8"Y$S[P/+#1A5X)R<D=LT
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M6:0Y:61OO,?<UIT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %#5[74;RT6/3-2&GSAP3*;<397!XP2.^#GVJ'0-"@T#3VMHI'F
MEED::>>3[TLC=6-:M% !1110 4444 6H?]4*?3(?]4*?0 5STO\ Q^3?[[?S
MKH:Y^7_C\F_WV_G0!8A[5?AJC$.E7X: + Z4444 %>>?&/\ Y%"T_P"O]/\
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M_)KG=&\4S:1?WTGV6*YL[_*W-I*?E=221SV(R>?>EU'6=!GT^:#3_#*V4\F
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MW'.<X/< ]*JOX@O/^$HDU^%O+NC<&=03D+D_=]QCCZ4E3DM/ZN-UHNTGO?\
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ML:20XZD<\9Q^7I64?%5E=Z!::;JNBB\FLHVCMKE;EHB@/3*@?-CC\OK3-/\
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M?8XO_A /^HG_ .0/_LJ/^$ _ZB?_ ) _^RKM**7]FX7^7\7_ )A]7I]CB_\
MA /^HG_Y _\ LJ/^$ _ZB?\ Y _^RKM**/[-PO\ +^+_ ,P^KT^QQ?\ P@'_
M %$__('_ -E1_P (!_U$_P#R!_\ 95VE%']FX7^7\7_F'U>GV.+_ .$ _P"H
MG_Y _P#LJ/\ A /^HG_Y _\ LJ[2BC^S<+_+^+_S#ZO3['%_\(!_U$__ "!_
M]E1_P@'_ %$__('_ -E7:44?V;A?Y?Q?^8?5Z?8XO_A /^HG_P"0/_LJ/^$
M_P"HG_Y _P#LJ[2BC^S<+_+^+_S#ZO3['%_\(!_U$_\ R!_]E1_P@'_43_\
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MHH **** "BBB@"U#_JA3Z9#_ *H4^@ K!D_X_)O]\_SK>K"E_P"/N7_?/\Z
M)XNU7XJHQ=JOQ4 34444 %>>?&/_ )%"T_Z_T_\ 1<E>AUYY\8_^10M/^O\
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MI9_OCZ5%0 4444 %%%% !6;=Z);7NM6.J3O*TMDKB&+(\L%A@L1C.<>]:5%
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MWUP>:E4VM?,IUD]/*QT3*5^$A5@0PU[!!'(/D4>.V.WPRN3M&A6Q SQGYO\
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MJ*>\NKF*&*>YFEC@7;$DCEA&/10>@^E-0:MY"E43O;J=9XM_Y$SP?_U[3?\
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M%9FP51U;6+#0['[9J,_DV^X)OV,W)Z#"@FKU<=\2F5/#,#NP55OH"23@ ;J
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MLUCN/])E_P!\_P Z )XNU78^E5(NU7$Z4 /HHHH *\\^,?\ R*%I_P!?Z?\
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MT_P9=0:'::)I5Y+# C7<][!YKO(PR0.?E&,<>_YPJE]D6Z/+>[_IG-:WX?\
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M^SR22LXC'FL$(8*&ZX.,=>AH=9):K4:P[;T>EK_<>3T5ZXD7A[QAX U?4(-
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M;TM*R(6$8V]6(Z#ZUEWL+:?XZU+4-6T*\U6VGBB6QE@MOM @ 'SKM_A)/?\
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MDO;E[1#E8&E8HOT7.!56BB@=[A1110(DMQ"US$+AF6$N!(RC)"YY(]\5U/\
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M.G6C->9XM;#SIOR,FBBBM3 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBI[6RN[V416EM-
M/(>BQ(6/Y"@9!7KGP?\ #\D:W.O3H561?(M\C[PSEF_, ?G65X5^%5_>S1W6
MN VEH,-Y&?WLGL?[H_7VKV>WMX;2WCM[>-8H8U"HB# 4#L*X\165N6)WX7#R
M4N>1)1117$>D%%%% !2-TI:0]* *L@JN@_TA/]X?SJU**KJ/WZ?[PH T:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ()(>Z_E4-7::T:OU'/K0!4H
MJ8P'L?SIODOZ?K0!'13_ "7_ +OZT>2_]W]: &44_P E_P"[^M'DO_=_6@!E
M%/\ )?\ N_K1Y+_W?UH 913_ "7_ +OZT>2_]W]: &44_P E_P"[^M'DO_=_
M6@!E%/\ )?\ N_K1Y+_W?UH 913_ "7_ +OZT>2_]W]: &44_P E_P"[^M'D
MO_=_6@!E%/\ )?\ N_K1Y+_W?UH 913_ "7_ +OZT>2_]W]: &44_P E_P"[
M^M'DO_=_6@!E%/\ )?\ N_K1Y+_W?UH 913_ "7_ +OZT>2_]W]: &44_P E
M_P"[^M'DO_=_6@!E%/\ )?\ N_K1Y+_W?UH 913_ "7_ +OZTH@<^@H CI54
ML< 5,L 'WCFI0 HP!B@!L<80>II]%% !1110 5G,/W[_ .\:T:J&"3S6;;P2
M3UH ?$*L5%&C+U%2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% $$BD] :A6-_-0[&QD=JNT4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img183648649_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img183648649_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Q!F8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZV@N(;F(2V\T<L9Z/&P8'\14E?*FDZUJ6AW@NM-NY;>4==AX8>C#H1[&O?\
MP+XTA\7::_F(L.H6^!/$O0YZ,OL?T_+.=7#N"NM4:4JZF[;,ZRBBBN<W"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHKR[XC_$6;2KA]%T60+=*/](N!R8\_P *^_J>WUJX0<W9$3FH*[/1
M[S4[#3P#>WUM; ]/.E5,_F:+34K#4 397MM<@<GR95?'Y&OE.>>:YF::>5Y9
M7.6=V+$GW)HAGEMIDF@E>*5#E7C8JRGU!'2NKZIIN<WUO78^MJ*\M^'/Q&FU
M2Y31=;E#7+#%O<D >81_"WOZ'O\ 7KZE7+.#@[,Z834U=!1114%A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5!=7UI8Q^9=W4-NG]Z:0(/S-<=\0_'7_"+6J6ED%?4[A=R[N1$G3<1W/H*\
M%O;^[U*Z:YO;F6XG;J\C%C712P[FKO1'/5KJ#LM6?4MIJ^F:@^VRU&TN6](9
MU<_H:NU\C*S(ZNC%64Y!!P0:]8^'/Q&NGOH-$UN<S)*=EO<R'+*W96/<'H#U
MS^E5,*XJ\7<5/$J3M)6/8:***Y3I"BBB@ HHHH **** "BBB@ HHHH ****
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M\ XY ,DW^ J[/5U%L9W6BIO<W=#\9-JGBF^T"[TTV5S;)YB%IMWF+QVVC'#
M]_TJKIGQ#MKZ/7+R:S,&F:4VW[2)=YF.X@ +@8)P._<5S_Q.CN/#^NV'BFP!
M5Y(I+24C^\4(4G\"?^^13HO!UR?@P;&UB+7]P%O6C'5SD$+]=@''J*?)"REW
MM_P0YYW<>U_^ 78_BH\:VUW?^'+RTTFX?;'>E]P/OMVC]#VXS6MXA\>1Z#KM
MCIJZ=+>B\@\V)X'RS,<A5"XYR0.<]Z\_U7Q(OB+P1I7A.PT^\;5HO)ADC,>
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MEKFH7:2*]Y]I<FV@."  .F[)X.>F?6NU^*Z2:3J^E>(+?(D,,UHQ'&,J=O\
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M#N=.1IO-@DD;<DJ[3R#@<\CCT--MS>ZW\)[S2$C:2[T6\#M$!EO*.[M[$M^
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M(&1^OI5727\+ZUX@T@IJ_BG4+Z"X22*.[D$BPL""=Q*\#Y1G![5*IQY;M?\
M *=27-9/_@G2ZE\2A8:YJ.CQ:+<7=Y;.J01P.6,^1DG 7Y0/QKL]/N9+S3;6
MZFMWMI9H4D>!\[HV(!*G('(SCH.E>?>&54_&7Q*Q R(.#CIS'7I595%%621I
M3<G=MA11161J%%%% !1110 4444 %%%% !7@GQ ^'USH5]-J.FP-+I,A+D(,
MFW]01_=]#^!]_>Z*TI573=T9U*:J*S/D6BOI>^\!>%M1E,EQHUOO)R3%NBR?
M^ $5-IG@SPYH\HELM)MTE4Y61P9&7Z%B2*Z_K<;;'+]5E?<\W^&OP^N6OH==
MU>!H883OMH)!AG;LQ'8#J/4_K[+117)4J.H[LZZ=-05D%%%%9EA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+5]*
MM=;TJYTZ\3=!.FUL=1W!'N#@CZ5=HH3MJ@:OH?,7B?PGJ?A:_:"\B+0%L0W*
MK\DH_H?4?_KK"KZUN+:"[@>"YACFA<8:.10RL/<'@US4WPW\(SRF1]&C#>B2
MR(/R5@*[H8M6]Y'%+"N_NL^=+:VGO+A+>VADFF<X6.-2S$^P%>]?#CP.WABS
M>]OPO]I7*@%1SY*==N?4]_H*ZG2O#^D:(I&FZ?;VQ(P61/F/U;J:TJRJXAS5
MEL:TL.H.[W"BBBN8Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M****YS<**** .$USP?KWB?7$35=2MAH$,_FQVT(/F,.P;@#/49R<9-=T %
M  '  I:*J4FTEV)44FV%<EK'A:^U#Q]H^O12VZVME'LD1V8.3\W08Q_$.XKK
M:*(R<=ARBI;A1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "J6KZ5:ZWI5SIUXFZ"=-K8ZCN"/<'!'TJ[10G;5 U?0^8O$_A/4_"U^
MT%Y$6@+8AN57Y)1_0^H__76%7UK<6T%W \%S#'-"XPT<BAE8>X/!KFIOAOX1
MGE,CZ-&&]$ED0?DK 5W0Q:M[R.*6%=_=9\Z6UM/>7"6]M#)-,YPL<:EF)]@*
M]Z^''@=O#%F][?A?[2N5 *CGR4Z[<^I[_05U.E>'](T12--T^WMB1@LB?,?J
MW4UI5E5Q#FK+8UI8=0=WN%%%%<QT!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 45%/=6]J@>XGBA4G ,CA03Z<TD-Y;7#;8;B&0]<(X/\J=G:XN9
M7M<FHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHH) &3P* "BL>Y\5:%:.4FU2V#+U"MN(_+-2Z;XBTC5SBQOXI6_N9*M_
MWR<&M'2J)<SB[>AFJU-OE4E?U-.BBBLS0**** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,()KMK&X/'DWT;0-G_@7'ZUT".DB!XV5D89#*<@U+BUN4I)[#J***0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **;)(D4;22.J
M(HR68X _&N=N/'.BI,8+.2;4[@<>581&8_F/E'YTU%O83DEN=)17+#5_%=_C
M[#X>@LXSTDU&YY_%$R?UI?[+\7W7-QXBM+0'^&SL@WZN3_*JY.[)Y^R.HHKE
MQX2O9/\ CY\5ZTY[^7(D0_\ '5H/@J,\GQ#XC)]M2<?RHY8]PO+L=117,?\
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MQ=ULS?+LP6*BXRTDOZN7****XSTPHHHH **** "BBB@ HHHH **** "BBB@
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M2QSQ)+#(LD;C<KH<AAZ@TG%H:DF/HHHJ2@HHHH **** "BBB@ HHHH ****
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M)26.!TSV'/:DO=&L-3OX;2YC=D*;LB5E88/8@Y'6G[K?.MD)SDG[-K<Y*_\
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MQ)I_B..Z:PN$N%MI!$\D8(1C@'C/;G]*B5-I7+C--V-FBBBH+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!DTT=O!)-*P6.-2S,>P')KY^U2];4=5NKQ
MN#-*SX] 3P*]6^(M^]GX8,49(:YE$9(_N\D_RQ^->/5[&74[1<^Y\SGE?FJ1
MI+IK]X4445Z1X(5V?P]UZ33]6737&ZWNWQ[J^.#^/3\JXRNB\#V9O/%MD,X$
M3&4_\!&?YXK'$1BZ4N;L=6"E..(@X;W1Z%X_T:35=!\Z%OWEH3+MQ]Y<<_CW
MKQNOH>\OK33X#->7$<$?]Z1L9_QKQ+Q9=V5]XEN[G3R&MW*X8+@$[1DX^N:X
MLNJ2:<&M.YZN=T(*2JIZO1K]3&4%F  )).,"O?\ 1+(:=HEE: $&.)0<^N,G
M]<UXUX8UY?#VIM=O:K<*T93:6P1R#D'!]*]6T/Q=I6O,(H)#%<D9\F488_3L
M:68*I))):+J/)'1@VW+WGI;^M[F]1117DGT@4444 %%%% !1110 4444 %%%
M% !1110 4444 4M6TRWUC3)K&Y!\N48R.JGL1[@UX)J^GMI.K75@[AS!(4W
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M+NQEW+G:Z,,/&W=6'8UHUQM_X9N+._;6O#DH@U #][;-_JKI1_"WH?0]JW=
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M%&7*O([RBJ&CZQ9Z[IL=]92;HWX*GAD;NK#L15^L6K:,W3OJ@HHHI#"BBB@
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MB5]'AX<E*,6K'P^,JJK7E-.Z;"BBBMCE"NY^'T$E@-1UV:-A:06S -TWG()
M_P"^?UKAJW[/5Y+/P=>V0GR;N=56//W% RQ_'Y1^=8UXN<.5=3KP=2-.K[27
M1-_.VA0UG6;S6[][J[D+$GY$!^5!Z 5GT45JDHJR.:4I3DY2=VPJSI]V]AJ-
MO=QDAH9%<8]C5:BAJZLQ)M.Z/HV.198DD0AD<!E([@TZN)^&FI7%YH]Q;3N7
M6V=1&3V4CI^&/UKMJ^:K4W3FX/H?>8:NJ]*-1=0HHHK,W"BBB@ HHHH ****
M "BBB@ HHHH **K7VHV>F6QN+VXC@B'\3GK[#U->=Z[\3W;=!HL.T=/M$PY_
M!?\ '\JZ*&&JUG[B.>OBJ5!>^_EU.XU_7+;0=+ENIY%$FT^5&3R[=@!7@][>
MW&H7DMU=2-)-(VYF-%[?76HW#7%Y/)-*W5G.:KU[^#P:P\7U;/G,;C7B9+2R
M04445VG$>R?#C5K>\\.I8)D7%ID.I[@L2"/Y5V-> ^'/$%QX<U+[7 BR!EV2
M1MT9<@_@>*]IT;Q#IVN6D4UM.@=QS"S#>I[@BOG,PPLJ=1S2T9]+EV+C4IJF
MW[R-6BBBO./3"BBB@ HHHH X_P 2@^(/$=CX84G[(J_;-1P?O1@X2,_[S=?8
M5UZJJ*%4 *!@ #@"N;\,6_FZEKFL/R]W=^4A/:.,;0/SS72UI-[1[&=-7O)]
M0HHHK,T"N>\;''A>X/\ M+_.NAKG?'''A2Z/IM/ZU4/B1,MC"N[K,I&:@^T>
M]9<UUNE8Y[TS[3[UPN9]3'#V1K_:/>C[1[UD?:?>C[3[TN8?L#7^T>]5;VYQ
M'UJE]I]ZI7UUP1FCF&J&IK^#)/,\9Q^T#UZG7D/P]D\SQCGTA;^M>O5V1^"/
M]=3Y[%JV(FO/]$%%%%,YPHHHH **** "BBD9@JEF("@9))X H I:OJUKHFF3
M7]X^V*,< <L['HJCN2:Y:PT^_P#[3A\3:\I%Q*I2* <K8H>@_P!X]S4VF(?%
M^MKK=PI_LBR<KIT1Z3..#,?;LOYUV#*&4JP!!X(/>M+\FG4A>\[]"GO#*I!!
M'M3)I54;CV'%5GB&G7J1H3]FF!VJ?X&'8>U0WT@$)^;%38LSM2U("0I$IPQR
M3V%85PQDSSCFIKE)G+[3AO0]JKA#(< AC[5:0AB+F3Y1U/-7U&(]I/7D^]1+
M!M5EZ'C)JS:QK<W\<1;"YY_G4R=AI'6:=%]BL(X2!N RQ]SS5CS,]Q5-Y"33
M0Y!KS'5DV;J!=(J:*0\*_7L:J129X-3NY('M5PE;WD2UT+5%(IW*#ZBEKM6I
MD%%%% !165J^JM:,EM:A7NWYPW1%]364FL:G:.))W2YA'WU$85@/48JE%L#=
MU6XEM[(M"=KLRINQ]W)ZUF0P1>;YDI::0?Q2MNQ3-9UFRGM(HH;F)O,(<G/W
M0.>?>LNXU= ^^'>5Q@ML.WZU23L*YTZ,&ZD?A4N\#A3U[&N9M-64,I=L*3BM
MV*<2L2HPN.,GDU+0RT,FN<UW2KN"]7Q#HBC^TX5VS0]%O(A_ W^T.QKH%))8
MYX R!0KCYN<\41DT[BDKH;HVKVNN:9%?VC$QOPRMPR,.JL.Q!J_7#WY/A+6C
MKL /]EW;A-2B7I&QX6<#]&KMT=9$5T8,K#((.013E&VJV%%WT>XM%%%04%%%
M% !1110 4C,J(SNP55&22< "EKD=>FD\1ZP/#%G(RVL8$FJ3(>0A^[$#ZMW]
MJJ,;LF3LB*WC;QSJ:WLX/_".VDF;:(]+R0'_ %C#^X#T'?K79U'!!%;01P0Q
MK'%&H5$48"@= *DHE*^VP1C;U"BBBI*"BBB@ JAJX_T(/U5)%9AZ@'I5^H;J
MW6ZMI(6) <8R.U" ;D#)SFHW^Z#FJAFN;1=MW"2@_P"6T?(^I'45*SAX@R,"
MK#((IV R]6O!&-JDON_2N2U>1?L^UF&68'&>M;FHAO-.2!CJ>U<M(C7$SMNW
M@MM#>PKHHQN[]CFQ,^6%EU")">3S5RWCPZE\;^G%0,FTKS\@.6%()'>4!> .
M_I71N<:21M&6%"%<C!]34B7EOG ?)]1TS]:S49LD^O7-3([J&!^93_#_ $J7
M$=R?4+,W+(RLL<B@$/C)!^M59K34&3GR)0!R%)4G\ZT(HI9HD"R,I7IP#D>A
MJY'"X"AASTSC&:S;MHS6*>\=#C3G[P!'."#V-(K%9,JBXQR>^:T4C626[0\$
M3/\ SI#:/VBW'V88J)*S.NG)RBFRNLA8# Y]*WM(+)*I()X/-48+%(V7S9!N
M/J<?D*U8Y8K;@@\>@Z^U0RRWJFGVVJV#6=XA:-^00<,A[,I[$4WPCXAN)I&T
M/5WSJ, )BG(P+J,'&X?[0[C\:N)I.HW2+)+<1P;QDH$RRCTZ]:-9\,)=Z1#'
M82>1J-DWG6=P>JR=\^H;H10FK<K)DG\2.BHK(\.:VNN:8)GC\F[A8PW5N>L4
MJ]1].X]C6O6;33LRDTU=!1112&%%%% !1110 5R/B;6+F]OO^$;T>4QW+KNO
M;I?^76(]A_MMV].M:7BC76T33E%M&)M1NG\FSA_O.>Y_V1U-9>BZ4ND61B>0
MS74S&6YN&ZRR'J?IZ>U:PC;WF95)?91;TVQMM)LHK2TC$<$8P!W)]3ZD^M7#
M@@G^]3 ,C'K2L69U11RQP*;U(V+6GS,)# 3E<97V]JS&;/C"Z\YL.EL@MP?[
MASN(_&M.6)=-LYKHOND2,XSP,_\ ZZS'T*"ZM(I':1+[&\72L=P8\_E[41MJ
MPFI62734T9)&$7R^O-*I'E%B,L.U89O;ZQE"W925!Q(47:P_VL=Q6BMU$[%(
MY QQG@T.-A*:985@[#=\HZFLVXECA9Y 3N8<\TVZO2BG'%<S<3A6>1IF">A/
M K2$+F52HD6;ZY\UL"L<2QB R !02>@Z\U*7EN/EAM)Y5/<(0*TM)TBY%VMS
M>6@4)_JD9A@'U([FM](K4YM9O0=8>&;N[MA-<7'V8L,I'LW''^UG^52#POJT
M4(C66S9%'R,68;OTXKIO.2,#()S[U9)'EJRD[6['L:YW6D=2H0L><I8R?;I8
M-00QR1_\L<]??/<5IF58RB!2 >!@<"NGO]*MM4C03JPD3_5RQG#I^/<>QKFM
M1TR\TA3*TGVJT'WG"X>/_>'<>]:*HIZ&3I.GKT[C#,[.%VD+W)-1QHL:LB$\
MG.:3RR[!QSQQ4J+M_A+-V&*H1/;1LYCD$A55.<>HJS<W'E^5<KSY$BR8]<&J
MT:".#RY&W# R*FT](KK6[6&<;H>2$[;@,C/K4ON5Y([@'(!'>F3Q">WDA8X#
MJ5)^M245Q'HF Z7=C'B: R1H,>9$<\>I'6HB89X2Z8&><XQ725@ZC9G3U,]N
MX\IW ,3#A2?0UK&5SGG!Q5UL<O<?;/#6IOKFGP.UN_\ R$;1.DB_\]%']X?J
M*[^RO+?4+*&\M95E@F4.CKT(-<_YC%>0,^G6L+1M23POXF;3"V-'OW!CS]VV
MG;^'V5OT-7*/.K]4*$^5V>S/1****YSI"BBB@ HHHH **** "BBB@#QS6M8U
MS1O$.O1S.4@)>:S2Y12K8/!3/7KVKC+/QGJQ\RZDGB:Y(VA=BYZYX'UKW2?3
MM,\1O<)K%G;7,<$SI'YJ#Y,''!Z\UQ'B2UB\+>)=-/A^T@@L;A-MR5B5D+;L
M $GH<'VKOI5$[1MJ<-6DTF[Z&IX>L]1U'0+>^O=::SO95):U95^7DX&"<Y(Q
M^=<GHMS.L4QE7;.93O4CD')S6//XVU8ZU<Q$6T4<1*IB/' Z=370>$XIM:L)
M+Q=',KK)AYI)_*20DDDKT!]\=*V@Y1;<V<E6G%QM36IK374AMWV8)8= *?>V
M%U#X'ENK75S-(;;<;/:I(4\,!SG@$G\*IW>HBPNY;&YTPQM'&9,QW#%6  /R
MGHW6N&C\8W\MI<QCR88""JH4!(4\8R?:B7,_A84H15^='7Z/=,EK;A2/>KFH
M32/9B-6PIP"P'3WI=#TV:[TR&[AT'REE' NKHQD8]B0<>G%9>K:_'%I5]OTV
M2.6WQ'L,K=3T.#U'O5.:EL9*E).S1K>-;.ZL-.MC%JIU"W:<"3A?W9[$D'O4
M=I<MC8"-NT8KB8_%=]>PVT=U$MPC2@FWA3YY".@'4Y^E>@#3+FSL/M"Z&JJL
M8DVM=DR8QG&T'.[VQ2C+ECRS>I=6G=ITUH-427VLV4)NC:H7/[\8^7Y3Z\51
M\3Q7-EXDL(Y;W[9;F,LD^T 9SRO![8'YUC>(?$_D:=;75K9F.X>0A2\C,$QP
M<@]#UJMINM76MZS9VMQ:->EEVK';C;Y>XC+,1R%X^@I:J7-T*5.+@U;4ZVUN
MG*\D<-QQ5G2K>34-9G+:D;#9$"&PN'YZ<U#?QSZ)9_:I=&01H<,(KHR,/?"D
M\>YKD=?\4S66K6T=C;K&7C#2/(QD!!YP,TY/F7NLBG3L_?1K3FXMO%NHQW$O
MFLF DI 'F# PWY5LPW<GE!LC=MQTKFO#ES/XAU:Y6336O9@-WG*_E1J ,!6(
MXS]3S707\[Z--!%<:4J)<':K17+,!VPS X!IJ2LHO<4Z;YFXK0T?#^GR7L-Q
M*=:-DYG*^454YX'/)SFLK2D$-]>IO+D7+C<>^&/-<C<^+KN#7;J"TC2"!3C]
MY\Q)'?)KH_!R7NMVDMS;Z/++(K_/.9C%'(2225Z X[XZ5,6XMN3T+J4E*"4%
MJ==.<VSGVKI/#G_(NV/_ %R%<W#H>K3,(I].2)#R7%ZQ _K^E==IMI]@TVWM
M=P;RD"Y'2N7$SBTDF=6"ISBVY*Q:HHHKD/0*=Y?+;R)".99 2!Z#UKGKOP#X
M<U:1[F;38DG?):2+*%CZG!QG\*NWASXCD'I;IC_OIJV;7_5U:;CJB&E+1G#2
M?";1&(V^8 .@WC_XDT1_"70E8&02,.X+_P" %>@457MJG<7L8=CF]-\,Z-X7
M+2Z;8PQ2D8>7!+D>F22<5T$$ZW$0D7Z$>AJM>]#4.B'-JW^]_2H=WJREH[(T
MZ***DH**** "BBB@ HHHH **** "BBB@ HHHH \B\6>,]1N]3N+2SN'M[2)S
M&!&=I?!P23U_"N.9F=BS,6)Y))ZUK^*;9;/Q1J,*\*)BP'INY_K6/7TM&$8P
M7*CX3%5*DZLO:.[38445K:/X;U37-QL;8O&IVM(Q"J#]3_2KE)15Y.QC"$IR
MY8*[,FBN[C^%VIM&#)>VBMZ#<?UQ2_\ "K=1_P"?^U_\>_PK#ZW0_F.O^S<7
M_(S@Z4@@#/UKMM1^&U[8Z;-=I>Q3/$I=HPA&0.3@^M<0:UIU85%>#N85\/5H
M-*HK7"BBBM# ***<B[W5=P7)QD]!0,]<^&UF+?PT;C'S7$S-GV' _4&NFU/4
M;?2=.FO;IB(HADXZD] ![YJOX>TY=*T&TLUD64(F2Z]&).21[<UE?$".:7PC
M<")"^'1GP.B@]?Y5\]*U7$:[-GVL%+#8+1:QC^-O\SS'7?$5WK.KRW@DDB0G
M$48?[B^E7?#/B^]T6] FD:>UE91(LC$[1GJOOBN9HKW'1@X<C6A\A'$U8U/:
MJ7O'T3:W4%[;)<6TJRPR#*NIX-35RWP]@E@\)0F7.))'= >RYQ_0G\:ZFOGJ
ML%";BNA]OAZCJTHS:LVKA11169L%%%% !1110 5E>(=<A\/Z1)>RC<P^6.//
MWV/05JUY?\5KIS>:?:9.Q8VDQZDG']/UKIPE%5JR@]CEQE9T:,IK<XG5M8OM
M:O&N;V9I'/W5_A0>@'850HHKZF,5%66Q\E*3D[R>H44450@HHHH *<DCQNKH
MS*RG(*G!!IM%(#K=)^(>M:?*HN91>P#@I+]['LW7/US7JFAZ_8^(+(7%G)R.
M)(V^\A]"/ZU\_5>TG5[O1;]+RSD*.O4=F'H1W%>?BLOIU5>"LSTL+F-2D[3=
MXGT/16=H>KPZYI$%_""HD&&0_P +#@BM&OGI1<6XO='TD9*45*.S"D<[48^@
MS2TC#*D>HJ2BEI%N+72X(\8."Q^I)/\ 6KU(JA4"CH!BEIMW=Q)65@HHHI#"
MJU]9QW]H]O)T;GD9'XCN/:K-%&P/4X&\\"?9D,L=W<>2IYCAP2H]MP)(_'\Z
M@'AK22 ?[7U 9]1'_P#$UZ+13]WK%%^VK+13?WL\Y?PYI"#+ZS?*/4B,?^RT
MUO#ND+UUJ]'U\K_XFN[U.P.H0+&)1&03R5W<%2IXR.<&JFHV-Q/<$11!TD6-
M=Y8#9M8DY_ ]JI*GV1+KXG_GX_O?^9R/_"-:7_T%[_\ [YC_ /B:B'@JVU&Y
M\FUO[YP!EY'"!5_)?TKTNBE[G\J*5;$?\_'][.;\.^$+;P^YDCDWR'DMCECC
M&2?8$X P.372444F[D>84444@"BBB@ HHHH *Y3Q3/-JU];^%K*1D:Z7S;Z5
M#S%;@\CV+'@?C71W][!IMA<7MR^R&",R.?8#-87@ZQF^QSZW?+C4-5<3N#_R
MSCQ^[3\%_4U<=/>(EK[IT-O;Q6EM';P1K'#$H1$4<*!P!4E%%064]2M'NX%\
MH@2QN'3=T/M65);Z@BE_L:M@<[9 370T4T[ <;,+68_O -_]TCD>U1O&@7Y.
M,>@KJ[^PCOX0C,4=3E7 Z57@T.SB7]ZIG?U<\?E5<R$<N]O<SJ'BA=HR< J,
MBM.RT<VC+/*1YF.%';ZFNC>)1"%10H7H *K2#>.E<N(J2UBC2"6Y2HIS(0:3
M!]*XKG0/B^]5S./Q%5X8^YJ?!)P.IJXF<GJ68?\ 5+3Z11M4#TJC>ZFMM,+>
M&&2XNF7<(H^P]2>PKT(JR2,&7))HH5W2R(B^K,!6!<SR:O/((YG2PC.P>6V/
M.;N<^@IT>FB4_:-15;BZ?EMW*Q_[*CIQ5H(H4(B!%7A5 P*M60%%+.WM4*PQ
MX=N68Y)^F336")RR@_4U=F 123VKGM3OSAD4;5]1U--:@)<%27"A%/H !5"9
MO*0&1NO&>U9LU\5(P2<#%(NI(RE92-IZAJT0B:1=O3IZ&KVFZK+;X4LQCYX/
M./I5(R1S1[HF#+TX.:9"VR3'K3>J$=.NLN">>""*T+&[,H)STZUR:LS8'0FM
MS3E9>2< CI6;0S2U,1S:9/%( R2#8X8<;3P:I^%II-&U"?PK=R%Q OG:?*QY
MEMR?N^Y4\?3%33.]V7AMHGE)^7(7Y1]32>*M,N!I-KJ=B-VI:01-%CK(H&'3
MZ,N?QQ37\KZDR_F70Z>BJVG7\&J:;;WULVZ&XC$B'V(JS66Q84444 %%%% &
M1XDUD:'HTERB>;<N1#;0CK)*W"K^?/T!I/#6B_V)I(BF?S;V9C-=S=Y)6Y8_
M3L/85E6X_P"$B\;RW3?-8:)F&$=GN6'SM_P$8'U)KI[FZ@LXO-N)4B3IECBK
M>BY2%J[DU%9?_"1:3_S^*?HK?X55GU.XU+]SIX>&$_?N77!^B@_SJ>5EFC=:
MO86<OESW2*_=>I'UQTJU#-'<1++#(KHW(93D&LJUL(;:/9%$.>68C+,?4GO4
M;Z/:Y+PF:W<GYO)D*#/KCI3L@-RBLK3[R:*Z.GWL@>3;NAE(QYJ^_N*U:35@
M"BBBD =1@UA3QO83O&$<V[G=&54G;GJ*W:S]<NIK+1;JXM\"5$RI(SCGK51U
M=A2?*FV<GXBN'@LDA,+Q>>V"S8!*]^.M8B%5CW%=H X'\JGW2W-P9KB5YI>F
M]SDX_I4MP@\E2$W/N! QUP:[8KE5CS9S<Y<Q1:-SC?P/2A/W1.5 3MCJ35B0
MB0[E_6FEHEDC1SAB<K5(D?'!^],GS;B,;<\5=@@=Y0&C8 G&3W-6[&U#@$BM
MFW2))A&5R5PQXXK*4[&D*=R"WM#&OO5P1G>"<%0.F.]2[6<DC ).:?+@<KR<
M<X]:Q<KG2HV..U#3)+.YFN5(%O+*1)GHA/1OIS27-G=Z?L,Z?(XRKJ<@_B*[
M!HUDBVR*"K+AE/0BL_2[..\L[W2IF9H;6?;"X/*C&0,^V2*;E=7"'N/EZ,YV
M&1YY$CB3?(QPH]372:;HERMY'->"-4B.Y55MQ9NWY5HV&BV>GR>9$K-+C =S
MDCZ>E:-9REV-PHHHJ!G(ZX#X9\0P^(HABQNBMMJ:CHO9)?P/!]C77 @C(.0:
M@O;.#4+&>SN4#PSH8W4]P1BL'P==S+:7.AWKEKW29/(+-UDBZQO^*\?A5OWH
MW[$+W96[G2T445!84444 %-D=(HVDD8*B@LS$\ #O3JY+QI<R7AL_#=LY674
MF)N'7K';KRY_'[OXFJC'F=B92Y5<S](9_$&KS^)9U/E$&#3HV'W(0>7^K']*
MZ#;C)-/CBBMX4BB0)&BA54=% & *0R9&1TK5NYBE;<1G"*">/K4$$TEW-MLF
M&1G=,1E8_IZL:AM;=-6NI)I@9+6-ML:9PK$=2?6MV-%B14C545>BJ, 4FU'3
MJ**<M>A2DT:&0#SI[B1LY):4\GZ=*N(FU=NYF]V/-//H:C>1%D5!G)Z5%VS3
ME2V*&J 126TK;<%]AST((JA+I]K(#LA2-^S)\I%:FH0FXM#&"-P(9=W3(K(+
MWFX@V3D <E&!K6.VAC42OJC+NGNXU*RV\C[>"Z\Y]\5G0H)+ZQW%9$9F.<<$
M@5OK-YP8!65D^\K=16'80&;4&O5^6)96"+VZ$$_RK>+T9R36JL=&DF,<\U,K
MR%Q\_P N.0?6L>YG$4\;@Y(!&WZ]Z(K\%P"V3FLG'J;J:6AT49AX\QSDGC Z
M5+$TF]D&"H/(/2LZ$&:,,"AQV+ &K5M'(S"0NR@'[O\ >K-HV3+>[!S@CV-+
M(RW$+QRX96!4_0\$4DDT<*;Y<;<]Q2%%+$J1M;G%27<YJQ\-S%-DNHS(L;%"
MBH,X!XP?0C!J+4+&72;NWBBGFN8KE6VJR[G5EQZ=1S76;2IP>M9&IWJZ=K=C
M=E=_^CRQJG^UP1^?2MHU)2D<TZ4(QT*EKH&JW4)E8I"/X5F&&/Y=*N:#IZV^
MH&>[N;;SD!6.))0QR>I-7%LKJZ0&^U"?#CYXH<*H]O6ISI=@8Q%]C@*#I\F#
M^?6IE4NK,N-*S32^\UR0.IHK%&B:>>L)/IOE8X_6HY=.GLE,NDSLC#K"[%D;
M\#T-9<L>YOSR6K1L7%Y;6@!N)XX@>F]@,U%>RV9TV6:Y=&M0FYFSQCVK$9K2
MPMGU'4&,\\AVY>/+9[(J]JKVFEW5VV+U/LVG"7SH['=EB>P8]ESSBK4%O<AU
M9/1+^O,CM]'DU9EN9A+9VC<Q6Z.?,8=B['I]!4UUX.TFXLY[>2.5O-4C<TS$
MJ>S#GJ*W]V ?4TP@L0 <'-'M)=&)4H+=79E^$-5N+JSGTS4FSJFFL(9R?^6B
M_P $@]F'Z@UTE<3XB==!UNP\21O^[4BUOE'\4+'AO^ M@_2NU!# $$$'D$5$
MUU74UIO2SZ"T445!H%%%% !1110 4444 >6CY/$^M;"REKILE6([UJQ:?;ZC
M,^GWX:\MGB#/'<,74\\=?3%91_Y&?6/^OIOYU!JS%/$EFZLRG[/_  L1W/I7
MJ\G-"*78\+VG)5E)ZZG16_PV\&- N[2H"W/!D/\ C7'67B?3M-M=1C%A-:QZ
M?(5"VDF%8 X&%/W373VB2RV_F&ZF .?E!&/Y5AQ> X]<MIWMM3FM!/Q*GEJZ
MR#)Y.1G.>^:R4>2_.[G4JJJVY(VL<YJ'C'2M7T[S-1TB2_5,[%GE"E3Z@@$C
MWQ77VGA+PK-X%BU[^Q+3[7]B%R(RQ90V-V,$\UE0?"6"TG8W.KSS6T)W>2L:
MJ']B?2M^XLT@T=X?/D^SK$%$8P%"^@ '3%#2EI!C=1T_B5SG&\<V=EH$-Z+:
M]A>1C&L4<VY01WR<<>U8>K>)-&U%H)[K05N[F1E59IY<%1G'.!EOSKJ'^&"Z
MK91I'K$\-ON+^0T2,%;OM.,X_.H[#X:6VF,MW=ZE+>,F!'&T:A%.>N.Y]*I2
MIW!J:1I^*_#GACPCI2ZO8:+;23),JDESD ]=IYVGWK'U/QY::=]ECCCU /.@
MDQYH(4'MGN??%;FLZ>E[;1VMS-+*DDFWYB.OY5E7_P *#?(DYUZ<K&@$0DA0
MLH],@#-2E&*M-W!3=1\T%8QM,N/#GB#QI8Z?<>'H=]VS^?<R2X+81FSM&!DD
M#DDUT/B&TT#P1J^GIIVCQA+P$/)#*5D&",8;GCGI3M*\"V_A^=+@W\]S>/DB
M9E4%!C&%XXZ\U+JFAPZS?06\]S<*ZKN292-R<]1D8]*=DWS)Z(3F_P"&UJS%
MU#QY:QZG+IB17KJF4<.PVM^&>F*3P5I_A3Q7KNH6DOAVWMH8(5D!,Q)9BV.V
M ![ 58O?A)))<F[;Q!*9I'^9_LZ@G\JU])\*V_AT-!:W4S2[1YLQ"AY.<\G'
M3T%'N-6@]2I2E#WI*Z*$UQI'AOQ9=:'9:9]F@5/,66VDVGE<G</XOSK$G\=Z
M=JR7%O/87-U:#K#<.I# ?GS[XXKHI?"\>M:O-)'?W%K=)\HF0*V<CH01R,5F
M'X/"*<+_ &],J.,OY<*@GGMZ47@M);@N:2YDMR[X"\.>$O%>D3WEQH%M!Y=T
MT21><S$@ 'DY&>M.C\;0:;!J5DMI+:6NE2-'''9,%4J&(  P,?F:U=-T>'2K
M?[+9S21PJQ^5<#)Z9/')]ZSU^'\.OK>26NISV8F.)5\M763D\D$9!SWS4M15
MY3>@0J2D^2*LT8\7Q5E2U>Y6*\E[!7G"_P!#7JWAC4Y=9\,Z?J4ZJLMS")&5
M>@SVKS^S^#-K93)-=ZQ/<6L3!S;+&JB3'8GT->G6,=O#8P1VD*0VZH!'&BA5
M4>@ K"M*FU[AU48S3]\L4445SFYYIXH\7RZ#XVN(9;/SK?[-&593A@>>/?\
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M* "BBB@ HHHH **** .4\5YU;5=*\-)DQW#_ &J\Q_SPC.<'_>; _"NK  &
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MQ:17L7ERJ3M.593AE/J#45I=W%G>)8WLAE27B"<C!)_NM[^_>K@-5M0MFO8
MJ.(Y4=9$<C.&!IH#5HK%%WK8 S!9,1V#L"W^%:&GWJW]H)@AC8,4=&ZJPZBD
MU8"U4<\$=S;R02KNCD4JP]0:DHI!N>>W^E3:->Q0,PEAESY4G? Z@CUZ4^)&
M+2 ].,5TOB#2I]02">U*F> MA'. X/49['BL"W8^<\$L3PSI]^-^H]_<>]=<
M9\T;GGSI\D[=.ADR;9'D\IN0>3Z&I$A1G5F4%EZ'%:ILHUW%$ W<G%/CL"C
ME#5<Z)Y&7+&/" %3S[5HJI)SV%16GF1H.>/0]*F<2O+&5=50?>&.M8-W9TQ5
MD*J,)68N2I'"^E3C"CH"?>FG;N !SQ3MN!N)QGN:AFB0R>8102RM@;$+9/08
M%1>'8!#H=LQ4B29?-D)ZLS<DFJ4,$OB$F21C'I0;Y(Q]ZXP>K'LN>U=" %
M  '  IRT7**'O2YN@M%%%9FP4444 %<IKH_L;Q7I6N+\L%R?[/O/3#',;'Z-
MQGWKJZRO$FEC6?#M]8#[\L1\L^CCE3^8%5!V>I,U=:&K163X9U0ZSX;L+]O]
M9)$!*/1QPP_,&M:DU9V8T[JX4444AA7G^F6C^(M4U'Q%]LN($ED-M:>5@9A0
MXSSZMDUT/C/4)-.\+7;6Y_TF<"V@QUWR':,?3.?PJ32]-33-+M;"' 2WB6,=
MLX')_.M8/EC<QJ+F?*9BR7NFW COEN+ZT;[DL$7S@_W6 _G4.I:I:_9G1[34
M+5'8#=+'A<9Y&0>.*W)7\J01L2K-T'K5>5(I$9)5+(PP1ZUHI*]VC&47:R9H
MP+%'"ODJ!$%RH7ICM4BN7'"X^@KCWTFUC)6)[J-1T43L /I6AH-]<>;=:=<2
MM-Y05XY6^\5/8^I%2Z>ETRHU=5%JQNL6#J N0>ISTHWX/'7UIGF(JDLW2JSS
MJA;YR<^_2H2-&[!>7 P=PP1W'>LW[4=_7%,O;DD,5&XCM5,.S(IQM)Z@UK&.
MAC*5V0:S=,]U#;P;8Y2A<S=P,XP*K62&&S$3$\%N1QGD\U)J<2"WCO!GS(Y0
M"?52<&F*YSC/'>ME\-D<S^-ME*9V;SMRMO+[3G^[V_"D@A"CDXP,#:>E3W&1
M(SE2 P S],U5>6157RU#'/()Z"K2)-[1'2%,R'?(3@L3_+TK=B;D[I2VXY4>
ME<9'>I#)@R*I]"<5IQZKMQD]>G-93@[W-H5$M#JDV21R+)AE S@^O:E##(]*
MYV+5.6'0L.M7HKLB-FP6P,X%8N#1LJB9H_:/.DD.TKM;'-<Y?,L_BM5N&PL)
M0Q)V*$9+?4D 8]JW%EWE0/O/T!K+A(G\4!PH;[-;E9&(Z%CP/KUJH:7]":FM
MEYG1!VV J,,?7M4H?*C<.?6JT;GJP YZ U-YK,3NQCM631T)C\C-# CJ1@^E
M0IE<[GSD\<=/:D99"7DCDR APF._K2L%S,.V_P#%:*N)$L8"3Z)(QX_'%:Q'
MI\WTK&\-A!HD3K_K'+-,3U,F3G-:LEP8@JKWY)%7/>W8SIOW>9]=28C R?P%
M,SWIJ;G+,3QZDU%+$'EC?>PV=@>#4HMLBU#3[74K62"[3?&Z%",]B*K>![Z6
M;1&TZ[;=>:9*;24GJP7[C?BN*MS2JCHK/MW' 'K6+:RC2_B&G40ZO;%&]/.B
MY!_%21^%5:\6B4TI7.UHHHK$Z HHHH **** "BBB@#RIY%7Q3JX+ $W3=3[U
M!J[JWB"S((/^CGH?<UVFH^%'>YFNK&XMXY)9#(WVB /@GKAJX_7-.N=.\1V:
M7-U!.6@)!CBV #)[9KU:-6,N5)ZGAXBA4@Y2:T-O3_\ CR7\:P_#NM7T4$\(
ME0A9&5/EVD#)ZFMZRVBW5,C%<KH<9,]VJ,H G8<C/\1K3E4F^8Q4Y1C>+L=!
M<ZGJ7DW!#1*V.<DL.E5YY97\'/*[YF-H6+X[X]*DN%P)P2#QV'M3&"MX1D4G
M_ET;O[&HY4EH7SRD_>8NCZ[J$NGPJ'C9SUXV#],U#JFJ:F-+RDD:?,,\;B.>
MV:K^'8V:UA(90/<5+J(_XEK9]:J5.">B)C6J/=DOBBXFM+*WF@<+(MPN"5R.
M_:KB:UJ$MH C1L @SDE?T%4?%NUM'1L\B=,?K3[*-_L3-N7&P<8HY(N-V@]I
M.+2BQ\U_?RZMI\<DB"%F;(49)&T\9JKK-_<V/B"P:"15#QE6#)NS\PJ:3 U.
MP)[.?_035/Q*H.L:801DJP_44*"O:V@^>5KWU-M]7U"4*P*%-W]\CMZ56L[R
M]N-<N$N9$9!""%1<<[NN:%C9;="S*?G[#VIME@:W-[PC_P!"I<D5L@52<E:3
M*<.JW=EXKOHXY%\KY6VE.<[1WK7;5=2=U8F,':=IW$_F,5SUPF?%]V%(Y13D
M\_PBMMD*&+<P/R=A3=.+2;0>UJ)M)Z"Z)<7%RETURZLPN& VK@ 8%5?#^MZA
M";V!94(69U0;,$#<>]6-$( NAD?Z\G]!6/H?_'[>_P#7PW_H1I<D9730.I./
MO1>IU4^JZO\ 9)/GA4[>Y+#I70^')99O#EA),V^1H06;&,FN;N/^/9_I72>&
M^/#EA_UR%<>(C&,59'H8.I*4GS.YJ4C'"D^U+39/]6WT-<AWO8\E\9G=XTD/
MK;1'^=3:9T_"JWBX[O&#G_IVB_K5G3.GX5[5'^$CY_$N]9LV4^ZE6EZ553[J
M5:7I4LF)2U#_ %9^E6_AV,6NI_\ 7R/_ $$54U'_ %1^E7/AY_Q[:G_U\C_T
M$5SXC^&=N#_B':4445YYZP4=**CG_P!1)_NFA";LB2BLV&Z>+@_,OH:O13)*
M/E//H>M5*#1$*D9$E%%%2:!1110 4444 %%%9^LZU9Z'8M=7D@4=$0?><^@%
M.,7)V1,YQA%RD[)'/_$>]@M_#9MG"F:X=1&".0 <DC^7XUY-:6YNKR"W#!#+
M(J;CT&3C-7==UNYU[4GO+@X!XCC!X1>P%9JL48,I((.017T&&HNE3Y>I\7C\
M4L37YTM%I\CT[6M*AL&TK1K<940B,G'WFDFC#'\0&KT"O&?$GB@:O]EE@+I.
M+>-92.-KC?NQ_P!] US\>H7D1!CNIT(Z;9",5R/!SJP7,[/4])9I2H5)<D;I
MV_ ][U.$7&E7D+#(DA=2/JIKY[/6O7?"WB]=<T^:VO7BCOD0X49'F*%Z_7KF
MO(JO TY4W.$O(RS>M3K*G4@]'?\ 0*!R:*EBCD/[U4)1#R<<9P3C\@?RKT3Q
M4KGHNE_#")H8Y-2O9-[ $Q0@#;[9.<_E6M_PK?0>/^/K_OZ/\*ZU&#HK#HPR
M*=7STL76;OS'VL,MPL8V4$_4Y%?AQH"G)6Y8>AE_P%96J^#-,T[6],-N)$M[
MIV@8%SE'VDHRGKG/\J]#KG_%X$>FVMX?^72]AFS[;L'^=52Q%5S2<GJ9XC!8
M>-)RC!*VOW$6GZZZ^ QJMT^9HH65B>K.I*C\20/SKQ9B68DG)/>NK\1:DT&D
M/HJ'"IJ%P7 ] WR_S)_"N3KU,+24%*7=_@?/YCB'5<(/[*U]>H4445UGFA7K
MWP^\0#4]*&GRC$]F@4'^\G0?ET_*O(:]"^%ELYO+^Z_@6-8_J2<_^RUQXZ,7
M1;?0]/*:DXXJ*CUW/3:***\$^Q"BBB@ HHHH *\_^*T>=*L)?[LS+^8_^M7H
M%8_B?0TU_1)K,G$H^>%O1QT_ ]/QKHPM14ZT9O8Y\73=6A*$=SP*BGS0R03/
M#*A21&*LIZ@CJ*97U9\>%%%%, HHHH **** "BBB@ KV7X<:H;_PT+9VS):/
MY?\ P$\K_4?A7C5==\/M1:SUU[;>56Y0KU_B'(_K^=<6/I>THONM3MR^M[*N
MGT>A[/165YTO_/1OSH\Z7_GHWYU\[[)GTGMUV-6BLKSI?^>C?G1YTO\ ST;\
MZ/9,/;KL:M%97G2_\]&_.CSI?^>C?G1[)A[==C5HK*\Z7_GHWYT>=+_ST;\Z
M/9,/;KL:M%97G2_\]&_.CSI?^>C?G1[)A[==C5K+TJ?S;S4US_J[G;_XZ*3S
MI?\ GHWYUSGAJ[EDU3Q$-[?)?XZ_["U2I.S)>(5UH=Q165YTO_/1OSH\Z7_G
MHWYU/LF5[==C5HK*\Z7_ )Z-^='G2_\ /1OSH]DP]NNQJT5E>=+_ ,]&_.CS
MI?\ GHWYT>R8>W78U:*RO.E_YZ-^='G2_P#/1OSH]DP]NNQJUF^(=1_LGP[J
M%_\ Q00,R^[8X_7%,\Z7_GHWYUSWBYY+NST_3"[$7U_#"PSU4-N;]%IQI:ZB
M=>ZLD;_A;3O[)\+Z=9'.](%,F>I<\M^I-:]%07D_V6RGN,9\M"V/7 K)N[N;
MI65CF/$E[-)J7V6.5TBB4%@C$98\\X]JH0F67:]S*\K+Q'YC9V#_ !JF)FED
M:25LNQW.Q[DTV^NC#;,L;?.PPN/4UM:RL!I_:X( PWINY.,]35NPN8W4 L"Y
MY) XS7&2WL<+K&NU<\ XZUJZ3/(S@.><]J30':(.#Z&ID.#@C(J" L$4G@XJ
MSN#A2""<<D5F,)88Y8WCD0/&ZX(/>JNFM)9:B=/,C/;O%YL&\Y*X."N?2KKD
M?>[8JA>N+2\L[]A^ZC+12G^ZK8P?P-"[ ;=%'6BI **** "L[78FET6Y"#+*
M X'KM(/]*LWM]:Z=:/=7D\<$"#+22-@"N4NO$NKZQ97#Z!I6VR$;'[??Y16&
M.J)]YOJ<"KC%O4ER2T.B:9I;'S("FYTWQE^F2.,UP=M\5+"*[DLM9L9[&YB<
MQR%?WB@@X/O^AK2L_"MY>65N=3\0W\L?E*1#:D0(!CIQR?SKBK?X9W>M:U<W
M4H?3],:5O*$I+S.@. <'GGKD_E6T(T]>9F52533E1Z?I^N:7JZ;M/OX+@]=J
M/\P^HZBGW$ZE'7G(&>1U%5M(\+:3X>@1=/M0K[?FF;EV^I_ITJ34YMEML Y&
M2#BL7:_NFL;V]XXW4G#W#8P<'M62XXX'7K5NZQ"9& ).2Q]2:K0YN%$A&U.^
M:T0R>Q4*VX\8YS5V1%6+"XQR1BBSA00AI, -Z]Z=<#!V*.,< 4T!I>#VN$UE
M0F?+=6WC_9'?\Z]!KG?"6GR6ME)<31E'E("AA@[1715E-W8(****@9E^)--&
MK^&]0L<9:6!@G^\!E?U I/#6HG5O#6G7S'YYH%+_ .\!AOU!K5KB?";O9Q:I
MIBNP6RU":-!GHC'>O_H5:17-%HRG+D:9VU%97G2_\]&_.CSI?^>C?G3]DR?;
MKL:M<AI#/=Z_XHUB,9:)A8VYZ_ZM<M_X\WZ5KR73Q1/(TC;5!8\^E4/ ,3+X
M.M;AQ^]O&DNGSW+N3_+%'+RQ;'&ISR2,".22>6.>::21\[B78GM2ZA<%(XHP
MQ"NP#$5%&X! Z=>/3DU7OY5FB5ER5##/'I5,T,Z>[43+$&*<\ 5M:1J)CNDC
M8]02":Y\[3-N(!(Z&K-O-LD#8Z=Z&,]%CEDEE#_((\=N_P"%3M(57(4L<XQ7
M/:=J@V ,>OK6S#=Q2, ' R<5DT,O;R%P>/KVH_AS4#SHS,5^89Q@5*7 C"CO
MR:0 6V*7QG:"V/7'-,T%-NDQ2EMSSDS.?=CFJE]/*D,=O!\UQ<%D0G@*,<L?
MH*T+*>QM[>*TANHF\I OWQDXIO8"]14#WUI&VU[F%6]"XI[3Q)"9FD41 9+9
MXQ4@25@^*K:(Z6UZ%VW,!7RY%.",L 1].:OPZM!-,B>7-&)#B-Y$PKGVJQ>6
MD5]9RVLP)CD7:<=1[U47RR3(J1YHM& D@? 90&]1W^M2&,2!021@YX-0)HNL
MP$1I+9RHO EDW D>X'>B2YO]/?RM1MR8_P"&:V0LA]B.H-;;[,YM5\2L:"OM
M9!Y98'J0>E6<(.0V?PK(&L01J)'M[Q8,X,[0E47ZYY_2M.-TD0.CJ4;HP88-
M1)-&D9)[$=SJ%M8JS7$F !D@*6./PJHTMWKJB"VBEMK)QB6XE7:S+Z(/?UIW
MB%2-!NMV1PN >YW# K?3A%XQP./2BZBK]1V<I.+>@D,200I#$H6-%"J!V I]
M%%9&X4444 %%%% !1110!RWA,?8=4\0:/T6WO/M$2^D<HW #\=U=37'WQ:Q^
M(\3H2JW^G%3CNT;Y_DU;?G2_\]&_.MG#F][N<_M5#W;&K165YTO_ #T;\Z/.
ME_YZ-^=+V3'[==C(\19U#Q=X?TL'Y(3)?R@]/D&U/U8_E6RS+OV;@6ZXS7-Z
M6YO/'6M73N6^RV\-HF3TSEV_F*Z#RXEF\[8#(1C)JI*UD)2YM1)'P.3TZ9J@
MTQ:?_6*(\=#ZU/>SQ;",%3CMTKG)KT[_ )>E5"-S.I.QJB2-F<-\PSV[?2J$
M5PFG:Q*\W,5RJ)'+V4C/RGTZU2.H"VCWMDIGMUJQ,T-U;_, T;CH:M1MN8N5
M]5N:D\Y?*$G'L:KM-L7YG./<UEV<SPW9M6D,B,F]6;EEP<8)[U<GD1(\M\_/
M '))[4<MM!J=U<=(Y#AF("C]30/F:HW$\<B)=0&(2?<.X$$^GL:L)&,9!_(T
M#(Y;5;F*>%V(C88X]?\ .*PEN)(9Y(9!O,;;3(G0_A702L$0*#CGC'4_2L/4
M-/N-)N!]J78LX,J$G\P?<5<.S,JO=$Y DAK/E+1;V(P!S6OI.A7FH0"5I&M+
M5SE21EY/< ]![UK2>#[3Y2;BZW*0?G8,"?<$4<\8NS8*G.2ND2:'I-I%H\)G
MM8II9U$DK2(&)SR![8%9FH>#S]I\[3[E0BG<L$N1M]@WI731!T3:\PD(XR$"
M_P J&;'%8*I)2;3.ETHN*31PT;/Y[0R(8YHVPZ'L:Z"Q<H/J,5)J.D6U_.+@
M336\X7:6CP0P[9S6?*+K2"KRRK<VA(#OLVO'[G'45JVIK0QY73>NQJS.4*/D
MY[50L;DP:OJ"[<K(4E)';(Q_,4V5]5N]/DU&WMH5M "4,CG<5!QG 'XTEM"]
ME%*^[S[F9=[R8P  . /:DE9.XW)MJQI&^ ;.>_%6(-43S/*XW$9)-<\9TRF0
M067 /8T_S I!) .>#2<$4JC.E$PW,Q;([+CI2->K&W4;2,&L(7;*I^;BJ[7;
MM<>65.W&=W:I]F5[0M17*Z9JS'/^AWC\^D<OK]#_ #K;283)NQT)7\B17,7
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M****11R7C3Q3>>'EACM+3<TJD^?("47V'J>]>4:AJ=YJMT;B]N'FD/=CP!Z
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M];2Q1$;(8D/+9X).>WI33IWT8WSI;&OKG@;PYX*M(M9VW\S13 +^_P"4)_B
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MEU>08+#9%&XY5>Y([$U H\F6:T=LF!L*WJ.U3== )].A%A&YED#S2-N<CI[
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MYU&T_!R>G>M9?#5OY+%KR\>3'#>9M /T JW8^$;">**>XN+JX0@'RG<!2??
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M[[H_"M=]>O7D5OLW\)QEA@US%PA_X2Z[  )*J>?H*W-K+Y6X*/D[&FZ4'9M
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M8<S5SKP>%>*J>S3MI<N?#Q<>$+<_WI'/_CV/Z5U-1P6\-K"L-O$D42_=1%
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MI]2LK<6KJ)"P+L<#&TGI^%5+_5#IWB&S!@,JRQ$<.!@[AZTUP/[5T]CV<_\
MH)JEXE3_ (G.FMURK#'XBA4X_#T&ZLG[_4ZB;Q(K[%%O)C=U"$CIZYJC#JS7
M^L3Q?9FB58@VYCU.<=*KQAA;IE"HW]S[4EB,:Y.?6$?^A4O91CJ@]O.:M(2R
MUL67B6^MWMV8 A@X<8^Z.W6M>3Q&))01:RG"GC81GZ'-<E<H1XOO, ME5.!]
M!6WAAY6Y"OR>M-T8.S8+$5(^ZMB;2[]M0%Q(83$$G90&.2>A_K2>&_$HMX[N
M)K1MT<K+D,#N^9N@ZU%H8"K=#_IX)_05CZ)_Q^WW_7PW_H1H]E&2Y6'MIP?-
M'<[:X\4$VDA%C.PVGC;M/3W-;&@W+7F@V5PR;#)$&*YSC\:YBX&;:0?[-='X
M;&/#E@/2(5QUZ<815CT,+6G4D^9FK1117*=P4444 %%%(!0 M%%% !1110 4
M444 %%%% !1110 4444 %%%% '!?%)C_ &38I@X,Y.?HO_UZ\MKZ(O(;6>UD
M6\CBD@ )<2J"N!W.:^?;QHGO9W@79"TC%%]%SP/RKVLOJ7AR6V/EL[H<M95;
M_%T]"-$:1L*I) )./0#)_2O7_ MA%9Q:B8EVCS4B/N5C&X_]],:Y+1](@T[P
M=>ZQ>21J]XGD6^3G"EL,?KU_ &NN\)ZYI/V(6_VZ(75Q<2R>63@Y9S@?EBIQ
ME1S@U%:)V*RNC&E5C*HTFU=?BOQ.MHHHKQSZ<*X3QG"5U"\(.!/IA(_WHI5;
M^5=W7'>/4C6&RGD=4!$\!8G'WXCC]5%=&%=JJ.+,(WH/^O+]3RW5KXZEJUU>
M$$>=(7 /853HHKZ%))61\5*3DW)[L****9(5[SX8@%MX8TV, C_1U8@^I&3^
MIKP_3Y(8M0MWN(//A#@O%DC>/3BOH5 %10J[5 P!C&*\O,I:1B?09#!<TY^B
M%JO?7<=A83W<IPD*%S^ JQ7"_$W4FM])MK"-L&Y<L_NJXX_,C\J\ZC3]I44.
MY[F*K^PHRJ=CRZ>5I[B29SEI&+$^Y-1T45]*?";A1110(]-^&WB 20G1)A\T
M8:2%O49R5_4FO0J\A^&UJ\WB?SA]V"%F;\?E_K7KU>#CHQC6?+U/L<HJ3GAE
MS=-%Z!1117&>F%%%% !1110!X+XNNS>^*]1E)R!,8Q]%^7^E8E7M:!77=0!Z
MBYD'_CQJC7V%))0BEV/BZK<JDF^["BBBM#,**** "BBB@ KN_A6I/B&[;L+4
MC_QY:X2O0/A2N=5OV]( /_'O_K5R8[_=Y'7@%?$P/5:***^6/K0HHHH ****
M "BBB@ HHHH 0D*"2< <DFO+O%L-_P",CH]S"+>UTX7@^SM*"SR(2 92.@3I
M@=2#GBO2-2_Y!5Y_UP?_ -!-<[I<23:1HD;J"K65NI'L5.?Y"M:;Y?>1E5CS
M>ZRZVG>)65E.O66",?\ (./_ ,<KGO!GA+7] TJXMH-:LXU>Y=B/LADSCY<Y
MW+_=Z8KL[.<R0M:RR 7,64;GD^C8]Q@U4T-6MK&=KB[61?/?YB^0,'!Y/J>?
MQH4Y*+7Z X1<DSD+_P 'Z])XUT[5DU6PGGMT>0*]NT:CGI@,>"6ZY]>*[71=
M5.J6TGFP&WN[>0PW,!;.QQ@\'N"""#Z&I;#]^9+XY_?X\O/:,?=_/D_C6=I(
MQXI\0X_O6Y_\AT2DY*SZ!&"@[KJ;U%%%9&H4444 %%%% !1110 5B^)]%?6=
M-4VL@AU&U<3V<W]R0=C['H?K6U133:=T)JZLS)\.ZVFNZ4MQL,-S&QBN8&ZQ
M2CAE/]/:M5E#J58 J1@@]ZY/7;:?P]JI\3Z=$TD#@+JEL@YD0=)5']Y>_J*Z
M>TNH+ZTBNK6598)5#HZG(8&JDNJV%%]'N<I=VB6U_/#$2$7&,]LC-4+RW)12
M.<=Z['4=,2]4R)\EP!A7]?8^U8D=N)X",!64E67/0BFF,YZ)"6QCG-=-I5J$
MC!*8]B*A32U4@J23Z$5L6P:*+:<D>_-)L8\(I.1C=TSZ56UEMFAW><8\LK]2
M>/ZU>55 )[DYJ#4+5;O3YH7?RT9?O>F.<U*W S5E$=N@8\*H'-9^HW($0PXX
MX(STI<W2VHEN;.1H/^>L8R"/7'4"FNUO=PY3:VX8SCG%:6$<K>7;1L[29"@\
M>]5_-$D892<'FM.[LW&8W@>3' 8$8(]_>J)M#G B<'I@]!^-4!GW-U#; 2RG
M:"P7<1TS4\*-*P(&1VJEXFM-N@SL<9!4C\Q6'X9U^>RD6WGCDFM<]47+)_\
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M;4D0Z1+J4PB&<J]P-I42@C&.NT9(+#GG;79FPLVMX[=K2 PQL'2,QC:K Y!
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M$>ISV"W=OI<,$%W'<.T5Q(S$*<X * ?K4I6=V6W=61T]%%%9&@4444 %%%%
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MMG:WH<#1117IG@%_1+$:EK=E9L"4EF56Q_=SS^F:]VL]-L=.C"6=I# H_N(
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MZ-IVF:IH;6=G%"S7T>2J\_>'?\::C%NR!N2U9VM<C\15$GA^"/>JDW2').,
M \UUU<9\1+!;O3[&0NP/VE8@H.!\_?\ 2E3^-!4^%CM#L?[;V7-ZZB*W41);
M(<<>K?4\^_X5N:O,WEQ:;;$)+< @D<>7&/O-^7%<M->36D'GRZE965_9_N?)
M7[\F,  Y/S CIQ5"R\1Z;>ZO/-K$LESM79"%7 P"<Y4?3Z5IR-NYGS)*QWC:
MCI>F6:J;J!(HEP%#@G ]A7%>(KQ]2L)[\VLWE//&D$KC"A ?YDYI5N]-U'4[
MD^1':V>%02?9BV%'7&T$ GU)X%6/$MOI2>'Q=:2\<RK,@,<<Y*,3GK@\'^OK
M3C%1:"4N9,Z^UU(W,WDO9W4#8)S)'\OYBKU4M-BEC@=I1*OF/N597W,HP!S]
M2"<#IFKM8/<V6P4444AF=K.AV&O68M[Z+=M.Z.5#M>)O[RMU!K 75M6\*,(=
M>#W^ECA-4B3+QC_ILH_]"%=A2$!@00"#P0:I2LK/8EQZK<BM;JWO;9+BUFCF
MA<962-@P(^HJ:N7N?"+6=R]]X:O#I=RYW/!MW6TQ_P!I.Q]UIJ>+Y=,=8/$^
MG2:<_07<>9+9S_O#E?HU/DO\.HN:WQ'545%;W,%Y L]M-'-$W*O&P8'\14M0
M6%<+XNM8+;6K>Z>%$AEA*EP-HW@YY([XKNJ;)&DJ%)$5U/4,,BKISY'<RJT_
M:1L>8_;[8KM,ZD#J22?S-8'B&YC;5-$9'5PMR3A#N/;L*]K6"%$V+%&J_P!T
M* *XCQA:6UOXG\(M#;Q1LVH'<40 G@=<5TPK)O8Y98>25[F!,9H)V2]B:&4C
M*QR#'RGO4:EI\K LDF.T49;'Y5ZO<V5K>!1<VT4P7IYB!L?G4D44<*!(HTC0
M=%48 J?K*ML/ZF[_ !:')^#=&N;62;4+N)HBZ".-'&&QG))';M77T45A.;F[
MLZJ=-4X\J"BBLS5O$.E:&@;4+V.)C]V('<[_ $4<FI2;T1;:6K-.LG6O$>GZ
M$B+<R-)<R\0VL(WRRGT51_/I60;_ ,2^(OETVU.BV#=;N\7=.X_V(_X?JU:F
MB^&=/T1GGB5Y[V3_ %MY<-OED_X$>@]AQ5<JC\1/,W\)DQZ)J?BB5+GQ*/L]
M@"&BTF-\@^AF8?>/^R.*ZO\ <VT 'R10H !T55']*DKGO&P#>%IU8!E,T ((
MR#^^2B_,T@MRILV/[2L?^?VW_P"_J_XT?VE8_P#/[;_]_5_QK)M?"NARVD,C
MZ;"6:-6)QW(J7_A$M!_Z!D/Y&BT0O(T?[1L?^?VW_P"_J_XU8!# $$$'D$5R
M?B#PWHUIH5W/!I\"R+&<';G'YUO:%_R+^F_]>L7_ * *32M=#3=[,76B!H6H
M9/6WD'XE37!>%;>74+&#2O/2*W4^<\B-\\A'93Z#G]:[;Q+:B[\.7\1=E A9
M\KU^7G'Z5Q6B1F#1+:TN+NTLH)$^U07$Q^?D\[3P 1BM:?P,SG\2.ZF:WT32
MV,48"IPB#J[G@?4DU%I[6VFVC?:[N$7,C&2=FD .X]OPZ5P<_B=+J\M+?4[\
MSVB-N<Q*%R><$$=1T_R:O7FJ:5<W=I#IU@HB4EG9[<MST&X %L#T]Z/9OJ'M
M%T-35-6CU>9X[2"6ZM+:-V=D'RE\$#.>PY-/\):D8/#EA"]G=,N"!+''N0Y8
M_C^E,BLM"FTRX2TO%:\$3LS1/Y<F<$_<[#VQ4O@E99-)M9S$\,0C==OF$HV7
MXV@G@#!Z\Y8^E)VY; K\USJJ***Q-@JKJ.FV>K6,EE?VZ3V\@PR./U'H?>K5
M%"=@W.)/]K^#,+*)M5T)?NR*-UQ:K_M#^-1Z]170Z;?V>I6J7=E<QW$#]'0Y
M'T/H?:M6N9U'P?&;Q]1T.Z;2M0;ES&N89O\ KI'T/U'-:<REON9.+CL;6XL<
M8'6N8G\*QBZ?R[V2.T9BQB4#(SU ;L*BD\37VCL(?$FGM9GH+V#,EL_X]4^A
MJ[%?_:8A+#-'+"W*LC9!_&M(J4=C*?)/22'BVM+&(1VT$<8 Z@<GZFJJR,^[
M*E<' S3Y9&8';R:BW C .>U4O,C3H31;?,&X D#(S4SLQWG_ +YJOMR$'?=^
MG>G2R*HQD#%(+FQH=TC6_P!D(VR1#/\ O#/6M:N>T:WG^W"9HG2,(1N88SG'
M2NAK&HO>.FDVXZF;*3<:H48_N[;#!?[S$=3]*M;E[]3V%5=00V\Z7J_= V2C
M_9['\*D2195#CD=C1T$G9M$I)(SCBF!CM!(P?2AGR1SQ44TB;=N[G&3@T)#;
M'2RLJ=B/>N;URU&HVKA4'G)\T1[@_P#UZUIYP<XKFK_7[2SO/LXD>ZNFX6TM
ME\R0GZ#I^-:TTT[HQJ-25F9,=K?.=J6<P;I\XP!^-6E>%0=(TFT35M78[II/
M^64!]7?L!Z#FM*U\.:YKV&U:8Z58'G[);OF:0>COT7Z"NQTW2['2+-;33[:.
MW@7HJ#J?4GN?<U<ZR6B,Z6&ZLQ]"\*KI]P-1U.X^WZL5V^>RX2%?[L:]%'OU
M-;1U&Q!P;RW!'_35?\:L-]T_2N'\&^'])O\ PS:SW5C#)(5 +%<9^4>E8?%>
M4CK^&T8G8?VE8_\ /[;_ /?U?\:/[2L?^?VW_P"_J_XUG?\ "):#_P! R'\C
M2'PEH.#_ ,2V'\C2]P?O&Q'+'.F^*177^\C BGXKE_ R+'IE^J*JJ+Z3"J,
M?*O:NG(R"/7TI25G8<7=7/,+:::+Q3K MY(5-U<M'YK-Q$I/WO8D?I7?Z7I-
MMI%MA#N?;\\K]2!_(>U<#I-J^EZGJS*\)M?M)M)Y;KE5[AB!CC/OQ2ZIX@ET
MVVFT^'68[J#[@,:AA@C)7=[?RK>47)V1A&2BKL[.PFBN+N35;F5(UD&RV5V
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MHW_3LX_,8KP&O-RGX)/S/3SC^)%>04445ZYXY;TNV-YJUG; 9\V9$_,@5]%
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MIIEQXGU:T@::?PW=I&N,L9(^,G'][WK3E<DK&=[-W.IKF/%7_(2T'_K^C_\
M0A3+SQ3J5A&CW6@S1([A%9IH@-Q!.,[N.AK)O=;DUC4M+,EJELEO=)([O=P%
M0H())P^>WI3A!IW%.::L>@5YKXZU^RU&?3[&UO=T$5T1=J$90I4@9WD=OFZ?
M7M7>C6=+8@#4K,D\ "=>?UK$LM.LQXUUF-8$17M;>5A'\N7+2Y;CN<#GVHIV
MB[L=3WE9#[>/PA'$T<<^F,K_ '@TRG=]<FJ\DNB3ZRB?:-,2VAV,I$D8"A><
M+Z$L1GV7WK6G\,Z9<_ZQ+C\+F3_XJJS^#-(?&5N>/2X?_&A2CW8.,NR)UN/#
M:A@L^E@,Q<XDCY)ZGZUROC7_ (1]])62SNK0W0F0!HIE9PN>>Y.,5T@\&Z.%
M"[+@CWN'_P :N0:!I]N!L2?_ (%<2'^;4*48NZN)QE)6=BEX=\2V6J0P69N_
M,U%8B9%V,-^T[68' !!.#QZUT%<UH%G;)XE\03K GG)/'$LF/F">4AV@^F><
M5TM1.U]"X7MJ%%%%24%%%% !3719$*.H96&"K#((IU% ',W'@C3EF:YTF:YT
M>Y;DO9/M1C_M(?E/Y5'N\9Z7P4L-;A'=3]FF/X<J?TKJJ*OG?74CD730Y8>-
M[>VP-7TG5--;^)I;8R1C_@:9%7[3Q?X=O?\ 4:S9$_W6E"G\C@UM51NM&TN^
M_P"/O3K2?_KK"K?S%%XOH%I+J68[JWF ,4\3@]"K@UQ_C;_D9?!__80/\A6G
M)X#\+R$G^QK="?\ GEE/_02*Y;Q-X*T2UUCP]';6DB1W%[Y<P^TRG*XSQEN/
MJ,&KI\O-O_7WD5.;EV/2BP49) ^M59]3T^U&;B^MH1_TTE5?YFL0?#[PP.NG
M.W^_=3-_-ZLP>"_#-LVZ/0['/J\0?^>:BT.[_KYEWGV(KCQWX;@8HNIQW$O:
M.V5I6/\ WR#4!\4:K?<:1X8OI >DMZ1;)]<'+'\JZ2"UM[5=MO!%"OI&@4?I
M4M%XK9!:3W9RO]C^)]5_Y"FN1V$)ZP:6F&_[^-S^0K2TKPMH^C.9;2S4W)^]
M<S$R2M]6;)K8HI.;>@U!+4****DH*Y_QK_R+$W_7>W_]')705B^*[2XO?#TT
M-K"TTWF1.(U(!8+(K'&2!T![U4/B1,_A9IV7_'A;?]<E_D*GKEX=:UN&".(>
M&;PA%"Y\R(9P/]^F)XJU*33S?+X?N3;!&<OYD?09SQN]C3Y&+G1I^*?^1:OO
M^N?]:LZ%_P B_IO_ %ZQ?^@"N0U+Q5/JFE36HTW8)DP&^UP?A_RTKI-)U/3K
M;1[&";4;-9(K>-'7[0AP0H!'6FXM1L)23E<S?'&OVUEH][I\5WY>HR0@K&(R
MQ*L<')Q@9 89-4/"T?AB/1+*:XN;+[9Y0\SS9P&4^G)X^E:>MPV5UKWAR\C2
M&1I+EXO.3!+)Y,AV[AU&1GZUJSZ!I]P"'2?U^6XD'\FJN9**0K-R;,74I="2
M.&WLI-*57=BP#1[2V, MZ@$[O^ UHPR^&H$C5;G3"4B6(,TD9)4= 33#X-T@
MJ5V7 !]+A_\ &D3P9HZ9PMR?K</_ (TKQMNQVE?9%?5V\+SZ?<![G3BPC8J!
M,O!QQ@9ZUC>!_$UC9:5%I]]>_.SJ(,HQ WG&PD# .[/7LPKJH/#.F6W^K2X'
M_;S)_P#%5G7VG69\9:+&]NCHD%Q*HD^;#@QX;GN/6FI1:Y1-23YCJ****Q-0
MHHHH **** &NBR(4=0RL,%6&017+WO@+37E:XTF:?2+EN2UH?W;'_:C/RG\,
M5U5%5&3CL3**EN>?2Z;XKTG.ZTM=6ASGS+9_*E_%&X_(U4'B/3[>3R]1CN=-
ME)^[>0,@_/I^M>F4V2-)4*2(KH>JL,@UHJW=&3H]F<9;WUG<KNMKJ"8'O'(&
MK3TJP:XNENG3$*<J6'WS_A4EWX*\-WK%YM&M0Y_CB3RS^:XJJO@33X>++4=8
MLP.BP7[X'_?6:;G%K02I23NSJ**Y?_A$KU3^Z\6:VH]&DC;^:T?\(IJ1X;Q=
MK./;RA_[)6?+'N:\S['17>/L<^>GEM_*LNV9(=.A$K*@" DL<51;P6)E*W7B
M+79U/!4W>T'ZA0*6+X?>&T(,UE)=,.]S.\GZ$XJERI6N2U)N]BMJ'B[1+)RC
MZG \G01PMYC'\%S5 :IK&JN#I.@7;J>D]X?L\?UP?F(_"NSLM)T[35"V-A;6
MP'_/*)5_D*N4>TBMD+V;>[.+B\'ZMJ/.NZTRQ'K:Z</+4^Q<_,?TKI-*T/3-
M$A\K3K**W!^\RCYF^K'D_C6A14RG*6Y<81CL%%%%06(WW3]*YKP#_P BE:_0
M?^@BNE894CVKB- N-<T31X+$^';N5HP S"2+&< <?/TXK2*O%HB3M),[BD;[
MI^E<Q%XEU:>>:%/#MSYD./,4RQ\9&1_%54^-KC?+&=(97C<QNKW4*D,.#P7%
M+V<@]I$N>"?^0?J'_7_)_P"@K6QJFKV.CP)+?W A61_+0[&8LV"<  $] :Y_
MPC>VMEIUT+RZMK=Y;MY522XC+;2% )VL1V/>I_%[Z?J?@S5G1[:Z\BW>1&1@
M_EN%."".AJFKSU)3M#0Y3P<^CWSZA=:[=6[73W&]?/D";L_Q!2>/Z=*ZV\F\
M.Q64\EK/IBW#)L$BR1EP.G!SGC^E:C:197$2[XY!E1G9,Z_R(JFWA#268L4N
M,GK_ *2Y_F:;G%NX*#2L5].;P]':J9I]*#M+YX3S(\1G& ![@8&?7-69Y_#,
MJ%9+K30IZ@3(,_7!YJ)?!>CJV[;<D^]P_P#C4T7A32H7W*EQG_KYD'\C4MQW
MNQI2[(XW0]:TW0_%6I[+M%TV60H%B!<# RK *#Q]X9'J*]'M+J"^M(KJVD$D
M$R!XW'1@>AKG/%>FVD7AXH(RRO<VZ,'=GR#*@(Y)X(KIHH8X(4AAC6.)%"HB
M# 4#H **C4DF$$T[#Z***S- R*XKQAI=Q<:Q;7R^8((H"I9(C)SNSR!R.*[3
M /-+5TYN$N9&=6FJD'%GG-OJ5NB !+TCLWV1L5C: K">[)SS.W5<?Q'M7K]>
M56-O<1WUY(Z*D;7,I#-(H_C/OFO0H5O:-Z6/)Q.&]C!.]S1O4*K,[9 /MGM6
M=]MC/AN6 +=!S:N 3;-M/RGH?3WK9G=FM6$025B,861?\:VD5A\/Y%*_-_9[
MC .>=AI5:G(D*A1]JV[[''>&P5LX :75D,.G-OW9] M.T:&:V@C$ZI'@#&Z5
M>?UJ[JGF2V>V)%DY&2LBX'/UK><M;G/!7?*9/B.[2YTD1QK<J1,A(EMV3N>Y
MK2L49K$H.OE@5O\ CV*2;PZD<2[G-S'@9QWK"T\/#&!-Y<;8Y5I5S_.LZ53G
M@V;8BE[&:5[E.[=;?4+,L)6VN>(XBS?=/0#K5+6IUN]6TUHQ*%7>,20E.<KZ
MUTUKYC^)--81CRUD;YPZG^!NP--\=03S:OI1@CWE4E)^8#NOK2]K:HHE*A>B
MZB9 J-);)C/#9/'L:SX[F.VUF0NL[?NL?NH2^.>^.E:EJVQ K/$#Z>8N?YU?
M\-B0^(+IWCV*;< '<#GYO:G4GR)LSH0]K)1N<8'\[Q7<S+OVF-"-\90_='8U
MT,D998WYP$/09[U7UVWN'\;7LJ1YC"1 L7 Q\ON:O1.!%@-&[ =!(N?YU49<
MT$R:D>2HXLR=,O8K=KE66Y.9N&2W9EZ#N/Y50T(,+J\)SS<-U7'\1[5WOA!9
M%LKSS$V$W).,@_PKZ5QMI;W$>I7TCQJL374I#&11_&??-32JJ4W$UK4.2DIW
MW-VX_P"/=_I71^'/^1=L?^N0KF)G+6S",)*Q'19%_P :ZCPZK+X>L0PPPB&1
M7/BOA1TX#639I9!H %& *7I7$>F%)D4 @T8H PO!/_(D:+_UZ1_RK>K!\$_\
MB1HO_7I'_*MZJG\3)A\**.L63ZCI4UK&R!VVE=X^5B&!PWL<8/L:K6=O?3ZP
M-0N[:*U$=N8%C23>SY8$DG X&.![GI6O123TL.VMPHHHI#"L'Q3_ *O2/^PI
M;_\ H5;U8/BG_5Z1_P!A2W_]"JH?$3/8WJ***DH**** "BBB@ HHZ5BZGXLT
M;2D<S7L;R*/]5$=[$^G'3\:J,)2=HJY%2I"FN:;LCCOBE>3?:+&R&1!L,I_V
MFSC]!_.O.ZWO$WBB?Q)/&TEO%%%"3Y87EL''4]^E8-?0X:FZ=)1:U/BL?6C6
MQ$IQ=TPHHHK<XPH[45M^&O#K>)+N:V2[C@>--XW*3NYQQ^E3*2@N:6Q=.G*I
M)0@KMF)0.M>@V_PLN3*/M.HQ+'GGRU))'XXJ;Q%X:\(Z(L+W$UU&^WB"%PSR
M^YST_05S_7*3DHQU?D=O]F8A0<YI12[LX/4--N]+N1!>0F*0J' )!RIZ$8IE
MC8W.I7:6MI$99WSM0$<X&3UK4\4Z^GB'48IX[<P1Q1")5+;B0"3D_G6987]S
MIEY'=VDICGCSM8 '&1CO6T7-PNU:1S3C2C5LFW&_SL>X^'--;2?#]G9R*JRH
MF9 #GYB<G^=:M>;:#\2I6GCM]7A0JQ"_:(^-ON1_A7I/6O Q%*I"=Y]3[+!8
MBC5II47HM KR/X@65GINIK#;VZ1B2*-TVCI@N#^?'Y5Z9K&L6FB6#W=W)A1P
MJ#[SGT KQ'6]8N-<U.2]N3@MPB#HB]@*ZLOIS<^?H>=G5>FJ:I_:_)$6E:=+
MJVIP6,)423-@%CP.,G]!7HTVG06WB?3],MUQ%#]F3Z[?-D)/N2 :\XTN^?3=
M4MKU.6AD#X]0#R*]3TN1-6\:2:C;$R6BJ664#Y<^7& ,^OS-Q77BW)._2S^\
M\_+8PE&WVN9?=_6_R&^./%J:3;R:9:E_MTJ<NO B4^_KBO*UOKM/N7,R]^'(
MKHOB'',GBV=Y$*HZ(8SC[PV@?S!KE:TPE*,*2:ZF&98BI4Q$E)_"[(]6\$^,
MO[1"Z;J4B+<HJK"Y)S+]??I]:[FOG_0X);G7;&&'(D:=,$=N>OX5] 5YN.HQ
MIS3CU/=RC$U*U)J?V>IP5JIM/&D4?9-1N%QZ"6(./U!KO:X?7(FM?%\-QM8(
M]Q:2EL<9R\9_0BNXK+$:J+\CHP2Y74CY_P# _0****YCN"BBB@ KD_B-*8_!
M\Z@X\R1%_7/]*ZRN-^)G_(IC_KX3^35T817KP]3FQCMAY^C/'****^L/D KV
M/X:Z:MIX:^UD?O+N0L3_ +*G '\S^->.5[YX3C\KPIIBXQ^X5OSY_K7EYK-J
MBHKJSU<H@G6<GT1+XCMVNO#>I0K]YK=\?4#-?/U?0?B&];3O#U_=HH9HX6V@
M^IX'\Z^?*C*;\DNUR\XM[2/>P4445ZYXYZ/\*;+,VH7Q'W56)3]>3_(5Z=7)
M_#FT%MX1BDQS<2/(?SV_^RUUE?+8Z?/B)/Y?<?68"GR8>*^?WA1117(=@444
M4 %%%% !1110 4444 5=3_Y!5Y_UP?\ ]!-<SIW_ ""]'_[!:_\ HLU;GOM3
M\0/=VNCBW@L8RT$E[<*7\QNC"-01P#QN)Z]JR-(U2TAEL=*U2:.RN[*V^S3Q
MS.$S@,H92>JD8((]:UC%I&3DFSKM%_Y 6G_]>T?_ *"*O5RUM?\ V2UBMHO$
M^B-'"@C0NHW$ 8&<28S4O]KR?]#+H7_?'_VVI<7<I2T+VG_\A_6/K#_Z!4&D
M_P#(U>(?]ZW_ /1=16>J:3I_VN\O=?TZ6:=@SLDBJJA1@ +N)_4YS5'2[;6M
M1O-0UFSNX["WOI%\J*XM"[M&B[5<_,,9Y.,=,55M[BOM8["BL+[#XE_Z#EG_
M . !_P#CE'V'Q+_T'+/_ , #_P#'*CE7<KF?8W:*POL'B7_H.6?_ ( '_P".
M4R+5-3TR_M[36UMY(;E_+@O;92J[^R.I)VD]B#@].*.7LPYNZ.@HHHJ2@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DIVQ.?12:S/#*%/
M#ED#W0G\R35O5)#%I=TPZ^60/J1@4^Q@%M86\ _Y9QJOY"JZ"ZEBBBBI&%%%
M% !1110!R^O'Q6^I&+3(T73]@_>0N@E)[C+Y _(US]WI-Y-(MM<:%>7-_*C2
MPW%UJBR[-A7D+]T<L.@%>D5DWRL_B"S1'V.UG<A6QG:=T7-:QG;2QE*%];G+
M:B_B2?[/_:^CQ7%K'(93")8QO*HQY.3VR?PJ5=,:\MXY(?!-FGF*&1Y;Q0H!
MYR=HS6Y>12PZ:BRS>:292"&+8'E/QD\FM/2_^039?]<$_P#013<[+1 H7>IP
M][X%ACM'N;]X,L1FVLXO+B[G!))8_F/I6_!'*?&VJB"58B+&UZIN'WI?<5H:
M_P#\@QO][^AJK9_\CSJW_7C:_P#H4U+F<EK_ %L'*D]/ZW+4ZZU&CM'<V#!5
MS\UNX_\ 9S6.=5\1G2KS4 VE;+8R@H8I,ML)'7=WQ727Q*Z?<D=1$Q_0USL9
MW>"=6;U-T?\ QYJ4=ARW+]NWB*:,2&72@#GI%)Z_[U7(XM6/^MN[,#T2W;/Y
ME_Z4[27:33D9NN]Q^3D5=J6]2DCG_#ZLNM^(@[[V^UQY;&,_N4KH*XVWU>;3
M=?\ $932;V[C%PCM)!LPN(4Z[F!KJ[*[CO["VO(@PBN(EE0,,'# $9_.G-/<
M4&MB>BBBH+"BBB@ HHHH **** "BBB@ K"U^#SM3T-\?ZN[W?^.FMVJ5]%YE
MQ9MC[DV?T-.+LQ25T7:***0PHHHH **** "BBB@ K&\1/KR6T(T&*!Y&<B5I
M",JN.J@D#/UK9HIIV=Q-75CSRZLM46,3ZSI>H:B"Z)LEU-$CW,P4?NT &,D=
M<TK0>*K'0YM/BTV.*P2)T"B2,LB'/ .>P/I77Z]_R#$_Z^K;_P!')4=U!/'!
MJ4DESYD;1/A,DXR"1QT&!QQUK53NMC)PUW.9MK-;F.1$\#V[>2YB<_:XQ\PQ
M[4-X(DO%:XNH;+3(T4LL-DGF2=/XI'X_)?QKJ=%ZZC_U^R?R%7[G_CUF_P!Q
MOY4G4:>@U336IQL5C%8P>%+6T_=(E_-M/WC_ *N;).>M=1)%JP/[J[LR/22W
M;/YA_P"E8,O^O\+?]?\ -_Z*FKK:4W_7S'!?U\CFTO?$4VIS64<FE Q1JY9H
MI.<LP_O?[/ZT:=>^([]9&#Z4OER,A_=2<[69<_>_V:DTIR_B;4<]HE'_ )$D
MI?#3DO?I_"LSD?C-+_A3>ST!;EU(]:)_>75@H_V;=S_[/6=.DR>-=(\Z82,;
M2Y^ZFT#F/W-='7+:[>2V7B_2)8K*XO&^RW \N#;NZQ\_,0*F.K'+1'4T5G:/
MJZ:O!.XMI[:2"8P213 ;E8 'L2.C"M&I:MH4G<****0PHHHH **** "BBB@
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M7#W=C#*^<[BN"?J1UK0QFBDFT[H;BFK-&5!X:T6VE$L.FVZ..A"?TK4
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M>[T60DOIDWE(3WA;YHS_ -\G;_P&JDM/02>OJ;]%%%9EA1110 4444 %%%%
M!1110 4444 %5KJY\H;$^^?TJ=V"(S'L*R^6S*W4GBN/%UG!<L=V:4XWU8H
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M9$-M;%1@/Y8;<P]1EL9[D$U:5HLAN\D=311169H%%%% !1110 4444 %%%%
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M4M64%%%%, J"\O+>PM)+J[F2&",9=W. !4]<QXYBAFT6%9EER+A7CDC8KY;
M$@\?D/<^U5%7=B9.RN9S:C/="ZGDTN]MX;R^M'MWDCX*!XQEO[N<'@^U==J?
M_(*N_P#KBW\JP&\)IJ>G1K-K.MA)%20H;H'!&".J]CC\JK2_#]G1D7Q1KP1@
M5*M<A@0>QXK1\KZD+F70EBUBR@LM9B>20NUS-MV0NP;MP0,'D8Z]:Q-L_C"^
MEOIH9(K:Q?+>8N"C*<B%<]^A=OHHX%:VIZ;JFBZ$ZQ>(Y4@15A1%M(@1DA0
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MU*6[):CLCMJ***YS<**** "BBB@ HHHH **** "BBB@ HHHS0 4444 %%%%
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M/@?4UVFG+Y>F6B8'RPH./]T43;L$$KEJBBBL340TM%% !1110 4444 %%%%
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M9 :F!##(((]J\]IK<])-/86BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HYHHH **.:* "BBB@ HHHH ***09[T +1110 4444 %%%%
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MM-&.(5Z4DNQ6\&Y7PS;PM]Z!Y(C_ ,!=A6]7.^$)"UIJ"$$%;Z1@#V#!7_\
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MQ-_:090=W"Y;<Q*_NRH&,T>SEL'M([G7OIUC);QV[V5NT$1S'&T2E4.".!C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>nktx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-16T16:12:19.8552+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://nkartatx.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:nktx="http://nkartatx.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>100040 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100050 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>100060 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100080 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>100090 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100100 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100110 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements1" id="DisclosureCollaborationAndLicenseAgreements1">
        <link:definition>100130 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits" id="Role_DisclosureEmployeeBenefits">
        <link:definition>100140 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100150 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100160 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100200 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>100210 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100220 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100230 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100240 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100250 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails">
        <link:definition>100270 - Disclosure - Basis of Presentation and Significant Accounting Polices - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100280 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100290 - Disclosure - Net Loss Per Share - Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails">
        <link:definition>100300 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Value of Financial Instrument (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails">
        <link:definition>100320 - Disclosure - Fair Value of Financial Instruments - Schedule of Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInPreferredStockPurchaseRightLiabilityDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInPreferredStockPurchaseRightLiabilityDetails">
        <link:definition>100330 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Preferred Stock Purchase Right Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100340 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100350 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>100370 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails" id="Role_DisclosureLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>100380 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails">
        <link:definition>100390 - Disclosure - Leases - Schedule of Supplemental Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100410 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100440 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Employee Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>100460 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100480 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails" id="Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails">
        <link:definition>100490 - Disclosure - Share-Based Compensation - Summary of Additional Information Related to Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails" id="DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>100500 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100510 - Disclosure - Share-Based Compensation - Summary of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails">
        <link:definition>100520 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100530 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails" id="Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100560 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>100570 - Disclosure - Income Taxes - Summary of Changes in Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_CollaborationAgreementAbstract" name="CollaborationAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract" name="LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent" name="AccruedPropertyAndEquipmentLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit" name="AdditionalNumberOfDaysToReplaceLetterOfCredit" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_AdditionalTenantImprovementAllowances" name="AdditionalTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" name="AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_AmountsOwedUnderAgreement" name="AmountsOwedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_AnnualLicenseMaintenanceFee" name="AnnualLicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees" name="AnnualResearchLicenseFeesAndCommercializationLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments" name="CashCashEquivalentsRestrictedCashAndShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid" name="CashReceivedForTenantImprovementAllowancesToBeRepaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_ChangesInOwnershipByStockholdersHoldingPercentage" name="ChangesInOwnershipByStockholdersHoldingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_DeferredOfferingCostsLiabilitiesCurrent" name="DeferredOfferingCostsLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_EmployeeStockPurchasePlanLookBackPeriod" name="EmployeeStockPurchasePlanLookBackPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_ExpectedBaseRentOverLeaseTerm" name="ExpectedBaseRentOverLeaseTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" name="FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_FairValueOfCommonStockIssued" name="FairValueOfCommonStockIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate" name="FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm" name="FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage" name="FairValueOfPreferredStockPurchaseRightLiabilityPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_Impairments" name="Impairments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" name="IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_IncomeTaxReconciliationPermanentItems" name="IncomeTaxReconciliationPermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" name="IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" name="IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" name="LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" name="LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_LicenseAgreementTerm" name="LicenseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_LicenseAgreementUpfrontPayment" name="LicenseAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis" name="MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment" name="MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_MonthlyBaseRent" name="MonthlyBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_NetSalesMilestonePayments" name="NetSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_NonCashInterestExpenseOnConvertibleNotes" name="NonCashInterestExpenseOnConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable" name="NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_NumberOfDaysToReplaceEachLetterOfCredit" name="NumberOfDaysToReplaceEachLetterOfCredit" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets" name="NumberOfNonExclusiveRightsToGeneEditingTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" name="NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_PaymentsMadeUnderCollaborativeArrangement" name="PaymentsMadeUnderCollaborativeArrangement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_PaymentsOfDeferredOfferingCosts" name="PaymentsOfDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_PercentageOfLicensorsRoyalties" name="PercentageOfLicensorsRoyalties" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_PercentageOfSublicensingIncome" name="PercentageOfSublicensingIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones" name="PotentialFuturePaymentsBasedOnAchievementOfMilestones" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_PotentialMilestonePayments" name="PotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" name="PreferredStockPurchaseRightLiabilityFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" name="ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts" name="ProceedsFromSecondaryOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_ReceivableUnderResearchCostSharingProvision" name="ReceivableUnderResearchCostSharingProvision" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" name="ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" name="RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" name="RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments" name="StockIssuedDuringPeriodSharesIssuedUpfrontPayments" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" name="StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" name="StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible" name="TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities" name="TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes" name="TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" name="TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes" name="TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes" name="TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_TenantImprovementReceivable" name="TenantImprovementReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_TenantImprovementsYetToReceiveFromLessor" name="TenantImprovementsYetToReceiveFromLessor" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions" name="WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_AdditionalLeaseAgreementMember" name="AdditionalLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_AfterYearTwoMember" name="AfterYearTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_AgreementWithFinancialInstitutionMember" name="AgreementWithFinancialInstitutionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_CarryForwardIndefinitelyMember" name="CarryForwardIndefinitelyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_CommonStockOptionsAndRestrictedStockUnitsMember" name="CommonStockOptionsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_CommonStockOptionsMember" name="CommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_ComputersAndSoftwareMember" name="ComputersAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_CorporateOfficeAndLaboratoryFacilitiesMember" name="CorporateOfficeAndLaboratoryFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_CorporateOfficeAndLaboratorySpaceMember" name="CorporateOfficeAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember" name="DevelopmentAndRegulatoryApprovalMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_ExpirationYearOneMember" name="ExpirationYearOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_ExpirationYearTwoMember" name="ExpirationYearTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_FollowOnOfferingOfStockMember" name="FollowOnOfferingOfStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember" name="GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember" name="InitialLeaseAgreementAndAdditionalLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_InitialLeaseAgreementMember" name="InitialLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_KPlanMember" name="KPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_MaxcyteLicenseAgreementMember" name="MaxcyteLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember" name="NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember" name="NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_NkCellProductsMember" name="NkCellProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_ResearchCollaborationAgreementMember" name="ResearchCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_ResearchEquipmentMember" name="ResearchEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember" name="SecondAmendmentOfAdditionalLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_SeparationAndReleaseAgreementMember" name="SeparationAndReleaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_ThirdAmendmentMember" name="ThirdAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_TwoThousandFifteenEquityIncentivePlanMember" name="TwoThousandFifteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember" name="TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_TwoThousandTwentyPerformanceIncentivePlanMember" name="TwoThousandTwentyPerformanceIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember" name="UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_VivariumMember" name="VivariumMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock" name="CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock" name="PreferredStockPurchaseRightLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_ReverseStockSplitPolicyPolicyTextBlock" name="ReverseStockSplitPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions" name="ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock" name="SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_TemporaryEquityPolicyTextBlock" name="TemporaryEquityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock" name="UnusualOrInfrequentItemsDisclosurePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>nktx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-16T16:12:21.7760+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" xlink:label="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" xlink:label="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ReceivableUnderResearchCostSharingProvision" xlink:label="nktx_ReceivableUnderResearchCostSharingProvision"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract" xlink:label="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="nktx_DeferredTaxAssetsDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions" xlink:label="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions" xlink:label="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MaxcyteLicenseAgreementMember" xlink:label="nktx_MaxcyteLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember" xlink:label="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit" xlink:label="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AmountsOwedUnderAgreement" xlink:label="nktx_AmountsOwedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CorporateOfficeAndLaboratoryFacilitiesMember" xlink:label="nktx_CorporateOfficeAndLaboratoryFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember" xlink:label="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" xlink:label="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments" xlink:label="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PercentageOfSublicensingIncome" xlink:label="nktx_PercentageOfSublicensingIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SeriesBConvertiblePreferredStockMember" xlink:label="nktx_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ResearchEquipmentMember" xlink:label="nktx_ResearchEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NonCashInterestExpenseOnConvertibleNotes" xlink:label="nktx_NonCashInterestExpenseOnConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" xlink:label="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_VivariumMember" xlink:label="nktx_VivariumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember" xlink:label="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_KPlanMember" xlink:label="nktx_KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock" xlink:label="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CarryForwardIndefinitelyMember" xlink:label="nktx_CarryForwardIndefinitelyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementMember" xlink:label="nktx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseExpirationMonthAndYear" xlink:label="nktx_LeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes" xlink:label="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CollaborationAndLicenseAgreementMember" xlink:label="nktx_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SecondAmendmentOfAdditionalLeaseAgreementMember" xlink:label="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TaxCreditCarryforwardExpirationYear" xlink:label="nktx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpectedBaseRentOverLeaseTerm" xlink:label="nktx_ExpectedBaseRentOverLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_OperatingLossCarryforwardsExpirationYear" xlink:label="nktx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment" xlink:label="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PotentialMilestonePayments" xlink:label="nktx_PotentialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccountingPoliciesLineItems" xlink:label="nktx_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SeparationAndReleaseAgreementMember" xlink:label="nktx_SeparationAndReleaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseExpirationYear" xlink:label="nktx_LeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CorporateOfficeAndLaboratorySpaceMember" xlink:label="nktx_CorporateOfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_EmployeeStockPurchasePlanLookBackPeriod" xlink:label="nktx_EmployeeStockPurchasePlanLookBackPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccountingPoliciesTable" xlink:label="nktx_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" xlink:label="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpirationYearTwoMember" xlink:label="nktx_ExpirationYearTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxesLineItems" xlink:label="nktx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="nktx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible" xlink:label="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CommonStockOptionsAndRestrictedStockUnitsMember" xlink:label="nktx_CommonStockOptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" xlink:label="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ChangesInOwnershipByStockholdersHoldingPercentage" xlink:label="nktx_ChangesInOwnershipByStockholdersHoldingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" xlink:label="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PaymentsMadeUnderCollaborativeArrangement" xlink:label="nktx_PaymentsMadeUnderCollaborativeArrangement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpirationYearOneMember" xlink:label="nktx_ExpirationYearOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandTwentyPerformanceIncentivePlanMember" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesSoldAtPar" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="us-gaap_DividendsShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CommonStockOptionsMember" xlink:label="nktx_CommonStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PaymentsOfDeferredOfferingCosts" xlink:label="nktx_PaymentsOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsLeaseLiability" xlink:label="nktx_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementTerm" xlink:label="nktx_LicenseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" xlink:label="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="nktx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis" xlink:label="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ReverseStockSplitPolicyPolicyTextBlock" xlink:label="nktx_ReverseStockSplitPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_InitialLeaseAgreementMember" xlink:label="nktx_InitialLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PercentageOfLicensorsRoyalties" xlink:label="nktx_PercentageOfLicensorsRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember" xlink:label="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityPolicyTextBlock" xlink:label="nktx_TemporaryEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalTenantImprovementAllowances" xlink:label="nktx_AdditionalTenantImprovementAllowances"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfDaysToReplaceEachLetterOfCredit" xlink:label="nktx_NumberOfDaysToReplaceEachLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" xlink:label="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NkCellProductsMember" xlink:label="nktx_NkCellProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable" xlink:label="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CollaborationAgreementAbstract" xlink:label="nktx_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxReconciliationPermanentItems" xlink:label="nktx_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember" xlink:label="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ComputersAndSoftwareMember" xlink:label="nktx_ComputersAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NetSalesMilestonePayments" xlink:label="nktx_NetSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AnnualLicenseMaintenanceFee" xlink:label="nktx_AnnualLicenseMaintenanceFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TenantImprovementReceivable" xlink:label="nktx_TenantImprovementReceivable"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseCommencementDate" xlink:label="nktx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones" xlink:label="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementUpfrontPayment" xlink:label="nktx_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MonthlyBaseRent" xlink:label="nktx_MonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:label="us-gaap_CommercialPaperAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid" xlink:label="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ResearchCollaborationAgreementMember" xlink:label="nktx_ResearchCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments" xlink:label="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ThirdAmendmentMember" xlink:label="nktx_ThirdAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfNonExclusiveRightsToGeneEditingTargets" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" xlink:label="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AtTheMarketOfferingMember" xlink:label="nktx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="nktx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AgreementWithFinancialInstitutionMember" xlink:label="nktx_AgreementWithFinancialInstitutionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" xlink:label="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees" xlink:label="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities" xlink:label="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember" xlink:label="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxesTable" xlink:label="nktx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts" xlink:label="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock" xlink:label="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TenantImprovementsYetToReceiveFromLessor" xlink:label="nktx_TenantImprovementsYetToReceiveFromLessor"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock" xlink:label="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent" xlink:label="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalLeaseAgreementMember" xlink:label="nktx_AdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AfterYearTwoMember" xlink:label="nktx_AfterYearTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_Impairments" xlink:label="nktx_Impairments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredOfferingCostsLiabilitiesCurrent" xlink:label="nktx_DeferredOfferingCostsLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FollowOnOfferingOfStockMember" xlink:label="nktx_FollowOnOfferingOfStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfCommonStockIssued" xlink:label="nktx_FairValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share limit as percentage of outstanding shares of common stock on last trading day in prior year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Share Limit As Percentage Of Outstanding Shares Of Common Stock On Last Trading Day In Prior Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in share limit as percentage of outstanding shares of common stock on last trading day in prior year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of non-exclusive rights to gene editing targets licenses received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Non Exclusive Rights To Gene Editing Targets licenses received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of non exclusive rights to gene editing targets licenses received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon secondary offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term (in years), outstanding ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of preferred stock purchase right liability to equity upon issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Reclassification Of Preferred Stock Purchase Right Liability To Equity Upon Issuance Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliations Reclassification of preferred stock purchase right liability to equity upon issuance of convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-use Assets Obtained in Exchange for Operating Lease Liabilities Resulting from New Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReceivableUnderResearchCostSharingProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Receivable under research cost sharing provision.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReceivableUnderResearchCostSharingProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable Under Research Cost Sharing Provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReceivableUnderResearchCostSharingProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable under research cost sharing provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities Arising From Obtaining Right Of Use Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets depreciation and amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Additional Information Related to Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Additional Information Related To Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based compensation additional information related to stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: weighted average unvested common stock issued upon early exercise of common stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of shares unvested common stock issued upon early exercise of common stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MaxcyteLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MaxCyte license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MaxcyteLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MaxCyte License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MaxcyteLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MaxCyte License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon employee stock purchase plan,share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average grant date fair value per share, outstanding ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average grant date fair value per share, outstanding beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Lease Agreement and Additional Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Lease Agreement And Additional Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Lease Agreement And Additional Lease Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional number of days to replace letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional number of days to replace letter of credit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AmountsOwedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amounts owed under agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AmountsOwedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amounts Owed Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AmountsOwedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts owed under the agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reserved for Future ESPP Issuances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance of Series B convertible preferred stock upon conversion of promissory notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Upon Conversion Of Promissory Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value upon conversion of promissory notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CorporateOfficeAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Office and Laboratory Facilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CorporateOfficeAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Office And Laboratory Facilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CorporateOfficeAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate office and laboratory facilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of the reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate cash proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from ESPP purchases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss and Tax Credit Carryforwards to Offset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss And Tax Credit Carryforwards To Offset [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and tax credit carryforwards to offset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Fair Value Of Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation change in fair value of derivative liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized loss on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from ATM offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From At The Market Offering Net of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from at the market offering net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents restricted cash and short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Short Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash cash equivalents restricted cash and short term investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PercentageOfSublicensingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of sublicensing income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PercentageOfSublicensingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Sublicensing Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PercentageOfSublicensingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of sublicensing income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of employee compensation eligible for plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matthew Plunkett</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Financial Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ResearchEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ResearchEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ResearchEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance and sale of equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of common shares used in net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used to compute net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, outstanding balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NonCashInterestExpenseOnConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NonCashInterestExpenseOnConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Expense On Convertible Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NonCashInterestExpenseOnConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash interest expense on convertible notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of prepaid expenses and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secondary Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases (decreases) related to tax positions taken in prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit notice period by financial institution before annual expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit Notice Period By Financial Institution Before Annual Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter of credit notice period by financial institution before annual expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value of stock option grants per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Available for sale securities, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_VivariumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vivarium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_VivariumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vivarium [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_VivariumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vivarium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Group Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GlaxoSmithKline Intellectual Property Development Limited and Glaxo Group Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of preferred stock purchase right liability percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Preferred Stock Purchase Right Liability Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of preferred stock purchase right liability percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation and amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401 (K) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">K Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">401 (K) Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of preferred stock purchase right liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, January 1, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Purchase Right Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Purchase Right Liability Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock purchase right liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CarryForwardIndefinitelyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carry Forward Indefinitely</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CarryForwardIndefinitelyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carry Forward Indefinitely [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CarryForwardIndefinitelyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carry forward indefinitely.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance for deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, conversion of convertible preferred stock to common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 54,350,179 shares authorized at December 31, 2022; no shares issued and outstanding at December 31, 2022 and 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary equity, reacquisition of beneficial conversion feature upon settlement of promissory notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Reacquisition Of Beneficial Conversion Feature Upon Settlement Of Promissory Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, reacquisition of beneficial conversion feature upon settlement of promissory notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of preferred stock purchase right liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock purchase right liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment Of Additional Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment Of Additional Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment of additional lease agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards, expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpectedBaseRentOverLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Base Rent Over Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpectedBaseRentOverLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expects to pay base rent over the lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpectedBaseRentOverLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected base rent over the lease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commons stock purchase price as percentage of fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards, expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability regard to loss contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Upon Completion Of Regulatory Milestone Related To Clinical Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment upon completion of regulatory milestone related to the clinical development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Information related to Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Information Related To Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental information related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term (in years), exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock option exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SeparationAndReleaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Separation and Release Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SeparationAndReleaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Separation And Release Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SeparationAndReleaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Separation and release agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CorporateOfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Office and Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CorporateOfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Office And Laboratory Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CorporateOfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate office and laboratory space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sale securities, Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of common shares used in net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used to compute net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_EmployeeStockPurchasePlanLookBackPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee stock purchase plan look-back period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_EmployeeStockPurchasePlanLookBackPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan look-back period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock purchase right liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Purchase Right Liability Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock purchase right liability fair value disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpirationYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2036</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpirationYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Year Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpirationYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration year two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions common stock fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of preferred stock purchase right liability outstanding term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Preferred Stock Purchase Right Liability Outstanding Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of preferred stock purchase right liability outstanding term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision or benefit for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, beneficial conversion feature upon issuance of convertible</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Beneficial Conversion Feature Upon Issuance Of Convertible</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity beneficial conversion feature upon issuance of convertible.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CommonStockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options And Restricted Stock Units Granted And Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CommonStockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CommonStockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options and restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock purchase right liability to equity upon issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Reclassification Of Preferred Stock Purchase Right Liability To Equity Upon Issuance Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity reclassification of preferred stock purchase right liability to equity upon issuance of convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued and sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon secondary offering, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ChangesInOwnershipByStockholdersHoldingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in ownership by stockholders holding percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ChangesInOwnershipByStockholdersHoldingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Ownership By Stockholders Holding Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ChangesInOwnershipByStockholdersHoldingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in ownership by stockholders holding percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance of Series B convertible preferred stock upon conversion of promissory notes, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Upon Conversion Of Promissory Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares upon conversion of promissory notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, conversion of convertible preferred stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee option to extend description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount held as collateral for letters of credit issued to landlord</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount held as collateral for letters of credit issued to landlord.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PaymentsMadeUnderCollaborativeArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments made under collaborative arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PaymentsMadeUnderCollaborativeArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Made Under Collaborative Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PaymentsMadeUnderCollaborativeArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount paid under the agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpirationYearOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2035</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpirationYearOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Year One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ExpirationYearOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration year one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reserved for Future Equity Award Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Performance Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty performance incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Sold at Par Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments, available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of preferred stock purchase right liability discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Preferred Stock Purchase Right Liability Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of preferred stock purchase right liability discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends issued for options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend, Share-Based Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividend, Share-based Payment Arrangement, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Realized loss on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gain or loss on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Realized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities, Maturity (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 100,000,000 shares authorized at December 31, 2022; 48,877,806 and 32,971,107 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PaymentsOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PaymentsOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PaymentsOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of research and development expense resulting from partial reimbursement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction Of Research And Development Expense Resulting From Partial Reimbursement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction of research and development expense resulting from partial reimbursement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Credit Carry Forwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum monthly base rent after increase on annual basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Monthly Base Rent After Increase on Annual Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum monthly base rent after increase on annual basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant date fair value per share, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value for the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_InitialLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial lease agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_InitialLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_InitialLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PercentageOfLicensorsRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of licensors royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PercentageOfLicensorsRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Licensors Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PercentageOfLicensorsRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of Licensors royalties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock public offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NUS and St. Jude</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National University Of Singapore And St Jude Children S Research Hospital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National University of Singapore and St. Jude Children's Research Hospital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued and current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of shares of common stock subject to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value vesting of shares of common stock subject to repurchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares subject to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term (in years), vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AdditionalTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AdditionalTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Tenant Improvement Allowances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AdditionalTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tenant improvement allowances.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual term of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NumberOfDaysToReplaceEachLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of days to replace each letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NumberOfDaysToReplaceEachLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days to replace each letter of credit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Product revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 Capitalized R&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets section one seventy four Capitalized Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets Section 174 capitalized R&amp;D.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NkCellProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NK cell products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NkCellProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NK Cell Products [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NkCellProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NK Cell Products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions of property and equipment in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Fixed Assets Acquired Included In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash or part noncash acquisition fixed assets acquired included in accounts payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, expected to be recognized over weighted average remaining service period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term (in years), outstanding balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CollaborationAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CollaborationAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Unit Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Gross Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan and 2015 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Performance Incentive And Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty performance incentive and two thousand fifteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discount and amortization of premium on investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters Option to Purchase Additional Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Receivable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sale securities,Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ComputersAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ComputersAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computers And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ComputersAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computers and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of shares of common stock subject to repurchase, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Vesting Of Shares Of Common Stock Subject To Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares vesting of shares of common stock subject to repurchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions taken in current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increases related to tax positions taken in current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 7)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued during period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NetSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NetSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NetSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AnnualLicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AnnualLicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AnnualLicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less tenant improvement receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant improvement receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LeaseCommencementDate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Others</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential future payments based on achievement of milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Future Payments Based On Achievement Of Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, term of contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends expected to be issued over life of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_MonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance of net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities recorded for agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Current Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory approval milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Approval Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory Approval Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received for tenant improvement allowances to be repaid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received for Tenant Improvement Allowances to be Repaid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received for tenant improvement allowances to be repaid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average exercise price, outstanding beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average exercise price, outstanding ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares issued upfront payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contribution, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of credit outstanding amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of non exclusive rights to gene editing targets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Non Exclusive Rights to Gene Editing Targets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of non-exclusive rights to gene editing targets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease not yet commenced minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Minimum Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease lease not yet commenced minimum lease payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Change in Preferred Stock Purchase Right Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, outstanding ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, outstanding beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, outstanding beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, outstanding ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liabilities resulting from modifications of existing leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-use Assets Obtained in Exchange for Operating Lease Liabilities Resulting from Modifications of Existing Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for operating lease liabilities resulting from modifications of existing leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AgreementWithFinancialInstitutionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement with Financial Institution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AgreementWithFinancialInstitutionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement With Financial Institution [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AgreementWithFinancialInstitutionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement with financial institution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued And Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (Decrease) in accounts payable and accrued and other liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual research license fees and Commercialization license fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Research License Fees and Commercialization License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual research license fees and Commercialization license fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, series B preferred stock purchase right (liability) upon issuance of Series B convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Preferred Stock Purchase Right Liability Reversal Upon Issuance Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, preferred stock purchase right (liability) reversal upon issuance of convertible securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Common Stock Upon Early Exercise of Common Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Stock Upon Early Exercise Of Common Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common stock upon early exercise of common stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preferred stock and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Components of Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAndMaintenanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAndMaintenanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Maintenance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of preferred stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of Series B convertible preferred stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from secondary offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Secondary Offering Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from secondary offering net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, penalties and interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, Short-term Investments and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Short Term Investments And Restricted Cash Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash cash equivalents short term investments and restricted cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock option , Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TenantImprovementsYetToReceiveFromLessor_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvements yet to receive from lessor.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TenantImprovementsYetToReceiveFromLessor_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements Yet To Receive From Lessor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_TenantImprovementsYetToReceiveFromLessor_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowances yet to receive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Or Infrequent Items Disclosure Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unusual or infrequent items disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Property And Equipment Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued property and equipment liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense contribution plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AdditionalLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional lease agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AfterYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After Year Two of the Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AfterYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After Year Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_AfterYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After year two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_Impairments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_Impairments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_Impairments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredOfferingCostsLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredOfferingCostsLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_DeferredOfferingCostsLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FollowOnOfferingOfStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow On Offering of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FollowOnOfferingOfStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering of Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FollowOnOfferingOfStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on offering of stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available for sale securities, Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit at statutory rates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nktx_FairValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" xlink:to="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" xlink:to="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" xlink:to="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" xlink:to="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ReceivableUnderResearchCostSharingProvision" xlink:to="nktx_ReceivableUnderResearchCostSharingProvision_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract" xlink:to="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="nktx_DeferredTaxAssetsDepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions" xlink:to="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions" xlink:to="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_MaxcyteLicenseAgreementMember" xlink:to="nktx_MaxcyteLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember" xlink:to="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit" xlink:to="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AmountsOwedUnderAgreement" xlink:to="nktx_AmountsOwedUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CorporateOfficeAndLaboratoryFacilitiesMember" xlink:to="nktx_CorporateOfficeAndLaboratoryFacilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember" xlink:to="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" xlink:to="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" xlink:to="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments" xlink:to="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_PercentageOfSublicensingIncome" xlink:to="nktx_PercentageOfSublicensingIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_SeriesBConvertiblePreferredStockMember" xlink:to="nktx_SeriesBConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ResearchEquipmentMember" xlink:to="nktx_ResearchEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NonCashInterestExpenseOnConvertibleNotes" xlink:to="nktx_NonCashInterestExpenseOnConvertibleNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" xlink:to="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_VivariumMember" xlink:to="nktx_VivariumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember" xlink:to="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_KPlanMember" xlink:to="nktx_KPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock" xlink:to="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CarryForwardIndefinitelyMember" xlink:to="nktx_CarryForwardIndefinitelyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LicenseAgreementMember" xlink:to="nktx_LicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LeaseExpirationMonthAndYear" xlink:to="nktx_LeaseExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes" xlink:to="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CollaborationAndLicenseAgreementMember" xlink:to="nktx_CollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember" xlink:to="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TaxCreditCarryforwardExpirationYear" xlink:to="nktx_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ExpectedBaseRentOverLeaseTerm" xlink:to="nktx_ExpectedBaseRentOverLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_OperatingLossCarryforwardsExpirationYear" xlink:to="nktx_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment" xlink:to="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_PotentialMilestonePayments" xlink:to="nktx_PotentialMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="nktx_AccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_SeparationAndReleaseAgreementMember" xlink:to="nktx_SeparationAndReleaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LeaseExpirationYear" xlink:to="nktx_LeaseExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CorporateOfficeAndLaboratorySpaceMember" xlink:to="nktx_CorporateOfficeAndLaboratorySpaceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_EmployeeStockPurchasePlanLookBackPeriod" xlink:to="nktx_EmployeeStockPurchasePlanLookBackPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AccountingPoliciesTable" xlink:to="nktx_AccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" xlink:to="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ExpirationYearTwoMember" xlink:to="nktx_ExpirationYearTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" xlink:to="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="nktx_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="nktx_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible" xlink:to="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CommonStockOptionsAndRestrictedStockUnitsMember" xlink:to="nktx_CommonStockOptionsAndRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" xlink:to="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ChangesInOwnershipByStockholdersHoldingPercentage" xlink:to="nktx_ChangesInOwnershipByStockholdersHoldingPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" xlink:to="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_PaymentsMadeUnderCollaborativeArrangement" xlink:to="nktx_PaymentsMadeUnderCollaborativeArrangement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ExpirationYearOneMember" xlink:to="nktx_ExpirationYearOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TwoThousandTwentyPerformanceIncentivePlanMember" xlink:to="nktx_TwoThousandTwentyPerformanceIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesSoldAtPar" xlink:to="us-gaap_AvailableforsaleSecuritiesSoldAtPar_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsShareBasedCompensation" xlink:to="us-gaap_DividendsShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CommonStockOptionsMember" xlink:to="nktx_CommonStockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_PaymentsOfDeferredOfferingCosts" xlink:to="nktx_PaymentsOfDeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_DeferredTaxAssetsLeaseLiability" xlink:to="nktx_DeferredTaxAssetsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LicenseAgreementTerm" xlink:to="nktx_LicenseAgreementTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" xlink:to="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="nktx_TwoThousandFifteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis" xlink:to="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ReverseStockSplitPolicyPolicyTextBlock" xlink:to="nktx_ReverseStockSplitPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_InitialLeaseAgreementMember" xlink:to="nktx_InitialLeaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_PercentageOfLicensorsRoyalties" xlink:to="nktx_PercentageOfLicensorsRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember" xlink:to="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" xlink:to="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TemporaryEquityPolicyTextBlock" xlink:to="nktx_TemporaryEquityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AdditionalTenantImprovementAllowances" xlink:to="nktx_AdditionalTenantImprovementAllowances_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NumberOfDaysToReplaceEachLetterOfCredit" xlink:to="nktx_NumberOfDaysToReplaceEachLetterOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" xlink:to="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NkCellProductsMember" xlink:to="nktx_NkCellProductsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable" xlink:to="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CollaborationAgreementAbstract" xlink:to="nktx_CollaborationAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_IncomeTaxReconciliationPermanentItems" xlink:to="nktx_IncomeTaxReconciliationPermanentItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember" xlink:to="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ComputersAndSoftwareMember" xlink:to="nktx_ComputersAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" xlink:to="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NetSalesMilestonePayments" xlink:to="nktx_NetSalesMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AnnualLicenseMaintenanceFee" xlink:to="nktx_AnnualLicenseMaintenanceFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TenantImprovementReceivable" xlink:to="nktx_TenantImprovementReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LeaseCommencementDate" xlink:to="nktx_LeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones" xlink:to="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LicenseAgreementUpfrontPayment" xlink:to="nktx_LicenseAgreementUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_MonthlyBaseRent" xlink:to="nktx_MonthlyBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:to="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperAtCarryingValue" xlink:to="us-gaap_CommercialPaperAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid" xlink:to="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ResearchCollaborationAgreementMember" xlink:to="nktx_ResearchCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments" xlink:to="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ThirdAmendmentMember" xlink:to="nktx_ThirdAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets" xlink:to="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" xlink:to="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AtTheMarketOfferingMember" xlink:to="nktx_AtTheMarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="nktx_AccruedResearchAndDevelopmentCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" xlink:to="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AgreementWithFinancialInstitutionMember" xlink:to="nktx_AgreementWithFinancialInstitutionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" xlink:to="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees" xlink:to="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities" xlink:to="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember" xlink:to="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_IncomeTaxesTable" xlink:to="nktx_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndMaintenanceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts" xlink:to="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock" xlink:to="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_TenantImprovementsYetToReceiveFromLessor" xlink:to="nktx_TenantImprovementsYetToReceiveFromLessor_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock" xlink:to="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent" xlink:to="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AdditionalLeaseAgreementMember" xlink:to="nktx_AdditionalLeaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_AfterYearTwoMember" xlink:to="nktx_AfterYearTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_Impairments" xlink:to="nktx_Impairments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_DeferredOfferingCostsLiabilitiesCurrent" xlink:to="nktx_DeferredOfferingCostsLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_FollowOnOfferingOfStockMember" xlink:to="nktx_FollowOnOfferingOfStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktx_FairValueOfCommonStockIssued" xlink:to="nktx_FairValueOfCommonStockIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>nktx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-16T16:12:19.4225+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="nktx-20221231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails" xlink:href="nktx-20221231.xsd#DisclosureStockholdersEquityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="nktx-20221231.xsd#DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AtTheMarketOfferingMember" xlink:label="nktx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible" xlink:label="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes" xlink:label="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities" xlink:label="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" xlink:label="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nktx_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccountingPoliciesLineItems" xlink:label="nktx_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccountingPoliciesTable" xlink:label="nktx_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember" xlink:label="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CollaborationAndLicenseAgreementMember" xlink:label="nktx_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_EmployeeStockPurchasePlanLookBackPeriod" xlink:label="nktx_EmployeeStockPurchasePlanLookBackPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="nktx_AccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_AccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_AccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_AccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_AccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="nktx_EmployeeStockPurchasePlanLookBackPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CommonStockOptionsMember" xlink:label="nktx_CommonStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember" xlink:label="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nktx_CommonStockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" xlink:label="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:label="us-gaap_CommercialPaperAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CommercialPaperAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SeriesBConvertiblePreferredStockMember" xlink:label="nktx_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesSoldAtPar" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_Impairments" xlink:label="nktx_Impairments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" xlink:label="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nktx_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AvailableforsaleSecuritiesSoldAtPar" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_Impairments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_InterestReceivableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ResearchEquipmentMember" xlink:label="nktx_ResearchEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ComputersAndSoftwareMember" xlink:label="nktx_ComputersAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_ResearchEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_ComputersAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ThirdAmendmentMember" xlink:label="nktx_ThirdAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_InitialLeaseAgreementMember" xlink:label="nktx_InitialLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CorporateOfficeAndLaboratorySpaceMember" xlink:label="nktx_CorporateOfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SecondAmendmentOfAdditionalLeaseAgreementMember" xlink:label="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_VivariumMember" xlink:label="nktx_VivariumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CorporateOfficeAndLaboratoryFacilitiesMember" xlink:label="nktx_CorporateOfficeAndLaboratoryFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseExpirationYear" xlink:label="nktx_LeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseExpirationMonthAndYear" xlink:label="nktx_LeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" xlink:label="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpectedBaseRentOverLeaseTerm" xlink:label="nktx_ExpectedBaseRentOverLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MonthlyBaseRent" xlink:label="nktx_MonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis" xlink:label="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TenantImprovementsYetToReceiveFromLessor" xlink:label="nktx_TenantImprovementsYetToReceiveFromLessor"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid" xlink:label="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseCommencementDate" xlink:label="nktx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalTenantImprovementAllowances" xlink:label="nktx_AdditionalTenantImprovementAllowances"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="nktx_ThirdAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_InitialLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_CorporateOfficeAndLaboratorySpaceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_VivariumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_CorporateOfficeAndLaboratoryFacilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_LeaseExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_ExpectedBaseRentOverLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_MonthlyBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_TenantImprovementsYetToReceiveFromLessor" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_LeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_AdditionalTenantImprovementAllowances" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AgreementWithFinancialInstitutionMember" xlink:label="nktx_AgreementWithFinancialInstitutionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" xlink:label="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_AgreementWithFinancialInstitutionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember" xlink:label="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AfterYearTwoMember" xlink:label="nktx_AfterYearTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ResearchCollaborationAgreementMember" xlink:label="nktx_ResearchCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" xlink:label="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MaxcyteLicenseAgreementMember" xlink:label="nktx_MaxcyteLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NkCellProductsMember" xlink:label="nktx_NkCellProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfNonExclusiveRightsToGeneEditingTargets" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementMember" xlink:label="nktx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones" xlink:label="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PaymentsMadeUnderCollaborativeArrangement" xlink:label="nktx_PaymentsMadeUnderCollaborativeArrangement"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AmountsOwedUnderAgreement" xlink:label="nktx_AmountsOwedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ReceivableUnderResearchCostSharingProvision" xlink:label="nktx_ReceivableUnderResearchCostSharingProvision"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementUpfrontPayment" xlink:label="nktx_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments" xlink:label="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfCommonStockIssued" xlink:label="nktx_FairValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AnnualLicenseMaintenanceFee" xlink:label="nktx_AnnualLicenseMaintenanceFee"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PotentialMilestonePayments" xlink:label="nktx_PotentialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PercentageOfLicensorsRoyalties" xlink:label="nktx_PercentageOfLicensorsRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PercentageOfSublicensingIncome" xlink:label="nktx_PercentageOfSublicensingIncome"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementTerm" xlink:label="nktx_LicenseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment" xlink:label="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NetSalesMilestonePayments" xlink:label="nktx_NetSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees" xlink:label="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nktx_AfterYearTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_ResearchCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndMaintenanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_MaxcyteLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nktx_NkCellProductsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_LicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PaymentsMadeUnderCollaborativeArrangement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_AmountsOwedUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_ReceivableUnderResearchCostSharingProvision" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_LicenseAgreementUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_FairValueOfCommonStockIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_AnnualLicenseMaintenanceFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PotentialMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PercentageOfLicensorsRoyalties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PercentageOfSublicensingIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_LicenseAgreementTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_NetSalesMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_KPlanMember" xlink:label="nktx_KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="nktx_KPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FollowOnOfferingOfStockMember" xlink:label="nktx_FollowOnOfferingOfStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nktx_FollowOnOfferingOfStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="nktx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SeparationAndReleaseAgreementMember" xlink:label="nktx_SeparationAndReleaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandTwentyPerformanceIncentivePlanMember" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" xlink:label="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="us-gaap_DividendsShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nktx_TwoThousandFifteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_SeparationAndReleaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nktx_TwoThousandTwentyPerformanceIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember" xlink:label="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandTwentyPerformanceIncentivePlanMember" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CommonStockOptionsAndRestrictedStockUnitsMember" xlink:label="nktx_CommonStockOptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nktx_TwoThousandTwentyPerformanceIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktx_CommonStockOptionsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxesLineItems" xlink:label="nktx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxesTable" xlink:label="nktx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpirationYearOneMember" xlink:label="nktx_ExpirationYearOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpirationYearTwoMember" xlink:label="nktx_ExpirationYearTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember" xlink:label="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CarryForwardIndefinitelyMember" xlink:label="nktx_CarryForwardIndefinitelyMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_OperatingLossCarryforwardsExpirationYear" xlink:label="nktx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TaxCreditCarryforwardExpirationYear" xlink:label="nktx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ChangesInOwnershipByStockholdersHoldingPercentage" xlink:label="nktx_ChangesInOwnershipByStockholdersHoldingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="nktx_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nktx_ExpirationYearOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nktx_ExpirationYearTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nktx_CarryForwardIndefinitelyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="nktx_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktx_IncomeTaxesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="nktx_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="nktx_ChangesInOwnershipByStockholdersHoldingPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" xlink:label="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalLeaseAgreementMember" xlink:label="nktx_AdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfDaysToReplaceEachLetterOfCredit" xlink:label="nktx_NumberOfDaysToReplaceEachLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember" xlink:label="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit" xlink:label="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_AdditionalLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nktx_NumberOfDaysToReplaceEachLetterOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>nktx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-16T16:12:19.5022+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="nktx-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="nktx-20221231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="nktx-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="nktx_NonCashInterestExpenseOnConvertibleNotes" order="5" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NonCashInterestExpenseOnConvertibleNotes" xlink:label="nktx_NonCashInterestExpenseOnConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nktx_PaymentsOfDeferredOfferingCosts" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="11" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" order="13" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts" xlink:label="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PaymentsOfDeferredOfferingCosts" xlink:label="nktx_PaymentsOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" xlink:label="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="nktx_AccruedResearchAndDevelopmentCostsCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="nktx_DeferredOfferingCostsLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="nktx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent" xlink:label="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredOfferingCostsLiabilitiesCurrent" xlink:label="nktx_DeferredOfferingCostsLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="nktx_TenantImprovementReceivable" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TenantImprovementReceivable" xlink:label="nktx_TenantImprovementReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="nktx_IncomeTaxReconciliationPermanentItems" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxReconciliationPermanentItems" xlink:label="nktx_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" xlink:label="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nktx_DeferredTaxAssetsDepreciationAndAmortization" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="nktx_DeferredTaxLiabilitiesRightOfUseAsset" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nktx_DeferredTaxAssetsLeaseLiability" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="nktx_DeferredTaxAssetsDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="nktx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" xlink:label="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsLeaseLiability" xlink:label="nktx_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>nktx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-16T16:12:19.4014+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="nktx-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="nktx-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="nktx-20221231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="nktx-20221231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="nktx-20221231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="nktx-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" xlink:href="nktx-20221231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:href="nktx-20221231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="nktx-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="nktx-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="nktx-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements1" xlink:href="nktx-20221231.xsd#DisclosureCollaborationAndLicenseAgreements1" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:href="nktx-20221231.xsd#Role_DisclosureEmployeeBenefits" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="nktx-20221231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="nktx-20221231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="nktx-20221231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="nktx-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInPreferredStockPurchaseRightLiabilityDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInPreferredStockPurchaseRightLiabilityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails" xlink:href="nktx-20221231.xsd#DisclosureStockholdersEquityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="nktx-20221231.xsd#DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails" xlink:href="nktx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="nktx-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NonCashInterestExpenseOnConvertibleNotes" xlink:label="nktx_NonCashInterestExpenseOnConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nktx_NonCashInterestExpenseOnConvertibleNotes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AtTheMarketOfferingMember" xlink:label="nktx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible" xlink:label="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes" xlink:label="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities" xlink:label="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" xlink:label="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_25"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_26"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nktx_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts" xlink:label="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable" xlink:label="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" xlink:label="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PaymentsOfDeferredOfferingCosts" xlink:label="nktx_PaymentsOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nktx_PaymentsOfDeferredOfferingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CollaborationAgreementAbstract" xlink:label="nktx_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_CollaborationAgreementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ReverseStockSplitPolicyPolicyTextBlock" xlink:label="nktx_ReverseStockSplitPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock" xlink:label="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock" xlink:label="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock" xlink:label="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TemporaryEquityPolicyTextBlock" xlink:label="nktx_TemporaryEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktx_ReverseStockSplitPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktx_TemporaryEquityPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions" xlink:label="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments" xlink:label="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember" xlink:label="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccountingPoliciesLineItems" xlink:label="nktx_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccountingPoliciesTable" xlink:label="nktx_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CollaborationAndLicenseAgreementMember" xlink:label="nktx_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_EmployeeStockPurchasePlanLookBackPeriod" xlink:label="nktx_EmployeeStockPurchasePlanLookBackPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nktx_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesTable" xlink:to="nktx_AccountingPoliciesLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="nktx_EmployeeStockPurchasePlanLookBackPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions" xlink:label="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CommonStockOptionsMember" xlink:label="nktx_CommonStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember" xlink:label="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nktx_CommonStockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" xlink:label="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:label="us-gaap_CommercialPaperAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CommercialPaperAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_ShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SeriesBConvertiblePreferredStockMember" xlink:label="nktx_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesSoldAtPar" xlink:label="us-gaap_AvailableforsaleSecuritiesSoldAtPar"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_Impairments" xlink:label="nktx_Impairments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" xlink:label="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm" xlink:label="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nktx_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AvailableforsaleSecuritiesSoldAtPar" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_Impairments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInPreferredStockPurchaseRightLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" xlink:label="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ResearchEquipmentMember" xlink:label="nktx_ResearchEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ComputersAndSoftwareMember" xlink:label="nktx_ComputersAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_ResearchEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_ComputersAndSoftwareMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="nktx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent" xlink:label="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredOfferingCostsLiabilitiesCurrent" xlink:label="nktx_DeferredOfferingCostsLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="nktx_AccruedResearchAndDevelopmentCostsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="nktx_DeferredOfferingCostsLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract" xlink:label="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ThirdAmendmentMember" xlink:label="nktx_ThirdAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_InitialLeaseAgreementMember" xlink:label="nktx_InitialLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CorporateOfficeAndLaboratorySpaceMember" xlink:label="nktx_CorporateOfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SecondAmendmentOfAdditionalLeaseAgreementMember" xlink:label="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_VivariumMember" xlink:label="nktx_VivariumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CorporateOfficeAndLaboratoryFacilitiesMember" xlink:label="nktx_CorporateOfficeAndLaboratoryFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" xlink:label="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseExpirationYear" xlink:label="nktx_LeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseExpirationMonthAndYear" xlink:label="nktx_LeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" xlink:label="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpectedBaseRentOverLeaseTerm" xlink:label="nktx_ExpectedBaseRentOverLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MonthlyBaseRent" xlink:label="nktx_MonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis" xlink:label="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TenantImprovementsYetToReceiveFromLessor" xlink:label="nktx_TenantImprovementsYetToReceiveFromLessor"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid" xlink:label="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LeaseCommencementDate" xlink:label="nktx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalTenantImprovementAllowances" xlink:label="nktx_AdditionalTenantImprovementAllowances"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="nktx_ThirdAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_InitialLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_CorporateOfficeAndLaboratorySpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_SecondAmendmentOfAdditionalLeaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_VivariumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nktx_CorporateOfficeAndLaboratoryFacilitiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_LeaseExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_LeaseExpirationMonthAndYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_ExpectedBaseRentOverLeaseTerm" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_MonthlyBaseRent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_TenantImprovementsYetToReceiveFromLessor" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_LeaseCommencementDate" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nktx_AdditionalTenantImprovementAllowances" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TenantImprovementReceivable" xlink:label="nktx_TenantImprovementReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="nktx_TenantImprovementReceivable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AgreementWithFinancialInstitutionMember" xlink:label="nktx_AgreementWithFinancialInstitutionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" xlink:label="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_AgreementWithFinancialInstitutionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember" xlink:label="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AfterYearTwoMember" xlink:label="nktx_AfterYearTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DevelopmentAndRegulatoryApprovalMilestonesMember" xlink:label="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ResearchCollaborationAgreementMember" xlink:label="nktx_ResearchCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CollaborationAgreementAbstract" xlink:label="nktx_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" xlink:label="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MaxcyteLicenseAgreementMember" xlink:label="nktx_MaxcyteLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NkCellProductsMember" xlink:label="nktx_NkCellProductsMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfNonExclusiveRightsToGeneEditingTargets" xlink:label="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementMember" xlink:label="nktx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones" xlink:label="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PaymentsMadeUnderCollaborativeArrangement" xlink:label="nktx_PaymentsMadeUnderCollaborativeArrangement"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AmountsOwedUnderAgreement" xlink:label="nktx_AmountsOwedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ReceivableUnderResearchCostSharingProvision" xlink:label="nktx_ReceivableUnderResearchCostSharingProvision"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementUpfrontPayment" xlink:label="nktx_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments" xlink:label="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FairValueOfCommonStockIssued" xlink:label="nktx_FairValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AnnualLicenseMaintenanceFee" xlink:label="nktx_AnnualLicenseMaintenanceFee"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PotentialMilestonePayments" xlink:label="nktx_PotentialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PercentageOfLicensorsRoyalties" xlink:label="nktx_PercentageOfLicensorsRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_PercentageOfSublicensingIncome" xlink:label="nktx_PercentageOfSublicensingIncome"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_LicenseAgreementTerm" xlink:label="nktx_LicenseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment" xlink:label="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NetSalesMilestonePayments" xlink:label="nktx_NetSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees" xlink:label="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nktx_AfterYearTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nktx_DevelopmentAndRegulatoryApprovalMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_ResearchCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_CollaborationAgreementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndMaintenanceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_MaxcyteLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nktx_NkCellProductsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_NumberOfNonExclusiveRightsToGeneEditingTargets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_LicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PaymentsMadeUnderCollaborativeArrangement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_AmountsOwedUnderAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_ReceivableUnderResearchCostSharingProvision" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_LicenseAgreementUpfrontPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_FairValueOfCommonStockIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_AnnualLicenseMaintenanceFee" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PotentialMilestonePayments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PercentageOfLicensorsRoyalties" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_PercentageOfSublicensingIncome" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_LicenseAgreementTerm" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_NetSalesMilestonePayments" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_KPlanMember" xlink:label="nktx_KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="nktx_KPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_FollowOnOfferingOfStockMember" xlink:label="nktx_FollowOnOfferingOfStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nktx_FollowOnOfferingOfStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="nktx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_SeparationAndReleaseAgreementMember" xlink:label="nktx_SeparationAndReleaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandTwentyPerformanceIncentivePlanMember" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" xlink:label="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="us-gaap_DividendsShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nktx_TwoThousandFifteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_SeparationAndReleaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nktx_TwoThousandTwentyPerformanceIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsShareBasedCompensation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember" xlink:label="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TwoThousandTwentyPerformanceIncentivePlanMember" xlink:label="nktx_TwoThousandTwentyPerformanceIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CommonStockOptionsAndRestrictedStockUnitsMember" xlink:label="nktx_CommonStockOptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nktx_TwoThousandTwentyPerformanceIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nktx_CommonStockOptionsAndRestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" xlink:label="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxesLineItems" xlink:label="nktx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxesTable" xlink:label="nktx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpirationYearOneMember" xlink:label="nktx_ExpirationYearOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ExpirationYearTwoMember" xlink:label="nktx_ExpirationYearTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember" xlink:label="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_CarryForwardIndefinitelyMember" xlink:label="nktx_CarryForwardIndefinitelyMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_OperatingLossCarryforwardsExpirationYear" xlink:label="nktx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_TaxCreditCarryforwardExpirationYear" xlink:label="nktx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_ChangesInOwnershipByStockholdersHoldingPercentage" xlink:label="nktx_ChangesInOwnershipByStockholdersHoldingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nktx_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nktx_ExpirationYearOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nktx_ExpirationYearTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="nktx_CarryForwardIndefinitelyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="nktx_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesTable" xlink:to="nktx_IncomeTaxesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="nktx_TaxCreditCarryforwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="nktx_ChangesInOwnershipByStockholdersHoldingPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxReconciliationPermanentItems" xlink:label="nktx_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" xlink:label="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nktx_IncomeTaxReconciliationPermanentItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="nktx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="nktx_DeferredTaxAssetsDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsLeaseLiability" xlink:label="nktx_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" xlink:label="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="nktx_DeferredTaxLiabilitiesRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="nktx_DeferredTaxLiabilitiesDepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="nktx_DeferredTaxAssetsDepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="nktx_DeferredTaxAssetsLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" xlink:label="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalLeaseAgreementMember" xlink:label="nktx_AdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_NumberOfDaysToReplaceEachLetterOfCredit" xlink:label="nktx_NumberOfDaysToReplaceEachLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember" xlink:label="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="nktx-20221231.xsd#nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit" xlink:label="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_AdditionalLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nktx_NumberOfDaysToReplaceEachLetterOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897096464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Nkarta, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4515206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6000 Shoreline Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">407-1049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,928,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001787400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the registrant&#8217;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897351664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 37,494<span></span>
</td>
<td class="nump">$ 60,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">314,649<span></span>
</td>
<td class="nump">177,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,545<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">360,688<span></span>
</td>
<td class="nump">245,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,743<span></span>
</td>
<td class="nump">2,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">61,908<span></span>
</td>
<td class="nump">12,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">45,749<span></span>
</td>
<td class="nump">11,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">472,938<span></span>
</td>
<td class="nump">273,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,761<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">4,249<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">16,036<span></span>
</td>
<td class="nump">9,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,046<span></span>
</td>
<td class="nump">12,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">78,685<span></span>
</td>
<td class="nump">9,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">100,731<span></span>
</td>
<td class="nump">22,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 54,350,179 shares authorized at December 31, 2022; no shares issued and outstanding at December 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 100,000,000 shares authorized at December 31, 2022; 48,877,806 and 32,971,107 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">690,814<span></span>
</td>
<td class="nump">455,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(679)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(317,933)<span></span>
</td>
<td class="num">(204,096)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">372,207<span></span>
</td>
<td class="nump">250,967<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 472,938<span></span>
</td>
<td class="nump">$ 273,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897070288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">54,350,179<span></span>
</td>
<td class="nump">54,350,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">48,877,806<span></span>
</td>
<td class="nump">32,971,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">48,877,806<span></span>
</td>
<td class="nump">32,971,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052892975456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 90,897,000<span></span>
</td>
<td class="nump">$ 63,412,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">28,058,000<span></span>
</td>
<td class="nump">23,017,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">118,955,000<span></span>
</td>
<td class="nump">86,429,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(118,955,000)<span></span>
</td>
<td class="num">(86,429,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">5,588,000<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(470,000)<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">5,118,000<span></span>
</td>
<td class="nump">354,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(113,837,000)<span></span>
</td>
<td class="num">(86,075,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(113,837,000)<span></span>
</td>
<td class="num">(86,075,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on securities</a></td>
<td class="num">(529,000)<span></span>
</td>
<td class="num">(153,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (114,366,000)<span></span>
</td>
<td class="num">$ (86,228,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.61)<span></span>
</td>
<td class="num">$ (2.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (2.61)<span></span>
</td>
<td class="num">$ (2.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in net loss per share, basic</a></td>
<td class="nump">43,631,722<span></span>
</td>
<td class="nump">32,856,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares used in net loss per share, diluted</a></td>
<td class="nump">43,631,722<span></span>
</td>
<td class="nump">32,856,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893089472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Secondary Offering</div></th>
<th class="th"><div>At-the-market offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Secondary Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>At-the-market offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Secondary Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At-the-market offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 321,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 439,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (118,021)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,627,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase', window );">Vesting of shares of common stock subject to repurchase</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase', window );">Vesting of shares of common stock subject to repurchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock option</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock option , Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">14,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments</a></td>
<td class="num">(153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(86,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">250,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(204,096)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,971,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon secondary offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,334<span></span>
</td>
<td class="nump">$ 1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,332<span></span>
</td>
<td class="nump">$ 1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon secondary offering, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,213<span></span>
</td>
<td class="nump">15,333,334<span></span>
</td>
<td class="nump">113,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase', window );">Vesting of shares of common stock subject to repurchase</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase', window );">Vesting of shares of common stock subject to repurchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock option</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock option , Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon employee stock purchase plan</a></td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon employee stock purchase plan,share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">16,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments</a></td>
<td class="num">(529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(113,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 372,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (317,933)<span></span>
</td>
<td class="num">$ (679)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,877,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares vesting of shares of common stock subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value vesting of shares of common stock subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893817072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (113,837)<span></span>
</td>
<td class="num">$ (86,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">16,856<span></span>
</td>
<td class="nump">14,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount and amortization of premium on investments, net</a></td>
<td class="num">(818)<span></span>
</td>
<td class="nump">3,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">3,935<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized loss on investments</a></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,489)<span></span>
</td>
<td class="num">(4,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">32,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities', window );">Accounts payable and accrued and other liabilities</a></td>
<td class="nump">2,757<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,000)<span></span>
</td>
<td class="num">(67,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(385,887)<span></span>
</td>
<td class="num">(227,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of available-for-sale securities</a></td>
<td class="nump">248,309<span></span>
</td>
<td class="nump">264,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(47,111)<span></span>
</td>
<td class="num">(5,025)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(184,689)<span></span>
</td>
<td class="nump">32,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts', window );">Proceeds from secondary offering, net of issuance costs</a></td>
<td class="nump">215,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts', window );">Proceeds from ATM offering, net of issuance costs</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP purchases</a></td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PaymentsOfDeferredOfferingCosts', window );">Payments of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">219,012<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(22,677)<span></span>
</td>
<td class="num">(34,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">62,914<span></span>
</td>
<td class="nump">97,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">40,237<span></span>
</td>
<td class="nump">62,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">37,494<span></span>
</td>
<td class="nump">60,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">2,743<span></span>
</td>
<td class="nump">2,098<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">40,237<span></span>
</td>
<td class="nump">62,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable', window );">Acquisitions of property and equipment in accounts payable</a></td>
<td class="nump">$ 4,579<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in accounts payable and accrued and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or part noncash acquisition fixed assets acquired included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_PaymentsOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_PaymentsOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from at the market offering net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from secondary offering net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895184672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of the Business</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nkarta, Inc. ("Nkarta" or the "Company") was incorporated in the State of Delaware in July 2015. The Company is a biopharmaceutical company developing engineered natural killer ("NK") cells to treat cancer. The Company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta&#8217;s goal is to develop off-the-shelf NK cell therapy product candidates to improve outcomes for patients. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s operations are based in South San Francisco, California, and it operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Management Plans</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, conducting preclinical studies and initiating clinical studies, and has not realized substantial revenues from its planned principal operations. In addition, the Company has a limited operating history, has incurred operating losses since inception and expects that it will continue to incur net losses into the foreseeable future as it continues its research and development activities. As of December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">317.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and cash, cash equivalents, restricted cash and short-term investments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">354.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ebt or equity financings or other arrangements to fund operations. Management believes that the Company&#8217;s current cash, cash equivalents, restricted cash and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897094928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principle ("U.S. GAAP").</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19 Pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic has caused disruptions in the global economy and has affected and may in the future affect the Company&#8217;s business and operations in the future. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act had no impact on the Company&#8217;s income tax provision for the year ended December 31, 2022. The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s financial statements and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accompanying </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">notes. On an ongoing basis, management evaluates its estimates, including those related to preclinical studies, fair value of assets and liabilities, share-based compensation and income taxes. Management bases its estimates on historical experience, knowledge of current events and actions it may undertake in the future that management believes to be reasonable under the circumstances. Actual results may differ from these estimates and assumptions.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality and are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the statements of operations and comprehensive loss.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable inputs such as quoted prices in active markets;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, Short-term Investments and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with insignificant interest rate risk and an original maturity of three months or less at the date of purchase to be cash equivalents. Cash includes demand deposits held in readily available checking accounts at a federally insured financial institution. Cash equivalents consist of money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-term Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments consist of commercial debt securities, commercial paper and Government securities, classified as available-for-sale securities and have maturities of greater than three months but less than one year. The Company has classified most of its available-for-sale investment securities as current assets on the balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carries these securities at fair value, and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to maintain letters of credit related to its office and lab space lease and the additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing. This cash is the collateral for those letters of credit and per the terms of the leases, must remain in place until one to two months after the termination of the leases. As the remaining terms of the leases as of December 31, 2022 is greater than one year, the related restricted cash has been classified as non-current.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and software and construction-in-progress are stated at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_491c5e57-d09d-4f35-9266-28735ed2f748;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December 31, 2022, there has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairment losses recorded by the Company.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. There has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such liabilities recorded by the Company as of December 31, 2022.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets ("ROU assets") which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the balance sheets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize lease liabilities and ROU assets for short-term leases with terms of twelve months or less.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option, employee stock purchase plan, and restricted stock unit grants, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options, employee stock purchase plan rights and restricted stock units and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options and employee stock purchase plan rights are estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options granted during the year have a maximum contractual term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected term of the employee stock purchase plan rights equals the</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> six-month </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">look-back period. The expected volatility is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury ("U.S. Treasury") yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options. The fair value of restricted stock units is based on the closing price of the Company's common stock as reported on The Nasdaq Global Market on the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s chief operating decision maker, its President and Chief Executive Officer, manages its operations and business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">segment for the purposes of allocating resources, makes operating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decisions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and evaluates financial performance. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> product revenue has been generated since inception and all assets are held in the United States.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include unvested common stock, unvested restricted stock options, and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895129824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Net Loss Per Share</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the computation of the basic and diluted net loss per share (in thousands except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.162%;"/>
        <td style="width:1.89%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.491999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.89%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.565999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,837</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,075</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,635,044</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,901,002</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: weighted average unvested common stock <br/>&#160;&#160;&#160;issued upon early exercise of common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,322</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,119</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average shares used to compute net loss<br/>&#160;&#160;&#160;per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,631,722</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,856,883</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.61</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.573%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.882%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.195%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,519,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,204,686</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356,728</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested common stock upon early exercise of common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">508</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,876,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,220,867</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052899343104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Fair Value of Financial Instruments</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the fair value of the Company&#8217;s financial instruments (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:39.51%;"/>
        <td style="width:1.219%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.957%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.219%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.85%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.219%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.85%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.219%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.957%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br/>in Active Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant <br/>Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,649</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,649</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">351,143</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,649</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:42.916%;"/>
        <td style="width:0.437%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.493%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.437%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.168%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.437%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.168%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.437%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.506%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br/>in Active Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant <br/>Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,018</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,018</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,534</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,534</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,290</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,018</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents and Short-Term Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and short-term investments consisted of commercial paper, corporate debt securities and Government securities. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments are classified as Level 1 within the fair value hierarchy if their quoted prices are available in active markets for identical securities. Investments in money market funds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million included in cash equivalents as of December 31, 2022 and 2021, respectively, were classified as Level 1 instruments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments in corporate debt securities, commercial paper and Government securities included in short-term investments are valued using Level 2 inputs. Level 2 securities are initially valued at the transaction price and subsequently valued and reported upon utilizing inputs other than quoted prices that are observable either directly or indirectly, such as quotes from third-party pricing vendors. Fair values determined by Level 2 inputs, which utilize data points that are observable such as quoted prices, interest rates and yield curves, require the exercise of judgment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and use of estimates, that if changed, could significantly affect the Company&#8217;s financial position and results of operations.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#8217;s short-term investments as of December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.958%;"/>
        <td style="width:1.183%;"/>
        <td style="width:14.279%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.109%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.097%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.297999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">315,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">762</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,649</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.958%;"/>
        <td style="width:1.183%;"/>
        <td style="width:14.279%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.109%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.097%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.297999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,548</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,466</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,602</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#8217;s available-for-sale securities as of December 31, 2022 and 2021 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December 31, 2022 and 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> It is neither management&#8217;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value, except for investments totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that were sold with a realized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in January 2023. The Company recorded this $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as an impairment loss for the year ended December 31, 2022. Unrealized gains and losses are included in accumulated other comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excludes accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment and to not measure an allowance for expected credit losses for accrued interest receivables. Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. It is the Company's policy to present the accrued interest receivable balance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as part of prepaid expenses and other current assets in the balance sheets. Accrued interest receivable related to short-term investments was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895436720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Balance Sheet Components</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets are comprised of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.853%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.161999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,616</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,538</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,929</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,154</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,545</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,692</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">roperty and equipment, net is comprised of the following (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,402</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">645</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,655</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,274</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,732</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,043</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,824</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,187</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,856</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued and Other Current Liabilities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other current liabilities are comprised of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.853%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.161999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,691</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,453</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,486</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,001</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued and current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">858</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,518</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,347</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895280128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has operating leases for its current corporate offices, laboratory space, manufacturing facility, and dedicated space in a vivarium in South San Francisco, California, as well as for an additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.851%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,220</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,581</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease expense </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">462</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,727</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-2.557%;padding-left:2.507%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Variable lease expense for the periods presented primarily included common area maintenance charges.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental information related to operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.851%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,887</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,239</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average remaining lease term was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years for the corporate office and laboratory space leases as of December 31, 2022. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The corporate office lease includes an option to renew for an additional seven years. However, the renewal option was not included in the lease term for calculating the lease liability, as the renewal option allows the Company to maintain operational flexibility, and the Company was not reasonably certain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that it would exercise the renewal option at the time of the lease commencement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average discount rate was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases and from modifications of existing leases, respectively, for the year ended December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of operating lease liabilities under existing operating leases as of December 31, 2022 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.968%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.093%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,206</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,671</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,467</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87,290</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,813</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less tenant improvement receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,837</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,249</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,685</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2018, the Company entered into a lease agreement for its corporate office and laboratory space located in South San Francisco, California with an expiration date in May </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">"Initial Lease Agreement"</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2019, the Company executed the first amendment to the Initial Lease Agreement for additional corporate space, laboratory space and manufacturing capabilities and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an extension</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to the lease term through April 2026. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, the Company signed a second amendment to the Initial Lease Agreement. The amended lease provides for an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eight-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> non-cancelable lease of additional office and laboratory space in the same building. The lease amendment for additional office and laboratory space provided for abatement of rent during the first three months of the lease and contains rent escalations during the term of the lease. The lease for this additional space commenced in January 2021 and expires in January </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease amendment also includes an extension of the lease term for the existing office and laboratory space beginning on May 1, 2020 and expiring in January 2029. The amendment to the Initial Lease Agreement also includes an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to extend</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the lease for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term.</span></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, the Company signed a third amendment to the Initial Lease Agreement which provides for the lease of additional space in the same building. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease amendment for this additional space commenced in April 2021 and expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the Company signed a fourth amendment to the Initial Lease Agreement which provides for the lease of additional space in the same building. The lease for additional office and laboratory space provides for abatement of rent during the first two months of the lease and contains rent escalations during the term of the lease. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease amendment of this additional space commenced in April 2022 and expires in January </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The lease amendment also includes this additional space in the Company&#8217;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to extend</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the amended Initial Lease Agreement for an additional seven-year term.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The other terms of the Initial Lease Agreement, as amended, remain unchanged.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company entered into a lease agreement for corporate office, manufacturing and laboratory space located in South San Francisco, California with an expiration date approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">twelve years </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after the lease's legal commencement date (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">"Additional Lease Agreement"</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease for this additional space and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obligation to pay rent commenced in January 2022. In addition to base rent, the Company is responsible for payment of direct expenses, which include operating, insurance and tax expenses. The lease also provides for certain tenant improvement allowances of up to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for tenant improvements and certain infrastructure upgrades in connection with the initial buildout of the premises, approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of which, if utilized, would need to be repaid by the Company over the lease term. In 2021, the Company delivered a security deposit in the form of a letter of credit o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">llion to the Landlord in connection with the Additional Lease Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company entered into an amendment to the Additional Lease Agreement. The lease amendment expressly includes manufacturing as a permitted use at the facility, clarifies that Silicon Valley Bank is an acceptable bank for purposes of issuing a letter of credit under the lease, revises the letter of credit transferability terms and replaces the form of letter of credit attached to the lease.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, the Company entered into fifth amendment to the Initial Lease Agreement and a second amendment to the Additional Lease Agreement for its existing facilities in South San Francisco, California. The fifth amendment to the Initial Lease Agreement includes an extension of the lease term for certain of the Company's existing facilities through July 31, 2030. The second amendment to the Additional Lease Agreement provides for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of additional tenant improvement allowances, in addition to the tenant improvement allowances of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million included in the original Additional Lease Agreement, and increases the base rent payments over the existing term of the lease.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895226448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Guarantee Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification period is for the officer&#8217;s or director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts under certain circumstances and subject to deductibles and exclusions. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> liabilities recorded for these agreements as of December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Letters of Credit</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in letter of credit agreements with a financial institution that are used as collateral for the Company&#8217;s corporate headquarters&#8217; operating lease and the additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing. The letters of credit automatically renew annually without amendment unless cancelled by the financial institutions within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the annual expiration date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895343744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_CollaborationAgreementAbstract', window );"><strong>Collaboration Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Collaboration and License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRISPR Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 5, 2021, the Company entered into the CRISPR Agreement with CRISPR to co-develop and co-commercialize an engineered CAR NK product candidate targeting the CD70 tumor antigen and a second novel NK plus T cell product candidate. In addition, the Company has received licenses from CRISPR for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> CRISPR-Cas9 gene editing targets and will receive a license from CRISPR for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> more CRISPR-Cas9 gene editing targets that can be engineered into an unlimited number of its own NK cell products. CRISPR also has an option to co-develop and co-commercialize a future CAR NK program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms of the CRISPR Agreement, the Company and CRISPR share equally in all research and development costs and potential profits worldwide related to the NKX070 product candidate, NK+T product candidate, and the potential future CAR NK program. For the NK+T program, CRISPR is responsible for gene-editing activities and T cell related activities, and Nkarta is responsible for NK cell related activities. The related impact of the cost sharing associated with the research and development activities is included in research and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expense on the condensed statements of operations. Expenses related to services performed by the Company are classified as research and development expense. Payments received from CRISPR for partial reimbursement of expenses are recorded as a reduction of research and development expense. Reduction of research and development expense resulting from partial reimbursement from CRISPR was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the Company had a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million receivable under the research cost sharing provision, which is included as part of prepaid expenses and other current assets in the condensed balance sheet.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ea</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ch non-collaboration product candidate incorporating a genome editing target licensed from CRISPR (a "CRISPR-licensed product candidate"), the Co</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mpany</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> would retain worldwide rights and may be required to make potential future payments based on the achievement of development and regulatory approval milestones </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">totaling less than mid-twenty million dollars</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for each CRISPR-licensed product candidate, as well as tiered royalties up to the mid-single digits on net product sales of such product. Further, for each CRISPR-licensed product candidate targeting a specified tumor antigen, the Company may be required to make potential future payments based on the achievement of development and regulatory approval milestones totaling less than high-forty million dollars</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for each CRISPR-licensed product candidate targeting the specified tumor antigen, as well as tiered royalties up to the mid-single digits on net product sales of such product. As of December 31, 2022, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t paid any amounts </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">r are any amounts owed by the Company under the CRISPR Agreement, and no milestones have been achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MaxCyte License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 26, 2021, the Company entered into a license agreement (the "MaxCyte Agreement") with MaxCyte, Inc. ("MaxCyte") to obtain non-exclusive clinical and commercial rights to use MaxCyte's cell loading technology to develop and commercialize in up to ten licensed products.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the MaxCyte Agreement, the Company must pay to MaxCyte annual research license fees and commercialization license fees, ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, for each instrument licensed by the Company. Further, the Company could be required to make milestone payments to MaxCyte upon completion of certain regulatory and commercial milestones related to the clinical development and commercialization of certain of the Company&#8217;s licensed products. The aggregate potential milestone payments range from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per licensed product. Additionally, the Company may be required to make net sales milestone payments totaling between $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per licensed product. As of December 31, 2022, no milestones have been achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">University of Singapore and St. Jude Children&#8217;s License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2016, the National University of Singapore ("NUS") and St. Jude Children&#8217;s Research Hospital ("St. Jude") and the Company entered into a license agreement under which NUS and St. Jude (the "Licensors") granted the Company an exclusive, royalty-bearing, worldwide license to its patent rights related to a method for expanding natural killer cells; a chimeric receptor with NKG2D specificity; and a method for supporting autonomous natural killer cell function ("NUS and St. Jude License Agreement"). The NUS and St. Jude License Agreement provides the Company with the rights to grant and authorize sublicenses to make, have made, use, sell, offer for sale and import products and otherwise exploit the patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license, the Company made an upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,800</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and issued NUS </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock. The Company determined that the upfront payment (SGD </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and value of the common stock issued ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> based on fair value at time of issuance) as part of the license agreement would be expensed upon execution of the contract as the license was acquired for research and development purposes which does not have alternative future uses, and the underlying technology has not reached technological feasibility, hence the Company expensed these costs during 2016.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company is required to pay an annual license maintenance fee of SGD </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, increasing to SGD </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year two of the agreement. Further, the Company could be required to make milestone payments to the Licensors upon completion of certain regulatory and commercial milestones related to the clinical development and commercialization of certain of the Company&#8217;s product candidates. The aggregate potential</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">milestone </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payments are approximately SGD </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company has also agreed to pay the Licensors royalties of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net sales of products sold by the Company or through a sublicense. Additionally, the Company agreed to pay the Licensors a tiered percentage of sublicensing income (ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%) based on the timing of capital raised and stage of clinical trials. The NUS and St. Jude License Agreement also includes certain performance objectives which obligate the Company to meet various milestones related to the clinical development and commercialization of certain of the Company&#8217;s product candidates over time for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after the effective date of the NUS and St. Jude License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> license maintenance fees included as part of research and development expenses for each of the years ended December 31, 2022 and 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_CollaborationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_CollaborationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052896199488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefits</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Employee Benefits</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2018, the Company adopted a defined contribution 401(k) plan that is available to eligible employees. </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. As part of the plan, the Company elected to make non-matching contributions via mandatory </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of compensation safe harbor nonelective contributions. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for expense related to the nonelective 401(k) contributions for the years ended December 31, 2022 and 2021, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895164176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Stockholders&#8217; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Amended and Restated Certificate of Incorporation dated July 14, 2020, the Company had a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> authorized shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,350,179</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> authorized shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 12, 2021, the Company filed a Registration Statement on Form S-3 (the "Shelf Registration Statement"), covering the offer and sale from time to time, pursuant to Rule 415 of the Securities Act of 1933, as amended (the "Securities Act"), of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate offering price of shares of the Company&#8217;s common stock, shares of the Company&#8217;s preferred stock, debt securities, warrants, and rights and units. The Shelf Registration Statement was declared effective by the Securities and Exchange Commission (the "SEC") on September 2, 2021. The Shelf Registration Statement included a prospectus covering the offer and sale from time to time of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate offering price of shares of the Company&#8217;s common stock through an &#8220;at-the-market&#8221; equity offering program (the "ATM Offering Program") with Cowen and Company, LLC, as sales agent. As of December 31, 2022, the Company has issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,213</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock pursuant to the ATM Offering Program, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting offering expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 28, 2022, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,333,334</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock in an underwritten public offering, including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares associated with the full exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The total net proceeds to the Company from the offering were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">215.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares were issued pursuant to the Company&#8217;s Shelf Registration Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895170352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Share-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2015 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company granted options under its 2015 Equity Incentive Plan (the "2015 Plan"</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2015 Plan allowed for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock unit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">awards </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and other stock awards, although only stock options were awarded under the 2015 Plan. Awards could be made to officers, directors, employees, non-employee directors, and consultants of the Company. In connection with the Board of Directors&#8217; and stockholders&#8217; approval of the 2020 Plan, the 2015 Plan was terminated as to future awards and any options then outstanding under the 2015 Plan remained outstanding and effective. As of December 31, 2022, there were an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,344,048</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of outstanding options issued under the 2015 Plan.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Performance Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s 2020 Performance Incentive Plan (the "2020 Plan") which was adopted by the Company&#8217;s board of directors in June 2020 and approved by the Company&#8217;s stockholders in July 2020, became effective upon the consummation of the IPO in July 2020. The 2020 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of December 31, 2022, a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,945,002</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock were authorized for issuance with respect to awards granted under the 2020 Plan (this number of shares gives effect to the annual increases in the 2020 Plan share limit, as described in the next sentence). The share limit will automatically increase on the first trading day in January of each year by an amount equal to the lesser of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of outstanding shares of the Company&#8217;s common stock on the last trading day in December in the prior year, or (2) such lesser number as determined by the Company&#8217;s board of directors. Any shares subject to awards granted under the 2020 Plan or the 2015 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2020 Plan. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,775,102</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares was available for issuance under the 2020 Plan as of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the stock option activity during the year ended December 31, 2022 (in thousands, except number of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares, exercise prices and contractual term):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.154%;"/>
        <td style="width:0.513%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.425%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.655%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.298%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.526%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.091%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.988%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.349%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br/>exercise price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br/>remaining contractual<br/>term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate <br/>Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,204,686</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.19</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,327,820</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.61</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">383,120</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">630,111</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.99</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,519,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,915</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,337,753</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,957</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at <br/>&#160;&#160;&#160;December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,519,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,915</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value represents the difference between the exercise price of stock options and the quoted closing market price of the Company&#8217;s common stock on the applicable date for all in-the-money stock options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional information related to the Company&#8217;s stock options is summarized below (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.324%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.129000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.438%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average grant-date fair value of stock option grants per share</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.60</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic value of options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,268</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the restricted stock unit activity during the year ended December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.384%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.030000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.187000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.99%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.006%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br/>grant date fair value per share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">389,388</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,660</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356,728</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s 2020 Employee Stock Purchase Plan (the "ESPP"), which was adopted by the Company&#8217;s board of directors in June 2020 and approved by the Company&#8217;s stockholders in July 2020, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">became effective upon the consummation of the IPO. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">952,524</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock were authorized for issuance under the ESPP. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation, subject to any plan limitations. The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP provides for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> offering periods, and at the end of each offering period, employees are able to purchase shares at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. During 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,754</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were issued under the ESPP resulting in aggregate cash proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ESPP purchases in 2021. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">890,770</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remained available for issuance under the ESPP (after giving effect to share purchases made under the ESPP through and including the ESPP offering period that ended on November 30, 2022).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liability for Early Exercise of Restricted Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain individuals were granted the ability to early exercise their stock options. The shares of common stock issued from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. Shares subject to repurchase by the Company were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">508</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,181</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, as of December 31, 2022 and 2021, respectively, and in each case the related liability recorded under other accrued and other current liabilities in the condensed balance sheets was insignificant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had reserved the following shares of common stock for future issuance:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.426%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.094%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options and restricted stock units granted and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,876,003</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved for future equity award grants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,775,102</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved for future ESPP issuances</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">890,770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,541,875</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense for the years ended December 31, 2022 and 2021 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64.324%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.129000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.438%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,326</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,530</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,856</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total unrecognized compensation cost related to stock options was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years as of December 31, 2022. The total unrecognized compensation cost related to restricted stock units was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years as of December 31, 2022. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized compensation cost related to ESPP, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which is expected to be recognized over a weighted-average remaining service period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Disclosures</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options was estimated on the date of grant using the Black-Scholes option pricing model with the following range of assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64.551%;"/>
        <td style="width:1.56%;"/>
        <td style="width:16.165%;"/>
        <td style="width:1.56%;"/>
        <td style="width:16.165%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.89</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value of the awards on the date of grant, net of forfeitures. The Company generally recognizes grant-date fair value of stock options granted to employees and non-employee service providers on a straight-line basis over the requisite service period, which is generally the vesting term of the respective awards. The Company determines the fair value of stock options with a service and performance condition, or performance-based options, based on the fair value of the Company&#8217;s common stock on the date of grant. The Company accounts for the impact of forfeitures as they occur. For purposes of calculating share-based compensation, the Company estimates the fair value of stock options issued using a Black-Scholes option-pricing model. The determination of the fair value of share-based payment awards utilizing the Black-Scholes option-pricing model is affected by the Company&#8217;s stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company opted to use the &#8220;simplified method&#8221; for estimating the expected term of employee options, whereby the expected term equals the average of the vesting term and the original contractual term of the option (generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company based its estimate of expected volatility on the historical volatilities of the common stock of comparable publicly traded biopharmaceutical companies over a period equal to the expected term</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle, and financial leverage to the Company.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected dividend yield. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t issued any dividends and do </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t expect to issue dividends over the life of the options, as a result the estimated dividend yield is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895164176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the Company&#8217;s net losses for the years ended December 31, 2022 and 2021, and since the Company has a full valuation allowance against deferred tax assets, there was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> tax provision or benefit for income taxes recorded in the years presented other than minimum amounts required for state tax purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation on income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.158%;"/>
        <td style="width:1.891%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.494%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.891%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.568%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at statutory rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,906</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,076</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,566</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,005</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,891</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,426</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,661</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">515</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets are shown below (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.148%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.6%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.784%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.674%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,732</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,767</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">316</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,999</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,552</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,367</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,189</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,616</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 Capitalized R&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,352</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,415</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,103</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance for deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,361</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,089</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">958</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#8217;s ability to realize these assets. The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">representing net future deductible amounts become deductible. Due to the Company&#8217;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are substantially offset by a valuation allowance at December 31, 2022 and 2021. The deferred tax assets were primarily comprised of federal and state tax net operating losses and tax credit carryforwards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had net operating loss ("NOL") carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. Of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million federal NOL carryforwards, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, if not utilized, while $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million can be carried forward indefinitely. The state NOL carryforwards will begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if not utilized.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also had federal and state research and development credit carry forwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, at December 31, 2022. The federal credits will begin expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> if not utilized. The California credits have no expiration date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"), as well as similar state provisions. The future utilization of the Company&#8217;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or more of the Company&#8217;s common stock. An assessment of such ownership changes under Section 382 was not completed through December 31, 2019. To the extent that an assessment is completed in the future, the Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2022, its federal and state returns for the years ended 2015 through the current period are still open to examination. In addition, all of the net operating losses and research and development credit carryforwards that may be used in future years are still subject to inquiry given that the statute of limitation for these items would begin in the year of the utilization. The balance of gross unrecognized tax benefits as of December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, all of which would affect the Company&#8217;s income tax expense if recognized, before consideration of the Company&#8217;s valuation allowance. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest and penalties for the years ended December 31, 2022 and 2021. The Company files income tax returns in the United States federal jurisdiction and the State of California and is not currently under examination by any taxing authority for any open tax year. Due to net operating loss carryforwards, all years remain open for income tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the changes in the Company&#8217;s gross unrecognized tax benefits (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,359</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">777</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases (decreases) related to tax positions taken in prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">863</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,339</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,359</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897189856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 10, 2023, Silicon Valley Bank ("SVB") in the United States was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 12, 2023, the U.S. Department of the Treasury, Federal Reserve, and FDIC jointly announced that the FDIC will complete its resolution of SVB in a manner that fully protects all depositors. As of March 10, 2023, we held $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in collateral money market accounts supporting letters of credit issued by SVB to the Landlord in connection with the Initial Lease Agreement and Additional Lease Agreement. We are working with the Landlord to replace the letters of credit issued by SVB with letters of credit from a different financial institution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897000928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principle ("U.S. GAAP").</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock', window );">COVID-19 Pandemic</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19 Pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic has caused disruptions in the global economy and has affected and may in the future affect the Company&#8217;s business and operations in the future. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act had no impact on the Company&#8217;s income tax provision for the year ended December 31, 2022. The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s financial statements and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accompanying </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">notes. On an ongoing basis, management evaluates its estimates, including those related to preclinical studies, fair value of assets and liabilities, share-based compensation and income taxes. Management bases its estimates on historical experience, knowledge of current events and actions it may undertake in the future that management believes to be reasonable under the circumstances. Actual results may differ from these estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality and are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable inputs such as quoted prices in active markets;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock', window );">Cash, Cash Equivalents, Short-term Investments and Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, Short-term Investments and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with insignificant interest rate risk and an original maturity of three months or less at the date of purchase to be cash equivalents. Cash includes demand deposits held in readily available checking accounts at a federally insured financial institution. Cash equivalents consist of money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-term Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments consist of commercial debt securities, commercial paper and Government securities, classified as available-for-sale securities and have maturities of greater than three months but less than one year. The Company has classified most of its available-for-sale investment securities as current assets on the balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carries these securities at fair value, and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to maintain letters of credit related to its office and lab space lease and the additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing. This cash is the collateral for those letters of credit and per the terms of the leases, must remain in place until one to two months after the termination of the leases. As the remaining terms of the leases as of December 31, 2022 is greater than one year, the related restricted cash has been classified as non-current.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and software and construction-in-progress are stated at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_491c5e57-d09d-4f35-9266-28735ed2f748;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December 31, 2022, there has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairment losses recorded by the Company.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. There has been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such liabilities recorded by the Company as of December 31, 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets ("ROU assets") which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the balance sheets.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize lease liabilities and ROU assets for short-term leases with terms of twelve months or less.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option, employee stock purchase plan, and restricted stock unit grants, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options, employee stock purchase plan rights and restricted stock units and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options and employee stock purchase plan rights are estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, expected dividend yield, and a risk-free interest rate. Options granted during the year have a maximum contractual term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected term of the employee stock purchase plan rights equals the</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> six-month </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">look-back period. The expected volatility is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury ("U.S. Treasury") yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options. The fair value of restricted stock units is based on the closing price of the Company's common stock as reported on The Nasdaq Global Market on the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s chief operating decision maker, its President and Chief Executive Officer, manages its operations and business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">segment for the purposes of allocating resources, makes operating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decisions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and evaluates financial performance. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> product revenue has been generated since inception and all assets are held in the United States.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#8217;s potentially dilutive securities, which include unvested common stock, unvested restricted stock options, and outstanding stock options under the Company&#8217;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents short term investments and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unusual or infrequent items disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893861616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the computation of the basic and diluted net loss per share (in thousands except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.162%;"/>
        <td style="width:1.89%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.491999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.89%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.565999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,837</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,075</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,635,044</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,901,002</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: weighted average unvested common stock <br/>&#160;&#160;&#160;issued upon early exercise of common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,322</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,119</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average shares used to compute net loss<br/>&#160;&#160;&#160;per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,631,722</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,856,883</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.61</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.573%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.882%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.195%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,519,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,204,686</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356,728</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested common stock upon early exercise of common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">508</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,876,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,220,867</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052894038672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of Fair Value of Financial Instrument</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the fair value of the Company&#8217;s financial instruments (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:39.51%;"/>
        <td style="width:1.219%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.957%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.219%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.85%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.219%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.85%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.219%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.957%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br/>in Active Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant <br/>Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,649</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,649</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">351,143</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,649</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:42.916%;"/>
        <td style="width:0.437%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.493%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.437%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.168%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.437%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.168%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.437%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.506%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br/>in Active Markets for<br/>Identical Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant <br/>Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,018</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,018</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,466</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,534</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,534</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,290</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,018</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Short-term Investments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#8217;s short-term investments as of December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.958%;"/>
        <td style="width:1.183%;"/>
        <td style="width:14.279%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.109%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.097%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.297999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">315,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">762</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,649</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.958%;"/>
        <td style="width:1.183%;"/>
        <td style="width:14.279%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.109%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.183%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.097%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.297999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,548</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,466</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,602</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893788752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets are comprised of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.853%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.161999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,616</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,538</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,929</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,154</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,545</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,692</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">roperty and equipment, net is comprised of the following (in thousands):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,402</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">645</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,655</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,274</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,732</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,043</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,824</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,187</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,856</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other current liabilities are comprised of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.853%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.161999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,691</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,453</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,486</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,001</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued and current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">858</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,518</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,347</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052894047920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.851%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,220</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,581</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease expense </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">462</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,727</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-2.557%;padding-left:2.507%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Variable lease expense for the periods presented primarily included common area maintenance charges.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Supplemental Information related to Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental information related to operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.851%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,887</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,239</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of operating lease liabilities under existing operating leases as of December 31, 2022 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.968%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.093%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,206</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,671</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,467</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87,290</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,813</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less tenant improvement receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,837</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,249</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,685</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897077808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the stock option activity during the year ended December 31, 2022 (in thousands, except number of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares, exercise prices and contractual term):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.154%;"/>
        <td style="width:0.513%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.425%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.655%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.298%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.526%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.091%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.988%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.349%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br/>exercise price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br/>remaining contractual<br/>term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate <br/>Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,204,686</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.19</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,327,820</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.61</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">383,120</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">630,111</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.99</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,519,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,915</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,337,753</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,957</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at <br/>&#160;&#160;&#160;December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,519,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,915</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions', window );">Summary of Additional Information Related to Stock Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional information related to the Company&#8217;s stock options is summarized below (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.324%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.129000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.438%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average grant-date fair value of stock option grants per share</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.60</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic value of options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,268</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the restricted stock unit activity during the year ended December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.384%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.030000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.187000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.99%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.006%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average<br/>grant date fair value per share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">389,388</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,660</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356,728</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Summary of Common Stock Reserved For Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had reserved the following shares of common stock for future issuance:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.426%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.094%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock options and restricted stock units granted and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,876,003</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved for future equity award grants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,775,102</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved for future ESPP issuances</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">890,770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,541,875</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense for the years ended December 31, 2022 and 2021 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64.324%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.129000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.554%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.438%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,326</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,530</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,856</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,461</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options was estimated on the date of grant using the Black-Scholes option pricing model with the following range of assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64.551%;"/>
        <td style="width:1.56%;"/>
        <td style="width:16.165%;"/>
        <td style="width:1.56%;"/>
        <td style="width:16.165%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.89</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation additional information related to stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893788496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation on income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.158%;"/>
        <td style="width:1.891%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.494%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.891%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.568%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at statutory rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,906</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,076</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,566</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,005</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,891</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,426</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,661</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">515</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets are shown below (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.148%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.6%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.784%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.674%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,732</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,767</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">316</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,999</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,552</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,367</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,189</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,616</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 Capitalized R&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,352</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,415</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,103</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance for deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,361</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,089</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">958</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Changes in Gross Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the changes in the Company&#8217;s gross unrecognized tax benefits (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,359</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">777</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases (decreases) related to tax positions taken in prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">863</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,339</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,359</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893052624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 317,933<span></span>
</td>
<td class="nump">$ 204,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments', window );">Cash, cash equivalents restricted cash and short-term investments</a></td>
<td class="nump">$ 354,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents restricted cash and short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052888938752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Polices - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Liability regard to loss contingencies</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of options granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_EmployeeStockPurchasePlanLookBackPeriod', window );">Employee stock purchase plan look-back period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of options granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_EmployeeStockPurchasePlanLookBackPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan look-back period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_EmployeeStockPurchasePlanLookBackPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893890832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (113,837)<span></span>
</td>
<td class="num">$ (86,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">43,635,044<span></span>
</td>
<td class="nump">32,901,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions', window );">Less: weighted average unvested common stock issued upon early exercise of common stock options</a></td>
<td class="num">(3,322)<span></span>
</td>
<td class="num">(44,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used to compute net loss per share, basic</a></td>
<td class="nump">43,631,722<span></span>
</td>
<td class="nump">32,856,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute net loss per share, diluted</a></td>
<td class="nump">43,631,722<span></span>
</td>
<td class="nump">32,856,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.61)<span></span>
</td>
<td class="num">$ (2.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.61)<span></span>
</td>
<td class="num">$ (2.62)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of shares unvested common stock issued upon early exercise of common stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893890832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">5,876,511<span></span>
</td>
<td class="nump">4,220,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktx_CommonStockOptionsMember', window );">Common Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">5,519,275<span></span>
</td>
<td class="nump">4,204,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">356,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember', window );">Unvested Common Stock Upon Early Exercise of Common Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">16,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktx_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktx_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897233536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Summary of Fair Value of Financial Instrument (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 36,494<span></span>
</td>
<td class="nump">$ 57,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">314,649<span></span>
</td>
<td class="nump">177,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">351,143<span></span>
</td>
<td class="nump">234,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">65,409<span></span>
</td>
<td class="nump">21,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">88,681<span></span>
</td>
<td class="nump">111,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">160,559<span></span>
</td>
<td class="nump">44,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">36,494<span></span>
</td>
<td class="nump">57,018<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">36,494<span></span>
</td>
<td class="nump">57,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">314,649<span></span>
</td>
<td class="nump">177,272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">314,649<span></span>
</td>
<td class="nump">177,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">65,409<span></span>
</td>
<td class="nump">21,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">88,681<span></span>
</td>
<td class="nump">111,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | U.S. Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total short-term investments</a></td>
<td class="nump">$ 160,559<span></span>
</td>
<td class="nump">$ 44,534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893094832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_Impairments', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gain or loss on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesSoldAtPar', window );">Investments sold</a></td>
<td class="nump">$ 67,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,500<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_Impairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_Impairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesSoldAtPar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with interest rate reset through auction process, sold at par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesSoldAtPar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052888638912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Short-term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available for sale securities, Amortized Cost</a></td>
<td class="nump">$ 315,328<span></span>
</td>
<td class="nump">$ 177,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available for sale securities, Unrealized Losses</a></td>
<td class="num">(762)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available for sale securities, Unrealized Gains</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities,Estimated Fair Value</a></td>
<td class="nump">314,649<span></span>
</td>
<td class="nump">177,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available for sale securities, Amortized Cost</a></td>
<td class="nump">88,995<span></span>
</td>
<td class="nump">111,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available for sale securities, Unrealized Losses</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available for sale securities, Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities,Estimated Fair Value</a></td>
<td class="nump">$ 88,681<span></span>
</td>
<td class="nump">$ 111,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Available-for-sale securities, Maturity (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available for sale securities, Amortized Cost</a></td>
<td class="nump">$ 65,532<span></span>
</td>
<td class="nump">$ 21,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available for sale securities, Unrealized Losses</a></td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities,Estimated Fair Value</a></td>
<td class="nump">$ 65,409<span></span>
</td>
<td class="nump">$ 21,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Available-for-sale securities, Maturity (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available for sale securities, Amortized Cost</a></td>
<td class="nump">$ 160,801<span></span>
</td>
<td class="nump">$ 44,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available for sale securities, Unrealized Losses</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available for sale securities, Unrealized Gains</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities,Estimated Fair Value</a></td>
<td class="nump">$ 160,559<span></span>
</td>
<td class="nump">$ 44,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. Government Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Available-for-sale securities, Maturity (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052896096560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 5,616<span></span>
</td>
<td class="nump">$ 4,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,929<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 8,545<span></span>
</td>
<td class="nump">$ 7,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893100288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 67,732<span></span>
</td>
<td class="nump">$ 16,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(5,824)<span></span>
</td>
<td class="num">(3,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">61,908<span></span>
</td>
<td class="nump">12,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,402<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_ResearchEquipmentMember', window );">Research Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">12,900<span></span>
</td>
<td class="nump">9,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_ComputersAndSoftwareMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 49,655<span></span>
</td>
<td class="nump">$ 2,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895182768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897641360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 6,691<span></span>
</td>
<td class="nump">$ 5,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">3,486<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent', window );">Accrued property and equipment</a></td>
<td class="nump">5,001<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other accrued and current liabilities</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accrued and other liabilities</a></td>
<td class="nump">$ 16,036<span></span>
</td>
<td class="nump">$ 9,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued property and equipment liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052988414560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 11,220<span></span>
</td>
<td class="nump">$ 2,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 11,727<span></span>
</td>
<td class="nump">$ 2,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052895152816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Information Related to Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 6,887<span></span>
</td>
<td class="nump">$ 2,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893666096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases', window );">Right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases', window );">Right-of-use assets obtained in exchange for operating lease liabilities resulting from modifications of existing leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid', window );">Cash received for tenant improvement allowances to be repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,749<span></span>
</td>
<td class="nump">$ 11,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_TenantImprovementsYetToReceiveFromLessor', window );">Tenant improvement allowances yet to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktx_ThirdAmendmentMember', window );">Third amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease amendment for this additional space commenced in April 2021 and expires in March 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktx_InitialLeaseAgreementMember', window );">Initial Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee option to extend description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease amendment of this additional space commenced in April 2022 and expires in January 2029. The lease amendment also includes this additional space in the Company&#8217;s option to extend the amended Initial Lease Agreement for an additional seven-year term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease amendment also includes an extension of the lease term for the existing office and laboratory space beginning on May 1, 2020 and expiring in January 2029. The amendment to the Initial Lease Agreement also includes an option to extend the lease for an additional seven-year term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktx_SecondAmendmentOfAdditionalLeaseAgreementMember', window );">Second Amendment Of Additional Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_TenantImprovementsYetToReceiveFromLessor', window );">Tenant improvement allowances yet to receive</a></td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AdditionalTenantImprovementAllowances', window );">Additional tenant improvement allowances</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_CorporateOfficeAndLaboratorySpaceMember', window );">Corporate Office and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_CorporateOfficeAndLaboratorySpaceMember', window );">Corporate Office and Laboratory Space | Initial Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee option to extend description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In April 2019, the Company executed the first amendment to the Initial Lease Agreement for additional corporate space, laboratory space and manufacturing capabilities and an extension to the lease term through April 2026. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_AdditionalTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_AdditionalTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for tenant improvement allowances to be repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for operating lease liabilities resulting from modifications of existing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_TenantImprovementsYetToReceiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvements yet to receive from lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_TenantImprovementsYetToReceiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktx_ThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktx_ThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktx_InitialLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktx_InitialLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktx_SecondAmendmentOfAdditionalLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktx_SecondAmendmentOfAdditionalLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_CorporateOfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktx_CorporateOfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893023104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 11,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">12,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">13,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">13,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">13,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2028 and thereafter</a></td>
<td class="nump">87,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">151,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(60,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_TenantImprovementReceivable', window );">Less tenant improvement receivable</a></td>
<td class="num">(7,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">82,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">4,249<span></span>
</td>
<td class="nump">$ 2,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current</a></td>
<td class="nump">78,685<span></span>
</td>
<td class="nump">$ 9,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 82,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_TenantImprovementReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_TenantImprovementReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897030608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Liabilities recorded for agreements</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktx_AgreementWithFinancialInstitutionMember', window );">Agreement with Financial Institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding amount</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktx_AgreementWithFinancialInstitutionMember', window );">Agreement with Financial Institution | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate', window );">Letter of credit notice period by financial institution before annual expiration date</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktx_AgreementWithFinancialInstitutionMember', window );">Agreement with Financial Institution | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate', window );">Letter of credit notice period by financial institution before annual expiration date</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Letter of credit notice period by financial institution before annual expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktx_AgreementWithFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktx_AgreementWithFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052889142016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 05, 2021 </div>
<div>CrisprCas9</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>SGD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,897,000<span></span>
</td>
<td class="nump">$ 63,412,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktx_ResearchCollaborationAgreementMember', window );">Research Collaboration Agreement | Development and Regulatory Approval Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement', window );">Reduction of research and development expense resulting from partial reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones', window );">Potential future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">totaling less than mid-twenty million dollars<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PaymentsMadeUnderCollaborativeArrangement', window );">Amount paid under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AmountsOwedUnderAgreement', window );">Amounts owed under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ReceivableUnderResearchCostSharingProvision', window );">Receivable under research cost sharing provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktx_MaxcyteLicenseAgreementMember', window );">MaxCyte License Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_NetSalesMilestonePayments', window );">Net sales milestone payments</a></td>
<td class="nump">61,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees', window );">Annual research license fees and Commercialization license fees</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktx_MaxcyteLicenseAgreementMember', window );">MaxCyte License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_NetSalesMilestonePayments', window );">Net sales milestone payments</a></td>
<td class="nump">116,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees', window );">Annual research license fees and Commercialization license fees</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktx_NkCellProductsMember', window );">NK Cell Products | Research Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived', window );">Number of non-exclusive rights to gene editing targets licenses received | CrisprCas9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktx_NkCellProductsMember', window );">NK Cell Products | Research Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_NumberOfNonExclusiveRightsToGeneEditingTargets', window );">Number of non-exclusive rights to gene editing targets | CrisprCas9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember', window );">NUS and St. Jude | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_LicenseAgreementUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,800<span></span>
</td>
<td class="nump">$ 42,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments', window );">Upfront payment, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_FairValueOfCommonStockIssued', window );">Fair value of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PercentageOfLicensorsRoyalties', window );">Percentage of licensors royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember', window );">NUS and St. Jude | License Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PercentageOfSublicensingIncome', window );">Percentage of sublicensing income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember', window );">NUS and St. Jude | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_PercentageOfSublicensingIncome', window );">Percentage of sublicensing income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_LicenseAgreementTerm', window );">License agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember', window );">NUS and St. Jude | License Maintenance Fees | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember', window );">NUS and St. Jude | After Year Two of the Agreement | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_AmountsOwedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts owed under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_AmountsOwedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual research license fees and Commercialization license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_FairValueOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_FairValueOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_LicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_LicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_NetSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_NetSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_NumberOfNonExclusiveRightsToGeneEditingTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non exclusive rights to gene editing targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_NumberOfNonExclusiveRightsToGeneEditingTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non exclusive rights to gene editing targets licenses received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_PaymentsMadeUnderCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments made under collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_PaymentsMadeUnderCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_PercentageOfLicensorsRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Licensors royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_PercentageOfLicensorsRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_PercentageOfSublicensingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sublicensing income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_PercentageOfSublicensingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential future payments based on achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ReceivableUnderResearchCostSharingProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable under research cost sharing provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ReceivableUnderResearchCostSharingProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction of research and development expense resulting from partial reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issued upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktx_ResearchCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktx_ResearchCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktx_DevelopmentAndRegulatoryApprovalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktx_DevelopmentAndRegulatoryApprovalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktx_MaxcyteLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktx_MaxcyteLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktx_NkCellProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktx_NkCellProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nktx_AfterYearTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nktx_AfterYearTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897066896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Details) - 401 (K) Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Defined contribution plan, description</a></td>
<td class="text">On January 1, 2018, the Company adopted a defined contribution 401(k) plan that is available to eligible employees. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer contribution, percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense contribution plan</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=nktx_KPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=nktx_KPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052889039920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2022</div></th>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,350,179<span></span>
</td>
<td class="nump">54,350,179<span></span>
</td>
<td class="nump">54,350,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance and sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="nump">15,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock public offering price</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="nump">$ 215.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwriters Option to Purchase Additional Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Follow On Offering of Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktx_FollowOnOfferingOfStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktx_FollowOnOfferingOfStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893950448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Aggregate cash proceeds</a></td>
<td class="nump">$ 445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock available for issuance</a></td>
<td class="nump">8,541,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 34,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, expected to be recognized over weighted average remaining service period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of options granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsShareBasedCompensation', window );">Dividends issued for options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Dividends expected to be issued over life of options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Estimated dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Shares subject to repurchase</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">16,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, expected to be recognized over weighted average remaining service period</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="nump">61,754<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance</a></td>
<td class="nump">952,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Aggregate cash proceeds</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock available for issuance</a></td>
<td class="nump">890,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of employee compensation eligible for plan</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Commons stock purchase price as percentage of fair value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, expected to be recognized over weighted average remaining service period</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="nump">1,344,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktx_TwoThousandTwentyPerformanceIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance</a></td>
<td class="nump">5,945,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear', window );">Increase in share limit as percentage of outstanding shares of common stock on last trading day in prior year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock available for issuance</a></td>
<td class="nump">1,775,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in share limit as percentage of outstanding shares of common stock on last trading day in prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind dividends declared for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktx_TwoThousandTwentyPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktx_TwoThousandTwentyPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897213056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Option Activity (Details) - 2020 Plan and 2015 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding beginning balance</a></td>
<td class="nump">4,204,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted</a></td>
<td class="nump">2,327,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, exercised</a></td>
<td class="num">(383,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, forfeited</a></td>
<td class="num">(630,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding ending balance</a></td>
<td class="nump">5,519,275<span></span>
</td>
<td class="nump">4,204,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, exercisable</a></td>
<td class="nump">2,337,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, vested and expected to vest</a></td>
<td class="nump">5,519,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding beginning balance</a></td>
<td class="nump">$ 19.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted</a></td>
<td class="nump">12.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised</a></td>
<td class="nump">3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited</a></td>
<td class="nump">21.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding ending balance</a></td>
<td class="nump">17.17<span></span>
</td>
<td class="nump">$ 19.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">17.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest</a></td>
<td class="nump">$ 17.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term (in years), outstanding balance</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term (in years), exercisable</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term (in years), vested and expected to vest</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding balance</a></td>
<td class="nump">$ 2,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 2,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897348800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Additional Information Related to Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of stock option grants per share</a></td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="nump">$ 30.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 4,268<span></span>
</td>
<td class="nump">$ 9,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893098064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Unit Activity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, outstanding beginning balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">389,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited | shares</a></td>
<td class="num">(32,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, outstanding ending balance | shares</a></td>
<td class="nump">356,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, granted | $ / shares</a></td>
<td class="nump">12.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, forfeited | $ / shares</a></td>
<td class="nump">12.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 12.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining contractual term (in years), outstanding ending balance</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052889040064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Common Stock Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">8,541,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Reserved for Future ESPP Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">890,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktx_TwoThousandTwentyPerformanceIncentivePlanMember', window );">Reserved for Future Equity Award Grants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,775,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktx_CommonStockOptionsAndRestrictedStockUnitsMember', window );">Common Stock Options And Restricted Stock Units Granted And Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">5,876,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktx_TwoThousandTwentyPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktx_TwoThousandTwentyPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktx_CommonStockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktx_CommonStockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052888609872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 16,856<span></span>
</td>
<td class="nump">$ 14,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7,326<span></span>
</td>
<td class="nump">6,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 9,530<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052897214896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">75.70%<span></span>
</td>
<td class="nump">77.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">78.90%<span></span>
</td>
<td class="nump">79.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">63.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">151.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue', window );">Common stock fair value</a></td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="nump">$ 15.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue', window );">Common stock fair value</a></td>
<td class="nump">$ 18.44<span></span>
</td>
<td class="nump">$ 54.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions common stock fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893413712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision or benefit for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance of net deferred tax assets</a></td>
<td class="nump">27,000,000.0<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">2,339,000<span></span>
</td>
<td class="nump">1,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 777,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember', window );">Net Operating Loss and Tax Credit Carryforwards to Offset | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_ChangesInOwnershipByStockholdersHoldingPercentage', window );">Changes in ownership by stockholders holding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">153,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Credit Carry Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, expire</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards, expire</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards, expire</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Carry Forward Indefinitely</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 150,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">California State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 65,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards, expire</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">California State | Research and Development Credit Carry Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_ChangesInOwnershipByStockholdersHoldingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in ownership by stockholders holding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_ChangesInOwnershipByStockholdersHoldingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nktx_ExpirationYearOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nktx_ExpirationYearOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nktx_ExpirationYearTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nktx_ExpirationYearTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nktx_CarryForwardIndefinitelyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nktx_CarryForwardIndefinitelyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893275808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory rates</a></td>
<td class="num">$ (23,906,000)<span></span>
</td>
<td class="num">$ (18,076,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(1,566,000)<span></span>
</td>
<td class="num">(1,005,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">1,891,000<span></span>
</td>
<td class="nump">592,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(3,426,000)<span></span>
</td>
<td class="num">(1,661,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="num">(515,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">27,007,000<span></span>
</td>
<td class="nump">20,665,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052892947632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 36,732<span></span>
</td>
<td class="nump">$ 33,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">11,999<span></span>
</td>
<td class="nump">6,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">19,062<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment', window );">Section 174 Capitalized R&amp;D</a></td>
<td class="nump">17,352<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">90,415<span></span>
</td>
<td class="nump">47,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(71,368)<span></span>
</td>
<td class="num">(44,361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">19,047<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(18,089)<span></span>
</td>
<td class="num">(2,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(958)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets Section 174 capitalized R&amp;D.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052896245200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Changes in Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 1,359<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to tax positions taken in prior years</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to tax positions taken in current year</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the year</a></td>
<td class="nump">$ 2,339<span></span>
</td>
<td class="nump">$ 1,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140052893264528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 10, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Initial Lease Agreement and Additional Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord', window );">Amount held as collateral for letters of credit issued to landlord</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount held as collateral for letters of credit issued to landlord.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>nktx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktx="http://nkartatx.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktx-20221231.xsd" xlink:type="simple"/>
    <context id="C_31abcc35-68e1-488a-b26e-29817aecaa5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0abf9930-6b9d-43f1-bcde-e0a41387b2cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktx:NkCellProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <context id="C_ac5b81a2-efd6-441c-b505-52b48bac16ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_328c18c4-b70f-49ff-8925-ad2743c6a99e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_187aafe4-a065-4b40-be67-1ac1dc3d08cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b79def7d-c6df-41a1-bf0c-919f674fb2ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktx:UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0c9c944a-ceec-4d30-8fa4-840b650e3911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d014bbfe-ee80-4fc5-925e-c46b0ee01917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3c1f1543-5dab-4779-b06e-a0d704393f4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e5303a92-212e-4aad-9186-0d262371436b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="C_d8d0678a-6dba-4324-ac26-5b00dadee7ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dad82f88-3e0b-4f88-88f6-fb0cde6e2f5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3a1834a9-94f0-4aab-abd5-ebb33501f4c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_00c5bf6f-2fc6-4028-b703-d38c7fb1eb15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_176fb4da-b4be-4abb-b573-31f43872e49d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktx:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_74c75d73-fb22-4295-b576-4cef5d2a18f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3ad6f663-9c17-49d2-af22-eb2005f970e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_104df7f6-48a5-4dc9-8ed3-ca5b85d25ef3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_229b2864-98b4-4ede-83cb-94419b551487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:CarryForwardIndefinitelyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_44eb9b84-6402-486d-8d17-eda195e16bed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7e5762e7-f7e7-4ca0-95b2-9a9aca43a951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1eb2f144-5565-4350-a09a-b2ab343aade0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">nktx:KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_57e7b3dc-ab16-4aa2-987e-e194bd6384a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0bf228a-dcc8-47a6-9520-a9d355912f12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktx:FollowOnOfferingOfStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3a8087e1-63e7-4651-bc43-c16820cff537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c452dd17-c870-489d-8326-cf1262b803dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_c60f034b-7278-446d-9f32-ef360df72d1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_43a91ef6-617a-4181-b769-aa8b7eeac784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ea510978-78aa-41fd-bda5-9491f506aa24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3983a133-278f-4146-b005-921fbc2b18af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9766f258-dd51-4457-9526-56fe0bcb58d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_444f64e4-77b4-4f0d-a3be-c07ea1bd14aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3ae365a0-6a87-4a4e-a567-430fbc72a73f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:ExpirationYearOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_18a918ed-b24c-4a30-91c4-1883263c2b4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b8ccfab3-765f-42cd-a915-348919b0824a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_18f31adc-2623-483c-a5cc-71db7010cc81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d1fc9433-2e3d-4914-a5c8-bc7a7bff7abf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_1bc72894-bc11-4b07-8e86-b0f46fc9cf6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d3d36e67-6511-40e9-9266-1efc22df210e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5ac1ee49-377e-467a-9ba3-17eff01ca117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fca8d672-8425-4bf2-a2fd-b3e697b44bd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_96c15272-baf2-49fd-8372-c7699ec34602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="C_56c70c9b-2181-46db-b6a8-a17ab68f0f6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktx:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ed9f3140-e20c-40cc-acc9-33bafd2a727b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e103274a-366e-48fb-b799-052573c606d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4adcd202-22d8-4ab3-b561-2ff39d168d3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a7932d5a-1ed2-47f6-8f53-4bf014a752e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <startDate>2020-07-14</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ddefd491-c663-47f5-b387-ddd0b74ee428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b32eb187-1110-42c8-a989-031bf9074bfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nktx:AfterYearTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="C_46288b47-1afa-44f0-be59-d2f91c284d71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_740287c6-87bc-41cd-9f00-710fff88daae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f580e365-5516-4a7a-ab29-b585665fbce7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_98fde113-4079-4ef0-aed0-57bc5371b89d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="C_3fec699f-ea28-4689-9337-687766f60d30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <instant>2020-07-14</instant>
        </period>
    </context>
    <context id="C_a4a20bb1-0ddc-4e5d-9ac6-131ac886e0ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a024a1ed-5c61-4be8-a5a7-9e8fa9a97eff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f88de343-0a59-45f7-9df8-b09992f4929c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0a03030f-25af-4ff1-945c-997f499c318d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d27112b2-cbb8-4700-a273-558f65b6fae8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_88e987e9-14ae-4a55-adf7-c0657a837adb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_001b7558-daa1-49c1-8059-798879009ca2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="C_3d09d41d-b86f-424c-9448-32c8e1aee0c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_26bd2db9-3e16-458f-8423-a038b4619fe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_62587f67-7720-4862-8bc3-ad2de14109b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d879caa7-595a-47ec-b94d-f39d5f4dde87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_feea12d5-fa67-4f8d-a138-14014b003a98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9156c0d3-efa4-45e5-8f61-29564c2a7e1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementAndAdditionalLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="C_a6a22efc-c313-4977-a01d-0fa7148647f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f4d8076e-e0bc-4c00-a7ca-5d44c39d9a6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b68d2390-4372-4de3-9b47-180a4a7b91f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktx:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5cee8cd7-5f97-41bd-add1-44d08b9bb04e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0f5f41de-e22b-492e-9aab-31a2107d81dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5c424608-d9ed-42fb-be8c-a8171cb6a5ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:ExpirationYearOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktx:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e8f4b60d-ae7d-4ecd-ad6a-e4de3f34ea9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d89cf241-714f-47ac-b0fd-90fc206d8545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:AgreementWithFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ed03bf83-d13d-4a93-9a1b-a266f8faf400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_583fcba6-1ff0-489b-a59a-27d2cc6bc251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7e258be6-92d4-4784-8087-1c605ecf79d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:MaxcyteLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="C_e12e22c5-6319-489d-998a-5a9b9f8b965c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_737c89a5-e439-47b8-8aaf-76cfec47c0ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bd5a17ec-15ba-48c4-a69b-663e0936c2fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_f80d2293-58a8-4680-be9d-fb127ceff8c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b23572bd-0d8a-4cf9-afdc-816a5cbc484c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="C_54a727df-02a6-4bb0-88ff-9fcf2ef7503f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:AgreementWithFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_242f872b-1115-4f14-a73e-62ca3a640241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_981a3fe1-5a1b-4bea-9a27-e819dcdf253c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="C_5494864e-30df-4f68-b4b1-cd4ad5b4ba91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2c1cfa1c-67c5-4c85-a0df-ba0a03295212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:AgreementWithFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fc9d6414-7006-461a-ad35-be8368d5db4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6f2f80b9-36c3-4ae7-b0df-62a4197809a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:SecondAmendmentOfAdditionalLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_42e1761d-f976-4772-b948-69c953e4e0be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">nktx:NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_dd275879-1ce5-41b8-bf9c-ea076c74e129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_141cfb9f-1119-4e34-b791-208f5def88e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="C_217c98a8-e1b0-496a-b167-e85ebc606b96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_23b5530e-7d65-4f89-a655-72c856a9b438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7d693d1f-0170-4af7-8991-dbab6eb94595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d5727518-e2f1-4921-a234-816384299bb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_5e4795d5-2002-4904-a3ea-f02d9bec752b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:MaxcyteLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="C_6595a8da-7252-4dae-89c8-5653af52ef0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_de1b3fd2-437c-46d9-9d40-3096dc12b8c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2ffabe62-fbe5-446e-b9de-8398a5aa0a92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2c954c54-02fd-4743-8a11-058f3cf49640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6097964e-eb40-4699-9cf6-6a9b004fabb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c7e114d6-1e43-4e3e-a721-90f9540d66a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c963d9bf-d21f-4940-8b1d-41239a955535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c494cf9e-deff-4d61-b7a3-4124b968194f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a7611da9-a17b-4506-b7d2-762f752b122e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9b8fd370-f133-4a2b-a2c1-752e3951322c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d26eec10-62b5-4c3b-988b-3b120717f7c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_51775edc-1ac6-4de8-ae0e-dabb7398d898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3bd6bac6-2a11-499d-8435-032d15a2aceb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_59d64f92-ff2e-4690-bf99-cc3623e46e80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_2914dfc3-b00d-4a26-95ed-1856d75544a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_52762d64-2657-4a85-b085-9b43b6ef6b2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3c0028db-df29-4aa0-adac-fef9ec3b7256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_24c0aaae-b891-4b96-8392-e3514173d5c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a7e0478f-dfc8-4a2e-bc04-3e92eb222605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktx:TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0dbf8ba2-16eb-4d47-8a53-2bcd7625019d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_99a492e6-fb70-4aea-a41e-5b84273ea158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_996ef9b2-0b0e-4010-a387-288c02df3d11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d61b13b8-5000-41ad-872b-a55642f66d70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c46e250-9967-4f2d-81f6-f41141108536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ab31f486-dd4c-4921-9836-0c2daa665d2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a8cd6f3e-33d2-431d-8c68-01cfb7d24237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktx:CommonStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9e0afc55-bbb0-416e-a754-625e5f859147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6be6113f-92b4-4ee7-a950-89b44b4f6055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">nktx:KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b01db192-8bff-49f9-aa8a-eb072e8e8931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktx:NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="C_bdd7e725-4ef2-4276-b95f-8ec6ebdac396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktx:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_ed817214-47bd-4dc1-80a6-cb7172f19a31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6a853c5f-fc86-43fd-bf06-21c2b2e36b23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktx:UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_71271a5b-183d-4f56-9d1b-7e8e195a7acb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d26a61da-14d4-4715-904f-6250145d2632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9997cb7c-7d06-42b6-b7a1-bf97634ec016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d1fe8023-9b9c-459a-9183-c5748a0f5ae1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b847b099-3feb-4070-a061-cbb4d32913b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d56636f3-c58d-42fd-837d-0a0954658fe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6740d2cc-da91-46a2-ad58-636e6c3384c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5d932bf8-0352-4715-adee-681c326862f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_41f74bcf-d3f3-4e8a-b3f5-64d52ddf8089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e7e05b12-6998-4ee3-a819-f951b803d26c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktx:CorporateOfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:InitialLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_9183cb74-8a77-407b-ac80-773ff92736bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e51d5a3b-deec-4d63-bc9d-87858ed3e409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e16f2952-c482-4fb5-b289-6a2484c1649e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:ExpirationYearTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9e12b052-9715-41fd-bddf-9db4bb8a1947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8785059f-96d4-4f04-8c0f-0809aa5b503b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b77baa8f-96a7-406d-a97a-325fd5089207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_f5787b06-caba-4869-913a-d42e3e4d8626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktx:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_81bfa481-ab6e-4a60-9e7f-38e17ed8e269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ff496bec-fe97-479b-a5c4-6ec81afca185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nktx:ExpirationYearTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1d7aca5b-833d-4eaf-8d07-daf876c42502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8074f9cd-476b-4fa5-a455-4be53c9fdce6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1068e57e-6f93-49e0-ba99-d2c70b9915f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktx:NkCellProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <context id="C_59e66b2e-c33f-48fe-ad46-f3ff01344f2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0f472547-d9cb-42a2-9d4b-f15637efe5f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:SecondAmendmentOfAdditionalLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="C_a6bef3a2-7f1b-4b5f-99b7-d7a3e86365c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktx:DevelopmentAndRegulatoryApprovalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktx:ResearchCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1cd10163-6e81-4530-a414-a8bef05e747e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_CrisprCas9">
        <measure>nktx:CrisprCas9</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_SGD">
        <measure>iso4217:SGD</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>nktx:Segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      id="F_198285a3-afca-45fe-b559-b79c053dd8b8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d1fe8023-9b9c-459a-9183-c5748a0f5ae1"
      id="F_491c5e57-d09d-4f35-9266-28735ed2f748">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:EntityCentralIndexKey
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_cd35d35f-e0f0-49de-af9e-1f263eba3ae9">0001787400</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_7a3231a8-b815-4c18-aeab-3a8b512a8687">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockValue
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      id="F_5658f9a6-0756-441f-93ac-997697fa2195"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      id="F_863703a1-6d57-4227-9b1e-b47b16972aad"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_d097accb-afd7-473f-ba55-bdffd509663b">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_ba20813a-d918-4a71-9738-db3869415333">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      id="F_039b0ac0-597a-43be-a936-17146b41c847"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_7efaeb9b-f3a8-43b7-95fd-16996ea57086">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_b4f4896d-ea70-4f7b-902a-2b11d4ab7800">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_363ec7b3-275b-4fc2-ab59-1e0891c4e450">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_fdd1647b-eff9-437a-b73c-8191080e46d4">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_046a9cbe-e7cf-4744-adaf-e9dc9d6d7b03">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_29622cfd-0e9e-4b5c-b7e7-dc1e5394c513">001-39370</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_81dd8a0f-77d4-40f5-b0d1-53a8eacd4c68">Nkarta, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_e20d9fce-f32b-4633-ae2d-ae7471c4d2db">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_7c5ee00f-3b05-4d96-aec2-91eb1ab954e0">47-4515206</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_734e44f5-0517-48fb-9cfe-1eedab0b258d">6000 Shoreline Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_ad35fc5e-fa84-4d6f-b5a9-5d3d27d623be">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_3b116f0e-fc92-41d6-a2ab-1880ede90440">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_163d56f3-df06-45c7-ab62-5e4ce2799a83">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_ec4bb150-2298-494a-b690-644b7da0acac">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_b3046f48-c7f9-47eb-b275-84d3d3772bcc">925</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_29a419bd-2cc4-4c66-b274-085cd674f9b6">407-1049</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_4cfe69d1-31cc-4434-ab09-942636c88e5e">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_43103304-b4ba-4e62-9abe-55117e94aa1f">NKTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_d818f2dd-3a75-4792-82d9-a7c003ada568">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_a5b03d0a-6677-468f-a604-80dbbc017894">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_455f6566-52ab-4ca7-b7f7-14c35de000f6">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_a48c1d08-3a0a-4df1-998e-daebc06e68d9">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_d531bec7-8b1f-4866-8bd3-36116e62d7e0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_d1f83016-c42c-471d-88c9-8b852416b019">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_ddb2cb31-1e92-415c-adb0-3b744ddbf048">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_cda045bf-6c82-4c6a-8622-8d823fcbc251">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_a534669e-ee18-457f-b467-be9e6209ec99">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_adb78635-051c-45b1-92cb-5b4b074abcdf">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_2a925dd2-bf1c-43f4-81df-6df5202faf30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_ed9f3140-e20c-40cc-acc9-33bafd2a727b"
      decimals="-5"
      id="F_e3d08270-791f-46de-ad37-e7599624030b"
      unitRef="U_USD">345900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_b23572bd-0d8a-4cf9-afdc-816a5cbc484c"
      decimals="INF"
      id="F_06034b31-cba6-44ba-ad00-9a7d6f519383"
      unitRef="U_shares">48928670</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_b9413a47-df93-4e0a-bfa0-f73ed6274473">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_962285eb-20f8-4f4a-baea-ebb6b265cf57">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_479c7b92-ce03-4a16-9d01-3adcb1e649a1">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_12cfa57e-57e4-4744-a033-25c6ce8ab73f">California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_111e0ab1-c95e-40eb-a2bc-007290248d15"
      unitRef="U_USD">37494000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_55d2631e-f25f-496d-ba20-17bd42f4297a"
      unitRef="U_USD">60816000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_511cac85-8410-455f-acd9-ab5d7b87e4fe"
      unitRef="U_USD">314649000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_4b0ee423-394a-448c-ab6f-c7a853f90058"
      unitRef="U_USD">177272000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_43e245bd-353a-4834-a73e-c7e1bc253dfc"
      unitRef="U_USD">8545000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_a6dd11b7-103b-43e4-934a-acc54545d0bc"
      unitRef="U_USD">7692000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_93a24b35-eb5c-43ae-8e31-fb5b723bdcfc"
      unitRef="U_USD">360688000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_0016913e-e79d-418b-8a1e-f12f994547e9"
      unitRef="U_USD">245780000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_3f973d1b-88bb-4db2-8806-95182fd51a42"
      unitRef="U_USD">2743000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_8652cb6a-3280-4406-8d1d-02bee7b39105"
      unitRef="U_USD">2098000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_a5263469-a984-46fb-8abf-254c23c1dfff"
      unitRef="U_USD">61908000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_84cd5b3b-bba5-432b-ac33-58ff98f8164e"
      unitRef="U_USD">12856000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_57d8a6dc-e12b-4657-9af8-681409f831fb"
      unitRef="U_USD">45749000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_53d29299-7394-4bc6-a79b-5aa91bfa3648"
      unitRef="U_USD">11678000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_8e1e6dd7-f42c-4cb8-87ed-7d20b2a4c2f4"
      unitRef="U_USD">1850000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_7613e14c-63c0-4a1a-9714-8452bbe3b2a3"
      unitRef="U_USD">1491000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_69bfc2a4-701c-4c75-9541-b93a71834913"
      unitRef="U_USD">472938000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_414bf7b1-e968-4e65-ade3-9285ad807079"
      unitRef="U_USD">273903000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_59b584d4-f351-4b66-a703-51db0da67be2"
      unitRef="U_USD">1761000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_a59d38c6-a80f-46f5-b81c-9131db42f713"
      unitRef="U_USD">1112000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_ea9919ea-81ee-4926-85f9-abb46e8229ef"
      unitRef="U_USD">4249000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_f89f0487-30af-4794-970c-737bfc6dde40"
      unitRef="U_USD">2484000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_1de04a01-177a-4c92-8450-5845f4fa5964"
      unitRef="U_USD">16036000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_288ca8c4-dedb-4893-b173-431f1f7aaa73"
      unitRef="U_USD">9347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_69d7af77-52cb-4ba3-a8a2-ea0d24b749fb"
      unitRef="U_USD">22046000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_2da773ef-060a-4319-9c40-58a51f61e8cc"
      unitRef="U_USD">12943000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_ab9206f7-eeb3-41dc-a3d0-1d0f117c1b17"
      unitRef="U_USD">78685000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_d8fd4783-6364-4ad8-a858-5bdf47986351"
      unitRef="U_USD">9975000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_e93b5ed3-1875-4b4f-9845-d3e8851bf188"
      unitRef="U_USD">18000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_2d2fc66f-538f-4381-9a06-a5bf6dcb57f3"
      unitRef="U_USD">100731000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_73e45353-0106-4c74-9003-1639922e46b4"
      unitRef="U_USD">22936000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_8c6a0b1b-c163-49c0-bca7-ed40c82f6c93"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_e15bd7a7-9fa0-4ee2-b6b2-53c30ebd4372"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_d0d337cd-02a6-4d1c-9e9b-5b367837e3e8"
      unitRef="U_shares">54350179</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_9c5f5530-0664-44b6-8430-519168e1ebfb"
      unitRef="U_shares">54350179</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_376f47c3-b51d-4839-8383-ac609fe1306e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_6f7bf634-9868-4e25-b03f-600691126f96"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_55a1d0c1-70de-4ce7-b6ef-fc2f2dde194e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_fb2c3656-cf93-44ae-bfe9-8d578179673f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_10c9d330-7985-42d8-aa9b-41159dd1c862"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_c8c18be9-0ac0-4330-adb7-f149f2344771"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_854bcd68-f6dd-40a3-b94f-7bc8d6ecadb5"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_3678723a-bd9e-4c4d-81e8-22f2a9f2dfcd"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_5524e24b-6f91-4e9f-98d2-6510acbb423c"
      unitRef="U_shares">48877806</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_5b8eb859-5888-4390-8e92-34ee07415eed"
      unitRef="U_shares">48877806</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_8af12453-5356-4c57-9f61-fce3ef225b7d"
      unitRef="U_shares">32971107</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_38af41ba-dc70-4250-ac12-f6075a2f9d9c"
      unitRef="U_shares">32971107</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_da546fcf-979e-4408-a56d-d5c635321b2d"
      unitRef="U_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_dcdcb700-45c8-47d8-b88d-4795dde730fd"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_02fdc582-c17b-4e5c-a6a8-ce66518bd22e"
      unitRef="U_USD">690814000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_7e913ec2-5396-472d-af7f-77d9e59387b8"
      unitRef="U_USD">455210000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_a3028601-b665-41d2-af74-ca07561ac183"
      unitRef="U_USD">-679000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_3f6195cd-3e3b-4e3c-83e0-445db5e4c72a"
      unitRef="U_USD">-150000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_f07b295a-ef52-4198-ad01-0f6926266287"
      unitRef="U_USD">-317933000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_66c6084b-ce03-40bf-ad15-2f03f0d25cc1"
      unitRef="U_USD">-204096000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_472125a9-e02c-42c3-b8a7-bce6340ab8bf"
      unitRef="U_USD">372207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_bf8e818f-0bc6-4bfa-8046-7da000c30a2c"
      unitRef="U_USD">250967000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_8b7ea332-ec2b-45d9-b17a-5b1ca7d4e7ea"
      unitRef="U_USD">472938000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_f0126fce-6bc2-448c-903f-dcd3ed0ebc22"
      unitRef="U_USD">273903000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_8a6496b9-e661-4e60-aa81-4df1f697eb08"
      unitRef="U_USD">90897000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_669cdd70-fe7b-4faf-8c85-58bc7b01cadd"
      unitRef="U_USD">63412000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_cb814061-4e8a-4eac-a55f-93f6142c8ad3"
      unitRef="U_USD">28058000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_7e684570-8149-4900-87af-23c93bb149dd"
      unitRef="U_USD">23017000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_3a1d6820-bbab-43f8-8f66-2128904689da"
      unitRef="U_USD">118955000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_98de15be-5b15-42b4-9acd-0cfb57a2ec6d"
      unitRef="U_USD">86429000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_43111545-39a2-4b56-a8d0-9a5f25fe96ff"
      unitRef="U_USD">-118955000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_aab2b4e9-36ce-4480-844e-7f783a3b0c72"
      unitRef="U_USD">-86429000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_026f615d-dd89-4c1e-b8e3-e7407224c017"
      unitRef="U_USD">5588000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_4ff4066e-da72-4886-ad88-1f941bd83e0d"
      unitRef="U_USD">370000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_b2d06ffd-7efb-4761-aace-9528e52682a7"
      unitRef="U_USD">-470000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_1edec751-a3c2-40c1-b1c0-e63ab0a6f96b"
      unitRef="U_USD">-16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_29b54b1c-2c17-4071-9084-b46ffd886f2a"
      unitRef="U_USD">5118000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_53e3eceb-62bd-4ad4-9375-a1aad2e3e680"
      unitRef="U_USD">354000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_2848cfb9-f223-4bf2-baeb-980397437541"
      unitRef="U_USD">-113837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_86efb2b0-02e2-487c-bd42-339a089c84e3"
      unitRef="U_USD">-86075000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_f26d2e2a-d63c-4b63-8670-3834eb06c7b0"
      unitRef="U_USD">-113837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_59e52909-6cae-4748-8aa2-78bfb5217063"
      unitRef="U_USD">-86075000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_cffd6df9-437f-4e2f-8b73-871086f1f378"
      unitRef="U_USD">-529000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_42ca0519-47f9-40aa-8d79-7e364844d031"
      unitRef="U_USD">-153000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_3a995be3-69d2-44fd-89d0-9238b3dccafb"
      unitRef="U_USD">-114366000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_9de13ff1-6011-4991-93fb-7d8fddaeb11e"
      unitRef="U_USD">-86228000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="2"
      id="F_2ce0ad60-2ac2-49e6-b545-a31da174b0d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="2"
      id="F_f25ea6cc-0c1d-4a39-90ee-9c492b19bfb5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="2"
      id="F_3ef81ae9-dfcc-4c0a-a11f-433b8c63ed09"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="2"
      id="F_0cb4a1c2-5e7d-4408-9caa-94b7252e1312"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="0"
      id="F_07ea61a1-5fe3-4a0b-a268-136fc5129688"
      unitRef="U_shares">43631722</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="0"
      id="F_37bfbcfc-25ee-435f-8df3-31f46764d864"
      unitRef="U_shares">43631722</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="0"
      id="F_b9dde344-7b2b-41a2-af12-df2094feda04"
      unitRef="U_shares">32856883</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="0"
      id="F_15220682-179b-400d-877f-8d14b2c76c03"
      unitRef="U_shares">32856883</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_a4a20bb1-0ddc-4e5d-9ac6-131ac886e0ba"
      decimals="0"
      id="F_84d220d1-5e9a-4ab8-a389-0a91fafc8311"
      unitRef="U_shares">32627963</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a4a20bb1-0ddc-4e5d-9ac6-131ac886e0ba"
      decimals="-3"
      id="F_d647aee1-a5b0-403e-a586-813cf6ed36b1"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0f5f41de-e22b-492e-9aab-31a2107d81dc"
      decimals="-3"
      id="F_7c7268a9-8008-4664-94e6-0fd4acb03020"
      unitRef="U_USD">439235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5ac1ee49-377e-467a-9ba3-17eff01ca117"
      decimals="-3"
      id="F_bee9e481-5a97-4579-b137-d135c72859e0"
      unitRef="U_USD">-118021000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3c46e250-9967-4f2d-81f6-f41141108536"
      decimals="-3"
      id="F_6d9d4c01-727a-4b3a-903a-d206233851c5"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32"
      decimals="-3"
      id="F_eb6f32e4-eeb4-4858-a8f9-e779a8b137fa"
      unitRef="U_USD">321220000</us-gaap:StockholdersEquity>
    <nktx:StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase
      contextRef="C_ea510978-78aa-41fd-bda5-9491f506aa24"
      decimals="INF"
      id="F_a9213aa3-1332-4959-b5fc-dc08bcc07239"
      unitRef="U_shares">62045</nktx:StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase>
    <nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
      contextRef="C_6740d2cc-da91-46a2-ad58-636e6c3384c2"
      decimals="-3"
      id="F_bfd4b668-f921-4c1a-b6b0-5e0693e31e84"
      unitRef="U_USD">35000</nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase>
    <nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_66b23e1e-0851-4144-bdd0-864720157fb4"
      unitRef="U_USD">35000</nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ea510978-78aa-41fd-bda5-9491f506aa24"
      decimals="INF"
      id="F_0df4c60e-6079-4094-908a-a5b5fb32b89f"
      unitRef="U_shares">281099</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6740d2cc-da91-46a2-ad58-636e6c3384c2"
      decimals="-3"
      id="F_ad718b2e-3319-4ca4-9b7e-b0b02fe312da"
      unitRef="U_USD">1479000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_d28a488b-ec4d-4cae-86c1-e15922d72873"
      unitRef="U_USD">1479000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6740d2cc-da91-46a2-ad58-636e6c3384c2"
      decimals="-3"
      id="F_f7bde141-c9d2-4ffd-bd89-84bae6322c30"
      unitRef="U_USD">14461000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_8d9efb70-3e2c-4d3c-92f6-2dc47656ff41"
      unitRef="U_USD">14461000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_d56636f3-c58d-42fd-837d-0a0954658fe0"
      decimals="-3"
      id="F_a5ba6296-1307-430b-a19b-952af0296d8f"
      unitRef="U_USD">-153000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_15577549-80b7-4794-b9b6-1d2925caf538"
      unitRef="U_USD">-153000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_51775edc-1ac6-4de8-ae0e-dabb7398d898"
      decimals="-3"
      id="F_0d520d38-4892-49f4-bc12-73b9ffe608b7"
      unitRef="U_USD">-86075000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_790063c2-1aca-40ec-8ba8-501a42bf4bec"
      unitRef="U_USD">-86075000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_8074f9cd-476b-4fa5-a455-4be53c9fdce6"
      decimals="INF"
      id="F_36a00aa6-a8d5-4a64-aed7-7d29a2240d22"
      unitRef="U_shares">32971107</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8074f9cd-476b-4fa5-a455-4be53c9fdce6"
      decimals="-3"
      id="F_3c8da132-ab66-4701-ac0c-68835373900d"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e103274a-366e-48fb-b799-052573c606d1"
      decimals="-3"
      id="F_26edfcc1-b7a4-4ab8-a2b9-9ec8582024e2"
      unitRef="U_USD">455210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fca8d672-8425-4bf2-a2fd-b3e697b44bd8"
      decimals="-3"
      id="F_6af22231-fafa-4874-9222-93c1dedef7e9"
      unitRef="U_USD">-204096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_31abcc35-68e1-488a-b26e-29817aecaa5c"
      decimals="-3"
      id="F_40fd5da4-4811-45e0-802a-e1667e2cb299"
      unitRef="U_USD">-150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_412e417f-326b-4b14-8b56-1da8055c266b"
      unitRef="U_USD">250967000</us-gaap:StockholdersEquity>
    <nktx:StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase
      contextRef="C_1cd10163-6e81-4530-a414-a8bef05e747e"
      decimals="0"
      id="F_c91d9ace-c11c-45b9-a7f6-c9fe15cb3202"
      unitRef="U_shares">15278</nktx:StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase>
    <nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
      contextRef="C_996ef9b2-0b0e-4010-a387-288c02df3d11"
      decimals="-3"
      id="F_a226d55b-a6e3-4d4f-a643-f9298d0d69e7"
      unitRef="U_USD">15000</nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase>
    <nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_128fef68-52c0-41d5-8698-27981e129ad5"
      unitRef="U_USD">15000</nktx:StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1cd10163-6e81-4530-a414-a8bef05e747e"
      decimals="0"
      id="F_cd713bf5-3319-4213-83f6-3b699d942cbb"
      unitRef="U_shares">383120</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_996ef9b2-0b0e-4010-a387-288c02df3d11"
      decimals="-3"
      id="F_d2f80c04-0e04-46fc-8154-7db78851ea8e"
      unitRef="U_USD">1397000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_c1cfb938-53dd-4692-9faf-76c94eb4d124"
      unitRef="U_USD">1397000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_1cd10163-6e81-4530-a414-a8bef05e747e"
      decimals="0"
      id="F_46f7b78b-dfbb-497f-be29-b8f1fdbec112"
      unitRef="U_shares">61754</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_996ef9b2-0b0e-4010-a387-288c02df3d11"
      decimals="-3"
      id="F_4bfbccf2-9090-4a2e-a4a2-1b379b561640"
      unitRef="U_USD">445000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_6a53c795-c460-4743-9087-eb7d64c236e6"
      unitRef="U_USD">445000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1d7aca5b-833d-4eaf-8d07-daf876c42502"
      decimals="0"
      id="F_c5333a9a-09b6-4fc0-b887-e59ecbbbebbd"
      unitRef="U_shares">15333334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1d7aca5b-833d-4eaf-8d07-daf876c42502"
      decimals="-3"
      id="F_4f9eeb14-dc5c-424c-9670-47c20bff5f92"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_217c98a8-e1b0-496a-b167-e85ebc606b96"
      decimals="-3"
      id="F_c4b39b7f-6f26-4a17-98c0-95230cafcddb"
      unitRef="U_USD">215332000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_187aafe4-a065-4b40-be67-1ac1dc3d08cc"
      decimals="-3"
      id="F_f708fd3f-c5e3-4efb-8d97-9fb6b3fa1520"
      unitRef="U_USD">215334000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_dd275879-1ce5-41b8-bf9c-ea076c74e129"
      decimals="0"
      id="F_27f1231c-f461-4742-a3af-2cfc14bab7e3"
      unitRef="U_shares">113213</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e51d5a3b-deec-4d63-bc9d-87858ed3e409"
      decimals="-3"
      id="F_d0d01c9b-f97b-4d24-b489-2840abe4d888"
      unitRef="U_USD">1559000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_328c18c4-b70f-49ff-8925-ad2743c6a99e"
      decimals="-3"
      id="F_3f04f876-53ce-4af3-9fde-1e9ef23f1e72"
      unitRef="U_USD">1559000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_996ef9b2-0b0e-4010-a387-288c02df3d11"
      decimals="-3"
      id="F_a7b769f2-34e7-4b4c-b5bc-0fe8970dcac8"
      unitRef="U_USD">16856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_3b4d1d88-0d87-43f1-a3c7-d78a51adcedd"
      unitRef="U_USD">16856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ddefd491-c663-47f5-b387-ddd0b74ee428"
      decimals="-3"
      id="F_de15f746-7d5a-4e81-87f6-735122863761"
      unitRef="U_USD">-529000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_d260072d-073b-4955-b10e-817bfbbddb43"
      unitRef="U_USD">-529000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_41f74bcf-d3f3-4e8a-b3f5-64d52ddf8089"
      decimals="-3"
      id="F_88de4f2e-4ed5-4d12-929e-8105bf912477"
      unitRef="U_USD">-113837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_eb1e5473-fef6-45fd-a227-93718e6727f9"
      unitRef="U_USD">-113837000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_3d09d41d-b86f-424c-9448-32c8e1aee0c0"
      decimals="0"
      id="F_77557ec3-52b4-4d84-9b60-47c3b8a0c865"
      unitRef="U_shares">48877806</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3d09d41d-b86f-424c-9448-32c8e1aee0c0"
      decimals="-3"
      id="F_3c445998-0c05-4248-b05a-aa2b756613d9"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_104df7f6-48a5-4dc9-8ed3-ca5b85d25ef3"
      decimals="-3"
      id="F_cd1fb674-0348-463c-b6e5-55dc722f9390"
      unitRef="U_USD">690814000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_242f872b-1115-4f14-a73e-62ca3a640241"
      decimals="-3"
      id="F_b8f07987-d4a9-4e18-ba13-5f2c7d89dd1d"
      unitRef="U_USD">-317933000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d3d36e67-6511-40e9-9266-1efc22df210e"
      decimals="-3"
      id="F_bbe289e2-b2ad-4b66-9be2-75e46307c592"
      unitRef="U_USD">-679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_6033e8ad-62b0-4ad4-b0f0-e7344d79c94d"
      unitRef="U_USD">372207000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_30432ea6-cb81-4dbc-a07a-e23e8c9242dd"
      unitRef="U_USD">-113837000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_9a67ee0e-015c-42e1-a90a-c819051c7521"
      unitRef="U_USD">-86075000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_65eba554-eb14-401a-8bce-5b61a10e52b3"
      unitRef="U_USD">16856000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_0b509e95-3260-47d4-b471-54f8c41e800b"
      unitRef="U_USD">14461000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_89d7fb50-d5c6-43a1-8713-8e6295d25184"
      unitRef="U_USD">2637000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_e93ff60f-c7bc-47bb-8ef4-b840a76337da"
      unitRef="U_USD">1756000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_a99ecb9e-e7fd-4bcf-98f8-103f08ac33be"
      unitRef="U_USD">818000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_c9569aac-b109-478b-b7f4-934d1cded489"
      unitRef="U_USD">-3237000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_aa7f33b4-2d89-4847-b488-f52505676918"
      unitRef="U_USD">3935000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_79f67574-c83b-41ae-8711-7fbc4742441d"
      unitRef="U_USD">367000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_fe58089a-1bdd-4a39-aeac-68000d89cf32"
      unitRef="U_USD">-490000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_a61fcb09-1448-4545-896d-08a46a66a3fb"
      unitRef="U_USD">30000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_45f7d157-d395-489a-92da-1b0fd91553fc"
      unitRef="U_USD">1489000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_21768bc4-844f-42f4-9aca-2524f5364d2d"
      unitRef="U_USD">4435000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_9af8cf50-a507-4249-8930-f5d6807c7c1d"
      unitRef="U_USD">32469000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <nktx:IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_565bef13-615d-49be-bc70-df50235354d8"
      unitRef="U_USD">2757000</nktx:IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities>
    <nktx:IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_694f928b-6567-4f6a-80ab-d743150c25a7"
      unitRef="U_USD">2792000</nktx:IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_e1da03a9-18ca-4082-a677-9a90c97767fe"
      unitRef="U_USD">-57000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_c734b83f-2a6e-44f5-a0a2-b04349de4b75"
      unitRef="U_USD">-67927000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_9dc3b7da-fe04-426e-b8ae-524c4daeab7b"
      unitRef="U_USD">385887000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_cf87267b-800b-4062-9a51-636095206f11"
      unitRef="U_USD">227282000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_8a3c3408-57df-4e93-aa9a-167ded76156d"
      unitRef="U_USD">248309000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_74f81f12-b31f-427c-9c70-00a1b4ec230f"
      unitRef="U_USD">264841000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_500b1649-49f5-40f9-920f-2b81d487e706"
      unitRef="U_USD">47111000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_d3ae322f-bfe9-4cc0-9fb7-95d1ab9f0b4b"
      unitRef="U_USD">5025000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_444663d3-607f-4ecc-a9eb-c8dcabcb1459"
      unitRef="U_USD">-184689000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_fc940210-19ff-4618-a59f-ec6471bacb91"
      unitRef="U_USD">32534000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <nktx:ProceedsFromSecondaryOfferingNetOfIssuanceCosts
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_f6059c82-0c29-47f2-b6f3-2c7c72765851"
      unitRef="U_USD">215611000</nktx:ProceedsFromSecondaryOfferingNetOfIssuanceCosts>
    <nktx:ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_15ad6665-6195-40e9-a6bd-0448300beedd"
      unitRef="U_USD">1559000</nktx:ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_2e51026f-8ee9-4524-aa43-05800e93c71f"
      unitRef="U_USD">445000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_8b99f856-20dc-42f1-94c8-430253a78331"
      unitRef="U_USD">1397000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_3cdf00a9-60f0-4148-b249-a4197e17fc39"
      unitRef="U_USD">1479000</us-gaap:ProceedsFromStockOptionsExercised>
    <nktx:PaymentsOfDeferredOfferingCosts
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_6953e061-7d7b-40e9-95bd-f332e1e1a443"
      unitRef="U_USD">277000</nktx:PaymentsOfDeferredOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_5b6b8008-8359-4d99-84f3-29d772c29782"
      unitRef="U_USD">219012000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_f2a1d00e-2b11-40c0-a792-2066c3692c42"
      unitRef="U_USD">1202000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_76770806-2c88-45b8-a9d3-40887e4e46bc"
      unitRef="U_USD">-22677000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_6fa2ed0a-4805-4c2e-91c9-5b3b1cd1fc25"
      unitRef="U_USD">-34191000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_66ecd308-2c0b-4fce-9fd3-c43c31df4288"
      unitRef="U_USD">62914000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32"
      decimals="-3"
      id="F_6302a8e8-527f-4d6b-a5db-6b9e151e4c44"
      unitRef="U_USD">97105000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_f1cd3a72-fa84-42a6-b917-91014622862f"
      unitRef="U_USD">40237000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_f6d33090-d430-48ba-81f7-8327ad52d9f9"
      unitRef="U_USD">62914000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_b0e9bb48-097f-4801-96e9-e8ebd1101c47"
      unitRef="U_USD">37494000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_6cde583e-c70b-46c3-a459-92bddf0f02ba"
      unitRef="U_USD">60816000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_25ce0740-dca6-4804-81fe-4bfc00b873a2"
      unitRef="U_USD">2743000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_8e714165-011e-4887-974e-e4cde818f000"
      unitRef="U_USD">2098000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_e27b0bf4-ae18-425d-9b39-80cd7461c065"
      unitRef="U_USD">40237000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_2892f732-b90b-4081-8587-2f4cfed44233"
      unitRef="U_USD">62914000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nktx:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_d46c164d-6865-47cb-bb38-b7659dce4fae"
      unitRef="U_USD">4579000</nktx:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable>
    <nktx:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_e2f6de27-c374-4c98-a761-d26d8b1c2830"
      unitRef="U_USD">238000</nktx:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_6c039e17-25c0-4b1e-9155-47bea22d4b07">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. Description of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Description of the Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Nkarta, Inc. ("Nkarta" or the "Company") was incorporated in the State of Delaware in July 2015. The Company is a biopharmaceutical company developing engineered natural killer ("NK") cells to treat cancer. The Company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta&#x2019;s goal is to develop off-the-shelf NK cell therapy product candidates to improve outcomes for patients. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s operations are based in South San Francisco, California, and it operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; segment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity and Management Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, conducting preclinical studies and initiating clinical studies, and has not realized substantial revenues from its planned principal operations. In addition, the Company has a limited operating history, has incurred operating losses since inception and expects that it will continue to incur net losses into the foreseeable future as it continues its research and development activities. As of December 31, 2022, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;317.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and cash, cash equivalents, restricted cash and short-term investments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;354.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through d&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ebt or equity financings or other arrangements to fund operations. Management believes that the Company&#x2019;s current cash, cash equivalents, restricted cash and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_35f05915-3d2c-4813-81a1-73e8c44a28d1"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-5"
      id="F_7a39650c-8465-4288-b1a4-6ea767aa3d1d"
      unitRef="U_USD">-317900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <nktx:CashCashEquivalentsRestrictedCashAndShortTermInvestments
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-5"
      id="F_c0146ffb-b91c-4354-bd53-18ae656a3c2a"
      unitRef="U_USD">354900000</nktx:CashCashEquivalentsRestrictedCashAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_3972a55d-07a7-4e47-b9cb-08b6a689e738">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principle ("U.S. GAAP").&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The COVID-19 pandemic has caused disruptions in the global economy and has affected and may in the future affect the Company&#x2019;s business and operations in the future. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act had no impact on the Company&#x2019;s income tax provision for the year ended December 31, 2022. The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#x2019;s financial statements and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;accompanying &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;notes. On an ongoing basis, management evaluates its estimates, including those related to preclinical studies, fair value of assets and liabilities, share-based compensation and income taxes. Management bases its estimates on historical experience, knowledge of current events and actions it may undertake in the future that management believes to be reasonable under the circumstances. Actual results may differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality and are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 3:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents, Short-term Investments and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with insignificant interest rate risk and an original maturity of three months or less at the date of purchase to be cash equivalents. Cash includes demand deposits held in readily available checking accounts at a federally insured financial institution. Cash equivalents consist of money market funds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments consist of commercial debt securities, commercial paper and Government securities, classified as available-for-sale securities and have maturities of greater than three months but less than one year. The Company has classified most of its available-for-sale investment securities as current assets on the balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;carries these securities at fair value, and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is required to maintain letters of credit related to its office and lab space lease and the additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing. This cash is the collateral for those letters of credit and per the terms of the leases, must remain in place until one to two months after the termination of the leases. As the remaining terms of the leases as of December 31, 2022 is greater than one year, the related restricted cash has been classified as non-current.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and software and construction-in-progress are stated at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_491c5e57-d09d-4f35-9266-28735ed2f748;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December 31, 2022, there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairment losses recorded by the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. There has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such liabilities recorded by the Company as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets ("ROU assets") which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize lease liabilities and ROU assets for short-term leases with terms of twelve months or less.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option, employee stock purchase plan, and restricted stock unit grants, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options, employee stock purchase plan rights and restricted stock units and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of stock options and employee stock purchase plan rights are estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. Options granted during the year have a maximum contractual term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected term of the employee stock purchase plan rights equals the&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; six-month &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;look-back period. The expected volatility is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury ("U.S. Treasury") yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options. The fair value of restricted stock units is based on the closing price of the Company's common stock as reported on The Nasdaq Global Market on the date of grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s chief operating decision maker, its President and Chief Executive Officer, manages its operations and business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;segment for the purposes of allocating resources, makes operating&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;decisions &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and evaluates financial performance. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; product revenue has been generated since inception and all assets are held in the United States.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities, which include unvested common stock, unvested restricted stock options, and outstanding stock options under the Company&#x2019;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were no significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_df2a1773-6154-41e7-a67f-56678eccc25a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principle ("U.S. GAAP").&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <nktx:UnusualOrInfrequentItemsDisclosurePolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_df6b93c0-6fe1-45de-95ae-6da9cda8ad64">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The COVID-19 pandemic has caused disruptions in the global economy and has affected and may in the future affect the Company&#x2019;s business and operations in the future. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act had no impact on the Company&#x2019;s income tax provision for the year ended December 31, 2022. The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</nktx:UnusualOrInfrequentItemsDisclosurePolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_836bf1b3-de33-4e4a-b52b-08f0d9b437ed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#x2019;s financial statements and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;accompanying &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;notes. On an ongoing basis, management evaluates its estimates, including those related to preclinical studies, fair value of assets and liabilities, share-based compensation and income taxes. Management bases its estimates on historical experience, knowledge of current events and actions it may undertake in the future that management believes to be reasonable under the circumstances. Actual results may differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_5d19048d-3be3-4f0d-8f33-b142ae41af9b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash, cash equivalents and short-term investments with various high credit quality and are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_bce4e0bc-2cf3-4238-8e4a-9b55c3dad0fe">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss consists of net loss and unrealized gains or losses on available-for-sale investments. The Company displays comprehensive loss and its components as part of the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_be0a0722-8e9b-4d87-aba5-b864814b4906">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 3:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable, accrued liabilities and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <nktx:CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_34434d35-5ee2-4d8d-9706-50cb8f50954b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents, Short-term Investments and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with insignificant interest rate risk and an original maturity of three months or less at the date of purchase to be cash equivalents. Cash includes demand deposits held in readily available checking accounts at a federally insured financial institution. Cash equivalents consist of money market funds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments consist of commercial debt securities, commercial paper and Government securities, classified as available-for-sale securities and have maturities of greater than three months but less than one year. The Company has classified most of its available-for-sale investment securities as current assets on the balance sheets because these are considered highly liquid securities and are available for use in current operations. The Company&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;carries these securities at fair value, and reports unrealized gains and losses as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is required to maintain letters of credit related to its office and lab space lease and the additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing. This cash is the collateral for those letters of credit and per the terms of the leases, must remain in place until one to two months after the termination of the leases. As the remaining terms of the leases as of December 31, 2022 is greater than one year, the related restricted cash has been classified as non-current.&lt;/span&gt;&lt;/p&gt;</nktx:CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_637a5edd-d044-4b45-be2b-333162293ba1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, which consist of leasehold improvements, furniture and fixtures, research equipment, computers and software and construction-in-progress are stated at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which ranges from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_491c5e57-d09d-4f35-9266-28735ed2f748;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the remaining life of the lease for leasehold improvements at the time the asset is placed into service.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_9b8fd370-f133-4a2b-a2c1-752e3951322c"
      id="F_ebe639a5-7164-4337-9890-5f1265501394">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_44c0a79a-5c25-4829-96ec-813dcabbcb9c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through December 31, 2022, there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairment losses recorded by the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_8181722c-4c81-437e-a3e3-573885011fef"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_98944738-a7ef-40e5-9948-94add03bd96c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and other benefits of research and development personnel, including associated share-based compensation, costs related to research activities, preclinical studies, clinical trial, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_298f6a2e-f2b0-466b-801c-530e3840027f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. There has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such liabilities recorded by the Company as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_5bf45f04-6b46-4205-9457-84bfc9e1902a"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_db44f29d-44b5-42ac-9390-e87293b468be">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the commencement date of a lease, the Company recognizes lease liabilities which represent its obligation to make lease payments, and right-of-use assets ("ROU assets") which represent its right to use the underlying asset during the lease term. The lease liability is measured at the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date. The ROU asset is measured at cost, which includes the initial measurement of the lease liability and initial direct costs incurred by the Company and excludes lease incentives. ROU assets are recorded in operating lease ROU assets and lease liabilities are recorded in operating lease liabilities, current and noncurrent in the balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company does not recognize lease liabilities and ROU assets for short-term leases with terms of twelve months or less.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_79eee969-f337-4128-96dc-0158ccae566b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense represents the cost of the grant-date fair value of employee, officer, director, and non-employee stock option, employee stock purchase plan, and restricted stock unit grants, estimated in accordance with the applicable accounting guidance, recognized using the straight-line method over the vesting period for service-based options, employee stock purchase plan rights and restricted stock units and using the graded vesting method for performance-based options. The vesting period generally approximates the expected service period of the awards. Forfeitures are recognized and accounted for as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of stock options and employee stock purchase plan rights are estimated using a Black-Scholes option pricing model on the date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, expected dividend yield, and a risk-free interest rate. Options granted during the year have a maximum contractual term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the average of the contractual term of the stock option and its weighted-average vesting period. The expected term of the employee stock purchase plan rights equals the&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; six-month &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;look-back period. The expected volatility is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future. The risk-free interest rates used are based on the U.S. Department of Treasury ("U.S. Treasury") yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the stock options. The fair value of restricted stock units is based on the closing price of the Company's common stock as reported on The Nasdaq Global Market on the date of grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_9b8fd370-f133-4a2b-a2c1-752e3951322c"
      id="F_34ef2807-349d-42f9-a2e4-6446a4a1c0c2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <nktx:EmployeeStockPurchasePlanLookBackPeriod
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_1079385b-d11b-4e89-aa96-58d9c7441f7f">P6M</nktx:EmployeeStockPurchasePlanLookBackPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_c1aff36c-c801-4653-86fb-0db8a8dae94b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_edc14200-435d-40f1-a460-1290b399e651">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s chief operating decision maker, its President and Chief Executive Officer, manages its operations and business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;segment for the purposes of allocating resources, makes operating&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;decisions &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and evaluates financial performance. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; product revenue has been generated since inception and all assets are held in the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_fbce195d-343b-452b-ae7b-c207dda70ef6"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a7932d5a-1ed2-47f6-8f53-4bf014a752e3"
      decimals="INF"
      id="F_61c4df49-7b53-44c8-aa6b-3e6185f84e63"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_fb3e24e5-e2ca-4ea6-8394-d032dbc41caa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company&#x2019;s potentially dilutive securities, which include unvested common stock, unvested restricted stock options, and outstanding stock options under the Company&#x2019;s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_aac70c5f-6d0e-401c-99fb-72787301fa0f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were no significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_2ddca2f2-495d-4c6a-bee9-8b2ac6b974db">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the computation of the basic and diluted net loss per share (in thousands except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.162%;"/&gt;
        &lt;td style="width:1.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.491999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.565999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,635,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,901,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: weighted average unvested common stock &lt;br/&gt;&#160;&#160;&#160;issued upon early exercise of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average shares used to compute net loss&lt;br/&gt;&#160;&#160;&#160;per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,631,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,856,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.573%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.882%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.195%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,519,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,204,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested common stock upon early exercise of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,876,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,220,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_52d38d83-34a6-4f6c-969d-c3ff087a7fd0">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the computation of the basic and diluted net loss per share (in thousands except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.162%;"/&gt;
        &lt;td style="width:1.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.491999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.565999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,635,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,901,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: weighted average unvested common stock &lt;br/&gt;&#160;&#160;&#160;issued upon early exercise of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average shares used to compute net loss&lt;br/&gt;&#160;&#160;&#160;per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,631,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,856,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_4e368d5b-7663-4ef3-b1ec-80b85963871a"
      unitRef="U_USD">-113837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_498a3610-d3ac-4284-9ee0-3722d374b60d"
      unitRef="U_USD">-86075000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="0"
      id="F_ee963da6-9966-42a1-9b3f-31b40d77577f"
      unitRef="U_shares">43635044</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="0"
      id="F_60901f20-caf4-429c-b355-8f8f9aeb48b4"
      unitRef="U_shares">32901002</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <nktx:WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="0"
      id="F_50b8346b-bfe0-4385-8e38-593960517af4"
      unitRef="U_shares">-3322</nktx:WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions>
    <nktx:WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="0"
      id="F_4db75677-9b47-40b5-ba2d-7559c75e06b5"
      unitRef="U_shares">-44119</nktx:WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_a8e81621-45a6-4bfa-8ada-8a26e9adb31e"
      unitRef="U_shares">43631722</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_128f5e54-7df0-4847-b59a-f0e96aeb4cce"
      unitRef="U_shares">43631722</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="INF"
      id="F_028f0fbd-bfed-4571-83a8-df870b714482"
      unitRef="U_shares">32856883</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="INF"
      id="F_33147547-584e-44b1-898e-617cdad6474d"
      unitRef="U_shares">32856883</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="2"
      id="F_3b8334b4-494e-483b-b09a-fbfdd980148a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="2"
      id="F_066524d9-687c-48e4-95f1-b5f3b4aca2ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="2"
      id="F_9fb78351-957b-4b80-849b-6610c4532919"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="2"
      id="F_c6275885-280a-48c3-896f-fa0474791270"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_626c7975-143c-4592-b226-dd297e5b4da8">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.573%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.882%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.195%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,519,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,204,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested common stock upon early exercise of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,876,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,220,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_56c70c9b-2181-46db-b6a8-a17ab68f0f6e"
      decimals="0"
      id="F_91e9e08c-c728-46cc-a8ed-edc9be2da6d5"
      unitRef="U_shares">5519275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f5787b06-caba-4869-913a-d42e3e4d8626"
      decimals="0"
      id="F_928e8996-6ece-499f-8d0c-379c953b55c5"
      unitRef="U_shares">4204686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0c9c944a-ceec-4d30-8fa4-840b650e3911"
      decimals="0"
      id="F_16ec8046-41d5-4712-87dc-7cc18468df64"
      unitRef="U_shares">356728</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6a853c5f-fc86-43fd-bf06-21c2b2e36b23"
      decimals="0"
      id="F_d05b1327-8b6e-413b-8e48-6dfce4e55ab5"
      unitRef="U_shares">508</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b79def7d-c6df-41a1-bf0c-919f674fb2ff"
      decimals="0"
      id="F_7ebb90df-f9f1-4074-898e-5742d29bbb27"
      unitRef="U_shares">16181</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="0"
      id="F_a2cf122b-8819-4140-9fef-8e2868f8082c"
      unitRef="U_shares">5876511</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="0"
      id="F_87bd7a3c-dacb-479a-9916-570ec7e9d133"
      unitRef="U_shares">4220867</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_fb19b8b9-162e-4f61-b5e0-f6fd6ea85928">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the fair value of the Company&#x2019;s financial instruments (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.51%;"/&gt;
        &lt;td style="width:1.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.957%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.85%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.85%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.957%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant &lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;314,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;314,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;351,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;314,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.916%;"/&gt;
        &lt;td style="width:0.437%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.493%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.437%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.168%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.437%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.168%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.437%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant &lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents and Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets measured at fair value on a recurring basis consist of the Company&#x2019;s cash equivalents and short-term investments. Cash equivalents consisted of money market funds and short-term investments consisted of commercial paper, corporate debt securities and Government securities. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments are classified as Level 1 within the fair value hierarchy if their quoted prices are available in active markets for identical securities. Investments in money market funds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million included in cash equivalents as of December 31, 2022 and 2021, respectively, were classified as Level 1 instruments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments in corporate debt securities, commercial paper and Government securities included in short-term investments are valued using Level 2 inputs. Level 2 securities are initially valued at the transaction price and subsequently valued and reported upon utilizing inputs other than quoted prices that are observable either directly or indirectly, such as quotes from third-party pricing vendors. Fair values determined by Level 2 inputs, which utilize data points that are observable such as quoted prices, interest rates and yield curves, require the exercise of judgment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and use of estimates, that if changed, could significantly affect the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s short-term investments as of December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.958%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:14.279%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.109%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.097%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.297999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;315,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;314,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.958%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:14.279%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.109%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.097%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.297999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers whether unrealized losses have resulted from a credit loss or other factors. The unrealized losses on the Company&#x2019;s available-for-sale securities as of December 31, 2022 and 2021 were caused by fluctuations in market value and interest rates as a result of the economic environment and not credit risk. The Company concluded that an allowance for credit losses was unnecessary as of December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; It is neither management&#x2019;s intention to sell nor is it more likely than not that the Company will be required to sell these investments prior to recovery of their cost basis or recovery of fair value, except for investments totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million that were sold with a realized loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in January 2023. The Company recorded this $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as an impairment loss for the year ended December 31, 2022. Unrealized gains and losses are included in accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company excludes accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment and to not measure an allowance for expected credit losses for accrued interest receivables. Accrued interest receivable is written off through net realized investment gains (losses) at the time the issuer of the bond defaults or is expected to default on payment. It is the Company's policy to present the accrued interest receivable balance &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as part of prepaid expenses and other current assets in the balance sheets. Accrued interest receivable related to short-term investments was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_cd8995a7-b65b-42df-bccc-4cc6cf6775dc">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the fair value of the Company&#x2019;s financial instruments (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.51%;"/&gt;
        &lt;td style="width:1.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.957%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.85%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.85%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.957%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant &lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;314,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;314,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;351,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;314,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.916%;"/&gt;
        &lt;td style="width:0.437%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.493%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.437%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.168%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.437%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.168%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.437%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active Markets for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant &lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_7cc17ce6-8210-401d-9b4c-bc42958173af"
      unitRef="U_USD">36494000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_5d932bf8-0352-4715-adee-681c326862f1"
      decimals="-3"
      id="F_5fadf217-bb91-4b51-9c66-639eeded3c14"
      unitRef="U_USD">36494000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648"
      decimals="-3"
      id="F_aa88c07d-12f3-4776-aa72-c255de88e54b"
      unitRef="U_USD">88681000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_d61b13b8-5000-41ad-872b-a55642f66d70"
      decimals="-3"
      id="F_459eba88-90a5-4298-a74a-a5ee2dc6a4e8"
      unitRef="U_USD">88681000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_e8f4b60d-ae7d-4ecd-ad6a-e4de3f34ea9b"
      decimals="-3"
      id="F_a606f5fa-5792-4724-9375-1ca4c913a7c0"
      unitRef="U_USD">65409000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_62587f67-7720-4862-8bc3-ad2de14109b8"
      decimals="-3"
      id="F_6015a657-cb31-4d8f-8860-22f759b1e0e2"
      unitRef="U_USD">65409000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_ed817214-47bd-4dc1-80a6-cb7172f19a31"
      decimals="-3"
      id="F_8d53efb2-7bde-4eb6-908b-bcabe3aa9996"
      unitRef="U_USD">160559000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_7e5762e7-f7e7-4ca0-95b2-9a9aca43a951"
      decimals="-3"
      id="F_c08fcb8c-8ef4-4bde-a53e-add5cfb5ca86"
      unitRef="U_USD">160559000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_847594c2-47db-46c3-bc7c-e76e723d0c41"
      unitRef="U_USD">314649000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_d27112b2-cbb8-4700-a273-558f65b6fae8"
      decimals="-3"
      id="F_8d363366-d7f5-42cd-a6a3-b1bed7f4e1f5"
      unitRef="U_USD">314649000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_333d58b7-7f86-4410-a670-7260ae276e21"
      unitRef="U_USD">351143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5d932bf8-0352-4715-adee-681c326862f1"
      decimals="-3"
      id="F_875a129d-80f1-49fd-b2e0-0e2277c141c2"
      unitRef="U_USD">36494000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d27112b2-cbb8-4700-a273-558f65b6fae8"
      decimals="-3"
      id="F_10b343f9-200f-469c-9f6d-fee5f21c405c"
      unitRef="U_USD">314649000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_d2a63fa8-e11b-4495-bbd2-4ebb6317e861"
      unitRef="U_USD">57018000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_e12e22c5-6319-489d-998a-5a9b9f8b965c"
      decimals="-3"
      id="F_a8f7d061-5841-48d6-a603-9917433f0fd5"
      unitRef="U_USD">57018000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5"
      decimals="-3"
      id="F_0ce1fb2f-6ec1-413a-8807-b72cbe1c39d3"
      unitRef="U_USD">111466000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_9e12b052-9715-41fd-bddf-9db4bb8a1947"
      decimals="-3"
      id="F_0e1d5e01-b557-4121-a7a2-1206529f0e53"
      unitRef="U_USD">111466000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_23b5530e-7d65-4f89-a655-72c856a9b438"
      decimals="-3"
      id="F_e022a817-8aaa-4a3e-bca9-09d184e823f3"
      unitRef="U_USD">21272000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_71271a5b-183d-4f56-9d1b-7e8e195a7acb"
      decimals="-3"
      id="F_ae86f00f-b062-4a4e-af5b-b7da871f6247"
      unitRef="U_USD">21272000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_c494cf9e-deff-4d61-b7a3-4124b968194f"
      decimals="-3"
      id="F_761961bd-1d70-44d7-8660-8f6e3aa2ccf4"
      unitRef="U_USD">44534000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_9997cb7c-7d06-42b6-b7a1-bf97634ec016"
      decimals="-3"
      id="F_c52d3f8d-fe31-4b06-8806-483a9e8849c1"
      unitRef="U_USD">44534000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_93e8a60f-8413-4f88-b8dd-ea211b8f1a56"
      unitRef="U_USD">177272000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_b8ccfab3-765f-42cd-a915-348919b0824a"
      decimals="-3"
      id="F_b638d9f3-3c8a-4037-865f-d9a9615963d8"
      unitRef="U_USD">177272000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_08e4956d-e1bf-4987-824a-4dfcdd039492"
      unitRef="U_USD">234290000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e12e22c5-6319-489d-998a-5a9b9f8b965c"
      decimals="-3"
      id="F_257b6845-4100-4dc6-931f-e67437e5daa9"
      unitRef="U_USD">57018000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b8ccfab3-765f-42cd-a915-348919b0824a"
      decimals="-3"
      id="F_b3da0b11-0d59-45db-9de1-570107eaecb8"
      unitRef="U_USD">177272000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_24c0aaae-b891-4b96-8392-e3514173d5c6"
      decimals="-5"
      id="F_ca648bbf-e73b-476f-8d86-dd5e8ec445c6"
      unitRef="U_USD">36500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ac5b81a2-efd6-441c-b505-52b48bac16ee"
      decimals="-5"
      id="F_486fad1c-3e30-4659-a202-a055b6848568"
      unitRef="U_USD">57000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_88e987e9-14ae-4a55-adf7-c0657a837adb"
      id="F_7d1f0539-509c-4892-9f7b-d1f5c67ba822">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s short-term investments as of December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.958%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:14.279%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.109%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.097%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.297999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;315,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;314,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.958%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:14.279%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.109%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.183%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.097%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.297999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_d26a61da-14d4-4715-904f-6250145d2632"
      id="F_95a1e782-7f2a-4820-8d5d-e3d6d2ed14a9">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648"
      decimals="-3"
      id="F_1cfe24f4-a2a5-4ef8-8e8b-09b86c301c81"
      unitRef="U_USD">88995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648"
      decimals="-3"
      id="F_409e61c4-41b3-43bb-8f86-5430d551f820"
      unitRef="U_USD">320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648"
      decimals="-3"
      id="F_c893b841-e117-4e5d-8514-03246797365b"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7e62f1d0-b90c-4233-a6cc-e85a4ae9a648"
      decimals="-3"
      id="F_758b4a28-43a4-485d-9588-5033507da8fd"
      unitRef="U_USD">88681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_81bfa481-ab6e-4a60-9e7f-38e17ed8e269"
      id="F_75528e76-e668-4a5f-a23f-ae22edb55c8c">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_737c89a5-e439-47b8-8aaf-76cfec47c0ae"
      decimals="-3"
      id="F_0e774a02-9fb1-4398-85f3-fd06ca6ff029"
      unitRef="U_USD">65532000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_737c89a5-e439-47b8-8aaf-76cfec47c0ae"
      decimals="-3"
      id="F_d5dfdc04-e313-4544-8215-7b726e556fa1"
      unitRef="U_USD">123000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_737c89a5-e439-47b8-8aaf-76cfec47c0ae"
      decimals="-3"
      id="F_6aa6962e-af8b-435d-9bbd-1546079e5575"
      unitRef="U_USD">65409000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_583fcba6-1ff0-489b-a59a-27d2cc6bc251"
      id="F_a174b3ab-d944-41b4-8a54-0b6d57e70cf5">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_18f31adc-2623-483c-a5cc-71db7010cc81"
      decimals="-3"
      id="F_bbf1cde9-7d76-4a70-8116-d236c0f81a52"
      unitRef="U_USD">160801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_18f31adc-2623-483c-a5cc-71db7010cc81"
      decimals="-3"
      id="F_dc2754b4-0206-4ecb-9fba-ef5fe417dc2f"
      unitRef="U_USD">319000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_18f31adc-2623-483c-a5cc-71db7010cc81"
      decimals="-3"
      id="F_92c2e7e7-d703-4de5-a737-6510c3300baa"
      unitRef="U_USD">77000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_18f31adc-2623-483c-a5cc-71db7010cc81"
      decimals="-3"
      id="F_9df1d7ea-e72d-48b3-9744-77eb43a5383a"
      unitRef="U_USD">160559000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_b8452c17-2b4c-47bc-874d-18c984ed7ff2"
      unitRef="U_USD">315328000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_a979b4b6-5490-4119-9736-2a8837521a9b"
      unitRef="U_USD">762000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_4089727b-f90d-4c8c-9144-007a715aa517"
      unitRef="U_USD">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_4ebbab00-18de-49ee-b0b5-7827b460536c"
      unitRef="U_USD">314649000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_1bc72894-bc11-4b07-8e86-b0f46fc9cf6c"
      id="F_27371710-9f86-4918-9844-ac6f87531dd9">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5"
      decimals="-3"
      id="F_35e625a7-1ae8-4737-8a3a-83cb27d711a3"
      unitRef="U_USD">111548000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5"
      decimals="-3"
      id="F_d71d707c-4a0d-4da0-8360-7518fc470fdd"
      unitRef="U_USD">89000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5"
      decimals="-3"
      id="F_f4f5210d-627c-43f6-b891-e80ba6de01c1"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b847b099-3feb-4070-a061-cbb4d32913b5"
      decimals="-3"
      id="F_a10fddcf-e1f8-4a59-9eee-a980d8bd1f1c"
      unitRef="U_USD">111466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_3fec699f-ea28-4689-9337-687766f60d30"
      id="F_c69f2cc1-041c-4d6c-bafb-3c7db0bca99a">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3ad6f663-9c17-49d2-af22-eb2005f970e2"
      decimals="-3"
      id="F_26a13b20-3f67-4302-b9df-e165c675cdf8"
      unitRef="U_USD">21272000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3ad6f663-9c17-49d2-af22-eb2005f970e2"
      decimals="-3"
      id="F_d77e6040-0970-404b-84bd-5e874abc4489"
      unitRef="U_USD">21272000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_c7e114d6-1e43-4e3e-a721-90f9540d66a2"
      id="F_8d608220-d0e0-4323-8681-11b9894d022c">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d014bbfe-ee80-4fc5-925e-c46b0ee01917"
      decimals="-3"
      id="F_bf175a11-dd9c-4a86-a214-2186d3e75049"
      unitRef="U_USD">44602000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d014bbfe-ee80-4fc5-925e-c46b0ee01917"
      decimals="-3"
      id="F_4e05a6be-b9ff-4242-9fab-5d68150ad4e4"
      unitRef="U_USD">68000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d014bbfe-ee80-4fc5-925e-c46b0ee01917"
      decimals="-3"
      id="F_f905ed52-6da8-453b-ba8d-6aa036fa817c"
      unitRef="U_USD">44534000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_34b2bbb5-a6ff-4353-ad39-a6101efafa48"
      unitRef="U_USD">177422000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_27dd4ab8-2cd8-40ee-9932-b73ebf706945"
      unitRef="U_USD">157000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_68d22c4b-c99b-4fef-9aa6-2324c28394e6"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_01a8ff62-7041-4ac3-8a5d-09737c3493aa"
      unitRef="U_USD">177272000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableforsaleSecuritiesSoldAtPar
      contextRef="C_bd5a17ec-15ba-48c4-a69b-663e0936c2fc"
      decimals="-5"
      id="F_15b8373d-e294-4e79-a30f-8ddaf9e099fc"
      unitRef="U_USD">67600000</us-gaap:AvailableforsaleSecuritiesSoldAtPar>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_bd5a17ec-15ba-48c4-a69b-663e0936c2fc"
      decimals="-5"
      id="F_32e03d96-f330-4305-8aa9-712e3c12d199"
      unitRef="U_USD">300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <nktx:Impairments
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-5"
      id="F_9a8d47ca-d413-4904-b510-16921c75df3f"
      unitRef="U_USD">300000</nktx:Impairments>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_3a8087e1-63e7-4651-bc43-c16820cff537"
      decimals="-5"
      id="F_cb25c1a2-f5d4-4810-8f8e-6e35bd181549"
      unitRef="U_USD">800000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_de1b3fd2-437c-46d9-9d40-3096dc12b8c7"
      decimals="-5"
      id="F_529b2aac-3c85-4dc9-ba40-3be03aa552f9"
      unitRef="U_USD">1000000.0</us-gaap:InterestReceivableCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_a4518eba-914a-48c2-9957-3a57176cb0e5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets are comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.759%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.853%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.161999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;P&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;roperty and equipment, net is comprised of the following (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.599%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computers and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization expense were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued and other current liabilities are comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.759%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.853%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.161999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued and current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <nktx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_e58e0066-e339-4b8c-bec1-29301170e3d5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets are comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.759%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.853%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.161999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</nktx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_71184a43-e06d-410b-a99c-fd6729b9f2dc"
      unitRef="U_USD">5616000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_b477b7e3-4eaa-488d-8978-b6ec123b783a"
      unitRef="U_USD">4538000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_09476528-0121-4c9f-a2ad-1e951d706a7d"
      unitRef="U_USD">2929000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_307d2114-cff3-4ab9-a25a-5423b4004d6d"
      unitRef="U_USD">3154000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_af0a1dd9-e0f8-46fa-99a0-109ac55243e8"
      unitRef="U_USD">8545000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_f315b8c2-a262-4a27-ba94-229e276388f5"
      unitRef="U_USD">7692000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_5147a44a-044a-401f-90c4-45403c911787">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;roperty and equipment, net is comprised of the following (in thousands):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.599%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computers and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ed03bf83-d13d-4a93-9a1b-a266f8faf400"
      decimals="-3"
      id="F_fa598145-21aa-49c9-aedb-753b5730f958"
      unitRef="U_USD">4402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d8d0678a-6dba-4324-ac26-5b00dadee7ad"
      decimals="-3"
      id="F_965b38cc-d561-45a9-9c10-2ea3e92f8314"
      unitRef="U_USD">3462000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a6a22efc-c313-4977-a01d-0fa7148647f3"
      decimals="-3"
      id="F_1e282a62-8f88-4574-86ac-7ed1ed879034"
      unitRef="U_USD">645000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2c954c54-02fd-4743-8a11-058f3cf49640"
      decimals="-3"
      id="F_d5dfa4af-fdc8-41aa-8b43-9db6a3b99466"
      unitRef="U_USD">544000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6595a8da-7252-4dae-89c8-5653af52ef0a"
      decimals="-3"
      id="F_850d7279-5e43-4220-99b5-78709dd50106"
      unitRef="U_USD">12900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_26bd2db9-3e16-458f-8423-a038b4619fe9"
      decimals="-3"
      id="F_ea877f48-6112-4020-bf76-ece3cbec9d67"
      unitRef="U_USD">9633000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3983a133-278f-4146-b005-921fbc2b18af"
      decimals="-3"
      id="F_91f4d483-24a9-466a-8607-cf1ce7db245d"
      unitRef="U_USD">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_43a91ef6-617a-4181-b769-aa8b7eeac784"
      decimals="-3"
      id="F_c8ad5cda-9452-423c-8367-9f972fcce8ec"
      unitRef="U_USD">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_46288b47-1afa-44f0-be59-d2f91c284d71"
      decimals="-3"
      id="F_d07d84e4-7075-40a1-b13e-a51522f085c6"
      unitRef="U_USD">49655000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2914dfc3-b00d-4a26-95ed-1856d75544a6"
      decimals="-3"
      id="F_30d45e90-d908-4e18-9b76-bc0e6b79e290"
      unitRef="U_USD">2274000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_33cb961d-c9c4-4a29-bda5-c4026eacaaa1"
      unitRef="U_USD">67732000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_02be0ed0-44c3-4be4-81cb-dcd5cf222ed3"
      unitRef="U_USD">16043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_97d5cbbd-7dc2-4444-9f93-856c6b71bb5c"
      unitRef="U_USD">5824000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_38bcff42-157f-4afa-94fe-66a49cc69b87"
      unitRef="U_USD">3187000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_873c9fbe-9da6-4283-9fa1-b74d8ed46aea"
      unitRef="U_USD">61908000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_0b3c4a43-542e-4a1f-809e-9e075b8bf04d"
      unitRef="U_USD">12856000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-5"
      id="F_40bc969e-be4e-434e-bec8-bb63cd3796f1"
      unitRef="U_USD">2600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-5"
      id="F_f11c2930-877d-4f58-92bd-90ac62421b1f"
      unitRef="U_USD">1800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_684c883b-b83d-4cac-919d-e6c1fcd3d6c0">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued and other current liabilities are comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.759%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.853%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.161999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued and current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_249f42e7-6a5a-4caf-9bbf-1703e0a817bc"
      unitRef="U_USD">6691000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_91701ce7-f2ef-4d48-a6d8-f68a2b6b014e"
      unitRef="U_USD">5453000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktx:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_9621b491-b1fd-4161-ad8d-47fbdc06c7f3"
      unitRef="U_USD">3486000</nktx:AccruedResearchAndDevelopmentCostsCurrent>
    <nktx:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_db498929-0dd8-4125-8a56-c2680ea12981"
      unitRef="U_USD">2280000</nktx:AccruedResearchAndDevelopmentCostsCurrent>
    <nktx:AccruedPropertyAndEquipmentLiabilitiesCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_9b0cc00d-9c16-436b-91d6-f93d684f3861"
      unitRef="U_USD">5001000</nktx:AccruedPropertyAndEquipmentLiabilitiesCurrent>
    <nktx:AccruedPropertyAndEquipmentLiabilitiesCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_80d8dac8-26e2-4fa6-b2a2-bc8f34cf6378"
      unitRef="U_USD">96000</nktx:AccruedPropertyAndEquipmentLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_c92c84e3-196b-4bdb-b963-3e30c83e9bb2"
      unitRef="U_USD">858000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_1f6a2169-29b5-430f-9e14-8edd55fa28a1"
      unitRef="U_USD">1518000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_5f48ffe0-abfc-48e0-b267-0b0f23f61045"
      unitRef="U_USD">16036000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_730e9d91-2c3a-453c-ac95-adce6c9db1a3"
      unitRef="U_USD">9347000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_ad4e1e74-6218-43c5-94ff-b688e7846b07">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has operating leases for its current corporate offices, laboratory space, manufacturing facility, and dedicated space in a vivarium in South San Francisco, California, as well as for an additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.752%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.851%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.16%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease expense &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-2.557%;padding-left:2.507%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  Variable lease expense for the periods presented primarily included common area maintenance charges.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental information related to operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.752%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.851%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.16%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average remaining lease term was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years for the corporate office and laboratory space leases as of December 31, 2022. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The corporate office lease includes an option to renew for an additional seven years. However, the renewal option was not included in the lease term for calculating the lease liability, as the renewal option allows the Company to maintain operational flexibility, and the Company was not reasonably certain&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;that it would exercise the renewal option at the time of the lease commencement. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average discount rate was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases and from modifications of existing leases, respectively, for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities of operating lease liabilities under existing operating leases as of December 31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.968%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.093%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less tenant improvement receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2018, the Company entered into a lease agreement for its corporate office and laboratory space located in South San Francisco, California with an expiration date in May &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;"Initial Lease Agreement"&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2019, the Company executed the first amendment to the Initial Lease Agreement for additional corporate space, laboratory space and manufacturing capabilities and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;an extension&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to the lease term through April 2026. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2020, the Company signed a second amendment to the Initial Lease Agreement. The amended lease provides for an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;eight-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; non-cancelable lease of additional office and laboratory space in the same building. The lease amendment for additional office and laboratory space provided for abatement of rent during the first three months of the lease and contains rent escalations during the term of the lease. The lease for this additional space commenced in January 2021 and expires in January &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease amendment also includes an extension of the lease term for the existing office and laboratory space beginning on May 1, 2020 and expiring in January 2029. The amendment to the Initial Lease Agreement also includes an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the lease for an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2021, the Company signed a third amendment to the Initial Lease Agreement which provides for the lease of additional space in the same building. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease amendment for this additional space commenced in April 2021 and expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2021, the Company signed a fourth amendment to the Initial Lease Agreement which provides for the lease of additional space in the same building. The lease for additional office and laboratory space provides for abatement of rent during the first two months of the lease and contains rent escalations during the term of the lease. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease amendment of this additional space commenced in April 2022 and expires in January &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The lease amendment also includes this additional space in the Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the amended Initial Lease Agreement for an additional seven-year term.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The other terms of the Initial Lease Agreement, as amended, remain unchanged.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2021, the Company entered into a lease agreement for corporate office, manufacturing and laboratory space located in South San Francisco, California with an expiration date approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;twelve years &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;after the lease's legal commencement date (the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;"Additional Lease Agreement"&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease for this additional space and the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company's &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;obligation to pay rent commenced in January 2022. In addition to base rent, the Company is responsible for payment of direct expenses, which include operating, insurance and tax expenses. The lease also provides for certain tenant improvement allowances of up to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for tenant improvements and certain infrastructure upgrades in connection with the initial buildout of the premises, approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of which, if utilized, would need to be repaid by the Company over the lease term. In 2021, the Company delivered a security deposit in the form of a letter of credit o&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;f $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; mi&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;llion to the Landlord in connection with the Additional Lease Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the Company entered into an amendment to the Additional Lease Agreement. The lease amendment expressly includes manufacturing as a permitted use at the facility, clarifies that Silicon Valley Bank is an acceptable bank for purposes of issuing a letter of credit under the lease, revises the letter of credit transferability terms and replaces the form of letter of credit attached to the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2022, the Company entered into fifth amendment to the Initial Lease Agreement and a second amendment to the Additional Lease Agreement for its existing facilities in South San Francisco, California. The fifth amendment to the Initial Lease Agreement includes an extension of the lease term for certain of the Company's existing facilities through July 31, 2030. The second amendment to the Additional Lease Agreement provides for approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of additional tenant improvement allowances, in addition to the tenant improvement allowances of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million included in the original Additional Lease Agreement, and increases the base rent payments over the existing term of the lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_a206aa47-2052-42a7-b2e9-c055f9889792">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.752%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.851%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.16%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease expense &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-2.557%;padding-left:2.507%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  Variable lease expense for the periods presented primarily included common area maintenance charges.&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_3a42334d-59bd-4dda-8fd4-5dbc1bb29fc0"
      unitRef="U_USD">11220000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_9f6f1a49-7fed-477e-8f7e-7f663c3768ee"
      unitRef="U_USD">2581000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_2b0d020a-59d2-4e8d-9636-bb7167ae0f37"
      unitRef="U_USD">462000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_c4912a96-9a5c-4368-9c1e-8c2bfb3d4802"
      unitRef="U_USD">302000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_71ca7e2e-0b57-4751-a787-901d5f52b68f"
      unitRef="U_USD">45000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_4f716a81-fbd5-42d9-81a0-1dbced75a17e"
      unitRef="U_USD">92000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_c0d8201d-6310-432f-9ad6-4a90d1854662"
      unitRef="U_USD">11727000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_88c9f0dd-92c5-4022-a537-e14e88610038"
      unitRef="U_USD">2975000</us-gaap:LeaseCost>
    <nktx:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_f2938ad9-e594-4cc5-889a-51cd44b4fc27">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental information related to operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.752%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.851%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.16%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</nktx:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_b7523c3c-b727-4818-a654-ed59be001dbc"
      unitRef="U_USD">6887000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_c7e1819e-093a-403a-9f3c-43e78bc78790"
      unitRef="U_USD">2239000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_2ffabe62-fbe5-446e-b9de-8398a5aa0a92"
      id="F_bdff1599-c311-4683-9e5e-87dfd7646350">P10Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="3"
      id="F_a5092ee0-07b2-421f-b21e-02a1e102bb9d"
      unitRef="U_pure">0.098</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <nktx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-5"
      id="F_390cc75c-5722-4972-b11a-fdbb93f67669"
      unitRef="U_USD">59500000</nktx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases>
    <nktx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-5"
      id="F_95719281-092f-4f31-8382-e02185750673"
      unitRef="U_USD">18700000</nktx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_05cfb7e8-6c93-467c-bbe3-2ae22d05ba63">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities of operating lease liabilities under existing operating leases as of December 31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.968%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.093%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total undiscounted future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less tenant improvement receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_226af516-437e-441d-bedf-34b035474231"
      unitRef="U_USD">11206000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_e928ab24-3511-42ec-a337-502ab25f31a8"
      unitRef="U_USD">12671000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_046ccf90-9eed-4093-9ac0-f8647a9f0300"
      unitRef="U_USD">13033000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_7a2b7bee-3120-495f-94d6-abc610321e31"
      unitRef="U_USD">13467000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_c88a0f74-021d-43dd-89f5-b9b35d64d0a8"
      unitRef="U_USD">13917000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_204c3623-c497-45e9-beef-f8f66c2dc0ff"
      unitRef="U_USD">87290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_7f869702-61c1-4956-8753-c41ae5f63990"
      unitRef="U_USD">151584000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_6466930d-b6e7-4fbc-8370-560c576ed1b0"
      unitRef="U_USD">60813000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <nktx:TenantImprovementReceivable
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_63c73621-0ea3-4cf3-bbc6-b4dfa14333f3"
      unitRef="U_USD">-7837000</nktx:TenantImprovementReceivable>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_6778643e-7887-4a0b-ac50-7fb98bcb3a7c"
      unitRef="U_USD">82934000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_c3fdd34b-8485-44bc-b2a3-28dd56cdcded"
      unitRef="U_USD">4249000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_910f78ac-17f2-4ced-9be0-a03c63549a24"
      unitRef="U_USD">78685000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_287f88d0-b51a-4f4b-9b0a-0aa643468e8c"
      unitRef="U_USD">82934000</us-gaap:OperatingLeaseLiability>
    <nktx:LeaseExpirationYear
      contextRef="C_d1fc9433-2e3d-4914-a5c8-bc7a7bff7abf"
      id="F_ac46f93b-84da-49c6-8839-40338f138aa2">2025</nktx:LeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_52762d64-2657-4a85-b085-9b43b6ef6b2d"
      id="F_f6d54e9a-8d69-48de-b20a-b7798b13721b">In April 2019, the Company executed the first amendment to the Initial Lease Agreement for additional corporate space, laboratory space and manufacturing capabilities and an extension to the lease term through April 2026. </us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_e7e05b12-6998-4ee3-a819-f951b803d26c"
      id="F_81164e46-cac2-4ba7-9a76-01b9fe1381e6">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_0dbf8ba2-16eb-4d47-8a53-2bcd7625019d"
      id="F_e69a77e3-93c9-47b6-9f16-c5689b49ad8c">P8Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <nktx:LeaseExpirationYear
      contextRef="C_59d64f92-ff2e-4690-bf99-cc3623e46e80"
      id="F_4ae5b06e-4516-4307-8402-acd40c03110f">2029</nktx:LeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_99a492e6-fb70-4aea-a41e-5b84273ea158"
      id="F_fa665cec-2f27-42c3-813f-dca68be4e396">The lease amendment also includes an extension of the lease term for the existing office and laboratory space beginning on May 1, 2020 and expiring in January 2029. The amendment to the Initial Lease Agreement also includes an option to extend the lease for an additional seven-year term.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_59d64f92-ff2e-4690-bf99-cc3623e46e80"
      id="F_157afab4-63a6-4442-bcb4-f8284012cee5">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_9766f258-dd51-4457-9526-56fe0bcb58d8"
      id="F_99fceea9-17e4-4870-bf3e-c0e154facb15">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_b68d2390-4372-4de3-9b47-180a4a7b91f9"
      id="F_266e6344-0fcf-4c98-ad9b-5ddfa1090a6d">The lease amendment for this additional space commenced in April 2021 and expires in March 2024.</us-gaap:LesseeOperatingLeaseDescription>
    <nktx:LeaseExpirationMonthAndYear
      contextRef="C_bdd7e725-4ef2-4276-b95f-8ec6ebdac396"
      id="F_f426bc54-ee18-4909-b808-6e5b96ecb629">2024-03</nktx:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_c452dd17-c870-489d-8326-cf1262b803dc"
      id="F_9b0ea8b8-ec1d-4711-960e-c38a825f7f6b">The lease amendment of this additional space commenced in April 2022 and expires in January 2029. The lease amendment also includes this additional space in the Company&#x2019;s option to extend the amended Initial Lease Agreement for an additional seven-year term.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <nktx:LeaseExpirationYear
      contextRef="C_c452dd17-c870-489d-8326-cf1262b803dc"
      id="F_a80154c7-3820-4f59-863a-17febdadfd19">2029</nktx:LeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_c452dd17-c870-489d-8326-cf1262b803dc"
      id="F_26347c69-9a91-47bc-90ef-e57714ac764f">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_00c5bf6f-2fc6-4028-b703-d38c7fb1eb15"
      id="F_e0e1895f-b3c0-4a9b-a559-44626e12679b">P12Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <nktx:TenantImprovementsYetToReceiveFromLessor
      contextRef="C_b77baa8f-96a7-406d-a97a-325fd5089207"
      decimals="-5"
      id="F_0a7062c7-e4b2-48db-bcb8-f9079f5e62ab"
      unitRef="U_USD">25200000</nktx:TenantImprovementsYetToReceiveFromLessor>
    <nktx:CashReceivedForTenantImprovementAllowancesToBeRepaid
      contextRef="C_d5727518-e2f1-4921-a234-816384299bb5"
      decimals="-5"
      id="F_c4ebb1ef-6999-4922-a11a-0dcb300f10c7"
      unitRef="U_USD">4400000</nktx:CashReceivedForTenantImprovementAllowancesToBeRepaid>
    <us-gaap:SecurityDeposit
      contextRef="C_4adcd202-22d8-4ab3-b561-2ff39d168d3f"
      decimals="-5"
      id="F_22bae3a6-8f8a-45e7-9272-ddc526a4a6a4"
      unitRef="U_USD">1600000</us-gaap:SecurityDeposit>
    <nktx:AdditionalTenantImprovementAllowances
      contextRef="C_6f2f80b9-36c3-4ae7-b0df-62a4197809a3"
      decimals="-5"
      id="F_9b49ef2d-467f-4902-ac0d-dfee29bac743"
      unitRef="U_USD">15000000.0</nktx:AdditionalTenantImprovementAllowances>
    <nktx:TenantImprovementsYetToReceiveFromLessor
      contextRef="C_0f472547-d9cb-42a2-9d4b-f15637efe5f6"
      decimals="-5"
      id="F_c911700a-681c-49cf-97e0-6af99cf8769d"
      unitRef="U_USD">25200000</nktx:TenantImprovementsYetToReceiveFromLessor>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_a7722cb4-5edd-41a8-b891-bf5a59f90fea">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Guarantee Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#x2019;s request in such capacity. The term of the indemnification period is for the officer&#x2019;s or director&#x2019;s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts under certain circumstances and subject to deductibles and exclusions. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; liabilities recorded for these agreements as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Letters of Credit&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in letter of credit agreements with a financial institution that are used as collateral for the Company&#x2019;s corporate headquarters&#x2019; operating lease and the additional facility in South San Francisco that the Company plans to use for corporate offices, laboratories and manufacturing. The letters of credit automatically renew annually without amendment unless cancelled by the financial institutions within &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the annual expiration date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="INF"
      id="F_4c27ff41-7840-4fcd-8257-82edc0ba9910"
      unitRef="U_USD">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_bb29f82f-f580-4160-bde6-5c8750f26e62"
      unitRef="U_USD">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_d89cf241-714f-47ac-b0fd-90fc206d8545"
      decimals="-5"
      id="F_fac4dc5d-b181-4949-8c0e-0b6f1e7b6535"
      unitRef="U_USD">2700000</us-gaap:LettersOfCreditOutstandingAmount>
    <nktx:LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate
      contextRef="C_2c1cfa1c-67c5-4c85-a0df-ba0a03295212"
      id="F_499bfcfa-fbbf-4dee-ba16-cda4e2927270">P30D</nktx:LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate>
    <nktx:LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate
      contextRef="C_54a727df-02a6-4bb0-88ff-9fcf2ef7503f"
      id="F_8f3dc299-8e5b-4fe1-b2be-a714782ae1f1">P60D</nktx:LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_0e58d3da-5b22-4f23-afc6-9dd5f7a0a03b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. Collaboration and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;CRISPR Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 5, 2021, the Company entered into the CRISPR Agreement with CRISPR to co-develop and co-commercialize an engineered CAR NK product candidate targeting the CD70 tumor antigen and a second novel NK plus T cell product candidate. In addition, the Company has received licenses from CRISPR for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; CRISPR-Cas9 gene editing targets and will receive a license from CRISPR for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; more CRISPR-Cas9 gene editing targets that can be engineered into an unlimited number of its own NK cell products. CRISPR also has an option to co-develop and co-commercialize a future CAR NK program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the terms of the CRISPR Agreement, the Company and CRISPR share equally in all research and development costs and potential profits worldwide related to the NKX070 product candidate, NK+T product candidate, and the potential future CAR NK program. For the NK+T program, CRISPR is responsible for gene-editing activities and T cell related activities, and Nkarta is responsible for NK cell related activities. The related impact of the cost sharing associated with the research and development activities is included in research and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;development &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;expense on the condensed statements of operations. Expenses related to services performed by the Company are classified as research and development expense. Payments received from CRISPR for partial reimbursement of expenses are recorded as a reduction of research and development expense. Reduction of research and development expense resulting from partial reimbursement from CRISPR was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the Company had a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million receivable under the research cost sharing provision, which is included as part of prepaid expenses and other current assets in the condensed balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ea&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ch non-collaboration product candidate incorporating a genome editing target licensed from CRISPR (a "CRISPR-licensed product candidate"), the Co&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;mpany&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; would retain worldwide rights and may be required to make potential future payments based on the achievement of development and regulatory approval milestones &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;totaling less than mid-twenty million dollars&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for each CRISPR-licensed product candidate, as well as tiered royalties up to the mid-single digits on net product sales of such product. Further, for each CRISPR-licensed product candidate targeting a specified tumor antigen, the Company may be required to make potential future payments based on the achievement of development and regulatory approval milestones totaling less than high-forty million dollars&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for each CRISPR-licensed product candidate targeting the specified tumor antigen, as well as tiered royalties up to the mid-single digits on net product sales of such product. As of December 31, 2022, the Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t paid any amounts &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;r are any amounts owed by the Company under the CRISPR Agreement, and no milestones have been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;MaxCyte License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 26, 2021, the Company entered into a license agreement (the "MaxCyte Agreement") with MaxCyte, Inc. ("MaxCyte") to obtain non-exclusive clinical and commercial rights to use MaxCyte's cell loading technology to develop and commercialize in up to ten licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the MaxCyte Agreement, the Company must pay to MaxCyte annual research license fees and commercialization license fees, ranging from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, for each instrument licensed by the Company. Further, the Company could be required to make milestone payments to MaxCyte upon completion of certain regulatory and commercial milestones related to the clinical development and commercialization of certain of the Company&#x2019;s licensed products. The aggregate potential milestone payments range from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per licensed product. Additionally, the Company may be required to make net sales milestone payments totaling between $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per licensed product. As of December 31, 2022, no milestones have been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;University of Singapore and St. Jude Children&#x2019;s License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2016, the National University of Singapore ("NUS") and St. Jude Children&#x2019;s Research Hospital ("St. Jude") and the Company entered into a license agreement under which NUS and St. Jude (the "Licensors") granted the Company an exclusive, royalty-bearing, worldwide license to its patent rights related to a method for expanding natural killer cells; a chimeric receptor with NKG2D specificity; and a method for supporting autonomous natural killer cell function ("NUS and St. Jude License Agreement"). The NUS and St. Jude License Agreement provides the Company with the rights to grant and authorize sublicenses to make, have made, use, sell, offer for sale and import products and otherwise exploit the patent rights.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the license, the Company made an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,800&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and issued NUS &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. The Company determined that the upfront payment (SGD &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) and value of the common stock issued ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; based on fair value at time of issuance) as part of the license agreement would be expensed upon execution of the contract as the license was acquired for research and development purposes which does not have alternative future uses, and the underlying technology has not reached technological feasibility, hence the Company expensed these costs during 2016.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, the Company is required to pay an annual license maintenance fee of SGD &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, increasing to SGD &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; after &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year two of the agreement. Further, the Company could be required to make milestone payments to the Licensors upon completion of certain regulatory and commercial milestones related to the clinical development and commercialization of certain of the Company&#x2019;s product candidates. The aggregate potential&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;milestone &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;payments are approximately SGD &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company has also agreed to pay the Licensors royalties of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of net sales of products sold by the Company or through a sublicense. Additionally, the Company agreed to pay the Licensors a tiered percentage of sublicensing income (ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%) based on the timing of capital raised and stage of clinical trials. The NUS and St. Jude License Agreement also includes certain performance objectives which obligate the Company to meet various milestones related to the clinical development and commercialization of certain of the Company&#x2019;s product candidates over time for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; after the effective date of the NUS and St. Jude License Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; license maintenance fees included as part of research and development expenses for each of the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nktx:NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived
      contextRef="C_1068e57e-6f93-49e0-ba99-d2c70b9915f6"
      decimals="INF"
      id="F_b15f81bf-119e-4530-b430-ab7514b4c520"
      unitRef="U_CrisprCas9">3</nktx:NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived>
    <nktx:NumberOfNonExclusiveRightsToGeneEditingTargets
      contextRef="C_0abf9930-6b9d-43f1-bcde-e0a41387b2cd"
      decimals="INF"
      id="F_9657f305-2365-4bda-bea5-b6295105cac3"
      unitRef="U_CrisprCas9">2</nktx:NumberOfNonExclusiveRightsToGeneEditingTargets>
    <nktx:ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement
      contextRef="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9"
      decimals="-5"
      id="F_0b6a8793-f608-4434-94d2-b59c4494c4eb"
      unitRef="U_USD">4200000</nktx:ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement>
    <nktx:ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement
      contextRef="C_a6bef3a2-7f1b-4b5f-99b7-d7a3e86365c0"
      decimals="-5"
      id="F_780a552b-2be3-459b-a825-295ec19ef044"
      unitRef="U_USD">2300000</nktx:ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement>
    <nktx:ReceivableUnderResearchCostSharingProvision
      contextRef="C_176fb4da-b4be-4abb-b573-31f43872e49d"
      decimals="-5"
      id="F_330856b4-2624-4770-8e54-d20718b0d3e0"
      unitRef="U_USD">1300000</nktx:ReceivableUnderResearchCostSharingProvision>
    <nktx:PotentialFuturePaymentsBasedOnAchievementOfMilestones
      contextRef="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9"
      id="F_34e547d7-c9a5-4f65-8b29-477886556173">totaling less than mid-twenty million dollars</nktx:PotentialFuturePaymentsBasedOnAchievementOfMilestones>
    <nktx:PaymentsMadeUnderCollaborativeArrangement
      contextRef="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9"
      decimals="INF"
      id="F_b5336f99-81c7-4c60-bc79-3dfc9f97da7a"
      unitRef="U_USD">0</nktx:PaymentsMadeUnderCollaborativeArrangement>
    <nktx:AmountsOwedUnderAgreement
      contextRef="C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9"
      decimals="INF"
      id="F_55cb52a2-e963-43fe-a9b0-3b8efba75891"
      unitRef="U_USD">0</nktx:AmountsOwedUnderAgreement>
    <nktx:AnnualResearchLicenseFeesAndCommercializationLicenseFees
      contextRef="C_5e4795d5-2002-4904-a3ea-f02d9bec752b"
      decimals="INF"
      id="F_600fe0ca-c92a-4b9d-aca6-dfe6c6d8027b"
      unitRef="U_USD">100000</nktx:AnnualResearchLicenseFeesAndCommercializationLicenseFees>
    <nktx:AnnualResearchLicenseFeesAndCommercializationLicenseFees
      contextRef="C_7e258be6-92d4-4784-8087-1c605ecf79d1"
      decimals="INF"
      id="F_03dda348-5866-4295-ae7c-0eb32b81cfc6"
      unitRef="U_USD">300000</nktx:AnnualResearchLicenseFeesAndCommercializationLicenseFees>
    <nktx:PotentialMilestonePayments
      contextRef="C_5e4795d5-2002-4904-a3ea-f02d9bec752b"
      decimals="INF"
      id="F_c64d96e1-fd11-4355-8102-ac1780f60834"
      unitRef="U_USD">10000000</nktx:PotentialMilestonePayments>
    <nktx:PotentialMilestonePayments
      contextRef="C_7e258be6-92d4-4784-8087-1c605ecf79d1"
      decimals="INF"
      id="F_a6d91e6a-f2a6-4ceb-8d4f-dc40773039ab"
      unitRef="U_USD">13000000</nktx:PotentialMilestonePayments>
    <nktx:NetSalesMilestonePayments
      contextRef="C_5e4795d5-2002-4904-a3ea-f02d9bec752b"
      decimals="INF"
      id="F_3142c0e8-5dc4-47fb-97a2-4947273d4c9d"
      unitRef="U_USD">61900000</nktx:NetSalesMilestonePayments>
    <nktx:NetSalesMilestonePayments
      contextRef="C_7e258be6-92d4-4784-8087-1c605ecf79d1"
      decimals="INF"
      id="F_d363f75e-2327-483d-a38a-490d90c4304f"
      unitRef="U_USD">116800000</nktx:NetSalesMilestonePayments>
    <nktx:LicenseAgreementUpfrontPayment
      contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931"
      decimals="0"
      id="F_d76be6bb-0436-4765-942f-60903402e48d"
      unitRef="U_USD">31800</nktx:LicenseAgreementUpfrontPayment>
    <nktx:StockIssuedDuringPeriodSharesIssuedUpfrontPayments
      contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931"
      decimals="INF"
      id="F_45a3c760-82ad-4438-90f7-2996bb714500"
      unitRef="U_shares">250000</nktx:StockIssuedDuringPeriodSharesIssuedUpfrontPayments>
    <nktx:LicenseAgreementUpfrontPayment
      contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931"
      decimals="0"
      id="F_12bb6b9a-f00a-4e6e-a799-a40834513033"
      unitRef="U_SGD">42750</nktx:LicenseAgreementUpfrontPayment>
    <nktx:FairValueOfCommonStockIssued
      contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931"
      decimals="0"
      id="F_e7a2f483-903f-49b8-8c24-cfd617b15f39"
      unitRef="U_USD">2500</nktx:FairValueOfCommonStockIssued>
    <nktx:AnnualLicenseMaintenanceFee
      contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931"
      decimals="0"
      id="F_d65d3074-269c-40c1-9dd3-4f6aa21fb4bc"
      unitRef="U_SGD">25000</nktx:AnnualLicenseMaintenanceFee>
    <nktx:AnnualLicenseMaintenanceFee
      contextRef="C_b32eb187-1110-42c8-a989-031bf9074bfb"
      decimals="0"
      id="F_d435a8fe-403f-4bd6-b86d-4f49e9b421cb"
      unitRef="U_SGD">50000</nktx:AnnualLicenseMaintenanceFee>
    <nktx:PotentialMilestonePayments
      contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931"
      decimals="-6"
      id="F_ca77a2f8-6482-4fa0-a923-0466dac340e2"
      unitRef="U_SGD">5000000</nktx:PotentialMilestonePayments>
    <nktx:PercentageOfLicensorsRoyalties
      contextRef="C_b01db192-8bff-49f9-aa8a-eb072e8e8931"
      decimals="3"
      id="F_5e9c350d-37f4-4e4f-a6e3-ee90830476e4"
      unitRef="U_pure">0.025</nktx:PercentageOfLicensorsRoyalties>
    <nktx:PercentageOfSublicensingIncome
      contextRef="C_98fde113-4079-4ef0-aed0-57bc5371b89d"
      decimals="3"
      id="F_80b03ed5-e103-49ec-aa25-0a43f1a9e169"
      unitRef="U_pure">0.075</nktx:PercentageOfSublicensingIncome>
    <nktx:PercentageOfSublicensingIncome
      contextRef="C_96c15272-baf2-49fd-8372-c7699ec34602"
      decimals="2"
      id="F_83b2bc1b-18dd-4239-b60f-2118b3e6f9b9"
      unitRef="U_pure">0.20</nktx:PercentageOfSublicensingIncome>
    <nktx:LicenseAgreementTerm
      contextRef="C_96c15272-baf2-49fd-8372-c7699ec34602"
      id="F_3dd3509b-26df-43a3-afb0-36f35f45e441">P120M</nktx:LicenseAgreementTerm>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_740287c6-87bc-41cd-9f00-710fff88daae"
      decimals="0"
      id="F_8c1e2ffc-3e34-4a3f-8360-8e42ebd314a2"
      unitRef="U_USD">37000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3a1834a9-94f0-4aab-abd5-ebb33501f4c8"
      decimals="0"
      id="F_8bab6f7d-5e91-4df7-b4ca-62392bc89830"
      unitRef="U_USD">37000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_23e019b8-6d97-48f3-88a7-24fb44711fa8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. Employee Benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 1, 2018, the Company adopted a defined contribution 401(k) plan that is available to eligible employees. &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. As part of the plan, the Company elected to make non-matching contributions via mandatory &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of compensation safe harbor nonelective contributions. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for expense related to the nonelective 401(k) contributions for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
      contextRef="C_1eb2f144-5565-4350-a09a-b2ab343aade0"
      id="F_78b340ce-6095-45c5-8620-f0fc40c1c5a2">On January 1, 2018, the Company adopted a defined contribution 401(k) plan that is available to eligible employees. </us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_1eb2f144-5565-4350-a09a-b2ab343aade0"
      decimals="2"
      id="F_d8bc000e-4504-47ca-b748-6aaa07343fe5"
      unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_1eb2f144-5565-4350-a09a-b2ab343aade0"
      decimals="-5"
      id="F_5dca5679-3b39-465e-9624-9e3853667ef3"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_6be6113f-92b4-4ee7-a950-89b44b4f6055"
      decimals="-5"
      id="F_fc4c08f4-6cf9-49a2-9563-1b530eda1d6f"
      unitRef="U_USD">600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_a70de548-e6cd-45f3-ae9c-68b5fa63a6c5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Amended and Restated Certificate of Incorporation dated July 14, 2020, the Company had a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; authorized shares of common stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,350,179&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; authorized shares of preferred stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 12, 2021, the Company filed a Registration Statement on Form S-3 (the "Shelf Registration Statement"), covering the offer and sale from time to time, pursuant to Rule 415 of the Securities Act of 1933, as amended (the "Securities Act"), of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in aggregate offering price of shares of the Company&#x2019;s common stock, shares of the Company&#x2019;s preferred stock, debt securities, warrants, and rights and units. The Shelf Registration Statement was declared effective by the Securities and Exchange Commission (the "SEC") on September 2, 2021. The Shelf Registration Statement included a prospectus covering the offer and sale from time to time of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in aggregate offering price of shares of the Company&#x2019;s common stock through an &#x201c;at-the-market&#x201d; equity offering program (the "ATM Offering Program") with Cowen and Company, LLC, as sales agent. As of December 31, 2022, the Company has issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,213&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock pursuant to the ATM Offering Program, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On April 28, 2022, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,333,334&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock in an underwritten public offering, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares associated with the full exercise of the underwriters&#x2019; option to purchase additional shares, at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The total net proceeds to the Company from the offering were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;215.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and offering expenses. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The shares were issued pursuant to the Company&#x2019;s Shelf Registration Statement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3"
      decimals="INF"
      id="F_88764f72-7c4f-4e62-bfce-514671613d2d"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3"
      decimals="INF"
      id="F_27593d56-435a-4ef6-bada-69633b9254bf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3"
      decimals="INF"
      id="F_81e4b9fd-6f25-44b6-8c25-3553f8ceb809"
      unitRef="U_shares">54350179</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3"
      decimals="INF"
      id="F_c3d9db06-481d-4b07-b12d-38666049ac1a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_e5303a92-212e-4aad-9186-0d262371436b"
      decimals="-5"
      id="F_ddadaa16-ef67-4071-92a2-216fd97bff63"
      unitRef="U_USD">500000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_e5303a92-212e-4aad-9186-0d262371436b"
      decimals="-5"
      id="F_a9358c3d-b072-4fda-aa11-0128a61f422a"
      unitRef="U_USD">150000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1cd10163-6e81-4530-a414-a8bef05e747e"
      decimals="INF"
      id="F_be3652b9-998d-49a8-8d05-030f44e91fcc"
      unitRef="U_shares">113213</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a0bf228a-dcc8-47a6-9520-a9d355912f12"
      decimals="-5"
      id="F_020191a0-a631-4f7a-8253-94904a6952b0"
      unitRef="U_USD">1600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_981a3fe1-5a1b-4bea-9a27-e819dcdf253c"
      decimals="INF"
      id="F_76f4fc27-1e37-4bc6-929e-eaedd0e438df"
      unitRef="U_shares">15333334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_001b7558-daa1-49c1-8059-798879009ca2"
      decimals="INF"
      id="F_62dff67b-23af-407c-92db-3f06cc96cefa"
      unitRef="U_shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_141cfb9f-1119-4e34-b791-208f5def88e6"
      decimals="2"
      id="F_6195d4b3-8319-4ec8-b550-b10c59a65323"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_981a3fe1-5a1b-4bea-9a27-e819dcdf253c"
      decimals="-5"
      id="F_1d9491c6-a6d7-42f6-ad35-004f834fa2b5"
      unitRef="U_USD">215300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_82c80976-ca74-4007-8024-612a9fed69ab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company granted options under its 2015 Equity Incentive Plan (the "2015 Plan"&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2015 Plan allowed for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock unit&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;awards &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and other stock awards, although only stock options were awarded under the 2015 Plan. Awards could be made to officers, directors, employees, non-employee directors, and consultants of the Company. In connection with the Board of Directors&#x2019; and stockholders&#x2019; approval of the 2020 Plan, the 2015 Plan was terminated as to future awards and any options then outstanding under the 2015 Plan remained outstanding and effective. As of December 31, 2022, there were an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,344,048&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock issuable upon the exercise of outstanding options issued under the 2015 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2020 Performance Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s 2020 Performance Incentive Plan (the "2020 Plan") which was adopted by the Company&#x2019;s board of directors in June 2020 and approved by the Company&#x2019;s stockholders in July 2020, became effective upon the consummation of the IPO in July 2020. The 2020 Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, stock bonuses, restricted stock, stock units and other forms of awards including cash awards to its officers, directors, employees, consultants and advisors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of December 31, 2022, a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,945,002&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock were authorized for issuance with respect to awards granted under the 2020 Plan (this number of shares gives effect to the annual increases in the 2020 Plan share limit, as described in the next sentence). The share limit will automatically increase on the first trading day in January of each year by an amount equal to the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of outstanding shares of the Company&#x2019;s common stock on the last trading day in December in the prior year, or (2) such lesser number as determined by the Company&#x2019;s board of directors. Any shares subject to awards granted under the 2020 Plan or the 2015 Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2020 Plan. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,775,102&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares was available for issuance under the 2020 Plan as of&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the stock option activity during the year ended December 31, 2022 (in thousands, except number of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;shares, exercise prices and contractual term):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.154%;"/&gt;
        &lt;td style="width:0.513%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.425%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.655%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.298%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.526%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.091%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.988%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.349%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average&lt;br/&gt;remaining contractual&lt;br/&gt;term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate &lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,204,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,327,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;383,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;630,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,519,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,337,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at &lt;br/&gt;&#160;&#160;&#160;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,519,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value represents the difference between the exercise price of stock options and the quoted closing market price of the Company&#x2019;s common stock on the applicable date for all in-the-money stock options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional information related to the Company&#x2019;s stock options is summarized below (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.324%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.129000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.438%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average grant-date fair value of stock option grants per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the restricted stock unit activity during the year ended December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.384%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.030000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.187000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.99%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average&lt;br/&gt;grant date fair value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;389,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan (the "ESPP"), which was adopted by the Company&#x2019;s board of directors in June 2020 and approved by the Company&#x2019;s stockholders in July 2020, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;became effective upon the consummation of the IPO. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;952,524&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock were authorized for issuance under the ESPP. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their eligible compensation, subject to any plan limitations. The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ESPP provides for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; offering periods, and at the end of each offering period, employees are able to purchase shares at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. During 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,754&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were issued under the ESPP resulting in aggregate cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ESPP purchases in 2021. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;890,770&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares remained available for issuance under the ESPP (after giving effect to share purchases made under the ESPP through and including the ESPP offering period that ended on November 30, 2022).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liability for Early Exercise of Restricted Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain individuals were granted the ability to early exercise their stock options. The shares of common stock issued from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into common stock and additional paid-in capital as the shares vest. Shares subject to repurchase by the Company were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,181&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, as of December 31, 2022 and 2021, respectively, and in each case the related liability recorded under other accrued and other current liabilities in the condensed balance sheets was insignificant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had reserved the following shares of common stock for future issuance:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.426%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options and restricted stock units granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,876,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reserved for future equity award grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,775,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reserved for future ESPP issuances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;890,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,541,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense for the years ended December 31, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.324%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.129000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.438%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total unrecognized compensation cost related to stock options was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average remaining service period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years as of December 31, 2022. The total unrecognized compensation cost related to restricted stock units was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average remaining service period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years as of December 31, 2022. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of unrecognized compensation cost related to ESPP, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;which is expected to be recognized over a weighted-average remaining service period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of stock options was estimated on the date of grant using the Black-Scholes option pricing model with the following range of assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.551%;"/&gt;
        &lt;td style="width:1.56%;"/&gt;
        &lt;td style="width:16.165%;"/&gt;
        &lt;td style="width:1.56%;"/&gt;
        &lt;td style="width:16.165%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value of the awards on the date of grant, net of forfeitures. The Company generally recognizes grant-date fair value of stock options granted to employees and non-employee service providers on a straight-line basis over the requisite service period, which is generally the vesting term of the respective awards. The Company determines the fair value of stock options with a service and performance condition, or performance-based options, based on the fair value of the Company&#x2019;s common stock on the date of grant. The Company accounts for the impact of forfeitures as they occur. For purposes of calculating share-based compensation, the Company estimates the fair value of stock options issued using a Black-Scholes option-pricing model. The determination of the fair value of share-based payment awards utilizing the Black-Scholes option-pricing model is affected by the Company&#x2019;s stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected term.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company opted to use the &#x201c;simplified method&#x201d; for estimating the expected term of employee options, whereby the expected term equals the average of the vesting term and the original contractual term of the option (generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected volatility.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company based its estimate of expected volatility on the historical volatilities of the common stock of comparable publicly traded biopharmaceutical companies over a period equal to the expected term&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle, and financial leverage to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t issued any dividends and do &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t expect to issue dividends over the life of the options, as a result the estimated dividend yield is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_3c1f1543-5dab-4779-b06e-a0d704393f4c"
      decimals="INF"
      id="F_297ccb12-166c-4fc5-ac3e-3b7153b8e5f3"
      unitRef="U_shares">1344048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_5494864e-30df-4f68-b4b1-cd4ad5b4ba91"
      decimals="INF"
      id="F_db72fc13-2875-4ef1-9145-ef02dbbb3585"
      unitRef="U_shares">5945002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <nktx:IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear
      contextRef="C_44eb9b84-6402-486d-8d17-eda195e16bed"
      decimals="2"
      id="F_b196c8d1-9a11-4353-8511-bd584fc5a014"
      unitRef="U_pure">0.05</nktx:IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5494864e-30df-4f68-b4b1-cd4ad5b4ba91"
      decimals="INF"
      id="F_da856218-6016-4adf-bb1c-c7d8285b94e6"
      unitRef="U_shares">1775102</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_10f042d7-9df3-4582-96a5-1f360396b9d6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the stock option activity during the year ended December 31, 2022 (in thousands, except number of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;shares, exercise prices and contractual term):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.154%;"/&gt;
        &lt;td style="width:0.513%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.425%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.655%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.298%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.526%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.091%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.988%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.349%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average&lt;br/&gt;remaining contractual&lt;br/&gt;term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate &lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,204,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,327,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;383,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;630,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,519,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,337,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at &lt;br/&gt;&#160;&#160;&#160;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,519,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c963d9bf-d21f-4940-8b1d-41239a955535"
      decimals="INF"
      id="F_d79a6fa4-faff-4f39-87c0-54224d0722e7"
      unitRef="U_shares">4204686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_c963d9bf-d21f-4940-8b1d-41239a955535"
      decimals="INF"
      id="F_aea1dc9a-6d26-4e68-8f3c-7b9c28bee938"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_a7e0478f-dfc8-4a2e-bc04-3e92eb222605"
      id="F_0398cdf0-24d1-484f-b521-d685526ee09e">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      decimals="0"
      id="F_810bcab9-30a8-4fe6-aee1-e3b6d7d05bfe"
      unitRef="U_shares">2327820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      decimals="2"
      id="F_8331564e-7309-41f4-8f25-fd64843fb059"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      decimals="0"
      id="F_09e7f906-4841-498b-bfac-491da20c693e"
      unitRef="U_shares">383120</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      decimals="2"
      id="F_96b3a53c-5819-4bb3-8ade-abc518116f9e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      decimals="0"
      id="F_4ea081b5-d925-4ae5-8d96-b2abd9b3e690"
      unitRef="U_shares">630111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      decimals="2"
      id="F_e1fc338f-afe3-4299-8e49-8cc96256ff29"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="INF"
      id="F_20443572-a301-472a-aea8-d314fb0c31c5"
      unitRef="U_shares">5519275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="2"
      id="F_a95c94b9-f177-4a64-9339-1cce20653ba7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      id="F_c697c62b-ad33-4697-81c8-4a1195c9962f">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="-3"
      id="F_d4a14960-dcc1-4115-9406-6e44b3df2a78"
      unitRef="U_USD">2915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="0"
      id="F_70a5cfa1-b780-4c73-b096-f2f9cfc11b2a"
      unitRef="U_shares">2337753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="2"
      id="F_b3d342fd-41ff-45b1-b5ea-4da5eddafb43"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      id="F_7e54a44d-1aad-4884-9ce6-fd8715a6686e">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="-3"
      id="F_43e1d9eb-6359-4ead-82c5-216de7344a80"
      unitRef="U_USD">1957000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="0"
      id="F_42d33993-84d3-4c73-b057-f4ab37a59c3c"
      unitRef="U_shares">5519275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="2"
      id="F_fa026a6e-5e1c-49bb-b114-2ce322a5b8dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_7d693d1f-0170-4af7-8991-dbab6eb94595"
      id="F_1ea6cf96-6370-4726-a88e-079ea402c21c">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_46ac69ef-68f5-4da9-862a-5bbe2eca90f7"
      decimals="-3"
      id="F_314d90ba-d998-42fa-a9c9-f54bc11bedec"
      unitRef="U_USD">2915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <nktx:ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_f77b0f7f-9bbe-4282-9f39-41cd896e11b9">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional information related to the Company&#x2019;s stock options is summarized below (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.324%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.129000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.438%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average grant-date fair value of stock option grants per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</nktx:ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="2"
      id="F_9a9193ea-84a2-4ace-ae25-ae46f5cf835c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="2"
      id="F_70ece0cd-74ea-480f-a8c7-15141bdfe7e0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_2d216ac2-ca28-492b-926e-180f24aa1cf2"
      unitRef="U_USD">4268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_3b8576d9-f25c-4be2-b2bd-313e04172d4c"
      unitRef="U_USD">9991000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_ee4ace3c-4d7f-430b-a214-f509e96f9a98">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the restricted stock unit activity during the year ended December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.384%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.030000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.187000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.99%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average&lt;br/&gt;grant date fair value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;389,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0a03030f-25af-4ff1-945c-997f499c318d"
      decimals="INF"
      id="F_eecc094b-913e-42d5-a4ee-a89fc08f6740"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0a03030f-25af-4ff1-945c-997f499c318d"
      decimals="INF"
      id="F_4493adc2-6e98-45e6-8649-3a9bf550f1c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c"
      decimals="INF"
      id="F_d3091255-c975-4664-a31e-00e9fa290e9c"
      unitRef="U_shares">389388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c"
      decimals="2"
      id="F_f20c2f51-e115-497f-b74c-494814a4479e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c"
      decimals="INF"
      id="F_e92acbf8-6125-475e-a1be-0bb000d8747f"
      unitRef="U_shares">32660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c"
      decimals="2"
      id="F_e4892dd1-2611-409e-b704-75ef1aaa3b91"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_dad82f88-3e0b-4f88-88f6-fb0cde6e2f5d"
      decimals="INF"
      id="F_dc520ff2-cdcf-44ce-8864-46923c72a799"
      unitRef="U_shares">356728</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_dad82f88-3e0b-4f88-88f6-fb0cde6e2f5d"
      decimals="INF"
      id="F_e5176ab0-21fb-49f2-a35e-1d2fdd8a44ad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c"
      id="F_2926f36a-eb28-40ce-afb8-e356102e9ab1">P1Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e"
      decimals="INF"
      id="F_142410ab-5272-4682-b730-b44d274f8712"
      unitRef="U_shares">952524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e"
      decimals="INF"
      id="F_eb6a1c6f-bcbc-42d6-aee0-4bf6d76a43c1"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      id="F_f6587cd3-d337-485d-8db4-cb34ada62636">P6M</nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      decimals="2"
      id="F_f1d72d0e-0345-4e37-b599-ce3c7db5551d"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      decimals="INF"
      id="F_185c0779-ad26-470b-ab12-9f8d83f61f61"
      unitRef="U_shares">61754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      decimals="-2"
      id="F_af72d8be-a8a8-4933-aae3-ee053959701a"
      unitRef="U_USD">400</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_ab31f486-dd4c-4921-9836-0c2daa665d2d"
      decimals="INF"
      id="F_545cb9d3-3f4d-4a90-a34c-327a5f2b1663"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e"
      decimals="INF"
      id="F_a67948f9-10f6-4669-8070-7c401836f6cb"
      unitRef="U_shares">890770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_a024a1ed-5c61-4be8-a5a7-9e8fa9a97eff"
      decimals="INF"
      id="F_18728d4b-a367-4832-92f6-62ee0d019faa"
      unitRef="U_shares">508</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_f580e365-5516-4a7a-ab29-b585665fbce7"
      decimals="INF"
      id="F_7ee04480-a723-4152-bd6e-0fb99b633477"
      unitRef="U_shares">16181</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <nktx:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_0d596e03-a051-4fff-955e-ba1d85dbc531">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had reserved the following shares of common stock for future issuance:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.426%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock options and restricted stock units granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,876,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reserved for future equity award grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,775,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reserved for future ESPP issuances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;890,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,541,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</nktx:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a8cd6f3e-33d2-431d-8c68-01cfb7d24237"
      decimals="INF"
      id="F_59dd0b18-a87f-4d4e-8fd2-a3b659c53f58"
      unitRef="U_shares">5876003</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5494864e-30df-4f68-b4b1-cd4ad5b4ba91"
      decimals="0"
      id="F_ad8fdb28-b9fd-40ab-a8c5-286c14b12076"
      unitRef="U_shares">1775102</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e"
      decimals="0"
      id="F_ab973b92-9bf3-4e16-841a-44311faf3c93"
      unitRef="U_shares">890770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="INF"
      id="F_aa07ec18-bb45-4fa3-b7cb-3b1902af6ae1"
      unitRef="U_shares">8541875</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_464ee3b6-5738-4427-b6dc-0a866f8b1041">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense for the years ended December 31, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.324%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.129000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.554%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.438%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5cee8cd7-5f97-41bd-add1-44d08b9bb04e"
      decimals="-3"
      id="F_6593086b-cfab-4856-be9e-2be1af8dab7d"
      unitRef="U_USD">7326000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_18a918ed-b24c-4a30-91c4-1883263c2b4d"
      decimals="-3"
      id="F_16e68958-e639-4946-9674-8cc0892dc945"
      unitRef="U_USD">6719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d26eec10-62b5-4c3b-988b-3b120717f7c4"
      decimals="-3"
      id="F_ee05a677-bbc7-4785-a8ec-6316769123ba"
      unitRef="U_USD">9530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f80d2293-58a8-4680-be9d-fb127ceff8c4"
      decimals="-3"
      id="F_31d7dfc4-94ca-4d0f-b349-a1282e6e0784"
      unitRef="U_USD">7742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_3b71c5cb-14c3-467d-a35c-e659b8ed367e"
      unitRef="U_USD">16856000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_7f88e04a-d5cc-4ffa-80c8-4262c9e11ff5"
      unitRef="U_USD">14461000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-5"
      id="F_5de5e07b-6fb1-491b-bdc4-55b3683c4d38"
      unitRef="U_USD">34200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_3c4fb24e-b03c-4933-abc7-e945886c7988">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_dad82f88-3e0b-4f88-88f6-fb0cde6e2f5d"
      decimals="-2"
      id="F_062b4c06-6401-4afe-89dc-3b3b6e668407"
      unitRef="U_USD">3700</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f88de343-0a59-45f7-9df8-b09992f4929c"
      id="F_e9d71cd7-fcbc-4ccf-9226-7e06b24fb75e">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_fc9d6414-7006-461a-ad35-be8368d5db4e"
      decimals="-2"
      id="F_c85a5b2a-c838-402e-82d1-22279de82167"
      unitRef="U_USD">100</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      id="F_1e4ac48d-fca3-434b-97e8-e13aee77289a">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_fa1ff00a-1a9f-4584-a51c-4a5254e6a169">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of stock options was estimated on the date of grant using the Black-Scholes option pricing model with the following range of assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.551%;"/&gt;
        &lt;td style="width:1.56%;"/&gt;
        &lt;td style="width:16.165%;"/&gt;
        &lt;td style="width:1.56%;"/&gt;
        &lt;td style="width:16.165%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue
      contextRef="C_f4d8076e-e0bc-4c00-a7ca-5d44c39d9a6f"
      decimals="2"
      id="F_cc9b9c81-94f7-4b90-b5cd-1799d95ee155"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.99</nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue>
    <nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue
      contextRef="C_8785059f-96d4-4f04-8c0f-0809aa5b503b"
      decimals="2"
      id="F_d058ff30-1962-4a0a-bc9b-4f86f38f6313"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.44</nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue>
    <nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue
      contextRef="C_a7611da9-a17b-4506-b7d2-762f752b122e"
      decimals="2"
      id="F_7f032ffd-6495-419e-a88d-4b764b0adb97"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.35</nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue>
    <nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue
      contextRef="C_74c75d73-fb22-4295-b576-4cef5d2a18f0"
      decimals="2"
      id="F_5d5a8483-b785-4346-9f43-3086442bd13c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">54.89</nktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_9183cb74-8a77-407b-ac80-773ff92736bd"
      decimals="3"
      id="F_81322160-d283-451c-9c50-a350ccaf9b72"
      unitRef="U_pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_9183cb74-8a77-407b-ac80-773ff92736bd"
      decimals="3"
      id="F_1d0526b0-3d19-46cf-853d-82e7cfe985b0"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18"
      decimals="3"
      id="F_858cedce-b912-45d7-90f9-677a61193a17"
      unitRef="U_pure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18"
      decimals="3"
      id="F_524f3d06-8f31-4d4c-bb14-67e91be671e0"
      unitRef="U_pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_9183cb74-8a77-407b-ac80-773ff92736bd"
      decimals="3"
      id="F_6907dce4-fd9e-41ea-80d8-17f30601ac74"
      unitRef="U_pure">0.757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_9183cb74-8a77-407b-ac80-773ff92736bd"
      decimals="3"
      id="F_4a063032-f288-4fb5-8972-c2df98b49c0a"
      unitRef="U_pure">0.789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18"
      decimals="3"
      id="F_fcb43e1e-27ba-46bc-b973-8127f17a0ddd"
      unitRef="U_pure">0.773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_2f3fbfdf-4ec2-42e1-ad88-6346ab9e8f18"
      decimals="3"
      id="F_0a364093-2093-4468-b660-254f36d56f39"
      unitRef="U_pure">0.799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f4d8076e-e0bc-4c00-a7ca-5d44c39d9a6f"
      id="F_ec605cf7-becd-4c39-ae31-9a9e0f6deafe">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8785059f-96d4-4f04-8c0f-0809aa5b503b"
      id="F_8300a31d-fdb6-4a49-9803-043a9ffac951">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a7611da9-a17b-4506-b7d2-762f752b122e"
      id="F_7ca5bb5c-9a69-409f-aabb-a22d77e0e435">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_74c75d73-fb22-4295-b576-4cef5d2a18f0"
      id="F_78f45160-ce84-4c0c-8134-ef0a2772e729">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      decimals="3"
      id="F_0d55db3f-6f65-40ac-bb6f-2ba89094f735"
      unitRef="U_pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      decimals="3"
      id="F_b2d6327f-181e-4e3f-b021-d5e949e68919"
      unitRef="U_pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      decimals="3"
      id="F_b4faa6aa-b8cf-4258-b5fc-de19221313fe"
      unitRef="U_pure">0.638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      decimals="3"
      id="F_a3097612-e6d5-4c75-bd04-232566584a7d"
      unitRef="U_pure">1.519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3c0028db-df29-4aa0-adac-fef9ec3b7256"
      id="F_873a237e-b0e7-4daf-ada9-c1390d9f0271">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_609cff8a-8ca4-4195-8e62-a3fc54ca4868">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DividendsShareBasedCompensation
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_cc9c3a56-53c1-4d97-8977-9309d9e4fc35"
      unitRef="U_USD">0</us-gaap:DividendsShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_ef58ef22-f66d-4324-8d2d-d67ce5d1c53f"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="2"
      id="F_ac3bd990-8b25-48a1-8547-8ffd5196bf7f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_51b990df-e72d-4c03-8420-c61c50cea7f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due to the Company&#x2019;s net losses for the years ended December 31, 2022 and 2021, and since the Company has a full valuation allowance against deferred tax assets, there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; tax provision or benefit for income taxes recorded in the years presented other than minimum amounts required for state tax purposes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation on income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.158%;"/&gt;
        &lt;td style="width:1.891%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.494%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.891%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.568%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit at statutory rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets are shown below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.148%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.784%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.674%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 174 Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#x2019;s ability to realize these assets. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;representing net future deductible amounts become deductible. Due to the Company&#x2019;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are substantially offset by a valuation allowance at December 31, 2022 and 2021. The deferred tax assets were primarily comprised of federal and state tax net operating losses and tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had net operating loss ("NOL") carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;153.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. Of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;153.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million federal NOL carryforwards, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million will begin expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, if not utilized, while $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million can be carried forward indefinitely. The state NOL carryforwards will begin expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, if not utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company also had federal and state research and development credit carry forwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, at December 31, 2022. The federal credits will begin expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; if not utilized. The California credits have no expiration date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"), as well as similar state provisions. The future utilization of the Company&#x2019;s NOL and tax credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% or more of the Company&#x2019;s common stock. An assessment of such ownership changes under Section 382 was not completed through December 31, 2019. To the extent that an assessment is completed in the future, the Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2022, its federal and state returns for the years ended 2015 through the current period are still open to examination. In addition, all of the net operating losses and research and development credit carryforwards that may be used in future years are still subject to inquiry given that the statute of limitation for these items would begin in the year of the utilization. The balance of gross unrecognized tax benefits as of December 31, 2022 and 2021 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, all of which would affect the Company&#x2019;s income tax expense if recognized, before consideration of the Company&#x2019;s valuation allowance. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; interest and penalties for the years ended December 31, 2022 and 2021. The Company files income tax returns in the United States federal jurisdiction and the State of California and is not currently under examination by any taxing authority for any open tax year. Due to net operating loss carryforwards, all years remain open for income tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the changes in the Company&#x2019;s gross unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.599%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases (decreases) related to tax positions taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to tax positions taken in current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="INF"
      id="F_b9cdc3fa-0e8d-4adc-abc6-228929ba32f6"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_08368f86-0e1c-40e9-bb50-6cfa6b157cc2"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_ce0660f4-ec08-437b-8f47-8f6e3d5588a3">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation on income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.158%;"/&gt;
        &lt;td style="width:1.891%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.494%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.891%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.568%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit at statutory rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_876c97b0-3f97-49a8-bbac-19a05032c7c1"
      unitRef="U_USD">-23906000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_6eddd498-c043-4e6b-85e7-6751c2429ec1"
      unitRef="U_USD">-18076000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_b67ce320-67b8-4ca1-9913-5037a7052ffe"
      unitRef="U_USD">-1566000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_1bb7078d-b52f-4308-ad69-dd32b47895b3"
      unitRef="U_USD">-1005000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <nktx:IncomeTaxReconciliationPermanentItems
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_d4f6d158-6820-42dc-8b8b-784fdc1a0b8f"
      unitRef="U_USD">1891000</nktx:IncomeTaxReconciliationPermanentItems>
    <nktx:IncomeTaxReconciliationPermanentItems
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_1629246d-cb0d-464d-9811-88aa48af5e19"
      unitRef="U_USD">592000</nktx:IncomeTaxReconciliationPermanentItems>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_b14337ed-47b0-4495-b649-109d327f4a9d"
      unitRef="U_USD">3426000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_b42969f4-4a00-4944-9db1-971370ae8fce"
      unitRef="U_USD">1661000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_fecdebf9-6755-42ae-85ff-6cbd9f72ec52"
      unitRef="U_USD">-0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_cc423002-d2bd-487d-a056-27d4200a015b"
      unitRef="U_USD">-515000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_ff1cd822-c10b-4529-977b-ebc069291022"
      unitRef="U_USD">27007000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_ae2267cf-6924-4d89-b475-6aca581f99fe"
      unitRef="U_USD">20665000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_93804940-6431-41d5-870d-06488aef792e"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_3c25a586-1576-4e48-bef3-e9ed2d46974f"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_67c4ad4d-3eba-4b96-bb50-034a6c6b9a84">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets are shown below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.148%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.784%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.674%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 174 Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_1ae0f5f9-5fdd-49eb-9102-3791dfe816d8"
      unitRef="U_USD">36732000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_9352f3fb-ae32-4de9-92e2-af2e286cf101"
      unitRef="U_USD">33767000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <nktx:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_557e0e69-b9a7-49bf-ba82-ee7e37c33d28"
      unitRef="U_USD">316000</nktx:DeferredTaxAssetsDepreciationAndAmortization>
    <nktx:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_7bd1b0be-c4bb-4671-af99-ebedd443df56"
      unitRef="U_USD">268000</nktx:DeferredTaxAssetsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_04d1d24e-8b72-405e-a4d9-95eba6371d7f"
      unitRef="U_USD">11999000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_6d94a95c-45a8-48f3-8f13-de5113603cab"
      unitRef="U_USD">6984000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_d909e2db-4624-40f6-83e9-caa21d413d3b"
      unitRef="U_USD">3552000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_111a9d54-b5ce-4ceb-913c-44ad12b87042"
      unitRef="U_USD">2245000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_74bda772-902f-4f8f-bde6-111e205a7548"
      unitRef="U_USD">1367000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_dfe6d7a9-187d-4a25-bbab-1284071fec21"
      unitRef="U_USD">1189000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <nktx:DeferredTaxAssetsLeaseLiability
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_ec334b6d-4a9a-452f-87b0-7222cc53d86b"
      unitRef="U_USD">19062000</nktx:DeferredTaxAssetsLeaseLiability>
    <nktx:DeferredTaxAssetsLeaseLiability
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_be526e7d-0a13-490f-9e63-f0d8edc6c2f4"
      unitRef="U_USD">2616000</nktx:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_86072953-28a1-440d-80be-9942a097a670"
      unitRef="U_USD">35000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_393f42f6-56e8-4c8a-ab2d-2042f8f9e742"
      unitRef="U_USD">34000</us-gaap:DeferredTaxAssetsOther>
    <nktx:DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_ace75c6e-ee2e-4737-b645-319ecd3c7206"
      unitRef="U_USD">17352000</nktx:DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment>
    <nktx:DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_7659b5c6-240c-40f3-9b51-e9f7e00be45f"
      unitRef="U_USD">0</nktx:DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_ce7d0e46-23cb-48ce-bbb0-766c78c555f6"
      unitRef="U_USD">90415000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_90057401-5d84-49a9-8c91-440ff8b2cf07"
      unitRef="U_USD">47103000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_456b0f50-3118-42c7-b0f2-7336226a243c"
      unitRef="U_USD">71368000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_72f25a6b-e2d1-4231-9320-e6e072f7f2cc"
      unitRef="U_USD">44361000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_2338aeed-62f6-4b1f-b217-d1a4af66120f"
      unitRef="U_USD">19047000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_398b7995-0ed0-4105-b1dd-493cf24e950c"
      unitRef="U_USD">2742000</us-gaap:DeferredTaxAssetsNet>
    <nktx:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_7cc5d1c9-afa3-40c8-a550-3587aa4d9ffd"
      unitRef="U_USD">18089000</nktx:DeferredTaxLiabilitiesRightOfUseAsset>
    <nktx:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_9e6c3c60-211c-437d-8a37-80e75e1242ee"
      unitRef="U_USD">2471000</nktx:DeferredTaxLiabilitiesRightOfUseAsset>
    <nktx:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_f60bcee7-1412-4470-b815-d4be81a4f4bc"
      unitRef="U_USD">958000</nktx:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <nktx:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_9160cbe3-01d9-4674-be8a-1da1004a7b65"
      unitRef="U_USD">271000</nktx:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_286befca-81bf-4bb7-835e-1ffeffa8c147"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_62cb9ebf-4185-4c5f-b143-db4612837c2c"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-5"
      id="F_ced0b91e-5fd3-4e6b-aeb8-c40900a1bfa4"
      unitRef="U_USD">27000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-5"
      id="F_693361f4-8df1-4bc2-8287-500aa9a28511"
      unitRef="U_USD">20700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c60f034b-7278-446d-9f32-ef360df72d1f"
      decimals="-5"
      id="F_c52fd815-855e-4376-b7b2-38f0f587106e"
      unitRef="U_USD">153300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_feea12d5-fa67-4f8d-a138-14014b003a98"
      decimals="-5"
      id="F_597d61e8-54e7-4905-b1b9-d0dfc9443a11"
      unitRef="U_USD">65100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c60f034b-7278-446d-9f32-ef360df72d1f"
      decimals="-5"
      id="F_9cd11126-6fdc-4c44-a298-28d4189d6206"
      unitRef="U_USD">153300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_3ae365a0-6a87-4a4e-a567-430fbc72a73f"
      decimals="-5"
      id="F_890af32f-dfe7-4b99-bfdc-412cecc99f40"
      unitRef="U_USD">200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e16f2952-c482-4fb5-b289-6a2484c1649e"
      decimals="-5"
      id="F_75ac444a-961b-4f23-a484-12b8408e99dd"
      unitRef="U_USD">3000000.0</us-gaap:OperatingLossCarryforwards>
    <nktx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_5c424608-d9ed-42fb-be8c-a8171cb6a5ea"
      id="F_9d2cbc3c-9072-4663-8701-1757a55c93be">2035</nktx:OperatingLossCarryforwardsExpirationYear>
    <nktx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_ff496bec-fe97-479b-a5c4-6ec81afca185"
      id="F_90ac06a0-6fdd-45bb-8309-9bb8a0a44dc8">2036</nktx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_229b2864-98b4-4ede-83cb-94419b551487"
      decimals="-5"
      id="F_9731ffc3-e125-4c4b-a0e6-c81244dc5fd3"
      unitRef="U_USD">150100000</us-gaap:OperatingLossCarryforwards>
    <nktx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_59e66b2e-c33f-48fe-ad46-f3ff01344f2e"
      id="F_c75e2da1-9c64-454c-af53-353ff2a72a5e">2036</nktx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_444f64e4-77b4-4f0d-a3be-c07ea1bd14aa"
      decimals="-5"
      id="F_71125502-0325-4082-af36-7f5c80b18978"
      unitRef="U_USD">9900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6097964e-eb40-4699-9cf6-6a9b004fabb9"
      decimals="-5"
      id="F_a4eedbbc-16bc-43d9-b1dc-0a6dc6c1269d"
      unitRef="U_USD">5600000</us-gaap:TaxCreditCarryforwardAmount>
    <nktx:TaxCreditCarryforwardExpirationYear
      contextRef="C_57e7b3dc-ab16-4aa2-987e-e194bd6384a0"
      id="F_e8dfc5c7-3c9e-47cd-81dc-f28f105bd9b5">2035</nktx:TaxCreditCarryforwardExpirationYear>
    <nktx:ChangesInOwnershipByStockholdersHoldingPercentage
      contextRef="C_42e1761d-f976-4772-b948-69c953e4e0be"
      decimals="2"
      id="F_21707fe8-4690-4f9f-a192-2e5e2f4beef8"
      unitRef="U_pure">0.05</nktx:ChangesInOwnershipByStockholdersHoldingPercentage>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-5"
      id="F_9a769682-44f4-46e8-a45f-1332a5cdaede"
      unitRef="U_USD">2300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-5"
      id="F_69136d3e-eddc-4a28-a953-cd9d4dd1e5cf"
      unitRef="U_USD">1400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="INF"
      id="F_01d20a1f-4278-4f36-9e4f-ce99b10181bc"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="INF"
      id="F_77ab1134-18db-47e5-8628-6ef8cfd31d6e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_c44a8a3b-a126-4e06-939c-392a0ceccaaa">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the changes in the Company&#x2019;s gross unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.599%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases (decreases) related to tax positions taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to tax positions taken in current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_7f4f8d23-bf9b-4acc-a8a1-9f2274d7745a"
      unitRef="U_USD">1359000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32"
      decimals="-3"
      id="F_c150de49-f889-4c61-b4a1-587d8d6e495f"
      unitRef="U_USD">777000</us-gaap:UnrecognizedTaxBenefits>
    <nktx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_729b3af3-27c1-444c-a870-9b0d6606f91f"
      unitRef="U_USD">-43000</nktx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <nktx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_87506651-c05b-40e1-af76-e618d6c0d957"
      unitRef="U_USD">-281000</nktx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      decimals="-3"
      id="F_91f86442-37f2-4420-8aef-bf2fb4810841"
      unitRef="U_USD">1023000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_d879caa7-595a-47ec-b94d-f39d5f4dde87"
      decimals="-3"
      id="F_2b59b50a-2bcf-46f4-a4dc-58dcc9400d8a"
      unitRef="U_USD">863000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0"
      decimals="-3"
      id="F_42c773bb-4995-4e11-aa00-679b2dfdaa21"
      unitRef="U_USD">2339000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9e0afc55-bbb0-416e-a754-625e5f859147"
      decimals="-3"
      id="F_bb48939a-bee2-4747-94fe-0f0a0c72fe9b"
      unitRef="U_USD">1359000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_3bd6bac6-2a11-499d-8435-032d15a2aceb"
      id="F_053360a8-c5ed-4625-b7c2-6d87c2dafdab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 10, 2023, Silicon Valley Bank ("SVB") in the United States was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 12, 2023, the U.S. Department of the Treasury, Federal Reserve, and FDIC jointly announced that the FDIC will complete its resolution of SVB in a manner that fully protects all depositors. As of March 10, 2023, we held $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in collateral money market accounts supporting letters of credit issued by SVB to the Landlord in connection with the Initial Lease Agreement and Additional Lease Agreement. We are working with the Landlord to replace the letters of credit issued by SVB with letters of credit from a different financial institution.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <nktx:AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord
      contextRef="C_9156c0d3-efa4-45e5-8f61-29564c2a7e1d"
      decimals="-5"
      id="F_70ebbca6-127c-4355-bc9a-744cb80d9224"
      unitRef="U_USD">2700000</nktx:AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $B(<%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !(B'!6#8-6>NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*$Y882;UI:.G#@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/
MGT"M#D+W$9]C'S"2Q70WNLXGH<.:G8B" $CZA$ZE<DKXJ7GHHU,T/>,1@M(?
MZHA05]4*')(RBA3,P"(L1"9;HX6.J*B/%[S1"SY\QB[#C ;LT*&G!+SDP.0\
M,9S'KH4;8(811I>^"V@68J[^B<T=8)?DF.R2&H:A')J<FW;@\/:T>\GK%M8G
M4E[C]"M90>> :W:=_-IL'O=;)NNJ;HJJ*?AJ7W-1<7'_\#Z[_O"[";O>V(/]
MQ\970=G"K[N07U!+ P04    " !(B'!6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M $B(<%;YT91=O@@  /TU   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9MK<Z,X&H7_BLK3U353%<?<<NM.4N7&]JZW.X['3L]L=FL_*"#'5 !Y)1$G
M_WY>@6U,2L@P)7])?'L/\"#@'%VNUY2]\"4A KTE<<IO.DLA5E]Z/1XL28+Y
M*5V1%+Y94)9@ 6_9<X^O&,%A7I3$/<>RSGL)CM+.[77^V93=7M-,Q%%*I@SQ
M+$DP>_]&8KJ^Z=B=[0>SZ'DIY >]V^L5?B9S(GZNI@S>]78J8920E$<T18PL
M;CI]^\O <V1!_HL_(K+F>Z^1/)0G2E_DFW%XT['D'I&8!$)*8/CW2GP2QU()
M]N/_&]'.;INR</_U5GV4'SP<S!/FQ*?QGU$HEC>=RPX*R0)GL9C1]3_)YH#.
MI%Y 8Y[_1>OBMV?G'11D7-!D4PQ[D$1I\1^_;4#L%5Q:-07.IL#Y4&![-07N
MIL!M6N!M"KR<3'$H.8<!%OCVFM$U8O+7H"9?Y##S:CC\*)7G?2X8?!M!G;@=
MT""#TR@03D,T3$4DWM$X+=J3/"]=]',^0+]^^@U]0E&*[J(XAH_Y=4_ QJ5$
M+]ALZ%NQ(:=F0[:#[F@JEARV$I*P*M"#O=[MNK/=]6^.5G% @E/DVB?(L1Q'
ML4.^OOP.LU-DNWFYJR@?Z,O_E:6P=4NU]<K1N+L3X>9Z;HV>3U\)0__M/W'!
MX&+XGXIPH>"I%>0=X@M?X8#<=. 6P E[)9W;S[_8Y]97%1V38@-#8A5RWHZ<
MIU,OF_##^XJHL.G+;:O[7<5'6]66CR&Q"I^S'9^S9GSZ:9KA&,W(BC*A J77
M$2Q3X?6U56U!&1*K@#K?@3IO!FI*6$3E[3!$<%-5MJD#2MM;4^V]25O?%IHA
ML0JTBQVTBX97'\/@!O*'1GT+TVLM<,R534Q;UI:6(;$*K<L=K4OM$6Z>L*,H
M)FB2)4^$J2CI-2S+[KI7[H6E(J4M;4O*D%B%U-6.U%434C/R',DG(C2P"4Z4
MEZ)>9_*"F< G8&J"4Q4P;75;8(;$*L!LJ[1R5A-D<*24P068&[@3-!=P"T.4
M(9]FJ6#O\#]4<CR@/ABJ\.F+VO(SI58%N.>%[28 '_ ;&H=P3XL645#8X/IK
M]8"D=]'USNPSQSI7TM,6MZ9G2*U*SRGI.4WH]<,0U/G)]@7Z ;]#]ZFZS>DE
MSRW+0O,E941^(UNP\K'BZV5:<S2D5N58!@%;ZY;U'!_65,E1+SG/(K@'V);2
MBNAK6\,[1A2PRRQ@Z]W\1WB^? <WOP>Z3I7@]')SFHDEFN,4C> 9%$0\4.'W
M]2JM$1XC+=AE7+#U/O\CPMT#9,KH:Y0&Z@M9K^GWE=B,1@=3:E5L97BP]9[_
M([8IY0+2UG^B5?T35Z]XY5F72I.GKVO-[1CQP2[S@ZTW_?D5VF<$UV/2"UPY
M9TI(1D.#*;4JI#(VV'K/_X,&T):F2YKJ<L,!$<^ZZ-J6=Z6D930XF%*KTBJC
M@ZWW_ ^1@'Q%%\AV?GWZ#<U)D#%H94ID>B6?)@G8O[F@P<L)^F2=@B&QT0HS
M](KCC* 588@O,5.F5KUV:Z;'"!=.&2X<O?V'>!]&Z3.:OR=/-%:A/" P^?[P
M;V4OK=$$84JM2JE,$([>[F^;&AJ^!4N</I/:U'I :-*?#_J_*WD9S0RFU*J\
MRLS@-,H,?L:8[$,J.H[R9@:F(U,.,QQ0?"2J*E]?U9K:,1*"4R8$IU%"&*>"
ML&+@3/93XBU&)36]8ATUH]' E%J56AD-G$;10/:],>2#IWVF3/E,.* SH6D7
M!P$!&1 )"T$E/:.IP)1:E5Z9"IQ&J6">X#A&WS(.7W/U]?GW1A'T9:UA'2,+
M.&46<!IE@6%"V+.\F_T#%"!'@IM8X53=YO2"M=2,)@%3:E5J91)P]$9^2^UM
M?RRA&(M1(M.KU2(SF@M,J561E;G :32>,%\2N"IUS4LO4SOPHJ]K#>L8L< I
M8X'3:$BAZNGGTKUS=)\)B.NIM+A*?B:MO+]1.\O5Y,R<UUOO\LJY/)=C.J\5
M8L<P_6YI^EV]9^\G) WST;U1C)5@#@C4-BQ]7>OI!\=P_6[I^EV]6=^-@8XB
M+G/Z(X& .((/E0_( V)U(\;ZLM;$CN'[W=+WNWJ7_I'89L2]GIE>;O2H)&;4
M\YM2JQ+;FQZD=^C;B+3?Q'03% [(=;NVTW5M)3:S,X..8?K=TO2[C4R_#^@8
M8!NG(7E#WXGR(7E 2G;]7%Q>>):R3U9?W)K:,<R^6YI]MY'9_X/&62HPVX0F
M]96I5YHHQTOT1:UA'</LNZ79=QN9_3_!@G5?4KH&:T$PIRE$PS'GF;JK]H!F
M#3:C;M^46A5;Z?9=O3\?^Z,9ZF=A)"A#?2$(^*_<\==:C;\Y>4A?UYK:,0R_
M6QI^MY'AGV9/<10 *HJ5W3UZE=9318VF@(W:^9[[=;VSTZN=]:VB*>V]J[?W
MV[94U^-ZH'S(4B[09YRLOJ)'FD%J__%CJJ1AM%O?E%IUZFSI\+T##G\#30XP
MR:M/!>Z A(_C:$%9&F$5+7UQZWFTQS#Z7FGT/;TWW](:12Q!XX$2UH'Y0$IO
MKR]J#>D8WMXKO;W7S-OSO9EH\"Q\DI/Y%@1,K'H&P2'5>__GW7#R,$?CB7\_
MF][/^@_# ?KVB&;#T7 VG/A#-)6#!S3E<NA/+ EBN\F#GW^Y=.R+KQP-R")*
MH[S+?,KHVWLQNR&/(M"&\RJY'F [5_J.D'PX @3S_H(EC4,P0DA0]$30 EQ1
MB-:16.:%/T_GI]O!QHCP8DG%=AQ(]CI$/%\NL\H8S^2,1E"9D><L+IY[MM?/
MM2)XZ5@HQ.\@L1"DV"L(XMO#6A01X%U&@$ N&RCH0B6OSO%&\FE*H:G*.>X(
M,X*B#V>$;<^(7-PQQ5 R'H]/T!B0<%EE>\5&M<K*>97ZT]FZ21L-7[V]]3*R
MBS9?=\2!);C=8NG,[M/=VJ9^OJ*G5_Z\6!AUAV4/+T<Q64"I=7H!7I05:XV*
M-X*N\M4W3U0(FN0OEP1#(Y(_@.\7E(KM&[F!W8JOV[\ 4$L#!!0    ( $B(
M<%9#)*I1T04  $\8   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK5EM
M;]LV$/XKA%=L+6#'(O5"*7$,M"Z&[<.VH&FWSXQ,QT0ET14II]FOWU%R)%ND
M%'?)AS:2<W=^CN3=\QRS>)#E5[7E7*/O>5:HZ\E6Z]WE?*[2+<^9NI [7L!O
M-K+,F8;7\GZN=B5GZ]HIS^;$\Z)YSD0Q62[JSV[*Y4)6.A,%ORF1JO*<E8\?
M>"8?KB=X\O3!)W&_U>:#^7*Q8_?\ENLONYL2WN9ME+7(>:&$+%#)-]>3]_AR
M16+C4%O\+?B#.GI&)I4[*;^:E]_7UQ//(.(93[4)P>#'GJ]XEIE(@./;(>BD
M_4[C>/S\%/W7.GE(YHXIOI+9/V*MM]>3>(+6?,.J3'^2#[_Q0T*AB9?*3-7_
MHX>#K3=!::6TS _.@" 71?.3?3\LQ)$##@8<R,&!G.O@'QS\.M$&69W61Z;9
M<E'*!U0::XAF'NJUJ;TA&U&8;;S5)?Q6@)]>?F 9*U*.;DT$A6;HR^U']/;-
M._0&B0)]WLI*L6*M%G,-7V9<YNDA\(<F,!D(_)&G%\C'4T0\0ASNJ_/=\:G[
M'%)L\R1MGJ2.YP_$6U5ER0N-F%*0YZ4KGR9 X Y@RNE2[5C*KR=0+XJ7>SY9
M_OP3CKPK5W:O%.PD5[_-U1^+OEPQM46P:R@U#_Q;)?8L@^2=N]B$HG4H4_/[
MI4^#)%C,]\?IV%:1%^.HM3K!&;0X@U&<MUM9ZIGF90YG;<^5S@W(*6)[)C)V
ME_$9M*F9 NPNX$WL\!@X#J(@Z2&WS3"EA!(W]+"%'HY"ORGYCHDUXM^AGRJN
MZN66>LM+*-KCD^9"'EJ0XC (>[AM(QHE ZBC%G4TBOJSU"P[ V!D+VWD17'<
M@VB;D2"DL><&25N0=!3D)S@(I4@U;\ZO"Q^UOY@&?@^=P\A+8C>VN,46/[/M
MP)^E?JRWVQ36SAS9*2JX=N&,+0@13KS^,MI6F,3A0&TE+=)D%.E?@)-I4=RC
MC /+H=+0V4QN9A6\#.]\8F&!';5JRK;".*(#:XN]CHJ\<<QU_62RN&^:PC#,
M0Z 3!''H]6"ZK(($#\ \8DQ\1A6-@,/V(E*2^/U]=]@1ZB>>/P"PHSI\'M=E
M@MV)3&C!W82'7Y7Q7BO::=(=Y^%QTGN?IK("^D []FBXPYFP[R"#"/?WQ6&%
M\4#KQ1W9X7&VZU?DT>Y,VYZ\ T8$=>L$;S-90*S2=%B1( X&P'=TA\?Y#E:W
MK* CVS1WE(83M<UCL.5^U(=MFR5^0 =@=WR'?X3PGH/JX#/B!194VPR3)!BJ
MVH[V\#COC9X/(!@D-V<=$YOW:!S%?7GA,$L2&@XDT?$C'B?(?@M_;LE'H_UP
M!W(PZ1 I=3R*QXFT.4+/Y>%@1,^COM5:;#L"S## ]:1C3C+.G"N9YZ*1SXWP
MEX4Y2;Q( 3!Z^Z?4'-%WSJ%G-+![!Y!SX'EYH-/D.SXF>)3N;K5,OVYEMN:E
M^J569?K1/>"-\OH/3WBO%.TTZZ-Y=I1/S02RX= -UDB9_*?HC7?A>1X&_BL1
MS'L5OT)A,/5#;XII@M26E69,J30,7>)?T\HU@B&;YW=0L$]S^A4JY).I4*KM
M^)56&AY,<W*YU4;VH'Y8]?^A"]PG[.6!3M>ZTQ;DF8$:RDL6(PL-Q3[UFG]G
MKW003V-*I[$7U<OGDVE"\11[]"4;,$7@N>/UW5CVZ-P.6]WTN<%A,L!NI%,_
M9%S]O%^OA:$LZ*5F<)Z) J:[G8#>Z@1IJY@(!B?<OY9PV 5A2/# "$HZO4.>
MU3M57F7,3*$'O2-S.%9;<X&Y!W*6RDD$Q-8QLXCV19K+"H=#H#NU0\;5SC'H
M-=^(5#BG4F(+F)D//<+O3] N0Q!$7C+$5YW6(>-:IR%5Y6C<3L"V5O$I2#/:
MQ^L8^4- .R C2:=JR+BJL31 76]GPX^MRS/G/.BP<\Z#\Z/;7G/5_@<K[T6A
M0#9NP-&[H+  97-[W;QHN:LO@.^DUC*O'[>< 6QC +_?2- 'AQ=SI]S^#6'Y
M'U!+ P04    " !(B'!6N!Z[A-L"  #8"0  &    'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;*V6T6Z;,!2&7\5BT[1)73"0!-(E2&VJJKN8%#7:=C'MPH&3
M8-5@9CM)MZ>?#92%A"2D6BZ";<[_\QUSC#W><O$D$P"%GE.6R8F5*)5?V[:,
M$DB)[/$<,GUGR45*E.Z*E2US 20N1"FS78R'=DIH9H7C8FPFPC%?*T8SF DD
MUVE*Q.];8'P[L1SK9>"1KA)E!NQPG),5S$%]S6="]^S:):8I9)+R# E83JP;
MYWKJ8",H(KY1V,J=-C*I+#A_,IW/\<3"A@@81,I8$'W9P!08,TZ:XU=E:M7/
M-,+=]HO[?9&\3F9!)$PY^TYCE4RLP$(Q+,F:J4>^?8 JH8'QBSB3Q3_:EK']
MOH6BM50\K<2:(*59>27/U43L")QC K<2N%T%7B7PBD1+LB*M.Z)(.!9\BX2)
MUFZF4<Q-H=;9T,R\QKD2^B[5.A7>$D:R"-#<.$CT?D8$9"H!12/"/J"/Z"VR
MD4STJ!S;2C_0R.RH,K\MS=TCYG<0]9#G7"$7NVZ+?-I=[C3EMDZSSM6M<W4+
M/^^(WUP1!;H$%>)+=$\SG3@E#,VXI$5)_;A92"5T8?UL2[7T[K=[F]5V+7,2
MP<32RTF"V( 5OGOC#/&GML3_DUEC&KQZ&KQ3[N%,+Q00 F*DJRMZND(Y$6A#
MV!K:TBZ]@L++?!,V(>YAC/7[V.PF=#:L@=JO4?N7H9:5B,A:)5S0/Q"W(9>>
M@QV60=\;8,<?[4%W"&Q@#VKLP:NPJ93K=N3! 0G>8ST5T8 <UI##5T'J;[U4
M)(MIMFHC'9XE/171(/5K4O\DZ92GJ5Z>7:K5[U:M9\,:G$'-&5S V:E4@X.Y
M<G#UVT/N$MF@'M74H\NICU?JZ("C'P2^'^#A'O!AH.>.?,?!?CNO@_]M6?AR
MXC-E6UEVX&Z)/ )N[VR[YLSSA8@5S21BL-12W/.UARB/$65'\;S8B1=<Z7V]
M:";ZZ 7"!.C[2\[52\=L[O5A+OP+4$L#!!0    ( $B(<%9F)[FA@@0  &42
M   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK9AM;]LV$,>_"J$-0PLT
MD4A9#\YL XW3;@76+4C6]34CG6VADNB1M)WMT^\H*9(=49H+^(VMA^/Q=[PC
M_R)G!R&_J0V )L]%7JJYL]%Z>^.Z*ME P=6UV$*);U9"%ESCK5R[:BN!IU6C
M(G>9YX5NP;/26<RJ9_=R,1,[G6<EW$NB=D7!Y3^WD(O#W*'.RX.';+W1YH&[
MF&WY&AY!?]G>2[QS6R]I5D"I,E$2":NY\Y[>+%G5H++X*X.#.KHF)I0G(;Z9
MFT_IW/$,$>20:.."X]\>EI#GQA-R_-TX==H^3</CZQ?O'ZO@,9@GKF I\J]9
MJC=S)W9("BN^R_6#./P*34"!\9>(7%6_Y%#;1I%#DIW2HF@:(T&1E?4_?VX&
MXJ@!#0<:L*8!>]U@,M# ;QKX5: U6176'==\,9/B0*2Q1F_FHAJ;JC5&DY4F
MC8]:XML,V^G%H^8:,"U:$;$B?VQ!<C.\BO R)4M18&UL3-+V0'X32I$K\N7Q
MCKSY\>W,U=B]<>(F35>W=5=LH"O*R&=1ZHTB'\H4TE,'+G*W\.P%_I:->KR#
MY)KX]!UA'F,6H.7YS>D(CM^.I5_Y\P?\-:-7K@D\XS13H&YLHU0[F=B=F&E[
MH[8\@;F#8Z] [L%9_/0##;V?;1%>R-E)O),VWLF8]\4#>N0RV52UDL(>UX2M
M*25;T+6GJ/)DEI;]8NK%T\CSO)F[/PZH;QCZ$\J.#4]@@Q8V&(7]!4K,3EZQ
M\A1G4J:TR=8>;+BUK^"(@L5>$/=Q+8:^1Z-!W+#%#4=Q_Q0:846OHFRP88^!
MTG@:!'W:OF4<3MATD#9J::-1VFII6$E1O!#C"F(CC7K]7PVA6DS'6>.6-1Z?
MI7H#DF1E(@H@;YIQ??N.E*"MTS6^Y'2]D+.3P*=MX-/1)'TJ-:!7W<1NBW7:
M&_0@B"U5W[?S3<D/9(9ZG1AYHXAU;IJ<5"FQRHS7KXW):?\UILT0!W.0\T@T
MZ3FS<[B2K-BT/[I8_1;LOJ$?3(:Q68?-1K%_Q\_"'*>JE8[9YJ8?^Y8UVF8;
MAUX4##-V&DK'1?3TF\/06F<EO:B*7LK;:<R=CM)Q(1W-R^0[\F*Q_9^\=/))
M@S.6S>3,[(QJ\7=GYT+>3B/OE)B.2_&7$O='>?8OI%7 !#<?"I*=S'1FUV/:
ME]FKX%2YFL LAC3PA[/5Z3$=%^3^++*"1KV/+:RMB1^&%E:+;1PR%@_3=HI,
M1W6OK7^"'P]$;;C$M1_W9EEBA:Y]38]!V'5(7_/:S=@ :R>B=%Q%/W!9X@>9
M(O?(^EBSWF7Y3K_>T32TT_-H[68#M*P35#8NJ%^K;2RD5WR/WV5K(.6N>$)P
MW.OA5"Y,*9L0%-DI+.^L--IU?BI87U^Q>'P:,?8J/HNES^(@C&-_(,1.B]FX
M%E\DQ'0X@ZROQD-!6G3;'J1[M&$O0*ZK<PR%O+M2U]O?]FE[5O*^.B%X]?R6
MWBSK$X_.37T \YG+=8;[^!Q6Z-*[CA!+UF<:]8T6V^I8X$EH+8KJ<@,\!6D,
M\/U*"/UR8SIH3Y86_P%02P,$%     @ 2(AP5KCN*9F8"   Q%H  !@   !X
M;"]W;W)K<VAE971S+W-H965T-2YX;6RUG&USH[8:AO^*QNWT96:]1L* O4TR
MT[5YY[0[3;?G,VLK,5T,+N!DM[_^".S8X<4*[+GS)0&;YWHDI!LAN*VKQS3[
MG&\X+\B7;9SDUZ--4>S>32;Y:L.W8?XVW?%$?'.79MNP$+O9_23?93Q<5T';
M>,(419]LPR@9W5Q5GWW(;J[2?1%'"?^0D7R_W8;9U_<\3A^O1W3T],$?T?VF
M*#^8W%SMPGM^RXN/NP^9V)N<*.MHRY,\2A.2\;OKT:_T7<"T,J ZXJ^(/^;/
MMDE9E4]I^KG<<=?7(Z4L$8_YJB@1H?CWP!<\CDN2*,<_1^CHE+,,?+[]1+>J
MRHO*? ISODCC_T;K8G,]FHW(FM^%^[CX(WUT^+%"50%7:9Q7?\GC\5AE1%;[
MO$BWQV!1@FV4'/Z'7XXGXED 52\$L&, :P;,+P2HQP"U$< N99@> Z9]BZ0=
M [1&@,HN!.C' +T9H%\(,(X!1K,.QH6 V3%@U@B87LHP/P;,&P':Q893GEI.
M:1;J8LBIL9NM?;%8]*FY:=7>DT/'JGKE,BS"FZLL?219>;S@E1M5UZ[B16>,
MDE*%MT4FOHU$7'%S6X0%%ZHJ<I+>D=LB77W>I/&:9_F/Q/QG'Q5?R9A\O%V2
MG[[_F7Q/HH3\N4GW>9BL\ZM)(0I08B:K8[+WAV3L0K(_TR*,.\(6\K!;ODJ3
MM;A&D-_O[G@6)?<=C*6<\6LQ+C9\+*XTG\6E+;W,,>6<1;K=BHM'=:(ZHJW^
MT:17M>P!P-YU=%XX5^MU5%XBPYA\"*/UV$W((MQ%W6WG?BNK7_V];\;W/AO^
M"RE6J_UV'PN9K,F2WT6KJ.B !/TAOXMB942TG!@V-^5X]L")FZS2+2<_!6F>
M_US'3X2B3[)F)UFS*M_T0K[W_#Y*$E%?\CZ,PV3%25B(TJ_>$I6^(4QA2I=Z
M#TRC8I;#]\.-RB@KCWUXKE9IZO*VX5V^"U?\>B0JF//L@8]N?OB.ZLHO7;)%
MPLR."M3+;B'3V4B8TR[[5)TS5:M7P$7F]) POUV!,:4SA=%Z#0)9(]4ZNWKJ
M[.JPSOZ&W&Y"4>)>G5[*'G@.%DC8$@DS#S"MIFV=&7.]J1!D5AL)<Y P%PGS
MD# ?"0M L)HNIR==3J6Z_(OG1:E*<6.9'_0HME:'.Y:\NF/)]Y_^%M,Q4J1B
M1K?;9ZN-F%!UB73:[KV-"^-"6I:ATD/"3"3,0L)L),QYN8U<9#X/"?.1L  $
MJXE..XE.>PW1/0V97>*3)APZ0B)A2R3,U%K]5V?*M-&%+61*&PESD# 7"?.0
M,!\)"T"PFE+UDU)UJ5+=/-]74[.F0/<[L<F_\&P5Y=6WAX_373G3[1*HWNJY
M=&K,&^.CM#!#A8>$F4B8A8392)C3IY5<9$8/"?.1L  $J^G...G.> 7=$=D(
M*4TX=(1$PI9(F&FT>C";467>Z,,6,J>-A#E(F(N$>4B8CX0%(%A-JK.35&=2
MJ5:*&Y=OV=:E5'<\R<-*C/Q+N=TY59QU7&:G>N,AU$*:=ZC(D# 3";.0,!L)
M<WHUDXM,Z2%A/A(6@& UC<U/&IM+-?8QR7@81_\*B<5I+J:+8CC<I%DQ+GBV
M)5'R(":4U0O"+K'-6ZTXIEKCB>)"FG^HUI P$PFSD# ;"7.0,!<)\Y P'PD+
M7NC9-:E1Y?RV79&*[3=>5"KK?'>NM%/.=,5H/NB4IQBJ)RC-A-(L*,V&TAPH
MS872/"C-[]DO U36NK2>&5FH5%IFLI:\[Z:=BJ/M"8VFS'6CJ3AIYL&*0]+,
M(TWVSAN:T(;2G(XFF&H:HPW/@0O-ZD%I?D<=QDR9BH[45$C'@513+@PJ9Z\'
ME9L]ZCW_TLOO;@4@'0 +*&T)I9E'6OT%^-R@5#&:<H%Z1* T!TISH30/2O.A
MM !%JROT;%"A<H>*_)%C?C+"/;G4WI"D\JR1Z"EPE>;=,S!YYL$*5ENC"1.W
MO>JTKI%EQW%4TQH/ DUHV:RNLM43VM"$#I3F7CJUC3IXO4ZM#RU;@*+5Y7'V
MB5"Y400D#]D3>GD)!LL$:C:!TDS:]F%0JC+:NBOL.$YT1[4E=KLGT8'6PX72
M/"C-A]("%*VNOK-AA+Z*8Z1396T/!6T]OH Z0* T$TJSH#0;2G-ZM)0+S>A!
M:3Z4%J!H=06>C2!4[@1Y!<^6/./@\0YJ'H'23-KAJ]"8,6L.=U!C")3F0&DN
ME.9!:3Z4%J!H==F>?23T-8PDG6IM.RNH.F\]AH0Z0Z T$TJSH#0;2G-ZM94+
MS>E!:3Z4%J!H=1&>'2)4;A%Y!3>7/./@L1-J-8'23-IV8:@SE39_\6=!L]I0
MF@.EN5":!Z7Y4%J HM5U>W:=4+GMY 7=;G=Q^I7SXV=/=[QD%X?= VC[=?VT
M:=U?R$LT6(E0)PJ49D%I-I3F]&DJ%YK2@])\*"U T>H_$S\;4IC<D/+M,GQ3
M356[Q"A/.73\A-*64)K)VM8(G1I:XP&J!4UJ0VD.E.9":1Z4YD-I 8I6U^W9
M[<+D;I=O<4:SMOV ZC.MX5)8R#,/%AS4[0*E65":#:4Y_1K+A2;UH#0?2@M0
MM+K@SB8;)C?9_%\V:=8VGXPUUOR%GKP$@X6'75D%2;.@-!M*<Z T%TKSH#0?
M2@M>ZN-UW9VM,TQNG9$YIEE[49,QI>I,;3XYE><8K"SHPBQ0F@6EV5": Z6Y
M4)H'I?E].V: 2EL7U]EXP^3&&[EGFG5J;MJR)ZD&8TT7Y4*>>;#DH!:9CCHT
MEWF )K2A-*>C^/I<F=%I\]X0ZJ"!TOR..HQ5:LQ5M:F0C@-UX]*P<C:],+GI
MI9]GNEL!T/50H+0EE&:RMDED.IL9QDS1FW*!6EV@- =*<Z$T#TKSH;0 13LH
M=/)LC=IR?>?_A-E]E.0DYG<"K[PU1+;LL&3R8:=(=]6RM9_2HDBWU>:&AVN>
ME0>([^_2M'C:*5?"/2U<??,_4$L#!!0    ( $B(<%81L\J/' <  .H@   8
M    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULM5I;<]LH%/XKC+>STYVI:P&Z
M.9MX)DG;V7UHZTG:W6<BX9BM+%S 2=-?OR#)DB40N8S[DLCRX?"="^=\@$_O
MN?@FUY0J\&-3E/)LLE9J>S*;R6Q--T2^Y5M:ZF]67&R(TA_%[4QN!25Y-6A3
MS% 0Q+,-8>5D<5J]6XK%*=^I@I5T*8#<;39$/%S0@M^?3>!D_^**W:Z5>3%;
MG&[)+;VFZNMV*?2G6:LE9QM:2L9+(.CJ;'(.3RYQ8@94$O\P>B\/GH$QY8;S
M;^;#W_G9)#"(:$$S9500_>^.7M*B,)HTCN^-TDD[IQEX^+S7_J$R7AMS0R2]
MY,6_+%?KLTDZ 3E=D5VAKOC]7[0Q*#+Z,E[(ZB^X;V2#"<AV4O%-,U@CV+"R
M_D]^-(XX& #CD0&H&8"& \*1 ;@9@"M#:V256>^((HM3P>^!,-):FWFH?%.-
MUM:PTH3Q6@G]+=/CU.):$45U6)0$? 4NB5R##SJT$DS!U^MWX/6K/\ KP$KP
M9<UWDI2Y/)TI/:T9/,N:*2[J*=#(%!"!C[Q4:PG>ESG-^PIF&F\+&NU!7R"O
MQG<T>PLP? -0@) #T.73AT,/'-SZ$%?Z\(B^RFNKRFLKP3= KS%!%"MOZR1E
MBE%YXO);K39TJS4+^$1N24;/)GJ%2BKNZ&3Q^V\P#OYTV7PD93T/A*T'0I_V
MQ2==;PHNG<E1CTRJD::HW"VF$.(4)Z>SNT/\#KDT#I*H%>LABUIDD3<VY_E_
M>A'5":ZX+CP9+S-64% VD,U;\YR9(.XDS4VV/SF"T3$C>"1E/3_%K9]B;P2O
MUT30J2F(.<CX1G<)2:HZ2W^89^HROM88'40,QFD4#^+JD K#&+K#FK1P$R_<
M=U3[(&,U1%V6 -EPH=C/1S$G%AH46ZEH"\'DP*X>XK1%G'H1GV>9H!4Z76=S
M)C.^*Y4-77^I+=NPG2XCI4[%.]ID[QN3I2Z+4@OL-(7IP");"*,#LWL6S5N+
MYOY%S\MIM6H*JM/&Y_2Y/?L<1P.(#J%X!"$,NNX6>#%>45*PGSJGJZ7>]ZBS
MDP46BG >#)#ZYWSA0H4''1MZ;?JLUE2XT7L'/K<<-=IZF86#D8B@#CWR-\LU
M*6^I'%19*:DNT&8U%(S<L&*\XC;JCV7CD;3UG=$1!^CMRHNEH%O"\OW:J3W
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M+W-H965T-RYX;6RM5UUOW#80_"N$4@0M<+FS+W:2)K:!V&G0-$UJQ/UX*/I
M42N),$4J).7+Y==W=J4[W^7#2(&^W$GD<C2[G!U*)ZL0KU-+E-6'SOET6K0Y
M]T\7BV1:ZG2:AYX\9NH0.YUQ&YM%ZB/I2A9U;K$\.'BTZ+3UQ=F)C%W&LY,P
M9&<]74:5AJ[3<7U.+JQ.B\-B,_#.-FWF@<792:\;NJ+\1W\9<;?8HE2V(Y]L
M\"I2?5H\/WQZ?L3Q$O"GI57:N5:<21G"-=^\JDZ+ R9$CDQF!(V_&[H@YQ@(
M--Y/F,7VD;QP]WJ#_E)R1RZE3G01W%^VRNUI\:10%=5Z</E=6/U,4S['C&>"
M2_*K5E/L0:',D'+HIL5@T%D__NL/4QV^9<%R6K 4WN.#A.4+G?7920PK%3D:
M:'PAJ<IJD+.>-^4J1\Q:K,MG+RB9:'NI4*C5^9 0D-+)(@.<0Q9F CH?@99?
M 3I<JC?!YS:IGWQ%U3[  JRVU)8;:N?+.Q%?D)FKAX<SM3Q8+N_ >[A-]:'@
M/?P*WF^QT=Y^U)SK3%T$GX*SE1[%X2MU&2F1SWI3BY?6:V^L=NH*@P0EYJ3^
M?EZF'*&E?[Y4HI' T9<)<'\]3;TV=%KT_*QX0\79_7N'CPZ>W9'>T3:]H[O0
M_\M.W@UT.%=?P?IT/+=T._?V6L>L9^J5Q[9]7XRWA0I1PHJ+T/7:KXL?U$HG
M9;T)L0\1=:UP(R%2989]04ZO="2>^&5P:PC@\'BN?D?,A*)L4EJ5-O2M1FL:
M&K(UV"@S35=T [OIK6\4^0;\*.(Y7N<A(NK:.D>1.;X&'0-'2"H'E6%J61GL
M.<7/GE8'-",PD+@#>-0-@S/M#6H?,A2"OQ6PD<7;U[?0ML*4K=>B,WZ\TJ5G
M4W%3#(]',G&P6>E*]VQ5RG;=X$E17</"0A2DACQQU1"=>DB8,-J"-I<K]61L
M;8V@52!5.II/^\(YH#JE]<S;0LG@1Q^0GMAK[W1FAU>93.N#"\T:1I1;U<?0
M1TL9ABU4M_64]#?!EO;):714.?A*HR!IZ'OLX4Y%9EL07+1<[VHSQT4(C;=;
MA0T="TC'AC+6<6*V R=4IZ>8;$+-#6%W^)Q)&8<0L,3I;5YOA%6&:BTA?".[
MS+W,\)O-'FMT_]Z3Y>'C9TDU 1MC):5)20BN'V#Y SBMVV;"@%'W:ZY2-1@1
M3\66,I9CPQ1G(4I/23CT\!=VDCV%;9^,PS:* 27943YOI#^N@-&J*]3U9613
M2B; PK2S@/163Y7)TWKB!H-4(0EJ)->Y^M6^'VS%5>'0-]KCR)6I2P<-"!EM
MIO[AO:VW[I=NW:_52*<D@F B]9J;2B><YV,O0(9YIVM6K'.#,\'Z >#<L4W@
M2(RAZGZNKBQO'O_THRGO+F^Q M4/[!!I@.M"3* #*>&'-X]%C-X(,4NUPVCO
M_ #.$/$U<FAFJMPX%$3NO0Q%;9,PT;W-VLV8$F\@CR$S TL4/TEYJ%C;4EU6
MI9:03^?'\C-A'S(DC'WYN,\:@S>$,D #,71"7=@@"NV%.O>(N=W\.5P4/E#9
M+Y=%*V<[RX69EH!3BUX(<3V3 " .,>[-NY#8+-)^R84X;  &,QD)1+2_<2QD
MAE,>KX@3BO7LEZTT'@XR8J=1]0 CE(T&QF9YDEPY2$?3CLXTMI2(;VI5U'"N
MGJ?1_ UU):QA<_)_FGXE[F+,T U.C@^\@UECI9^_PZK'\Q_QHN3<)CNC4SN3
M7T5H@1OM6,HSYI2C-8P@DR*:%FIZD E&:/T- D;9C\C'1[?(\]T.ZJ6#4)'/
M:[8K 1-2'ALS5LAOC!?;^(;RR-1&$0PV*G?<JQ*G$!'>NA@4MDLPLVOBNB7:
M*_'>H>;AG97PYG: 5PQ@L,'-;0Q#TRJHH\Q\B'/M8!Z3+?@F\6!@ X13P9.:
MR2( 5X/"GIAW:E62LT@P?6876PL4Y?K\?^R;%(<]&.<OTJM9)PS-!(4I>5'N
MKL PVO''$,LVE,XVDQVS=X.Q(YW >T4.3MB-+[S2TM(-UG&K5=-[3$9/@BY>
M<_+\2R]XBYW7]HYPQ%W(NX )@\_C&_QV=/O]\WQ\[;\-'S^>WN"$M&#IJ,;2
M@_GCXT+%\8-DO,FAEX^ ,F1\4LAEBV\XBAR ^3K :*<;?L#VJ_#L7U!+ P04
M    " !(B'!6*FT6 'X6   &00  &    'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;*U<6Y/;-K+^*ZS9JCU)E:2QQ\DFZ]BN&M]R7)7$4YXX^W#J/$ D)"%#
M$3( CD;Y]>?K;@ $)<KV;IV'=48D+MV-[J\O:.ZSO75W?J-UJ!ZV;>>?7VQ"
MV#V]O/3U1F^57]B=[O!F9=U6!?QTZTN_<UHU/&G;7EX]>O2/RZTRW<6+9_SL
MQKUX9OO0FD[?N,KWVZURAY>ZM?OG%X\OTH,/9KT)].#RQ;.=6NM;'3[N;AQ^
M7>95&K/5G3>VJYQ>/;^X?OSTY7<TG@?\8?3>%W]7Q,G2VCOZ\:YY?O&("-*M
MK@.MH/"?>_U*MRTM!#(^Q34O\I8TL?P[K?Z6>0<O2^7U*]O^RS1A\_SBQXNJ
MT2O5M^&#W?^WCOQ\3^O5MO7\;[67L=]C<-W[8+=Q,BC8FD[^JQZB'(H)/SXZ
M,^$J3KABNF4CIO*U"NK%,V?WE:/16(W^8%9Y-H@S'1W*;7!X:S OO'BIO/&5
M754W3GO=!26RZIKJUJP[LS*UZD)U7=>V[X+IUM6-;4UMM']V&; ]+7)9QZU>
MRE979[9Z?%7]:KNP\=6;KM'->(%+T)V)OTK$O[SZ[(JO=;VHGCR>55>/KJX^
ML]Z3+(PGO-Z3,^M-L%G]S_72!P?E^=\ICF6][Z;7(X-ZZG>JUL\O=B1>=Z\O
M7OS];X__\>BGSU#[7:;VN\^M_O][=)_?ZFI1_<>[G9GY^T;#)&N[W:GN0.-7
MIE-=;51;>0S1,/S@JXVZU]52ZZZ" '?*Z:8R'<]S#49K6$O85!\7MXMJK3OM
M5-L>Z+7>!0Q5 S4[9[#XKM75-Q<\_.?KZYN+;Q?5J_=_O'L]?_S/Z@:\Z*VI
MF;+\=)>>;I2O:M5[+-L8[_H=<>&)FH#QZ]8N0;FN;6>W!Q8+35"K%="'*,&#
MK3JDX:L^]$['U_SDE0CB[W_[\>KQ#S_Y:ME[G('W/!,0[-1H/UE@4;TC9/0[
MO-%5L/PJ43R+ZSK;J7OC>E]=FV96?="MT2M>]@U3"]YN==T[$PXXOE!]0],N
M7EU_>'-+OR^^K?;@Q..06?C8I57["B?XJW+UIKKZ@<WOT4+DEJ;-*K6UD+O%
M:@Z4X S\#-/KMF^@$T$]X$CLO?',E=.MXF/"ZD#EOFO4LB56#LZV+8^N<?8F
M8 U KG:D':12>KMK[4&[+#=O18421UB"-6E6=?!P49#8J+60;1],:_X:-+E6
MSAV6JKZK,,[8!K.VMF'=%NE'$=-2D(2&Z /H:7KQ,*W9FA!'TG)!UYL.<]L*
MZNK$#<D:X*?1T&C0RC.W.FRP704G6WWJ58LM2=A;$A%; @D+-(7#D9BA94W5
M61H*B*)3F5(FB-UN]5CHO!<-/FCE*DV(7 %/]7:)\TJ8&G>3Y< %V5*OF0=]
MK]H>=LIKI.U7LGVF#MO@S K3WEEOB.,9J2T<)^-"H=YR"GY3K1 M^$7U$7J-
M$6]\,/# V)GH$2@0R>'E)'# 3D N!2VD!0-*D-EC[T^] 0$PR0Z1!PL8+&W5
MG:YTWHIH41[12C3UL%&A-%DH>$];@1KK@B#3E/0GZ>/%2_CK+/9<5.])$R&W
MM:6'2X+.64EF$KMGP69BDVFQ#6TLI,8F!:+ %RD:$)TUT0<,HO$K95Q%B[&
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M)_S$]7H4O4W,'[UUHZ"HB-084<U(F0IG5CC\3G'D)1-\5E6*A#A@H'^K-T/
M,*MNA\GOBFB!*/V 7SAV.GZ>Q__0B^-5CG,2MA^L 8BA0 ,*T!J,;D[C$?BG
MPEGG#,Y1&L,^FX,2@AZSAD-H<?1!TDAF$5:&?) K6&33G)U+=-#0"G2$/0Q.
M22Z^U"<!D\AER(*1I]..V3F39R=MI.HJA7#9?5;U1M=WK"_IY,D,)H*9R6@I
M[EN&;BE>!-%@21^2EE/N37'4]#G=3@=[Q6)PM5OMF(!&+T-*Q#F9*-[MU(Y
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MV@G0_4I1!0P;9V#_=V'Q'5!+ P04    " !(B'!6)Z,6;,<(  #I&   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6S-65MSV[@5?M>OP&AWMLF,(HG4
MU8[M&>?6IM-,L^MD^]#I T1"(FH28 #0CO;7]SL 19&ZV-M..],7BP!Q#KYS
MQ0?ZZE&;>YL)X=CW(E?VNI\Y5UZ.1C;)1,'M4)="X<U:FX([#,UF9$LC>.J%
MBGP4C\?S4<&EZM]<^;G/YN9*5RZ72GPVS%9%P<WVC<CUXW4_ZN\F?I&;S-'$
MZ.:JY!MQ)]S7\K/!:-1H264AE)5:,2/6U_W;Z/+-E-;[!;]*\6A;SXPL66E]
M3X./Z75_3(!$+A)'&CA^'L1;D>>D"#"^U3K[S98DV'[>:?_@;8<M*V[%6YW_
M3:8NN^XO^RP5:U[E[A?]^"=1VS,C?8G.K?_+'L/:R;S/DLHZ7=3"0%!(%7[Y
M]]H/+8'E^(Q 7 O$'G?8R*-\QQV_N3+ZD1E:#6WTX$WUT@ G%07ESAF\E9!S
M-Q^X-.Q7GE>"Z37[(!57B>0Y^ZBL,Q6\[^S5R&$C6CY*:J5O@M+XC-(H9I^T
M<IEE[U4JTJZ"$1 V,.,=S#?QDQK?B63()M& Q>,X?D+?I#%[XO5-GC?[G;1)
MKFUEA&5_OUW!;&3*/TX9'51.3ZNDZKFT)4_$=1_E885Y$/V;GWZ(YN/73P">
M-H"G3VG_3^/TM-+ID/T.O>Q+)MA:YZA?J3;,\54.5X4JEK\)YN@UJ7G8J:&9
MM[HHN=K^],,RCA:O+5LWJF5+]0NIL%I7EJO4OKSLM>!\$IR"$M9]M=BZARP0
MQ4H8GPD_5]J)E'TV,@&<.[E1<BT3KAS[*_8W[9G>K;7"V<O>6VXS)KY5$E!)
M[V4/>2JV*"ASCP:XKH""_<@F\\'T8MI^\&;$K_=/O;M,&_?*"5/ H =A71$4
MOM6FU(8[@=ZP<LR*I#+224%ZE\O!?!EUU!U.0;XHA/&.*GD).^:SP71\T8AT
MA[T_Z@=A%.W=W@I)-YC-]D('X]X7[:#?GC2!S(ZF@_GTH@/T:*Y6@C>S:!!-
M)QV_'2W^_PCL;#$81\OVPW\GL%$4#:;S>4??T=QQ:.-H$"_B1B8,>U^'=T-V
M.J[3Z6 VF38"W>%S48T6"[]=!^3A7!/5>#(=Q!?CMJ^.%7BWO]^[G:&,67#@
M%P+PL05@WUNX#QHK0AZDC+M._\!1C>,>-AMJ-SARI66)!@VP[EQS20["[W&<
M=L20'>;*3CF00'UQG#?GE75%DX/X#C!S+F=(Y\D8#WV[K0UD>N5 K"PK40SD
M#:D"#R-"LS8:8 !B#PBX%:B4\>HW0@G#\WR+S0DXFK\]T:Q;TBU\%=4ELPZ*
MN(%U*SK0J/-C?5DY.\!ODE<IK3("1I(/<'2F J]61M\+,TH%'&S8-ZIGS!*F
ME0S^'&F#O=?"P-YVDG C6)(C05#@E!F6_44\B)Q%H$4N\X=%!W\F8:))LBV3
M/C-DO5WJ/2:"0O[ 95YCKVE@'6 <2P B4^R-?I)WPM"&!;D3>0'G4<\;SD#,
M\MQS3)A(!3,<-U/!30 $'<=IZI5TNA\1'*\'#QB"293"0\ZW _8HSOJG=:H>
M83^;AH.CG#V?F!U+SI0#>=L')JT3**"+ZZ09-N-V)1B*"YY]JM;2: D4:224
MLCSP=Q_04(L5LO%;A1U; IAO\K JL;YR,I>_A:*AS9GVIX?+N#K($4PY#Z.5
MY4+ZU:E$)Z)M*$W4;C0 A"0C[X?<#J6(_#3IJY(;MVWJ]4&H5%.2?VARUN[+
M$?6P/7 18IQ)Z [H$3"0>E9J2=X]A;,#9&<1%2>V0%@813UTFZT4>8HK!7BI
MI;Q"&II WL1WR@#KN\$_JW3C T\B59B#'EEP7\,> DHM@1<W(J7\J:#5[H]D
M^(JCL!/W# LLM95N5S. BEN4+P9<-XWO;W4G?(9X'FYP+C&?*;0C(GJTM/>)
M.TK9+;LML 7V3]E7A7MP?OCXOG97^@1EB-A6<$-9!9-J:GAQ,</#"S:)Q^PE
MGN8-/3QF#@?R((6S20S9*)Y MLL5SW'$K@JBB,MQ1/M'%]"Q6.Q8XY[H1;/!
M)%YZD(MY[$$N)WNZ=^2TZ'_L-*)8LVD M+SP>!9[YO6LUP[HU^^G80=Z0,/F
M8_+^?-ER?B!GC?.(/$WCV&.-9HL]V)I4M4]]SRI2'(YH!L+WH6KO*=Q5+3!D
M'*=8J!M,^@;$60(Z)9U?0NA"QUNC@?H>1%L<*]+J9"$UA^8K')&O+*=>TVK:
MS]53.*DX.HAO<NN\2EP5ZMJ?IN$<#8<X"1TV+.M)(%FWXWP"7M&%3)A0#])H
MU70II=W.<"/M_?#0E?6I%;HG^@WU$S0AX<_^EL>P[2/VK92"6=9RLWW63)RT
M:(>6J?JX"/2+D#5^),.4;W1.PX-Y#KR&9+ K:D*P7-[C; _G$IGB<;8B N8#
MH978M>RT481%5G3:'-H_E.,]SBG*W&WM/)P]B89S YG&DO;[/9T:X"A(1.D"
M*VKI=93$U(/1E1;#>4-N/%8?:JMQ#!!'\W%K95A@2>/AI,6(V)^YJLB_\.&D
M&R\"9D*XI#T0I*2 .!9*XZ/O]1-6<I<O24'?FXX#-FRWFHUGU!3".NJ!@>S)
M#4^2JJAR[FF]CRM84FE$1M\B474DUD4-MY&T)5%3B58Z^\)<0<LA<Z7]:8HW
MC;$=H9#R)VKPL"?NK"\K=$U?SNN:SZZW%##:)ERTPJCM/@]!^Z2K[V+']2&^
M$_TD=)U"H5='MB)V0GI: O?<GG]+V?\(_"@,N@0 O]'5)D,5N7WNM*XE(6 O
MPM8O&VXHBT !I+65,#N?K32LJC_+^E3'9HT1L+9^16VOY%O2OROB5LW] :6D
M<YEL2<)_S5-ATR=L1NAR[S:D*9%  @11>#OU )2MB5B=4KC?^B"$RW!]M=GI
M\!]TG_&B$2%%J1V<9CW4SJB$E@<7E*AU/_GWKB##4Y\R1ZW/SSAP-_XC.]V-
M*^7"E^AFMOF.?QL^7^^7AW\"?.)F0\'.Q1JBX^%BUD=3]Q_6P\#ITG_,1DDY
M7?C'3.#6:6@!WJ\U>' ]H V:_V[<_ M02P,$%     @ 2(AP5GB,&LH,!
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MP7M"/8+Y\+M15@5U4U"8$R^AG%^;TD&6>_7Z[)]*VI % AA6V4)9PO$9X9C
M/#K[93LNC>078C3J1]$0%U'_<CXZ^P0_RD6J=L:]'+T2DVDDQL/H['YMK#_W
MRF8[@R:7XBHZ^\UX^/' ,K-HQLM<S2Y9WI&ER(?D8&BL3>($XSZG@!=6@[9U
M2L&)TY+,A=<R8E94 T$%P*L<D8(WU]*NE!N(^[(H4@4.)Z5T'FI(H/.4483(
M[8'VC_O[3KJU**1. L0R4U)@&[59GA(9EBLM:]<&/853"(+ 2B=L,0E<LC8
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M <MTHD<*J8YP.+4L>,8ZU6>LD::#)Q0 R*2DZ5=E!YTZ7(V@6TJM=\B<P0-
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M=7]8PPV.51 @TOF#"UU)9F3*X:"266$R,UW0QM5FL]UI@FL, !AJ/= <-_5
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M6''3V6WU535WB$+%J)04FS7\M=)$BESYF4E#TC^65!T1&(5$/8?"]W _M:*
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M]$Z/.Z$KJ!^\*?D#[-AX;W+^.5-H "QMP/N) 53$!V+0?)&__!=02P,$%
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M7^@=_Q\(UD9VV@>*Q[DY$?^@)5N$,V20@CFS,F!8/0,IE C,F41 Y_80JE.
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M08[WDNN->_CZN)9H'/]V"O+6N$,AR(3SU&&R!J-[@:L#1W]$/B9'NVP@ELR
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MO, (71:G"#PO0:'/"^AW7YP-F&A]1\@4N &RP!]!B_D8D:^$KBDA2.(O_MQ
M9'EV7I2RK,K<W.\^M#_E%D:*M97:4.#B$<Q6&AV3#'95E>E2R%MIDD+(#)+A
M?.,I\.T [)7KO+I>BSQ+=PX3M\HHNQ DK3K*MFP#\=82C_,J3<12(; 3)<H<
MXJUTK SH)QJ,0A!<JLTVS>^5<B+ZG^TEQ&6,HP%)T%)!:BH;$PV@?7J<.42\
MU>6:G[_+P08M_N!)_?#=/ IG+YD@"[7.4_#?W(<"\QN9^A,0H4.6*>B**&YE
M(4IE@%R2%$N_<K&JRLJKQJJ6',BK#00R@?P!&V:)SJX/J0[&HHQ#[M9:2)34
M:J48Z:%=5@!01&V6(."1A%G$\=8\\+#K:Z.NP1ZM#H/1>!P,QW-14)0PA3C?
M;* N:UQ=%)5<IDI46]PCIM2=,K$N>'N;&R\/[3CF %9ORG!VA4.?"#"G^N+!
M/3ZFG$7Z9^)VK>,UFT(FX K,+._;CE&37GI'J'T*82;^7F7.PFPJ-OUQ&FUW
ML;L1&+0[@(?'<J,:$S4Z9*=%6<!^Z7SJX]6OG?T>&9Q<%AF*)P+#UTJF>J7K
M&'\,,-A'RSRK"G4 )X(67+2!@NS#_N/\''RE%7M&+(NUOXMPT!RIIR.^'=5L
MA>1&%UATPLLE:)<V1"?!8CP)AL.HY=6';-?Q=!L?%?#-Z&\.@=G[R><8.T!I
M"UY)!B>-3P)M9_?V@E_J0F05LPD&'"O7L%3A?((HT2:99; 3:0R%)I1.?M E
MQIM%JC>Z# A5$E7$1B]QM%N:J;M2%' $!79=5FEM@@!I2M+EY'0Q?.F^/DXX
MIUQI4X E(]EHB;QG=Y1@#7D% BB)J+I7TE HD$-N\@HNJ,C'O"2I*@HK[O/P
M3$S$]U[UUC:--MK(\00C.593N<]I[1).(UNC84'B-Q"X>!Z=H12'!(Y%QPKK
MTB+V4W "?@@(=XP7U?(_C_>+?!?;R[5$WH6ELKP46ZD3!(5*X2:&\-[4@$LI
M$TZI:/L][F[!##VGK3%Y:6K7-_F'!>?HO"7 7DG-AH(#6B^Z5>04A9>CHC/P
M?"NM&K:5B=?L( T3I-:8L9^5Z>3% J-23GFEO.-H(4CDM+!,];5TJ,->"%C,
M 8OR!NQP:J%(R]#0,#&KN^*0ZJ#T)L;#8#:;!&$3XXSW'9IU]!XR@SR,(S9R
M5CF!+;%?,C7;PP$6.%UWL-0V6E3K)97A'5C 4:*H+]@_03QG!\VK NY/J'<7
MJVVY!Q3!CLH+7^UPR<XA!SN?O>C]LHLP?W)KII)S"1="I[E_XZTO 7J_MLN)
M<H_94(R#:#@.IO.I>";"Q2!<B/D@ZOWD_#L*1M$LF$.G8328AKW+VE6?B]%\
M%(1X<B9&@VG40U.Y4KKD1]/1, C#$(^B<+!8/,1%!$"?A(L@FDV(B]D@G(&+
M$-=1L @G_E2VU,'M8',T"V:3D=T^7@C\H>M@,9GU_D X4*U&U=0= ;R- HH2
M(G?R;/:6IJ+2L(Y&!Q\+%(N50E!P=T3^3&Z1:,"^(81&$)2W2NU45$UL=0IK
MXHS6?:URXBU.\X(T!8_\HLIFTV/!$TD_10H@;27$-(4*$@*8/\?C<ZQ7.Z4]
M B])-%UREK*S$3NF<$&?'Z^-6H5A$T>$98BP([&PI;Z#DY?-,07<_)\44I=[
M(=6S!H:K]O;<G)'DW,HHM7$VV5&OQYOFS&<P\'2(?Z/A8#[K?=RQ*24O)U&#
MS,\H4*9S_%\$BT7X&! YTG\]$4V>%/\/ASN;+GH).=Q5'>JC^2(8S><<Z-UH
M'D7!=$IQCD>(1A=.GI*G\V",CR;38!:1"NF(J0@',W'IF[[/K*$KGY!.-PLG
M=]EVX?+SU57_+/C_;14ZN7 QB8))-/Z?5;M-OB0]V91(5[X'075RK<FEZXJ=
MRP:OYR>P094/5%K$7$J6:\/#!10@!L&#,BBI8AMJ(%9MZ92P*2H1TC4G<6NP
M$W0J,M1I6S(\U\'2X5DM$5E,HYIF!13ZCN /I7Y.0$VN"EC0>>)F#;*T>)TE
M=3V\L[#5Q'!=QH%_0#>@-&]5QS3S,?X'8Y4#]QIR'@ON^T6\V[S#*%>&1XKI
MPSL&XH.%)-MN35& 36J78W?:Z_Q9PWB,3HXVZO;P@9M":#]6*F'S/A-#).4-
M*D28B"WDAQ99[FSEE,C!0W!UHAN<+X8H$(>>OWI^\F"%R"<]ERM45]2K$=]-
MLV831,,'#[!V]GHG)H=I>N#Z\:X=N/JWX Y[_ +\L)(,K21HY?ZAY5*GE!.(
MY4MI@!J7K2',IR:16,#[U:6G]\J4D!I<)! D0<WH#.7;$ZX&'&U(IYAT78W8
M"-LI!.J^\O"HB)#$Y!L;)EUR%,'9C4T.._6-Z61#7^?JK%)U(4:^$\>Y29IV
MG'W4(/ZI*J%%W$O&:X!&J@:=8>U:VISK4CZ(HC+S(4D+&L[J^.R0KQ?;:HO1
MF?;=Y"F BQMD:CR;G[X)\[[L"7M"=9)HX07D;D\Z>3'Y9STGV-?HOB*IB4R4
MVE#WQY5=S-C*'E>9;<XS'=!;JIVA8TG-X3IO,(HT8GGG6$7:4_K&3AQ0IZWI
M/0*?T%1!),&N)ELE8I=9[X2:UI!E[;Q4 JC;_OX8N7UA&\?6WB304J;L*ORN
MR"K7=9^$=5F!*#0L#!CKIB0>-]7E+C7DYQ YEEM-Z=9Y4D='G_?F "WWZA8#
M-@ GPWK@2L>%TR"<AW7C=Z0UY:4$>X&?1,$<Z7W@D,;FHUC:R*WUWFBSUK(%
M+#NU@\Y,Y4QG[\05% .?\QMU,X]"5"9(LN2\7>U2 44U\G6F5V@M,NCDO=6I
M1:1/]A61+3-^M./PCQY[3\VM6Q&<"..IE)WJ^@@<T5%N\NYA_D6OTSJ\[^3/
M5K-UL#1O/)9UU8J=23"?38/A<-3KR.D.5_9-4&>X40\O#N[@/.%Y+GPJZ\V#
MR3C$49,3;[3NZ%JY!4M>T*Z,N,&E!3ZRJ+4HCDXJO,.Y:K%P2B^Z;=NCFC.2
M4YK8IL5$P7'S+;^%?"9FP2BB\0+*_W#1^TEEZ%I2%X; 4$TO*;DF7@23T1#+
M9^.H]QO7OL5#<CZCV)I/>'HQ#L93VYG9PKG**"+@LM]V=\<Y,LY1X")G1W,X
M'D2^6O%]A"XZ$X2E$JT3D-D1;E#E3G=F2Q-V9'@"91=?H:U$-)@X$YT<5SU5
MGB/^[01#W_57RS6"[AZ0ZZ&W6<SK<!!Z7FU]\5@-4(C]9=*AC+7"#<2/5,O_
MP47\!W0Y:5Y4A%6_K4^-)*PEJ*#9,+\NO27NG9U]\U,5OJQ\E\KXR_GG&)TE
MP: M<:A.X2%1GJBTJ9<:U.3O /AU#8!F8\]]3""[XK(+GBU9GHG)8+$0YQ1Q
M\\&8QVR3P6C"=R;CP7S1^Z2++^<KHWA>IL@9P0UD"P=3M$3G@B+K>]C6_@JA
MSN][E]Y"*+%@4DYHLPE<E9;,YH,%+F:SP<C^7M#O9@\58XQ9;)8S<$CL3.$\
M]56SF&ME:O'NM4KWYQCD.8^0@!BKMQS@?3H:S*UXDY"9WUN\R_00K.XM.LUL
MIP:NG;K8#XU'E&G4'^R6JLT-"\'^#7'MN5T?YQK-O3 XX-*!R!2_T5S9X1)%
M2K>,O[:Y(>T(\Z@IWVDYFH\+ZF"V8P'#G$I!*8@ X)R^+R%A@1F,#+;20H8O
M=*EVH*"%+PWCM,'W*FQAIY>FHG,JZDI>OZ,JFA'!,>R@6)<U+R3BMO7VG&HX
M;:<DJ %:3UP:K=\0=TRZ;\C'#",ZYNT*Y-J2YGVVQOUXU_RNVD9W%:,L!9P2
MRZZ+X8)/IG%%,>7+P .U0+>.]+[YL![]-(-Q5AY$V?,.REH!O:4Z [N=<UJ<
M;MV'62XN*H*';Z>0O7LF.9?D\<0#8T?7N')5U7K7U +_H#6M4/N(%30W4[U2
MZ$&.8&#G/8K')[AS!]BZSF GKXC,RC4OQ'LT?%G *=SG"QN%>C/A^^%+VW9:
M2WI=J0YNTGC.QW3MT;=4.?BVN[.<WV%;E_ )WEFN$ZO^14P]%MA]'5>/SFP2
M?M[$?3AT.-Y21*-<FJVI8V]1>'#)D:F,E7>-FI@^]K+6)"=QW0]KDX"$VC"W
MC-[VVQ:1E-G-0@A0V8T/ZY54#?I(85T>R& NQEN'U ]U,_WMPH)CTO  ;ELM
M4QT3)AI)!<=2YUM$QD;&JN)O%)Q$3,V68:[&ZGQRL&?XO3>TMNERHXSF_(8Z
MMS<QS3ZR#NS1^ O*3R7]_Z;HRQ=R#=<-4QB(^#Y.E6W!5W")+-;@+%7.B;H6
M'8@C=8-EK0DH&T=U:%*0=]#X]\%G;*&/-RI#WSX@/54;?LO(X ^K5<9:P;/_
M6%VUX[1;6^P/U#+0]"C).<K'NNWQ<KO 'LG?_=#2UJHZ@;(B.Y%CAR#2S8YW
MBHJ=F@?*^:9,+@:'/CR]:'TJO%'FFC^(YB\0L])^-5S?K;^Y?FL_-6Z6VP^V
M?Y8&08]P5"ML'0YFD[[]9,K_*/,M?WB\S,LRW_#E6L&S#2W \U6>E_X''5!_
MB?[FOU!+ P04    " !(B'!6"G:5%_P*  "P'@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6R566F/VS@2_=Z_@O!D@PZ@N"W)9XX&<LQB \PD03J9
MQ6*Q'VB)MIGH\)!4NSV_?E\5)?F2W1,@2,L46:SSU2/U:E.:'W:EE!,/>5;8
MU[V5<^L7-S<V6:E<VGZY5@7>+$J32X>?9GECUT;)E!?EV4TT&(QO<JF+WNTK
M'OML;E^5E<MTH3X;8:L\EV;[5F7EYG4O[#4#7_1RY6C@YO;56B[5G7+?UI\-
M?MVT4E*=J\+JLA!&+5[WWH0OW@YI/D_X0ZN-W7L69,F\+'_0CP_IZ]Z %%*9
M2AQ)D/ASK]ZI+"-!4.//6F:OW9(6[C\WTO_)ML.6N;3J79G]6Z=N];HW[8E4
M+625N2_EYE^JMF=$\I(RL_R_V/BY<=P3265=F=>+H4&N"_]7/M1^V%LP'9Q9
M$-4+(M;;;\1:OI=.WKXRY488F@UI],"F\FHHIPL*RITS>*NQSMU^*)(R5^*K
M?%#VU8V#1!J_2>K5;_WJZ,SJ,!*_EX5;6?%KD:KT4, -5&GUB1I]WD87);Y7
M25_$82"B011=D!>W]L4L+W[4/O%>VR0K;664^.^;N74&&?&_+IN]Q&&W1*J2
M%W8M$_6ZAS*PRMRKWNW37\+QX.4%?8>MOL-+TA^-Q\75W;J%45_LBQ7O*R5<
M*=Q*B7=EOI;%]NDOTRB<O+2B  S 1Q:S4/ \9:NDL4)1? 6BH_*Y,FV$A"Q2
M>L!/>K*Z2-2^8+&25DBQJ+),W,NLDKX4,V"!I*ER"=RPCNI(&8,=' (EL;^S
M <E!K#:04)3\8FW*>\UP -WFJE +[5A/[<US;)Y126E(6UWL&<#^*!R&2Y*+
M-[*@@M)YE0N9EU7A:.F?E28U2*AUTBF_;V76)7S2%V]8>I'H3'M3\.]@\]JO
M7J# BW5%>\ZW0J[7V5872WY/LBM7FJU8J%09F>U)$8;W]8*:@ AM:^#4?T&>
MI/B0%ZVX9C/+RB( ]MF+J__ 7%^.!^&ZXG!1J*X^[+9JG"C=GDJTOQ5/Q+6(
MXF V&(MG_".<!H,)?ES=L6-V"@>L9;EH;6FD8DTP&M-Z>AH,1EC\60%+"T1"
M:*=RB_'I+!2C673U!0&2)EEQ)J7J'@UCG=/$!!'1B,ZUB(-AU(@;CT.(^\3!
MY/R-7F)\%-(F[Q#<):G8F731!+I,X O(&.U[0SV@UUD%:QN!NZ<[O2ST0B>R
M#FM)-EBRNJN..O)92"2S796; OZ!*B>!.Q.M]Z>B7EQ])(>OX6Q'&<4)DDA#
MZ52:C30IA2\>!Y,XHH<XF(PG$(0:2.J\)1\C28W3?_F!.!R+:#Q]/ IA&,QF
M,S$.9M/AU=T*5CVGMIBR5^"^6EPP&L& (!J.KMXDB:DPH78OQ3P>3_!_.)U=
M_::P6*"<YJ@IMQ7A+!B,:>4X'/OH^O2*1R+&?G4S#R=#\4ZNM9,9U\.7IS)?
MOWR/\2#&OG70KKZ6F- 9C-D@&")5AI,@',17?W1D"4% U\IK,2']IYR&PR$>
M*0\[HM2615<.DIE#Y& P&4:'BQM7:(4X,TEZ7BZ>5W 2BZT+<3KC_:-@./';
M7XKMM9B-O+X1SZ;LZ3*M*^^_GH!Y<9I[M".]9( FY)$7T;XXLW_J&U.%N<9A
M*OD @+M$0C? >5QH3=I@&3@I)0--:YP%Q";]NW0!?!G%>0ML?@+'] =H!UG6
M.!!#@_YD-\2E?JG_H;^L%7/,;$L-ES6PME'<:]>H"UGG6E[K;?09"V>B=VU6
MBF$.D(HV@,A2P?S /KZ+%:6C!T X =F: N];)*QM *K+W1O8QHOGC7HJ]0X#
MI=4Y@7RMM1?8J3-IE*HU\0. 1 5<Y/V6: &F7;>H'-$NK)+SK&T=:64:[R"=
M= G4 B1N5AKH0X/H#S &1P61Z@4V5H@;Y4/=RFDM95(M'&E7P?TDOVGG<^7W
M:=_T+W&?E;;<_J"OIT">TV0R^4%CGC: !VB*L5"4Z% H.*$[J7+H<6!FJ8_*
M8U$C4#U7$5TA\FHQ.0)&U0J<$\!-IP+;1=_2R <R;T$P0HRDNTC=A33WZ=&I
M*7&UM='$4+(M-P.CJ;SV> %3Q)95G>*(\DA"+WVW\4VMZ6F@7]U5>!R#M NC
MKGL?/_W6>W8HDL2!F)GR@?,](R@(1W$_/L*"\:@?-D/P_[W4&6<RPPZR2W6G
M>" TY!?;@+O)OAO>(988*[2L/;+'_QJZ>8PIGWPI'VO8B(5YA\8%F#KH1T>F
MQ'M Q^DU5TN4'9JSYG+$<S1 M_4AC\?B4 TVB3*R<KI.1U1LYM4:[+P$58CH
ML$;:,VI2"N*1/:#=CDWZ6G-A=:K]!>5(IR,M^@>-2F:VY#PXS3QSF=\<TZB.
M_)CU9T<N'?7'N^0X=%97-7E=&]4:7G4I%MW&[E*HD;&20"8<EEB +^P4:O?%
M-U[9XC&E$3F<U/];#FG]D<LM1160\AU&4O[+?7R!D*+"GTSGX&9> 8^XX+UH
M92N]%HDGY[LIUN,@B68#RB2I&%[X!"J);U=9ZH>;0YTOMX#Z<GMH Z0U_#">
M1HV='W#H,P5T^@+;BHJ2)%7T,IQ-QRQ YOYT>TW3>_2Z]XQ?;!1"@K\6JF:R
M.1&VI]":7=257YVZ^+C#-"X_!W#L)P_/W1WSY[W/C TA1D<GK;SON<_N @*_
MH?,E/U9EQG2#?4X_Q$C\@X+ O>N,3= KQSXL  #=T![.("RQ%3+K./86% \[
M'43+'_/]V2I3CING*:OEZKA^PAG<[CNX>G"T#>LK#W;6=D_04<H\0B/K(O.]
MS3FCYQ4=AWT.<ANV&$SX)@%[\O7"\_GV.?VE"T+MFUA-84]%<&TJ2*+F3<IL
MN4EW QF#@GJ01"=8<8WQA#U+K]<E.8 B?^KB ZO[)SS>DPH%!2ODH:^>SG*Y
M4^9>H\$1GRRVA]V*FIH!:P!UJAT&WI=L+S1J0JDN4(:21?>=$R(^:G.!7C(X
M(,:>,WJ&X\A/=%--$?3^XOSW1#R%A;YQ[PCQ6?;Q<WC8(A<RH[(^V>K:]4;L
MU-NK6ET09&W%$EVB\#)VMT)<:GLE7#L%'O8W)ILZ$ZE3[%UQ-8;MX9"/^EQF
M3.SP?FF("54%76(M"SXY[]T"V4=/.5REQ_TP.F%+87]XMA_Z"'B2[RV1X/:)
MZRQ+?7HW@U:XTSYHRJ@Y*UV$WPZV>U@7::E\8=!FB6?FYYV%.-:MS.[NAHA@
MWRM3I]B#$R'X%U^1'V[5"B4C47$ %78>C)09GWME?6O"7MU>#IK<74F1\:=N
MX\UWEZEGMORY*]]#@Q;@@ <!:VJZ3M%O!:,,WQWN(. [CH VU4E[;T%3_?TB
M[-AC./1.UQW"UW^VK;O(7KGSJ0;*8'^J:EFY56D(UQ<U>GF(@'9D8GL:[#@M
M'!%I2EOO%:/H4Y<7='CU?(@[QRWJ$'T/FLOQ9GSVK74\.A+OUE DZT,VW$H(
MY%$&."33[Y6E43Z-'[F',?[+G3BXX&X<I7<WV+7B35LB-62#;!YY^^)CV0;R
M2!RS48*^7; @ +B!$WQ#F_C^FB\ F.*TM]O6H_QA&SNNY<>0[&]>KKZML;$&
M8 ;5@G2J(82!]0E=6(YF^#N93.B^F"^.L$>JZL=G2(N, ^'J+Q5\3<#45OY0
MA3=>PTD^IM=B&/O[N"G=Q^U$/BZFZ7ZL61@,HEA,Q_&Q(:C=(Q.B((YGK2E=
M7ZIN]KXBYLHL^5LILY;"^0^*[6C[.?:-_PJYF^Z_Y?XN#1QI1:866#KH3T8]
M8?SW4?_#E6O^)CDOG2MS?EPIB52B"7B_*,%LZA^T0?N1^O;_4$L#!!0    (
M $B(<%8EC,"$AP,  ,L'   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;(U5;6_;-A#^*P=M*#; D&PY?5EJ&["3!@W0HD&\IA^*?J"ED\6%(M4C%=7_
MOD?2UKPF]?I%(N_EN>?NR..L-W1O:T0'WQJE[3RIG6O/L\P6-3;"IJ9%S9K*
M4",<;VF;V990E,&I45D^'K_(&B%ULI@%V0TM9J9S2FJ\(;!=TPC:K5"9?IY,
MDH/@5FYKYP798M:*+:[1?6QOB'?9@%+*!K651@-A-4^6D_/5F;</!G<2>WNT
M!I_)QIA[O[DNY\G8$T*%A?,(@G\/>(%*>2"F\76/F0PAO>/Q^H!^%7+G7#;"
MXH51GV3IZGGR*H$2*]$I=VOZM[C/Y[G'*XRRX0M]M,W_2J#HK#/-WID9-%+'
MO_BVK\.1PZOQ3QSRO4,>>,= @>6E<&(Q(],#>6M&\XN0:O!F<E+[IJP=L5:R
MGUNLNXW%KQUJ!V\>^&MGF6-8K\R*/<0J0N0_@9CD\-YH5UMXHTLL_PN0,9^!
M5'X@M<I/(EYBD<)T,H)\G.<G\*9#DM. -_W5).'S<F,=\9'X\E2^$>WL:31_
M3<YM*PJ<)WP/+-(#)HMGOTU>C%^?X'HV<#T[A?YK#3D)\33!R32%QW7XH.&]
MH**&R3A4>SJ"M52RX/MR)Y3"':R$OH<_DO7=*OD3I 97(WS4TF$):R<<6NB%
MA4(9RY+-+N@OA)(\+[04<(FM(-?XD*:"*ZF%+J10<$/&'2ZF+N%::_,@_'8$
M?2V9D&A;([4/XQ&OL$1B-X8S5CJVMQTQ%,<RU!H*KDSSZO+Z@GDR(\("^;Y3
M>I1C?L@Q))&NTQ_H>?'?/-H8>S<:8M[&$HX"41\ _O',U(X%VG1,PG,4+A+U
M^EXJ!85I6H4.03K/QAK5!9(<AXOI2RGX(FN-%+VK3C%D&^MB@:O/TR5D:\BF
ML+3>\\=F]0@UJA)^ASQ]R?-!*1^"L7DN*.Z.Y]\8S7WDD7O/,UX4!5-F?-MQ
M@<E)O05FR98!OR LN;S2VBZVTU-U)J3VCO-7ALH(S\1C^WKIZJ"_YE/A6_N.
M"XBPW!)B**POV[)D6+9^K$[A$X(@#-/;LQGPAG@<G[!5?*"#_/_H!H#'1A69
MADM>RJI"\KRJX3!*;9UTH3TI/'6'LZ,!VR!MPS/"I]Z7,L[:03J\5,LXH/\U
MC\\<=W#+\9A@Q:[C].7S!"@^'7'C3!O&]<8X'OYA6?-KB^0-6%\9/B'[C0\P
MO-^+[U!+ P04    " !(B'!6J8K76:,7  #820  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6RU7&N3VS:R_2NLV:K=I$J:5Q(G<6Q7C5^YKDIBER?.
M?MBZ'R 2DI A"9D 1Z/\^GNZ&P!!B9+M3=T/<48B\6ITGS[=:.C)UG9W;JVU
M+QZ:NG5/S];>;QY?7+ARK1OESNU&MWBRM%VC/#YVJPNWZ;2JN%%37UQ?7CZZ
M:)1ISYX]X>_>=<^>V-[7IM7ONL+U3:.ZW7-=V^W3LZNS^,5[LUI[^N+BV9.-
M6NE;[3]LWG7X=)%ZJ4RC6V=L6W1Z^?3LYNKQ\^M+:L!O_&'TUF5_%[24A;5W
M].%-]?3LDF:D:UUZZD+A?_?ZA:YKZ@GS^!@Z/4MC4L/\[]C[:UX\%K-03K^P
M];]-Y==/SWXX*RJ]5'WMW]OM_^BPH.^HO]+6CO\MMO+NHQ_/BK)WWC:A,6;0
MF%;^KQZ"(+(&/UP>:7 =&ESSO&4@GN5+Y=6S)YW=%AV]C=[H#UXJM\;D3$N[
M<NL[/#5HYY\]5\ZXPBZ+=YUVNO5*9-56Q:U9M69I2M7ZXJ8L;=]ZTZZ*=[8V
MI=&N^"K^]?63"X^94'\791CUN8QZ?634J^OB5]OZM2M>M96NQAU<8 EI'==Q
M'<^O3_;X4I?GQ3=7L^+Z\OKZ1'_?)+E\P_U]<Z2_J17_YV;A? <]^M^I%4M_
MWT[W1\;UV&U4J9^>;4C2W;T^>_;/?UP]NOSIQ&R_3;/]]E3OT[LX-<F3W4Q/
M<EI#?E]K6%1IFXUJ=R2EI6E56QI5%PZO:!BN=\5:W>MBH75;H+^-ZG15F);;
M=17>UE!VORX^G-^>%RO=ZD[5]8X>ZXW'JVK8@TUGT/FFUL579_SZSS<W[\Z^
M/B].".^[)+SO3@KOQ=L_WKR<7_U8O(/:Z\:44X([V<6TX [Z9:&E;S?QV[5R
M1:EZAQ57QG7]A@3L2% >[Z]JNX!0=6E;V^S8,JF!6BZ!:R0D?-&H77Q]V?N^
MT^$Q?_-"]NB?__CA^NK[GURQZ!UF[QRW!+IW:C2>='!>O"'0=1L\T86W_"C.
M>!;Z[6RK[DW7N^+&5+/BO:Z-7G*WKWBV6-NM+OO.^!T0Q!=?4;.S%S?O7]W2
MY[.OBRU6XH SK!<8I5;; LKUJ^K*=7']/5OSY;G(+3:;%:JQ4 F+WCK,!.KA
M9FA>UGT%(_7J =IB[XWC576Z5JQ!Z!UXW[>56M2TE%UGZYK?+J&6QJ,/@+GN
M2'%)VW6SJ>U.=TENSHIVQQ6A"U;R6='">09!8J#:0K:]-[7Y:P#34G7=;J'*
MNP+O&5NA56,KAE>1?A Q=05):(C>8SY5+[ZK-HWQX4WJSNMRW:)M7<"2.G%P
MT@?64VGH(.;*+1OMUQBN@/\N/O:JQI D[(9$Q$9*PL*<_&Y/S-"RJF@MO0K$
MHUV94B:(W39Z+'0>BU[>:=45F@"^ #SK9H']BA =1I/NL HR\U[S&O2]JGM
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MDFJ('[S=\$_W+*SWMN$_J4Q$=_0"GB\M\"I\H '2CSD]^S]02P,$%     @
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M-<#]C40%=!-[0/],6GP'4$L#!!0    ( $B(<%8;.7TM-@0  (4,   9
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MV,:!.=YU(,?R,S=\,E)R390]C6C6<*DZ;R0G2GLI4Z/PJ4 _,[GA0I%O/*^
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MQ1UV\+KA!5]0]82",J^0!?F)!+$7#L*VX=)@%UNK,UU*97XVH I,Z!FT*6K
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MJS.7^#\!E#V S^<2?X@V"QN@^><Q^0M02P,$%     @ 2(AP5C\Y\/8#!
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MC(:BTCGC,)=$545!Y?<)Y&(S<GQGNW##TDR;!3<:EC2%!>C;<BYQYK8H"2N
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M7Z$A-+1XF:#*_:)MLS<*4%8I+5@C;#1@A-?_^+DQQ(' X)1 T@@DKP22Y(3
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MI-@3::P1S3Q8;:PWLF'<I'&I);YEZ*=GOV&E?!)*D05(LMQ2">1GLK0Y9?^
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M?F>]:R\+(G'"V4^:JV+L7#J0XY(T3-WSS1?L_%B!&6?2/F'3Q7H.9(U4O.S
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M)_N=52=.U4#0O#RT>:)"T+2\C("$P%2 ?+ZE5+P,U#E0<^[G_PM02P,$%
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M&9L@K8-Y/Q-";PXV03V(DS]02P,$%     @ 2(AP5NI -;N7 @  ' 8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULK55A;],P$/TKIS"A38*E2;IN
MC#32VH*8Q,2T,OCL)M?&FF,'VVG'O^?LI%DWVHD/?&GL\[WG>\_V-=TH_6!*
M1 N/E9!F')36UI=A:/(2*V9.58V25I9*5\S25*]"4VMDA0=5(HP'@U%8,2Z#
M+/6Q6YVEJK&"2[S58)JJ8OKW!(7:C(,HV ;N^*JT+A!F:<U6.$=[7]]JFH4]
M2\$KE(8K"1J7X^ JNIP.7;Y/^,%Q8W;&X)0LE'IPD^MB' Q<02@PMXZ!T6>-
M4Q3"$5$9OSK.H-_2 7?'6_;/7CMI63"#4R5^\L*6X^ B@ *7K!'V3FV^8*?G
MS/'E2AC_"YLN=Q! WABKJ@Y,%51<ME_VV/FP XA&!P!Q!XA? H8' $D'2+S0
MMC(O:\8LRU*M-J!=-K&Y@??&HTD-E^X4YU;3*B><S;XB>6#@/<SI?A2-0%!+
MF#=U+9#.RC(!U[*]*\[T.Q3,8@%6P;<:-07E"CJ*XQE:QH4Y(;+[^0R.CT[@
M"+B$[Z5J#).%24-+%;M]P[RK;M)6%Q^H+HKA1DE;&O@D"RR>$X0DM=<;;_5.
MXE<99YB?0A*]@W@0QWL*FOX[/'JEG*2W/_%\R0&^*3,EU(P70"8#JU0CK2'3
M<M&07N>>+1$J<KC1_D#<\0AG. C.%EQPRW&OL>V^P_W[NMYP:6J6XSB@QV]0
MKS'(WKZ)1H./^TSY3V3/+!KV%@U?8\^>+EKNS%I2WS'0&&PM4_VJ=V6O%2W_
MN>=W76V=C2XNSM-PO2OQ[Z0X3C[T26WIX<Y#JU"O?/\QD+MC:^]@'^U;W)5_
MV2_B$VI];:=ZHFG[Y@W3*RX-R5D2Y>#T_"P W?:B=F)5[9_S0EEJ#GY84OM&
M[1)H?:F4W4[<!OT?0O8'4$L#!!0    ( $B(<%83+HMP?PH  *9P   9
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;,6=;6^CN!J&_XJ57:UVI6D3(&F2
MV;92I[RN9C2CZ>SNA]7YX(+3H.4E"Z2=2N?''QMH'!+'"=V[.E_:)/!<-G!C
M'OLV</F4%W^72\8J\CU-LO)JL*RJU?OAL R7+*7E>;YB&5^RR(N45OQK\3 L
M5P6C41V4)D-S-+H8IC3.!M>7]6]?BNO+?%TE<<:^%*1<IRDMGC^P)'^Z&AB#
MEQ^^Q@_+2OPPO+Y<T0=VQZK?5U\*_FVXH41QRK(RSC-2L,75X,9X'UAS$5"O
M\4?,GLJMST1LRGV>_RV^!-'58"1JQ!(65@)!^;]'=LN21)!X/?YIH8--F2)P
M^_,+W:TWGF_,/2W9;9[\&4?5\FHP&Y"(+>@ZJ;[F3SYK-V@B>&&>E/5?\M2N
M.QJ0<%U6>=H&\QJD<=;\I]_;';$5P#GJ +,-,'<"#I9@M0'6;@GC P'C-F!\
M:L"D#9CL!E@' B[:@(M3 Z9MP/34C9ZU ;-3MV'>!M3Z&C;'KS[X-JWH]661
M/Y%"K,UIXD.MH#J:'_,X$V*_JPJ^-.9QU?5'QI52DC-R$T6QD!]-2) U)Y$0
MX\\VJVB<E+_P57Z_L\G//_Y"?B1Q1KXM\W5)LZB\'%:\'H(V#-LR/S1EF@?*
M-,BG/*N6)7&RB$6*>/](O*D!#/D.V.P%\V4O?#"UQ)OUPSFQC'?$')FFHD*W
M^O#/8;4)-Q3AMC[\MW6B#7>.A--,&^[JPS_1YY?HD2+:.S7:F*F.I#[:9J%V
MOP>GAQL:&5B;D\&J>=;!DZ$L&2/U.4%L5H9%O*K/@K\^\C5)4+&T_(]*[PUV
MK,:*Z]7[<D5#=C7@%Z22%8]L</W3#\;%Z%>5UI P&PESD# 7"?.0,!\)"T"P
MCI['&SV/=?3K/^M+/8O.Z",K>.I"HK@,\W56D8)63"5D+:^OD)$P&PESD# 7
M"?.0,+^!&:.:)M+>Q^O1^6C.&^K';8F"RNQ(=+*1Z$0KT3J[/LL79VO>Y%+>
M_%8ER>]YRI&Q2*09['NXI!F7+D])"$_QN7#C[($D=1.=Q/0^3GC:PC,87C6>
MWXIEBR)/2<;3['HE97ZBK5-?F2-A-A+F(&$N$N8A87X#FVZI?#*?C$8[*@<5
MV5'YQ4;E%_\7E:=Y%"_BL$[5.7'!07$I0Y7:U]:TK_:1,!L)<Y P%PGSD#"_
M@4VVM&_,IGO:!Q79T?YTH_VI5OM-4OUN5];O2,6*5&@VY'VY@H:52JQ:=%^Q
M(F&V?J-Y%_69T4)U CK(:KA(F(>$^4A8 ()U!#S;"'BF/9:WM%SRAC=D\2-O
MK44+7;&,\B0Z3E=%_LA2QC_3),F?:!;R-KK*R3WC 2L:JP8W/FA+ZZMI),R>
M[5U(Q^/=ML1!EN@B81X2YB-A 0C6D>]\(]_YD?9W)XE0:5*+Z*M)),Q&PAPD
MS$7"/"3,G^\E!3-S;HUWD@)0D1U1&B,Y[CSJFQ(K1Y*UE+[*A-)L*,V!TEPH
MS8/2_);6N<Y,IN/YCCX5JQG&Q52.7G25M^5X&%KE?:+?XW2=*M6FC>RM-B3-
MAM(<*,V%TCPHS8?2 A2MJUU3:M=\&X>BY:*4C:394)H#I;E0F@>E^5!:@*)U
ME2VM-T/KA%Q_T_:IGEDE^E5M+TPI<*@'!Z79+6W[2F9.S+V>%;10%TKSH#0?
M2@M0M*YRI<EFZ%VVCZRJ6"%&LFX+%L7*<2P]HK<ZH<X:E.9 :2Z4YD%I/I06
MH&A=$4L;SIB\46(!]=*@-!M*<Z T%TKSH#0?2@M0M*ZRI?5FZ+VW.Q:NB[AZ
M)A%;Y>6!YAEJBD%I-I3F0&DNE.9!:3Z4%K2TSF#$Q58&UQ6G],8,O4_T;1D7
M$:$\W8U$RJO4)M0#@])L*,V!TEPHS8/2?"@M0-&Z&I;VF#%[H]0!ZH1!:3:4
MYD!I+I3F06D^E!:@:%UE2^?,T%MGGW>G+$12W4I!0VTT*,V&TAPHS872/"C-
M/R*1;TO63M/:7,2;*0++N"14WE-1ETC"/.5KA,VDKYM5$2?UU'5"LXBP[ZN8
MUT<L^42+<"F6C,^59\5;.'>F=.Y,O7/7-/1U=9M[1%)Q,T:]#6+.B^K$T!/[
MGAA0F@VE.4?VG3BF9R-+=1) Z^%!:3Z4%J!H7?U*_\_4^W]!QD]*?DHV.KYY
M*!@[E'OK2;UU"_4#H30'2G.A- ]*\Z&T $7K:EGZ@>8;^8$FU ^$TFPHS8'2
M7"C-@])\*"U T;K*EGZ@J?<#]W+O>FJ[2)Z$TY(W*J]R_C/_43G/4E] ;XGK
MJUL5:Y4M:4,KX4!I[NLVR8-6PH?2 A2M*UII!9K'K$#1#HN)[4I!0DU *,V&
MTAPHS3VRTV<'I]I[T'KX4%J HG6E*@T_4W_CW5XO[F#?#6KP':D5[Q_-E?*$
M.GE0FONZ3?*@E?"AM !%ZVI36G:FWK)KL]K=B_RQX3<]M;=2]754#?SPQ*3/
MN(^Y.^[S&\W6M'@6R^;G1%4"3<J<KQDFZTC<::(LC(,J'GJ;IRN:/?_TP\PT
MIK^6^WM3K%23>;4.](GKH2R:=<I@CRP[$XU%?9U3#5#9T /A0&DNE.9!:?XK
M)-<5!,V:@UL_BJA6XTM$?;-=,S#)Y%VB^6(1<\4(&2;T/N=7@IS+KY'1/7N(
MLZQ>2XQ(/I/V&2%2M&*94K6R>EQMHL!#\MJKO5*DS1:\2HH!Z@!U6S+I[YIZ
M?_>.A3G?BIO-#OF\V'[2SBE#4%#[%TJSH30'2G.A- ]*\Z&T $7K2ES:O^8;
MV;\FU/Z%TFPHS8'27"C-@])\*"U T;K*EO:O><3;^Y=3TEO\D6G?M_I:]%8N
MU.>%TEPHS8/2?"@M0-&ZCS&3%JVEMQFW4@SMO>HJU5J*V^XFHSW5ZFO05[50
MF@.EN5":!Z7Y4%J HG55*XU92V_,WN;%2O1!&,^2-_V2C[)?<B?*5DH6:M-"
M:3:4YD!I+I3F06D^E!:@:%UE2YO6>B.;UH+:M%":#:4Y4)H+I7E0F@^E!2A:
M5]E;3TS5FX1[CY@LF'C$MGQZV2$S3,_MK6SL0U.Q3TW%/C85^]Q4[(-3]5HQ
M1HU31^;-E,&2&#,2T6=5&AJ@:M;5M71RK5.<W!/L,3VGMXZAIBZ4YD!I+I3F
M'3F:YLB<* 4+=711M*YDI:-KZ8W&D])G\M]#@_%*<4.]7RC-AM(<*,V%TCPH
MS8?2 A2MJWGI%%L7;Y180[UB*,V&TAPHS872/"C-A]("%*VK;.D<6GKG\"O+
MV%,]?G<@?X;Z@E":#:4Y4)I[9+=/#T\F@];#A]("%*TK5ND!6OI'I/[[R;KZ
M GK+&6H&0FD.E.9":=Z1PWQ@1K /K42 HG6U+%T_Z]CS4E\U^4Q/[2U@J"<(
MI3E0F@NE>5":_QI:("?X&?-WVS/QN)!8N*Y8,ZEI$1=E=?I,J7KVDW3UPDU?
MKZ[ N_WI6Z+SE])LO:!AM:ZG:H5T)5\D(!9W9HNUY6_-%JN61;Y^6,KYBA?G
M1'F^0KW.X=:[S%)6/-0OPBM)_=J:YH5>FU\W+]N[J5\QM_/[!^.]U[PR3V*:
M-_A]HL5#G)5\6Q<<.3J?\CY,T;P4K_E2Y:OZC6GW>57E:?UQR6C$"K$"7[[(
M\^KEBRA@\VK"Z_\!4$L#!!0    ( $B(<%:<$"6=M@,  %</   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;+6776_;-A2&_PJA%4,++)&H;V>V@3;!
MT 'I&C3]N!AV0<O'-E%)U$C*;O[]2$F1'8FA"R&[L451Y^7S4J3.X?S ^'>Q
M Y#H1Y&78N'LI*RN7%=D.RB(N&05E*IGPWA!I&KRK2LJ#F3=!!6YZWM>[!:$
MELYRWMR[X\LYJV5.2[CC2-1%0?C#.\C98>%@Y_'&)[K=27W#7<XKLH5[D%^J
M.ZY:;J^RI@64@K(2<=@LG+?XZAK'.J!YXBN%@SBY1MK*BK'ONO'G>N%XF@AR
MR*26(.IO#]>0YUI)<?S;B3K]F#KP]/I1_8_&O#*S(@*N6?Z-KN5NX:0.6L.&
MU+G\Q [OH3,4:;V,Y:+Y18?N6<]!62TD*[I@15#0LOTG/[J). G X3,!?A?@
M_VQ T 4$C=&6K+%U0R19SCD[(*Z?5FKZHIF;)EJYH:5^C?>2JUZJXN3R%M0<
M"'2![M4"6=<Y(+9!'XBL.954=:C6QPHXD;3<HN9A=$O)BN9M]^L;D(3FXHU2
M^')_@UZ_>H->(5JBSSM6"U*NQ=R5"E,/YF8=TKL6R7\&Z0:R2Q3@WY#O^;XA
M_/KGP_'3<%=-3C]#?C]#?J,7V&?H[[<K(;E:=?^8'+42H5E";\4K49$,%H[:
M:P+X'ISEK[_@V/O=Y.^%Q)ZX#7JW@4U]J28M,!ELHY(F2G\:]DN,?2^>N_M3
M<JOV1/*P)P_/D8<F\C8J.B7WXP0/R*W:$\FCGCPZ1QZ9R*,Q>> %P8#<JCV1
M/.[)XW/DL8D\-I"'<3(@MVI/)$]Z\N0<>6(B3PSD,SPDMVI/)$][\O0<>8K4
MEQ7)':C$O9' 34;2D9$T\6?>P(AUJ(E&9KV1F=7(9R9)CNIR347&ZE+"&FUJ
ME7A YSE:U 7*FWQ3D0=5-TAC)IF-7U>$HS0<V+2"3+2)O6.*]:Q&;T$(1(NJ
MUA:I,JH&D<:\Z(WL7,1>BH=;WC[>5#\G)0,^[T="24JI;7&V!_V"5%67 =V3
M50Y&<WAL+DF#X=:RCSW5VS'98VMV[18EZTN>=@GFQY+':,T?;S9_%@Q7H7WH
MJ=:.F1T'UD+FX_.FKHRN7BB;=^;_C]H 'XL#;*\.KFO.U1HU^AQ7"*$?SH8O
M+QQ50'YX\J%YRG5,_=B>^_]BY45F81O7 $D:I]$0+AK!S69)] S<,;MC>WIO
M-\/3U?)@Q(Q'XQLWP(MF?/?DU*./G!\(W])2*-Z-DO<N$S4IO#W%M0W)JN8@
MM&)2':N:RYTZ^0+7#ZC^#6/RL:'/5OU9>OD?4$L#!!0    ( $B(<%:1#+7_
M:P,  -X.   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;+U776_;-A3]
M*Q=:,;3 &GTXL9/4%I X*Q8@ 8(&W1Z&/M#2M4U4)#62CA-@/WZ7E*Q8F2PT
MK= \Q*+$>WC/X>''G6Z5_FK6B!8>12'-+%A;6YZ'H<G6*)@Y4B5*^K)46C!+
M3;T*3:F1Y3Y(%&$21>-0,"Z#=.K?W>ETJC:VX!+O-)B-$$P_76*AMK,@#G8O
M/O'5VKH783HMV0KOT7XN[S2UP@8EYP*EX4J"QN4LN(C/Y_'(!?@>?W+<FKUG
M<%062GUUC>M\%D0N(RPPLPZ"T<\#SK$H'!+E\4\-&C1CNL#]YQWZ1T^>R"R8
MP;DJ_N*Y7<^"TP!R7+)-83^I[1]8$SIQ>)DJC/\/V[IO%$"V,5:).I@R$%Q6
MO^RQ%F(O(!X?"$CJ@.1EP/&!@%$=X)4+J\P\K2MF63K5:@O:]28T]^"U\='$
MADLWC?=6TU=.<3:=*R&XI7FQ!IC,8:ZDY7*%,N-HX#U<Y#EW>K,"KF7E&J?^
MVRNTC!?F'77Y?'\%;]^\FX:6\G&H85:/?5F-G1P8.T[@EH9;&_A=YIBW 4(B
MTK!)=FPNDU[$*\R.8!3_!DF4)!T)S;\]/.Y)9]2(._)XHP-X-\J8%XK^?4-]
MX-JB,%^Z%*L C[L!W9H^-R7+<!;0HC6H'S!(?_TE'D<?NM@.!-;B?MQP/^Y#
M3V\X6_""O$.D-69*TPP#&0C82B-ZPW7QKT G'M1M00]I- T?]DGU]6AE>M)D
M>M*;Z<4N(5IZ=@T?N60T5][PQG*[<8;O2K47];53-1!82X!Q(\!X:)N.A^0^
M$%B+^Z3A/NFW*5J+VH!:0J:1]CJ@L\Y8V@I)#&!";:3M$F#R/Q<FD\C]O7!K
M[^C?R>VTX7;ZP\:&?^&6/7*Q$5TL>_%?.\T#@;6D.&ND.!O:XF=#<A\(K,4]
MCI[/^.@;3+[G<:DLSQ!*U%SEL'B"9>,-ON>-!=*&C70OD!OZ@H\EU]7QGS.+
MG>=]?Q[CB"*?NO;]>7_D]RJT=PN*!UDJ7!Y:*OT#O-8O0Z&UY4B>Y4B&7BXU
MXE#\!T)K\W^^M\6]5Z.?N&#Z\QCU+)A!+W?A7@4A4*]\864@<\=?54PT;YOB
M[<*7+.%S]ZKRNV5Z19I @4L*C8XF=+7153%5-:PJ?3VR4):J&_^XI@(4M>M
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MB?[.3O5 +]I"PD!]-;1SL='.A;7SMVE>JE%C&<534JK%MTY+G$3K65&;@JS
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MUK1M-0S;-FY0:+,,13/UT'BRGMV3?>1"C0PRFE<98S5,Y*(@(G^/$AD?F!]
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M+8#20BB-0FD,13-UUAB^_HDW[SW]'LU0MQ=*"Z"T$$JC-<W8F]!VE^9CQ<Q
M-UZOW]GKO9VIB0OYIXH_^=MKKJ>M^LYTVXOKT_(5U .&T@(H+832*)3&4#13
M7HT'['^X!^Q#/6 H+8#20BB-0FD,13-UUGC OMT#[KZ!P0[L+!NH 0REA35M
M[Y+U[F(<ZA*C:"L]]+>>T9-R,:\>OU2HR4B9R=6#33:?;A[Q=%L]V&CG\\"Y
M#)V6SZESR58/<&KPJ^=)/41B'F<%2?A,-34X&ZM$+%:/:%J]D?FR>D+0<RYE
MGE8O%SR:<J$+J+_/\ERNW^@&-@_*NOD?4$L#!!0    ( $B(<%9)/&T@^0(
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M27&X951/R/,"^OLUY^KE)*^@WAJ^_ ]02P,$%     @ 2(AP5BM:^8%X!@
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M6HO47DX9C9DT!>#WL1!Z?6,:V)SA&OP/4$L#!!0    ( $B(<%:LSQ$1Z00
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M)N@Y":6X59WJ^:\E6PLU3 PLJ9!T8):?A_^0A4].A(\)^L(2N13HUR2 X-"
MI7)1)(2\)>2!&"T^@M]&#K[51*0FH,GEP[$A'*>8'R>UYYCF!]7,SYASFBQ
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ME2??.9:WD_E$T$QW9 LJ9'^GAY%LP8&I /E\2:G83=0&95/O_P-02P,$%
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MF>*5B,T47VM _.L&C"3Q[S:6!QC8+F"U _G]>:"F_)PH@EW%O&%/,(XD"89
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 2(AP5IE<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !(B'!6^=&47;X(  #]-0  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 2(AP5D,DJE'1!0
M3Q@  !@              ("! 1$  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( $B(<%:X'KN$VP(  -@)   8              " @0@7
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !(B'!69B>Y
MH8($  !E$@  &               @($9&@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ 2(AP5KCN*9F8"   Q%H  !@
M ("!T1X  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $B(
M<%81L\J/' <  .H@   8              " @9\G  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " !(B'!6_F/@ D0&   A#@  &
M        @('Q+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ 2(AP5BIM%@!^%@  !D$  !@              ("!:S4  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $B(<%:_I2KAM@,  #H(   8
M              " @1],  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " !(B'!6)Z,6;,<(  #I&   &0              @($+4   >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $B(<%9XC!K*# 0
M ,,)   9              " @0E9  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ 2(AP5O*:A5S,"0  0!X  !D              ("!
M3%T  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !(B'!6
M=L\U'V,$   $"@  &0              @(%/9P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( $B(<%:CUON8@ H  )T?   9
M      " @>EK  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ 2(AP5B[3+#<K P  "@<  !D              ("!H'8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !(B'!6RF2SD <%  !Z#
M&0              @($">@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( $B(<%;CJA>>20\  )4N   9              " @4!_  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 2(AP5@IVE1?\
M"@  L!X  !D              ("!P(X  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " !(B'!6)8S A(<#  #+!P  &0
M@('SF0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $B(
M<%:IBM=9HQ<  -A)   9              " @;&=  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ 2(AP5LY<S0OM P  ,@D  !D
M         ("!B[4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " !(B'!6&SE]+38$  "%#   &0              @(&ON0  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $B(<%8_.?#V P0  #X*
M   9              " @1R^  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ 2(AP5NML6,T@!   = H  !D              ("!5L(
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !(B'!6H3/_
MLF<&  #R$0  &0              @(&MQ@  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( $B(<%;"VZAU2P4  .H,   9
M  " @4O-  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M2(AP5@_0WXST @  NP<  !D              ("!S=(  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " !(B'!6<EN ?NL#   V$0  &0
M            @('XU0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( $B(<%9L"*<(@ ,  ',+   9              " @1K:  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 2(AP5M_MGY:@ P
MQP\  !D              ("!T=T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " !(B'!6Q:X-?\8$  #+'   &0              @(&H
MX0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $B(<%8>
M3ICK200  %H5   9              " @:7F  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ 2(AP5IGVH,I(!0  8R   !D
M     ("!)>L  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $B(<%:,O+!WN (  )0'   9              "
M@6S]  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 2(AP
M5NI -;N7 @  ' 8  !D              ("!6P ! 'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " !(B'!6$RZ+<'\*  "F<   &0
M        @($I P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( $B(<%:<$"6=M@,  %</   9              " @=\- 0!X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 2(AP5I$,M?]K P  W@X
M !D              ("!S!$! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " !(B'!6OP3P$C0*   T:P  &0              @(%N%0$
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( $B(<%9)/&T@
M^0(  "0(   9              " @=D? 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ 2(AP5H]88A*\!0  )BX  !D
M ("!"2,! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !(
MB'!6*UKY@7@&  #/)0  &0              @('\* $ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $B(<%:LSQ$1Z00  -\7   9
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M970U,2YX;6Q02P$"% ,4    " !(B'!604-$3<@$   6&0  &0
M    @($!0@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M $B(<%:O?_PCFP8  $,W   9              " @0!' 0!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ 2(AP5B7CO%=K P  "PH  !D
M             ("!TDT! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    " !(B'!65J5V6!H$  #!#@  &0              @(%T40$ >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $B(<%:4V?$1_P(
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( $B(<%:"9UWOM 0   0F   /
M      "  <M? 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !(B'!6\R"+
M>>D!   2(@  &@              @ &L9 $ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !(B'!6LFA)V-4!  "_(0  $P
M    @ '-9@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     00!! +X1  #3
%: $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>163</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements1</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Basis of Presentation and Significant Accounting Polices - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Polices - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Net Loss Per Share - Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Value of Financial Instrument (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Summary of Fair Value of Financial Instrument (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value of Financial Instruments - Schedule of Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Leases - Schedule of Supplemental Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Employee Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employee Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Share-Based Compensation - Summary of Additional Information Related to Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Additional Information Related to Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Share-Based Compensation - Summary of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails</Role>
      <ShortName>Income Taxes - Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes - Summary of Changes in Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Changes in Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nktx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:PropertyPlantAndEquipmentUsefulLife -  nktx-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="nktx-20221231.htm">nktx-20221231.htm</File>
    <File>nktx-20221231.xsd</File>
    <File>nktx-20221231_cal.xml</File>
    <File>nktx-20221231_def.xml</File>
    <File>nktx-20221231_lab.xml</File>
    <File>nktx-20221231_pre.xml</File>
    <File>nktx-ex10_3c.htm</File>
    <File>nktx-ex10_3e.htm</File>
    <File>nktx-ex10_3f.htm</File>
    <File>nktx-ex23_1.htm</File>
    <File>nktx-ex31_1.htm</File>
    <File>nktx-ex31_2.htm</File>
    <File>nktx-ex32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img183648649_0.jpg</File>
    <File>img183648649_1.jpg</File>
    <File>img183648649_2.jpg</File>
    <File>img183648649_3.jpg</File>
    <File>img183648649_4.jpg</File>
    <File>img183648649_5.jpg</File>
    <File>img183648649_6.jpg</File>
    <File>img183648649_7.jpg</File>
    <File>img183648649_8.jpg</File>
    <File>img183648649_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="539">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 539,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 163,
   "dts": {
    "calculationLink": {
     "local": [
      "nktx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nktx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nktx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 594,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 5,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 9
   },
   "keyCustom": 59,
   "keyStandard": 281,
   "memberCustom": 28,
   "memberStandard": 32,
   "nsprefix": "nktx",
   "nsuri": "http://nkartatx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements1",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Employee Benefits",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Description of Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-5",
      "lang": null,
      "name": "nktx:CashCashEquivalentsRestrictedCashAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Basis of Presentation and Significant Accounting Polices - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Significant Accounting Polices - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Net Loss Per Share - Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Value of Financial Instrument (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails",
     "shortName": "Fair Value of Financial Instruments - Summary of Fair Value of Financial Instrument (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nktx:Impairments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair Value of Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nktx:Impairments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Fair Value of Financial Instruments - Schedule of Short-term Investments (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
     "shortName": "Fair Value of Financial Instruments - Schedule of Short-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nktx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nktx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Leases - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nktx:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Leases - Schedule of Supplemental Information Related to Operating Leases (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Information Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nktx:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GuaranteeObligationsCurrentCarryingValue",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:GuaranteeObligationsCurrentCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GuaranteeObligationsCurrentCarryingValue",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:GuaranteeObligationsCurrentCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_c4c5522f-21b4-4d77-94c4-5d1cb3d81ce9",
      "decimals": "-5",
      "lang": null,
      "name": "nktx:ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_1eb2f144-5565-4350-a09a-b2ab343aade0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Employee Benefits - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails",
     "shortName": "Employee Benefits - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_1eb2f144-5565-4350-a09a-b2ab343aade0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_0ac1e0ad-03e9-4856-a284-9cc42d6c22e3",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromStockPlans",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_c963d9bf-d21f-4940-8b1d-41239a955535",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_7d693d1f-0170-4af7-8991-dbab6eb94595",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nktx:ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Share-Based Compensation - Summary of Additional Information Related to Stock Options (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails",
     "shortName": "Share-Based Compensation - Summary of Additional Information Related to Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nktx:ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_0a03030f-25af-4ff1-945c-997f499c318d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
     "shortName": "Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_0a03030f-25af-4ff1-945c-997f499c318d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_b9b2ce9a-a3ec-4f18-8a1d-a21b0b1aaf32",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nktx:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Share-Based Compensation - Summary of Common Stock Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Share-Based Compensation - Summary of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "nktx:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_a8cd6f3e-33d2-431d-8c68-01cfb7d24237",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails",
     "shortName": "Share-Based Compensation - Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_9183cb74-8a77-407b-ac80-773ff92736bd",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails",
     "shortName": "Income Taxes - Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_aefac9ac-d285-41b4-bb2c-5a55a643d2c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_9e0afc55-bbb0-416e-a754-625e5f859147",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Income Taxes - Summary of Changes in Gross Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Changes in Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "lang": null,
      "name": "nktx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_9156c0d3-efa4-45e5-8f61-29564c2a7e1d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nktx:AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Subsequent Events - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_9156c0d3-efa4-45e5-8f61-29564c2a7e1d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nktx:AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktx-20221231.htm",
      "contextRef": "C_3bd6bac6-2a11-499d-8435-032d15a2aceb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r665",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r665",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r665",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r665",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r665",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktx_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktx_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktx_AccruedPropertyAndEquipmentLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued property and equipment liabilities current.",
        "label": "Accrued Property And Equipment Liabilities Current",
        "terseLabel": "Accrued property and equipment"
       }
      }
     },
     "localname": "AccruedPropertyAndEquipmentLiabilitiesCurrent",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs current.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_AdditionalLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional lease agreement.",
        "label": "Additional Lease Agreement [Member]",
        "terseLabel": "Additional Lease Agreement"
       }
      }
     },
     "localname": "AdditionalLeaseAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_AdditionalNumberOfDaysToReplaceLetterOfCredit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional number of days to replace letter of credit.",
        "label": "Additional number of days to replace letter of credit"
       }
      }
     },
     "localname": "AdditionalNumberOfDaysToReplaceLetterOfCredit",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktx_AdditionalTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional tenant improvement allowances.",
        "label": "Additional Tenant Improvement Allowances",
        "terseLabel": "Additional tenant improvement allowances"
       }
      }
     },
     "localname": "AdditionalTenantImprovementAllowances",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_AfterYearTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After year two.",
        "label": "After Year Two [Member]",
        "terseLabel": "After Year Two of the Agreement"
       }
      }
     },
     "localname": "AfterYearTwoMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_AgreementWithFinancialInstitutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with financial institution.",
        "label": "Agreement With Financial Institution [Member]",
        "terseLabel": "Agreement with Financial Institution"
       }
      }
     },
     "localname": "AgreementWithFinancialInstitutionMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount held as collateral for letters of credit issued to landlord.",
        "label": "Amount held as collateral for letters of credit issued to landlord"
       }
      }
     },
     "localname": "AmountHeldAsCollateralForLettersOfCreditIssuedToLandlord",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_AmountsOwedUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts owed under agreement.",
        "label": "Amounts Owed Under Agreement",
        "terseLabel": "Amounts owed under the agreement"
       }
      }
     },
     "localname": "AmountsOwedUnderAgreement",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_AnnualLicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fee.",
        "label": "Annual License Maintenance Fee",
        "terseLabel": "Annual license maintenance fee"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFee",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual research license fees and Commercialization license fees.",
        "label": "Annual Research License Fees and Commercialization License Fees",
        "terseLabel": "Annual research license fees and Commercialization license fees"
       }
      }
     },
     "localname": "AnnualResearchLicenseFeesAndCommercializationLicenseFees",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-the-market offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_CarryForwardIndefinitelyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carry forward indefinitely.",
        "label": "Carry Forward Indefinitely [Member]",
        "terseLabel": "Carry Forward Indefinitely"
       }
      }
     },
     "localname": "CarryForwardIndefinitelyMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_CashCashEquivalentsRestrictedCashAndShortTermInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents restricted cash and short term investments.",
        "label": "Cash Cash Equivalents Restricted Cash And Short Term Investments",
        "terseLabel": "Cash, cash equivalents restricted cash and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndShortTermInvestments",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents short term investments and restricted cash.",
        "label": "Cash Cash Equivalents Short Term Investments And Restricted Cash Policy [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Short-term Investments and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsShortTermInvestmentsAndRestrictedCashPolicyTextBlock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktx_CashReceivedForTenantImprovementAllowancesToBeRepaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for tenant improvement allowances to be repaid.",
        "label": "Cash Received for Tenant Improvement Allowances to be Repaid",
        "terseLabel": "Cash received for tenant improvement allowances to be repaid"
       }
      }
     },
     "localname": "CashReceivedForTenantImprovementAllowancesToBeRepaid",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_ChangesInOwnershipByStockholdersHoldingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in ownership by stockholders holding percentage.",
        "label": "Changes In Ownership By Stockholders Holding Percentage",
        "terseLabel": "Changes in ownership by stockholders holding percentage"
       }
      }
     },
     "localname": "ChangesInOwnershipByStockholdersHoldingPercentage",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktx_CollaborationAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementAbstract",
     "nsuri": "http://nkartatx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nktx_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_CommonStockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options and restricted stock units.",
        "label": "Common Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Common Stock Options And Restricted Stock Units Granted And Outstanding"
       }
      }
     },
     "localname": "CommonStockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_CommonStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options.",
        "label": "Common Stock Options [Member]",
        "terseLabel": "Common Stock Options"
       }
      }
     },
     "localname": "CommonStockOptionsMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_ComputersAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers and software.",
        "label": "Computers And Software [Member]",
        "terseLabel": "Computers and Software"
       }
      }
     },
     "localname": "ComputersAndSoftwareMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_CorporateOfficeAndLaboratoryFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate office and laboratory facilities.",
        "label": "Corporate Office And Laboratory Facilities [Member]",
        "terseLabel": "Corporate Office and Laboratory Facilities"
       }
      }
     },
     "localname": "CorporateOfficeAndLaboratoryFacilitiesMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_CorporateOfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate office and laboratory space.",
        "label": "Corporate Office And Laboratory Space [Member]",
        "terseLabel": "Corporate Office and Laboratory Space"
       }
      }
     },
     "localname": "CorporateOfficeAndLaboratorySpaceMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_DeferredOfferingCostsLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs liabilities current.",
        "label": "Deferred Offering Costs Liabilities Current",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsLiabilitiesCurrent",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_DeferredTaxAssetsDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets depreciation and amortization.",
        "label": "Deferred Tax Assets Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets Section 174 capitalized R&amp;D.",
        "label": "Deferred Tax Assets section one seventy four Capitalized Research and development",
        "terseLabel": "Section 174 Capitalized R&amp;D"
       }
      }
     },
     "localname": "DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation and amortization.",
        "label": "Deferred Tax Liabilities Depreciation And Amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_DevelopmentAndRegulatoryApprovalMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulatory approval milestones.",
        "label": "Development and Regulatory Approval Milestones [Member]",
        "terseLabel": "Development and Regulatory Approval Milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryApprovalMilestonesMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_EmployeeStockPurchasePlanLookBackPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan look-back period.",
        "label": "Employee stock purchase plan look-back period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanLookBackPeriod",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktx_ExpectedBaseRentOverLeaseTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected base rent over the lease term.",
        "label": "Expected Base Rent Over Lease Term",
        "terseLabel": "Expects to pay base rent over the lease term"
       }
      }
     },
     "localname": "ExpectedBaseRentOverLeaseTerm",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_ExpirationYearOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration year one.",
        "label": "Expiration Year One [Member]",
        "terseLabel": "2035"
       }
      }
     },
     "localname": "ExpirationYearOneMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_ExpirationYearTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration year two.",
        "label": "Expiration Year Two [Member]",
        "terseLabel": "2036"
       }
      }
     },
     "localname": "ExpirationYearTwoMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliations Reclassification of preferred stock purchase right liability to equity upon issuance of convertible preferred stock.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Reclassification Of Preferred Stock Purchase Right Liability To Equity Upon Issuance Of Convertible Preferred Stock",
        "negatedLabel": "Reclassification of preferred stock purchase right liability to equity upon issuance of convertible preferred stock"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInPreferredStockPurchaseRightLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_FairValueOfCommonStockIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock issued.",
        "label": "Fair Value Of Common Stock Issued",
        "terseLabel": "Fair value of common stock issued"
       }
      }
     },
     "localname": "FairValueOfCommonStockIssued",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of preferred stock purchase right liability discount rate.",
        "label": "Fair Value Of Preferred Stock Purchase Right Liability Discount Rate",
        "terseLabel": "Fair value of preferred stock purchase right liability discount rate"
       }
      }
     },
     "localname": "FairValueOfPreferredStockPurchaseRightLiabilityDiscountRate",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktx_FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of preferred stock purchase right liability outstanding term.",
        "label": "Fair Value Of Preferred Stock Purchase Right Liability Outstanding Term",
        "terseLabel": "Fair value of preferred stock purchase right liability outstanding term"
       }
      }
     },
     "localname": "FairValueOfPreferredStockPurchaseRightLiabilityOutstandingTerm",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktx_FairValueOfPreferredStockPurchaseRightLiabilityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of preferred stock purchase right liability percentage.",
        "label": "Fair Value Of Preferred Stock Purchase Right Liability Percentage",
        "terseLabel": "Fair value of preferred stock purchase right liability percentage"
       }
      }
     },
     "localname": "FairValueOfPreferredStockPurchaseRightLiabilityPercentage",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktx_FollowOnOfferingOfStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on offering of stock.",
        "label": "Follow On Offering of Stock [Member]",
        "terseLabel": "Follow On Offering of Stock"
       }
      }
     },
     "localname": "FollowOnOfferingOfStockMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property Development Limited and Glaxo Group Limited.",
        "label": "Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Group Limited [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoGroupLimitedMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_Impairments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairments.",
        "label": "Impairments",
        "terseLabel": "Impairments"
       }
      }
     },
     "localname": "Impairments",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation change in fair value of derivative liability.",
        "label": "Income Tax Reconciliation Change In Fair Value Of Derivative Liability",
        "terseLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_IncomeTaxReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentItems",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktx_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktx_IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in accounts payable and accrued and other liabilities.",
        "label": "Increase Decrease In Accounts Payable And Accrued And Other Liabilities",
        "terseLabel": "Accounts payable and accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in share limit as percentage of outstanding shares of common stock on last trading day in prior year.",
        "label": "Increase In Share Limit As Percentage Of Outstanding Shares Of Common Stock On Last Trading Day In Prior Year",
        "terseLabel": "Increase in share limit as percentage of outstanding shares of common stock on last trading day in prior year"
       }
      }
     },
     "localname": "IncreaseInShareLimitAsPercentageOfOutstandingSharesOfCommonStockOnLastTradingDayInPriorYear",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktx_InitialLeaseAgreementAndAdditionalLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Lease Agreement And Additional Lease Agreement.",
        "label": "Initial Lease Agreement And Additional Lease Agreement [Member]",
        "terseLabel": "Initial Lease Agreement and Additional Lease Agreement"
       }
      }
     },
     "localname": "InitialLeaseAgreementAndAdditionalLeaseAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_InitialLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial lease agreement.",
        "label": "Initial Lease Agreement [Member]",
        "terseLabel": "Initial Lease Agreement"
       }
      }
     },
     "localname": "InitialLeaseAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_KPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "401 (K) Plan.",
        "label": "K Plan [Member]",
        "terseLabel": "401 (K) Plan"
       }
      }
     },
     "localname": "KPlanMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "LeaseCommencementDate",
        "verboseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "nktx_LeaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration month and year"
       }
      }
     },
     "localname": "LeaseExpirationMonthAndYear",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "nktx_LeaseExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration year.",
        "label": "Lease Expiration Year",
        "terseLabel": "Lease expiration year"
       }
      }
     },
     "localname": "LeaseExpirationYear",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "nktx_LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities arising from obtaining right-of-use assets",
        "label": "Lease Liabilities Arising From Obtaining Right Of Use Assets [Abstract]",
        "terseLabel": "Lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsAbstract",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktx_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease lease not yet commenced minimum lease payments.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Minimum Lease Payments",
        "terseLabel": "Operating lease not yet commenced minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit notice period by financial institution before annual expiration date.",
        "label": "Letter Of Credit Notice Period By Financial Institution Before Annual Expiration Date",
        "terseLabel": "Letter of credit notice period by financial institution before annual expiration date"
       }
      }
     },
     "localname": "LetterOfCreditNoticePeriodByFinancialInstitutionBeforeAnnualExpirationDate",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktx_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_LicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement term.",
        "label": "License Agreement Term",
        "terseLabel": "License agreement term"
       }
      }
     },
     "localname": "LicenseAgreementTerm",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktx_LicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement upfront payment.",
        "label": "License Agreement Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPayment",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_MaxcyteLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MaxCyte license agreement.",
        "label": "MaxCyte License Agreement [Member]",
        "terseLabel": "MaxCyte License Agreement"
       }
      }
     },
     "localname": "MaxcyteLicenseAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum monthly base rent after increase on annual basis.",
        "label": "Maximum Monthly Base Rent After Increase on Annual Basis",
        "terseLabel": "Maximum monthly base rent after increase on annual basis"
       }
      }
     },
     "localname": "MaximumMonthlyBaseRentAfterIncreaseOnAnnualBasis",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment upon completion of regulatory milestone related to the clinical development.",
        "label": "Milestone Payment Upon Completion Of Regulatory Milestone Related To Clinical Development",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentUponCompletionOfRegulatoryMilestoneRelatedToClinicalDevelopment",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_MonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly base rent.",
        "label": "Monthly Base Rent",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "localname": "MonthlyBaseRent",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National University of Singapore and St. Jude Children's Research Hospital.",
        "label": "National University Of Singapore And St Jude Children S Research Hospital [Member]",
        "terseLabel": "NUS and St. Jude"
       }
      }
     },
     "localname": "NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss and tax credit carryforwards to offset.",
        "label": "Net Operating Loss And Tax Credit Carryforwards To Offset [Member]",
        "terseLabel": "Net Operating Loss and Tax Credit Carryforwards to Offset"
       }
      }
     },
     "localname": "NetOperatingLossAndTaxCreditCarryforwardsToOffsetMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_NetSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales milestone payments.",
        "label": "Net Sales Milestone Payments",
        "terseLabel": "Net sales milestone payments"
       }
      }
     },
     "localname": "NetSalesMilestonePayments",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_NkCellProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NK cell products.",
        "label": "NK Cell Products [Member]",
        "terseLabel": "NK Cell Products"
       }
      }
     },
     "localname": "NkCellProductsMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_NonCashInterestExpenseOnConvertibleNotes": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense on convertible notes.",
        "label": "Non Cash Interest Expense On Convertible Notes",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpenseOnConvertibleNotes",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or part noncash acquisition fixed assets acquired included in accounts payable.",
        "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired Included In Accounts Payable",
        "terseLabel": "Acquisitions of property and equipment in accounts payable"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredIncludedInAccountsPayable",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_NumberOfDaysToReplaceEachLetterOfCredit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days to replace each letter of credit.",
        "label": "Number of days to replace each letter of credit"
       }
      }
     },
     "localname": "NumberOfDaysToReplaceEachLetterOfCredit",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktx_NumberOfNonExclusiveRightsToGeneEditingTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non exclusive rights to gene editing targets.",
        "label": "Number of Non Exclusive Rights to Gene Editing Targets",
        "terseLabel": "Number of non-exclusive rights to gene editing targets"
       }
      }
     },
     "localname": "NumberOfNonExclusiveRightsToGeneEditingTargets",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non exclusive rights to gene editing targets licenses received.",
        "label": "Number Of Non Exclusive Rights To Gene Editing Targets licenses received",
        "terseLabel": "Number of non-exclusive rights to gene editing targets licenses received"
       }
      }
     },
     "localname": "NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards, expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expire"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "nktx_PaymentsMadeUnderCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments made under collaborative arrangement.",
        "label": "Payments Made Under Collaborative Arrangement",
        "terseLabel": "Amount paid under the agreement"
       }
      }
     },
     "localname": "PaymentsMadeUnderCollaborativeArrangement",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_PaymentsOfDeferredOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of deferred offering costs.",
        "label": "Payments of Deferred Offering Costs",
        "negatedLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfDeferredOfferingCosts",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_PercentageOfLicensorsRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Licensors royalties.",
        "label": "Percentage Of Licensors Royalties",
        "terseLabel": "Percentage of licensors royalties"
       }
      }
     },
     "localname": "PercentageOfLicensorsRoyalties",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktx_PercentageOfSublicensingIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sublicensing income.",
        "label": "Percentage Of Sublicensing Income",
        "terseLabel": "Percentage of sublicensing income"
       }
      }
     },
     "localname": "PercentageOfSublicensingIncome",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future payments based on achievement of milestones.",
        "label": "Potential Future Payments Based On Achievement Of Milestones",
        "terseLabel": "Potential future payments"
       }
      }
     },
     "localname": "PotentialFuturePaymentsBasedOnAchievementOfMilestones",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktx_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payments.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_PreferredStockPurchaseRightLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock purchase right liability fair value disclosure.",
        "label": "Preferred Stock Purchase Right Liability Fair Value Disclosure",
        "terseLabel": "Preferred stock purchase right liability"
       }
      }
     },
     "localname": "PreferredStockPurchaseRightLiabilityFairValueDisclosure",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_PreferredStockPurchaseRightLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock purchase right liability.",
        "label": "Preferred Stock Purchase Right Liability Policy [Text Block]",
        "terseLabel": "Preferred Stock Purchase Right Liability"
       }
      }
     },
     "localname": "PreferredStockPurchaseRightLiabilityPolicyTextBlock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from at the market offering net of issuance costs.",
        "label": "Proceeds From At The Market Offering Net of Issuance Costs",
        "terseLabel": "Proceeds from ATM offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_ProceedsFromSecondaryOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from secondary offering net of issuance costs.",
        "label": "Proceeds From Secondary Offering Net Of Issuance Costs",
        "terseLabel": "Proceeds from secondary offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromSecondaryOfferingNetOfIssuanceCosts",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_ReceivableUnderResearchCostSharingProvision": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable under research cost sharing provision.",
        "label": "Receivable Under Research Cost Sharing Provision",
        "terseLabel": "Receivable under research cost sharing provision"
       }
      }
     },
     "localname": "ReceivableUnderResearchCostSharingProvision",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction of research and development expense resulting from partial reimbursement.",
        "label": "Reduction Of Research And Development Expense Resulting From Partial Reimbursement",
        "terseLabel": "Reduction of research and development expense resulting from partial reimbursement"
       }
      }
     },
     "localname": "ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_ResearchCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration agreement.",
        "label": "Research Collaboration Agreement [Member]",
        "terseLabel": "Research Collaboration Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment.",
        "label": "Research Equipment [Member]",
        "terseLabel": "Research Equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_ReverseStockSplitPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split policy.",
        "label": "Reverse Stock Split Policy Policy [Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyPolicyTextBlock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for operating lease liabilities resulting from modifications of existing leases.",
        "label": "Right-of-use Assets Obtained in Exchange for Operating Lease Liabilities Resulting from Modifications of Existing Leases",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities resulting from modifications of existing leases"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases.",
        "label": "Right-of-use Assets Obtained in Exchange for Operating Lease Liabilities Resulting from New Leases",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities resulting from new leases"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prepaid expenses and other current assets.",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based compensation additional information related to stock options.",
        "label": "Schedule Of Share Based Compensation Additional Information Related To Stock Options",
        "terseLabel": "Summary of Additional Information Related to Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental information related to operating leases.",
        "label": "Schedule Of Supplemental Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Information related to Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_SecondAmendmentOfAdditionalLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment of additional lease agreement.",
        "label": "Second Amendment Of Additional Lease Agreement [Member]",
        "terseLabel": "Second Amendment Of Additional Lease Agreement"
       }
      }
     },
     "localname": "SecondAmendmentOfAdditionalLeaseAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_SeparationAndReleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation and release agreement.",
        "label": "Separation And Release Agreement [Member]",
        "terseLabel": "Separation and Release Agreement"
       }
      }
     },
     "localname": "SeparationAndReleaseAgreementMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions common stock fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock Fair Value",
        "terseLabel": "Common stock fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStockFairValue",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares issued upfront payments.",
        "label": "Stock Issued During Period Shares Issued Upfront Payments",
        "terseLabel": "Upfront payment, shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedUpfrontPayments",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktx_StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares vesting of shares of common stock subject to repurchase.",
        "label": "Stock Issued During Period Shares Vesting Of Shares Of Common Stock Subject To Repurchase",
        "terseLabel": "Vesting of shares of common stock subject to repurchase, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfSharesOfCommonStockSubjectToRepurchase",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktx_StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value vesting of shares of common stock subject to repurchase.",
        "label": "Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase",
        "terseLabel": "Vesting of shares of common stock subject to repurchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of common stock reserved for future issuance.",
        "label": "Summary Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Summary of Common Stock Reserved For Future Issuance"
       }
      }
     },
     "localname": "SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards, expire"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "nktx_TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity beneficial conversion feature upon issuance of convertible.",
        "label": "Temporary Equity Beneficial Conversion Feature Upon Issuance Of Convertible",
        "terseLabel": "Temporary equity, beneficial conversion feature upon issuance of convertible"
       }
      }
     },
     "localname": "TemporaryEquityBeneficialConversionFeatureUponIssuanceOfConvertible",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity.",
        "label": "Temporary Equity Policy [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, preferred stock purchase right (liability) reversal upon issuance of convertible securities.",
        "label": "Temporary Equity Preferred Stock Purchase Right Liability Reversal Upon Issuance Of Convertible Securities",
        "terseLabel": "Temporary equity, series B preferred stock purchase right (liability) upon issuance of Series B convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityPreferredStockPurchaseRightLiabilityReversalUponIssuanceOfConvertibleSecurities",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, reacquisition of beneficial conversion feature upon settlement of promissory notes.",
        "label": "Temporary Equity Reacquisition Of Beneficial Conversion Feature Upon Settlement Of Promissory Notes",
        "negatedLabel": "Temporary equity, reacquisition of beneficial conversion feature upon settlement of promissory notes"
       }
      }
     },
     "localname": "TemporaryEquityReacquisitionOfBeneficialConversionFeatureUponSettlementOfPromissoryNotes",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity reclassification of preferred stock purchase right liability to equity upon issuance of convertible preferred stock.",
        "label": "Temporary Equity Reclassification Of Preferred Stock Purchase Right Liability To Equity Upon Issuance Of Convertible Preferred Stock",
        "terseLabel": "Reclassification of preferred stock purchase right liability to equity upon issuance of convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityReclassificationOfPreferredStockPurchaseRightLiabilityToEquityUponIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Temporary equity, Issuance of Series B convertible preferred stock, net of issuance costs, Shares",
        "verboseLabel": "Sale of preferred stock, net of issuance costs, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktx_TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares upon conversion of promissory notes.",
        "label": "Temporary Equity Stock Issued During Period Shares Upon Conversion Of Promissory Notes",
        "terseLabel": "Temporary equity, issuance of Series B convertible preferred stock upon conversion of promissory notes, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesUponConversionOfPromissoryNotes",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktx_TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period value upon conversion of promissory notes.",
        "label": "Temporary Equity Stock Issued During Period Value Upon Conversion Of Promissory Notes",
        "terseLabel": "Temporary equity, issuance of Series B convertible preferred stock upon conversion of promissory notes"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueUponConversionOfPromissoryNotes",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_TenantImprovementReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement receivable.",
        "label": "Tenant improvement receivable",
        "terseLabel": "Less tenant improvement receivable"
       }
      }
     },
     "localname": "TenantImprovementReceivable",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_TenantImprovementsYetToReceiveFromLessor": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvements yet to receive from lessor.",
        "label": "Tenant Improvements Yet To Receive From Lessor",
        "terseLabel": "Tenant improvement allowances yet to receive"
       }
      }
     },
     "localname": "TenantImprovementsYetToReceiveFromLessor",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_ThirdAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third amendment.",
        "label": "Third Amendment [Member]",
        "terseLabel": "Third amendment"
       }
      }
     },
     "localname": "ThirdAmendmentMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen equity incentive plan.",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty performance incentive and two thousand fifteen equity incentive plan.",
        "label": "Two Thousand Twenty Performance Incentive And Two Thousand Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan and 2015 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyPerformanceIncentiveAndTwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_TwoThousandTwentyPerformanceIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty performance incentive plan.",
        "label": "Two Thousand Twenty Performance Incentive Plan [Member]",
        "terseLabel": "2020 Plan",
        "verboseLabel": "Reserved for Future Equity Award Grants"
       }
      }
     },
     "localname": "TwoThousandTwentyPerformanceIncentivePlanMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.",
        "label": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions",
        "terseLabel": "Increases (decreases) related to tax positions taken in prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktx_UnusualOrInfrequentItemsDisclosurePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unusual or infrequent items disclosure.",
        "label": "Unusual Or Infrequent Items Disclosure Policy [Text Block]",
        "terseLabel": "COVID-19 Pandemic"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemsDisclosurePolicyTextBlock",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktx_UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common stock upon early exercise of common stock options.",
        "label": "Unvested Common Stock Upon Early Exercise Of Common Stock Options [Member]",
        "terseLabel": "Unvested Common Stock Upon Early Exercise of Common Stock Options"
       }
      }
     },
     "localname": "UnvestedCommonStockUponEarlyExerciseOfCommonStockOptionsMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_VivariumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vivarium.",
        "label": "Vivarium [Member]",
        "terseLabel": "Vivarium"
       }
      }
     },
     "localname": "VivariumMember",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktx_WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average number of shares unvested common stock issued upon early exercise of common stock options.",
        "label": "Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options",
        "terseLabel": "Less: weighted average unvested common stock issued upon early exercise of common stock options"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions",
     "nsuri": "http://nkartatx.com/20221231",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Matthew Plunkett"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r292",
      "r298",
      "r626",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r386",
      "r574",
      "r588",
      "r621",
      "r622",
      "r637",
      "r649",
      "r659",
      "r713",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r386",
      "r574",
      "r588",
      "r621",
      "r622",
      "r637",
      "r649",
      "r659",
      "r713",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r240",
      "r575",
      "r638",
      "r658",
      "r708",
      "r709",
      "r714",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r240",
      "r575",
      "r638",
      "r658",
      "r708",
      "r709",
      "r714",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r346",
      "r386",
      "r418",
      "r419",
      "r420",
      "r550",
      "r574",
      "r588",
      "r621",
      "r622",
      "r637",
      "r649",
      "r659",
      "r705",
      "r713",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r346",
      "r386",
      "r418",
      "r419",
      "r420",
      "r550",
      "r574",
      "r588",
      "r621",
      "r622",
      "r637",
      "r649",
      "r659",
      "r705",
      "r713",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r292",
      "r298",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r199",
      "r387",
      "r673",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r199",
      "r387",
      "r673",
      "r674",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r697",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total accrued and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued and current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r657"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of discount and amortization of premium on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued Liabilities, Current, Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63",
      "r149"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r155",
      "r584",
      "r596",
      "r600"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r20",
      "r23",
      "r113",
      "r540",
      "r591",
      "r592",
      "r681",
      "r682",
      "r683",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r689",
      "r690",
      "r691",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r186",
      "r187",
      "r188",
      "r189",
      "r199",
      "r243",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r427",
      "r428",
      "r429",
      "r449",
      "r450",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r576",
      "r577",
      "r578",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r101",
      "r102",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r123",
      "r131",
      "r151",
      "r177",
      "r225",
      "r234",
      "r238",
      "r251",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r468",
      "r472",
      "r494",
      "r657",
      "r711",
      "r712",
      "r758"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r145",
      "r158",
      "r177",
      "r251",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r468",
      "r472",
      "r494",
      "r657",
      "r711",
      "r712",
      "r758"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available for sale securities, Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available for sale securities, Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r247",
      "r268"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Available for sale securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r56",
      "r246",
      "r268",
      "r579"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available for sale securities,Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r55",
      "r268"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments, available-for-sale",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesSoldAtPar": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with interest rate reset through auction process, sold at par value.",
        "label": "Debt Securities, Available-for-Sale, Sold at Par Value",
        "terseLabel": "Investments sold"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesSoldAtPar",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r40",
      "r147",
      "r624"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r35",
      "r40",
      "r44"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance",
        "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r35",
      "r40",
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r122"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r139",
      "r140",
      "r185",
      "r243",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r449",
      "r461",
      "r462",
      "r474",
      "r477",
      "r478",
      "r488",
      "r495",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r535",
      "r536",
      "r576",
      "r577",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r139",
      "r140",
      "r243",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r449",
      "r461",
      "r462",
      "r463",
      "r474",
      "r477",
      "r478",
      "r479",
      "r482",
      "r488",
      "r495",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r535",
      "r536",
      "r576",
      "r577",
      "r589",
      "r590",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r186",
      "r198",
      "r245",
      "r260",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r177",
      "r202",
      "r203",
      "r205",
      "r207",
      "r214",
      "r215",
      "r251",
      "r283",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r296",
      "r297",
      "r300",
      "r304",
      "r311",
      "r494",
      "r623",
      "r672",
      "r687",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Commercial Paper, at Carrying Value",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r16",
      "r127",
      "r135"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r276",
      "r277",
      "r617",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "verboseLabel": "Number of common stock available for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r689",
      "r690",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Shares issued during period"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r657"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized at December 31, 2022; 48,877,806 and 32,971,107 shares issued and outstanding at December 31, 2022 and 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r87",
      "r90",
      "r91",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefits"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r162",
      "r164",
      "r169",
      "r580",
      "r585"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r129",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Temporary equity, conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Temporary equity, conversion of convertible preferred stock to common stock, Shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r296",
      "r297",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r639",
      "r641",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r698"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "negatedLabel": "Realized loss on investments",
        "terseLabel": "Realized gain or loss on available-for-sale securities",
        "totalLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss), Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Realized loss on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Short-term Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Available-for-sale securities, Maturity (in years)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r704"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r745"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r745"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "verboseLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r112",
      "r746"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r112",
      "r746"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r110",
      "r112",
      "r746"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r112",
      "r746"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r112",
      "r746"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance for deferred tax assets",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer contribution, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r38",
      "r61"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r38",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of defined contribution pension and other postretirement plans.",
        "label": "Defined Contribution Plan, Description",
        "terseLabel": "Defined contribution plan, description"
       }
      }
     },
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r392",
      "r423",
      "r424",
      "r426",
      "r431",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind dividends declared for award under share-based payment arrangement.",
        "label": "Dividend, Share-Based Payment Arrangement",
        "terseLabel": "Dividends issued for options",
        "totalLabel": "Dividend, Share-based Payment Arrangement, Total"
       }
      }
     },
     "localname": "DividendsShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r170",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r200",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r486",
      "r487",
      "r581",
      "r586",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r170",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r486",
      "r487",
      "r581",
      "r586",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, expected to be recognized over weighted average remaining service period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan",
        "verboseLabel": "Reserved for Future ESPP Issuances"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r76",
      "r141",
      "r166",
      "r167",
      "r168",
      "r182",
      "r183",
      "r184",
      "r187",
      "r195",
      "r197",
      "r213",
      "r259",
      "r312",
      "r427",
      "r428",
      "r429",
      "r451",
      "r452",
      "r485",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r540",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r489",
      "r490",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r118",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Financial Instrument"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r293",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r490",
      "r547",
      "r548",
      "r549",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r293",
      "r348",
      "r353",
      "r490",
      "r547",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r293",
      "r348",
      "r353",
      "r490",
      "r548",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r293",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r490",
      "r549",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Change in Preferred Stock Purchase Right Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Change in fair value of preferred stock purchase right liability",
        "terseLabel": "Change in fair value of preferred stock purchase right liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInPreferredStockPurchaseRightLiabilityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, December 31, 2020",
        "periodStartLabel": "Balance, January 1, 2020",
        "terseLabel": "Estimated fair value of preferred stock purchase right liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangeInPreferredStockPurchaseRightLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r293",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r547",
      "r548",
      "r549",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r295",
      "r309",
      "r475",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r634",
      "r700",
      "r701",
      "r702",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.",
        "label": "Guarantor Obligations, Current Carrying Value",
        "terseLabel": "Liabilities recorded for agreements"
       }
      }
     },
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r38",
      "r60",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses on long-lived assets",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r178",
      "r437",
      "r441",
      "r447",
      "r454",
      "r456",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r179",
      "r196",
      "r197",
      "r224",
      "r435",
      "r455",
      "r457",
      "r587"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense",
        "verboseLabel": "Provision or benefit for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r165",
      "r433",
      "r434",
      "r441",
      "r442",
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r743"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at statutory rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r743"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r743"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r743"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOnIncomeTaxesAmountComputedByApplyingStatutoryFederalIncomeTaxRateToNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r684",
      "r754"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r677"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r28",
      "r30"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income",
        "totalLabel": "Investment Income, Net, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r532",
      "r656"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee option to extend description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r177",
      "r251",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r469",
      "r472",
      "r473",
      "r494",
      "r632",
      "r711",
      "r758",
      "r759"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r124",
      "r133",
      "r657",
      "r688",
      "r703",
      "r750"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preferred stock and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r146",
      "r177",
      "r251",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r469",
      "r472",
      "r473",
      "r494",
      "r657",
      "r711",
      "r758",
      "r759"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndMaintenanceMember": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and process of preserving asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Maintenance [Member]",
        "terseLabel": "License Maintenance Fees"
       }
      }
     },
     "localname": "LicenseAndMaintenanceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r278",
      "r279",
      "r280",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r278",
      "r673"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "terseLabel": "Liability regard to loss contingencies"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r36",
      "r39"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r39",
      "r128",
      "r136",
      "r144",
      "r161",
      "r163",
      "r168",
      "r177",
      "r186",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r204",
      "r225",
      "r233",
      "r237",
      "r239",
      "r251",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r487",
      "r494",
      "r633",
      "r711"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "terseLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r225",
      "r233",
      "r237",
      "r239",
      "r633"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r525",
      "r656"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total lease liability",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r520",
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r531",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r530",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future rental payments receivable within one year of the balance sheet date under an operating lease.",
        "label": "Operating Leases, Future Minimum Payments Receivable, Current",
        "terseLabel": "Operating lease receivable"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r157",
      "r657"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:",
        "verboseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r159",
      "r160"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on short-term investments",
        "verboseLabel": "Unrealized loss on securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r115",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Others",
        "totalLabel": "Other Noncash Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters Option to Purchase Additional Shares"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r32",
      "r54",
      "r171"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of available-for-sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r657"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; 54,350,179 shares authorized at December 31, 2022; no shares issued and outstanding at December 31, 2022 and 2021",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r679"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r156",
      "r272",
      "r273",
      "r625"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Prepaid Expense, Current, Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Secondary Offering"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs",
        "verboseLabel": "Proceeds from issuance initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from public offering",
        "verboseLabel": "Net proceeds from offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Issuance and sale of equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r54",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of available-for-sale securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r99"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from ESPP purchases",
        "verboseLabel": "Aggregate cash proceeds"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r144",
      "r161",
      "r163",
      "r173",
      "r177",
      "r186",
      "r196",
      "r197",
      "r225",
      "r233",
      "r237",
      "r239",
      "r251",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r467",
      "r470",
      "r471",
      "r487",
      "r494",
      "r582",
      "r633",
      "r654",
      "r655",
      "r683",
      "r711"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r62",
      "r148"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r64",
      "r134",
      "r583",
      "r657"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r104",
      "r137",
      "r766"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development Credit Carry Forwards"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r675",
      "r686",
      "r767",
      "r769"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r616",
      "r676",
      "r686"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Options"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "verboseLabel": "Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r83",
      "r132",
      "r595",
      "r600",
      "r657"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r141",
      "r182",
      "r183",
      "r184",
      "r187",
      "r195",
      "r197",
      "r259",
      "r427",
      "r428",
      "r429",
      "r451",
      "r452",
      "r485",
      "r591",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r88",
      "r89",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r221",
      "r222",
      "r232",
      "r235",
      "r236",
      "r240",
      "r241",
      "r242",
      "r321",
      "r322",
      "r575"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Product revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r529",
      "r656"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases",
        "verboseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock public offering price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summarizes the Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation on Income Taxes Amount Computed by Applying Statutory Federal Income Tax Rate to Net Loss"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r389",
      "r391",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Stock Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r152",
      "r153",
      "r154",
      "r214",
      "r296",
      "r297",
      "r298",
      "r300",
      "r304",
      "r309",
      "r311",
      "r637",
      "r672",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r653",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Changes in Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of shares, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value for the ESPP",
        "verboseLabel": "Weighted-average grant date fair value per share, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, outstanding ending balance",
        "periodStartLabel": "Number of shares, outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant date fair value per share, outstanding ending balance",
        "periodStartLabel": "Weighted-average grant date fair value per share, outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted-average remaining contractual term (in years), outstanding ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Number of shares, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Dividends expected to be issued over life of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Estimated dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum percentage of employee compensation eligible for plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of common stock authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of stock option grants per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAdditionalInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, outstanding ending balance",
        "periodStartLabel": "Number of shares, outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, outstanding ending balance",
        "periodStartLabel": "Weighted-average exercise price, outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of shares, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r396",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Contractual term of options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term (in years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term (in years), outstanding balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term (in years), vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Commons stock purchase price as percentage of fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r125",
      "r126",
      "r130",
      "r678"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Total short-term investments",
        "totalLabel": "Short-term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r613",
      "r614",
      "r615",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r526",
      "r656"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r45",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "California State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r177",
      "r202",
      "r203",
      "r205",
      "r207",
      "r214",
      "r215",
      "r251",
      "r283",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r296",
      "r297",
      "r300",
      "r304",
      "r311",
      "r494",
      "r623",
      "r672",
      "r687",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummarizesOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r76",
      "r141",
      "r166",
      "r167",
      "r168",
      "r182",
      "r183",
      "r184",
      "r187",
      "r195",
      "r197",
      "r213",
      "r259",
      "r312",
      "r427",
      "r428",
      "r429",
      "r451",
      "r452",
      "r485",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r540",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r213",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r18",
      "r76",
      "r77",
      "r83",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock, Shares",
        "verboseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r2",
      "r3",
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock upon employee stock purchase plan,share"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon secondary offering, net of issuance costs, Shares",
        "verboseLabel": "Common stock shares issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r76",
      "r83",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares, exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock option , Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r19",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r2",
      "r3",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock upon employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon secondary offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock option"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Shares subject to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r53",
      "r657",
      "r688",
      "r703",
      "r750"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r176",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r312",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Description of the reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r510",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r510",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r510",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r510",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r541",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationScheduleOfFairValueOfStockOptionsEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued",
        "verboseLabel": "Temporary equity, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Temporary equity, Issuance of Series B convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r248",
      "r249",
      "r295",
      "r309",
      "r475",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r700",
      "r701",
      "r702",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r186",
      "r187",
      "r188",
      "r189",
      "r199",
      "r243",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r427",
      "r428",
      "r429",
      "r449",
      "r450",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r576",
      "r577",
      "r578",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r630",
      "r639",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. Government Securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r432",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at the beginning of the year",
        "terseLabel": "Gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefits, penalties and interest expense",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions taken in current year",
        "verboseLabel": "Increases related to tax positions taken in current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r216",
      "r217",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance of net deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r527",
      "r656"
     ],
     "calculation": {
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares used to compute net loss per share, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted-average number of common shares used in net loss per share, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r200",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares used to compute net loss per share, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average number of common shares used in net loss per share, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nkartatx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://nkartatx.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r663": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r664": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r665": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r666": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r668": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r671": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0000950170-23-008523-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-008523-xbrl.zip
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MR[!H^).A83*IC>H4-N551:"AD]?S*XZY+0&HN?1;04(%;6CM2;HCQ.Z'U4+
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MX]RCY)IMJH89,3^]"=L;:H2TRVQT(EN[Y6EFY^U-^>M!A(ES379)G20L.8#
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MF-U#HIS_4I\U97O0%>K[Y#,Q1L9A>C/'CDKFHK<%:TI&O<C.,,UISO*(/TF
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MDVG]5$,I,WC9>Z0<NFY*,\Q>C,D0DR-=DRVD8X/C@_,=_8] B2@GPH3,(3^
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M1F$J&X)!B=ME>$RIQV7TEK+Y]\;A[0*?FP7/VA7YOLPKU)[\6\S?IO'3DP\
M'[[GR<-==GZ)2A/*!7;;&,X4KMH=!L8Q\VVI+X&.JCSD*GD]ZO7;N%"Q@]XT
M<EJJ\QCH+I5N-3'[A"1N.DM6!#R1**"NPK8KGAC]]K0<:%S7,N&XO_N&4!3:
M'MW.[^WHC5TD__V\5*>QYE[,POZ$\RAM+6*8W/-"+&8\ABU&.KL,8:\$C'L?
MSB>)C0K3/!Z8"_:C+2VZ _1K'1'?@A5,=/^" RU)0(;:.[XS4/>-LGY:>T;?
M5_#,@RS K4^YN3Q&#?(5LM-!JZLV?/E"8V'!X41(1J"2B?A&:+(P]F$:"G6T
MMZP<$-6<[TCIW-% /G5C\M[/3E16J&=_ J5#)Y=FS?<($A%"9#1U9-82[EKX
MZK"PWS,=MV&RL &\_G'KL9 8_07 -S+VS,E?XEP(K=YU,C\LLAE1D)[P*9%+
M9@GRN-=W1D<WW7#GUI=T:,IE#0/QV9[2471C>/8?\1'TV9+ Y8\[P*Z\YQV@
M&F'Y_W!7YEH1"5K+KQ3)]2G)=10!_UG0Q?1-RF\R@.X @50WG/]ZAR=N2HYO
MD]:YP/.]:&'^Q.S;PWJ5%6X355R:P P#%[0Y(_U]A\=GA+E5O@-T3P<8W &X
MXFH+YAGN??4]ZY<[6M>'K<O*_WK'3/R&/XX(,II2>C_!O8-#;=X!0L>71R^/
MIR$'4Y ;<R8#2)\ 2+U!EC9M,[%GO"]RLZV4YTDPL;;BJZ*%WA(0#'Y86F;T
M(K^/'M!N_$ X]F:J9G!UMI]?N(K 2O83MT5Z>KD7@1_8B5F%;SF66OL]2\SK
M7W$O<1_D^=%)"E@U^QG3;HMR)]6^:PCY(ZXM*1JR-$J#1'?T@*Q"=A$O8*QP
M(1=FQFBB1Z^NO$H;LEIO,U&$3&K7XC]N<ZT977[$"7S8*)0<G3*H4U5/WG_]
MS<P9)N*\ZR2 .J[D>U<?=YVD1!^HE!^\0&=GR .VBF3;3"C6EL<R(4&'CQS%
MC(9C!N/8IYWO'9IPA0J=U\IBA;T ";I0EM+/CPYH."4*3+I.EU@$L30*MB-E
MMSC[_WHSB7@&Q)0ZJ#MP1ANF'+VB^=#]_&4>1TG;@6)S)C3GVRQ0 2]Y*-''
MCLJ/L<QUZGKR)\CT,1(\(ZD6O!E7Q[6/U3:*>)!?4-Q1,K<EY;D[*#J3[2!3
M>F%A;/ ] (_"+5+A>0H2;R\-:6>5B&M>3E;,K9R#&ZT;!:;\ WQL18+SYSF^
MV%Z/8.SW7ON/9Z-_=OF=82[''T!B&S1M(\)FJPO"QTT<A0ZM[T9G"V+E.4:N
MT_MIYN$95F,&G/5.MV8I4YZ!D+"UVP^#NB&:L+C.$A!MVTI QE=*KKS]D+C4
MPPK[G5?3GF@J#3GZWV..C-:)^V]^,*SANX<^QM6;0_S4T11VG=(-3OE";.O
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M)4WA&J=P<T]:+-!%\A3"3QO9S@(<RW?>GT#ZK>]KU&]UR*9-4J?\L:Z_Y1W
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MOC^?MW[SO$KR4P".5;G@V<&I]N0HRX6).Q?SM]L7KPV#ZD^U93E+G-,>_;B
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M5>/!\W<W8QM&KD!1JP&/<A,<%7#[BBO2AJTD1>LK[3UYW3E-VC,>WY"-;!W
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MSY&T)7QS0Q^+ (8A/@#KDX&LFD5V^)(XVP))S-.B@+NV>.MQ!4!?-EL ;C@
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M18$LR2Y2)2"$Y(D?F1XJ[-=O)YT11A NNVD#/<B>B"7M3")NV@' +3X#T&5
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MS=IR10&G$W-XV$#.T_H,34"?XS/)].^!G?%%!C9&,D?FE&+N2LFT<6#;JOG
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M#UAX<2:#7DR3WH]N HJ;#==?O: =78@P]7 K%G<CK0V0D.]1'8;^A'.0M6.
M+0"X&@S&QI-!W5* 8P342<R_&Q".P-@K4B^ L1  'NHQ,VDVY[:UXYE873:S
M,Q9:[</B[_0T]R3$S/!\@ ,._8/@G\SBW\0LBMI8W#)(=$<YV.7GH=8KET[2
M"K0LXR+-6Q_#2K90P @.UY$^CA(2 ';LG/FPU0JGJ)EU0$HYL43!G8D@ -Z*
MABT#(\SK*3LW#E[_E&V:"@QW$VI5&$(KLA"7OWBOJ+8BWCRNJMMH;S;#J%8W
M &[5O]OW%O_$L#\Q[/^"81[\[BBJ$&95?\"_F@1-GYJ"'9&%49A8ISM-^BQD
M>3\P1 0@\54ZW0N)5)^?<RB_GUK;ULY+!AV3?0ET[/G5/U'IWX)*>W826%_=
MXAT;&PXA5 X31%H 7L9'/?%F.M1'3(U #PN&5H>F4Q0KU.Q?11L^UNI8;/NC
M^TX%5ZZX"F>>[/T^WAQ6O-N35LM K!:?RC^>=( +EK&2:NMA>[#F#KV#<@1/
MM\'U<+?GQAV7YMM>/IJ7K7+E?:%NMNCE;U?,=D5CD0\.EQ][#,8^A49L1"9?
M\";4P+_2WZ*+VJY1]"G\-#_>,FU7?W-.9QE,.<?/(7'/GGF6HL6!LHYSW4MP
M>!%T%S"7$(K=EZ%(_D;:1NH!$;0_JF%O:RB8X6,M[V'7NK_4X^I+!.NKZ59"
MQCXY3+R*-E%>_M1BQ=< P/8:9.L P'U'U\D@%@C5OU:0N6A"JD#O>-]:X(Z8
MS\-BO1R >3E6Y#9I=-S8@BKS4V:(H,]HU-')"[+NT>9*IB2 UM6T_@P#_^>%
M@3-YT\;4R=\.:ROPB4V?U+@8@N FB9++4I[@2/T Z"!+':D,D'F[@N%G#W7"
MTTP89@1"W*O=N!F8Q JYFD(0WP+L^\+1OY\F]E1 $9X2@##LGJ<=<?_7=*5!
ML<-]=HQK#R6CRNO2.XSE% 3FVY9\P%@UV *@-:YX,NB;C$\@6AH(P3ACD)AA
MY.I9^&*A/8-WT*: (ZIBK#Q'94"_0H%!AT;O?_Q>(YI?2,J9O%^@V%,(KS&N
M,F9"'5F67J"&8I- $G,YT+D40 ^G$G_^C.VN'3ZV,F/X%R3^Z$MBGAI#OF2D
MKOS^N@.'[01\WRJ-*76_T5!PJ_OZ+Y^,_'0LZ]BT;GYN8=?DC3R^@S4U.<H)
MF4K:CUS.%,Q\BE.;4>7);+VT7E4MRQ?>V:;==:]+=,;\+ES(@<>R<9GQ*MLE
M;W=X9^#Y(B.]FY==.4O"'SZ:CAJ@S54+RU$ZADTTW56Y*'TD462@R Y_P\L4
MH# ")&TT&70(,_->M$!W?UQ_WTK9?MBIF:@->U@EZ[1W\J(!$.!872MQC5]8
MBO?H11"X987(H/> '[V )8-\G5>U)0-*"A%UA(;;U@KG\+"P>EBE_#AXBPZV
MC*#%:Y!!!VF#8#,*9%!C*01MY,U0A%H&&M<!P5,,"3SA ,:^QM>17D )&54D
M1G6=[E+3SY81=P'@8YQTC_.!+>@9G#J]^FT5OABH:1]N;Z_C@YPZIYIG07G1
M^&B?#Z4K4#+H')J"ZE\(E $A2>I5)+%Y45V!'L'1E07O98 T@S_+ETA[;M/6
M0BB?R)T@0,8-25G8C5K)3]G>:3 3"HL/APDL/,X?;C9@'A()0K6+ZJJQR]/"
M'C @,%O91!WV_I4DRI9TRDHG94^Z"1DT1CE8"0J,%$"GB68(P<B;6<&):.O]
MNCS]V#S."%PE*]29Z]Q%!J%95NSMN4D6@^^AI6F%M>JJ25F&I#I<*/'0Z.9M
M?X(U*NUSB&2F=F30A0=N'N%3X:YKTO[;8$I789/7P+B,6"-$D-/P33XD_GII
MFP#DW/H;+HF]S@1K(,+0F_NJ=JGWOI^6WXLWR0FHF+\O>\:65F2D#V3*=1DR
M!?/?9//?,9=4<X'J4)(D:0/ \];A1VL.A?%@KEI9D6T:@N:HZ?:Y&#)(Z(#9
M:(E=8>UE4A[P8@0PHA^?!0&3+I4')>>%\&CH*#.K'&66RF\#5 BM"SS["1FT
M*0*@.Y,^"8R%!CF=7YP  FY8V[8",BPTO[+$Q\F+.)Y4%%I;UAN(R&K[ROE]
M-K>K//4U&60*W.UK1TB3)XG"_O??Q3#=.DD#C*4A=O-> A8;B?+$4&#XC,CE
M][1X%/27\4<:WOH\F'#.-(7VV4=_Y-=BY%KW! 3-"73\ ')3UY\ \-\7_H#@
MSY!!D\9@++P\L"X!=H$ :YZ=@ &A%NVR!"VUU?Q\,Q\B.<29D($#XIJ_MI:>
MKJ''UU4GLI5TPM!'MR$#EWTVMM68!O-ZBNV32D+RIB'8#(K*7H418@ (?H5(
MX<TR>?F&,3EZ;44XD4/$-0*&JM]L(S'"@%%0CC 0!((AIU\DG8%QG _8^B"5
MT["XNG1JV%@=8 ('/HU>5O1&#@C&FTVS6X'G813%!4A Y %8;9E'8%[HY\C(
M$(LW)F:+7=MMG#]K8TKG&N34;/$CG23LB\U$8XH)*CHHSX9Z+,ZDI;]*T&X2
MC15[']WQ_I*5[JU_(+RJOP@/\YN$M[/UM+2ES3B8:08+<'UL@'=$4^%=0ML"
MKUDK8_2I\>W1CQZ1C!KIC8O)2/ *SYW-R/@D-$FI%48MX!1J43JO/F!$]$[W
M,WMK O:]'D$!!.-L4PH@(!\4AE   ;Z0R<H\9!^OJ_2S9B$TU,0'P@9JM1WF
M&&W:7$WK8=D_H*> =(>3 D14_UJ; W CE\^=&6:*]H24CF6)(4X-]%?8 9,D
MNW1!3'5TH#WHNZG,A5\ &:XK.CRD.TZR>)=>F'$>4D4(D2?1@RD3^0J82#=8
M9>C..S[^Q;YEE0AM@#USO::>D13JNXNW>*>AC8"XCOVU^30$KTT"\. =A'2K
MB@RJZ0">B01N![AHPUL8OGA+.' 44+4@60#?=FJE\X!*JENMBHSD*(GNEG=(
MJY31Z( @87O_%>=QV4@,P^WLR!/%-V*^6]X)O8CX1^+B4U\X-*($69=ERMEN
M$^DX42LI,SX$J^2<M@WZ-+K JULHL31K@*3&*KT[\#F56&7H-,G"B$WTH5)X
MG.4_@K>[*XA):.AFG,-O ,-?6KLS[?0.F)E&OANZC_&:@ 6T.C&0>"A*+>NX
MPV> ?T& C*VA[3,4$:.=$M0!?0REY)DJ3TP1HT;$I=L6]'1=>@['WQL7SX#M
MD$!1ZCJ@+.:-1[U3_R4OS/#SG;I0!3;,)O!<DW^Q*6,EO@OPB#B?[&, #SZ
MZI<N<7[>M.TD;'&D)7X"YKF*L$S^+.;./A8]3C)KC);,C2- _AO8EP=(BTN
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MH%BCE*3A/[?3Y#E.#-$Q..#H8EX>"249!FVZG#V9G99S@+[L)BR@IU>1QAE
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M3?^&A,JD]<(@X=MAKRM+72]_5)5.A6?G89]XV;M1 X;PCE6*%7=/-5C![BU
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MMJT=Y_J 5*DMN/_'03&-#%C0[SJM3(HVS$VY&(7S&4<+G<=26,M$1BGHSG!
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M>'>R7G]Y7?3FB,\S&:QNG2M!, C^IM_V$I?&@YND]VBWSW7WYM2MUTS0QYD
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MYN:7CD0P4P0EW=MW2ZAVHUKBCAWO"YUEQ_!^[.*>'LL#C('MD[Z6I.K,$Q6
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M+:_+C1LJ9IK(4[4LM-5%,?EEYYZ[1.JY,GD8[,!NM16[ELI!BUNR=U3I>PJ
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M$/MG$3P2$I+[I/?IR<CHQ3B8.<3^'P]<)X"2&/\Y024^WB/ '4H\?$H\7 ^
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M/UFWT+;"V"-5_#S)RXJZ!$+*";O"DM+<C=N5-P+Q33O(*ULMD*-LH!F18-,
M-WM[3X/!8?DE/N<:/^'<*S5E9H/&QE.L\C9DMWT=P0<AR^ZY6)9$NU:X\<9S
MHOI2W]R\!NC6 'NHQ%.&0"]RW<4(Y>$JJ+T^>.HB.$NJIDREK/%+O(0QZN<C
MAVB#Y*Z#\8X&+3_CXXX!%].%C<!XCYN':#B6*Y=O]M1J_Z@.![ =,!@[N?C[
MR[-IH=ZF.#!KK94G]PDFU@WX#&CH5=C-?,!254_2#'Q/,=($^) D.PB<1 4=
MA*%R,="#/V2;ZUM?Z/5O;%S[&YU2+BJOGF@M5E5OGRV975V)JK?!@!W2^Q/
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M&.,_O#TA:DJT*J)8KC'IWQ>\,ERV[]F6$6H*=7'&K=,-^1"8SI[M!!\$B"E
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M]PA^VO(%*@;)"',=TEHD[T^(4PB);@\4P[]#3,!*+%&O[^GF49C>3TWTL>&
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M7/EL<S5G=H,X(:ZNB8TN:@0HRL//25=;Q\8XD3;!Y&)8G3RMGN7K7Z9'?I$
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M6.W?R)[_VK(3.N:]\V.-3\OCQ"S,X.S'*3#";2O)%ZMY/]MI^=C-44CRZOM
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M%0G8%Q(ENXCR*9,$)/KN/WG[W39<;J/.2,?-Y^-/XN64.1V27NG\X@$&<23
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M$L:_"WOBZ,8_SWX!Y.6: K',-S0$M[0\!Z.>]GIHI*P1$'@GR.QZ.8.&_G+
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M.&G4*Y%4(_?*;J[/[LOFKA&8WI14)W/+CPNM$('4HI;/*'Q<UY)"65ZN7&9
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M=P[I+[DQP%[XK^F,UC]..)@UD/]U/R*R5B[+3N1>(CME%MUA*[!*2@Y5T'(
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M)D">6%";0P7M\:+AT508I=56L3C5_PZ9EXT(-Z$FY('1\^(8'POR)U.P9Q_
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MV))NRQ,\;PS[V$C1B11&7!T9?1.NR]C9G;"W[!5NX04BJS?7,_S58$Y_@18
M2";'^9-+@ >35TI-1#@4?/IGA9;Y>:3.G^U*EZJ"AD2!2X IHR!KDF1$ +\
ML1K< R3(D IQ(4I<Q5FF"P/MT3W '-B/@NSSS1A]+N'PFC+_NC[.!0&]X :/
MU/.I="K>V.*]7?+S-E%2H3&_J#T+&^-#7&L[:*>LJ!Z5@B*2SA>)[;G$"RUU
MT(G\$.?1R3#;/-6_5Z;W,G<=XO)_0(^!52Q2;;9_DU?8>1C12-Z8'/[&C+F2
MNLJY^'%H[E=C"]:/9]N\7WM=!@G"1IFZ9QK)L "OZOHWS 9LU0B6#[9K/[O>
M!ZTA_?Y]031;/[]G@[ Y4 L#C]%'J=W%<<N9^"ENE@L.%ZO<\S%-6>:B^WH%
M; 4$&L)F+H,:M_VM!>=XJ9)I$R7JC\/T_*GSS1NB"^"3A?]*Y=#OHXC'=5$$
MPEEH*XZ;AI=$F@@=YR/JFGN,K%E/LIB +7BJUY(V,H Q\KO<FR@>A7&0/GA-
MKQ*1H<RI=KW[GNCH,AVR;O&<7Y-SJ ]9ZO]&OE5V3.XHZ"SUOIXHW\[K!/_G
MCJF0)"UJK3QUHWN8*J);+!L&-)\%XI;3$S(0DGU_Q6TK69%D-=9_JOWQ/<"]
M%++8=Q=E/RN85[=S,L68P;0]^78RI-AJOA5WUFK;,\_3RJ0I(3]MEV/WUJ\Y
MK<N%HY]*73??&P*[H)]7W1S"V)!NT!7CWR&YKQ]:WQ[;-PCU#QTYTF[P5JS4
M'AN3N:L)"1A16JI5,UH\"Q'J[EPZ';#6UQI[A6M/%'#@#TR:=X'HTLAZ0.JT
M>,(PQ JF\2<_W_P)9JS:\(7G<.P5V/2,A17/ZPK%<3#XK-0T7ID"?$:AG=2I
M_()&10.>+'8)\-0# T]O5J_&06<6,/H4F-.#QFZG+Q-MTG]]L]+&)81:WLQZ
M?8[(7$QPTI F)")3!C 5]G<.&:7H@,S66!9X;M+2[B4 P-,>@[L$4)E&[>F0
MGP=;XVEAY<B-:>V0 BNN4*$Z^<%;+?H^!*8-+$%PG%L1&[L8X)%&CE58KS=I
M@.^C5A#$N2O6\;L$A)^$]'^$^N;2;]>+!UF;=K,;+8D4, Z]EER3'11+8)+9
M7\SQRO("G5YDR!M%W>BB%:(5.K-LC+N!C-!VK]Q2$LAIUE&O0(N4NY[%0FOZ
M21<X;V!TX+_N"6\G7>Y3G%?R]:]9\,A'2#)W0VC'JY_&ELQ"P.?5KQX/5'!>
M MBHO""Y6N+-"T/ 'RK@7XB6 QMN[,Q(U3NY34GO8'X)J8,O<,WHQ]>,Y*55
M/:;.5AO/(9AN5)O(7G%;>%XOK+2MH/+T/7+_P^]"=RT)B@=$=15SI/'C/Z73
M<SS?3KD4/UT"F*7C0^^U;F3X9+&)A,RN.6TJ>/G+@_&E +?@F'VY2X"Z8G9[
MM=@V2T9+@'9NZV]_3$QFY]C?FG@L)]Z"8#9R6 %KMA3,+MG]\6.F(F?YOXI%
M6=/!-]I3;HZI5IGMZ+:4]0&@ HS;% TLW@C7@HJ@DUBH&S^<H/8-EQN-6F+B
M9VL*2V93ZIRM"3,15W$C%5U0IW'HN1RVMN6V^/1??)C$&C^#[*>=7@(Z+P$R
M_=B5_?]Y4)]6,5AXSRZ1">PB[79>;__?Q%=2B."[.!OJ68T,%$AZN@>4;\%I
M>7\N+_HV,,9#>1&3_\>@N>'L?ZXC:U*KCR+3[ZNE&B9II_9S6H]TXU5Z]G.W
M7T4\!!N)<W<#\NM&;Q_"I!FF;#9GHC^YCBE@WS_1,+_='*U)U5@%$MGG_6*L
MQ?+^_W;5^O\__M\9E]/_ U!+ P04    " !(B'!60=/2#NCQ   ;)0$ $@
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M^!?_XE_\BW_Q[R)2&QDHYHQIL+2LMXS=:7+;9/C.[>T?X9>B$HF ,Z.XQR?
MX..+/A4W^.51C%[&S_1?&EAQ?OL 6O'-.)9XM23X3-^,,=Q>4_#=JK"SZ\/8
M?,W:ZO+"HAH(1#_L_(*"R>M/!;IB41>MLS "]\&H2QDN^H@Q=&==OFDHZ:P.
MQN6R$:=PVB7XLEWVO"[1-\'^CU5[4\A4S6Y+M+B5&F\)".79U8IAB>11$MRQ
M*7?["1"1<5!LU._]+/.5=[9(FBCJ C@OS@?R!(BUG.W"LLOZR&FJV=9B+)A(
M]^WK*V2AV8-=I[-535[" P$39"T+20?#_P ?'O"CP_.V$L1EW^O7:&D)2&0W
MJF2CWH65<J*0BYSZSBMOGE@O&TTYUIR<<=7D#(%=0V3-DDG0RGLW+J8[LK=J
MPZH$>,(-V!E?.!V#Q<V%5%VT,Q];S;,:MM^3A4H1Z,M^[[]FJ!"@WU+XMI.>
MP.FFAG:">E%HQ=U6)&X\_$O(MP#8)I$Q-"AH2-I.=]YC]#H%>?L;R#(LQ1W1
MVT63H4Z/Y12/1CJM]'+,#>65I\AO58[P622AM_W$YLY\8E%,>:^E4^#BOO#/
MP_:N4Z^-RP,]7\CP V,W('\.HO#S+NQK :83=>["!8GBT2C'%\7+8B9@344O
MC<.=]+FD<V\7?<1 %W5#Q[UQU7PX,;#L9(6.;>3W- I38,1T(^.\1V1M6&I6
M=;0Q.%&P#TOZ+&>OHT8#/Q3YO*:\0.;:\/'=VG.P!PMC\_,VF(N:FD'&!X3R
M9O7[S:O.W3ZEN]RY;RW"8'?_V/$6_]:EMQ.NVI+4>1]8#S.\?*NOBRV*EQ\+
MU3N;&B/$_<>C= 0G2A11!18%'86X!.PU[4FCS-Z:>\RP1H9.GOX6O9O/]N=)
M1"QOIJTE59^VA+,9S(KG-/U$-PGX!,;_42LPO=DR)R%O [N[,(QK5 Z0N1Z)
MB.+-2Z7SI_9ZGF#"VK"WB]_P$VG3A%C6[0K"65I#V SXJD0E;Z#XN$N8?(P*
M'ZM\8\7"T)Q?4[.DV>;!MZ)"14#8F!Q.I3C,(LEK8@SO@V+S1"PY5C<"B5^N
MR245Q#[7H/K"GC=PWWI:W4&QV<O?;U/V#3DYYMKB'XVQV9(WE@P] "G#J*9_
M73O#)4W&#:<]V4PX<%7'#C]L)F-_=>M6QR?Y!21K6S%]>5D)- [ZV#R])LAO
M=SY.#K9(WR6NV1+S8,BONL_["J8)>0*H=$SMY<FW-KI\2!S1+QZNV?)!^@B&
M;:W?\B#)G@ U6 \[)=6_Z#2DP]5&EF<#60P-'N0;8><K!_"#"O+5M5&7%AR2
MKH_[+]X#\'Q.!KVN[Z!I(-]KG:7<G'G;]BS,?9TD>>HTC%=NTF+P -U^2H$G
M %WU9:L#055-@5W)UP;SE<(Z2?=9:TB'A0,8!U&Z>49H6)MAX?6\^+<8#F[.
M$Z!'01KV0F-.[C%HXVNCTRK!88984[85Z'DQ--_N^<_]E_V<8[4L(K>?<L !
M[+L^S,FA@T\ ZMHK_HCZR<*7 WX^.0E[1LAGG0XPUGNVKN](YG82GBMC<>58
MQ3+3I<7\/_-$G&9(QNATCG:[D\ YD@$^PXWFK/@7%O.2' ,=1-_U'I3A+)&"
M>4113@^97]67*?31[)7-_(NH 8!A:(VWUZ@$ SSZK,^+AS&+N]#!N'IQ''/T
MG2\2S:8&,]]XT=/^"1 V=%R[^P3 82Z&8QC-2_AY%ME*,4Y==HHMX'-O;19:
MMDKSH$2*,H*?;0>;C+_T#$.+I7S[G1\E%KS7P=+713QY*L5_M&34YN]H94.E
MZ(RW-^! \49>]!2X9E<;PM.2-_20P \WC;\:[=!_ F!FA#J:9VO(_AH<Z.<@
MHS@;IJ!@D72-A0K.1R/I$83GO]6(Y8$5!_-\D>/+!>%HUU3O+N+?OMJ'9FR6
MGP=R(X:H:KA7=RQ79VNSP=+/((>^0ZW%MF]D72M-9('$R9A3NP<M(:XG/1+3
M\4FQ[7$/F@GFYT<&5BV-]RJ/D'83B^,#B4HJ)541=07&<Q%:" Z2>=*Q^;'0
M<.;S M+P-L.U!HH\&-VXUTU[<)!VG/5_Y<C-NS^&_ 1O5AF2>,-PE#,O6^O/
M.5G]0%2Y:-O$+%Y>H$^R).?EPS!*72?R6V&;QD[8MM4WQ*!XY1++Z>1[([#5
MB3Y^4>NG76[/VTX0Z4&"KV/N([C0GKO*::.UV6%+CQ$O@L8'@V13%\F;HHE@
M*K%[4Q>@=+CI 7T;^/EEZ%U<*+S:.8K-==,9Q=N]+YU(@,#H1\B6]K8+P GM
MCM0AKUA+QY'[@.?HE/ @\%=WQN6$7O.\1TQ[4V/3G(-UJVDG#@CSMU0%GKWA
MHVJ_4K#UK'-UU9;U NV6=IRRKU7D?JB)VK9:&)AZTA_?M=S.3K"IT)QRK-G$
M+^4UFLVKG&=^9GBN^B82<Z>>ZR&T-+-.H\)\QJQ)"7 2?3+0=BQ2(%OG$@BG
MUEZZZ-[P,SQ<<@"56]Z%%:RVC+VU5C^6?+?/G!M4OF"GSKD4=P7)^;B,NJ)4
M5^[\L8X:!AQYT(+M?X @[+@;NX! 7L/BY76)GP:Z(ER)JF_<ATM)TK8#=/;U
M$12;XT=-UBW 8GFOP\$/,2E70[:^IJ.U PQGAK^? ,&GO(<Z1":".;I-$QZ%
M[F_KRUTDE?8%B=OV4IQ]F[3LTS56FQ5H-]$BD,]4@5^DJ&;\B38,)X@.8"-+
M!S.*R?!=D#4(D-XK0GW14RL\Z>!!=8;^<WZ-!"Y46&7L$R_( =1)?G,KKI3[
M$'LU<I1%&U>S#@V)+Y?:GQ[XPJ=&DD?:7C@!NE;P-*3@]O5A<PE[ IPENIM8
ME.@C*@?HT)P:2Z)/<0U(SS6<M M\/FM6-W/%5RC=;Y,,8.?A+MI=9YE&=Y"4
M_;EYR1=:9D!8+XY7=$8=>JP&$3?0>5[1>IF3/(SCR%A3%LWW<QB [Z[-*1C
M_VG],:]LR?AXLVM";+3Y*,351!"N9AA_Z\]2M#3A!RHT+E!A2<I(WW4CQEO.
MIMBX$<P,(A8+["P\!&/#(J(N1T^*G^W:- 0D#P_)KSFY)@8VRAH_'.,[ITWX
M9.O,5)]M_\A6A\2?RZZEG_%%4?CLL(DRA-Y25OFK?4>/4VTM<4IKDI.:IS5N
MB,7S$97D&.VB/SBJ\K>%(<'GBM2Z0J/4Q>25Q%S,NR-7%'1QP <9A&>QW1,
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MFO5!\@F*ZY'A.MHTNO-3R<N@^+^OJW/I RZ^"B)A:]5=!D8:47Z0T26[.S[
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MRHT2,M0E$JJ?OPA^8,D77-.0I2$\IC$\]7D"Q$I1C5<!DQ 1;^>H%*&)@&F
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M0Q;P#TC4[@U5G@#?PTH?D:;P2OX/*?V,?-Q_=C2K^&-#>VO\D"^KA9%^JT^
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M@],3(HKQR]<M6B.(9U8C)17:2?='MQW.=9VQK;_5;N6(S_O6T/8G8=NN7D[
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M/-YHP!U7;N^&ASYR72X=KG:@^%@*)]*6_M,F&9])\.>&IS7BZ E0/^^=5*1
M*/!)8^J3V0M/BPF21I5;1B1;P!(U &83?453J@N/_2/6X67[B<XAKGNLQ93
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M(:?;K_T9R-Y.EFS9]_7T+=Z<S"> N9L1MRWLQE,#_ZRY>7O0Q";I=]U,^+2
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MPF:4",IOYWG.3!W4T5(O;R(DUV/?SGAQN+[K8O0:YS@@^<345L;,YJ*^4FU
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M4,7+@2?[3!U1N]-_M7%5*%GWA?)ORD^5S6P1%.$[$]RE=76&?:LVQI>A OR
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M,!U_-UCZQ9Z0([.[I>.ZH\Q8Q"+Y_70;[N0.E%KB!"4+,Z>#I:#M92=&;FS
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M DZP^.%,8K/[ %RBD)68.2_#5OU"Z!&F#'!%6P-%XY)DM/GE5VLDP',.#PD
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MU2G?73M2$%9B"6M/:<TQ!<&%X@^2PD+4,BK M>)3L&PE/$)&B ;2H]V]MK]
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M9_Z[%UU*E1)"@,56O T+T[6>WEH%A10-OX<<V><BV[9].?_@PKAA2W-A^_S
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M=&55\7H_+V5B/=)A%S;B2W392G52D18W6Y+R/9=GJ,PM?[SUMQBE2FADAZ_
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ME^=YU3Z)/R\8%*LSDW=).$)XIK,[=M.5G//-5I*'4,:$7X4KU65[FC,HPU)
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MUM49J8%;RETU'PG#*[8H^$ I-/558LK%I?K4F6&Y7T;\STJ60JIU%3@M-O#
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M (L% X<%\](-D+_:B0#SKP'\GP,&%@X> 1&$A(SRYG5!+28 "P,'!PL/AX
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MAM!GPOXO!@;Y4Z;0%ES.9L5"R@L@4LYV*WTN\;."PX?<TJ+>8=".R.RK[N]
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M;J(M>'+7_U"^+GT&+- 2S23!P,.2:^=#=*GS L"Z;NI/Y(S59F";C^:]DYN
MV,A>(.RG^O*A@Z\K)"<Y]CC26&;EZ^!%K+&[D_C74,&G\O="2CJJ;D*1^ IX
MGMKC+51N_-'[E.\XHG.L+XE1(5>*H ).T0VZ0([3(&RS9\JSIGX3WJ4[A;>I
M)U6H.",;\MP4$:FS;IL^0'UPA56M%[NB]2?MUZY-S>[M.U\>X G=[9:?J+L&
M:K\A8*M9W78^THZ>@Q9K&S(S_S',]6&5,:*+'WRH@L8\,?I:#5#FW9:0O "]
M7DP*UAI=3?X+C+H'.-:-5JE-?@3 Y1R)O3XD=Q^?B"P]@>A;U>)"%HV)LB1\
M:GI^(_FO-N2I%CUPME3!L#GVG.R$-)VSKK_&R;K"K8*NAMOG":Y+G\ST@Z?V
MH?,7()CYTZ\V:JA/Y^4H-:_N0+5LH?T.MLX]+:BQ]'62#&/B$>9;OFMH%ZS.
MFSZ;&3;XD?4+Y&=*GV9_7DPYES;>,VQHY='IT6F*PO21#M<M8R/!B)T/F<CQ
M,'C\\=.YT"\G8BE/^PUZVZ,R<D_GNOX:H8<Y-;A5?Z^]2+'JAD6-MH-%0A]L
M&[35<$'RI:HC=BF2  6K?L(>;>CQ<T%7QO7-Z@.S8SMF"X)0J,ED><W@5-54
MS0XS'#>?@JB_!!6"" BTK[OZ2Y#(M;V[[MYKI*1B?OF ZQ+N3U$(P>8S<[/*
M^VZ_?K@\[MKL8Z97H_/:83-Z^5R:SQ-_,L=H!.2#W_X.0FU.0Q2YWFG]U)6.
M.<Y/1[*?H_64JE S(!NV_6M_$.? ,OV\PM_I [9K05=R7NI-,&(2O5N"J>'0
MIQ+/!F4,%/=HO6.L"7(N#(T+B31/ZQ<@QE[HR5/L\3#Y;"?@7-T6S;QJ/YUN
MDN*/A]G""IU2(X[9 L:) O<MY^KCE[/ATU!/.I9X(^86<$WA>H'Q6Q0'-R!C
MHF'P Y*GSF2I857-N7PL:0L253!K6C$BT!_$R3J9,GM%O&=S,)-.4065J!#=
MT(%^<,*H'I+]@\HR9"=X\'!3SO=7$&&\MOUGM<5"G,.2@5>Z#Z5Z?+L=9MW8
M:Z(2$;PKGYCM\F9O/;-ISH6&:E2VMK3^@EA2>A8FP9/.A2OH.G-Z_%W!;1M[
M)B%'7QJTN@TDG/2TZN5O-.:A(-NLQ=:6:8UOQPQO757Y<>;=[%7P"#MMLQ[_
M>*@10T_@8(*J$7W%(J=])M$5#E*!NMD6+U$'J35*I-DF?-<(Z.237ML,0UDY
MF_T)^OE,>-"D$)SO+V-Z^2WMV*5!<R L^N)'M+\KWE^H]XQFC4X)GU"P.BM4
MS^4DTBQD[4>_8A7]M]%"_JUS>6M]]:, A.QV9TVHE1149)-27@IGZ_YY)^^U
MG=A:K!4JS;C_J);Q,UEL).^LOILKVEJ\+4;3R(WM+2U%(S<H+'G/<16PJ/-!
M_L#/0-,3W?Z[;1YO<8#0T(T/O#@1$KIQ)296X?(HNW45"6>V$-F9Y#2XE]LP
MU1-7U<,GO=J$=3)7S.[+O1^QDV2^02HJ_Y3V\X\"Y8BIY9<XG$;,=FZ!ACZR
MI JQB18&'Y.SVA;6]W6]5_/#H-^E*_J[RS]234DBIB6$H<YCC^R)?]V7_C1+
MGZQ85^,CR7R37 )11$J#I_N9:UXKP;[?9MDK]\\2\6ET7U(ZQL0*H*(]Y(MM
MRM+)(5J5X5MK,4BVC7O"5YSUFZ=8ENR>G\Y: ^[U1>R]M6Q5>]4U+OIT\;AY
M>$"DT#)H&SGTB6.O!FOCP?7*[ ^V9'2"7>99#AR%3\<+('W KW3VO-J=CE,S
MOG"_;F-55]MZ-/0UUI6 )IB'Y_[>78G.IQ7>T7(\7:Y<2VL1DK\,9>]\9IQT
MLN11:]DOS<"F)]E%7=HE_2-"6==&\_<>TBT$ZCAF;FSQYX@UI]\C/>N:(L%F
MR@KM)..?.BFCG&W1+S&R6(L\NA@?I'\!S'UU23R2)\\E_)U(+2'I9+/,IK4Z
M<AP5R57-;N%!HX,!%.<'8F\VPF_:]] ?RQ?G=@1IS>L$8<[>S$$=EDMSIEEF
M^ *U"(,5<Z,3J"\CTG=G&@4TI">"@MY# A_)-YKE'.9Z]SUO;.!_FMA3L]Z'
M84C?8A! U6=[!<D2I1O!6-3\*O3]X1#1B*?.&\[N C]!"KTNZ[P#,M80 <;Y
MQ*\)?@GK<78PW*3M"T+ATJVKQ<2UB4,0:'21!=%TD#^'QRKOF$4>T35*'-]%
MJ#]&EK&=5[%0*!GL6,NG=23;&DOG&J<TRO@OI7^_46S:45\@C7C7KD(7.SY"
MJ[]4UX5<R'@<PA+-[/<[CP!\D2JI<*F[5)P#EAEH+>8;7J"^F4<92R<79(/J
MS\4F/TDN3CK9ANLI[%>"+=*:5[>P)F:/W(4"7O>ZRO@+<#A _@1H_(9NW9&3
M\C-SKN+G4:DR3SK?D@^5N=>%F]*F9<UIR0Y,+"Y"<.)XX(M][=.7U.G"'[&^
M;>IQ<7^/+ZM@GFNMG4#]/6HG86<GQ-C8O@)F"?OU8?FBK1@BYN%B:_)-8'DI
ME+2%_FO\8G8A(6UU^SK=!/79\4BCN0?:<'B+S3&U7/1%6/215^OA\(DW,?0%
MT/ UUVX/,XZ5(H"G_Q[=\7RVP ZM+ _J]H9M]@FR@RIT82^*X%]?YC8Y*Q^@
M;S@4.\B8G!5Z\'F&JC>U#UVL@EZS#5O/1DH[[@$BT_%7#F$W] >U*BD$U5NJ
MY[ORKC6A7U_NO]T&Y46Q:[=GP%R'1Q"3BXX^HC1;XZR?!G$,8X\,['Z9."E_
M%ZRNM5TC84Y,$B/9O\OIWXYNZQ@97/=,=78^>>S8JUC/E<1Z)DY 61P/$9T"
MJY?FV234+U>RG'PZ;.SR2NQ.S"#F%R,/J'UC27Q&4I.(@A)WQ\8COLM]K/0E
M>324W_IM@#?%8?7GF8N3$'@_/#HK.SAZX*LC-5FNG>4$AQ#<@;MI#[-!]Z6"
MV8Q&=!6$B(\0AH;7O^$99R5Q0Z)KGE\_P65!=VSA$#^"2^X=(R%[*G9FE,B6
M_>&A$KGSQW9KZ81R=?)-A5\W@C#-U9/;D]_3OOYP=Y/'I0<1[.[K1G:W8_5L
MM/_D(NK&/X4''P!(2_[BJZP>7DRS' %3*E*U<EJ9EM=A[X_AL,.Z&OI Z:U,
M*=#X=;X7@-#UN\ G^>0%AH3M[\QV0R6^!#Y(=/P14U+FIN7MA6O3IW496;ON
MX2WMJ/QJN=#T7C8..7GJB MJ$B8\A(87 !+40%DKB*I .M*XR;-N=R[C6![&
MB\?,@-CZ5NULN:UQ'7^LXF^\AU-8TV5E!X'1%17GH"?+&6+1FE]QN/C&B)'+
M]MWWY;E-FZ-=AS"O]4/5U>Z6M#:K4(^2ML0[,IYU<C3HCYZ+@V3!)*'YJ\T/
M:<['MV]8CD,\TL&0S856B;717_YS2Z[B][AU4XZ[7D4U#-$NGO/7ACZL(?-0
MTS4OA<X?ZD1A-S%/5:JNSR-'<W N>@,"%I&AWJ06L]Y<U><* 2>EQQ]4T'B7
MV!F;T=DOBD8T?GQV-G>T-#@\8_2^M!V>NQHX#SVDY[<_'SB5G*GO+S!/N M9
M=%,S":#COF9.%T#P>"\NBDWXN31%?*V @@S*_U4#9N,T:"$B:T.R16$]38UC
MV4C%).DM QT!_)F'G0/2FO*"U!_MGES-"7Z8/*A*=Z+[2*2;0(L<S&H!DXTH
M1"5&05\BSXT\H-PQS7M3??J58]A'O[GQ=X ' 9'D.L%^5!<HVF\.1C]GW3:H
M*:\^>#3X4:-$HN@@6XCE';8Q-[37';T[#.!-SGD!4$Y[!$FF/^2?Z;=;FG]S
M?UA9..'_-?H@Q&1*VF0_RV%U?7P?<#4V G5UTE% AE;(M%1.E=5 C6)DR.N%
MQ_^(:PQ<0@PE2?N+R=Z\ +'>Y^0SFR^ L/85,USG?6#TNIZ$0LM,.2?3P]P2
MH0VU"1%V+I 9ZS=*U_K5U6?]N23W\<-T"[M 3ZS^BEN;;G0S0>\V\#4>5)^'
M_6"P+HE_?FW5=?8<7VQI4+TP9W8DMA4H2V^=-R4KP^+5*V:?O=OEK.V5G[A1
M@6#!*]"-FGF _[,THJN(#T+Q@'.L7YT#1;E878_3?]L\M3!S_N9/TY_H/[F-
M1D\3XNA(+\#UC-BJ'[]3\5Y.5U-DL.,^1Q2>[-_EL)-B!Y@^B-$(^%2-[K3N
M9YW&I0"Q1$-M\WCI;E6#98I&@*P*SR#OIK_4Z:&&16!H[N*>-G-ZHF5#IR5F
MN(P3]XG7J':[M'KSGYRJ!B4QW$!<)3'@?P=\/TQ&3]J0X]Z_KRULK'U/_OU&
M7D(TGF*RQNN-S-E3XMQ5"7T9Q<A&943!5&R_D/98=K@O?78(\%^BJ-@\P7TD
M13"M4'176[[Y:Z2]7A?/ 1)5'FU\GI99\E=>YS2,6'. DON6W1I^MP3;/7:E
M7$D8 ???#Z0!0ND_")*=H*QR<9^ %93&I@?99(2&6)YNF[V,VX$_!A--]_2P
M;YB8]'@G^&287(^/-PDDLQ6+<^90TD/H@>S_'_]^A(U'_^/[9."__MG_;Y'#
MH0@CAON_,4C-_F.OJZ.+D'.'^9#TS=E_"'/\G,1<<\N\SO^1K"U*PI,WS)7(
MKPQCEJDD_/?_F>94&(DW6=M65"89GAE7V=@O]'^YF_X3$&,Y@)KOL1Q+XT:Z
M7KA+$]_3_#<OQ22:$CDT602CDF4GOH<B0+Y.3(+E<V'$:,W!KTH98(8!YO^!
M /\'R,EL9I11Y\(_G'DG\//9/>=Z3 [):"8=\51\6']]I+9#%SY<72G^VUC=
M/X)&L1QA&1FY81"8N\%7#Q]VD?-H1H[=PBW?Y=Y]-3(>N2OVNS%Z%K2 ;-)#
M 8[PX=W*V  %N2 \N.[N/W.\ % %3W[5JE5O0Y]P024P2Y F\62R/3?>0$%$
MBV"Q5#L!6=>CN43D(Y>&RV(OZ,\+0)2"OJN*09CI=; CM"YX=DJ^OV9:H'!>
M@$'FZF+CO=+P*-3KMW3 +FZ9] +\O.UZ+6\BKY^$>J,]O=9G]/[>V:<ZOW*\
MYTL3=-M_74/&?W9'^+9DEK2]-^!\Q7?K!2CXL!EYGMT)+LANK( J\ O5D-=_
MH'N=CGW&&<4P$;(QF'PTUV1QG-+@:.,]>\!&N#AC<_<)AX-XDPE\2)RMAT[^
MT=TW*[?F=UJ_A0_=WGS5F'&6!O7A?G!XSM@4\]^5$0/[G*6Y^CS[)%YE0G>[
MUGP@%_\V(R4&-GB=\?09_.<+F1< >39H]+']PRO%ZP/=<CB'??XZK5^^ !\&
M[WW"R?_STG]8D]F8_A%\V34/69P5"H*^]A#(JT'G&761DX]FKR8IK. V],J!
MJ5X;,OZG!N^,33E;,E?/JS9] =9_T7><<*R!=3O.9X."A&R4CB'0R:"(1T%Y
MP:7&5X>&HNS*B3,E"0J<W0KM#T)>/:#QJM=JX\[U\!_V$\<:#<Y_F?L"[-[Y
M*)SG5W1CH-?+_./W4(21])"=H$A^?AW8.Q]IT<U5#)O%F^W1]6>.TK>\%DS)
M@GQG9Q1>K0ZO)DF]<NP&54?6L_A@G!<8-DXJZ<Z_&M1U]&"Q>Y8KR']VQOUI
M\%[Y7\_CX'=;W_R7*Y0SR%Q=,:#/!O\FE+[<_0.Q&;NN&*Q^48PZR@^J&,NL
M_ZDOS>!I4Z2G%LQDD?--DS5 >'"LB&G!5K]KQ2=\W:<46$##:O.C/G_3@AT^
M4/LFQW)^YG%.KJ+IRS,N#R4. '9*D-GFBJ;_,,":[(.5.'[OI$:0?%5DO5)6
M$@MD,1?CBE,R)!7C2 9Q^&\69H<@_GOKC'?<^0FX0C-_:L/-C_/T^.154U3B
M/*/Q7P#UUN76 -8WI8?C\[J0@D7Q6=Z?:[^SY$-/=O_LMK?:N_<&V7_SR24>
MC+7W<6*O[2Z@D80[\?4P;M8C%Y?CX)BLS_ 1Y%\,/+PB\U4'19A^M'"G\K5O
M$Q8Z32X\^5)'"L]J7J? 1^W]K7\1.P $5_ "Z%<?6[V+F;$L2J6IRDCT2Q X
ML)3,3W?=_)T8P_3=;//6:NT%8"RC*EM)L3;!^()!W26 9'(_4T1RJMR:J4*V
MCK_QVPIWR[AV8Y8JYH#&0_,F'33 7<S /5D3BT5S8B,OBO4HX%9\/B<EF,&\
M*(O-7:5:H86TE3%D7"+1B-9PY'3>PG(4NLU*%P5LE/T,$$:@Y#X,P.M\TVE-
M#3[Y9B>RW P?*:LA9KE!;#E8N(;Y>_[Y5"@R3S0XEY&NL8$RE-SY_;T5[D1E
MC%VEH=,= G?"\BT .91]S^J? W\9$JFBK%<49A49>8/ 2$WA4Q)*VB8B"U_W
M.:N3U$)\J1"QYRJ3A4J"N(Z+8C.5AC]7<ZZR0'8K,Y,C!$!!]*+O,C6SX8T5
M[E06V'XLO/'KF./)%,-?,8H4.D&1965*N ,IN,>>1'A<Y<)LBPL>*85=WX$X
MD+(AF) 7P!,%X(:?#)(&;./Q/U*&^ZS!)@Z$AO40O@"^*,KH#!_!PJ!$\L>+
MR&<H;@ 5X=.4Z3/ \+3?N@?33/4"I"N] *NP<1)D/M/_HD*CM9=>(]-U>P'4
M"/XA,-=\#>TXG]N.@N^_Y=["Y',WW;&:/G7*4G)M#BJMGH2XV4Q+J+9$#/3L
M.-A'P49N4)]_R<UN3.]L^Y4@A;,M%OZ)9"L>#C8_G)+ @(4U0FJ!IUQ\2T]'
M.'%"5Z8U5Z_/G9[.3T^O$CVD8VL-)WD@W'4F-,X=/GLSAV:>X!!58BES&"DZ
M=DCJ>HYA;IB>@+,!XV*=[DGU'W.0-HY139X!GL+.G5P52;C!T&<WB7\$&+!\
MN-M\NY:=V(J+:AN/\7@>^7R'ZZ;D,_HJYS1:/CM*US8><Q_7Y[8O9S#HV54B
M0\\_38P5[6+S&-?P_@C7S?[?5OK)9_LMB9 87/X5>MA2- F+O&9]=11E0H)O
MXY!K+? ,H0\).A[W_^R7CN;LW[#Z]@48HA*ZPHRL&)O]RJBEA$*?'2WR/Z,^
MD)1C_CCVCF 2/$R5SJZ40, ](N'^-=)YD["T^0%ZW+@<^S2UD=?:</&.!7&'
MG_[$!Z7$\EL"VPA\3/KG]&#U&DIEERIZ@>VG.<2%:7^7]T+Q9'KG"FDT@(^3
M@\_[F:,0^RA>QXV4U CSI0B9@Q%7"]KIL^T(A<]L/O?31;9@4LA]4C"97[4Z
M;2!/!S9E&Z\-8>E=C9]-.$W=YXKA&E.*!_=Q1V0I*_/BM<BTH+:#VK"*^]['
M0_Q%):10DH+8L?I73V- \!BFH@21%T 5"B.)#%+)WP2T1C?E40IY6Q5UNK\M
M-V =2\?>17#]>;S+,[JDDK$#HJ3NIT*/)TI80+*I#U/C=8@#XK]BPL;D* 1K
M?)WHUR9=C!-Y,DWV<H=I#]3?1&3'<C1F&OWWNE/.),(,L;%513=]YU[NK1CC
M@J]N/SO&\E^,HN?;6D!(9Z;@07C",1[' ALCK;H;>=+^L4=G_$K2L2$^^+*"
MY+ME(CG_S_O)*SG\5?&JBYR[77"3^9SG!;FRI61$"UCVBXWS+.%&W\]GBC%E
MNWQV)D-W$@TS^W0)NCP[<BSJ&+YES [YZ_A?%!XF]],2#G39E(U3-+%*31'S
M[%0;,Y_TV0]\T..MC?RG=X7M,6N?]FYW4Y^=)&0:_'M-8[9#@08QDBBIW;N)
M12:+1-F/LK84+)HF?F,^O/-[#D6T%!$ZO_0]\MY0B0=CHSM#HCZ1>QIZ<S+/
M_AZ8F1G*YN/4W<RI]EK=EVUJ=67)2Z9=OO!*IZ9KA BN&:?7'9NB:->DD++:
MOU]=H=@*<R'8B(6Y'5_4U.JQ$4G8470A<=J/\>'-NI':G QX]&EF[&!R$;RV
MQE@TE@E<;CKXINOC)&$+$<J3*NI;")CS7W81Q;F3B@AH),_'V)9CY:8L"RP"
MXV?Z'VP_!I+S-NY#+/;>7_-Y)"PB&8MTZ$.O2\/E)V8&)IAX@)A-,A-!7@S=
MFSW78N>_&[TGQ TF)@1]2X_X^XME:+0HRC^J^8S>VQ<,-[CL*X2=D)F#2!M*
MF84TK<77RW)#!V-8VZGBC?:U5VSN1 8"2$P$#C_AAV_2,(?JG$\9UDN;&WNK
MD?).XOYY&+[T8CB,<M"YRE7K=UF'09X(L-U@@JJPQ_>>7.UTP.WN1$'8/P$L
M[/("=N(?V2P^Q)&<4$_&!9*S<@_CPPQ\(KD1$(S+/>X@W0_G%7>^T'Q0"?18
M\S*#<7?*.Y8;9GAM2/)34HF4S0M:\3'Q\W$DAT,46B0\4[T%IX[S?N3_^.;T
M96E.C23A"B_(&O<^;[RM65?G@CF;E/7I\L3]F4-OZ04P7Q'(AKNQ_/YT:0HK
M?EA#MDGZ&H_E,9!M_Y*? N*LD187YVHYRE>38RNI/&KS014+OVH:J=6_(QU
M7"IWZJU_75 :C4>13Q19*KX)Q]\VV66-8;_*^Y/HE=:TFXWZ9'&&I1@7<_$D
M57IR,OR57Z4IQ.\;X4;NLGY\V DWBFNA'^YC2&(#QC"S.$8>-Q=H6!B#E#[_
M%-ZS9GTR&=!F8 ._UAPU<:V% &Y^E'*R(5B?9?>!6.CR.:-O]BM3V'D@.,?0
M9_#1IV_65'GPEY(8;LA_R!^J_]\07M2='"BQF&PF*\Z_D?D>3\8%,?GR3$J
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MD%O3W%J**7@Y] 6058]O84!!"%#36"R3/.ES)Q^)_SO:&.!"I<N 2 M$J&G
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M*;F@"D)#)DA@%KC5X05V)N*T!3.8Q&][DD:VU]+:WJEAU^8RO$3_$/,$[$N
M3]2D%(1=4VB'Z#:]-27- &OP_.76NV_))=K>IOR7"7S'#$5-$SR!:&.KKRV?
MO!K*0G;1-&Y$&>PV=<T_.GNQZXH34B+MDEY7.ZTL1W(.#AL&KLT0V+ZH^P-+
M9=6!]KFTB^&>':AQ'4KI4UY2$(H.F=1]VPZG1GM@'XTI>-W5=9Y!S4T^/QJ]
M+K=K(5;;5\:YX$4_GL2?!!SHX\F33>$'\Q!I!$\Z?V<3OA(E?)-"X;V$,?C=
M9^KGF*NDF:% N(C>!@-*^P6^M_X.YL(=HKNQ.@(@,($&I*3SJVJW4R//<#QP
MR;;3+:3L;,*7[:SUAF^G+,PR$K*[!!2L!PC!SO8I<6NZ'$H.M3F.QY?@_4>4
M/2=N;5$\2S83+3\J)\N)37)RW680^<NN)XF-$&E36X*_ .;\1+Z#M+M)[>6U
M:=]//_QHJID985KJGY?Z_2A5='^L2&QIJ3I$KW-^_B(_I0*0V90X_/$J_<VC
MO#7O [TA@NQFR'Q1C#\Z5$^Y+SW15G<JXY'!,@KG7<(/ILQ[H>OM9G[;M\15
M%=48/]Q0U$RYC]-'O3!Y\E\FGFIBL?X"M L&?S8P09/5+I0C#F_%3\*\O)%?
M\'FBTKJ_R?IX+NQ?'F(^.\WW?6#^G6WQ#_7_ZW#7JNC4_@+>KV^&3J>&[JJT
M=!=!@=S.X77.2Q4J_UEL]]_&[S^BBOP+('KQX9]1SCBZKZRJT>_;86+_O7OQ
MZ;]-7U33X,+>)8I[IDGC""KB25L\O6!N+LW,CXW5%G?.IR:#ZC9^%30G\_9(
M7P/SRTVTN &Y>*D@TN/)I@+5!/2;\-H!L14872!==UDBTN:3YP=VDZ*MU?7V
M'"4:WRPS@>AG:$Z)P3V]?>1;)IJNZ29&SN!.$4NTB\^;FM%4MAQL+!E!F4VC
MDF+;RM>JQ<MOZI_X^H4$J>[(9?2Z<&$U.\H)'FFU3ODP&CT,!.L=63=_SM3.
MF!V=V(;([OE:=9++\V":.SB6Y@=/P"T?JMC;@OX(7)YN;VG$IC,IT._U[E"&
M!1S%??8!'>7OWOJ.2*^H;[._1-E1#73H/DFS8YQG!*O1EGK+MGYN[W4N;0Q*
M^LBVW'ZRY'4H\^>1?<D'O](%9Y+2"5+$7GUGZ![@?9H$0[M=+8MM-=%N#>?F
MFSUD<$F"589OV3=!C<<2RX>!GRDQR)96IHOL0I@^S.B,_N@EM8*T^6 \Q\5R
MZZ8XOJILFL4^(>(/"N],(*C$7V]?!S9<A'DBFJ6G=?C*>0;(0=>VV[5[.B%P
ME'%_<EY5CY\W_4NCU=9&$LO/\:3<H:/]LR'UMU(9ON%YS;LYG@&HGS,R2/+1
M].9"V6LEN!"KKG3=OP,F;F.K($7TC(,KB4$=J;L3KBRK79;7CPYY,"W3;.]N
MWVYE-]2LN8Q\;"Q_PO[$<=/5'ZTR0B4J1&O["5W M96@&\#9VI4*KE_1?K*E
MM1#WW-?V*JF9!Q2O]Y6O7DFL'1'=YGV&M4L 6VENC)MZQMC)DW<Q0*937NV1
M*:FQFMI JQY_V- 5%>>\;YH]T9$9<FHCE?N[TF:^PT&13 H@99"/G7,T5/X$
M54A[V,]5R6[[T;B-'G[ZI%K>:BG#ANA8!];9;Z@M:%Y'RYQAXE6X[/#IVX 3
ME?IA'K9<I[+-_F.*Q0FFZ;H6$$XXNK3X;4.]"D]B6.A;GPJ$"=H?TDZLO?H$
M6'X[T[__LC!_C%7'YYV-J5]_R_&@&L[!G)SZI%!_:=]W.ZU@E@,412#"=+S@
M>[%]6M_/&(DWM&B<\\K+2Q+^"@M+2+T*6KK%47;S2LR]+2>(U-16S:1[C+_[
M [GG,VEC@",MZ6.5+;S1U%RN9C-5F5P?FI;GKFQ"4.O/RFR ]#-R6+P=@KW]
MPYOATI$$+T6N7W&H@GU0O--B^)UH4OI&"&0'$_3VCTO!=Q#2Q?LR@VP00D:N
ME[MC8FST.$-<>_3!=5760#&T6*-@><)=BCOXY"MI[3+J7,VB3%I#OP%/*%EG
M0^VCQ[M.\LOL8M4F)?L;QK2GB-%!247P@4B>WM-:H^5@+0DJ;2* /FTT5[?L
MP_D'+^_&9&&)0B^<"/Q?L!@6SCJ<9JFIY#PXUT0-%[96;\M9L2GM!U+RGUI:
M7=WWY;TX><SI+#A(72_)PK(]#?G_7.^4QZ/YQ)6'1],8D3:-DWD2<]/X^HZP
M5*?0V(DW\<0+OGM]5/;LSR-?UN*/%/_'5MO_F^=9"3)8<%K1AEJO;1T5./TT
M H)#32=&6B6>V@>0FHGIGF^[J )#G6M XKZ'6'Q*0$-^-41ST7,NC..I3?+A
M_CPCP=?9IJ.?D.]Z^-B_L<KX^5/'\1*\R!5WNDR,%KJ!H3PEMY2T=I [XV3)
M$AQ$SIF"-T9?-UF]?M,;DJ^V@]0DW<EGKB9 ^KX04&:AYH4_^'#IZN8J&#J@
MI$WNAQAP2H1R9@.;\X-;EW(_+R5U($9"#(UHQU[='"$]W81Y&6TQKC=QF\NV
MO]#/9))L J%_ ;#QL3KGJ>.](;J)V7B23T^7TA4<9,C-1CZ58(HHEB3C *$!
MG$KG-+NN[@*.*IV9 M.Y K*95WMF#3QY-\9),.RQE*5>4HH;O3)#Q@XDCH,;
M$4Y=V?=YV>EQB3&(!YFJF:9]-([[V*VALZZ<-IX$!-(S)EB_<B3?_PI ^XQ8
M14?T_:-.* <Y7M@M4EZ$N*OUHE2 02:1RVYHP+_,TE]:Y[PD+#-1OC!,?EQD
M>C43;0N_A4K76>2-,$6V;&AJ1I]N0Q;XK>A1UCT/^U=B#EP;$4(T+E&O'DHJ
MS,T#&#9MS$S)]H 7<CH*1\;?/V2HTNV+R)-A">40J_HLP:WN#*C:H.+3F&-Z
MF: INHH/] 0T3)(XN68DWN'JW4<;75B>'?C3D^6'03.FA]4@Z"M:NAW>?O.$
M,#KWGW]@36>UR8/")$#=S*KV+(<I#GK+M3\P9AZGU^_<VX*?-GXW4&&(B[:2
MIL"2K-0<*A*6+,R2U8O>5>9C-T%A89>9OU2^7R)::N$H->;IUR\-Q'7FR^/>
MQ1.% -^5LBV6RV5Q$HN'SR'?D;(E-YPD?>'&MKW\=,.67V[F_]WWY&7OVW=
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M'*E/A _V7)0OAQ%@%[ '6@$?T@#S/V12M/UZ@ XY*H)"*I.2 TY83-9 ?A8
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MS.?,GTQ50<C3%8(C&IN$ME1CVQIW@RJ-^E'WAYJE%-#7(V;8Y/3YZ.ASM[2
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M0Q-311_%)4PJAR-=_VQ9E1[)B2LN;P\QS>E!X)2=&PX9J]P>F,8#)(M')U?
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MN/MA4&1-TJ&4A#-K%VM2A92LX"2I,J.D1;G34.MGBHM6Q]>_U;U&'@ 570^
M;MNZC]\@AQ\VE3,*EUX/Y_>E;83\?#XIUQUU)7.Q/_5S;1'M <#](>28IKKF
M=/+F_1_MS?(KP].2M4TQIK4#H8 ^_P= Z,$]L/ XTZ%M,.J*[N)P>A:H>\MT
M"@.57ST[+?DY[($U0.EZ>_JW,1\8+>\D9HBG/X+N9']ZUM^AL.U+.N_7^]U[
M/3,Q314_A";=Z5% R,%\9<A/T&0KW=**W<I\=2UVX?+KX40.HN/GFXI]:9M4
M_=?V:*"7B?".D$BV6U9*R[/-%>H'P.3CI7>!3HA["*=D$UWWE_1GA+HIT@*3
MVM%#?O./.,KV 8 K\Y-ODB+!LE-RG<[.];BN];'KS_^KZ^^C.8:(*!PBT[!=
MQ;UN)$(BT?JOW66X1;+.;P0>"9<P8S$ Z>#TBD/#'_YRL3'^_GR);GG%;G)_
M]![8MT[ G7@A\N4WX8^?+T/2:8/7_F8OBD]^ #QRPTM=SBCYNBS2S&2Y#O+Z
MHX@,7/!WGR9Z6_A5 A_/0@=JC$Q8"*=L;)[_F_'F1YX3I?DFW5,Q+J5J%UFS
M'P X!=E7G\<#=T8[#&TVZX[:VFBGAA@3*4#E:R7Y_<,>ROV7Z"&(KM4'0*M/
M#<&;5\@M^ZTXY-4(VY8K0WUP21?]JE<LY*<&7Z7;2.6X<TE.,G_\="+GZZ=+
MZ,3-^:?]!?*R>H7#98E&45XV3U84$THD?)96YC] ;L2I;^,@+ABJU"KY3SRD
M*MN3]U-W_24<5:I"X7^&'@!Z/%DH]R='D#??A*'^WU>P7#M:GJ[OO*KK$=_7
M"4[KCQ(0?MM,)>[&KHLASY:R<WV]8\BJLO\<%ILX_NGI$&WS+&*=BH+1T,A5
MEJE\?C%NO[/I?NU>/I%'INU+$FS38UU#V2H%\FQG!/OT@]P#X(-/.1'9SGJ-
M8?G]G)!WN.!>0PBG;\:71Z$HS_JLFTP+FI3KB;JYOQ6B.\[<R94[_>!/\0#0
MFI[YXW#7?UOQK]BZ_178.VXKOE<%CVXM[8'R+:NX+?+%LVXOMOV#E[X9_X@8
M#_; ]&U%VQ]-=;\OFG_"PF_P'@":!Z-TQUD.7\YZ;QX * N?QGE"/GU)IS4)
M\7X<65[=U$?7>%S] 5#@^\_@_R5K,73Z 4)WMC\]X^]P-_W?#+B?YA6?9.1T
MF7>1BSX $FW+"BD<PE1/CQ)D=N:_]'[Z\0]9JF<WU7]YE;PRF66884-:?&SI
M]#&=LN5!05$B"""'89>65-QR3.52&N#^WP<R_W\SZ#%F.6QE.<0FIX\#AY@,
MH:5$:1=D#!76S%=EFH/;5NE-R\J#WE\AIX=LX4$AF=LFWUCO"5%V](1R#0J6
M\XF?O9[2]7J?WM9D=*Q5M"IB%G)1=4U>2Q.O.<>8@S4ZIU,G?+']1Y?\21*F
MPU.2I(Q)%:.W#0VWD2R5BPXD*(D9<+_I5?9O??A\EV5/NW>@7F5HG3\30P+>
M,W]I%DV7O+HLKP,A,)/P28A]\MR1<":.<9,XQ9<_&W+0NV($ =ORXK9)+A"X
M&FDU6HYU- \"# @@*:J_<Q1CH;=SX6AWLFI6V_PIOI$C^Z*&:JO\8H!3AKO:
MJU^%E$[LMBK4+"00Z()8WI&]HG%((:D-C4K"V\*0$0$75Z\T";]3$F NMWZS
MM-WU"IT8[UB\T+76SF1=Y[-#MHPW$;8$Z9[FUV]OGM9.#B8P4SMIB54W$'\M
MX.Q$RE>?@3_/24Z[5_H;XY!Z[2[_LG>8-_K\'=/,9P>J[X]K6K>U@'U_Q#Q-
MZBLX>@;"78X$KZ(#;F&^%\4O-%4B+Y[R[\=C!FZEO$F)X,:Y*E/%W%Z1^+X9
M$EA8JTW0*-3FXY2!3CM7V7?;AI"JI*09"A6]A$&!5*I8*V%/5.FR5AX )D:I
MP\'1TMN,-9S6^>7G<+_H#/G4"R!@N3\V6+E90:@'#<53$SHR'BX'3- :!H85
MF@!@3,EC6U@6YP?:?T:W@*Z=!$[Q#65K1:3]MFH49[X'DM1Q,#7UQGHB;M!J
MJ[;^B#H20U-1C"4OC^S/%W"'$TS,"04AB!JKOP924B/-:4#__+*>C> "GBXY
MH?M!K.H;:= L.OL53#A+S<OX^ N/!GY1_%?;G"=@XM(<,GEA"&82J[C/N+JG
M=@UG\!7$2B>Y0,]..CR?Y';I+&PAK#H=?K?\%5?<?/5F:G/$[K.B7#"-KD>E
MA IC7N,6S[[<$B9'Y&!YBFH6OOF$[V(10FPO&5GS0D%D>2W#W^ %*&'Y%_&B
MAUVJ3*_$Y%8B<Y+89=7P*/EP)< ]3%=9PAI5(%7%WOM3\T CLF$PU%E[\0$P
M:ZKM.>;V1GP(;+923)[J43_N%GB?[N9"@_7:),H^MD 7^N3WE+SL*/0,$N\Y
M)!/)_^*;&TBEV!HETV$W9" M$(G.'(A<#1L%<!AMQJ= LHW,X[;KG%T$OQ4V
MO5 KOJ<["KDX,3TXK9.%_;&-3]$??C(YN5(I0<KB+O@MYM#<V(HK8\Q0,FY2
M-V?#BJ!LEX>"S<JCG+PN R?V)2PAC\Y$1U')D-M;\*X310,:[JBN1XE+*%JN
MR]$],< #U%:Q4*3XKZ4\!3454\Q04CB0-$= -A376\!7%+8\BO(WVT-7I?),
M*"[81$X=P,'&G&."IR7V-T6'0)SL<W(8=VDY:S@\6@;.#M!")50&HZ)Z>)Z7
M6R9, 0;,"#D9R&W1+ZNQDC4 N/:4Y*1HP"=Q&4G0"2[\;@ EZCIPWS8.8':C
M,^DPA6]F&<<.X_M_\BK_YPH*@>!DS*AP#BFYHM*0SO<X].%$.N:"6T.A(.H<
MS?++K-F1<*6QOH&^@[V<O7Q^3OARC:'P.#""4QG<-+*)MZ^(.;1J_+VQ3L03
MLEZ\WN*8D,D>.UJFB8(8W3LX@.H/$1WQ!V<5_V*>G((NH[<15PP-J%Y64D?K
MAL65DQ-5:@8R.T;OS5Y/P\BID12X-M179 +X27(P^QZQ496&#>\=68+!1=7Z
M)SF>V\@<*8XB\GFY?MS1!/??R$&\)W%:8=%2]N:2F C&/.Q77>S*V%W^0)6.
MS^Z_XV0E<.^&KG4P3W]@Q@!7MY.UE]0;.):ZB>1F0N=2U$78Y5SE9DH%Z,G3
MIR'M5:P_Y]W*<8,X.R.P?$U@[S:+<N K-[91W/';%(>*PIB,\Q8$H5W1=+7\
M.W(%2W1F]\V,/U^^]QHG\P%UM%6@MH!#YS<N1KE:+L5NQ<H_AG>)5B$'2=$?
M33Q!XY)[Q<;ECK8:EW]<D6VVRWBXFUN ;1YQ:GNB( %)Z$AUB@RN9(JTT_9"
M%BON[YT5^!F:M?D-I0+3&7B;'NIS4=':XNM%4>E3Y+2=8\ADL0 0_,ZT8/.$
MNN6'&V?C2]4. +Z>/5J[CV3"M/"$UO4$VHH<(_$7+B)P10)3ZM:V)-U)Y9H9
M"8$"Y]8K @#GH%',Q@8 -7DI)-Z,GCM(8-^QJ2&J!4.)1JSR96)*[?V8/<IP
MKB$;9LZIOWF2(T9^=BB:D(32&"@.;<+))H\6=.C0V V1#.?4>LH\] C"M'80
MM:!=79*L!, HN/2 *"%B)GE-?O%CV$J=*7;OB6R4TN=7#JDJ5>7?J"?KLE4&
MW O!\;):6([JO,RZ)( D%[)LCT2G>\N-WH"(A29PZ#HRP\L@T6'#M^S=!6/8
MC/T4$[1 B6.W=$32&8&U-!VH\GE<@N$!8+#,>5.D'2<;@[-TBZ\72WDHCTGX
M4Y\YTZ%[5\.X&=^$A7[#4Y;Q<H)7QXEF&*XI$=?$/S4XZ^.IPX[3KR L%][,
M>; X*B(Q(#$)%,D^4+&./Z5.L+<S>'T9*2UW>C)3_<<Z'Q%G!0AV43:A\5 2
MO6]:X^?HPPCJ1UT:GV(TYL&KWR1:.<0*>,FZ-QY:"N6G*=^Y%_(TM^;\X1U%
M8&OO9Q4QK0GIDGZW@!1')Q>C)@+GUBJ!X@(*,&R=WQ#V%.%J@^W;>A,XQ9B-
MHK;-2]NMPLQF*M=-\?!B:G_&F0XQ,UL""#DP]KT%#>DE7=R32W;)'P!>(?'/
M;]F8'&3F%J*4G4MO'>8CO\]JFR7>LE$3_4[919/93SPI:TWH?0",/-.2.7YR
M+V@<^7U.R]TLY)8MY )M2N8H^5XPI->+3Z!D%^T>]6]>X^^SYMIQZXL(M?%;
MU6:BFXV0>/:3WN2QQ&"95:9;^_JZA Z:G2_]9A&_#^2C*(4> &QTCTP(W)/^
M^C.06&%-'?3]7G"_W\M'W7W<47:> BMNK?QW)+HRB8/A,)99Q0. LD*:94$,
M<>E\/ Y)L_HSN6G=7MJUHJ"76R_PRD^:U21SP6MOHN\N.7%;4X:,.]W#JWI-
M !I)MZ[,A2%:$)9W2F0BXC/JYG B/MK#I-ZU?O?(?__O0EMK<N0'-TWI7X\-
M4!O]60L@'N!8,B21]"MN>0!8.6(E%"O_GBI%E-Z'?DJ\.Y49*!N!,X\ACN%U
MLG[;;/>RGZ+_WHQ8KR'Z@^J(]<]S "W3!)$-/D_PB$QX7X'_3[=^_(9@W:$(
MD8[]TPQW[Z]]^SH5OZ4TMIMG6H"01IF!W$?X,/@ *!(N?@"\33PI&>%-^)38
MVXYY\ATMGO3?QQ^-, (\ "QVL?Z.S-\*?8)V"VTGZYV%?U!VF?ZVG'E/VOF7
M#9FK[K^M/%.V4/1 0Z#GA5C^> 0Y3+<.H^N6Y71S"_^P_)[OD_@"5Z*T!'W8
M76P%W6_LQ[^XG?0PR<SE_,_ONUR/N.C=]GW1O[<B3X:LEQ\K$SV*B_U'O-*Z
MDG:4]9)'MS^6]E^V8=+BHG0GS/_*QE]QT38+]-M/_!.V2W?UV#M*K$24!T 6
M:XG,*MH_!.I+VI^LAX=LX?TC(0Y4"!93NKF<L*N%?YN_YDJ6%NO=OB'5>@!\
M5OX](>G9@?9XL7WW+_5':84&BT&7^H ++S=0#8VF-[0P(>LOW8JK47W_$TXW
M:@3RT8J]T^+8<-<0_,ITRED#2^#\7G5:P9K#:DINDN>4D,K0%S5P!&YW<.-=
M)Y2XD/Z;UTESBO2.4(DZ_4_H1;\6,JY?: D-9BZ>Z.)XQ1^@TFQ>*+1.MY87
M=HY&AZP-ZFFZ^V$2]W4+*28A;9JHXVF02X @K[3AB2FED)S,]UF=Y-<ZA_N+
M,- @! $#$AW("OUMP6Z?!#Y/M>0"=PT<$@#VZ(ME)0[]UB"IRGZ?O(*L,M :
MSYQ8O] 7+]_4A'FV.-?L2)X\'NT"PT\N(=.$4S5<<_F'\Z<-U(3[CNG=H&*K
ME"!'&R_ <W?U@A?Z/13K<!U6S4T_WZI#-K&M] C0,+00_%:VR>(D3(XA"@B]
MT3?+;% ZYM-+$D:E=5Q2V^K],J++_.[SJK_!STA#5=K1V\PE)C:&2'XAQ6A>
MS,GS\A[7O,R+M5SF$VF<)%0-U<L8PWN3#]0Z5JTZ@YR8"]9%&*)"\AI*:*Q,
MR48)I5UF,3@_SY[T$6V"^T4\V,V'EA!"MLX-BN, (A.H:)0D+4[%R]&> ?'@
M)KQ!)].RI [O\\I7PN:^00L>;[-X^L65[N8ESW9D*7KROD6N\IA093W9TWB/
M_ZM#U&JFYCB+6I>$GB$32F>E2AE\YIED4L9I9&ZW4,S7J2RZ9-_VC1 0NTB/
M[ZG/TP=QJ?( K9067!$W^6TF8%<+=\/4"C73WA7 3I22H82.;J6N6#G5S)4D
MUJ<01R.6,VJFM^_.KV F/B1&K<(".@C7YA X*0KI[3S";%KUN=K;2D27H-KW
M6#<5"\K& RG')4[WUJ(J[;[6K6"YC52#=]FKE.8QASV:0)MX9KZVGJ1[X%4:
MVCB/;G@H%K-UG$*KCL!3PC5^*4[,U[E'%D&</[*HTG?RO"O@H8=8%)A))ALZ
M7_$=@[!WU+H*^+"V-=J2^FE!"#)JS1?V0<J.UBT0FGHL3_W%EY_=+LFKAEA_
MCI-)Q1(FTA]^)>I-Y97(I ;XP?675;0.!HM-MQ *.O92)>S\!*QK*P/I[[V$
MZ+5DI0@ ?"E8)BYWRP[[8@?:=%EY.BC&8:L^94<6 ^P#XCK4]X(H@O0-/3MQ
M ]^G^@/=HHN\ ??>536# M"<H>_YKWXN>_3$[/V>YHD)+"W5G2EH1S0KP=R/
MC%KOV5M:LA;F!V9GOR'FB_[$7(G^XJ2H_&S&F3+:A)(" ?=UG;QX93??U+9P
MOYDPP;A)_ !H6L8P"*+2F[6*;0[\T"A/Y=[2LBX] GG=1_;%IMQD9P*[EEXE
MB>@G=6'EK@/0_-O/;Z->RJSM'OK #9/%=KS?!01Z)QB=!J\8CD>>-C"#<!8W
M% %>EW43^(8<:\%OU7Y.A&Q_#.%\NGHIHGFD&Z=.NC39$$>TJ2<;FKPTH2HU
MB@6G+T)CFT*>03<F9('(.4$4TL&^=AC^$HF;@W%:8>V+4Y1D:-BLX)"E*DAW
M:GNA2O5M4<I!TW./J;U8\L1ESP.SF0Y/5YH.):2SV_!+SS&<:O"&IH'B2Q.;
M0BU_R8G=HSR7@]NV:I.7#X!THF1^_WH265$JQ,\=XQE#!S+D$,F+#6MB?W2#
MR:[([Z^;GMB)_@H@X=PX;X!Z3T528EL_ )0+6!G:$ER4I=\AH_7=)3F8N6\;
M)?T5SL_+AC.0"$8UW$[FU26Y6:;R]1?/;*?ETOX,+BNXR3X 6&&-(YDSOLF"
MAAE[5.N<5C3NAUR<4]\JQBS"6?%K4+CY@ '3L8I%TLXE+3,WP\N?T^$E1FHN
MULE9 Z<HH<N_?FM]9G5%H\<M*I3WG*DYI$=IN_<V8!5CN#>@J?)F<O4\TKH0
M?]IW.K_KJ&BUZTB#("^O&*R@X%W?=> /TJ#?401(L$U-D%_GN#BXR^*U7>>H
M%^JJJBV$$B"FD(?2Y6=EWV7Q4G?MARX$M64QU__K2__CI_45:VH7$/OE8ST7
MZ;*43"# ^CI'A$Y7D>61XDRJ^X5@FA9H7KH,6JBKPJ'!)U9(ODTIPW0O_^3B
MFG)_[_U)E,R:QJ-I ST:O>2Z";W&DO]8AL548)-UP 0:$?S%[51Y[8LEVXH,
MO:QCO:LZ6['[47<Q-FX&&QFSN!W67?\Z\-J*X>?\*)]LP*V (0&4\ZW*KZ8I
M;^2!K_=I]';<!'XQJ,"1KU=TAD]4N_6TK$)L3[7D.Y=X^@ G ,]E'"YVBET6
M,8"RE42&I" ^5A+8T\FZ=TKQA+"$5NJAHCA:<GX41&-0U?%'F"2S)NBQBN#K
M_>RJM('D+M9YZKD2?SBB[QU9=]#NMK@/G)2=)^CO\<>6]XE8+'-X4<STS5W[
M:Y4A6O@7?R(M1XGBL+Q[,@-^I[<NM"^'/3AFR7N&Z)X+Z>!_C>S9=1C@X$61
M:%",[6!IY1%CSD.[E:H:>"J\#])O;X8^/]%-]8IPWPW!]>'@'_2R'2-<N=5[
MQA;\S-X<$CQM884I'9(OQP[**^Q0Q8_;&N:I;A6[%)QJC,?45)7R')4$(]A.
MRQ6Z?FSM:*[5]SD\.QYHIR%<,$IFR@2EDB:?D4E2-MY'8-%>H)LS6&JJ!:>9
MJ1)D?^,@(<H*\+W6-4]/6P7(7I0+JA]DTCNO6N9NYL,(ET<!_?[Z<_B%<$U^
MO4 #>YU)P@#*+VV-:8 [=Y7 >.BIMFGET&7E5\=GW)J.Z!\9U#ZF2T\-P3ID
MF --9(Z>$\BV\-94R)<%N\R5+9LA\,U6OY0'5+H2S(\],93R\ ?^X58@6^K/
M\BWB-6AJ%>@8Y^O>+9KZAK?18*7SE./=+A8<E"/O)J[%10A*6?Q\? 7GU(["
M5'9U;(Q#-V++L2IB#@_P!AH5C[.:]WE //6$81XTS?YIG?ZB%?BR)+*#:#F/
M7IX*NA\;:\J\ FBK)(\='6U*&\6^E$URDCG'N2%_^5>8B?8X_92TWD<^9FHZ
MQR9J4T1S\ 5#V5"J-1NW>\)<>6RI:VY>@#X9D0"F1W!V-8MP!2($S*V_K_?9
MBIZSK<?BMR[E?#COY  ',O$'.@WV-[T"![RP 7';<![W]W@8"R,>;TQ64*AQ
M$H03]_2Y2P74.VX\31K9%WR0M@T*>N'1M8HSD%RH[B1*R^1(X*FB&K<68A&(
M#'9R@=&'*BMH8[ T0@1#\Z.=IAR-;-Q[CM12$-3(>J,2WJ-W-*JBJ%F$:.28
MF=!IN0H34.\@4=O61V^BISOB3@4*P\@EGRB6I8T["6T+L_F.=//F#*5=X&K@
MK(A%K;$1IKY=1WO/(CI>VR5""BNX66/R]8DV:)G+(<?W9?(95Q#$I2O>ZQ-O
MI$/Q5\;F: >K3 ]?T'7#QN0OGN5AO/(WE+<$=]6@R0.:5KPW/G?K1$H6DQ>U
MR\]5&I&U,U027O'*;F(RNH;ZH(6"]D.0EF/2*L=<L8,#_[M?7&DG$E9?/]-<
M97])][:#>Q2P.OEE]L%0$L4>53@V1:=]:1Q'$ILCV'<F9\FK2%[845CP=BMK
M-U 7)9JF7>AE=IB4&"RMTXICD$8YX!VX3CWH.F_:*$7LT*J5@,$F7FXS-V[S
M.6/+E L,-%AS<]:;MSZ[8R"T%>>.KLIGWOCV!XA-5$J"\L,;L:;.V-+HJPX5
MYW678\\?Y3]-E%]XJIY)/!,<XOD\X.QJCBE$;KAX>\>>\>:-/A;DDUHD%B9.
M&&)50X.AI8WG>?ZEP_@*EH3G+[FU;+R@%C'S-UP.V'0!_)C^>PD_3$S3NJ8,
M4R#\2E[-!=\3N8&HY<=8<'$-^84U$MY5?2FR-8KQ*7=(^*6I*@7 LNVG[>ZS
MN7MOS>-%"+=']P=:/UMJVRRX5_AWW@]J"JZD[I'<*MUH73Y:W<-QE$K>"Y@"
MR$8O O$W1&*P)8I! *VF:%T8Z);)]:>NB"=8&[G*I 6:NKFH-) 6G^ S3!X5
MM=:CPBZE<7@ @ 4.U'30*M:2M&7Q<L F8 "'/>SO_)@#E+TD)2G\WQPT30!M
MY0 P.K!)6Q:#!:B%&F<B!W8(&_'K*X.&[#+0G0HM&#Y;)PY94P?(G!(G_J$\
MX.#_&S%.]7^UHO_?1?V?;?IDP'P-577WGB)%,3W"DGIYP4PE(<D_L,*93T_-
MH+;U!TD/  <QK/PQQ!D9S/C=3 5262+JL%VL4HY\L"()BSFA!(X/U'%JXI5#
M;Q;25V7K4F8ZZ88K$<S&<:,-AZU$#R+@_)#T:#A'$MF>+-X4VJR0DMT(;)O*
MK_\ENI5O\:@6%?C0I0G)^C*&16EYZZN B%F(G_[;W&BLDH*BZ^E!<@KJ[;QI
MM0'B,;977>3ZV8V&D=KR"0[:43[K:&24FLQ:P]T1N@ARB[Q3!QR)M$TBYJRA
M[FK5,W8TJ XX2_)\%$(-3HYB$S3S87Z79L:W5=3^-0*MS&' YA<1#4I%J*V'
M9_*25M209),^X!)F *#634! #W:E'(L]LA=GP@AS@W&P<C+([P]_]LLC48N@
MVUTF[^*[[%$Y".D2%)4E1#*[5R</L>.[:7;8+!EIP\- +9=[K?Y[.ES[E@1R
MP&(M7G]6>&_'ZK9@#[\Q"ZM G$WK8-O>D7)FJ%*(N%'4UN JKN+3TKT#A7I
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M+BMOD]I[R*^J&KD7H\9 R*0:9F@$/77B3^ OG_9O=@DE,;7U.#Y+09P#W40
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M"B_J0B=*4HT3@_Z\0,=A+:NS(ZH[&Q-.%P01IL*4A$*<0"EKD80@+?=M.5E
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M#A#W19FHGB"3YLUF*\@+:>D"77YU4<]4HI&<1F_7+!S;2KF=Q4UDWX0XDY:
M$EXRT<K3V!K [)S9.QB+.2,2R/ 2PVM0M(/D6GP@N R&AK$K.H?'5+?L1YT^
MVN/2I*BU/T7SEE(A?$K+I<'Q$ X\]H<'ZC^(4]0"9@OGT'Q#85:$]TE+4YHZ
M%LZR_^63^N*254A*CR7'I?KUEXL )J-IFV9P@8(9WM!<QNUN8S;>E]&AARRV
MDJICPD_<OE A@=-H_DSJU(O8N6UJ.?\,A/T;"^[A>F _Z?,Z>*&=#WLLA67'
MKWUAWTO[E&*I7F1-T=*0R</=/++7%?L,A/+?;YE_3GH/=/]:')!:;0C@W+:/
M/I2_@<Y3K]\9UQSEA@P$GF[#E0A-8[UR;5BX69[; 0(=+.PY&1@YB*Q $HB1
M$L".R,E%'9;)R4$=DF7A4058.?QM^TF!:3YEB&DL,"*2WUV@;J2B@0;D="A"
M5+11OB"D%="//VWK43N[Z.291TJ)H9Z)JC\QR3D_>$D1A:>R>UJ2KAPNEPYH
M?BHEOM1G*KD[UJ]MN?QH, .K0[NQKZCY:=R9<0^@!EWJ10\SNPPU%JFI5*C2
MQZ3\T=9[Z8K=.DBGY!,^"+W"[=_PJ'2KOSW)6N1FB/QZ%L.!E7(8=+.%; Y=
M&D-5]*(P&%LW.\M?BS6U@Q9*3:I(F[?B<N6[3Y&0K@<*[' 9UR()Q%S"%7M=
M)]KUZAU2?XSBX9+ZST)^D%JB1K.@ &A!K06DN#T->Y[,\=_P'VE90#A8S#_C
M2MIQS'$$IFZ".<  +B%JD PE12Z6X-*=5%FK8\WAWW>9J2[S/$!U>/KE/:"^
M8E]&]JSV\[\09/2_!"!A]S-0Y.G2O-6I&G8O"I<[[#5N:4C)[SD!"+442"?-
M)5<;M7:_D]T#(=E=IL*-<8U23Z>G95L-#$D)50?FU$MOBK(.0IJ)'!JEX\56
M;)11H4>JO'K3P+)]P4H,C,"[WX&3ATNO"<]25W$CO6!CU4X(RKM6VNB!5,RX
M>'EV-/^69R6(&A\:N>.2WF)U1[:61G0XT$0. 4U5S;T$OW?2QV76[>I3*G+&
M.L33^LRAQ*/@5D#1(YO6QSUD"8D$JFB.07KD_ QMQ2J]_MADBU3D7S_2>\/
M#".GHNOQS 1;?HB6S1MI3;5DN.,U^EK&2/7Z#TU3^4P_V4GW9B+Y+.]">L7(
MUT<?S*V@U4(Q-<&BU+ NP>T,-R5G9Q_88VTC@@X0Y->A[-B9Z9-Q'F0.GRI^
M<<136&&K&K[W_F=)9GNB"\CDM9-VM(/82\N$/ED4@>%:&I@4WNAG#C7NDB"Q
MJ$^*IQ)3W.)D0<M<U^%2K?5QN[%K',MA[JX\! 3R+PX-F_$]'%X9'20VC#FF
M+054BCF9H;1TBN'"]'_UZ?.OK8KC:5D*KM "AZ9-1=ZK.TY5'&S5Q'U^U;J
MV>&0;C.5]X)NPR$I+=U!RLX[_9EGD?D6(VYQZ"MF!(KW .[P<((P1WIUQ'.^
MK=@076[:@;U?RL&/MG\_YPE>,YQ%J8LP ;#0J@1,)Y O)'+Z\^?+B.5XR3X>
MEVUDST[H-90+;GJ^?8B?]IV6AX01-PXNSZZHFJIRY!VG*(EU3EMM5M*/(5LW
M^,+AHX9IO]JCZBH5E+]9R[)Y2J.\\9:X6D?8_W4[-%M3<2-I_OT98@I?)J#
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MO*!LLW=WK/]\Y4M5_KO_1NM_^=3^JTA<'^W055\=K;Q Q#=__$=*^AJ&U_C
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MEC3T_S><RO]NLH"P QW_+V&:F/\#7I/O?\>R\7_H_]#_A+#N?_\W4$L#!!0
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M=SA?7,5_$)Y2W(!!S:6\0V!HUX])2,,]2[O[3;3ODOVO">;S;TGVIV"_Y((
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MZ3C R1PIC=L; 4J8<TF8??MYR_>OEF\_<,&/0TKGQ@2>3:\90 ?ERD K;^!
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M8 M)W99N:WL^\A!8\'RCM$2"^O"!P9DRB6VFIEQZ5[9YI"Z!GW<,X^<)KNG
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M[F.X(@ 'AKYG\^,*)_L!T(:+G$$XD!T)';S(*4_:7<9%5#J**),K:75_9FF
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M:R^:T:Y2^?P\F"CG:U^@J0ZL\3$6A&Y$OHD_>1('",5#:0/BXQA(]_X4'\^
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M&D=5T@L%00>&D?:I5G/IT2ZAY0 ^C<US19NP-TW0*+;L%''0-6FSQ#].+UT
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MX8Q93@\:&,6-&%81@5L6_D1@V9Z;?3D;%%@3\FN(P+94:*D!'^G+9>/D7=W
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M03_8I(=ZO\86MWP1I#"/,\MN,]T.RB\WV>PZ],EUU@FW!;)JM=E*GV9?Y:2
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MR-$^81@;QS\3.Z#+A*!?TM!J/T@.&E.*E767$4GH]RZDTQA0%KW[/B#C 2_
M$GMVI099&\NP8O'&^!(37M>I,U\P7[$^NV&FUY95]&L.9>7B:.VL=)9^+..8
M=?WTTYLYK[?K3*+Y.:U^>L.Q?7R<@>_<OJ1#LBWXI*>-S+.7Z&S$^4[Z_NP
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MI003H"B"0$+O&U5JSM:DC!%0TB,"-TV\9822SD2B=FB)0.U[^E=B(?9\>[R
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MH"Q;4H8W"3O"7[E0J61@D8UBI8O$EC3B0Z6NS)KCYGI8%4S'"2ITO[*?5[A
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MW8+K\+OWSKVS9LVL>7+?&GMUUOZG9-?YJNKLVM^N.D]S3ZL 0B5YL#P "1D
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MWA!,4IF$_+I>+ 8^K1,R2[<);')&T!^FTW^@_0NR_S)@'_^;D/T[L/_ M0#
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M6A,O.6IM-TC?/ZN$LJ@@F!S&6L3]+ZC^ZP6)X%5\M'8Y01<R9:Z]=2PAN1#
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MNRJ"BVOV.PE/F*#Y@'!UMWS*D8<#N,CRURD;XQ5_VEK<#7G-]=A1'%GAGR?
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MLH^+.:%_^QV L7X%RZ:O18I_IMY8;  6%;#GA$:UFFKO!/()TY 2<!&)/D\
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M\WUG=^N=7J'D&_J=T+O*0RG8K40(S]1+O>EB$M/FMY!I2YK0WTT>JY9)I'N
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MS:Z")[=M-$U!VMV?U8BVW9>4O :)<=/XJUX5M&7\,"JJ4)Z??#O;HC>C]P2
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MG-!>ZIPSZBG$G#YDOT\87&1X;&K(0AIT9D_ C4I.I=AAPQ)M(V,0D&A$B$Q
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M.E>[JJG?'$J9)(H*"O":*(T"6]$2!?:CO26SK?I!\3^V0-5"-P(M(ZH.>R_
M7@*;,56V+8;&M333;RZ%/BL[?&F>^Z/\VJI@<F)']G/7!)RTZC)AB9PIDWON
M6!EY9+R2+^;K5FL&%^-G8H:L&KKM\WZO5&\VSOH7:@:V=OSX OR?)AGQZ)*=
MS.7YHJ>;6AT#?N3F[^JNWW'3<G"MST)WM2LK/J)CB9TN%(W7-N2K^R4\&WG=
M@AY*H>'RSV':O^SJ],DV3(@QQ^SSW0E3*;6%N8IH_*!Z6F^MVH)I/A:FK&\@
M)?JMI=3DU=ADC/IXN<W06B=;K@U'JQ%<*6 K-/,8Q:Y[%T,?6:<EZ^Z5J6?F
M^$!VQ5A_SJ"C#G@V%HU+NTGA[,*?M[7/=TV6#^(LH0NF%V^639.CJ^S[YYRT
M=P)5W2=%[*].(5Z;.0.+5VEN;\#6YZB>V^C5)MFR.M)H\ ZCUUF43)M#QR&[
M&HL)):P3YSXSQKE=K^%75N+##-U-)EI&0R-N6U=LQ[-#$U--4/-]B -1SJ-F
M9%ZTK6V^B_1%N0>0$_X*<E1L'*.DF6$S1BM'DZL4!YY<FRQTQ1'_'N&1AOO!
M5G+<7R]343"5 H,2@,_FWL8S650^F!*X]K.U9W!VY:,WEZ]DF(0\ :5$MKV0
M.BHTRP\1.++#+4QM[?]L[<J6]U <1Q*K9'@R2AU1([VW\R6F<\OWH/R=-:0Y
MNA79<#?1W+<7H&42</L,+M_OP8W=TX#Q1:*?H0V2W1_8.(;GF/]@_AW>D[,M
M_;$F&IE)ELB)C?Z#,8/ [6%1'+J(Z#"@CWJE25S!^D=77N !PS[%BJ@TM55S
M7FJ'+73S Q+-Q7A!HMA(BJF"EPJ.Q[X>67(UUE9!E"#U.IF5^?K"1XUH'%:&
MLEVE5DFC=PJM10S7$9M*ZXR]Q:0HQW+_84)$)Z3V57#C2).> )A=CZ)O'=2E
M_H.KYK")!KPIH[VU#LJ&7 =L2]5)GO]K7)3]OR\N&E$,X"1=RN2%S.D37A1$
M(VS2@T\UZTJ%>RH0K;K#CAK, Z.L<L/.[OURW;0\H(%G1B%Z_D@8E*W9WLW>
MW6[2[,HK^<L^D<^MSLTA.-(@*]!/5VXJI55N^$(,NX*3J[H(3Q"I[:9+(IO]
M7$1'2=+'=,Y_]4/RT-67<?F.3U9CV7%W[#R:H^+=R7VD2)&KJ[H-I0NE/RTQ
MYA(A3P#KQD'"TDVU'2?P!>_Y#:<YB4LR%N4U2RV<M#-XG:2T&P2WM=>.U,M,
M)9?=.DL#58<G*4NEGLT%[HY_ #$=%G*I]GU 3SATH@U!#8(A.*NP$)@1]^@I
MWS2HPAH$R')D_"NF[LZ0-@(A/175 L'B8?(]#5!$2!('5'/(/S.5IQ$X-4Q*
M?:O!^RK#Y*HT?QVX^RE>VLA$X'"N8%5XPBSA5HOU/9TM3/!PF^*B'.7(M$<#
M,(=*R!:<BH%"VG$ZVX5TTTL! D2VWBVS];HN>12]YAME=95<OLA#ZEV SA3(
MT=\YE9+LN.]*:4=/F+/H+O[%ARB3#)<A9+K*#[P)X"A(;X1*?DK+2&^EU\4O
M9?IJL!(16P2/H:?%!Y8KG:EBPR_R,$@20E?R>6+F=MA-"+D5F.-;1FLO\M!T
MU-E2'AVC]8!'62>BP\X9T;$ZT+C2,OCXHL^QXF@P5KXH-EC9G7AD_V=DT1Y%
M:$BK)YFHRI>!X1$N]O/FRRN4U\&TQ_CL23O-U3X0I"= P+3)9Q".ST0+D]G#
M2DD&J$YI;TV%5G:ABCF!"JE9'M7OKZH3T-J14O$6"8;>%B.J'.:!TTJ.,E,Z
M-(9>-Y#$:-(O*+&6KG4+&/V&M./[8.^KM.7@X;*-7)CN3#%JOF ?_4M/9F=C
MO90V8=<((JK$R[@]'@*N),C@_2Z$*R\,W!O)4=75IJ=6)*A!+I997CPOTGJ-
MHN GQ>:--/,Q3)PC<^9>R2H9TJ[',E4\4BUQ8%L"OL>3KMP7S"R>1WB@ZR6[
M0Z'35N^R:#+@@;0R]8A7R*C+'(!W^IOIZ^6@<.F\':R20I.EQR> QI>M3._-
MAAV"4J-E%)@1VS]7.G'_MS==V/ XF0!N*\)CEZ8YDMMGDOO&9CU-G]>S@FP,
M@V8W@F::AVZDSLD4P_G##;0LL^50(XI!N%O92B)4YJ"X !U49W$"R6(U2/0B
M>,Q,"?")%<5^.^=Q:MC/T20:UA"+IY],[#=)P@&R_Z-;C[EKL@*WX.G@@KU7
MZ'&DD=YJKWJV_U,.6-YN4JO3;*"?VS16D8U\<Z8_Q?)@']Y!:CM,?S_DZ+%C
M+9U=6>R>5\=I3#*E0I@C4+DQ+*I0P07=F2]HC%.P>]R")*:KH[=GN/J[U/Z8
M<]@B,X]+^JP&3NSJ'E%6SRC'Y^@FH]B'4;?NP@*+/ZOZ.3%:FLNV97FZ2-EO
M7OS$?0+8Q&VT1$:TB@<#(W:U+?OX8YQ3]?L6OY%O+ F-ZB5"^%_@RZ8OK5&H
M!^F!:MA:4YI>IB\>)/PQCRA9W[-?-^U_7S;FRS4>FT\7[>E2C$9H!B%WA:R!
M7_(*H=10CHGI.9XV=3HP.LO&=80B&HM'IW\G92VU#C\>@..V->SU9BZKF_<V
MLVL5A =G$=G';<1Z,\SW@O$_/M8SQOI4:J8,J GRN]D5S/CKZ5,:HAMX _?+
M'3H@NJDL6M"_3OS$1FE8D'(1M38Z-X4NKLN@O++5.0HTD[8'-$-Z_4W-)\!L
M65N^R9![, ;BRY PRR,RNU9(U,BJMDZU4MCZ2AF_V!-@T,C!Q$0ZH((7$--5
M-_[H Z<EV.L+%*=+Z5OJ$ZAOD0?6F<KU=_)]8P<3IT?>_/#3QX/[J-W]@)SW
MJ<BF#QP(/0'V]?!/O)5E)S^56T+8/8%%S8%X,6I[#OXOV W4&3"_V9;X$^2-
MOJN?7$/0&?L,4MQL[)EV)%W/TCORB[J\,E5]S]-+Q]GJ*DJP_2ZXWPP77WJ#
MUBA#.2,-6^F3K^7Q%FQD2,+[N(>,7@-=/V^K))%P?YS:C1UK&S9#\CI:("E6
M] [["YYH@JIK H-ON@X*4V5VQ]3G-H>8 6&A\%^2W6P'ZGGE-36C_2.+ SE.
M$UL<GAMTCW_O[O2J8_Y,U\8OJPTX#(MTN,>5%@OU-Y-Q#"0[3=7D^_@I1Z$]
M-A(=8? LQK4!+H$<U=R O,,=7C1>BDBQ=5A=7&:+ES&-8]'6\2MZ&GEULTW5
M,PT!*7[;)D%29M5/FBV9\5DA*H"M+ @N:^D;(R]6I-)0M?U_O4[]K]_>L1QP
M-R1A+3\7Y_?S)/$9^0$&0JR> "9Z#0%:T#^?'X,V<R_@XCB/4GIF%\/_LA]2
M_;?OAS;!V/+%1?M2>'G:=6!$>GB"9H=3:8,?53G?QBI-(%NQF_4!@1N @7KF
M_>BM[V=*/>$QVO5=77Y.!7?,/&=P;X U06EYI1XYA>ED-=*VQ49+A]\#.V+\
M1T97Y!ILZR&]DC4:^AN]6MJ%K"('1Y@Z29F/=QTR(&)^>:M1T^G&AF>(70@=
M&E4KM44OP #NRCH+@W 3YKC[%<:L%!RWBG1&PH?R,$^E<:XGPL=J$,G5^G1_
MI7#U1\707H70**#LJ_B,$#6>V2$=2%BR:H;T2R&2T_ 2M-&'4*E0V5C:BN4'
M*4;?_E271A1%ALX$RQJ'][.Z8F+ .4(Z^#7&J FBBG1IMCXC.2O>?TL1 N[N
M$NH.B?VSE1],!=23HU233@Z4V_QFS>+R<[X)RB;'*;!$OAP5=,:'''XL%*8Y
MYQ)TDHSH0J%89\DK&A ZU 9^;5SNB".EHQLR*U9*Y/):#U4:3U04VBKP:1M4
M,C>9R[/6<O73]?D1&2>FG:A[44YQ@T11=F6^ELL8"I>>^&IUK/)V==6-3?:O
M$G;RKL8(="@/2ZPWUI>?4-Z+<R7%U_2[=HLC91Y:CP;?3,*0QX"H5CAN6V])
MLT!V(Q(^)L4>VX]>U,G@ER@TY_DX'I0EC%%N+Q-FDGPPT)/9<'I*4H#&,%DF
M?5SVU\!!YC -^$Q"T<WSR!8WAF\$?,,5X=[CX"Q*4XDO@K?QY*8] 6J,(P7=
MC)MT.X+?R4\,A5*LWM(:06!*(SNIB" !;GT@$J/_W\Q&"F+ 5;6[JG=C[L'/
M[X>,@00F@3RAUS,W[V.FL\),B,%"_6ST_4M-W9MC?TRR?S5XKAEN37K8G+V*
M:38QZ5Y5-+'-HKDNXW*I$3-V=0+YK@"Y!/O[%S8#EH*PO>E.AZHK^OH6U9N4
M'103A;0+RH[W+T;!WJ\FSC^+T_PT-J+7_;5F<*;>!7':H%6R?_8\BXI G*2:
MBGG_^P!*$:A1 X-MO1X]S=KX,<CJL:FY\_9,J,H,&+WK%71Q0WL!K\NNS%4J
MKL/E 4^M>A0SQ[N*[S"*:,YE:N]+,70KF8-.>.VYVYCBC/S?QZ)Q"9/24?W$
M('L9R_:KS=Y$ ]5",!92PBN]_='>DIM/%6>P/$^/ XR]FNB ?*?,9]HTQ44T
M]/+*HZ<ZUJ1EI--_6CD]R&,=@,RMQK[^BHGFO=5'_ZBP[T\ VX3[%D>KKVB0
M';U$4XZ7J=$+QHF&H@V>PY(Q9G$RB>]Q@P=K#\6L&&;JN&1D6K@5DMF_DXG?
M'!NM[&S-?.F8ZBZSUUR)C!U0?IL$T0) "/* /%HW$G+C4RXIAF?EJ S!N=G2
M>11R#4O+8O[3EZ59WP#0<9W9%RN!:R,)(:16Y+N]O)+5DB)?#!!<:T7A,Y<.
M/A^;#G\$%)V5$=0$(?+K$:/[0^^3*5+J.+R]SFFFA3\:VZE.[5EWM#FEBX6-
M6:C9)E+():MO#E*\$?MDGNB/-(5 5RA3A?!@H3I6.KL.1MO>;S7DI1OMQ0^-
M1LYNF7?MZ_U:MC%K5(/5AJ;_80D65W\"O*M84<=-"H]Q?WE?-M))+,XSDWF@
MO+*SX\2/>121#7#* R[S&4'ZCEQ]+JL%Y3M@BUKQ0];2#=3E&P\<Y1^/.!KQ
M8ZLS=L0#_VHRV3A@+67G^@QA4(SJ>6-Z<PNQ!&,P%Z4&%I69'L\#=B\JBNJ;
ME4G8'NF$U"T4.Q+38[[9J& FGQ6V5?(.;./F>Q',(NKY8S1V%_BG3J+!5 '!
MGL,U0HCS&/_O^B47VVZZ(8N,&]87:_592^^M8Q<HY+22RH59*Q>W/'/$.K^
M)\B9 $V+9%;1J_@^%2NT,]55YSAZTX40AH#7VM]Y 8-(#<&2?+I,)^$M_K[U
MNCC$'KXEOQN]!TWTG2 0\ESKU).XE!>X/-\"[;7< \9D"^!&.FP#69Q<!S^"
MB"!]2V/;(11/ *>@@0;+*993/L5V"<+\!6=GC*.IH(86NMR1=@LK![<_C\/(
ML0<,@%S[+EQ-&6X8X #0;\:2\?,47"EM,(HX?QG(]?O'YZV$KQ FY^K?1E-O
M.69*-%MQ8_D0V;5(B$JG6'VOHX$:H+T4I'701#MX+>5(4NH7Q!O;3@M/E!3@
MO/9QOA@;CU5% [FF2R3IW_Y"^_<_1PH1,%$8(<7CZR= @K[&X/V9Y*_&>S'W
M/_O(?NGZ-WJVL-XGP"=CC2= M<+-3&Z$S\EA>- V[ G K@(%[13 Y/Z++A:C
MP_  +$I(HQC%=*OC]%//9!(%+%V4)S,)464" 8R14XQA[X&LA&=3 WX0YVD2
MH>V<;%51K-J4:_%D?%5K$S4;/8-%1VNW0*F]#[F_JDU^4AI+[LW^AFLWAM78
MD*A>,0@#/"1RTVBSM<9'.W9X%WKEYXO4%%@CK@/'RBMW;BB&A9ZM424QW7L&
M!HEIT]D?[Q>$Q"$KZYN;K^+?-ZC&1#&7XNRO%++519&B12"+PG3IHBTS6SD2
M_:?"9$)"?[$BO8RUD_$+'2R6EZW;+GZS9!+;U4_',M2SJ(1]<:S!0/XR@J'U
MO)*U0DHHSQQ,'=(/JM["0!1YTD%5E@COM-!E0=)CS)^DQ[67MH/YCL'$S8_J
MI!,"K8@.-77[F$W%$"^Z-VYJ@*+V*?AA[!*H/LB-)TGG0Z_X>8[GWS\?SGJZ
MNG@A43?8MUE7:I;U<>Q"O+4[]NT0+(8HKE+?+XN;9!61Q'21^5([:)*61V/V
M;\PW Q77ZAIC7.D7!S&@PF7.H!]@-252B_'0P7V]["& Y?]"V5L'M=U&V\)!
M Q0O4"A:W(N[%J>X:RD$"P[!I5CQ(,&*NP5W;W'7XL7;H,7="MR^[[GGWC/?
M=V?NN7]D)O,DDYG,_)Z]U]IK[[4+5UKK.*(Y>46G.F:&3C"\19 5J'/MNHB7
M364K/WOT]&RK*G8K9F*L8O10-<5*Y#)FNG!RJ!^KH<A[8XE+Y(YF-$QG"G5D
MAB)!WN^2+M)1S+.]OSV6'UZQCRL4BV[4B!*F %W F])5-W0X'Y?H<\ AJO4?
MMW:_B@V=G^W/Y+/JX/OF) _ W;'EXHUB+4SG\A(+Y[# ].="?-'TWK5")1^Y
M=LM*V9HW,I+,A<QG@E"!+<H.T0I"_,RC.2+:2^@# #WYT5^P.)%+^&OQ(IC&
M,(I7/F!OY&BFR!IE1_-61PIM$(\OCO3!;Q8_7",6[UW]M]F<U5_5(>6%SB].
M#%\])(Y-?L#&91RJOS"2EX/),(U#>;CWM3!C=M\*E64] _ G6 >BY?6(!FDI
M)*0GQ&*'^,91A8_4)X4I]Y!':5@!12E2VD,(U5#QO?;6\/57J3YZ0M.6'11(
MBM41HE6.]6UQSP 77<0G;Q1GX:?<,&LY#P^$<1)Q5KQSP4!*XB9>CN<EL';3
M_:JLB;[MS$YQ3T6$R $)U7]15$V)*E1RM%T2KX"C7*Z1EA6IR3= HDD=)+1W
M:/?#<&5I6<$1C!]-.CBO>?3G]W+LUZ 2YB%E'].QA;QY0BP/V6@%HT38NV@C
M92.9_Y/ +QQ/ 7!?^4L/IOYA@'ZN,W7^D&< S9A$X/8_#-'$W(45A@TN)/HM
MHJ&XT>FJN)Z3O+,_9*02Q.4WC8R28:2!7,4 >$,Q _L+>F>$BLR[ ;/[$=&
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MYSM]O?=A:QVD-M&TPP@@>/B**(=D@;&K,7%,4Y.JRG+==#Q T%<16(@+/N^
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M0:S2L#SR.G6/S=UB/NWL\]:2H$H)O:$J17TOG,4F1HF/=MU(85RTV_K )J&
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M.N!>WV6%U"8Z:H(/J@YD/_7X<\F6LX:;I-'8*][]I!=^051+CR.\L85SOL\
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M@%-PALJ\B FY7_.3U#"Q*S?5])=99W:0?3Y=BYG"I:@,\7X@Y\[?]*;)-4
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MS*%L><W$?;T]9@%S4OZ0/K\?[<#&1?1AJQW6&XI /&5V(UO0C;"4W- S*N<
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M__%#F4F]QX8ES(L ZX<9+I4#.YA"YR6AZ])D/_,FS:DTEE?SNK: .0Y6?#4
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MW11GJ@@1&Z[[>IL*.N,$:K>1<YA#?E?%6D4#+J)^9/5 ?2U\X.6Q5J3*H;Z
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M'K2[+A+O1]F\RE$;-*.:8!V@5N'\.&L+,:?BBJ8%=ESG&1P)F,Z_-P)6KV(
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M!2:6'DYBP!<=UT/-@NP>"P"<+EM9&K>'48HXK6!5J-!:I$R==E]-SECX4%O
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M1$QP"10['-+B/1SYFW\V1/_\#>58;;(Q0&3CUN2=FH9U4SPQZKU-7+>![LM
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MUW\TX'X26$,>_LX?2W8\C5!4U\V$B#D%W5XN"9FX9NSV4%L%Z_NJ2'$"8UU
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M258Y176*Z[]/>OA$OA:PP@G-3*32::UT4H>H-!N5/:U4,.D(2DU0YF"W^I"
M'!X]2O>YV+^J--V,$,%1LI#+RX4B,"+=H-W)M16?D-\>='RCUP2KP]>2MUA9
M&"!><:I_@(<&^5%KZW,(^A3=<O&2;Y/ND3]()D&@.</S>$*/"U&=S/3$P*67
MZTF"?,6N.?+*Q7"VT=>)*Y4*VV+&/XKDQ4^,5P?WJ7Q(CW6Y&M^MTH+5:G>_
MK4N%":1E)0B4,.I"3PV;WYPLKONU2!T$/PG*/P,:JS=>](?PWR!+IH_M@[BB
MMCY-C-%*=J%<CH@QR+KY$S$U?W A$QEX!G@$QABI:Z"]U6-@WY&FGBE7S%<
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M<P!N1"2+0S@BR(;T9C[RE.U0 ;A#3L)>3'U-"Q36TCB:=13/;ZF)8'H?>;K
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M]6&IU4TJB;^X8&IRQYWNHGF^\':T*YYX0%JD)Y,A<-P1_U8+G4A5V4J8:M)
M8%#0S@5(>IG/#@<^C?SUJJXNSM3TJ+Q4"92KQ'DA%MN"WK*AT8P$E(TC 1D,
M;B6'AU/9K@R+&V<@AY?]O2][>0^-_E4+:]7TBFP3(<?MDB_ ("-\CD;!HMP$
MJ SF#SH"1;:B!K0+@/EXFK=US@D>A/'4*%!Q<\*2:D"-A^O&Y$D'0 *5J0*O
M@_QT.!@).%-Q-KHS>2"&Z":\E1HXI&;Y\A9\@590H,0"L;129Y&;LL[<:GEV
M2%M^>E2"PT*$$\*(^;Z>E68RS,)-JSOI*B*;+P2JP[Z09AQ-JY+#6;#WJ*P%
M&)R]AELS[\-J,&<WO]UO3WU@3I$=:GY9]BE>E+]-C*@V::B'C?AS K,?[DO4
MNB-005'*V'<UK;IG?HXQ2E,"1H]AR=VNU/0U(=H_&[W%7%@.KC!X0_Q\29F/
MO_7RYIV&]Y$U,N".,Y^7'&F9F*2\>1&1)PE[,G RW''HV.'#6C6>/5Z\7A47
M'//D8.>K:>I\^:WF<N?R#7XZHMD$416CJ!$V&?9<*;:J3FMEM/J!?N2W^U"'
M[_3<EUJ<71"DB,KF-_4POURK,T.+N]=.&2C:'_T-$L)='_%3.UZ#-@UELJQN
MIP.@!FI*EL;ADC\;7G(JA+NDG(!_E.F>@#MEJ^9A/(/2/?-+[UUR(E-'&TQJ
M1<KVM513LIEX2H/S5+D@?B[F2;"&KKD(R%I%37.-@J.5GH=,)-4P&8L'?J@/
M8U/(:FGPTZB5>4%\F70/WS6M;O:&.!K?%1_SI@]>'T;8TB45K02RP\]>:5"U
MMD4]E<8KP*0)L"X_,1MP-<0:S?&/\YWM)GNQC5-(&#% #HE1BM[4E%+STS#B
M*S[W5NA,QS>;VJC].>9,6APON:F7RAMDBAG64?I%1A__$'(AJMOA5M9Z)N5N
M-76N/Q?\3K5@$:?AB\!^I+5_"ZRM8+?F?-8 YL.\_:U/*'$8#=SJH8ZZSGO?
MH1IT@?8A7R$N,7QTG&ES1<UIZV#"UI@E4DM)JV[S0:FXIDC'6-]F[UAF)<^"
M*T;[@R36F<HOR;:IN!R-I&% Q+LF$D1CU@,-H#_H%]"_^H?#VIB*IM!)29UP
M^AL5*:*9+^B$*N)_@C?N2:X1]^I]]/:]?G090@QT699FO>3S5&'+C44*"4AS
MC>9 ".7=3O.QPLRE*=9%,1[2N<#%7VO#Y^\=>%$669"K",H_JZ&#9G+K)/M
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MNH#FYLD[__\\5_Y;&P.3U-0)PR=3<?SPBPK_%AZ,RB+,-JZ;9JS1Y+$Q7G@
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MDH*SJMU83D,0\$QF]A!Z&'\*T[<6VRC2N.?M07Y#[4S:N&G+T2I4^Q/]30G
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MI_$PGA+RS WFR/O$B-4T]Y.*MK@-?B.Y].=V /179CO,ZD;CVPE=M:F^/_R
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M42MG%X:V]H></8QP1K,_O1U.G..!"5F]3?B$'8]>(?9Y RLA8Q:3IUM24W\
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M *V#QXICC-Y:4=YN3P&D_D.\DO"!BQ$[0L&CX!)N53U;1A\@SFH656>9OBU
M-UCG]\AC^H_ ^S"5K9IVK;9@E)SGJJ_&'JEJ!P-<-\9V3V%E?3Q&@1'?L9<^
M\N[B/6U^.4HU00+!>Y_%%H4[5Y=@J_[<I_:%!C5=XG;Q>3GWC(AN\7[F&T,;
M>9&TT/"[=#G8J\)7^$:>VU#PBUR(S>1^8\MHH4M<W@P.1?(KJ6C .D,FO$8J
M24@UO*6&>F]0SUAZ"G3/K6 2<7CSM.7OL.];W5J<&W^-]1/>/H^JGJM[ME;Y
MHTX9'(E0$Y5&_PO!(Q7J6VUQ&0'8#T,8<<FHPDB6M,=R3[R'6M_GG[HRGC@;
M>7&?'-,!DIB8=''E' AP=\08\>Y^H<RW9#Y/W#<L:4/KV:// /N16O9AS8[%
M2.CT-/P&^Q-L+N+U=W*BN&BGWH:2T:2GQ.G)^7_+-N8CQH]]F!%B^UV-'#"H
MRT9;[>=K[_Q9#:+XPL"X!+TO/N;UX=93.[$1?)$,? BEJB&1C6WK42=AO*0M
M8LU&#KM#PE(EYK>N<$Q$'^IUUB->AKDOB,UL/@"&P.S?EI8/TK?==Y5.C*./
M4+0S!) 2P_E1:9[/MUA?%ZEIESP.F!-RBB<C6J8W2N*UJF;/BUI9TX21&Y,H
M84MK*T7>;@(.7&Z"#C9B,\S,$-Y!/8^2K:Y>)V3T-*,N0T.R&3HG/3!>(9XS
M$]_8!/@D7"&1M)]&7G1N)_,-,B_U,L;5G ?+)'6-D\J XNH/Q1C=JZMC>)4K
MF!9LX_%VK"MKKE5[+IGQ5BZKR:TCIJG:3%QOW>JW6L <[M^TI8RQH-:WQA[>
MG^]'&JMB5*N,+ZSI#\SIED;QY"I(F,+$WL'WO12MW;0(K&LKV>:>B%U:W.\(
M -"7PU>*<N>D4--3HF6'0\[0<1_'NY"50Q6)^]&SUJ6M^P? V$*5SU>QH\ET
M,U$9C1/C\+;5E]-OI\1Z+MNXEGZ?HI;9*2QLMS%OVR#.B>J7CC/#!J>3_0VE
MQF#K?;+YD)1-WY(U^>:6A=HCT]DQBEZ;#&)-1E/:W_\/N1OT$B2(/0&!*6^[
MSK9_W=MU,P,C.:,+R#_U >7401:!U^E@O1NG9I3>5=Q2$%)'589DT/5?PP62
MCPR8-@8)%LHLA3\ ^G+OZ8:_/,6*,@@OZ@:.MC* .QWO6KX^ +"N%NY[-B-]
M(\3WN9RWS&KY[H[$]0 7$[#DTMF[W /2!P!PX3+KO<]A"__Z5E^ML]:_/54*
M C_<SM85Z(LM\X<RN,*1(L5,;'8E1F#Y]?DYW9UM,I?'GJC4H@W'#N%<DZF9
M%:RT5U3V(/B.F5_:/&;M 1 >[WR["P(9+1)-<_CSB:_H0/?\7U6W5$^](IHS
ME'9^SO@QMI_&22@R^EWPY?3:FK>'W==X;R>,B;SOJ5RRLBN"%+0U/58SG!Z*
M/9GT,"B5Q8^*C&^SE]@P$[$?EK1)(P:,FVV=U[S/?V4W(?CRX@WZF\G7DI"
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M/IKM>;G5J?%=L*A63SEW3!6DDX)[MTZPM$J)I)F5YS1/]=60\!]-],74LP=
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M-__^Y]>W */&IMJ*QW31% I9-6YA@!+(365^J*FMRX/KC;@"2W15[)\D)^M
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M1>>U(-;W[=&%4=U\&89MO%<[J/$#5Q <?"O_TP0/AQNY.]GYQ\D<G^6TZ_7
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M,@G8?1,/G2A4]4S[Q^YK1E=3_'P%'FRKSJ33;V-#>+R%[/Y>S ^1?W+_'(P
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M$>9U&>(7;@B%-+M?VC\"(Q,16?,PIT@H5L'*Q*[P/-.X#\\_#X[&/P%&JD_
M[HN6"\DG(-$EY;'EN/W2+ND/W+M;D-:(=#(O47=J8G:4P-SV.]*KK]11XZA*
MFM!H&1$JF=;I K*$6=0?E17CRF*DEM?;:0]0PCA6*6,%\/7W:+5O')9D]0CU
M))2UJZ_VBO1.MPL*RY"]RRS#Y7>)2X!'CVQLOJX5K/HSY41P!1RZ/5UQ$F=
MB\5$R[O;Q5A:*OM9\ FXVC_Y)BQ4Y %>[_L&J9U.>I.P(#M/.T*MDD)LV+WF
M'\W78<0Q)?;+OC8#=$PAI#V5IV\;:5N/6Z=JC^1P$(>P,5OA4:_Y:\:/TB/(
M4/0<HR&O+H'7@Q8[)RA(1I:D@RH#,-L399V%W-.9NENNRQ^[#'ES+W^9LR9K
MR@6&J]82^/DW+9J\8PFMDQ_Q57"3X\OSHXUXM(9C]!%4<4[,-@BP?F"<PI8
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MT\\O#34E)A)EG]'#T/W1V=MER E+3D-(4Q\GJ@:<DE&(@K=/,;C'Q-S>FD2
M 4F!F&X7&93[DQ97;Z'+561:>[S/T;%^-.D5:J)5Y_$S*$ 48?2BST8C')UA
MHVU1L-+>ET:[0/OMIC9.N"\+Q=4#=;B*#/_S)5'A/75V2D5,K+Z2WWNI9K?1
M!="'@J@IY,;FU4W9((5#$G A H7-#""!G &IK5%XMF%UY<5MCPUT,[ V3<D-
M3]H3@!8;6G_R[+Z\Y5?3C^_P/<<JER&I] CQTN2XS&K/3BL/O9@=N";(<ET?
MP;YU%EF)+C)05%9,!.75^>5;U.YFHTAA:I^6L_?&?_B*_BU',O83PU4X+.N5
M?R=/08_WM7'MWQ2.CIKA^>@=DE$<E8^+_[4?>;Q5;L1U+/G_J4[ZU>HK6RE)
M>$'.LA""PZT/^UAF*"\SMF\8ZFFI>Q/_*78BS/LW^H@[WQ_NZTW<U]&'$D^
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M?FZWS-,HP(L2O=@D6 2+IC'*S=O>;?]IP#:VE.!)EYG6SBP"\-53-P=,/)E
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M)VT-^5 O1)W:Q^.S=(G&TC7WFM3X/DRD8"&H"MW*VNJH6'!Z7;*7E_!&@:S
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M8"G'&A3#EI!XLS>@(CXN:+J:9#*_1W#K'9TE4SW28\#V[;0_I(+C<R+V=P2
M#K22Y#]_F[2Q 0M^/;+&SY7I%_$S3/8UC!L3CE] FU!R;=IYFYR1OA.Y.TF<
MP5P^=Y]F$$7TMHVB!AEX=OA(H4?+?-03Q]1L:BJNP8D7)\F-]@:=;3@1<S7K
MI.=K"#GU6"7J^&'EG#0%N* AF/?'IO'@A/ALH3HU:37H]E)0SK#D.J[=N?=6
M=$X?XSJ+N\ ^O)K+<KT&D.B,#^Z<9<T7%,NYCA.%D@3/:20O@J53/B;3;CUJ
M^>(7/80 %"*A=<0OS32:&V>;NQ>7%)BKETEO)DDPR&KWII:^6E!9]I'@V\P7
ML8^K[]HH@7HJ%FW7E\P::;L:UMUQ-8BG1'3;5=7V*$>!JT>=])\OZ>?K7ULY
M]K_-K(S2RRQ4^(@/^L$54S3OZJ=643]F<OR.YWDO$:YFR:I9@,BCWKL.4G)4
MKRZ TZ1M5=6W9XVG.IQV^3\RNW?0@:YK=7E[3!W\1K<\ 8X'W+L&G)?#S-;+
MB;A"'-..,":U_^SZI']0\9^O[.[HK8!1\.V/I,<=KS-BKQ3JJ\/T+VPXF3_#
MOX19)!'4:K7]X]:2IGRSJUO.4O%<D?7&X\*3T-VYR J_-MYMUSV9E4^A>(KO
M_RR$&H:[299+QNYS_6FY]051:<E9$B)D<G2J-"[DLSXG.Y;.@7I-G8;J-U'R
MTJL9Z3'U_K?$LW1!51!LSH/,1:_$04#TE=E=6:+7LMWX!,G>79'\I6S_S*)'
MD+R>)!]MSNBYKJ06V'_L0,O!YGF\SC/NW*.^K6V^?+RHT,,:$NO)[0=\^,'W
M#TY:L$-S=<RFB!O5[@JM$B69&\:M?J]6TN5N,_HS9;]\:,/O?[IFY<'3QN"0
M;3$"<3:;.U,"9;D.N ^U/;$3KL)QUM#P1NFY*'P#[#"9AJQ239NE0\]PI'[#
M,\;B+ 2 '!<._*6:GY<'Z17^ _;V?/F]8$5;TO66(#UO%SU4X5^OE/T7B.BV
M!>9.=^_X@'L=Z;+,]H GVRD7PQ JS=+D;X^\&9OP/T!+Q-^^^,^0_7\WJ6$A
M + O1C!01-%NVSAHG8KM=PP#X=_1L* E[\P>KSKF*"MG\?]=<=] 5H //NL2
M'%>A"O*+9Q]H>HH [&3?WU5<&P)#K?X7?0'\R!+SV>H,3,4=]Z5+/78: \OR
M"K]M:1*IK13WJ70?#D<RW+&.>J[F'T8D/[^2-B16E/$Q]]113\;\=5'I_T%_
M?KNMEO+BCOW;G9>1&U(2^/#1@<K;M2;.H&_Q53'PHS..!RT0_^.DT\::U O=
M89M*3R0W0V/L+$N!F#9U '8CTG5I"<.Q=_!]RVH"R4LBGY8??#V/N38J=A(-
M3TI$3E K.=F@6F1CI2^/<CHP;[8-/[5N3=M"GN9X9(0#=H3I&@&%4PY>?@K6
M(L]Y%SN!5_(<NS%]J&ODJE.&^>8RZEX\.$'$^>!DG!$GPM;GLF[V5#U7^#/J
MYXHZZE\%!>[]P9D*ER6@.XD!UNH;#\^F5K(F>?>+U1JNI1OJ9CP$H/@*=/LF
M;^F9"@)@>"UT<II$28%3JSITAN]X/R?N8J1R54(W0^B\2'(GZ7OD*7[9U&)2
MIPVIN'%;2&H\' )Z9 NHWBF@:4JFSUJX7[:\C"';9K$BK'%;&'=YY8YS@I]E
M@!P)PYV@=F2,VJ7O53AY5&KD31'>7G$^1*C9EZEM!J<:?:%47MWK:V0?+9J3
MBU:[TT/&<":]N-!E5J!?I@7!WAX!<W-'NB9C!,NF1=N1-;P,V7HDXTRW=U%4
M0KXM3%PVQ?4<M;0Z3E$B@7-[G\3:LZIU$5O8.G,MK_#>H>/6.](M=====;Q\
MIS[Z)O+).%HXF'5Y(5S_;#(<RMA_\D*91@J3DE%J5S 3.#R<\"VVB9#SFUY2
MF'"3?G<]2NAYO7!:_EZ$N;/?^P \EA>RU"$8+[[HV2*Q"5]LX"]X?G#F#PLD
M,BQS_*K!]E':,F786U59[B?W&1ZQH@L[3&R%9N2\0$ZO1SE8:?0PH5]ZE(,(
MIZ]-.=$1%)EMSH\:ZI15=)BWZF$%\HC1>(F:+!*V7Q"B5E7&<JQVC"NE^Q%E
MR"82U#D>GQV]LH2J-2V2MQ-M<9LTCF%'=RLKAF?AT!Y#)(1^[[JC_.L O&=W
M6K XJ_%K @;$_GZK^LN]4UU+.(-"O"6,4K#9=NY;\ILIHGWW3Q6>"JFR*TGN
M7NR:GBN$:M+.![@,1&A$(/FF@K(3A[G^XXJWL5-R_$X-"PV2ED;FW'XM20-]
M0_K=F0UC)#WQ=/XV:_-3HHK9^NRGK=ABT?!M%@3@<19QJ&:_E20]G1/9.9_'
M$KJ<>::9"X:MR3B7PW?+6&'1E'H7TV;UTETO)D486N;L(FT"9/5.P$NU-'O!
MZL>(!@+P))H"IP>_AKP*->NDN==:T=3DP!2PC3K^$71R:G>M)MQ2<.T\U,D?
M0M#\=,D^#F=38)>#P:$V:?IJ[WID@,?X;.<V/!9#/TXY:M+18P!-+46N^6U%
MNZU,8@%2+\45LFHXIIEI9S)EU:AXS\RO.P3 H\)[(7=@C.JN=F^QT+6E<^DX
M9N])+LD;<#5*X,=H;UOI05LAB$S+<0=<AC4& ;!J.5>>#.U3MCHRY$S?C)I=
M=X&_*!WEG,'.6D5_-3')QG''S?O^"WGO(#9^W0YLUZP1W]0T1UO7-5@_4"IJ
M1ZS#YM(Y7BXP[6.F%0(@=%WL\2%27[\^=LT1:IV4N15+$@8>A5-9\-/$?5VS
M$NM ^G!F-9)6?^=8QL26BM%#OEB%:R_'=+2MI&C>O)B#LFJ#J;!25Q14%W#X
M\T"P'YRKT$]YDBSP//(&.FWS6-.\>O)@%82KO:.N_I3(ZAT61ZX0AA65C=C!
MD7Q"-S?Q]V'.VO,O8_O,;%$Z";%QZ-K,[!V\Z\E5:%WHF^&KJ*EC3"@1$B/1
MP\5=1.0SR-ZH7S9G@X>)?>5EE?F!&+*YUWF5<N2G)!>$E <B&I<'R&5[/ASA
M198=R[ITBK4>9%1=DW'Q\;YJ\W.5X%>D$>5& 6MC7#8KTO[%7-NA+2F.MPXW
MBFCT1L#.M$"F*/7((>\)B9ZN9O)1)\+B T_"TH6W-Q+\WSH+O-![MMYE"536
MNV-)O)2[N*!W51=K'N=B4?LI).K%K:W-D)GPD<\V$S6TM,,OQ3N)$6,("UT0
M:+C*Y#$DS+=I1AO</_O1+O&QO4.BAQ-YU;@KDQ)Q3S!,(??K2YS*G3CV[^/K
M#,Q?SC['YRS3Z1I*3@DR,/0U^AV\3#U_00<J)CA6%OL6;5/U)>-EU)$#3L<B
M,?%D2H'^D-NEK!P_SINE_D7=,%L?(Z>VHYT]M<H4M!Z[=-:*PMWC'6+/0B54
MUY 2!C*9U"W@BI9[V^_%DI6PN$S[&JW&@,ME=XDWI<#W*PKCQ#,G6)>1X.6A
M)T,>J5A*2$94FBCCD<SR^"YL_=W2:"57<G1\0O5EN>(V(Z3>+2ML^T7L2^IC
M%X1.0HS.TZQ4HO[ N\*<2+A#&(=)?YO:7MK<[NUE'7:DC=- .2&Q.35Y@XI?
M6'*3A]*2:[]"='N-.VK"RD6I[Z9JS'?=QMJ/ZBG?W>G)+!" 3EC#M;,KQWWR
MK<ZGI3$JOONGRHWGP<-J >5:\0YF)^; )UPMY;O/=E_&$;SNP^]\6RRQCHPO
MF(?L6,):C #(2*LO%]?_*J0";_]\,0P;V<)O556ZTTO/&QM^0$+CO7]ZS^B8
M]]/^\.<6KQ$ ]S&7]67(_L2FZC80S?@4!J9$ (9D^0@>X)/R/1/C4H=))>1K
MN/L#N/TI]/HW#,V/3X'Y;<! WPN<E)41@ C/EL SO$>A6'K07''U](/?<W[X
M(L4KU< F3^!AF)QJM.[6\[=2%P[W]$@FT%;^C2E]UF="#UU"/%A[DN83HPJ5
M.!?GA9UICA<\E3ESIE4*<;+<IR]&@;EX*O2!K='NM,,OLB'M#GD/;&$HW*VT
M7.>ON643.<$PFRO>GQ,S#4%6^,81@"W_G/OC)9@J\#AQ%W+6/@:_MH$SQEUF
M QON_"_B3=,4]3P>!K?!' 1 D 5T%(  K.8^:,76@P#)+U.N.B G*A +@[N6
M6N&'0AF9?/3)+ "PR\E.#U3@9+'(FG/$9VJ[3J_QR)O-RISO!IO[639*&7H)
MN\Z.ZH+Q%_VYQAJ$Y%^0X)Q'!PTM-ULXZY#N!KG06R:D.XLCN%L' N"9<I+Q
M3[]3L?X__@SCMN=OT-B(<RY)8G7W=5BD#[;W!TAWJN:ZWF<((V#Z 1SKG"X-
M-KT$]2( H=PVSYN^WV]%X1BWT=U,2+#*CZC3.H10#? 8.7&J/Z<+/73X>I!^
M6PWI3A/F'O<0 3_44X, X.LJMJI[X?"[=>.RSD_=D!W@MT':P7F0(1+]/S0%
MM,(UWK(56O*':JA?>GT"59<V+<V[5*JC/&C#;Q]!T KR=VV84GK0!NZ6OVB#
MZ23.02&;R]5_7"9PYL+O#HRQ<-_C(6ZK?QR_JW_6/?6'[H5?RSFQW:S]9I3G
M@5')2Z^/\-GV*XC=XH@. 8RV/@YV4H4 -),\0.\,^ M=6;CK+ *P](#=NQ3O
M4S3^S>>_^?PWG_^-?"(+@O-<?*?@-P]%9H5W3VG>;U2"5(>NQ_L?Z3JR$G7C
MRL]/WG#4IM=Y0/"D'> EO71WF<\@29KPN88'86SADC!PK**=<U39MFBFA60\
M]O92(9887%0)#NQ5O*]R>6B E0<N%*XG^(J-DYUC8I"X.7SLE#3=&9OP/[&,
M]X\HGW(Q[JICC%#!PJ^'T222&":&0DWV<2Y^EVP.J7ZPXUN)H*N^![,(6$HO
M!?US NC_PJ=%7JMEV=H_CHRJ?-\LG V5;L7C-K<NA*5#3Q\Z,N2DO<O2$J4-
MV'TC#C=" !A[HM<D&K6OW+T3"[9_KB, VZ(U&N[A:<&=RKH*=NF-,CBA6N61
MEZ&L/T40@/?]=&>T]7)LJP-AJ>U\G@W2"N;C_G0SGWNVH$II2@)IW94TX^?Q
M3,FZSAOC[(7(SR/>"L(K_VJ7[T\AW65</-N%. <%?_L?_H^?/O_)D[^7D2GG
M+ (O1P$=5M,C64.S;/*U=9XU0/G@!*O%PW\VB_$?SV;\@\"N@9T\WM3- 8>G
MO%11]"]1GN4A643[VBL(CM\B ,%.(%PM\\NK3?98Q7U1']\M@+5E='1/C7M/
M_*R'(6$R$>79,ZF$\>(-(4+37.$J?)D0QU.&OKU-BX5KW\.SCGKO(&K;8#"!
M2U",_*E.E OI6LM')F6%D\TLXTSQK'E-\_J83-"N\H>:,\\6@]YB+2@IY7DI
M0Q_8(6<<YE*P.RO4'6<?ZSMI*J$2QI(LI2>:B@;P$A$^WU,@T]7>N9QT(>8.
M\H[MI0HZ8H;UJ)X/BMN/*UW:514*N^E=<5T@ +@6Y%2U4-G)4"7D&<QGV;VK
M^N) GR(6L1Z7V^J$2SDQ^=%BDU//2 ^68FO !58RSK ZB[BPU$YV^U:<;9&N
M1R>!]ZO:JOA#7L6BHJ@99)FWC)D1\M);T9H[5H(1LOQB5&(OD:,8H_*2?PBA
MVMHI*I=;KS;(=!=Z4S2$MY]>>TKBS-#4W<GR*;<X [H=0FP%U+IJ.LDD6/@G
M!X_D1YUHJG0CI+W F_R/AI$BMT&,Z[F9*P3UQ(FQO[:=AHAV%U^-992/8[)&
M#II(J,QV4)%(\LZBB81W)ZV4$.\VX]?4^[99+;"BTPTJS1$^YF%%;VN[VF8,
M#'2$'-Q[C\F>P<(KW^CSF!S4(I_W#BEH_1$XVM2B)E;/],>EVR+9=?=!H83=
M7)8"LS &3KP^D2YU%)^:BK,FOA]37AO:.%!K'[1BM.M 3?N@_"-51*N$LL']
M0J<XG<]A!5$!BQY1J^A&W]*)2"EC9S.B>L@ AP\>Q;^JVE[1O3\U?;U25\HI
M5&U->\)DW/H+F'/.GE(W'_ A]='YXY34/75A\LFB"^UW05M^SA/?<'/L8_@
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M3"&=70XUL+$!O[#DZ)50$/9Q=P>^)VE^,'61X&[]2RQ0WYYIVVUR@<OQKI=
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MP']":.-Z+Z('CKVA-WW<K[?V2DVJF1*N(6P)RT)D311S-[B@+,>8M2%ICLF
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M /SC%;-_9J7D[0(8 1!:10":NTC^RGS&W^K_#OFT DJZWX.%@_X7V \_>(H
M_&S>@AO<!W^!NUR5G HB /_T2O@_27*.-=ERMLAVMZ]8/P7WZ'K 2U!0)=/O
MV(HI-X'_%O[?PO];^'\+__]SX>/9L);X;MI3;]>GG/[^TH=+/[C>J]]"O"^[
MF!W17M>QMR35G;/9;)$E[<H)]/0E[#:"J%&%MU=3CF63*5_@%Q%\6WM3+PRJ
M=U &H-BI)&X>\3B[5YJ-99%K6?0.:DO[/!C*7.H?K[YU'@2223"9U W(PD6C
M$(!62$0N%TM09#UP-)E] 44YL$H/ZD-*$5//]C<SKTZYH_0!%?*'[:7_B]TU
M4WQ+A #\87PS_C#>^&GB -/[/PQX^!^V6\T?[U'*7^RW\%_!PG^E#).JPIYK
MD*(&\97OOM,Z O"^ O7#ZXI73_>NKVY)H?MF5)QCY@M/,B=^K,3'M;/(T++D
M+$@R0NPAD8&K[#@[&O:>/"<RW*B)Q4)JK@A P=/;-QEH51)6XY=%DXSIKUW-
M.+9JA8FNXTT>'1A\<>]C3[E'XQHSUW]*%30I)^-<2U6H" N^3ER'Q^S]!FGN
MK1E5#)\L0*]Z<) =JODI*CY_K*Z62M?[^AV@]LU9*?<W\GB;JER Y #:'_NO
M 1@9%F.AMT!E]>W4IWTF/AN#1]831@!40.M_@G/_=&Z.L7]G:H1*,-8%'<JN
MF?X1;4?\RWKL?M&#0_W[>#)2X[@G1JK969M5WG6KMHX<[L^R)*YI*^N4UY_X
M_33@-,=?9E&*JF \U;<!/^R=NYP>+=>DD86CU6V#JT^V?"^.GNVI\;A;1<1.
M:W21R(Q1^E.4\2'[#8=-A*X&UCP@49]"3\:I"-U=D 4/ ;FLC08J3G]R3^3M
M+73SRUQU#3\=<DE6N'!Z$X]6G.CQ8'BJ?G:@J5N>GKGM)[XU<AD#^U'V\,9]
M;2+0PMX>3F!E+Q<6C^J)9S.Y]@[R*HD<ZR32!FIKO]4'^U1@#EJ+G%!Q7!EY
MO[;.&91IPLK135 S<U=M-LYO;<1F^7-.97U-A8?93. QMRL?S'4HRVVA)/"B
M8,^HKG*4"^,K4, 8.K.@C8:&C$DN@K>F*-07PUW-D9LC3=)%)4G)SH];6/A:
MA$P$OV7%X\1LBH$@8'G2>AZ)((E$AA*)[R=.4V*X?(S5C,ZWXGV'<?4L,+'K
MA#!PE[\X;>6KHYQ$MQFL J5 NS#W%QXLIT1_0]$<G+:SA$DQ:7.>X-%?V6*V
M@EU[1AB&%,&N NA!\X,.S>YX.)7EE$]YQPGN0L^]R-?>GS3'%&K,FVD9AZ6!
MS:[4QC3$-KP6!_J&J+W1<O#%VNN]XW)<915/U/(^Q1U@ML].SNK7ZGR.I:J]
M:1&[)A^=*Q+?/ZH8_GD,"CP0E%LU.Y^;H0U[&3I?R8QDA!F6&CY:]_-B*%#X
M5=DD[$-9?]K.)$%9YQ'FY',WF0Y"QO[HY+JA*C>R9]'VYC?(Z=^4]0S$7?10
M*D9-CJ>"CKC >/6RG#4QJ*]G4 :'IW\&4""%33ATS&Z&KH;J.@HI=/"K%O*X
M2=&5!_9'T;91L22[/YK;$<L#[Y0RNE0W)#N(.\,)CYNBP,3GLZT\+[4 #LS2
M/8F[&H_.!10@,BFR)Q*A11;#.^[A_IQ?F:W7GQ7&1MPXO--8)KN_Z<DYS]YU
M5D=1:"AK'=&+7#EZ,CUSW:,W9OTQ6+%A;,6TK/)'=5%;MX2'*8KK3M]Y89*-
M?I2 =I* RK%)C('CWM?,@.&Y1E.0J]/"S=J>:)Z+$792S$Q_*/_^CJ3RJ<)T
MY^I\?R2\-,^J=F_XA2IX7%W_I?X32YL7$J/4"$!0>)1!_)2GZ?.:01'!%J![
MK7K91*.X@]!]6!"5Q%" KO!(8R8O*2#U\_3:XM>!AGD:Y")#2NA8F7(F>+@X
M)U.HX]VT!U&'Q*#4C0CAD!+VFZ$UO="5[8V3E[F< ]JMW+%:7NV\VKF<5_YI
MKZ21>]W/>ZRE;A7Y3G>?!7('OEA>PIEU#;A2##B4CK0JI*X3>P&09?CPJ%?0
MWFS,$V3NMNQEHQTE[3\0$I$I4\C];/_1_)OD^Z]%)8'/[E/T3Y!1:MS<57^:
MDMGV,K)@P*79H C 7E,-/$0K2'H!!@U1C?NULEU\]KYR3)!C.1CR7&^G=%?]
M]DL1624/U9MW4"EF]1:FV[#$32^>.XZ>6><T$T<P%H]&50TXP<V2ZC3J W\!
MVRK?D/?T9I)\]7",0M:%X"GTD%/6@^Q%*X=KK"[WG&)3_+&6:!S#ICAZMRS[
M;2)P;+':JBI!]BC0/;GBP4E=],,Z2-QYQO0Q@4PC=YG\B_5%VGAU?R^^P"%L
MB#6]B>#M<)SLL1'_J:O;Q8#,K804A8=S+.\S7![VL#JJEMP>SZ'<[9:Y1<QQ
M)Z82S% ,U3'G7DRU 1N\D^1:)7X?G!)KMXS9@O 9 7)3<7=!I'>CPL1FLQ.#
MP58>WF,#>)_$V\N8ESB_;[1B^. 4<4_*\71[XTX9Q[T;JSP0>_]%1YSKB[!2
MZ7J$NN#]O,/>@63EGA7*/NSBX2L]@M&D]J#Y%WM*LP;15MB;W DE?0_*E$_A
M*/U@SQ_FVGN%;$$; J<_OBRXSU@A/)<3'7PA5'EY&6H9M8S[(6 Y6<CCLH<J
M/YHX<Y;WE4TZI/WU6$)_^$%)I=7+.9#+AN&1*1D$V-%D-&5H96RVA%[")E=(
M>^"D2#QH2-*^+U;CHF/O6@1DDOD?['UE7%O?MFTHM!1O*127%M=BP;4M7MR=
MXI#B[BWN6J %BE,TP1V*6RDN@>#N$C1 @$?_1^ZY[[US[GGWW/L^W0\SOWS8
MV6MGR5QCS#W7F$=:0:<E_:>1!FJ:DZ;<1<T&\#=4:#@M")JSS7SR\^ON?O_Z
M$QB+I1&4>FJPJCMW>GL8/YYA>MRD3U&@]X/I(MA4,[RVY@7LZB&!RKN_1&G1
MZWV>I[B'O%H9GFMFN\RY P1[:7A*MY,X6Y9VW\R\M/_%<9NT<[8.U2P<5@P]
M&E&1) POU!#1NI6H_(T9OI0D_3D*>T2UP8B*2=J*HQQ2UBE.E%T2F*\6 L']
M_*]$"U'2P/? +O4/]5SS-[J-BTC/@C]$%-1Y4/Q(6_!T<W$,0\$ RUUGOJ_D
MU,MN!S30S-L:,\WDNGLX%WX'T.\] :891A-:T71UU>XT!1.HZ/Y?WWC^FRDW
M3XKV.U#+DPU\Y3T0?:L#\*Z@=MM.352:,)[8AVF_*9+F[$M@GY*BD*!L8?ID
M%\&<=/^$,%>R:R46^QD2(K>]P[GL1M.8^KR'L+^;<%1L9'_O8J#G[DEW /9;
M_Z]--^#Z'C%=0-,_$2-'BWMW?L(:YB"!O"D!0P2;2->ZV;YN&Y-5IV1I"13Y
M]ZD:(?"."4>A__;]IQ=-]KY63C''^6]Y8T2C>A*Y ;/<?UGH[3^")Z4_<GV9
MN60]';8Z'^IJ4M_6Z$:P,Q!<2/P%GC0ARNYA/%OH3>#[6UM].@+U#N$*F2+Y
MKW,'HM1W@#Z6#JIS]-#?=0F]V[T^32 I?)?3?-6W8069YY$"V-\Y&5 9B7WQ
M;LX6"3=YU+W%W#^761\Z4]P<AOIXOR^8G]\1!'?75#^M>L:>I_0%W1PE1G8/
M5Q!* UK!L?E=70+H^WH!;6@ZI\%%H[^_#1TU0<%213UW3M$@5/:/NFA530F_
M?CG)BL@"=P2Q!9,N.K&\C3#>%15C?>?;)2@A+VVP;>6DB;(]$*3R.O[)F"X0
M]UJ_] S4I""MA'B_PJ)@J<:GF[SK2?FHGIOXR<]L"0%J_#<.> 5@XWG_?L**
M>^;2?@<8M=<7(63^UGC6H)A_Y5(QY\-QOYH@]_/7V/,.<$I;0OF<$Q'9YA4:
MK+G#6$/80*09SOT0'QN[4+29:GB\('-44?U@MCY)GC96!^&Y3/&F,X,E9%./
M0U?^I;#FU(:Y)YUM ^U#AH_9#5=:B2J2_-W?9TT^)\K2>C%T-LD<-C.M7.M8
MQCQ,97PB_Z*CY!G]7$8G?W]1,]N2KW1GXZGN8ACIPH!B!;T1L$#S1 8-IUZT
M7GBEHIG)V]I^J8RH762"4T&8X[&IYX/J(**A$4_^OFU]5\L!^K7$VU(C+CGV
MQ<EAB:.>5M-"FUNFBJ9O'[+A@+ANG@(LLF23["9_DL/9A6BJY2GP=Y#;!6P<
M-F.=G% Z9@#L('0HX-<G/XER0M<]V6'^QE?&,I<$G/S@EN)6]T,('E-69&6/
M+Q-3ABF\H!^39:O:T"O&*!P?!7TWLCMEB#W%AG0ZXGDP$_RQ(8DV;;A]MKJ(
M]F3'&6'1G!Q!(33C\D:#S7WB5(%,,:W;""M->AS;OG!F1\R*=V^G=$L]*BI.
M+.P.L$C?P- (17*ZBGZINTC&E[I,)O/.(7)#%WO1SM]MIJ*>;7&-O^G2E!%^
MM')6!A2QD;6;1$H LY\3$=G7'[:C;WPXN? '>%LTXJ%OBS*-(S5L75>B=3U4
M(DLUJPPO0Y9_9CP(H0&871MK18^J,&NU9*Q+@<&N%5M^OS-@2[KN .<XC7>
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M<FQRQYXY"9POY9E</G,_I'XE :4A&%2QHYZ %$S034QU+74"/^>QBN.Z%Y]
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MWS\?.?I=+J0CI*P;5MCY6]3Z.3N-9RG[RRCS!7H-DAT9?L@;I3$?M?S+3-/
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M$<) \\*0055Z!51GH:[Z2UR92W:/)62\'8X7L;#=8QQVV'Z[M2Q]>0%IQ"\
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MHJ;1,$JD/KY47EOM,UO*NX^Y1^?\49&#-R:)KYN?+G+E(3(F6-4\?-5T-&5
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MK:9CK[/0L@%Z)7GKA77!6$>C"4%@R!-Y2_8*\!R+;-[L%H*V3Z+55 +@ TI
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MI\I5.A4C[$M-9;45H_;;X^3>(]U>KP[,:-_+#,=_VZAG,>0='!P /ZJ1#CJ
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M1X\NMII'6+3O+5\'HGT'LI\5-=\#KA$MXUW<;+_>_?" G&L?RUCF"O E_@K
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MOLU)__I*_;1KO&=2:DG7KY3\^P#,I>@,?FG#S-*:K+PB.\JM*NV-44BD=P5
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M^H0G)5XNOABZ.:"U0(IP3=U,,2?<KKD+B9@)*<NW2:F )GNRGGSMZS)'P]4
M9-L#;@ H1%CT#CI%F> :^%L$<T,!Q;-)F."Q!B+TS76#5.R4#:BM?E$$RYO:
MRMJD!;?!:1J7R#I2?MK8UNR5!CL>AKE#&D?AA_LE&WTG_I#C"@'$S@>3.%;
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MYF6PXZ)UWK0[,KI-9\0JG>FVZE@1]A$&V/7!1E26=8I&!3B=7HP.V'C]H2I
MLA242&F;E7BE+[Z0?'&/O$=V8_&;ORTY Y_H#GW1&85N>&CY!%/O]Y+Z"N6V
M>N!4I7ML%UVMJ,DQ1>CZT*I^0N M .!:]S#9WHEW?[QVGN;&Q,R]JB1R+7?R
M>?Z?<F(]C=><O_4C;F94[G %6#VZ N"MB^.&EW1JK%R;*YT Q=_1)/-KP.BI
M5)7VE8W^>XZ'+=Y=K[<)3[\+9J@]Q:R(1P_03'.V=[;F#-G HD[TR0[3#%VR
M'6ZB@]4W):_<Q2SF4>BW:JY8!K*336M4Z\>AM7YG2J>O^Z1WJID#G6G"S>;
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MSY;^%,UMWG[-E+,<R,,0S2M M^LERW?!L^;ERB;E#@KZ=]#=YE0[,; _M5$
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MU/H*0'<B?P7P4+XD'9_0CE5?M2Q27KI6[AK$?[9B^J\*X-7T_P)02P,$%
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M?G/53S/U,-D*6JN\$[NRC1%YE#AN=]MQY.B_.$\&X2WY,Y3G9MQ>CJ'Q= 5
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M8'3._& 9DW%)+$#U/S(9)3I745BLM()LZ)\M.YU8'/:;33E2X]%;8Z#BW$B
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M=84B.>;(@J'4=OMG!*HKS5$QN1X:_[!W/:A/'@CPJ?9X&:*;KEN767^R8W'
MD!%O'@/#(1SIF]U@C:'+3S8PH?7ZH3%YI47* PT[];'(CPPZ9]B@=R(5%"G-
MOS-K/ EK]"EV9L8"KN(V(1^?SF5AHW' 'U-OSXN]A3]G!!T!A5V87*6=K9(W
MR9H)(WXWHXR!1%,$R5/-7U9\2NLJ.OHQ0X,I7X%T%1)S6UK(_-F[",W[66Q.
M8?*?RC7ZQ@B=HT;=-)%3SL\Q^9B#[0<JHH+F<Z] F&M]LW_/TTC$KIL(FR"@
M?*=)E;GCF";B=ES[V%&GTRUH+EYU>EW2+>R1;G;UBX1)[J"7LUY6/)<$CBW3
MMOAWH^T@[PY5'E\WNCC_1HU3=:U-"4%UBI R-@]5-$'AEV-00ISZ3!%J-.HN
M39U8+O72'"]U$MJ7'7 V5,PN9U3(LO*NC%D$30'G"2@S*4=6\'VDK7FP:KH*
MNR2?@:L2 *6@@BV^$PZI &";"JL+3[MV\0K[Y-%3"UA-]>$+.,+ZL/*V#3P+
M.8+$;_/&$BK(0)XV.^ZZJWKM.'34C!L[F_"GF?U/H^O:=67[9,C6-CS+HW\J
MS8V. I+ALLR)DXN_^'67<;A;7 M?=T=6OK'WAL4U4Q=!;^37'$U13< -E%V"
MO':9:<.2)C-HYE&BA.]CN=)XPLDSTKGSN\[L8_/O)K''F7ARLN?M0RT6ZNW<
MF$XH3[E78.F37D$!@XUVB3]%5HT4FT-$NTAD0[>KG%G#V#Y3-[=9O/'7_3WZ
M!3K 1].J;P29*+8U(%E M@8ICYUTO5+M&3GV2]@??U\U^T$'U]0C7PV; JP:
M5M-9+JE70+>A^IM"3*IC<Y"+C=F4YG;5HKR6=6UVE>K4) 1Q5&RA\?:<\? 6
MDXJFQ3QNSV8XMH-#KLR]UH$7A9_@#V^IFE_K0GQI7K$48?#HNA;V-\'('!OY
M4#;\Y3Y0G:XN2GXI4>RQ(5QQ\L^=.3[A]J2S')]8:^@O"FJ9UEC,KE+6M-GB
M$ZJ2("0Z7S45Z,B^<^6G*(*@5Z!0^GZFL3SNK5"O+G;.6B;=%24(^&_)9/CL
M%7@*8@P\C'P%Z">*.<7^TR5Z@KS"J2)"@#4=NS6'9!"Z7*1</#A$5#9;H7 /
MPKLU\:&YGF]W=5\;G_N[L^:">%ACZ4=.\WX$0STL$4^^A\^[#S/U2OS7Y=8[
MI(O5*)8[JO<;=0JEBNH4Q))08JBK0JB*3;HNK=-TB':F=<)\2)4-!3CT6\-A
M:I)LI""A_0$)=$<Y D$2?C6H7\\+/[#>*9.I'"Y62.E&X&V H30YR(1$A6Q<
MC@DOV%'%PZ;,T%,G(K*<[X/Q;K(1,PTVH<%H2HI2O^% O"5BH H<Y.^,0=%N
MA6G<C5R$H(5X2B(S4W \XU;UEN\,=4%AU3)7(V IB-[H+VFW)3V5*$-%S"[=
MQDG'D-;L_@IDX46J?2P5.:WTZ<CT+V-0JW_D=C &:"EY#S+SGI>F4A[271;+
MJBD%,93^KBR"43KC]-Q4PQV$U8]U76VYQV-U0N_5%FTQ^N3IH]&V>W!,U:4:
MF;]$GSR,)88XW7^J,!NLH$]\S V(48GQX'X\-_/=2(X8?9\'0R(MIR):3NCO
M .],(%L5MVZ:\ K,5.@X;/Y _YEEVL.LU4 G*Q1E2^V%3;:EZ32WVU"A%)>@
MIH=51:0&$C-('_/*AEV6(\AE&J;EA.VOD4U0&,4"B9[(@L6MFPJ(QC\WKKE*
MDA7DL_[W981I<VZ*!90T5>)$$/:R*C);)X@*O'EZC9R%I<R<G"^8H$=IW]PB
MB.*I<>+5-TP^Q?QDSICR8%I7GT9X#%Z+QI=RTA02VTV?534UA?MIDS(SSNB<
MW8ME>OXP1LYYS+TJ_SMV9AXZ%\5YZ0'<^._;4-P9BIP(Z'*;[63;;F4H**]
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M]+MP8$HUXXHH"G&-C)&0UJ[(9A@;<&WF<7ZGNWU@I\.1-2BQDK-LGZ#]32K
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M3]S+PB_#J^T''!?!P]2B?<2(1;10&KXJ6)ZE9%_/K#1 5->%)7#JSPM)H$C
M2H5?K06;+-*I4W!2"4T1X-CN8D0+2"9,")'=*21CXP-AS<3(84I3__@Z5ZR
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M)^.NYCHR.*D=-T6"L(FR>("IHH:)'[CP7!\12L(Z52$^JGU]1:;PH *88Z(
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MB@[7-N FWQN-BH4TA1(I_E2A^B)^/3("O/I[4-Q.>W0"O\6%(I39?=473KI
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M&-S7^41J4T+BE5*9]N43Y09E[-B7-R43S$O,M&$*?Z23!2OX?*,[V2DV&4W
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MPJF0NQ625,ZPFV F(A*",/\OUYL:Y>$BCNS2'0*Q%9K+FI;V]S38ARGT B\
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M1WL4:S;$4?+SLCNW%*?]9K[0/.?T*8?E;8S5'4,,95 3"K=A9P?;</FRC_5
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ML9;H6>FGSASF79,-I,?C#XARF8@12'F4.A9OLG8@'*%3A3S: WJ9W-_I<HX
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M7S0C?\]J,-;PV'77PX=IWD)F,;CK^KL9HEFC",7Y7DM6M!0+<4Q16!6K[PP
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M=SDN>VT/=DTFBLZ9^>5/<LPJQR85H(]Q>!R@6\_K"P@Q57].;T4\<*![]4T
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M:O^Y[XF%BE"/UV*6P^YKN#KT"=FE$P.I\KU0W.+VF:ZR5$($05@5;.Z4"-@
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MXVF<KC3GS3J;ID <:L.F>Y&*[3>[O,-!=;,?G"=Y\ !4?L*F:\MZ60':U6Z
M)UEA9"<RBY>$'RL,5&BSX;D958XG%D^5:%QKB)H>NNL*\ZZVD82'*O545XDL
M?93L?_LML6D1NFURY%NDU?19Q(V*]SV\FY,PZ1: [8QU,:5JYOO&(NF:XQ;P
M00@S@*;Z5NP]+![LU8IR$ ].%)EIKVOY,Y9K\;4DR98KPP7Z?ML5K=]\,_0!
M*&/?9#G<=5VR?ERD\'W'6?@>_3!9U3V:Z"=(38\D,].8SMF)$+]AP0V98?8Q
M'M6>]=HNT?[3$:VQ/'F?A,)\8%QWGK\7N <HMJD#50O5A2FJZR7K'>U"*N\A
M.611V[(@@'4:51&H(0K\KZS>(( 1PP'P1LX;? <6-]IRO"G05[(R!]RU#,?7
ME'\SOXRMZ@>Q&\ZW2#D2$.$%L;<;]/I5"-)EQO:M9=H"EC/18DRAU"N[?67/
MZ%56D#!+TJ9U[6_Y>QV]XGI/TC_%J'B]GU%@@X3EO6J#S8N:V[7L*EFY+-^7
M:*&!"5P0!9'J7&W;S%<,KHAVG8XH71KFD*AM]?ND6DOHV5HJ+3:\X\1C9CXH
MA11\(@H8I?S$OC@SMV6X:-'I:K[RH$-ABQBJQM.;[@W3E4R%A'BYO5G3V>@J
MOPPS&^/M5.6_U%5Q3>H^$,=3!MLR,XZJ)JFC\[025YE3)Z?6Q$B6$N%Y!;L&
MP7.>55/+/L;N>C;Y_'1O^RHYB$?>K#&)O@ABN>H&ID6VOH$OHH+$B>45_*#B
M]1"!>7O\*P<-+Z'/J7/QCK.!25$JM$Q%EJ&MBIX)7:M8'R+:Z9<K9AQ_VL3L
MNK\L?Z5GI,.W1; [6ZCY)[.7@[S26PIFBT.H*-N5Z2O?*@:*U<4=4D-R( :4
M6R7HCZ.>"A5F:8( N@B%?A3=O]!(0[+./UCE\7_8&BM%GB>/[^#,;/K_%9Y[
MUXA!@**RJC@0T3E4F^'XVU3SW37=5_ $:;'RQ2A;'>K7OO(;9ZQ_)2[3_" I
M[N/KHR5=^_2P6CQ"^W^#+R6Y#5N.VQKWHM5R.4A!\Z,XSV+(A^V/Y9U(59W?
M19T!+V\!IC,3I)=$[V[ZAZ .*S0F<2%"MX#'AE\?4@4JO<_0-&3+C#1JE8#+
M7,,4'ZXPJ,;6%N]S",@.\<^/LBJ-Q7==Z(>^H:)XH)X]9M/[8U<#<&K^*VRY
MT%VP\>NNL:;VP]$)UXAQIO08*47J>ZE[?!!)/H;AW"8U$=%V-&SZ$ N'C#"W
MY;?Y9,\',W,AG0^6]G&KAHT"B1^>,48;B(J-"/WHDP=CA.5LF@GRR45_&]B:
M?8YJ3R(4_VYE/HEK8\D?#GN$/;;CTF&")RI%;-3X43%D4:*._L1Z&<=ASO)Q
M78H0<(_<O#X1I1F<0IH^IM+K=XIZ^^YM!+_$&]-X#IUPWY/"3E;%]HOFTOTN
MJ588#K?F%"-R(C$#7SU"S@)?S:T.('7YG7@.XIW- -?_QL-EE14QE<O$_AD>
M14=0V#W?LF;/:/-PBR.=T96*K6!(D<3>,JR%-G/41K8(&,]_/JH[4<[RNA<^
M30'RH7F8D*0G:3LW2AAE+!)STT".EJ\4VEJM:SJ'S7^O"%V*)Z@P[ C\EJ2K
MQ1TF^R)C4Q;]"%A 55)L-1Q@X%;5)KC.6LV\S(],)NFR\8XK%:W8]?9Q(PE.
M$0Q[W"/F$LJ<)&N2*!O8O9"$^#^4O658F]^W+1J<4MR*!*<X%"\NA4#00/
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MLQ)#+]6,R\IQ6KC1>Z88P;W,GY8Q DO5R*RA.R<5<CC P.!E-T%VZ!B -7=
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M 9;MJWE@ML59]JO=E][DP:([%<>A-G7X:R<#C_"F$2=?UD)+^J*G5W>HG'%
M/4>:(-ICTB55O-)SY"#+R>]E!UL#W\U-@I@(P8T(!:K<%R?QQ>YO9UOH";[3
M,)^58@,DL"_'(6SOL&LVISX:*=G&NP'.RC9"DO 0KR7MD@G16UDL1K+<WPHU
M/L6'XLCL5"/DL!F-?WI-.+8V6D^B>-6MHK\4;3/L8KBKE[5L!G:457B>>+H_
M:32$BW-Z$>Z@3$FK5H1BT<0'[Q'#O+?FY6_?A!=,$CJR/9&450T(R7X!D)K"
MDAMOO<2"OXD.FI(<A"EM:]RCU"IT3#M%6!8/U>H26TU'C+"?<R":FC*R[;:P
M.EX:DP7;ZA[I832OE&RIX%=9@H<MNH1^.0S=?X;7#=%ZZ8C:/F)-M,7OPX@^
M5F.4UK/9DI"9ZN*)M<=463W6((^4=>08!NH57)'(<F$V?B,J,U7*2[8\/KH'
MV?/ULAL*A3SO6_,Z>;<:C-MH_;$,<+G]H::H1<X3O*OK'^8Y?E*ZF:<(_5N^
MYK=;R^*A+)?&^3>S* ]"@13W<@WK44FUXV]\<=#G#";Z-5'5Q. #08D'@-SL
M$LUM(]D 8!#AQ0CX=+FP:SY"?>HF"V$(F43X=AKOA@+6(P<*"F!<)P40Q^SN
M=G^@?J%@!P^(MJS5E^>3CV7X9P.G=AJ9VF0\&49A#]BBAX$ Y8:DS+5O@6!C
MM%*1R2!O6X4*/>#=4Z_S?LN7N_,K3!3FQL-TRKUW+^7I#F'DN\VEEWO!C6'K
M?N+7GE==PGQPT^]^-K,#L'1TN/IV8\/$')D6FS\H7HA_1FQT/R#O8G00^?W9
MPN.AQV",A;P8!R>IV2S[XQYL^)'P>Q!>]@95!=)!_-HGV[T;3FN$%]MYEI):
MY)2W#'D!9@4UO\=@5=9I.>SN?PF7P521NBB4>%%"PHH$SZH"7Q=N#P.;/TF@
M;V4P /2_0HZ2S$U6YSDW $9ZO[=Q0V8&(9=:/H7A\6L@2OUD%HEBCARXI@Z+
MD"KM):*?13Y'D&Y_0!6WI>NC_.=IYTCWX.\T56.9ZW)L*KUJ];86\M,S>>H>
M2U$'-C]V3W8SX> ".!A#[:9 KBO&D;\?=5?0/$NIQ"4YC$U2*L;^_)B>J6XO
MJE7];PH:4*2"/9K[X9-=*(VP778^(:9'&S9+5B:8;EKS=Z ?^_%4_=E\6=G1
M>@0>X/4G=Y(@).IY UD.R3\OJUX>>[QM^IAV@XFM6NE^'-8LZ#@72?LAZ4U$
MG(%<8;K#U'N^@W.Q&X/,*R^LR,6!H(^50\4MKZ3F?6='N35ML&;@N>A1G+[W
MKT9X3R0@ZW(E.;9(+1_^7K[;J^S-@%/]AMGX7\L)+Q=&UM]ZCOW,4H-^VVYS
M,J4*7Y  ![+^WDCZ,VUJPD[V42,B<ABOPT&5[%5R-O?A0GURU;@EH[YRB_<C
ME@D\/:@J]1-[-L:!7!5A@G!I.GT=RN/H:ZAH37F6ZDOND4<R9XAN-DH!_?/U
M)#JECS0E5&?()#5P %5Q,SDPE[Z6P0&A(&WL]>UZMFA7TX:H9SO32E6H?)?0
ME>@BAZ6I"RL#3Y5IV7*EJ";'S4:ZUJZ2J[<:E,0@\4L>MDMHVV)!T@%%-QB[
M;:PV& $"$Y$K>OH9[\IDIYKF,3VVQLG@/FL)[3?P&E+NBTJ<ECGO*RAO^]//
MH#6[N,C;H+VUV6<VTI;36TL!]=D$K\U]!1SGRZQ+-&^?\/@^*SLT"::+LIRR
M>LSZ>3PUD/'=1C5"53S*+_"E4WOUCW-EK*U7CE]B33MX#H[T**K9*4Y:D*XV
MRN5M7MH>4V<X5_%!\F2:PE2N^(.!\_(Y&L8&*8@@.8JO>JEN@=<&R5,LNBV3
M[H,,@;UJ*@/W"S=L_DP%>_(YZDQ,D("-;;K<=_?>Y&+G9?(RT*!-QORYE:P*
MV)Y[U.'6"MQ])?^:+O73>Q"GM;EI9I)?0?EB"\V1-KGOI'J24Z&A*.YVH9WT
MFT+)1Q*B!%MA&F 2RHXR0A$5^Z)_=Q5S/^KG%XH3Q5=QM)0LME:0V6G4^1P;
MTN?QZ<JE86!;<E'X67FTC?X/.\'0C[C]-(Q?RI<TN@98(.##DRZ][ < SZP?
MAO\^#$5,^W:\2<?.XTLVAMI%E/XO/+E9-N%$@S2\VG+/>C9KSH4*KT?2CO:]
M(6RWB0*R>ZJ/>:@L"&IX%'\1Z3=+WO1&+,V(T1>X.(_1$+^(R-U<1Q2!Y'T/
MQJ8VDK1G2V8^42O+<X2T!83 ]J&"2 9WIU2<P4\J&P\ /K;-(%A;/S;7N'*#
MU,_VO@P(3>4DE<4;4QVVZC286C='W:W! X"U\Y]Z8%_4S<NT=U".<6;XB.#O
M@Z,KJXE/UP[E_V6:#4NU_R]M!/_;P+3*@I2L9Y+.:+$6]XO"L4&A$" =M#@B
M-SBY!8D%Q[9=44ZLHB&\F5,6Z<QQMW9NL-G<Z)0*%IN&$(Q?1CH)[$!.J9J
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MMG'JFO96V=F,.67LT>J2>]Q_\) ![IPMNR]P]>F[>TD0&H^LYW(W^"?5HZ*
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M1(=-!CL L%=S>=QQ><6=H^],5>OF4,&3_HQ;>_BK957>XQ5O%,67J-'>B =
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M,^%N$Y- R(S5O?=7X6\K# !F=RDX#&^99B,,)/PW2ZM+Z6#J:H"PR.$P+@S
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M9%(.SS]X.$LO>)T6YM>]VX."5 M[+BN :%'%<(/YGW=%Z\2C)W4Y8]SO<TW
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M_M<[,[_WG9DULN;#?)B3==?*73<W]^QSS[/W?IYS+WH>O0X@59)3E ,\> @
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M:7-DXFJ-G+KO*4A=KD AGXI4%H?=J$T(KO=\5RBWLID0 W/4$TN']?$R1&%
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M&6>.B/I!P7H6(O&@6,-+I ,;OJJ*+%U3W\O6M'TMW3!96*$Q.4:=52TOM3U
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M6]7>,%7NG!O]_-"-(S4%"R>(]2&)"8_L)N)CPRQ<_:V%BXN+@ R=X4D\E37
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ME$(3'R8^^I>7H(C 8;>Q8<Y4I<YFSD4]+>PB_-MA_7+8\<3RAP;7%AN.>5'
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MU,DCW_LI?;'>M[WLMK\XA-DG=B%TH"V7?V477_#>(,_D?R[+C4@)@0>@=FC
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MY(1/?Q=ZSZ8JL,Q=GVL'OQ<X&0.GPL-->!&C*T-R+FOE^CD_:T;]^<\J,6)
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M73T8]R7AD2<9B'ZB;87F^'XQX3*JZC[SW9F+W5P0>IZTAP>,=[DM6/PXQ)K
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MS0;LA-XG*UYIUX_%X(@977W?N<FP6E]#+&$DX6]SL?HNZO_J.X6+IPE,I"9
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M/IXJYV7JE\<0$,J,^9\]M>S_=(CTK1G=A=W8W7L#[P$P_N/B3CW;-H;[PT)
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M\"W/W*2Q^:SKC9NJS-4I(PDK$UE)S0NV@(%\\%\-'V(A2YQ;2P0B[.8KI2[
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MU7H=%Y <6\D"ERJ>AQ9LU0?!Q;G<L[]S1T Y5#,*2]Z(6.;D=H1Q5P9$<:J
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M$]D8NG7'O4;%W:-B,)2?.WB?06T\1/Q\U"$<'U>RO<QG;0TWZ%-J;\PN 9/
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MM@N8R,ODN7%I<S!#^X;<,1X I![,DSH@-(6BXY);+QDDY*3F3";?80(   &
MVI36[Q?ZLN N8CSI M(+ =(1!8-\V?^JGD0!^;:*)1 IB"\!Y4/_H^YB4\1D
M17^,L >,7=OBE"=%"OGY"NW[=.UQ.]=YQUYZ7J,'$RJP"T11<5P;F0SQKU!Q
M':"[WZ&\,+GQT:SX7Y-THEBQ7R@HYTDB"]2W 46S]VO>BKI%WY 7K7E^K/GR
M$$ZAQZ__K=(I(15YE=OE?IEXE@N>J^UO+_/QPUS,JDICTK < 777%]KZAXZU
MPIPCN%2)D,4FEJ^VX^;I39%HT_WFH9M$R1AJ.JEFAJ1<,?M2%JI_Q7AD-[41
M=B5=E-JXS$5\*QO1. Z'V ;^1'5UH83T)18O"6  XU^_IUDOWCO:;)Y)U73-
M*9PFS-%2<IT^<]@5*(9@IFJD0J?#$D K4H0#>9&+&(P)M7WD22;ARRAQ6ISG
MFM8O;L%JG2_V!$7F+,?E* Y8&I0E _S%R:O^J0(D5#>%A/+%C!*]-_8&_$+7
M^E*1J;<'4H:;_A1)F_.J?.84OD5SHYG&KUH]7;W-OF]V!C8WG&B%-@6/^TGI
M%:32J8E4:DM8RND&$JIJ<62%YKXNM22NPHD][#RUT#,U#'ZJX>>^,Z_R%,Y4
ME PJ-"_9^;U+[K4(*5G^L0[7MD>+_(8Z10ZH^T_5<1*%E;@UO1\W.X6P*3$Q
MM(OI/)W'A:C(YL5YO.)++(%G553;$5N :&*RH1>D^3'2']U,;3P./N$PS7CI
M9KKY2$5I3!G[2Y/AK:15[-6\%\@?8H'#PY+Y6D:262BD3T#!JQCD;.RJH:N:
MAKTB1#8>*WX"ZYK"1T"$OF*3IWX:Z!4754E!% WZ> *:Z@ +O&., K2E(*4Z
MR9LFK%/%[^&]KDV\*VLN>25+UC&FA.O1F['*^.W@,*)I3^4G2@=3Y-YC@ '(
M[$E\2_^.&J]5FB9*!!+>D[.1.C7HG D4Z1!PJ+(K\S!NF#QA[*3U9;S](CK;
MZU7(]P!8TG>X&<]FK$1G*IV=5M6%Z5W&F>7FY3L4O$M40I&K6Q?S /<9_2HI
M9@\1(YIZJ[:XI!,RN$_T(:;9G?'7$(!))6Z:QC%THBHOJ_)MLVK6G[TW.89&
M.?SE9-%TQ4_A*(+L$=F!HHIJ-2=7@>5VB8/8QL1I*5;^X47*OXP!XFF4L?N4
M)X?.\=J\3B>HG;6NI>9\%<]_ZEL_E3%#7_"CNR@+- \\Z.D<C,!07'W77FA@
M+K@3[IJS.K-M);<_G$& ,![J\3!U(3E5IE0=?HV-"ICSHZL7^1S!&"S"F(/0
M6UB=_/P):C*<*#U_%/E3++VS4.Z$I%/5(,5E)O,M#E=%$_O].0FPU%:YZ,_<
MCG*1G&-0#]W9QX&SLB75\*WC8J\=QY;O!A%G;$/QVOSL4<WLSS+LO%^7O_1?
M<TTZ%?SR7XC[ZJ"XNFW/)D (P8([A#06W!V:"!:"!F\DP:%I)#C!">X0(+A+
M PW!W3T$:Z AC;MK<!V^>V?FW7=G[IOWJJ;J_;&JSJZS]ZDM9Z_U6WLOZ>BX
MY*W_+!Z&0#2_RMMQL7,M-)*1(+P'E'Y\M[L"XA$!'L'LXR:S83*;R?FJAO,S
M6TA^0P.%M9GVP%6O_-JB;7O1<E$0J<U4[S%8<I8]J_>K^S*SN6N?6D2:151Z
M\4)XUL//ENB1%&SK_#+PMY#OC+Q)\* YVQX;87W4D[T=[=T42.K;_C-8X2 \
MZABQ3[TCPK67Z4G<6RD[(S^;9TI#YZ$QV>,I.69WLB.:-TFO3NZ06;G;\%T"
M_.P&_JQ7T\$ _A:AW%]?.SFM)D/*A!N?KXUU7G)**A"4A74..R5!^_Q_*,#^
M9V<SRE6)^\>F0?,,2;'# -(_':WCS6K+3=?EA#L?]/1X7?R00O$7K9H =%^L
M8[B5NF/3KIEZ.5/LB3/I\,PV%<M73_["/E=8,9B##9BH?Y 4L<IM>-DK,J20
M=S'>U;C6]_OD5OVEN230S/)WJY_OR)):_[GBZ\O$H6T[-4.9HZZ[CZ"SHWM
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M,2#Z^^OB :)H3_3HHBR\BB.B3A>7\9-(.[5J+58[CMVZ3GD1$5$,OVU,F7N
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M>$-J)F\8X#)YFV?>E$BE>*NQ9AM3\T<V>VL_GFP3F" K<B]<ESE-#*HG)#[
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MC5>V-4]1=2U!1QA+WSWH3!'R6U^@$E?DC\0R]J7+_O#VW(1-UI%*-_8)7%X
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M@TG/5T56=_3ARHI>(J6NY,+9,YY?37,"@108IAFWQ4E^3$UQ&SUQBK:Q\_<
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MC+#+0WYGB!,3QJR:^6'9SGKLK^QH.AT\@TR-SU1=Z.EP6 ")6Y;M9$#=8RO
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M%!*:)=9*$BBY8.\I$Y*1)\D'ZBR?@S&^ @OD/K.GUJ2^;WQ BD&F"&=:.;5
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M_737P%R&EGHM:>[8;+L!EJ=W%^F[+356NIO45AK?SU@'3=JJ%)@YW4C/4);
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MC_3V2_P%\A&!^@ ++G!%?QI/?]@S/(QUM2<RFX@AB\<2<9W9R[8*@Z/"[U:
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M0O>!(_\0 *?LLT39O3:2N\_;TO(KN\E_/\S28RK;H^RZSK%+\Y^3I4'2V"G
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M(<>+<K J_4O'BB4-R8+?M/)^O[:HC_+U)P:YUS0D\H!B3=,J2#;W<8I5>/%
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M FOD'FX> <?TOY=QS#_4*S2E21 ]9%?;CX".\$< I>0_U&OD 'IWQ&;+V8\
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M@/MKEG>(FK7R1D3L"X6(^)DT+3 7("FR3T[^\)LC,)9YB [%A 5P.T I6\%
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M&D;!W$&W-PG5(=\U%!=@=<S;;(N[#WAUZ1P1!QEV53]^."Q]=^7QW8A5:?.
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M/3<<A]RJP7R(P'46O6Y9KB;HP@JCL=;>8V?,QG6Q$ BVM>N-G4SK?LY.MHJ
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MQ',Y>FJJ-%,B0.J0+]<E!=&UAVR#A]R@#+[C[4YD0Z+HTAR6*/%XA&IIO+Q
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M]QTCD+]"7OI^#"@=IUQ'(8)?<6EF:HY^R/ M0/G,6)D3GSLC0QWGS#-U)NM
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M";CF%<EU76ORW@#^6%E?,8S]& SQD\7.#/K*9/(HFN8J6=S_\:@N]RG=R;I
M,!8I3%JUHB.C[KLCDS$S(7=L 0N,/D'-#JU^@5J^S+L?J$-RR/$-ER_@\_;J
MM@'>T\[;9J$YJIJO&)FT?O@<5,"M/N= /,TVT)C>TJ397E_4/>C9V/Z9)7+:
M/V?&<]?(W'PL=W<;4FY5/YRY?-8[/[AUO;.URHK)$2_?D1@#E4"R1AW[KOD<
MHD,V%V9O $HTN[=#?M0MW #.]]@N1#WN^7D#*QO*/(6F!A13:#WN_UA37W/7
MO+T\AM!7N?WSMYK4=CJ[1[[BVG=O-C-7>IU?T0:@DDGS0^E6 JT;0%<KTDP$
MB_%!KD@'@/7Z.4PM?W;#07HZ)5;7GUAY6S'\Y/'UO8EBJ79@QH1QK,%KA;F:
MZ>]T'(M/D)>+I7A?M5C%?6!&&M_<I+<;WV2]3W9SZN7KZ[R!ZJAZ[KD]+RD^
M7!UK71ES.\+O]\!HX3U$_-=A/?_%!IT&S\2>$&'32[IV';X0_9P]Y&7\N<!5
M2,<-H( .)4M\K<EUU>TJGSU!35.K**1%%L]2\\W62\*./4D12 X";D\;Y[DD
M;-BBIJV'3>\&]97-3' ]J4]S"U&^JY.!TUXI&ALPPR^ RVK[Z0I'Y3T44I\@
M R'SVV8W@)Y3\0PQ<?H,9!%G*)2=/ZY(59*0<!_^!/377H* .=,9]C8IH U0
M109VO,+.[21 2_OD;LCJ9_W:ZB6*IQ+-Q1'%E9A6'<6FIY3=(?><ID8UX^7&
M<=AYS.HJ8"F8\0H,BUI=0%%/7+P+63M?^=J4BYMW?013+S&:KF6G?1VDR++R
MP?L=__4X5YI%Y*',]FKPY:K/3M.P9&'9U Y+^6R)>0['[(%AX0W@V_P-X/>Q
M<>\&?2_V^RO A28K+\V,!7-[?=:R..?EL+3?;+OD3#/<<\B)*Q=<A@N(MH4Y
M2/IQO/W9ATD=+U/])?_88@=VV#2)][A7W<:,SQ@=Y\I='$*&\(@^Z_&E>"<7
M>5"TUR*,A>KTNFNQ)/UL&(E0TZL4,@^EK('+#5T?ZGP:M/.5112^;A&BD3CZ
M4=)05BK8Q!?DH34N]SLK^[1QO3TO>[_LG?]96CFGP]^]= ,0+L7;>9.Q<F<P
M,HD&-$ORS1^J&C1U "Z A<'I16YET&9M#.5D(- &XDFGEDV77N?8)R^QR+#[
MV3CGEN*/N?'4_\21X-3>60PW5YU)R%-"OVW84P8;^<OX]Q9Q3B(=EZ,&&M;N
M>'[SYDK0*;UTP^>X$7=>&+>CJT3."L<(KW*QT\KU@26 VL0%B=TIVN^3SOX1
M,),_LQ;8S(N_)DGXN*,P3[<5%;_8V-*8SJHC.@XR#9,3; SUDUB42PL0__7.
M4"^^:F0ST*G$:OH/WN><%+1<KT4Q8^6X^*S<0- E&<T(=-POD]^+@\KX7!#<
M ";!Z8E&F*\U8.YZ4@3BM;)"W?.X, SMD&1I20NJ*8:AI EF,F=9PY%@HBI+
MPQJVKJ58X4=B2-V*RG&(#5EZN1=R%:#U3]U7D*\[,"]<YK8WSXJ$0U/R=Y9T
M4PQLL;@%U1C!8-\$4_]"]")AJ?+U,0FE3F?T?TN[<CMF'F. EN8'UN'M/XXI
MZ:;!]ZHU91,C1&:T!^:>?;.,%]&VU2,V(JR>:."I#M\]ME1>B-6J5'K89JYF
M'*_O^KN./6'ZO@4M'%EATK%DNI'9L'<#&)9P!=(?W,E/U&N/V*]^W-JD6?S#
M*<.(PG."[S,F0,"G![69I6FYXQHH=P-(/@3= .!5-X OHBYXUZ?\,H:+S(X&
M+>CUT]^]814U[N]E-\.13;FC\UP-,'5[Y?04,9[!(_9D3> R1CP$'+-BVS1M
M/F3\Z. ?W=A?D<8_)1RN0I/YR=)TQF3@<7,##*<D3I1.PN(_=\7#5.,7Y%NJ
MM6HUH^/)+[8+4]I.? FK-FKY.5/]Y?\MWO#_%_\AD_&X?\)T;_A:@R[S!@ )
M.=+'&.#9OA:Q+:B-L?V3VKB4N_?/WR*#!YACLG^K^D5DO7],?[%X-A;M?+?O
MW,!Z-W%5@=G@7S2W_UL#A%LQ9676Q=FV$Q3A>PHDTJFOUIEJG<=W'_?:V$K8
M<<E7.6T5SV_S?8WMUC<TI+O:WG+\K4*;]<T0:&[R;60K>+)T>&EJYUZ[C3C7
ME\Y0YV/WV0=9^EW/I;\9FJ_=XY@C0+T7F,1O=AE/.($I2D,=)%0RN&+=CVYC
M",WHI6;JX<TVA5(:K@+W<6*OQ !A7%R25[PI^[BZ?+ 5,%6SIJD!4\\;J>A$
M6Q%M(C=_:.>))!09OE]<FBNZ5RGFT7=R"!:Q=S+VJ!X0EP3B^_O@W(0CI7#!
MG>-=2F@LJ*%]+-.@#F/GJ ZVC5YPL;V/+#T?KX[2V@"1JBWP6C)-..%&N^-V
M<#U#@+YZ@)NN1>)'T<WL*WW#4;@W+^25Z9D;^3:J]$$%89)/3A.13<SP7NMJ
M3*!N49\'MM:DAZR:69TO1:WIT?!;@"$AZ??^AS# ;BF<Q_P&0+4A)SYVI E4
MDM8T>12A**Q0*V)JI12&J9$<=&"&;AIN\U\:BT<)!(I@Z]LNO$QO (BV@3;[
M7A:!S%//W.O>]])8WO2]ZZ_E70N6R@ICU>QMT#>:G_A?*(G9<A$))4B(TM7Q
M?[U]W)':BPU.:[KZU=Q%3]APL,JUUP/P/C*F!2\ZJ75]6+@WGZ#9\2D0,<]J
M>7%'-I'XL(I<6G-?;]C-,V1!XK.MR(F3[0?!&</KTT4%(!]M'^FV9S=LI01<
MY*R[[B/EE7\GS;QR5.N)G"OS^]OF(Z(0%>_-7<J-@QYW;PC3,/E/]ZW#?!F[
MS"\/]WL SHZPF896VU.C,A[55!D.#8"D?MA([M-S>#6X0)%L(MB^WUZ=_BW=
M67;)O 5QA/>DBXP<UC[[P5]G._/TUMW$F7A?3_9S[BM_8\4%YAEKA1&OY*MB
M- X40B0\+<(M7D'=>)L0$-QV1#"A:Q$2Y:WE+F-7O'9NV*W+.5-1ATB.O)\4
M? ,H>TA&\-D6;71H.2*C6V3B+%7NG.&?E4P@-DC=O='$,-7!9@;8*H6SF^T_
M0T-S%U61$Y5>ZBZ+JK"5Q3=^P BE_*9>0*].*_\'.&[#]SPW[ H)\941?#9^
MGE/.?JOPO3+WP YQXM^5X79]U*2TI\527OD*X<)PAYC(?9J5ISB] KMYWP+D
MM ()]44&K1FO6C4>LTP ]T:'=2%TI WCG&+Y?D@L@TU7SD\A:V;4X7B54RXO
M"KF7T5SI+' 24=.:*S'A:)U&=1_*6E)M!M@NA>MK?=NW&S6;G<''<+=TUH+L
M@#$TAC)I%-I;BZVOLHW&1.5I-Z3T\*% JBFI2BK16NGIIXPXTN-S$L!.:3G,
M1?R;B1KK5Z],8\V<0XY@$U?H68![S/]7R".>ZS)(\_KLVKO.9$=^U.X&$/A/
MK[=<_C$?N70]_C%WJ5>$:_^UB$>K@!'>R:8$_W#S_H:>[/2[9[]2VO176008
M=SN&15?2J6"YO>E/![(1H3'<%<(D&S> >8*V&(GXZ[*"=;3&AW'<P:[M)UFA
MY^X6+4((:C4>&X_G;_)>>5KNE#@5X$]?267D5:C95%C<?O '=UD^!-"M.6?-
MD937&()4^(B6T* WAGCUT<NC]8R5#M!<=6W&_* !Z##Q?GGZ-)1+^4#&)J@8
M3"<H\LU,PXSQMP7O:RI5#RF6L%W38()Z9,M^6[:;-Y%^Y]9%03HA;V"<'W&8
MFFSJ :7]E)5K#X2ZZZ]N9[*O\3NIYKJ0(A ;%O#-FHA;LBEI?6M< .6K@GS=
MSYXVCX;DO\_X"/SZWN$,ND:I$=EUZB,GG+NJTCQRU QBG<'A5@9F!QQG5%7]
MSL)U$$[-6[$GH-+)C2$EH!BC%V^.2CTI="7"4 5A<]%/<,W)&G9NY.U]'I13
M<<D_MH/#TC4EG(B"8FYM4$R_GU& QU!2S*R=TWT2&:98A\6/_4)-6^J4?AH:
MG?YHZ,OP?2, [?U@MC&=GM>\9AEC_!5\38ULW&>+G ^]6UDX!J W&I&P"__
M/#"7',=*K,V36[, D7\YQH_X)=UE)FPZ):U0[>FVHK&L34H_Y!^'-A2HI2X:
M#+;W4-9!29EB6@I.!)\CA99"*GG,&39'J TK?O/5G];CC<D67XXN']0KNCP
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M$@/J% ]_L2,9C16VNAFM.]LX\UH'AB$*'IZM0 &"[)Z)[;_"VQ\/S1*\)V$
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M-B 2[O9E/B>QM9-DG 8\/-KQ_\W3+U[<P2*<8K9[SBJJHNE..;E3]+%AEV_
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M&C;D<F?TFO"UC3P$!&XB\2#9&T!O\P8W8>1>>M4!OL^\K7'46AO9%$%-9 <
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MM69]Y6X 11X&!HA9O44.I+'TE!O+9/\^!<1YX=[C;[G4SNZ#^1" X+$DRU7
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M\;K*[,]T*\W,P6.NUN0G[8T9PFE^IFGGH5J**K1E2;HJ-'?_8YH.;R7>X0;
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MI+POS+:Q>PEQHKB)RTK/DV9K=J*-_;@;K K'ZI67@))]=2H6U?\[TNW^RB-
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MF(M=%3)L-U)HR(\(0MU/L!;$=4S)@<8"W>B;N/@0XR2?I9C^C@7.7BR!0[V
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MU=G54I4\5_ZD5$_LM-PWSF]IL%&C4[466N*P$S=Y794)![?FPSACV*!+$<Y
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M=T,T/K"JH110;E!R311A5*@SGSW0B?<9N^J[6+X6!'B:O5=>*QS7S<=''$#
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MRC6Q'SXKQPXYH@($02-QVO4*M& K[*IO_@TEIQYN/G>5=3.T-ZGN>M$*<T\
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M[\>O5%E13G0I/R83<'RCN^NZU30I-_2+'1V,M,]P5$8KI(B[+,/^H*O3%3>
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MW!;:63[9]K9I>YK[;>FV9@F$-+DT&S7#G^+Q/.PUUQXE6'=!^+,K/4619<#
M=OQG.?-W/P%(E-MOVU\!8K7X'N'F5F_>\R01/FS3P$:]YD,X=\]OBN<=;9J0
M)Y.6=.%=T$6ZKJLT)I[TBVQ'R ._X0SB79KCFEZ?6%L@%R9(6[7$4KH9+;O<
M9J>\-$'_0942_$C_EWJ<-[(:TTRP:#9;@CA?J 0;7]F)9#/G1GI']I("Q-WH
MC+"+3/Z7*47-4_E!Q(5CV-PQ0N2^^<"? FF,W=A#@T9U];(6/VX!W[4$MUF%
MIIK!27&</R1";@8HDV3SOE]3;BGO6?.29T ?X)WO]MH'U>B#E=Y^#T 0,0"=
M#XCYV$HW>#NA_;K<(KH)&GR2>F:8L-V[HF^#054G07(/OK6Q=7DC<U4/(G_W
MD TD^U>X5&JDM.AG\#^1F)HG-\OBLJRK,_D JHS^:LS;[S/S!(Z6GML#GY=2
ML^PW3_:6>K&BW?@%"EWK;PPO'5@[JDRH^*T:S!ZJ(MVB50@@Y/U#QWIL=!%J
M=;%NI@*N9-VQE;:]'/8^O0\&A7;ULL-36Z)E=B6C" C%:R)/#(?JU4VA"K8$
M6G-S6,'8HGD>9J:D;J,J$VWLA5XNZT/3C%/DDN-TN^M' XFZTQ!$\7*]O7)1
M=\H<SHB.CZE]'Q<<+RBYG'Y+_J[>!STANI$$\_<;7C*-OCR #D2;CG,N<HCQ
M<YYW7DRJ%:Z@D\/#* :[D675_67W#3B[ R/>X&QW5RAQ$9\./K$]L;WE_8SW
M##3R1B(T0R[!3F)@J<Q[%FVTGUQ@<H135CE=(-LR&M(.V:F\:5OO4?'.Y@A:
M0JB2@G0,O;1D^YG;U/X'4T7]=[3+\,5@WKX>Y8W T.4HA;?'S454VQ1Q1,'3
M5KI\*QE70BOE'&<Y$7+OZKIL#7L#IH2!Q F8/U%OR5HG-*)0M_-#N:[U1DB0
MM,;C6C0KD>*CX#OM*0Z&C,B+RKN BI9X$F@ X8!%YZJB!LQFG6F<IDJFM?04
MRN6R;B),9=J$A"LU*8$C@?WF *'(-3UXN(_L32>%[F6R5 :A)E4ISZ,(P)UW
M5$Z6Q-'7TZAFY[9LQTA]TC73HJ;)_/<8[Q&##)VLJ.>V2R86_VS8T76[#O\&
MF9&*N8$([^H9@P)4$'EV:==AV#X:]UDW2E/^)OCE6(,]D_S4)<%L1O63N']H
MCHP?4@GXPU]C^/5_W$Y^<W/$TJ<42^2"^78 VYF/EC&#QT78BCW]-EEH,?\\
M'@?3IG?T?D@E17;?V.%U2F*LQX]7  JH;F)>TI9 3V8^%5E@X#$"]-T' Z)W
M:;H8RRQ C([M"BM73$HEB+=JV8WI-&(^,5^!+AWT8!!X:A!%6\T3@#8S(OEO
MYMIX:8.4X&X;1U_ AY+G37G7@N6>7^<AL&/J=$HOR_"VUDAK'B\]=Q7A^#]B
M^4TQOPK_6-C\-;QW_U<L[)N[^[ODBE1N54H6L:)L21YDNG]VFN)U.-O5R@V7
MY:_90-YE8JSTM73]5 +NG3BH:7P4%+QC)YX:$DYX!20J1\-\/M+IBC>GS?@Z
MN4"XLC:G@+$I/I-/D\*J^OK1T949UD1%29A=CKC=_4$ M0T   [@]C8E7.:!
MZ;O$4OM?[?I'PC^O)=FX(46"![EP+X!6-T?H96N/LQ?UK>7C"8;AH<8@/4]I
M15R?*;R8<2#JL[,**Y43QE3&V^170'I-*F![#II623*R(DWI.>IVV^,'177M
M<^%F+#UMW86#@L/2;!@Z.;"9&AY5AGL#JO1NCK4,'54Z6R3B'K(!3S;FLV=!
M_0*%5[7(+(]0XOQ&M4*C"^RY5$'ZD1&[K<>OO:T2?R!"6]_0ZFO!9V:B77Y.
M#"'XV14[=3:J;T$M$0B78%=I9X=U&]W(5*@J5*N.RR_63@U,;-:F<A#]T<?5
MSREQ18H 632 Y3//H?92<!<W:N$3.+?TQ.]PPN ;0W545*#"V _70_4OD:Q8
M]A04U@A-')R6INY45&[?[+W6V?-,1 2X(1[X[A<M@:13./U(A)H?JF+81_4;
M9N3@@(U?3^AUH)*J%0=<#]"8+5Z#:>70GU^,-Z<77@'>?M',\5O\/]W?30J(
MACN6YL ^(_5RF\XJ6L ,A^K(Y@GM'Z[2ZSP:L\D:?607GGYGGJF@XQ'4T9V(
M4S44U3"YAR\JZX6$5^H? G_HH+=SIU\ZF_I+O/OUL@WD>0;E&*K2+I0._8_5
M6 S),VW?/$N/L*PZ\#$'W3+U#9I'- I> 18@QS'P,?[L7'OI8-Y!(H?&9%;J
M0P0(H<(YYP\P>[;,M'C)^I/SLO5%&$68<U.9X##QSAQ8H*5]I(C_(+S>$57+
M^L-OCX;9E:<5_17?*1F_<>,3GJ*94_L*)LHV::&QFJAJ1M$<1XC-KSTIS 6C
MVD#;S]J&]<</ZA5!;CP)]EEI,VC0!XLD79?9B'P9?/+&6-2Z%7GP2O]D_1!%
M(/?C,.X^S42BSMER^,U64CD[H>_HVL^-V"13P<,F3V<) 7"O2[441DIN,_RE
M#6*0 +V%68PHKXX3M;0^<FWP&1 _.K[#I!= ^]'"('=-U^7(>V#(5=OBRGK
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M"\HJEL--@[._*NP17LFWM-.6$&JR._-H>.-;(!THOJW_P6RNDB^><9S#6<U
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M/\60#$.8NW7S49BUK(33E"_U)&YTAQ%<[IKP7:(8",F-RL@,B^4,Y140@'.
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M2<E@F:JOOIR1#;6\;&-F=MA7,%!+@ HIE2=!T@VA=I]D(J>_)?W^J%HI(^+
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M(U,6#3X @*?0MHM<MNAEM0JDJ* R$:YD[Q,1IIHKW3 B_ZB/;%_@&. ^IN?
M9Z(75U*[ %.,7P%J]0_B!&H8,@4^99#Z[C5<L^86\Q7RV&H83765*/T@Q7N]
M!*L\_:G?81T5OS3>C5S:7/VF2)OJ9J_VMH_E;<U\0'8#6B4]%RBK-[?XZWHR
MD#S2\SEK!-(JA7W'\5*'>PO1?B/.>'JJ5,&ZN9QBFN"?QC&'F%D;!./T,,*4
M%BS/GODSAH=M;Z@\,ZT3D/I.VBD/^P'P3BFMK?"]Q'&_CX;=?)]4%PT<=F09
M!9VVU!(P!/(AO%"_G0^(WUY\5+N\*<L:FXW!\Z!.0>DJV4*-VL[#6RRZ3#D
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ME8_H.*5]RNP2A5N;_)C@A6%@4^/Y8+T&936Y->L?P:U_MA]2-7.+X$J00(Y
M8?_X"ZZ=#_H%7V_0R^Z)VV[7?.9G1JA!S7(5,XBD]2Z]="!M(4TV66]\"N])
MI'Q\2WOF7@R7XV#![[?([DL%2.: :YMR>CN"P4N%-H[2*D]=4AQ@A/R-6D)2
M9K;U9Y%]KR5B;K90 _Q':4^N96H\O%56/*V7[ H; EVWV<K"=".SANC&_K3N
M&B)I&&1ATD1<:E99,[_T%W:&\G1I?F;#@4JB1,A7@<,S2KN=E*1+_RSZ+>K9
M96C&:BS'U8$-=_PG<9',[.3/=M/)3!'XN9C2]@SV77ZA@HCDI;(E2[_1?ZMP
MGPQ>QNND_Z#>FNA'7$$T7YTFKT59<R!=Y 6X*'^'F#:&<&)UE ZW^#3/5#1>
M"JVA5/'>]EF*!LH>$_6925CP#L!_USWFSL1]9V[V.+0J;KSPU6(&'^:OE:*!
MV-[R0?$2LG5M23D''I!(,"6\4F7XK>?["F#F19BK.;/$5"0(2GA#X-]^$/'T
M&="H8$M#7'QD;>6F_-/KBG GFX5/K88C8_$]<M!O00:^#Q91++3."]7O(;J2
M%"QQK;0(9Z\ 8)W5(MO:">%&K*DL!5/O%\)F<R.U9PQX%6D.I^)[YR;!/C)Q
M1IGX!FB?M"=O.0G:B*I92]3OFAK1B" >A"@2418;)M%^?>JS-=J2]#V&9'OP
M,'0VE3A+DG/.GMX)."=1 FSQ:#+UT 0]"-2 00U=)#DR2YQ4=(3318@#HD65
MW\&KHN8F<;&;VB&X+_KT>T$ED(Y<RU9HXU4<3@QE$NO@D;R>+D-YX?M'I1QT
M(:^\[M(;6-E8JI$IIE_,VZ"2P:![6%FR;#G;MLPH1\>57AQ?.@.V5;KW,9)0
MQJYI[%Q!JD+VH%R+W$D47_>)-L&Y()KY,/'>TZ5.O9V>@:X.P($FAA3H:,2N
M;#!LX;9H 76S5<I(J^L7+,=,G^I>A!&)1%W]]MC='K:LI;\!WZ3KSRZ;P(1&
M2Y!\#TX\S<-/<&_TKB(:WK7_=C>[EGVXHFB:W)E-<[# 6ESB9M4MR&$--3D!
M^KV3=]\XI=X:\_&F2&Z;I7"5ZRT[Z<G.;[HU(E&5(ZT!$!).GE)-AJL$KNJG
M^7^8=6"NV)_FI!XK*ZX.<0'MYK\"X(,60X_0W))[[\+G1>9.!*0)7DZE&CJ4
MGY1J-CLWF(*N*V?^\PB&V+SZS%S&U'AN_7\[,?]FMV#G0JBANC:EQ2[9A'^N
M0L>OHX#]\':SBBF;=)RHY[/J.)$?J[;DBX2?Z4M'QOT,?AWV!55&.5M.W5\4
MB;GRH%D^.(I8M'#>7D*E+7U<-JG[Q'5N^K6UOA3%M>LOT(QVGC.@F:Y?UI=@
M->:L /H&BRY)!QNAO\=^GM87S)=EZOSI4 S8WX4WO=<@-("+U6O,.FW@A< _
MR63KM/QF\^;%&_/9JU7>Z>2'SH#!C3O1%:[IH5%N$$.%*TXB<EF8W(GV+K+:
M0^ ;BG6<^24OV>XZKT],/H]8TZ<@D\_D;'U)7-RF\%?:2KY4@5,>W'QM5[JB
MGMX,^*4@$S\&_ZU1TLDU$B'%N@H1,=,WH@\ !#FEJ90X4W<BX7"]?8(!+@\=
M>.[\I9O/\5&VV*X.2I*^F<ZG6L"F< Y[\=SL8Q'=UC0\=8ML/1R\ 1X\Q[&6
MT#NC%DB2-7&- -=CY#T:%HO&G_IMGJ<C?HR0E"53IM6U(J9M:GCG>AM,!> V
M]!JL4N)D8XWOSW"^'R) 4<1<99R_+,TF!Y9VC</0+\DJ6:N!"1/K6*^;Q_#
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M$-Y@,-3HL!?J*A)'8V"1FKEFM$UM0B-,&.8HEJ;D3QMW5:M<9\?7T)!(;J5
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MI)DNXA8L*;B[T=OQ</W'@1C \N+Z%)WPZ9&HFS^?,]Y?)33S,.3(M.SXG2V
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M81=C0 I;#M:E!!+W[T<]+T"?9CX.7S8N2TASC.%/T44)&_\1"!<:1A:FA,U
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M>)^<,_\7,T7_:U4+$4?=3+?V+!1+1^[CR>>@M7A\ 7_HQX*^LJJI.B2C!/(
MN0(*8Y[U8!W,_K*DW]OZ,[Y'.\6+03,]%2$G<FQ#>):^R<J5A' WY4VJNY"=
MY<UP#>3PP5OQQE<,-Q_C*Z/&::U4RE@AFHL>HP/MT_"\@SF72GE78]O")LGP
M.!EN2F-%RMBS(UW4VKM)\5WO"D"L?TWT_1S]ZOO?,]85A IM=6HM0NVR(4DQ
M#@KK?R[&K$#TS$+=IMJE!)GOZ"Q6J<YO:\QH6F->GBM%!$H>%,>4IU%(O6:A
MO[LJ4&4WX"Y@(A[BH?!C"XOK?FZC2,!HZ_-"]=!AC93XDH7>I71#$:V?60+M
M=7-M>?7-L)J_HNJ+ 2'DY0"%I%%ONMJ,*/U#!R^SH6_XYJ!F(ER3QU/:T,LM
MB"9L)46]A(3 4=KLS3=4"YL&W _%TOP[&C@G.XQIZ[CX?21#VAJD*#>ZD@J0
MU<G7H>.277$M<F,GFGKACN<2/O1@UTIV5X*ZF]HJ,8E^ ]$ATP %3P]5A?1K
M0Z\#*\NCC/?G>P%0\EF7M>$)N7>O;X XFGN_?:F[0@L2CBE&,>3'H"[^?6)U
MJ#^?]ST%A^.WZE2UJ=G!P_UJ:1H -<^)SFKA>9=N^V4A07#&$=QWBN^$9!3+
M1F'3>3%UDD5T5T?PV=J+8YVOE!?R&0FX:EBK? E+S/-*)XQ2*HHTQ'Y$LR>G
MH5E>@K/'K8%%2#;318U8"'0!W(MV7WP%Z8D__DGDI7K6#MJY9ON&DA1F'U6%
M@N&1(3VB.^>D5;<TI+EZS=0MZJ3"[AGOOD<AP*M:MS(UKO-XR5'*8"'(,BD^
MO6C4$#-JIZ+V)(0@(&&?$9^X48'J!NXEF-G)H]%XMPCTOE(\M -*2/=-3]GZ
MX-P'ZXI7A-^F4<4_T(<A;%MZ=JUB)W:ADH&[/1>PD78USPG3_&#X822;9[)N
MB/*VRA)^@*KVVS$O@*M!1G?U9PW#YEJM,[%ASPO;AO/J']X N&8$W:R+8_;.
M LU$IU)>#7!.G\(P',\TSKPXW,LL8_46OXDDEG!^Y!>/[^4EPI D/H+WP3H:
MEU.RX,0L"V3LP*\:^R[9V$Y31$/'T&,VHHAXC]M%\J4R4UFT)(>J2SS91M#U
M#P(-,>_C;'#FICRN>$W[U(G8+,ZC8:T5_V^V3RR$@0[2@EMM.N/7)N<WF?/'
MY2Y]K348:36&<'N"*PPDMC#?++:48N5^UZLW&^Y1=8O%.#AT^-^<0.095A6%
M);S&$AC4F^B]Y"IE7=/&G%G14O65'.\W6W0_JA#T_C(O"ADVV/RR@33*IN=L
M>NZI%AIO>\.G;!!&(!:*UU)AAV[U.)=_<.NRZ),)GY]BU1#ZKK>)!O;0PFCC
M5J8VL?L7N[+X5Q+KS=__742I*TA#[RQUR\9_-ORBI'A*\5HGD,KXC:&9P0,'
MN*]BN9#GWOCC)==DV3I>N[:-_H>JN'_RQ]='H+D-6=_C]!N@/4@N]!?#(>GA
MV&0DO&_)M.]1XQM@7)SU47,[)"Z:,&*8;O4O#% M>@/,V?^C M-;T>DTKG<Q
M\X\3(L[_:[.;/+"KYP_/-U&E">F\.P)KBW"I<BR]GZC[%MJ]!Z#L5N--Q22/
MN[)\Q:H)Y!7*;SDI,8R_XC]!G(V<]#:T4FZ;K+/,H:Z."3Q+1(:E#?GF<_'/
M"M,XWMJ+/81"IF$U3VPNSW[/1[FHTNI%.;?<%_>)/[/VB!_Q4OK"ZL+U^V-T
M\*R7,;=[+LL%T!WOYX3$@=<8/_2A0,/-0_5T+4?Y%4B9VHXTG"MV\%_(,I0"
MRF6.+0&OB<"X@5W0)8C[-ED9YOF)3505K,4SF;S@4NWOWDOW>E[VMFZ]8@BX
MEZTW01:H/@(ZL(2;A/'A]B)GVRQ%:Q.Z1*KJTF 8E4H:$;BY=UO+O*5D&.(/
MO7$41<KHA<QQ8F8\?M^_#^)8,91P_40?("T0Q)N; 6QL2,!YJB83O:8 [E#L
MZYYD;R_N=3,IW&Y*73\(#EB@81<]S'O$+IV7RVSN>C;))7Z49O]9*M43N6M.
M$])E3RE_%PW)[,RM*"B4P9[)B@R$AI1J:Q0S!&&#(M*S#E,J.$%L,FU<_D%_
MOVLDT$:&_B19 BNU5GTA7=Q9=&,MQ"7PUJWF8._S_63D3Q\R&A(QT>7ANL19
M.E_6I]'(8@/?O:6GY$&-^GN2#[]\D;3R^\DB=M5MLJ4I?2.W]*P]U]O LHTU
MN"0JT.Y2+)G(> T!F"W(=2:2Z(=YPIB[<)>R<05F9@+Y\D(XM+5\^ZT2":=$
MAF8!N9RP P-2WIH&U9R_+*9/,.E_C:/>.\.2N;I/575' Y\P"P&ZT<<UQCG6
M26CE,^AF<%\S\H12/^K5JSY+>Y (VC]S/R;_M7_/OK'_MCL-R_Q[>&=4WM63
M.N(<(_0Z@U&V)9ZRDMD@*O<:&:="Y47$S9*>H-RU;QT6F1Y:[[Q9/>8\? @7
MK?Y,4Z,>*AE>EOJ0GJN8/48NF31_;'Y'H93Z=<QQQ'&(6#:^L4TA9+WDBHHJ
M>TI;N\O8'%B+5$T[9P%)@3!TV9P>WT[6A_S[D,Z^"X00ZV<>6_B9;=:ZTH&=
MUNBP!U,B+ '>.?P\MSV)J0KG8AQI&Z/6]A5K;%I7*>0B8OL(M]T6J*M,)'C\
M]/K /C273/H5Y[#PG+N"[-YZ8X"Y59>R01DCY3M5!^GE'+?R/8;B!GA*R<XZ
M2<U!59ID,2B%@[E%TT]FCULP[I"V#/5_+0.H@C;>QR-X'=A&VJXB+Y2)>%6$
M+(JZI QN?N[&MB 9+O*2.F% [R9 ;<^'72;*N\@FBS.U(UJ'+.<TJ5:MNK,S
M\H!V/ ,/E%8[@5^_994G=J?(:3L/CB!VJQH%O6ZAV5]S0 [V))#]AML0BJZA
M%=[27Y*:P^B#>3H0)J$2&">?T..V#>MX-;>8+A-67E9^LO=O,716;$#>FTL[
M%X^8Z4_9Y-0G-[+V(RT*5*TV2=R;0I=K!A,38GFH0DVMJIY+BZLA\ALI+:B<
M-) O8UTD]BGVI;1>U([Y^*<JY\$ACSX)T18>>IGPPYK?>.%4=R/UDA%FFUFK
MZB5Z^@KH!1Z>Z5L3<=$=9NLYCRA+LO.BEQ"3#S)VJZT'EAM[Q#7[9Y\Y\HX^
MIG([[??<H<PI13+^07?H*NZSB&&25#D/ZN9,F=Z]DXP*V9B6V=@02-!Q>0-8
M7I7'RE<^H7QN5^1T!WM5&Q)&-E06GT+UVVL39G>I$I#4<G/1$-D?'@64TGBA
M _YP[]"$]RUI1/P^+YU&KC4UN]+,>^5> S6Z,GQ2KO8U6-DSC;O ,B]Z'\=)
MG0\>0 5)G/.?^EQ>3?)+=5'Y%A+_52F#^X0AC(]0Q!'$]3-/.KF,&827MMU]
MT$CW!C"=.@!/J\IGL5V_D'\@ZI=.V6B_'N41[!I7&?0Z6!*RI[]8_Z@5,B]Q
MQ]'W*V,@157,4;'F2$UO)_1(?"AFMW0N;GM[M%%8LSJ1$5W[-TJ.\"D#"52[
M"8VN5X&1!MXRI;J_$20<K&=Q^,4)1-QK*;2SYUH(M!G>7?;$8ICH&FD.%RQD
MG/UQTZ?[!AB0\7V"BWPAU VW#_-:"R7XA19U<"[ADY_\N[.-EZ\FYG>G]=]D
M4=6O[S;MVT-:Y$F?.3#;8A9A('J8TWB&*V9R'EP66+&0_ILL\T!7(?5+X^3Q
M'C&E/^F5DB7O;V3>+T_5J-\D&V;6U>+BG$;G]'(%?'*:B#4Z:\P3.MTHN9#1
M1]_I%]T<6O[.J58QVZ_:L:^Q'MA&:\Q:*B7J58,= !WHOI9F@P^5C=]UV0D>
M0]J\(XO*6=\ $K\G$X?3L;L5N++[_U$L@DC[RSM=GC2;R.?F5 B?.LY6+"W]
MR26+\W]9+"3NT6I@W BSDU(C8I$:P'^FJWT?H-<%)]Z_X?'913#N#7"?-+PT
M4FW<!#?XA4%6="*0,5$C2K]R =N&1_U4ZEC^:^Y @J6D51(A\FING?S<5YJI
M;!S,IH2O5U)+:1$9?]3? !R4X:FNL+&C#/$MK?'XP:[ /_U;'-C::?V'ZOX*
MF_FE_O.G6)++[[$C>2DEHYM\E77.;@<PTS)F9*S%=\EF(EADXTR5@8L#EWOL
M0_E:)WDA:3A$7-GE#J,WL[I=C))X-]#>=-!$GM5%!#R?)JKUW\<_B6:5:J'Y
M!3-7=4VQ6 '2BS1EIP:'SAD.^7UL]C\ZTX[_;/>/$1O_B+$PGU RX(T/4W:@
M0:G]L>*4W3XGP)K8>Y<"M^05=OQ!TYCLJGVI$?=KY42K3+VDTC#;HG+-A-W-
M1U#"IH2K35E?UC5)0,D0OUD89+4;DG!V9XGEXN#J#1AE(-G]*DT31!)0B\FG
M9V2E]"X"\"[>)K.EDF1&'3D!N40S.H,/N3)Z*\S^Z\@'\)"?CQ;FQ3.5%'6#
MR(<EN8(O1ZM-8+ &1&0BIB>51J"T=/)D31]F121MJPH["7CS(F.9:HTV>DB-
MRU#<\=0QV/_>?0SJ#!P\LF^X_?U3G\;><HMF/:2WN63"B_:?E0RZY S7'!VK
MB?K -\!G-O1GKYEZKYLB=C=(AP>$BU_C#G$@#8?PZN%*M975AFF;6W6^<6SG
M+R:"UC;%-H&=,BP3C>F>/Z&)B^^<I;K11$=:-#,E-WV"F7<N=!>485%..!HH
MM-=LR^&6H@R*E%8DZ3:I34[^A75/N@?IF8P=")#]N9.)G'Q] WWY9..2(?R'
M4".";7F6@]TZ5<55FB"!\\3<[%>=7)C#C7&G%&>] IH;!T9CJ 320Z2P<NV3
M\!#LV('.8X-CJ5B9(KO_^QT>TL'J.NZ([(+EI5*_$?Q% 4T'(67E95WC2D+\
M%POL3$L'-R@%H84I'9V9F7GBD'OAD@X6C/,_IHP6/7<4;Z(9,8+/2!C2)]+J
M2]VM_V),B=!%)>\/_GVO0> +A;(>X0&]6@5.#WB>*R99*V6%E>[H$R5RJQC)
MU9'6:P%X]N:$9:D1RD2,(D0\FUY%#ARF6CY/HCW_#('#_)4!<?HE&0_,E%\C
M$,0P,VFXO5@MWJ"SP>4]6(Z\[R[&= LH"?>G#QXJ?<XQI%-00V$W9N4T.ATB
M1P60^7<C&MOD/N)2']',Y'2R*'YW;OHN.)(?JL]"/@FK-HEL&U$)]2O/4KX_
MSSGBWS,>JVL-&3;=E32,)<6:";K<7%9-<WJJ.:R)I"U_8\DO71P!;L]ATKD9
M\46,EGA>'&B1N*GW]_)>Z,K&+'/M>\PX5S=<>:W5].TZC_)-X"]8J!77GX;Q
MF>?)SO^BH.W2M^8YT$7YLC*<;>A_?W0%(Q<N/W)L7P1/+N -?@- P?43A/H[
M:2P&O"@&.7F#^8K#(]ZL+V2?XZ+\T_V;'E5KC_ SC%.<S>)YD%=D?6]*=63Q
M!@SE61T4)/A .J>]KZ-<3>\+"\"'G+^P=ZH+':0*4<(/41VX#"Z[5"S9^!V+
MPJ2(YRPQ%%CZ)IL7RA'[$:"&AP16'F%5_<9N)E_5> VC]X6A=(.+ F&EHJF:
MIT:M^;'EZ'O*M<]$&>E'6EX<MMM5ED-]L41<R;6PU^^@\_<2G6XY&9N;AQN(
M"(.N,-)W?_"A/.MA\?3AB[VX_KK&D5KQBH.+@8:O#]I'EIGG.>4C!IK3]-(E
M"FHP?@ RM[]0TS(KGTF3REC_KQ>A_ L+K9-S7[PO$K#13BY-NP\8>VT;N^)H
M<MTX,&S-.)Q=7-R4SF>6*^^7\$DCV+OALVSQQ="&+G/VR\'Y?ZC"&SB*GFTQ
M'^&C&"M5D!ZXYB5$O[_ZUEO]S+/Y(<G:Y-= 2-)*O$QL[,!1!@-HX&N#6CE8
M++SU*%^I\&/E]AN@UOQ20KX8F8,*<97QH)QC:(U^_27.IH]LV<-3G>%7J/%Y
M7"(*AHRUK#X:&R1F0V&A"\!]<EVT(NHF(GY=:SM.$(388P8NIO.2J\ESBSFY
MOJ]?ZM5Y R!SW4\39+1X-9N 5OE/B5J<]L:=2TA()#G'X]4IIE,2570.PC.U
M;<(^3L!93EN"%#?YFABMK<O)U4S 01M7@7.3M1K=7(HF0*:9X(X60Q3TT6HO
MS9;:'[;24X_3"5)O $/#.OM*QQ1B[@'=4/4TQIPA7(*VY<7T'Z@HEH0)\*$#
MO9,>/D!5U>F"J59A T.I!:.04EM*PUUB%L4H]!.^=YX\?UF;O,H%N6_WEKS-
MCJ;A!3:MY,8^6EX[PZ&3RM&=@]62[:7-AC_>@=K)#4/IB(7;+H1[XCL*9UJ,
MHW(.=X.(^M>U^2=5JS\$RZOGD2_(B35A+J*W4S&UR:CE-0*1H6=9F-T3.YI8
M"F?-0LASWAXWVZ GKO,TXV!41UQ$WPWF%L [F>*]?09'R\_QC;0/? 0V<<2I
M7TNG%0;VF6/=!0Z76_=#0!MQ]$3K^JY%K0*;A$4XIS H8GT,)?$T-+L"CCU\
M8GC@[#> _, +O.%^YL6#YQO@&^H;()M (,TX5^2VYM?NK^FC4XX7R>,8TFIF
MEVM7DHP<J%G-@&.NMCRM,D7O!_@#K432BQ.:R5HGEG"T8=\I%DT%3,CX03[(
MT>>*_:])]L_OU#$XFF_R5-B0F]1E8 N3EZ_GF9*U\4Z;JE4WJ./<WFZCP>A\
M/M"UU2X4C/WNX,A49ER3/LB9.0RJ+ 8V?RF5'M'B(UK.H(-@(2Q<^BX IL_=
MXJGERCY<6R&OZ#)/2/!G=4V\VNZ)'K@XA/%K?3L-^/H<!"Y5?) #$11>^;Q7
MU5M4\$]!#"Q:1@X?>51[):E-@6O.T!PVV%3:+_OR1Q]-TF(&LHJ'C9@C!ON4
MDU^63WG+^QT!6-JH+$[#\3Y@XM\7*:B(PP[Z*/<5'VCDU$DU";%YI(3*4TBI
M.C" EP8U!670]79K:7.JXIHBBH3%M3#'Z#O@8H60"!)LL_ K,IT_+#@3BVQ>
M&B93.^PM"93.>SF7<L9O%'O]OFF@Z5?=1^01BA)*=X-Z-%GSB8_<"#KR0]U[
M8PXJ5K&5Q3U, ["W52[IBP9HWJ5JK^+7QEQUIW@I%SPKA'7A=P;&**[3&S-K
M-LPWVSG&0 X]X\/>SW8NKD3(*=-_//*#%R\^=&D6_[6R,E@$X8:[[!OW2&G2
M,[Y04;&YWG=8$K.9/QD@W?@F\+/PI*2HO7!QB^$%C+8'K$JDZ;9V+W"5)E.C
MH<]0(I,L\)@S7W\#X%.WYHSN6TT#98E+?]@)"#P<Z/&I"+/77^6-]T_T_Z0?
MM!.N,"A'B]LR*AM+ZMIU/E#;C4M+5!OB_=/;X(,@;/_I#= 7KE)\9N1N6TX9
M92 9G1S,%SLBK,L"DMI(;4V%F6T/F#@1CP@WMGC/7Z2N.$?T6K?%^SXET<'G
MD55V ,7>]*480',) IXZ[^RJMN5$9O<?<(PHWS0<_GU/[J;C>"1L$H)X3?$(
M8["40V\ &'W?! LAE$KPBPN0A]3ZZN?$-,'L+-/K7,X:>"OYDS.I;B%PQ(W7
MX#&]ZV.LO:$EW6-)G%!1>9&EB&S#,^Q8Z>GF^M,KY-MNQ""$MEQU_'_]+?[P
MU.W*LNH6J=P8LLN5/IBIG%%WO,H\HQ"]4=H21RDSM-,K:6+#=N_@BWRN?7N9
MHC!9?,G/N%G2:EZA])>6+_!__:^3):;G@T'GLQD(SQ<(5[NM^L[ LT67&*;:
M)4TL)1!WO'"?#O+E%4\^7H&'NS&/C(J9-=#Q^*^C"B#L2,X3OGJ@#[;ZN&7T
M56<:I/_[C0BWG_^_B0V/M*=Y#1?IDNAB["@!IDC+F0HY#>5EJWS2Z48P\7B!
MD1:]YVO!U[*9J.8-N 3J>5<C-C%#C%4(IB: &.GMM!2O"YGU8ND6 IG#0WP\
MUHSU;75+>=[90<MBZTW$.Y6'ZNAG>3^APJN21Y]D6]/-%9G17O;Z^B?&C^XL
M89\<1I%@L_J5'T!W_U3I)WOSS^K$OZJR]1"YLH#Y#ZGCV,BWBG1,'R"I_ZF\
M; ;9<>%\H;C.$ZSOF/"#\NW[-T!&X&7N_Q>QIO:0=VIW!D'K/OP6./8-H(L1
MN0OO+*1O^[ O1+_G9?V=4@\OY99S.(%5TJ61=%E?\2#%/@Y<Z<D#M7*^5B6+
M9_X483:J(HY2.(T9K5AN6)M?8CYAD2!O2[;H&&<_HPAUGY*X=758&KC+=2@\
MKU"I$)J]MKR_P=_[TAIRB:,AOHQ(T\X+BEL39BUVNKQC32"^O2E6F<15Z@B>
M&I]<,M?.[3:6I9.A'1@;5!PGD1?$RV^V1V&1IFQZRI;JF\Z 5WTWTO;C^T1S
M);]!G?!"!X5@<H%HUJ&>\HHK"@K"8%%^S0W-H[HJ2>['!]O"X4DT-A+DS-Y"
M"?@!YL'^^MOQ 7O[!GNQ?;9#3^3I22NCV@#)QD_+HT_;#.,N $\8N0FG!T;H
MRBG+;?*25](>R:][4+JL-T8GQ+*YCY"O4DTY1O$K ^F3S.O]:64P-_0-$&S>
M,?041-Q>&].(?S>[I3)KDF%5"XJH#.F@^/073]V10\&+JXNY5/FO_8%$DNR>
M%_=[W*4X+A*+^'#5[C4R/=M>AI0S_H2&?O*JWO &'ZS-#:.A-VS$K8.LI"Y8
MPH=(K^H>:THU+0;U=RPRDDH12"4*7$58]"S$K%F;12M:DBP:DIJFBLF4>OCR
M#-1L>3E--:46X]X[M4EHC2AYL[.9WB2Y)@V8 4V4K!G_F" P]57[+\(".)=5
M)JWF71;F6Z@S]$O9<D@BG&E0,^-"$@UE;,%X<[2B!!7:ETL/T<&;16VEL).M
MQ>(]Z78I5=K0Q6QF.JR9T ,-@Q")+[P3>$U?TF;*?M;IU>G6'V44IA03^3CY
M(ZP054%) H$'W_5/=QVFO=\UIE.U3VU68*W</LFY_(VX<]R]OB".16GRGH_]
M>X@0K=!C> =!I.H87S3F; H#>1%WFR6*IU/[1X,V7FO*)>XC&@9*RPD-P3]K
M5^,^:M[^O_>RGDL>-@W_&O)PNY^NILY21DSWP$, G1>F@\TS,*]_S=VZV_I&
M\2^KII_\I_F#< /\:WAG(]8\!E\&T1]-J8E]D_,Y\XE1Z224$PK5Q;%!"%)J
MN D#[J8<->?5="K> H<>M+ 1OSH<W7^W-H<PN]/FQ3Y<Z*JGIW'B%-N^.Q%_
M'K@1O!$ *LB?4I8!!U<'L"SN:*&-+'!I3E8.#"7EENJ3>?4QX,:(>ZU?C:?)
MA]X]F,NF0KZ$#$W<+%4# G-_$;[6()QL)0K,&5B%*RG;YYO7HSK^B88/MB'_
MQ60MIEP-2:3_6H1YN)V8U9,=-I9P,54H.<@T6B2BD#VG]_)P#6->%SLVDFUH
MB[A_3+NH]ZQ_-%\<^RGUT3?8VJ@2 BZV\9FA1_A,E"IB9 00*)X\\!A6?I"V
M-[7'Z\6_H_B"P'\[8K4DJ"]^:1Q&'T2B#[CH,U1\ZGL?F]I>((/$A,3>9B(@
MO-T00UW?^NO%",WAZPU"XQV4=Z^"_8AA5K+1KR:+3,O(F%N@48!!X-K,X&4G
M<,22>\<H0H+_*< =NXG\&7(;&W&X9RCN:.>6 783\XA(=]ZK0#FGWO:U'R.5
MF9YR+F72\%CJ[U1[NI#*U_6%53H8L# GJ$P(/313%@>^_Z%!AYU0G3=(0%[H
M)M#CWFU7%1[FK2!C6GF2<ET/$U>,#Z</V:QC8JD]FO;'2S(>"(I4CBBQ6.\>
M9E+A%WOOH$'TPC<KF=ATE<$7J7W(\<%W^93?CX<#PK@L_8>;P]QOR%(CP1DY
MD^[0,J=^'"3652Y,M)L_43L'QT=+%U$W00X P )9H_ Y%ZEJE0(QE-"_,D@P
M&(<**JLR"B/.9[WSL4BNJJ0//!J1[W5(7)??:B.'&5N 4C<:GG9_>JT;GV4.
MMUE,#'->.OE#50D90./S;WH#@(!3_S3<4A^C&+FM."HZSF@%2-._HO)_A7CR
M6]5C][:R&/!]#7@JFL>]I]_W:S];WVS=*E+_WS!-(K1<=*-+('8?:3(Q2LZ5
M( <+[&?"W_9=8WK4$.$7N'R^FSR]40?XJ.<5$N,CQYW.1!BH9[#SM=:JGZ(Y
M7@,E-@G[5*.^2'YUXUCLV3@RVUGCASH -G3TT?^H4735DXL<FYAU;'+Z"/4&
M@6@5?BR,+<HP+W(; CB_TKVL06U'V'*"%AI@<ZZ?Z8EE.C_0-+36!!E<#FAQ
MHF\(C$BZ.\&A<O<J.V"_ 8#4TV7CFVG,&9MLB9]B''CU)PD# Z\^1C263;WD
MSN0%<_(?SVNB]V9]T:%C_&RTVB?D9#TV61K_(?F6/8*2@:(8A1?9SEB%N%%O
M[[PLLT9GD,713LNW!7<0?7HJ_.?I8-EE#SX"A8NK_8'"4&-:IJ&B""'C=B,%
MJM.N8LXM:;P%Q7-99],1DSS39L3L&28OH)3FG)N8Y]A2[E/4&1;KEU<J 7&Y
MK?+<0JHA(T[/E5\=?77&8VYC7YR3L@^64F1KW8W<NJI/R#IN$-X %6KM2IH
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MF,/BF&.:0FY^'V=STVJ?39/H<&*I4X4KV>_V>ENV90.IOILV40/G$70_^!3
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M)=.5X/Z*TH0:UD$$,KF]6TV%)Y6]Y7?UR A,H[CD_,1"D6">7\\S4_/7;B^
MW/2B=8V_RFT\?<FUDN,VAI#_401Y?_CA22G?"8_Y4-6)GL\#57;O(+T NW+N
MON\L("U?,XIW6T3)!5HQ0*Q?K%*ZLOB@I@.R2\[1D7D.5UB0%LR]ODAO"*N;
M[?\1[01>7OKYFIC?);Y5R /L(RP-_(YK][XGFQ<W)V_,59M1YML).X:%QFH
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MTL8=>W%N:DT(/!:X\%RSGE+RV:\%KHB2V/RKH,NB,2@LVM%^TUILI]*,.M[
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MJB)']'ZMZ M[07[I-4*12GZ'K;>O^S.!_Y*_A>^]1FI6*Q*!>@K)/%.9J2^
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MF'@>,Q#XUDAIS/;[>%3SC./N629W4HKP@F'FO[^P"3W$_F\DX(OURCGFGQ?
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M>OB3*=T';]T69, J(; 3U6FBY7$JCAYSS" "*Q*>W7NB).X 'H=1E)1H'X-
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M_$GE RQ5#S-BE !$J;36?0GV%I:K['<B5W J9O^$D3#'D'L= ;G6TDM[4.C
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MQD(B;LV.5B9ZV-:&?*_U:FC(+*&UU!-18A+*HN>@I:9@]:\FLC]GVS8=3M&
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MB]\J&-& ;_KRT-2/>:1-)2$]:EINS![N7;6ZN5PZJ6V\JI]"8MRX5JN/+'
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M,\4IH.]T.(^$2WW94WC,3#6ODK) C923LDZRHX>#3.U/I1>I]I%"CQDO85P
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MC1==J+TPQ^@=-R+>NZ,E)@BSEK'G]K5_H[#)FMC^>5N8RC?J0$5A?F].U>9
MC<+ O6LAXG=S[>_?D>/+7>;-_7JXW9[/PEV+W6\6CF"77EM= NIY@<U-:Y',
MZVQ!6,%LN6:/82=8+WV8K23[.#GPD35>J=W#=>T+_2.\EDR(J5".>)AQE5/+
M (HD6HFA@68'OX@7[[Z;K.Q'P^K3LDD8$VE/MBSH*%YS7,MEJ?[+?V:0_+^)
MG U+65:1SIY6!,37,5JJK6NGZ!*SX9K('@>4>\>>9^VN3'E86UOQE KC2)_#
M^Z+'L_= Z_*_T,7QK$]L*,K)O@R-4-M/X3%E7 _&B:I'5DZ?O+^EI;YRYK/
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M^&HV]*)1N9W(98&97KS)ZH:4ILKM:&?'_#!;RN/>23V?_/ER>ZHF+3WQ;4J
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MB4R#-=QH%(>VG:TXE]&*-F%'MFLM;37>[G$BJ$@1INW-:>18M:X+F?>!Y4^
M@R]^#!WV*/D%!5+5U@)SLOA4='8!G824Q9=\]\4U[5CS$[$?P14(!JHE.B$(
MY/WA$Z=M>2RFXTG,1D-HS&:T<6*'SCS+,<V(AYWP2+%1K=:X-H]L;4FW%B;A
M"[VG*T:KN?0#P<X_L]UNZ5;5ZPKR]U-8/AV\_KPE@ZV.)UGS&3L.#R#%YGD
M<?C,W$)OC9AL-4:2%4F) )_A;I)Q@R22GPZ;1AW9_?$ $H==:-GEMU5&K97=
MYWVA3'R Q4?XM5C.M+TZWBZP,_6AZC\S1M0X/QQK$VDL=T*^()&YD(B[O!56
MT<X+F5FA#\QRUT^F,'E5" ?ZG?(K=_Q",T=92,GW!V#0P]! Z>$8ZT"BO&U<
M:BP[XPF T<+7SVA/Y?<;=!T><<\#TWB07+X'_9;)?0*8ECD66 ].ZD<^_W'0
M\"> %%X)4MB'1R-BG:"5D:E'(Z6]#V.LVT JOX2=\GO2!4@GD\!V,;C\;60N
M+PL'45>&N&/G>7%36SQ-M]5M78&0@H\]JCC374)(PHZ0:9N:L(*MU=F!HT\
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M+J'EG_ZJ^N/K_?TIT1>S2E-[AZ9GAV^^^@W+3+>SIR15W?.RIJ^5<0\.W@G
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M4/I=@DKW$I#U:M!2ZU:I_ R:875X]/E%THU(AYZA"BA^ M2">;Y/>"@ET7'
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M?4(C;8Q+):?]S6E]X&T=ZIJGN59=\OF:S0DKNQHC>:S"R",Q\[ ,B/$(]]#
MZ^LPB01CHK]FISY>S0II7!)*&GAP-8+#K;#$H+<1_I11F"1:^BQT>Q=#\,V<
MY4$S#VE97R&.A9AU^S!Q+&SJ+Z]"' M"&;DR$<1#1QX+E2 BY#'A%(3L,#:N
M"7O+F-=?DN;)B\T\4R*]2D!%9B[1'M87 8V8<"F!_?M RI3'(R]:>R+]UPH[
M;DA\=Q5DVS.^$0;K,6F)^5.:$J[BF(1 L+E(=&QH?SGJ.O*G-M,<IZGK>Q'C
MQ ]#D%EC([!N> **JQ=$O@S=4/76RM/CC)H5RD>,*ZD\[$#@*:QK+'PB@I 2
MSQ@_432,57]](-,H.%3LEU5_J$'..3"-VVI3+H1'B>^I@(,6KH#R83I:; (?
MM0J7,AX%GEY[$MK7$A<7D[(I>V+BHI0VBB642,RCA),*0.&*(Z*4<D7$0%?V
M^LLC>FR^Z('L(WQ/"PIW22EUT8T#LF\2 ]_PJ3")&P$R]+*(4']U*US=%.B.
M0(?B<!OS%5L-K!O]M\<7Q:#'K0B,6>C%L6!8#]9PPK!JC-!!0I1G$BJ]F*FH
MM^+/5Q5:VBVL[=W6]]_/X5&XUFIC/%L1%CZ))##:2("F127&,[LNB:AKC(EC
MQ7GOU.VAKL]&$)YGXI\FB%V,;2)!8)/M(DZX\!(0[>,@# ,CI.ZMK^!AM<,V
M19Q/8J,TI2"?NE%"F 86P+5R20"D)O C*N+^%1E:7[^(@7QLA-SB&RW#)#%$
M<R\F+ 3)._']B(1QA '6H:O\WN7JKL]I\M++WKCH6':Y NU* XD"#D'@VAE)
MI&2>"J77#XO#8B3XO+WA4>86QCU7".#12H'LIP.0_; S%_4IEW$<:E?T-F"P
M#VDYZW&H<]=CG&I% AEB/)(&_3_@$4'#/T]X@B$/?;V5'L@O*]2-4/W1/O.)
MRT%Q98&!2U F)L)-DL0S+/&2WD:&/7<5VAXH BYW??BO(5[ #6'&4)*PP':Z
MA+M+I$_CWHF??;F^-3E<0F OB38@3!DL,L<3$H<>)X$0VM.2)Z[IK6KVK;6K
M=O#'9RF(OZ90:"^BU!,>D4)@81(7E#HO\D';CDT8B-!PW5O/0_^S#%9X47&L
ML<A0 L(BQQ*_ ;97 Q8FW3"(>.Q'7/7.C]"?^A]]X%\N%5& ";V<8Z=<24GL
M@B 2)7$<):Z;2-Z[\+VOB ,Y.-?E3I85]@974T>W3\K!=0!BQ(L?!D +0Q]E
MRL!F[XPJ(N(0$\*8Q&*A,?$]&6O*M79E[TP9?;K"-=5Q#87RE$B(K]$^#6P3
M0Z=] M)J+%A($Z.3OM[*PW.).OOD=,2FR*BA%\21"2,211Z6: H]$@OI8VM2
MI2FC;B*^:_GFP8MY2#/=I[0:KE(&!OXK.8](D 0<9& MB4B8(A@V%ABFE%Y_
M*>:O94'/$P1IM.;44P$Q'(L+F%@13OT89%+L4N=BMZS>8M-]908LB\(DR4+R
M[&^3,JU4*M<3SKJFBC$T"*6K?**QD2<+=$! AZ/$2X*028]'FO;60(("IOYS
M@@+"^7(U87' 4_C'EE:JP;SG:9CLN@ODS<&)3UR?T)4$I/.0>YXVDD@?G;E)
M%(&P F*E:WA$@4.RJ+^] ;XJE.?]I(0KG%A_Z_OT$C]M3" /L)W8C4)-L-@3
M81+M,I'D)%",2>!+"0][ZS;H3]>5![GZ-].<(,)8>7X",BWF #*E?9+8^+S8
MY8Q'(J&FMWJ'I9M=4Z4)S]#\,V^(':6EVH&GU(N-:@JDUK%4('*:! 0I*D"0
M4@KKO"DW%HD0+NM=G-[&U.MY)ON> 5V!*J#8GB> K7J:)-A7T:?<HVZD8MK?
M8L ]3A!:H2L^D,QCH1L3E6A%F(<I7("%A,<THE*$/-"]#9#XOHJD]0"=)9-!
MX'F&>!3K*BJ0DA,F&0A@ "H^8+/LKUUO:*GX@@!1QX:)$,MZZDAA$C&*"B$G
M&F4^XS/-D]XZ_EZTT3"1QF.4@,YLL*.'Q!)3BB2ND9X;JCA@:^\WNP[Z,"4%
M?T_KT4*<**C2FV0.T\KUA8E]HB@6>>,)*$B<"L*],#2QX08.M:\7U//6\*LL
M!17[1@H>$FJ,;:$!%Q0DG'B1\J0,A?1>2,NTQQ9/O'=5SU3$;97):]H+8J%#
MDG@*1*XH9@1[WA J0S?0TD1)_THLK#]6_RYB#:^25[5^XD0PVW_%"Q_H>YH?
M^K@"'!YHUC(@H4^3IME.DL2<!"#_)"8621CT5K]>A2>7;HK+/?(C&2<\  G5
MAXN*1$QBS@V)0FFT9)%T^Y>#VLO$F!625J$"3M&Q30/! 7E D>4A\-HP]+6;
M^*'T3&^19\6^P<=2/__A6J =NB+/>^PJSP,9-HBYS6/#_'L@@490+Y+:&+C2
MOE[@@PS&O^D<Z&%F_:MG:9X"^G$,IGX:D_$SE7CW_"#RA"*N D;&I$D(-TJ2
MF(8\D$*RF*T=*[^.)#5N:'\EDC_#NF_*$-<#\9\)X9(X-H8D!O1J;:+ [5^Y
MIN>5]IY!->^!_<MCGHD!2[" 3D"8P6+MD:])Z$GN<VR;SGJG%?2Y(NTJ(XYB
MRGVC*<C@5&!N(R<)]R*B8YHHJ8P7^/V5*E8=D?Q5\LP]X1'[GPY>9 A[P!(,
M,-+$=[$@I@EC(IB@1"K&50 ?>=);7/[6C+%-R@;S))6&4TG""!1M)N. <+PI
MP3'[TDL"KW]MJM=7XF/@R;=7B4]4R( 31ZX+LEM(.>'*#]"=[H>Q"I3H;_C*
MUT:G;0KNA@;D)!<344+I$\9U1 3B;NAQ1I,H=A/>V[#.NS#L2,,^9^%@,.S)
MXF^O8]H#Z]<T0U=4=\_3- HI*/I)!)@68?E_X*$D3&02^)II5_0.TYZ (M_>
MP;&IOJ3K SAE7H,T_4=1H<-EZ2/5<7%@3*777?LH>3"5AJ$KK"KK14$<P8Q2
M!QAD"-*62231W(U"&3%-O=Z&L/12/&\X?GT\TA]X^05@S!BXCOST1?)XRD 6
M%(E!O1O+O?D,"YY3XKFQ"90V<:S# 7KZHMPM]BZ8U]<>I0_02"9H<-94N(0E
M(2>"AJC@!UI@S7N1;#H,?%M,ZRKAX5.9GL-204^4+[>,I^>+(/!=32(5HA4O
M3@@/@X!$'BB9(4\$\WN;.=BW*+95^FI5F/B*&@"("!"<FXC$"1!Y);@(-4B:
M0=+;*+;-*^'3 SQ4001"(06*[AFL0@+ Q#U@[3$-_9AY22+$VB_\&YQST8.=
M<S!T12DZFD5)H (0>%QLMP9,E?N:$^-Z*A%:1H'7N[C;Y[6%?4_12"'6"H@5
M!P868/H=UT X94R",/"Y"3QMW-[FDO2U[,<JH[-!8/4-=IWQ(XEMYQ*2*.82
MWTU"):DG8MG;TG3/7RUK/;*&9PP7.O2($6B.8*$F(E& -SZH& 'G+D]ZYUS8
MB*[;Z_(%)0&3 2,N]G]E$?-)S"DPV" VOC2@#+*7$3__Y&4"5EG>R$VB!!VJ
M6@!U8V$"=$Z:D*!&Y;H,$$[TUL1WAQ'W>AK9JJ27%U\#1D::4J:P\3G@*].^
M)CP"@$M< ]CLJC#L;Y'!(9UBM;1!)J$/FHHAR@,%GR5 (&)!@913ST]X$@2!
M/^CV?;]#N#9I$DV4-G"'*J1$1-S'.V0B"6.:L-X%27X3/G<(C/TO'XS$O;DF
M'H648OUK3B-!6."&<$V@?42A9]!.0#VO=U[:[[1:S_-$>B<B-LJ/7&*HC\$9
M'N:A2DIL#]0DH+[G]2Y2\BDY8!\LHUZHM:0N"3V!L6^^($D<"^(#]KH1C4PT
M9%ALW*4&-(H"K22AV F'*>R^HEU@IZ 817X2J[B_!2M[$SS> _KI"Q4*O$(/
M31 L212)F1\0U_<4#;C'I5Z[,7Y#(!XC,TWB$6,\C18!%X-^$B*E'WJ^9J&.
M>VNV^>IJG&N&=9>XP0-OT Y=D:L\ 0W>2)\(U\7"%5Y($J!AA,9!J*(@8(SW
M-NBB[ZUV5RCS!QY(]X!KQ N#"*XI#N#"X!\8RB!";4+A];;<[JH1;;7P\5QV
M]!Y0;U^ZKA<K093Q$@ J[A*NN"1&FT2#2!IY06]Q__D#ZWMP@1Z3+N=<$Q$G
MV.XO"=&_Y1'M!Y31R%>![.T%/B3.Z0.(H%=-].O[2:X>;6;=G H9*[32\TB[
M+(H-8+F,D<,#N$B7$5\GGA:>YX7N8)E]2>J+JX2)!0<0"K4 -91%).:!3SPA
M%4@1@4O[USJ[1T+Y8K_<8%79RPG'*KTA,<+&/FI..*.:!")F7N1K3H/>V@9Z
M<"D]8+8B$9[4"<? /(FE ;#2$%6$>U2X@G)N_+5[.[\6?%>7?)^ D@$'0%SA
M@J+O4A 5_3@B7AQ+UU/&5[2WN=1]JS?= UA6(174%S$)X,@)HUP16_6"!T'(
M/!."ZM];NTVO&E4]H(17JUD^H:]QA<*C+UFH060@0 "P!Y,'@$(-<#%&0<.@
M;ASXO=4P'HKW4D[.L,JS5K8F-(XK]0AG.]>-KV/-0L;J1'WA4\/BD"C%9!-O
MG\1^2%SI*<[#,%#]M1+U3*%_'M&=QU*%QM?$]VTX,8@7L0PQ$UP:]/$SS^]M
M)/&UMN.M76V:\]AX\BM;5/UF(_)-H8>)=KF104 $EA!CH&$1'@6,@%JE Q,'
M"65]Z-ZWIOA/H4-*?4,2#[L4:!T1G@!OB!/!F& F=(/>6A(.=9V6EAN@WG\-
M3']_L;8 X5(E:()]2#&D*\&B?SSF1 LW\G2LX\3OG=R.L1^VLX@NQW!(5]<,
M0!]Y(Z4#W3C7904K!F:1YJ<<Y"PT_!S5?YLHO3M*,U7J_*B+ZOUK4:TTU_8N
MI?AIDY)H^.!B(<W0%8&64I&.O  (@0%>Y44A$4E@2*QEJ(7BTN]ONG:?>H)]
M%6%868E7K6(:>10KGPM%F+(-XGE(I(C@>T,3WC_"L"FQGJNLL\1!PY* 54:"
M6,]\HX@P;D@\*CWA:3\47F_K+.W #"K-)FALGYW\WJ7,@#ZK]V5QAJK6I+;T
M_,!T(46?='DTXB6H]\LGF,/3SS8O3:LY,?,SZ'@P4W:U=XD9\A70Z)M"Z(NT
MZ434BR@/!*$QMB Q04@2106)@,W3). 1E[U+(>ZE3><%5V!07LA#JCBAS#:]
MH %)7(9EVP*7L@!^7K\->VU4_]M,;0\21S>[U4F2)!'P=4DBA044/8$) YQB
MJ%X4^DQ+D M[>^M]H@Q]%SQ622FHT3&68$]$(@G#+DD),!8B@XC%W#4!U[V3
M#[^WILPQR.YNDA#?H)_?C5S"W9""""^8\KV$^NNOKM(S8MX?] G"T \-XDML
MN[\J$ON1(BYWDX"%06QT;QUL??:;],"DQK7A,N&2*"^VA2X9$<*3).!!P$/F
M*T^N_6J?3Q^%%6&O/*(X1AR&W"-<!3$!8->A]/V8R=X*D+V. W@>6 Y4XGO"
MQ,3UL; 0Z@-<:4W"F$K?"^/0,[WC\M]E$">C)F)"&J)\@Z468DZ$;P(2,A5X
M2IG8C7M;>J.?J67/U%\YTFX@8+HP26)TH?G8$#XA)@FHB%U@'F'O4G.'/(X'
M>V+B!^=P-4-7E.\-BAGH]XS$/(I0$1"$R]@E4>0;DWB1'XH7$_;QH(( &TH;
M JH"[@L"'%AB^0V?"(FYIU$<Q%KYFKF;3N.?K_[Q=U5-7=/08/\<(ED,8IT1
M 1%>G! 0U['+'PU9TML*(?=5S7H'OU9U*FV$0'FU,G<^O_QD3W@.7/8NQVE3
M]>F?FI?'%\6F2(N)IIYPX?X3E.A!=E1$@)!($B68$#&GR?JCE)Y3K'_9X;TK
M-%,A:W&#!" C1'^0<4&&D*XA+C;PX8$(7+^W/L/^E!)ZP75J1!0)SF,$$(ZB
M9:@(3R).?"\P*@"ETW-[1TF>K9C>0C7PQZ"E"> TA!L2R6T#[3 A"?4Y4<S3
M( :J./1ZZ[!;?]3'D\=S/(]M+J;"<!93@LT1"..A2Q(=&>+'FD9:Q=H+>Z<.
MK+]E\0,X\M-%9JQ09#-8XUAH++Z0 *&-$DS&DHR$6L:4&\EIW%MGWO<ELO>
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MGJUM"P,/&7C(IAS9\^NL3T"APE6>YP^8Q^$<Y/K'_I[IL\-7S46FKYF3<#E
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M'X_VK2JW4BW/>0\/X+BY%WS:.]P_>.>\/SSXX"S]S_'!9C#!9?\9%,8GB,G
M4.RTPBANYWT*@@=0*E0Q[E8OOFD%M[ B+PD]3QI%7)UHS+N0H%[HB"A)=> G
M3 ;TT:QHSX:+X_Z:[6WXG;G8,";Q(_<KM8C!13JX2'MV9'T(LYE[9;Q"PA93
MI;"H/HDB+,/DFH (5U$2^#S67"HFPW@UA.U0GZ95#6)VC5W5GB%(Y9N.[3:
M^?B%ES7?<O9SN;U.,\GF!FU%JQ2]?MB[Y+*V,.44QBFGL.3PRJG&6F)*F'+2
MW$GKRI$CN!Q=_K@NJ7*E6QMBA09&V/,C6[#VS1\;G]3%V]69_Q8.Q\[]*(-@
MX-YK$;PQY Z+8+1VB^ UTT<#.,NM'TO,$<]E$+Q/7ODF:GF+N*(]5R5&:F)\
M3Q 6^C[AVE/PCXA%5#+E*;$:<04+1#0%-E-, @;P;&M([19*W[0.5C@",[]Q
MGN=PXJV4)[W3&;_@F)_ZS ;" 2/NC2Z7@=8N"/"^< /"5!(",DB/)%0+RD42
M,/UH/W:#$<?\<K_-OI<6*Y[+3+%24&<180$-/#?\"F"_@TN$+X%+A-=MYINK
MAH0K54,L(W"*TBFP*HCSK[G"0*"7S(/*4YUS%+S$@T[GN:\][_*4Y^F_[=\_
MOBC^,^#:+;BVOWVX?;3MM)6TR^= KA=YL(M,W/E8;"]%J$$3ZK?<YS/-F,%:
M?C3"XGN")-)H0K567+C""V*U&KEO1ZE25U7[KS_2W+9?W629+W1=USD:%:7.
M8#<.*'9E_149AYNVW?OB,%<)EESY@0&5!&:*&782,D0$/"&!\I47J=#SA5X7
M6'H;#I9'$WBY0]U[PS$?R@%70>(>)E^N!YA\06EH7  FF7B$406ZK<<%H7'L
M:J43E[$5Z;8M%.W"QX/RN+C8= /.43&I1\X1;.!]B47K*UD,!&XE,$E#7P78
M7ED9[&@?R B[)'@DT$QJ+TH2'J\H$J2%2:MR'I2?RN(<M*)G<)RN]*IV=]:=
MVO]4OKK-USPW7 +6D@E! Y=X'C8T31@G(DQ<$C(F(L5=+KE<*29^*JJ:9_]/
M.K8N@,W&PX2Y\0,BLP:+YW=N+/BAA7V,NAB7P(#2,<\<?:FE[9($7V.WVVHP
MR7T7P "TST'B=Z?!Z'N.>EYIO/D/3Y<^*7R7A8;%1$:8/AEI0807!< <06_W
MH\@3\M&\%)6K'4#NY^&>*[V9Q OZI4ZM='<_/F'>KI=P1A.AB"<E(TR&(0(>
M(VX<2!5BMR#QZ.)HMH?'IU&1/UM@_4JOA[D1H>ZLFN83*5)KS2?]WH)C5\N6
M9Z'5?_G/2\^ER=O*J76FQPCS3FZ!?LL!X2V;H)#D<*#"@%-S?'S5P++2_0T1
MLD.$[-U'MIH:D"L]6:=/*25/E;%ZXTA7:]2>MN1M$P!TJ94SGI35!#,!ZL*!
M$=:G3;T?Q(^HLF*5F1U9OUE?X="GR05X?G!Y=JK4QY(3?KP=N^$],>; <VAR
MSQC/W?:3> 43P8JB('EH2/MSF>X6V:6+*-0RS,%DLUK9Z3BM,YLRI;D<.3+C
M5?7<IKI;+]^Q+_*"8*O[/]KQ?NP]3-Q#&E=ZGS=(8[^NL/=WM7'X6W+47X;@
MQU7)D%=G,/T/S^^P&*C@0 4'K'UHMGV;]VV%&'TI1]BPU0%%#U8%W\RTP;X'
M,F,UJ^\T7(-)H\-$4>)3*0EC/B-<N E)F!?ZH8QC'3PZ,K2U$%Q13UC!=^--
M'DT/6L<VH=UR_@LNT'6I ZJK<\ZSB7;&V$1WU-],S6^%]:@?3&NE=_G,3.M[
M)CT^=7W?940PP0G3H4<2+C0) DHCG3#.J7DLZ6D%]4:^W'BZ\_'WXW\,)&4@
M*6N]D0VG*BJFL?&4(CZ/ L*BQ".QIQ+"(^FZ/E<\>'SIK$Z@V6ME7ELZZT;Q
M"92(GZSNQ'H)S_%(.Q]YI?B?C=#C8*\E73M__+&[JJR8IR($#S]\W]_RHRU&
M>W#^/[2'_UM6")XY1SK3LFXOH>]1?\_HY5RA\^NKO)RG"U[.I7%;3Q*9OLK*
M>D6NUQ66LM*%KL99.T!]DY2>*TQ(UXZX<N1( ^$_PR9[:0/<<_7^TLKASH7.
M,O(E+RY@QYI7 #$*?J@F&.;$*T=ID^9-.<##2:8=Y@8=FLQA%V#,]K=@C#U[
M7$R%?/C-9 Q*N.25[N.Q_E-73T43UKL1IRU9?V^FWS>\\[94YD"XOG(Y"<,H
M(BR,#>$A*)&QJX20+HWBY-$M99K\HK\#./^.T'S4 O.^A>6O0^I- LN/SYV-
M^A3 &JXF^&M@$%_-(/*BAF_^G*0H.8' 9+!F?&G[>E3+)2D?:PPU?0YF\M2V
M,["'#8&.9V /+ A,&(0A"; D 9,\(B(R$:%,^H'2KNN:1V<N-.SA?XILDM>\
MM+T!RJ_L-[9)X#BPA8$MK(8M7(RT+="WR!O>.#_0'YT1: C($93#LVS*%N;Y
MA=#M )CT#A8QITMT]CED&_BS;86CX-?\U Z%DY':YEY0S[']'BOG!Y@/<-*I
M)G+D5*,"2Y:C0R\M8!$C7E]G;!>\NLG5[,/M'GX$Y2=7S@]>LT>A-5SL1/P+
M+3@PW@Z%AW 5[3S8^:JRB["+Y%7M)*ZC^%5U"^];DZ3-8DF5&Q.?@[C-E*$D
M26)-%-<@:(<ZC%6R&E*Z.RE+V'/3XPO=-36OO[:#XR91U#D&_Z))ZDL7U&:<
M\27<%QM8X'.Q0,L9@"F<I74-;,2:]\LB1Z=>=N7H<UU>.?OHS>#2UG=XQVO>
M]-RZQB!G<\PK5//FMD-].LF:&I-'Y-CY 9V5T5O/][:G]KC4]NH88Z^.=7/+
M9KU3)JBK'Y^4Q:G IT++B,2"&L)BT!MBH7SBAY0"@_-4M*HRW7.WAY?7<KR!
MQ6TJ>@\L;A/O:V!QS\?BK(LH@W/1#I<26!PF^BE+]=$_E"_]U@'"09;\4,&V
MX$.K8R%/DL49'.;5%NJ#,!DH47@#IPX<Z44]ZG[>!O50VY59;Y1M+6RK*#4I
M^O+M;0ML?E=OIP,?,.3V14Z'HF;8#;]ER=.QG=^,>H)XG;8[K^)NKP2XGR-/
M-7C:/-7-:9;D^=N^[]^?@7KO",;8/6-8M!U[]PW"];#'K\?;=H/PH>FP *+Q
MM^0#=$4F6J#&TF./B]-]5,/KZ"65#U@AMOZQG. ^,GKR>[S['E[NS7(;PV6^
M5$2^*6 /=[VYB#M@[O>#N3L#\WV1.#R@\'>#PG<PWSLT*W\['!2KE1@P5GR9
M=^(M7 G^\O,K[]5P8<.%#1<V7-AW?&&KKR/2K[M\(@/]FOSKU,2^2T,BF2<)
MBZ@B<2P3$HLX\!@-A4M7%$)F@W!W084Y+<JK);FX=I!5;F0[Z+G2<E>;E'?3
M.;:> @']0HI!IQLN\_O0Z<+AKE\&X@Z8^_U@[M%M@1_#[;\(7'Z!J+S9:H82
MGA0^)53;CL2!)%P)E_@B8@Q^-"Y[=,V?1LVPF/WKI$IS754WU0Q1%)F $44M
MBLN-)V/7!9!']:,<;,T;9E@9+&'#A0T7-ES8<&'?C:UYT.>60\3>\LC\%Z4
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MYQSN_;9S^&[_XV_.^X/#O\-'\L?!P>_X]]'QSO'>A[V/QT</N0"V'?C^W5=
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MK<$]Y<BTE),S> N<>#65DBY@.5-D7'U>RHJC80>JL=H#O<EB[]'-._D%I0?
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MSI_B&%N<[ [UR;H[KILY6M?*-&$0QXR!(#7*$89'MQF$MU&/H0;(8VN #$5
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MA,6C69VT<X.9Q$\N[@QMT;]"YL%4!,!1##R\*VC8TI&+ZCJ11H?+4MJ/Y88
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M(M<EU9\3?,04F%S0D<IV N<4#5;7*P$B!96Z13;YVX=/'?EH2I==.5DAK2(
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M_BQK?7S@&;'4I?57<[3S D6A1C"O*U[FY*NU>LC1:J7_[X_N,#N9S2K..N)
MCB>6<[T8;!YW6PVSZDV2X%D6VES%<\)[;I?P#[]!>9!/WC+YP=<V1.=PF/V3
MF_J2W>17%-G'KBS^C59F4Q'RBP=%4.#BY9N3'3L5"U.TF %>%.><KQ$A!LL2
M-4ZP[+L][$T@O8[D$ 40$O$NQ7[@H!\$6T2[B[8SE_-ESYOD4V+#<AN-)FF
M70NCX=LOW6H3&)B-"<1+=G!C@;35A\O8R.P9\=1@7&G2[XM)4E&FT)X?/Y,
M()NKW^F?$P[1BD6I9A&,U.(BX_9XD_KY5#E$;!RW# 0<_H?F'C9-,1:J),B
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M_9@'%QJNXFH=>A04*)"X=$HX&9DC@Q60JTO#84=8^G-K)PC7'4_;MR$(5S!
MITU3S8J E=C?$Y+>7$MEK&+"H1\CR> H+P ]2-W,W:%'JJZ"SH#C)L4V"T8;
MUR).;-)F"$;0^,Z\I.%L+$J-YO-;,Y\Q4/;.F$^#[J,O>9\1X9J3H@$8_/_O
M+I=\5@L.AD5=_2%M U[2.Z2Y((@W >WD9=6MYIQ-D&E4?@<*+>=NS27[M)4;
MH @STP+IW[57HSFZ+0MI-$>?W1R=!@#*W;%&EFQKZR[BO5=*!!,<D#06VI6P
M(@2_Y$5=A#Z 3!5^OT*^T=CX68*F0D2Y<7U9^;I#;?9*&^CY5.#W51LXE^@J
MVDK&E97!BO.*R</_C<H\HXZA86HX?VGZ0FG WER["Y0=+=HM68RC1?L"%JWA
M'-$>_/17O9S(?;R>=8&C$QD75.M$:+</AX*^'S34449*#)VW<Q//>105"]&J
M5%WZ_)A456 0\17OY7U4<7#,15\_'?I[[^!X%@X S4:SN_L6$3=>T2AN_GGR
MTLB[T M(.XQG])\M([&,TA+R02LW/W=*QN&302"A-_(F4TS7R[X%P-GE]6QY
MF/W<U;@%W(6),G!ZQ1/O[G#^NAG,6QN=O?=\Q(A 7HW!9WNSZSU'P^R.%4&C
M.XQ4%[=DG8X>R&>WT,\-@X'\AE&]:2O!G7%$_LGB3,!8,!&E**_EZ#"AH 6(
MUH[5-B\*NBPR.9TI7Z=L$MJVT0SGG_D4DQDTB(H*SQ5\5_3OL9(2%"D]QU'&
MG2D"'3@Y/Z\=,!C9Z>OL-?VKS<WYNB*[=WQTOT=Z5/^USDY>ON"</G/1)7V)
MP#"XY*Q5+(%X4. &S&&UUR"VL^=LVFYN2)%L9SR!O%2PZ?P<1E/'-Y7^'31\
MSQAGP7Q[1O;A:4'V?!DM)OH7AO9DWT67^]Y?3T)>.E V2[T3L"-TJ1P\''Q2
MM,[,/!=&Z"&9[=3(- ?6NK16SO%.$<\&_2TF].C8AQF,@Y4L<TC]U4^YX<_M
M=;"3_[S,8&-HK;A0N;'"#@^;CU:TAJ(/=06/>"-M[DWT1 (T=R@5EV#W6.07
M5<W)1BV:\+$-)%8^\Q64,>J^-=9I//,^?UDCV&ZND29NHX'58 C6@E%3R)GQ
M[$; LSMS0EI1)%&F1?576CZ@;Y4HS>X%REG;N7C]R6SUA69Q>6%TA=T"1O2B
M*H3HCP%\]'& Z?@=65AO'9I)XO(*S[^7=!C-WFU9<J/9^^QF[V5%GAO$VQF!
MFW8/\_Z"/F@4@PMUA)1 3U^_X4UY9PQ>JJ0=I35BE#<]TR7S74 ^-39_N\I[
MWK#QO$(OGDSFFF<<(K<L%MBCR*=/KBHF;-/[1%#R74AZVY<R-AN)5\,CC#&!
MS"BJY64VA%%Q^3#[M;H$@(<!RE%3!;FRB%BDG(W+@DQ<VMI=&?NHV1I]W#1!
M4?@4R53[%"_]2J!(Q0<A2X5XPS><A1V;_6R]/QJ;_3YSL]_H*(R.PM?I*#S-
M5P9J"F>6M/65RV):R!%V1QR!M_N2-E"]P0!66V,LM+-?X*V 9,53E.BQ,Q36
MB[*'CB-3A8ETU^F0O"@DQ"K*!4NO^]Q3('_)[7;Z"H0],;F=9ANW'C4204FX
M@I*O8RX8Q=A.P\L.;S>6BL&/]'K0I[_OPAT])\AERUEX0M8-9<T0[[$49<E)
M1)&;D2PLNT+B>DIY*&X$C$I%6JV2.\_1D=88MWGH\J1].*LY$0;!-M=>PF^Q
M0;.;R_SR(^[D5NW!T<)__@Q8V#-(J8-^2?>&N\BMK96W;+I7[XC-?XENX:9:
M%6H14@4&F@+5;4N>'K9_9B %\&WCCQ5* TR0> ':,#+D5<D%]IQG))+-,I4)
M+V:$<ON\SKD.Q=9?8FV16N/GE\$=F#7MZ6OLF%$<6/P.U\6LKN+!%.5%M;I@
MS;G+\L#S[[)AULM8/2I6*XJ(>GU<B<K+UJVJ8NX;@VT*O&4-\:6TH_F*?2/B
MS;J9R)[_<N^,8LAS\-,8D-'Y !'1\ZKI%6_ M;9R>9V'QNS&I,N$68TGT2;'
MWDY5AN-J>)*2@V@JZ4ZNZ4CIAL<Z28\AM)E,8^4.__X&;J]O;?CFDUX2IBNY
MU$6GOK6F[)2=>/4=5.5,CL@D[HZ1'H,B7_':'P_"VV*8QH/P2QV$=^1<^VSG
M\R=])VQ*#QB<"9_>N8UC\F& R&&W<!!86XR7BKHSOHD_74P2,(>4Q[\[UP?)
M0K=IC9@RE<NB&^7G<1I?Y4Y8;DL/,YE>(]JI74)1ZG8A!%'?98#LF5H+WE'.
MD(WUE!&!$2MV6I>+65>X?'?9I(VI7@N,.4X4<2,PF91X.S]726__F)!$E)4B
M=P[^#!Y1#L&J<?ON%T%2_/<"6XGT4%2+R,^8[N;7X_69#N(P>QWFF*D%X09M
MJD94?R,R51Z6D6YGG(\-&7-5%?M@CGPDTOBHG2C?OPZ1QND26L8E,*.\R,_$
MS\)&&HDU/CF$3PMB$@0P(9.UAZ=HJ9X$5&2UC&D)&Q"0.D]N+&34'@X7E0/Y
M(][H7>1A?^^XY*%Y:\CE!AN6("TE'@3&KF>!Z'%F8LHNA#5Y/Y"!46/)A.11
M+\0LK%//L94^""L>L T3SI&YX>44X2>IN HVFB9X1$9_Z0TPA@:?W0U]9@")
M.^-:_EYZ+KLE^2U5S58R,19BLQA3FD"-O>$ )(#A +C*"J1D=,6ZFL*>M&ZV
M9%>5*30 :DC2,R T2KI3#6H'Z!F7"]XO<RQ,\$&J"2W*7M9+X!4QGIENQ165
M*+<?##O7/(RI/V>2/&3J[,MC[N.VK,[1P'U^ Q>CT>^*C7M5%VO 22.#96(D
M'FLDL61"3VJ>EB#E8?A66YJ45ZRSH;^::9. GS5T*:SF06@Y&!KF[@QJ&=45
MF-1B!./?GO4S6J'/;H5>D2<@^^3N*-']EK9>"<%M<%BZNN2R:X;M/U\AF&-R
M-+)5J\4!>&*Y1@-6-=BFXR,*<+>-R4TPVZN4^YIEQ93&"P<BX1US)('FGOIA
M,WI!MV_IC/;G\U-PU-L*15I7&S;[CABA?UITU7M H+[;NEMMK]TU$YC,+%94
M#?F0LZ+A1V5_M&'^H1V1,%KYI:9(-3IC[+TI"; C)<V8?%,S5^9,%4V/25Y3
M9A(STFHNYWD]CX//A:?\WGGXD>7C4^05NMKGOZ.@(GNUREMZ%^LQ%7[CT\V+
M.PY%-CK7O%T<NCHDT*DVSK1GC?&>E9]D:[/L5%0KC M\PE HJ@V<[(GE'1#@
MA+P1BW_4(N6 ;<AMV;H1XT'&*"+O?'#),1Y^;O*(=%GD\R'Q56O+DJO;HG&J
M#^(V(AS.-H";-$.FWRM&/&]#U_JF)F-0N);[#?L#M6_ZQJ@)2(+,-YUHQP^K
M(Z:]H:K5L'.."(4MT] V:()!3DP%M+A_<0JD*Z@=N\UFE6"/)U$\6BYA&X--
M5BRQ-51*UDO&1M\KUDRP*]%H&'T?*87G;<@Y$ J76#K2/$Q%)%5BR_'XK, )
M?Y,[XEO E/!VAB@&F.8R.5S06SI8%A'+?W@=$S&V^US?1CP>VWUNHMUG5 ;Z
M\V5;3L#- +[@:!:6P$/RYS#S3&[)/$^P)PW]SRQI)Z0C(JG^%IXO*JYY[O Y
MC77+6[ "QH#V"VRZ-T:5QFDE#SQ@'OZ)Z$09<>Q:FG=#:"8\/(H9F&W;BN%C
MH7GFP'J9)&S;2%*I<-*M!!A5KG HH<M@GT7V=$,N!W2[P&+KUBD8WN,1:O E
M*0J"'KC8:..5$&+3_Y*C4E=&ARVP:R.%$ \G;B!:.'Z^YLF8X;HEJW,T"%^"
MB'6'+35$>0.<TA*W01AYB#)Z:)>'"-*V>G2/<?/=EI4P;KXOU6 <*9$Z:)Z:
MT\OG;<2.SF!E#[^VF'^VS&O:A70;FO!9Q'+,C$E\$O>0J8K>\3U:GKXJ/H]9
MUG#<G+=DI8R;\XN<C/-"-*S(C71U6Q5UTN9PF)UYW*[MQJ:;'FPJ=DPY&<H!
M;@3O[6]65IC:9EU+-L"J(AF.2U"LB3.>G>?KKNT?S%67[%?&_ Z3-'N/79XF
M[A(=ZKD?=9 _S6IZZE;5)?<2<YX=2,,9\J1)KEEZ6,F%JI')QCN.T]*6"#_,
MGL$!\WG;Y!(0)X((,-(>)>?'SVOIBX&^&K['C5/<G*"^V80EL'&J3%)X4KL#
MCO]IJ !Z&Z=[KY+LG5V_GPGP?$<JX-+,5M20>P ]26T5);^9PG[SA9J=,M .
M3%G_;%CEPTSJGV_>/G\9X-%1680=LO7T^8N#XX<II0OMN-85)9T":_K<@X/C
MIT^U'5XYD_E7+X0W^3"3*W"%3,\-E(UF*+UA7,HB9Q<53ABP7KO&;W!@A51N
MK"BC4TYNE$WI\URHXI\G7(H3CAFE)%BAU:5C?KN8WAAD-VVQYEQ-F$(PS7B&
M01?@]%&CO4X;L$SL%Y/)!-6H=M3[:P;H=],G$AV,1[V8>!-UUD^]YLBN2E*8
MB:?DA/+C\>FK54WZ'BM#\H/D-0UQ]LO+5[WP.'0-[7;GZ,EMF2J6JU_2/-*H
M(Y4F57W"*F. 1"_X/LQ.!-@%]RP[*<N./(>7SK5:^\2?WE2SPFE#TG/F"/!D
M? N5UM"U]>;YVU-CY+Y$"Q0=,R4.D1YE-BYN=*[:<^KI7'F.F#52)T@@:-S;
MJ8U5?*;HQUDV%(U9M)\:KN%>Z[%',_^I )=WQ="_(I][G<^J=V1SX73O8^B_
M1*/(5+$,0N=%[WJYAZ\CNH+5M;4A+EMMUYME-7=H&A8D>"G=POA!]M>+,]M=
M&@"(.][2LF[HB@G6DYGCXW9B-49\@C4.5Q?M@%++YOM.,48<!,!%FM>W,XCQ
M[@PK2# "M5M)=PS]?8]X0%*)4^9[^G-\%;$ BN  [^=:)7]]6V:0ES#6Z>A@
M\\> D'Q9LK+'0Q=A-%H'RX2']0^GG&1D1)S-U1!*@?O7F]US9NALE6O[PU#"
M+H;0[CEA+IU[Q\LPGIM"68/<P=QIFP%]N5A[LILP)?:NXF-Q]X@-/53T,26A
M:ZI5A_-3OD]+!Z"&6J%__7/);N/%N-8NQQI>='T-GOB0I159.^P?^;+B.B2X
M1+$HU37%*Y#<T[;E'1H*0?3]>_@Z_CT^C/PUBF<V2PR5SI%F":* T..;:U*,
M%AAJ5W+L,IY$:DD185"CFTX6JNTT38,SWU"*D0DLOL/NVT[ZNRN%X3Q>5W$K
M, V.#4K_O1S&.WOW8>-1S_>-%SR\Q<V->Z(^J:NQ8, A@>FJ4$;#!&^6?'1/
M5U4%\0TR$!T3,>F-Q>:]>OKRM%%W]5:?VK<46C)"G*X_JS^,$*<OMPYO<!D6
M:[*-]>S_^B_ZC^,?[C]Z\,.C!S_^?T>'_]J<_Q>Y8.WP'VS^^#$?W3O>O'^R
ME&7WX/@Q_8!W;<_[11_TCJ0VWW *^B>**?,U>4<9N.]7AY/L*<Z#0XI(CQ]D
M)]UY=OS@R?&]!]\]_I[N_\/Q07^3CE;O3[Z''T>K]R6!G5]D.G8]H&_D$#C>
M=P@<#QT";/?M$+A_?/U#8'SO'SL=8R:-D1W6$<*AV1MZKAR=:W<FJX80M5T6
M]1S9A?6',T^G)Z\;3TLX3R#<$VC72%Z=%H$KF2\Y)OMU%_FJ\_F"4$WW)'DS
MCNE1G^0D%!?=*2[%O=T\NF@_18U0F@>64O*K?L^^W!":&T-/8A.7;2S#T_#[
MUNO2-1 QAZ[KM)?1=]A(\21DF)(BS,_0RZF8;>>_CX^.M4WJOX^.?^3$#3_R
M0FFEZ9Z=%YW\_;\?'+&LN>2'0-@\K]!?:7D^R2CTJ72&G[LG3R"_!SH"%689
MLN7QO[*%+M^_#M&?X8R_L@?<NY,EN[B3!4K8K+5>*/1OFK ;6%*-RE] U:K1
M71XI3_'FI#LO"MZ7"LDNN#^O$11WE._D;_.2UT(1%MZ<*?::FTH@?4OYH_'H
MON:4_B(=G,^D@_/.]/QS KU"L7:W7!2?U&V*244C*W_&&P,Y6TY?/W_SZO7!
M:=[\&)WYR%T+C["4?U>K?%IIKI^3SO*U<&8E,M@!@\Y=M,4L553M'=-6>+9Z
M%1^PUI52J+IQ[9 3E[]7VJ8"A3II'-DI[1UFWH% MEV1$N_*:O:."^F >K@:
MO;'<K]M8Y9XI0_N-M5XH1P_6V*1*92AJR15*X&BL<<%1*X1[U EN=3;]J]O^
M.Z0?=V3_:P5MH:#RMFB[#[OM_<[U*VJFD[[ED.[PJ"6\WV6>J\,/RD:0%$GA
M*Q:H"/R1.P.).#T&>0$:S"EJZE+SC>2B!H7O@P\?PH50/03]010[])! <:R"
M4B1;MU@U)IZ);MJX?W=,(L?L)Y'J5N 2'QJB57-C5<X514"A4WZ8(^6**G?>
MJ)73YOZHV'B8]?>!72A"/B0^(N,G!"DWR/#>-2Z6!Y7\3A.+X5Q6]6H^D:61
MEHE![>)Y_4%H7&[#BC&\6+]^S2?0P$/L';7P,!B'#*_FMJUS@1P$/IN8\CXO
MTZ><]($AN^K28[+[1LS9\=&8[1ZSW=]*MOO>OFSWO<&2YU'(=M]_^!'9[MNY
M"<9<]VTWQ@,*#'3:OW-;RPXW5_F9'&YYCEP5IH$S4B*122<_+H28U9'3BK/8
MH\^R8F%=,KT,D?A?&\$7'F8GY"6N5IT@O^;F[Q1K7(/]G4G?24J\!.%F0E)6
M>V/T[/<- 3UH59XUEW1S\85\)< @@I/]2=E)=GIV_W_\'^_O3Q\]^>X/U^;?
M:RZ9>[ KP+>5G$' 6S<5^WU+^_J#1NY/D\E]R)K?WV?-[P_6+G^,K?D/7W_M
M\K8"ET;O.GC7QZ-W/7K7MV1?CDRJ1NWYJM@P"P+<CU?J\YQ&/@\Y!F=%P_JP
M6WR ?*CUJ#9VP[0 JY4OFPRXG>A<\Z]@HZ\ M=.JWE3,[^E"\S879$(YYBHO
MV=BPHBR7;\S@!*>#5]J3'9-<%C<A:8(2U%FAC4.2IEQ[Q6WCU*L.73I8?:]C
MM/X^XN$MS2B9Q6^MA?S&-LZP,_E@GS/Y8# U\"!R)N]]  W]9\4BORW#?7T(
MB6!X;MOR^LKM\N]#!MG@4AJV]YH_)T*UY)F0?/M@*B*&C$:0"L)76S6E4=R/
M4KDT=(5^_B DF7,^ 8-55GM.'D#BWKH7D_P _74_;HO+RA_.$P0HG.?\ULF@
MH?JV-PS1H4 ]212*?-FZAPK:V_NI3U,(=8'H+ T\6@_XU];%^;E,G\(&I@('
MXD),*>4Z+N2]*W& -"U/L/ @H#G<E])T[J4H%Q!J=+>+PN!T"S=K0_^LU!I;
M-XO0@)@0O?9T._1(TYR6D;!5<RV^Z>H+!_X(%.VGD;24\JC0 TZ[5CI)<4JO
MZ6"GT[=9\T*46\N4X,WTR&Q5RC2&$.R9_T2=3YY^@K+D14&3P/+'S8Q&(EW-
MC-^BR3?!TB9*4<DCVQS82\$HY"_^/>;-M9Y'5QPJR>)"T&"F3L09NGFAY)WH
MT::I/^;>0>,D2*5:Z7,7Y.'0P'2<?-U!VO#ZKW5V\O(%OX(E+1Y7']1%\RY[
M>?9&B==I1[7%@03K$^DJ)8-[(%H\&-C6,*?J7(G6-4VI]I+#,Y,\'$TR&L9+
M7N\E75761?S.#+$9]W#S4\^V,ZDBNH*!+#3=3KJ#9;EV#:->OGOMSE&%SDZ^
MYW;:R^J*SSS]/NI$?W$65:IE8%XT6RC<5S374K&?R*QL5O%L\@@'1:UE__3>
M46QE4<L^4'"?#DF6'_\A\'4P#";5)5!,D&!>P"F[7@M(0);)/;[$U^-&WCH_
M\BL_Z)^7V1F9(8:*W3NZ=SS)?CX[D7(!LQG2)BVS>=V=ZZ+R$(+8: P8C,.,
MKORSF]8=-C-X5!A3@%+_7 EY*IJ/# 3"<^DI-RE1#,!L$1VH%2N<J$WK[9%@
M$%B!0P#Q8F38\,B8^6KK_#T=_FO3=A<"R)5[7\B.E2V8Z]X(P\-64X"-VC_>
M,(P3H?U<;9950W.T!E =GWIQ!DV)FK:H34BB.,\N!.R^N$AT97I=] \_P#V5
MQUYQZ[X<HJ)!S?O:MZG3 +P(!Y\,MWE/W**TX9^-P+ZEM.J8W_^(_/Z],;]_
MAPN,#_?EA!X.%AA_B)HCCW[\^@N,(V#DMMN??_9:S-@AFL:@V@^I=TV"E$L$
MV95<1=%H8-%O^ N]@S!I,=F5D>U*F!MR*1PF^? 8+I3)%()-2"B/TZCY"G"P
MQ+S-+E1UA<2[D@UR4JB..7XBQ*^U!4I$><W<C/%&^7R&L.]=.TFC68"B;=*$
M22\;H[,A45ZO27 290*,#BL)^2P?%9%L#7=+AC[%\( G*T"C:8@-&G?2YLP(
MADTQ_3S.^>#=VG7CW(T]<+-T\[#ZHE<<2-9IHKL9D[X)-:>M".5>5DYHIAOS
M4X!HVI12K*=CAQ&*!7Y!^M1?&GX((M$B.ID[/9QQT^;PO>PAH397U_DV4'$-
MK A-@F(RIW65SY.$6]JG*DTY:T-D2T]J40[M@RC%-9][U3J?/554^!4-K"BD
M)2LG3KO<S%;0? FW&6-;]#BSX_2?Q^%'J[Z_T74)**$F,HL\GTGA#JE"A*?T
MQXN\9L9.NK20:\D-I%M3&Q8F 38'N>BF6A6JQ^,5=-"'Y9GBH(G#=Q=X'(68
M]$#T^Q^/_J+9<=M!-+5(Q:!%6 %S_RB9&O%->V43YI\-6KX>Z=3/WGP<I3"8
M74=I6\<:_PV+M.]-6UM>N)>X[B5YKLI+#^2@=W+=:3[4[GD3:6@Z+&>SJK8:
M"V,0W)P[]M]$QFR2/=O0WE\7T3V>T?^_5L" 8DNXW0ENF_$&/WOVVIA-E:=0
M+ @&@)S\D!WA"DMBBN[1,C@BHY^C'6I#\[-U>2V#*-WE:GLP+_+SLF)Z44M5
M<9HJ9V+] WR<;3.9\U7&H M8MN0>]X_^TBNW.#A=S#/:3>%X,A"Y*]>N]4U+
M=)Y(5[N_;5QLT..,1:D;/I.\K>7+1HU;M(W>N02O,38(W72*X_Z8XAAU3F_!
M0@0PX0-% 9/\8,$UT:Q/ZF?&AQ[5S3:X$GFTK\P2Y<IWRS5N<?N1LL]>G&F.
M'B7U'?9=.^GHAWKNY$/,T+Z7_08ECM1;'62%L795X>R5PY-)89TGO%8CRII"
MQS\^:7I*-%S>>(&:LY0VY1I=$_HW+*#:.3TED]"1YZX]M?PMNNUK]\=%7A;9
MBZ(3FL()O\UGY?D*<_PW>NI2BC0O8?(!=;MW1,<1&6]:!GDM9R83[.A)P&&>
M=Q*LXT1I3Z0:4IC40&@C0344W\WE0=95T_:X4_2IVQ!!L0(N3TT.978*]2#7
M )IC%/KI*89HR;6\FJ^:ZL\^@[P0F6.^7O"%4)-NW";GHU9K/?H ]C74M@^X
M#F7O\S)/W9PYG<07O@P>:MM1";T-E>\6+;T)[SJJW7RKRRJ]D5Y8*&?(B5K'
M:H=)GP_6U5!Y/;G):!]OGIA$UTPS6]+J#H#1N"^=EK1VIL.@>F%**VT>D\.X
M1C('^!]YF8D=8%8K^M9T52"ODV ?KD+6"*WX+)\S?7G8=%\/_N#6K=?AFL6C
M?36+1Q_$L3Y\<*,UBY$5:JQ9#-4LEB!]N#0O*V0OR?L0?=MN^B_Z0R-AO_6"
M!@]K)_]IDB, 9*AJWUR!&_#3@/T@RW3O 7V@@Q;1-/!8<-SB3RBH,05IT,2T
M&5G%.M_&B4+U\@:X-J+C%A64Z)Z<\5ATK'[1M4;'H7+;FM8PB0^?8TS"WN$F
MW@ 8E%ON>)X#K09(, =_:H>]CI/!^_R8;\URC_9LM&?#.+H3B@Q7 >J6ER4]
MP<RE^<2@KH*=N2>"-8Y6C\WEGGN47/'M6=<>5(L%RF)ZR^.)WO;><9S#FYM"
M'N!HBLB?5S[D@V,(E!S3S#GV^UA),P#68'$M)V=F6,UTC(73JAI;M('01#F
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MW5!?HC"Z%WCQ./)S[:(DSW'OPL+(V7\D:ZM<YOPJ/2!J9L/E/$2R6FM<%P?
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M/_)Z7&]&?PF1[&O/:#72R7VR2<Z[=EG5PLPTC$90.NN%FX.RD"[-#,DPCZ
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M*_T5]YT;PJ\O9298YYAG)??$*#UV%QW,F+Z\:?E.<XC_>E]]Q+E#41*.=[6
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M:S=7L']E!?N;N8)]JQ7LV:7Y]2Z-9"ZCP^;V$I=L-=DO=JVZTDGZ$/G)@]"
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M5C0"__D>H\A6VC_[5?0O[A:9A+;Y5[5"^"B/G6;;)F1AQW@\DPYGFGAE=HI
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M<7M5KAQ80A:TW,F'W?J:.XYLSD'' ):IW)"54#0%7;@M!+>.GLP2M&HV?+8
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MR8TM5?ULG9<5HV.A98\;BG.QC1MDF5W:-./E1OPJK,?I(H'Y'=Z)T\GT8RG
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M^>BI\OWXK(L5D2?RD>E>DXY!HY@3%R*P'N*@VK#AD*XG<6?YD-JRC^A]4E\
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M+"FQ6"U98*9(=EO)P#BS=\W.ZZ1[]$6(Q.%KQICW*$=P4WZ ;QM5() 4",F
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MOM^EF;[0BM32:2<89.G5&(M$:<X]+#-2R?-&DE8XNF!+:6XF% VA4P:6CX!
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M:S +,Q9V%@\ R(-M5AK!K6V3C.TN8HA)[.B9PK'B2JZ4G) OZF\IRMX]=?\
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M+ER!G%XJ,:^;'XVZ2U_X'R]357KFM@URY)$PF2+C>BOILGSH&XBA0XO5@;P
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M5&>&&<LB[)2K\V/)GPB>'6)K&1FE"/68<7;XSB$;ZDIIYI,Z?*3)L[G0L@Y
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MLAI8SN1-"D@HXMQ" ?_J)"$\RYM/@55[@A6;-%I\&4Z:&;#5G,"1AAY66#Y
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M%I+>NJJ2<].*L1(/6K*6%TC7$C)D<_$?_O+E9WQMKIN5E&"]\=$L0OBRB]M
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M\L9)6C%1_].1MP[S0A!$N2O7DL14S*V(9Y\XZM&TTSE27S>HAH\]?#WK^(I
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M5 <"GXH%LO-/,$_H\(4M(+WL,XPG.(IVW"$Q7J_A$&(W'7U"A/>U\QE7"U<
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MJI"CY"V1^E;TN<&EP)K [N.WO!R-X36E5*45>\//,V-U-?41)>8UPW+E#"P
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M$.7N'9&L((0I^Z%W460@=L8;*AXI#W/MM^E&UFH+L,2-U(JG49$IW_ E/D*
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M"]E^_#NGG6C,6V&*V[L0/QUJQ\ 6(HB2ZY_M!QD19AOQ%-E:"!'T6$Q(=*#
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M('<.?C$]0+?DOI?=S'9:$5!!#?#M@X(!+MK\*@ZTM(7"MTF(_HN-F_%8%W%
M4VNTJ\ X:5W@K;!O?= 7FEB&L3P8*P>C WQ27RTI$OFXMLD)[_(.>)?[$]YE
MPKL<P4),H"<"QC0WCYPZ;EE<[C+T49P8>1*ORI%:B.S=>MK(#LJ73+YB"$V?
M!LNC;3=*0"F8F7XG6$ZY9QS/!1]?'6[Z&7)6"Q2E 581(;5!H!@N 9@CWE>2
M(2D09+B]VU/'SG]TT1C-L\\/MQ9$#=YOW@ RKV,<WV LO)5*N(90?_E0CXJB
MO+3'58N"Y<!&S[_\T]=[>QAY3ILJW_UE6;DW^U7)7R@"H_5HM^-OG71;&L6O
MV2I/Z-W7W5] 3$8.C1NUX?#@V"<>_>FC,^ID3/V EC5&Y(3']=K[#O?!:\8\
M'LI'7YR?/?KRX8.OSN\_>O#H_(L_\99-D>SYN=^TH[60/M8'/^9_^*]AT+*/
M0Y.0>>AHA]T"P3F#]9"DC7WR55,5<LU:4#'X4I77=1S+R/6^#N9'@ZW_.YGA
M9(:?JADFJ 5+U.W[#DB.N<EZCF<F)^NY"^N)I'3V$F"3<1S-1$W&<0Q'2PAS
MV2>+*EN3J1S-M$VF<@RF8@=)7!>9C.1H)FPRDKLQDHAQ(4H1#.IB4X1_K%,X
MF<U=F,V/)D_9M-E/N<A@_<MMN9#O>TN_??IX,I2CF;3)4.["4 P (;"[.)[W
M9B*GS&0I1S-KDZ7<C2>V[+N<*[P*QLI,QC%1WF+TT495:[OHZT7Z/6O 8"W@
MR;R.9ZHG\[H;\UJH@K(58B:3.)KIF4SB+DQBB<XK[K&B8*;WHCUE=]&T*A,B
MYK(LMRHTRNURD^$<S21.AG,7AM/U':.KQ6#2$&<$YC>=-,<S>9/!W'%LLP%G
M\5;(3]=HHV=B@3?R7RE.=S*;HYG"R6SNPFPL5=:Y\C]]._E=QS,WDSW<A3V4
M]2]]+05]YI:?S.%(IF8RASLQ!W0MET87L"@O2X;N+UK6N*F0/LXK81LZ8"E3
MY]IOG +F"ZV=-$DOFO4<XD(Z(<H[;Y-P@ ,U7ZQ*=^E5?J4A;9S-1PMH1F5C
M?G)$C#JD1UZT+E<A@R *ZPE2L6@&5#\Q4MT:K,'ST+<F&E8XLB&A<TY?1%GW
MC##(J)6$S9A&+13\P',4&K"-6(C)LGYG,=X!YW4@D]KDN\84ZH0;("9W03^V
M=>V#M8/^HZEK5X4.;&,"4RF[,6J+>;_E'G,C!/":,=*T%YZ%5D#K"KTY2SP[
MY=]PZ-9#%WI,I9UT.I8@)2G7\[X5O05M]M?'3UOHWS;NGMP@6C7&Z<'C4+E<
MF*JKYLJU^POX4^LTG[B7#M-SZ.)HF$FOKX698MFT!WA-4_(D*WC.!M3KPDE7
MZLXR>@O6W*:U4[$ "PWKE7 E\#;:^Q3W3>G$1*DTVI3\1DQ?:"?"T<E/<)YN
MK,02W*<YR1Q+UV_="-F1RK-M://^<^N6HL"[,UZ4CJRA$?I2EO?"B5PV?4?K
M<TL'OR=X4>5=VKM/%MB'67J(!H ]PY^\/O%KZ.[D2,W1J<&J/F1L(A$OI'[Z
M?$T;<3%=ST9LY(]HI&?K5CKY54\CUZFR,5^;_F=GW(MK.F.W3.#+W(71<RN+
MS<[3N=@?<-#!YDJ6(/:J##KD-""=<Z]3!K Q(M5.F$F5'[1C'3:,U$Y4&?:&
M74DC"_,!USB+-VT)OA7,@$IK/'6&Y-".#?_85\PSXRGV#RP1?A\TV\8(W8CR
M?KBBZ&H5]J*5RRDF8*E@6Q";9N/IRE@L%DHB++NYP;K;]R'VA"WG;9.S:!]9
MX(8+A#8LPE^K/N?8[GN:_9T\@TLX'D(<RLI20P'G:V<E""DG+-=@38<P8NV,
MI!.S-@O<MLFW7=Y6Y>CWZ98SF\"&UTA"U!<1J_+\WV@Z/C6W9R+8\00[#R:"
MG8E@YP@6(CSNNE_/$8XN1\XQ3A#P$=L9+?"6!D9Z/W"0<@*@Z;<:?DJ Q_ZS
M.,]0K7_L=\!*R=)B.CS:'UOP0H)7QWC=PF'D77^E93<A*_81A&-X[%Q(W?_3
M[,6-;ZC!QK4Z"DU-EP$X9BWB,*)LZ__@$SJ-G 1SG-^+IFTYF%!V;/_U(IX
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M03M\M!S4""DYUF,1D_1 '[?*MYLC\MY,*34+$?#;+(T?483%%W@YM344+4"
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M1)$^743%PPE1,2$JCF A!@\]]DL$ASM2WAA+XQU25A"P ._M^0:'AFRQL4R
M5!'B*F,2W# 0POC[;UK"/,U>J/C ,+Q%S$#G!,=IB*37#B=3)[$&Q93LBBWY
M0>-;M7*46%B2ZP-*"8:/QIG_(XU[CP("JA;^,WJ3Q_0G.E ?+T2S L?C$WIW
MD0[PZ C.,.X_ .#'0ND/X0$OJFV/S_+&0KE0[2(56!KDIK]899HPX3JS\_'S
M15]+5K"]Y'I8>#"NQOE'81^G;UG^&?SC;KL-<6XY=*UTK/#*%(_1O3J]U3I_
MS5XBG?)K "6_-U?PL8[<4T2.P_$1&=#A5U\Z>I\J>\%>"3^H]/$BKQ,E1SDU
M2I-/5X'GLUW!P<<<\ZBWK!E-RWYKQ_D@5&]^L?)D21[!8AL&WETVU:4X._&[
MVWQHU6Q(1"B+TN+W"%'J/1%SBVQIDY753A>R=Y-2*8P$$,5EQ1$+75A:Q2?0
M(Z!3*JS-"0U+JR3Y%TX[F58V+S*Q&M, ES0]*V]8/D221_([!L;2KZJ\31I#
M8[DNZ_?4 1PK[4:.HV:E:(B3BFVCQ2MF'1E&/;Q;+=!R*L0*WL<S-?9KA9?)
MZRQZ7V_8MH[1#E=Y"X^PII492[7,5,O4;ZIEO:QZIYA>#8 8M>%J0?JV%^37
M_R=2W(IFR:.W0*LB7K?*CI#CST\0!W9[.^R>+$QMO)>"O HY1;K$A44.Y [;
MF,4")6+4*G:&B)C6X6/4<D0[;)9NNBLZQ<CL6IH16?Y.PNMD!GG=67)S/%OU
MJ?G*$ZQJ?'C_'M8V;^'K)%$2TB!#@&-=)$:$2GG303-* ']TG5@=[T;B=I.?
M^4Z GV-!N8YZK+,TP4:?Z14@ML<+ZI>>[H8GIT\, :M?2-D)M/SJZ@OV8^\,
M)&M9K@%WPCM"9P_@>Q(X[0B**DQ2J-?\:D1MZN9X)=1?DY3B<^9"]P#/_I)4
M$H/;P/S1[+"ZGH%2>E#^ILQ6<L3-$NU.>!3NQM#,*,?4UY<EWTZR4]<K@$8@
MSC9G^=-(M3O?8/]E[UE@#?P2H.Z@6>#J4BMZI.R#L[.[HL6]VMN567E>'>=$
M=K1S+I.RX.+KL3/]B#>W7W5*O>3Q^,#>]' 2!A-7?&U[:*>.]+;<5F0_-J]_
M"_OV2V][\6]?H"+P;)8]V[IU=B97HSCV<5TC3'[I4!C'VOH62^GLWLD_)[79
M][I> ZQ+=A Y$T3X>K]_I4W"T(#1/2@V"?1N?'Y2V.(ZWOO7.&UMUS080X J
M\8_GUSW+M;?=.[AO,8R8(.@?]E;VV)90%.ER29B.<EIAR:J1BAE7ZI#[<:G[
M);%ZXFFV[K*DQT$BHBD$!>)8TAW.ZDSUM%V^U0K@+( =1BO8GJ@XG-1C/<4P
MS+2E&-'S\$]0^^X7*A*X9YDQ9H\] $%N'Q3('34R7U9.1_&:0MU8J_6:G$%^
MCACG,TB-<A8/23S,SO"[G-4I=7\9^.^:35WD75+S]GL1IS:*PY5)P:\B<Q45
MPWT/P4>5K)AVE9L/J,2%UCN_U\EUC05<I5TGR7$8%EC8 &@UO]9\YN LGJ1^
M)YJ7B>;E0QCS/_Q7\ RB$S;Q+D))1MQ=+ZX#VS>$CD<)3?1C1S.YDT'=C?J
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MULUDJW=IJTFQ=I:TY 9JQ-9=X!Z3T1S-!$Y&<Q=&<]6TK\EPR")BDILR*NZ
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MI'87FO8E]Q9\X' (6366BT@7M)BWUDGY!6VJFK/[C+9<1M4PK =;HZ+J(UH
M)BS;QZK,K$C99?>_/.>SXOZ7]SW'#7Q<WG6UX\._47!"!MF&U,$J.5/K3O1!
ML8_.@J/UMK0#-X=P/Y9N]_0L=CLXR_(*G5:AF=5E,*2G+,3MVPZ&;0QQ*X5B
MK;0@8YG,/#YTQ"%ZVX#-,E=*YX@#+''+]<=6$JN#O)V]O1Q#VN1-<X=4(+W%
M,B2K]P@>]CK14DSCM;,B>E;)K,ADZ,2$<8]"@!]/7YUF2U<PGZP>N>F4:)8H
MZJ.(O 4<K^5^II@N1(L:7L3;KX\I)]]&RKIV&H]X ;D]LL*QLG]%3HNV3O11
M,!+R[H/U)P_+CH ]IU9?]<;AX<1[T*NJ_QI?BL-1OE+(HYE3:M1/ZCYK^=^_
M(#E9HJNT_Z8A.C-;H.=(+CI<"Q2NT=X7HKW!NS.50';1L$":^:'>19\9$1V6
M:EX%B@5[X72NDEGP2<1D$Y,T"*YLE>U?187$C0,#+B1?%S^<Z[_-5.8QI,VG
M\_KF _KC,+B-3C2*LHNULK$9AN?LT8-TDY]3_%77OO4R! 3"1P_F8#V8!JF$
M\S->QH[;AK%R(QHV-H@:P=:Z[[823FPX%?D?. %(0*P!4?F/3_YP^;5E^# :
M_#3LS..&&=UZV4#S*W,:5GD7[;Y<I1.9<-EIF-L[$,"B;,G;3+[3/4@ZT.)8
M'B3(#),9= %(R&ROD8PHOR[9=L_-FIW2JVY<7DD.*6"@UDW!W:.T!PD1HVS+
M@13O)D\?]J>P>=YF7#95I0YFR_54"WEOP%R0/>')*4I4R.NBLS,Q:O'? T%=
MD["=*E,?R@I\_P!8$180<B=C@1#L7NS6DO5C$^]"3AL)FUYW#G$JQAA(K>D:
M2]C3:<ZW,41%"=*D+;W7<CXM>Q;]L@4_\-UUG^1V)4?.C]S1'FW,&MBSI(."
MJ:Z[ID(#>M]*L'.!X.*Z^L8/G$CEC3>[Z"E:H9'2&LKXC?QS\1&@K1PMPTXR
MM,UP.#-"1;379\7)\4!T-$;Z:C!+0T ,=HINQ>XY(T7U.E,#](=B_K_S_OK"
M \D\=3&:>E (%*X-Q%0^N2$!S7Q'WI+$%D]=!7X#Q_Z3I_U"U?$$:'/VQ,3_
M\$ W)H -&!\CPNI**QSUG=?[@U()#*A<#K_GT>Z!$\]R%0/6.^V4-2 18.GK
MS;8SP:7$]CB^WU2Y4/ S4YV:CFR9 ,QKL6DZ4:<3-2"+KC>:0P9CJ,^ Y@QT
MZM+(B'R%HN^6=(Q6<D8&7)S@WPX@%)EJG3_RQAVMW^QMSRV,X/+HQB$S>-*_
M#-;2)/8SB?U\"F(_>;]=-2UB=BM9S*N\?DW6YA:O?;%BP">5=A_,?9NM'D3S
MAM$F,2NJE7='^_QC"@AL(I?-EB43JI).R4)W'G,*HW2FTB9U/:<?@SINY!Q.
MZH!'L]8F^[X+^T;CXKPJ.X;_5WG7"3_;B(DR]H8/;81;3)',*4W?$BJ_$69/
MSJPC]&MJ.MM+X,64"H"Y,JI\EP!JC+%\X*'J:<_P?[F75K]RNLXO31O]=/^!
M)],^FF4VF?:=B/(RV^).4SEU=>CP5>C8*B];:2@\;%,2%3]9 5/VC6_]>BZM
M7T;>^J)U'8YB83&,LKA)V>\LX/R2%)/ 4D$[B,=G=2*'X[X;VR2^GDS\2);;
M9.)W?'K7PG>P8':R4AHG%ZY 4II;#$<<:T.=SNFEZ6'I/Y$?YDL)H9":WICE
MQ50)K!>'#"[PI750=+/V9-S?"R.H$SZ=UT>\L"9CO@MCMAYAH1E,/-S@A=,!
M*VP:?.9JTABQ\\5*F"3X<,TSNF/;KV=&;5QEE_D"4!KG]?4F"SSBU3!9X)U[
MS'63')IE-Z ;ZM<]1%.9O9*%69@LQHZYR:Z.<HXGN[H3-U4$:0&Z].GD XE@
M*,<"YK6; 5TJ0:6@P:*"K# [OHNP_-1/\P[]-/>G?IK;Z*>9=O=I=_\4=G>C
M+N,ZFX]:Q"W2TL!U4$YP1 %M':G#1+5W_<63M'K_[$#U_O2=#H4)^G'S21:9
MS3 Q.)Y1V^&RJO6 F.8URCL1H]&JZ5A!W7!27427UR58CNM0'!\5C&]:>C<?
MT 1X:]*9RC$08#S.*_R\VNHN80BDF7U;A$5"NWJZSUA3POD]W\OG,4Q_DVY,
M--C[;>=?^955-;DYJAN6-)-R9G-5*T<;.,Q%]_UL7"57\ UA>V1Y6#8.;AYT
M'R?AUV02[T"Z5._"XO6GZG4(M\:#69LVA>9QL@.=0(<A>,RIT1Y"X,FN+RW"
MC$!O-N#0[6MM.*30SC$)+@Z$==FON2"P2R7*]\48 S6@T# $*D#!E4N/5<K&
MBW<"1EW4G[F_9(Q#]^,RG D2_EN8\JZU&@6#HCMCB7PZ)$3UE%A4.(=2I)O8
MP+!49EV%<1-N,V<D&UTVOZ2;H1_CE[X0<+?<">L6H8*V#M_RAC\AL3_L ^#Y
MVV(B+28)>'FVUY#O"G9#C/9>6EK[EG?^)RN4D5M/E[_G3V6?-2TW)'&*'!\N
M^+=5LV _#*OUD"_&)\TO?5MVA4ABRLVMZ;\H12M3KVA]2T_MS]&5/O=M3]+K
M3I;:X9@)YI/7N[]\J#O]E#R:DD>?0O*(S+Z\%&'3?&&>*D-7',="ADVQHK5;
MY=5R*J@=S0Q.5G,G71EB*N!J::TSJLK+-<Y'E&?0;0N4]+(L>O(IZ2PO>N:"
M4E&?VN.F8VBG,?A[W6OABW="PR1=5GL(S,D4CV593*9X5*:8H_.^V[+>.KF[
M*JGDN<;R80KG9OG&FR1ZXD(Y_7,RT"-9+).!WH6!RE%V$S,UH9=AF: TWN]\
MN<Q+.B"+9D'A:.VF<N/[*S>6W5Y,'[;+LE-"%\'B@>=*6)DQI6&_%;)&OZE*
MK@(Y;^26O:+/X>M8\!'OVU@0W[S1+#A(@C5%H:S* -@R3;;D']21DJ6&G(2D
M"^.4!V<ZE PEO'&<(E'RKL/#P8D0X<VJ2G?)3#/FW_4FQ#04';?[=^'!?>]^
M$/,5R9N+OE)8/XO7\;@&OKZDSN6?91X+"O/;7>7T\)[G92BGV/'4D!\Z>N./
M*V4_;06W1SJ1+85V-TUY7I-5]*B4'VM.A'*.DO_X>$U/LLC?FEAL7==4EWR*
M@+T,:QF\1^GIDBL3J)T\R9ZTOV.<AOKSN<^\)M\ -VLNG*2UL;3$VX00;NHK
MLXA:R,UVROZ+OKH>I6K;VL@V'?3L67O,PL0V8LF3F_JS</!(37NCO4*H4?U&
M_*I')=!2SJW1VD?4_7X*#V]Z-$:_=G[?UQQZD'C7L5@X!D1'ETL\@_.H@D,O
MU/KR'%Y+OG +>4GF"WO'[+P6= N>%1U*;MZ.X Y7X/QB,K[P>*=DF= Y7[F*
MR5>W1@S6UTI2O&7I65HR5RLG7M6AQ+V0%L4KZ[K3*U7%T,/WH*%,)\$G>A(P
MZD$[E-L,G$"T()7W39$*D6 R*+1:LV]VX4'[!Q&1%'2@;'N"MJ'/9.L?N"[:
M4]F(E(;]E1ZM ^K;TSCO Q<5=#&0R#(F[%6C5QW:!-JVI)J<Q^[5*.7ZO(WC
M&:XJ#VK)$MAL6:RXBTK.8S5F2R#<+#&8T#H$JC/>;O#B?-;$F1!U&<>NSKNE
M7?@T>UQQU(720+7S?/J\N;#R2R/:R]L!,/%&B-&RCG3-MPU[ZWT=;]5E[;>D
M9CG+%.K( LNF(N[AJMO=1M93KJSP20FC\T+G(C]E6#9V_3L6&^H:IE,, D%Z
M,O$PKL'CU@HBD@<_/O.[=Q/Z_17,VJ/$VA_7'CPUA[Q#<\B#J3GDO8FM3$BN
MFXVH9<=?EMWK[-N<#Y)I?-\W4LYK#Y>=%T] 6+C.%VWC3%W,'R<)180&3F6]
M-+DR[Y&U')UQO-IS_HW<.4&74D2!H.-FS.PW<:0_F-E]SYOX?U,@V_3=8.:6
M8D@&NKW>?S@LPC'J6825$#5X7+\:D+" ,SZRLOCS$)66B0@D:RK*X[&$B470
MEC+A9Q2V[NB*BE>;YS7S3'>[;NO666[)T(NJF<.=]N\F<N3DIG[+NC[ [B]8
MZ%)?B7%NM;M0_U55"LA@^ECT/!8GW?NRT@.K0 ,'.)PY[3@/4%$@T4*^CQ,Y
MV8K6#?F&5W0&=Y_/&.WL6GY26%73@E><+:I7U!TMEAXSWFN,1 ]3E36YQ)79
M82S,@.R4&Y7WE?__X..5^67VV'2TV+GO5*V"9DQGE&(7]\;+^\+C=Q1U]%C:
M%/ @S,&:E+5/ERAL*IK!QQP%^*)3<FMS]Z_&.ZT&4C_&*$(Q9(_KE_B.SJ[7
M@.+G .U6 2Y-)W0]?BUL$4[XH%"_+=_9T'*E"RIM/G,*N>(#6P:'?39E-C4$
M*AU@KSO45_(HW#?ID65D]RHN%1M;W-\@1GG2T=BZP:JB_U(=J2>Z5?FK L'#
M+?2P11[OKN^P]T$,1;82H2/WNXA_-L'-A3UZ(&20;KPS%?@$KZHV,?'+L"B8
M[7F^0G39X.FJ^(N:3+%O[O=O#%8H'?!=^!E"W):S?I'^0GATP1Q35.V*TTC=
M-CX71 !&-4>'FWER.-DCKIF*DI/<]?#I\H5T:JE^#&OJ7#E((,@?]7. JIT$
MZ5"7D\'RN1*\")ZB=O@R9I*^KYORX% -N13KJ>T[G^B(\@:B[B!W@R!"$^Z"
M%I<5KBP9*]JW2[*%O$4*15(EUQ[ZH<EF0,VY795M<0+AKUVT;)D(C/N ]#*L
M7X?4BC)X1E_UR8G.WJ[PS3DCNQ R#W+8!56?.1V#NMTP ^DDV?->3S[D6R,E
M IG=+3:*"W;'*O9!U/73!%=0R#.CCE2@.M T5_W6[96-9UIKD?4NB3+64D$9
MG;:]M5-?Z0+[HE6GF,VJ]<T-\F/C?J;]^M8"ARD#+ROB6W:FRS4[K$KKJYZ.
M"*!#"%UBBV3A2#5R?.7$P0&M1E=;+C]D\,6UP@IB*&O;LU8//52%;BPP%8*"
MT&%O$LYOVNO<8E73"%[H&K%-EC/+J",T>"4<!(DF1[S L=F9XJ8X<W3B5EE-
MB['%&_(2BYY^1C<1<N0@[CCUGTSHP D=>+1C_H?_BN0/Q<^D[<8+,')8!P<K
M/L,FQ/O13-]D,G=A,AP=P"?;6'"+*9C3@<?98>:I\*X:%U9?U\U5'7MMDPT=
MS7Q.-G0G72-=QW&Y3P_%28Y1QY95@N'Y"@A%O6,G>4=6A@QN=))-',(+</D+
M/>EJ>FI!U-2NFHSR:!;(9)1W8I0%N7ED*!5W9G4L;Z&U$=,UU>S_-K#\YI8D
M:9F!ZG!,.FE5',M,3]9U5VXCO1_ SJ$D$OC](FCCEE,SAGYF8?<W9<>VB!,0
MAD4'V%KB,[+);<DE#ZFKH57'8^?R\73.3"C56I]EDO3/=  >S7*93/1NF%S-
M\L@\7[M=C//EPF CO(7XR+N-LWTT!H "_5ZMSVN#X^<>3,0E53B^9)=37'@\
MJV&RP#NQ0(89C!C4((B#-4JA2TJR7%+F X_.N[K+%T/8E78G"'Q;RO7Y5G^L
M]?QR<,X:CGU8F8W:O)IV%]2DKF7EGPQX,N!/P8!QYI5U=.I=,%9YZ[C1#U _
M=FI]Q/C.Q4P^;O^<5#1C=!?3!3LY>QLNBYMGS+"];?[:=H-!W5.$I!JTXW1.
M(2!ATXF_[.-A5W,#-W>Q3%0([VM%I7"M)0KNKK[(A8/W,#PC"G>B#B3H< L&
M WB:T/H_,Y0%HUD#^F).(QF5Z>GO5<YDU+2', [ U\I\P9[Y,O+Z0CI@:7UN
MM2-;($:"S.4^/)HD[M"B9:N W'S=M-OR/Y(6U4N?9M\U+?/&^]=0>@'MWE+>
M26YLYC\E*]MS$9OM ,K4138JCP6X7"E@)&UVXBYH[L#S*"]OAPRZE#.27PT/
M-6?,'=TL(HHHR*JJ9K/F2L@R07M-+52?; O5%U,+U=1"=71HOY^<;H5S%],%
M1_0PK ]O7 @HY,K1,+%23ZZ*=U4XSLP[4$Z_=>%PCTRS!/!Z[O _RDEB_>*Y
MU3:S95-5S96TN9-K7#:L&A?CSYDS S&$=?((OENU H!1(#<D/)(VX"/<1A>'
M4['Q"LCKREVR2P+H0N<%1^9E$QW_\F!X-^5MPE,Y\H:+Q*T14@%YANAIN;D<
MYUFV<WD+2#Z[=4N:-VV=]V,T0]_^GN?4S]%PM"U##SD XFEZ_?K4N@3Q"B2?
MFL@G%8:[VX9I\4=[!:W::H<E733LYV]Z$3BG946VLEBI(&0#GI^09O;I9,0O
MW(NR\[_T+3'V,VP6S55]T>9%A$2?1=HB8SIE)F[%N\QTYDUGGC$5.N1<.<FJ
M9\Z8Y(Q0\TF),F^WUB;F5[7LQ[(^A:ZE+GJ*YOEH"_NLMPY;W&("?3<;;,U2
M7 W]6D:ZY[8E&G5.,W+WU,),QT?:@^P.?"A=8Y<+)A3;E^WA.A%-(VS(OQU_
M&2D+!,K7G2]C)_>>>D_VK3"^@8V%4R(C["S^<:]6#1Y9'K?OQBS?;QI-]/Z:
M*Y$D>U\'TASNXI-.!!M\3[J;#']\^%^I/LQKQSQGLH=@A/<?/7Z&!7?3^-&C
M+\C-EGE9=:*MA#Q\6^VB?5(WN9I7Q95Y]15>#APY<^^#1(,ME?3 D12>WV][
M#),V3P&_[MO:VIB%)VWPSNB<5,,@WZ>7IA'STB2)N)/>P"CY$F5.R:FRE>NW
M=RY^^"K%@BRD61MW$#DW:$-C4)O_9&H1>]]!HZ0%8Z\W8.J-X(A\4_5>@U<(
M9QX?\,)=!!BCS7GP7^&A^Y9!7D,0%TV\8.M)XKD/W*(1.&0ZL:<36]L:QU;=
MU=A"KLAS!+YAP5W\A@54"C1+?/-I?86L>J&$PLSRQ3=A;1-G=QFT7C.U8=[.
M<]K93IZ_J<AE!8<D>P+,IVD,C]\\T;QU(VR4W^==D?];(D^DG&%IUG87=ZK@
M#$C>4QR04!*6!Z<M/U=G(D(Z1FVW(':CXX,3]$."#W@.Y"L\3PTV#).'B<CC
MBND6PI$ EM68 4/M.D\L.U]C['DLK.^0S\@#5AX5"^1[X]2D,G9^GQI]G*2;
ME9?"WNO[1PA1.%]FG;]VHDV(I,>E>%!\QN,EL!:[?NUY-^BWU6[J57T/COF(
M>:F!H!9$'N6%+E,(EETPRDEL8L0*/"&'5RN&1QE6@SA>-JF1S9B5\-^9.J0
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MXIJ)[T)2,O+PY>G$^Y<3/+P+,E6^/KH76JK'/E,.+4[^QB_OW4\*')G/1J@
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M07N^V5DX[M'F^[$Y'+&%9 NAW6;<5O:RM*(>J(8"(+S^9;B2P6U:2-% _TG
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M>_1L*PL1;[=;TWKP<DC?__.'__':1S!T?W'A%:UVTC&$2CZ(+A@B<'9/&D>
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MZ#1$ ONO1G_R"G_J-]P6'4D)_./Y7U_A3RH@0(LJR(=;T[9<VQ[R]\(?_NZ
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M] BG(+964:R%L_O.@T ZD@;LJAG)"1()$@D2"1*7/ 6!N_)LYRC8G"#QH-D
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MK]XA*6YJ%2=2J_#Y]N$!\OHI=V%L+!@\<6/!!U2/U)*CGD!G7O0\_ _F</Z
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MB <0 R"K"84?Z9#?@^0*AYWHS-[&8<<]LQX+A_W9R_;"\ Z<[@"O&&,&>(>
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M\\[AX^J_@H1BLT5[-ME61S0'J28K+RQYPXILUAUI:':B7B#H=.9/ZZ[S'#[
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MO%NYRFQ"N,T<X43>J&356X3,O4RVI'7<#SM^Y:E4:=_#B8'=GBL?35W5O7+
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M4W5M?=3%"=_,5CD0XZ?M.ID:'+>C!YAOWU> YG7? K7;E<$_IQS]P]@I5VP
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M=(NB('<6J>NZ@#)Y:P26;>L9@77L:N1+$&N:D9QPGW!?+P8AW#\YW/==[G+
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M@H,6 RV6T.&X?RT& 74(J']Y0)US8YFC%C%K"L0,H4A0$0+JN%!.$,JJZF9
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M'7H#XO_2UC1A&#=2,D#YT![,+EH9W1#V8_C9IN&  ^4'CI-/=&F<,,$GK\;
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ME!Q7NM*'S9[&\4_MMW_ZJ1?>U^/D3-(9*T?S28$XFK8X2HSD*>EAR/9(/:4
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M8,,>&W*9ZYQACHK*.,2LR)&40B)25L::JB1%.4K'T4&4_^@E^=\V@CPVGN]
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M6>@ *4Q544U%Q>D]CO_[<5 &(T_JH43,,*%)1OVFCC"?@J1+C.0 !0 *I'5
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M<[]5^*%&)R/?GXKW]XWRGW^(WLE^H_7;.PM?[TJR===E)983V?YDM7^!C?8
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MXY>FPWBC^S8Z^F<&)1=OM,N5Y5[$==T.T>3-,(E^=D5?'-W7, \#*T)X.+Y
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MC>\)'MI]AO*2H8 F/*-M-SC\Z()WIF-<=2-^ R'[JIRN/'[CJP^^GJXB__C
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M<)$GGC>9>@DZRV[\>5MA[<_=4!6^J:7KK@G.IFXQ[6PG)>]('"HZ9:\"I.K
MSV'3YMFNG+YKH4IH"Q(S&N.XZ$[@=M&HGK+-T"KZ4V_7@=?V]G?L1S%L%N5?
M.0"3X>G]JL+3^V!B>*']%73:Y,9ZS^VB[]<4D_T^]C' 6((SI"UNHFO=5X9T
MQ=_ETH26Y,W2V5B0M 5-/0W[LO8^PS 6T?=AR.@N!R0T=MAC_RCN'JYN_]QI
M"R[WJZ^B^93],/<40>_T11/[!,1[;AJI7S;&S@=;8S =XZ'L:X'[[;F9+SO
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MD0U!^.2$MWHGQ%51*$FC0DGE?[BW&!F1HV1CC?66,VL$A+A  H:%;96)'4@
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M"^ 3P"> 3XR+3Q#L&&?)((IQ0EP:CTR2 :481:+$<RQ\'_4@>^83_1>% *$
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MPVA4";JI7#<O%C^ >WT9]_I#]/'$Q67#R.0O;ME\]U>**:G'?L&O A@?JFX
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MMCUNXK_7TS,[*X<YGI*'A68]=7K!GO4",%MUCRM03]7J 50#5 .S ?6,2SV
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MC(M/.!8L=H0@'$3F!B(X9$(D2"A,L(HV>M=+U<A^^<0>2D> 4 "A>'FQ Z$
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MXDO!<P^ZN1L]]W0\Q A+HM(4J40MXIIBI(,(*+(@ XV!\-UFV8%**TFPB/#
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MV9<*CK"30:BHL$\[_E=HEKRS$I&4,.+:.&2%L8BJ0+V7SE-!H(@+BK@J,6V
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M'=$YZS!&1(>(N(D1.>P$4CJ3$2ZQ8')G?EX?O&.OY8",\(GD]?8^!'[Q](+
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MJ--0@ ",C@ PK (EA".?$D/<.I,)@+!(<,H<QY@'N4, OB3!LR<"P"9$<"
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M>I2X,DV,MS1\?TP6"KYK =V[*Y<H-XG3J)"TI0K)VX2,<PD1A5G$5A/E>FE
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M"T.B#\&\H6'NR/=9?KNY!WNQOU*/<5>FX@,N?ZU,$U#4"BW]QE:JRBRGC/&
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MOI%(.%TOXV4F ='KJ81/M)DOW/>>/,+ %__7]W+703(8"/F?C(7+N&DS\Y\
M> \ 'C/8>R4R6BF: <\HBAPA%J60H8XEJ:0T3^[=]'MYOM_2'VU\W;9QU?[F
M2F@1P\_S'S_Z8SM_'W]:+&]"XB]7Q?J_QW8]*R_\M%R<Y(?>M'6Z-[4J;Z16
MQ8. *,S1_:T,!VX"3;[ K&-!.=@#(WC("(Q0Q%!-4';^"?'$"-),4Q0Q)5HH
M@:5B-1G!KXLP35/?A?;M;^G'C]/VJM]9+X9!]-']Y0MC,8SIO.DVS] BH75;
M&I(5O32+K6+*ZW&KFKM*#J\?*,J1QU8_3<H*:DK6Z"*GELVO^]O)=:T5KA*W
M>MN^<U(N<AJSK,_B['QRF<$K6:8F[K1CN<EN"FG8?Z<_+'QR*FHDO6&(2^4S
MU8TLVT"D-&#AK'R2H5QUK,VJB'<;P_FO=K5>YO_NJ;$?H<"A.CO9RKFL[KQ8
M'UK\^:GRFKQ<SCOM_NZAYI_1!A R20\V1.RO_V$OW0Z5.3+R<8T"#>NQH6".
M?@P;:T?!OH=*]G\T_(4.&/??^RP[VX)>(VE^5M>"J*=3 #0"J75':Y\&_KIK
M&3!@<ZY]0=1CX- *Y*4]]9XCE!Q$L'I.[U:FSY?>\'[!(3"5:6*\%?@'=_X=
M4N;;3""ETB9!).),1<0YR9J/(2'&'6:"*TX9Z6.C_,%,X$69_0_K^(_\->\^
MQ-E9_#5_YW$_E?>$3"B6U<ZZJ@SF7KZ.'MI C)/D\7K"M<KT.2R2U^O!H\HT
M,1JA T<;'D;>S=&BH=HZRA$39>>51H\L8PH)3/.?16+$[LP7W2='*[GU=Q\6
M_5 S.I&*5'LJ$L )\F\'0<U$/=F#RO0Y+&H&@>D A [4;'@8>3<UPUQZGPQ&
M)L: .#8,9=*%4=*2*VL29GCGY/?>J=GQ,L9^R!F;8,8@;U8S/$'>;/SD3-:3
M-JA,G\,B9Q":#D#H0,Z&AY%WDS-EJ5,N1L0(Q8@;D9#A02+KO"2841*?=V^S
MD+.?%NME7]R,RWI;DP(Z0>+L(+B9JB=O4)D^A\7-(#(=@-"!FPT/(^_IYZJU
MQ4EQA"D)*/.J@+1) CGCF B2!_S\>YH_3<]ZRYL9TBLW W0: #>#O%E-N).Y
MF;YHD)CE7WK:U9-%J$R]PZ)J>^Q[_?3CN*,&S>J.U=UUO!*H7RT0?,^1 \P]
MDY0ASXU"7$2#7(P))9VD]#1XG-)S4K_7Q37TRO]T9FL&5YN;V]O)\U%CW]Z3
M>=<E2T1WM?XXY%;,19P7%Z] DP/$M'>+E9V53CG;YIYEC.5ZM5[&)G]B>K(^
MV?;5.=T"3#W9D<JL>%B<$P+P 0@=TH/#P]-[MFZ3ED9ABB3QI=F<D$@K42@C
ML5$DR<SNN*=]<L1^TH*"3(3FD!>L&98@+SAR E=,OIF>G*Y776O0[ 9B6U$?
MH<H4/"R6!B4L Q#ZX%G: $'O&^@;_@#;E%Q*PW!>MS(JQ)/S2#.%D9#8"R5C
M(&[_;/./:RF%'S_Z_-9-B[M^YICCB2:]GN08,]36W>CI6R@W/&3JFG^V\U5A
ML,O%63?YJEE&'Z=GI55T/<F6RK0]+![;:U@/.]Q59R7'L\,]0$0%7OP@+V9>
M,4D)PM$RQ'UBF>-ZB1P/R1+.&$L[8T(^AQ=W\W3>=?[LYRMW]ONE-WL\]6WS
MHLP_/<B!U223^FJ3KT/?E ?.?'=D!+OZ0\"_S:[^ [-QZLF/56;WPR+6>ZRC
MHD>T8'98K,M GZJI==U8_91&UGNM/GU(P_6S<V"U%ZQ6*9V):$1*:X6XQ0Y9
M+S!2R1GMO&-6^?YG0U_F>?NI,*43PWJM)'A>9*R>SHZF^  RN#4ATF_W,\Q7
M]:2D*M-S;13S\;/&#JZ L395@7IJ5<^S)E[VF7>!M,N7+Y$WZ^4RUC3%#SQ?
M+2%$99H8C= '[\,@CW'10H6E$!AW2/.2D^#.(T<M0U2'(*0//L2PQSS&%KM[
M26?PS,-,M=D,@*+G2$T 7ZL?B/ZQF"/_9,X&V8IZZ -4FE7,[:#2##C@PQS0
M$)R4SGR.J$01]S$@XR)&%C,OF>#&4KY'#IC]@>^1!BH]D5I B=:H< XJK( Z
M7E98W=SU.J\G[U&9J0Z+1$)5%515057583-1JE72.F#D!+&()^XR$\4685LX
M)9<Z:JBJ@JJJEV:@^>=RLN2O%TK^Q_HD7]GGW\/T['YA?7UP%.!.2? CP=C#
MLB"T$M_ZTC#Y\[SYU9XW%!,]*3VHFS>+D_Q$YTWGR#:]9Q:-W5)B^WX9-X=Y
M,SXUTU6;H7)YNLA0%YM%2E,?NU[6,^O*WQ;+\Z9[LF:V\';3R*9YNUBOCINW
M66@9N>:^-!.8-&^R3/,5YU/;?)CFE_.K\>/IM$!HANY0+C_=W.@^3L)=.HNM
MF6U]A?5<)L/*SE7(OL)XB;1F!G',F$Z$:6OI;5\12/*&,X9H9"%_AG!DA=?(
M>6652TE9EVZ<*^O\PX^7SUH:O Y_4=V8U'P;P7;U-\ G;+XIMC*2A_FO_V#\
M^Y\S,9GFV+=;D,WK"T/O7AO)<WY[])SPD600/!J+=) 9-'2(R-%,-9U21CO"
M%"7N-GP(JB0-DB,J12GZSWS3X?R/<9PY&9-T-#RF7<MOIP5,WBU^_)@?/0P?
M4+*7>GVZG,Z*GS*W_-3'Z+LF:>6/:;IL5TT6SSQT7BJ[KO+G>]9VY\1L"-,B
MK/SRE2_KGG2RZ\>*<\LWO<X!P6J]+ 72WIY>UD9W+S_C"M.$2!ZY1-YZBKBS
M"AFK),+$F12S@R)1WEYA444L'*%(&J,1CY$AJXE!R0CB-,[!C/2/66$_?IRV
M63D^_I9N+;8;H8M;+#)SF*^6ZSC\5=BQDOQSFQ]WY.YM:S@;UI>)X$G^-3_"
M^^-+.Z3R"DT?(80>3 !H_QYH/\4WX;2T*,A@:O/G\[O#H['TJ'F77^S>G3^^
M;2Z^7)Q-0[ZY#F?GSPF-468D5!G<#//9^2HGD4DD(Z60.CM38\-NG@<'E[2S
M%!$9'>*!*Z2MR%3>^9#=LLBNYU'.]_=X8J?SB]_>9>.Y@8DH2_956"]+5J6-
M\^&OI>Y+T'F.7$8.BO-25Y1CUC@KR9GM(E^DZQ3BH2 X1[#%@-J\@!JWGLY"
M7B(;L]D&UY>F=HN7/'31K8V%S6=<)B_=%?)=E?WN)FQ8RA4WRC >8W.2'^JX
M+>^Z0OER^?*P>>VVFP_'DISLPM+V^H4Z=W#]H]<?HMS&ZGC:7K__S9WZQ<E)
M(0Q=%N!_91)EEQT D>Z;NW _Z^3::\\(%]Q&X;",B(L,$ISA;/H<4V1]X-AC
M1@C>&?8B3";JR5"4$LT?E 8CEXQ!OAL;DVE9U/@@0GTS;K-_WJ#12BE\](@F
MF@- ZAG2A"44O)7:11Z9V:'TQEAN:)0H.85ST!@MLIQ$))SF5+%HB="'&#3>
MA:QVUBXRQOC9.G3QVA6AOPF&'<9ML"SF]^18IZ#?0T#L8J:-\^Y=&VY%)AV]
MND*W\MI-Z#/76--CXM6=NW_&E4F$LLDZCB2S&2(YI\CY_&O2-$,EH3Y&\12(
MA&#SYNI== ]:5D2W1,.X0?::Z6V#A6O\X1E7N3$I+V1K$%&1(ZY56;$L(H\C
M$3Q9[\C.*C=*RD2%1B$(DBU#*&0$E4C(%'&V$:'#H_#W]SB/'^QL_ %#&\_B
M_! "AN)%CC[QC)#.Z">=<3VBN">ED>.2Y>,S&DU^*']\,XEQA5(WP[Z' KQG
M1"\J992,<X233XA[HY$-QB$12B=,;+"5.V?MG-2!LNR9.5,4\5!R)HXK1#2V
MW"IG2#*/0:\?<K2XG'9.:_CKZ;Z@_!&1[?_/WILVMY$D:8/?]U>DU4S/6V7+
M8,>=$:JV,5-)I5[-VUV2E=2].Q_C%/$6"+"1@"3.KU^/R$P<!'B)()4 HV=*
M)($\P\/='[^7_M$MN_8IS0A.I76"HQ"(0EQCC:S""DDP<[4,SDJJMS:"]W6H
MJ4 \I"1]6DMDM8A(!2>#]<9ET^-Z>_;OR:?P<N*S7;N!RU+\/GL<DL@_!@7V
M=S,#R0 TYL>MP(KN>AK=]<[-IS;,;M)=<;J8I<28)U9>FXZ]^_DDFSO[)+],
M]^Z1?$J;P>)@E%4H..(1KPE!6F*P&9@RBHI81[D5Z'=<4.])C5PR,;C2'BD&
M-H.+A$J: [%W"L,^!Y]-)NS=]2X=@#_9* SFHJL14Q3(&X5&2C*3ZM^2*O71
MDRW]>Y\M4?S)A_N&NT,^FZZ]W?N]$]&=;OB/?_N:LF%^;I[6PF"\=E(C;31)
M<56'- X1!5'7A!M72[X5*-F7K"M>P&?A!>QS"&Y,VMKP#Z[\27?RN!SZ(B7Q
M,865:M]VB9FN6:^3RC3]FIX BDJY"=5BXL[,Y%/PIP7*[]D-M1CO\D'=(9O^
M:B;]R95,P\=*K#<7@->_CD!^AO&3@J2  U')PV"92W%+;9$1@)0XEU0&T VU
MWL+-&#MAHXR(1B<1QU0A6V.&/%.NCI:$[)^_79<D)_N[^ JNG<JGCMO=/O\2
MQI]#E>1C<Y^4O0-\51/G8<W0_5\-_/R4,WM;2R$S6][U1Y>__W*E#Y]?"O\!
MOLE=4J:2R(=]NNN-A_A*U3J8 /D2OF9SYEOK%7<\W#UAQ:H:^\ W"R%J;6W;
M(M&_G"V;E%R83Z&MV$59 KXPXR_FLOGYA^K/I5ATM27_O(<]6:!NUQ.Y!;;_
M:[?WX0!?:&J!/*:WMB_,9>MQOBYKE9Z"P;64V.D4FV3Y+%M<Z\A_E%S7S<5T
MTHQ2TG 2]G#QWK'I1[/@Y@F3ATD3FI/.;]\Y@E:COD[@HV:1<'VG%<S7Y4D;
M#J7D1MKPO[LP2P[T70-YS7@\_9(NF6W(Q45ZBTUKX-\?PQPXP,VQNYD$-C66
MU-4H<$M3A9]-*7$*18UK'460U&P9,+:NK3$J(BU-#0:,],CHVB!&1?0"*TUQ
M??/@R>:_P_SCM!T_&=[,IN?)OIG.KFTM(3=:2X@;6TM0<4JO;2QQX Q>P07&
MB7@9;VUQ0UN]UW/+:!)GIIG/%LGZ#L ;GV;&M^$$N.(DM-L@F]2)V4>=[R4'
MSL .[WTR\)[GH\S7A:_NT3*:!PNF?$PUBAIQ32DRA!B$O;,,XTBPJ[<*[T5-
M:T$4"C22= Y!AC*.%)%,<:JUM6*#KUZ9YJQC(O]F.MMBLY=+X?AQ^DOX/5R8
MD=\+C_'3ZWNW' N+P?;/B@S4%BB6^6@,]_*@W*:+L:\F(57K@L),ZC(M:V4O
M-U0F4&!V)1<[:]MMMYH/8Z#?K"]86\Q&\_3AQ;09S?MP22)%CGC#Y>;)/0"_
M.S@%CI@>R;K'(E!N[OI$K0DI;5U%91 7H4::UA1Y[P25AAOX[ZI X<8[#SL.
M4>H5XL8R9(4DB,;(M"=2>1:O>AH_=%OP=;L#]R(NR*D\8G%Q)&_22KTN)>=O
M "3@$?UU8.%Z3]WI07IZ2MCHX6&CWQ+JV)T"MADZFFRG@-VPGW:F&H#="!9I
M S!TF6]P)=($6+@"R_-\-$^QI44Z>][J4N-R'[N3RHT-O-(HYRK EQ_@8WBA
MZI]@4X;+ZA<S^2-9ONEQG0L7N9L96,CP:3: %S,0D*W9.6J:1;[IMGH&&JX#
M@12]_)S0=/?1E:/G8!TW$>SEMM5>%QQ-H!Y0QMBX[KP>#FR=;^9SX\Y::+)*
M)"L;?<]M7!:?%LT\>U!NV.9Q%.^3[)B(?'W'@NOY8]G%;%GAUVWP46OJW1)2
M;=GKGL]ZG^+#WAKMOEWYW'8];]^@(T>@6:X^9+A]Q&]8F<T<SF*\WKW7O>4Z
M1.H1EW5,J?>IBAQ[Y&,(5,-KUIQ=Q9HRTJBPU8A)QU(%;XTL]F#_4L.)KA76
MAFT8KRO"W6"W[@=^BE-\Q/AS::ZNQ=YN])0F1^R&V[?-/[[%MUI8YD9_CR:D
MQM@@J8A+C18CTG7 2)JHX0]52[U5MH0CKZG@-?+:6<2IH4A[;E$D0K(ZQ""B
M+'[41^6:3I/YWM$RG8T PP #7:]63K*JAA-GZ?,6D"WC)GU<I%DY@)9Z;CO#
M_VI@;ZM+[O]557^!GX^=Z5W7E*8Z>!$\R'QB%+)*$V2C,$)'C6,P5_<NLUX"
MX26BAB1?94J(Y4P@S*@GPE"@K+WJ6@#=#W \+\_+B4^)2[ L 3!):%X#+AE/
MF\4L?(1[_#*>NC]^R)42%PFJMFFPWQCM5(<"7.UT[!]MQ]>GU=KRYRV\08!;
M;81;%UH^JW5NST\/^6(TA^=WUZ[\7Q<&@/<\K(F08I#M.0FI-\#.DMG?KW)3
M?3D#<\Q>5MF1[L/YI+7VD[74YJ?.6DYH(]C3V6:T.65DIR/!P';M[*6$A.!U
MQZ'5%>TET@']!:H1@"OX\<4T^;$_9Z_ ?'?)PRS\:Q&:[.-O%NXLM^%T8/6W
M]LZZME@^O&N#^Q>P(%.?G!-]35SW+*N+KSW4ZD,P^L(<UKB]P[D!<VAQ7EU,
MTTHF.\^< ^5SX"\N<LQPJ<W6K5R7(R Y\O&OQ6C6>AO.S1]AY>QHMI]YC2SP
MW(O)> 3"*/B?J[/I%UCIV:8EG0FY6M9$I'ZY5TD$%U/@N\O6>9,OUW2&\$76
M)&T-U22Y;39? !X7KIL5M(&+S.8]?H;ONA=O5Z+IWJC?$6XT<XOS9MYBXG3Y
M9F'_3TI^@$L"BE@ 2,IW:ZNW %HDP[A+;EB]VN,T6#U UMT-I;FC=8R<H%KQ
M5'CF %I04<,_P3MLC=8$;_4O"=A$)P2RUL(Y1 9D:L'!^A2 HI70A-=7X<A2
M,+];ILTTW:C=5V8VNP3>_:<9 _380M,K#/WVMS?;B=< I%>)USM?T5JJHZ(1
M1:'RXV)D?9!(.%4+'*D,<JLM^[>,\'B25YQ,=Y@)1VHW]/.TDAI),F36MRUL
MA=Z:D#/9:'X-IEGVB;?.K*ZP,SG(;_?*%FC[K9#K;]DOG@GP*CO&"^!Z1,!5
M'$,W:3,0VMP[X9$E*AG*7"/E<$#8RDA";:5@6]VXO-(NTJ0!"8^(UR#T+8X>
M@27N*)9>";ZC0BCO^7>QW?'O%O.$4U('A)<9R^S')W1:'ZUH7[F$=L35UFR*
M7()6Q=$D15, - ,>G8_FB]:7FJ"H2<EV3<KG2:-EQF,#UX+C>JB^90>LBN;.
M@O'_ I6="-E_O\J?7>LHD6M,5QZJ/J1Y3;RG?:QU!'PQ-I,F@=9%5[MQM7"O
M61L<T$\%V BP]F'9I:#M5VH!HL_DD5KCG'X,5#"3R2+_F=8N91:N@CA@!X0&
MEB!W)!Z'91K5SN5M%_]INQ!QK6UTT:!H;4RMI0*R)C7A]H8'FC)PZBTP2AV!
M,XA#LG: U!S -9-"(=9@@QG5@A)ZI0M"6L:>=7^;PO*%]]G&^^7R3;\2;U<+
M\4L FH67>5E7S1-> _EV5@%Z<WGX6H?AXR[[2]SXE',W(O..:E!&05@PL@)!
MEMID-8&EI*@)))*M5JC<P':'C8QI:I^:+"VE8D0:&(2&")8+NSH8ZE'W]=%4
MMTI< 8\V1[[!.V=6JPVNEG ?9MK8/8,V9(\,C(-0GGF#A*44&)@R9%(]N?9>
MQ#IKFJW"C6\+VHP[)##Z'%[.9JGE0E+=CQBQ>92ZO<&:M==M-)4B-LNU3QY4
MP&!_ PDZ68]&[B%P4]:[K0;\_>V'][]?6?.]AFP.)D+VR"+T7=M<7IS<EBF:
MOVC)LM85,!E@W:=PC)LB'SZ'\?2BZ[6'<KGC+$$+>/2<HC:!10WYLJ]>_E[]
M]K]39EARUB>[PX]R+X4YK'R8]\WX7KVN<35?G.?0PWST*4PV\_,F4[ACOM!X
MT50?JV2\;%]TH[QR.[XQZRIWJG'+U$T59]/S_M62558<*S<X5BP141$PR@C1
M:>@)P\AR^,?86A!NN1-TRS(C6 +>K0-*0U%! 08XQP (]M35V&I-KF;<@,ZU
M"<'^-IW\VL9S/H??TSLW'Z=_!>/VUT3<R:>/>?<TG71N^IJL#9_+J]FHN9B]
M,HV^EW<]#[LY6J=+N]E16I4*N"Q4H5W0CA];Q\.7$7!7QRTIQ[K3@5>YI2W^
M+3QS4V*G%'5D6"#*I  +#N"C#4:@U$M9$"R<<5N)G=BD>1? 6-("7N0L@J7H
M?$ !&TZ8JBUU_@$\LQ<>^;(K!'4<' (Z*-S.)MG#!XHGA>77U%U?;[$,MU>3
M3)Q<M)!R&[Y,DA9;5U_-:<]3N0X_!^(GU:J'WZWZM@^AKU3MIYDY/TS[KB"]
MARWF/W+ZQ)&P8M^E>=FM\"HTW81X.<6N/:(Y2S&!\*_6"YZ2K[-":T+NP9XS
MD%J6.F_;=32=XEMEY@ 7Q<2P(/+&'AXN)=^,<]>\#B;_]K__/PR8=0N#GL W
M__?'79_W<835378S;O6F"UST%TJ?GO2OMJ,U2!)0J!=021I_7DT6[J!R__"K
M;]OG^>T/,YN;71?MI=3VF6TDHO]\!(OOEKT+TE+FU6]+PIHI2*ETU+*.\5HB
MK#WWJ-E($UX_Y2"%6NEJM=>N5GIM;4M7J^_6U:JHW'9QUX78D2C>KDE4-9UT
M0CUMB11@;^;=7(:LDKM >4ZX_+7K*[6N)G,^;DK<A..2-1&VFG8D+>W&H"=2
MGG".WU^K'[IG.JW>]RFR2W?.5;OT G1:4J^S,#JWBUFSG"31-[_*]UUFD^7,
MUUF;3-KFI=[^$+_?Y_!TP&+<EEZF1]W]?.MO\:5D^=QB6&,KC:HU0U%BA3AG
M'&GN*;)".\XU3^V MGO*.R$HC8BF7$[NZQJE Y'PQ%GF%7%!;QC62RJ_B[]W
M-'XY\:]7%.YV_>\]?5-%V/N6NK^O$W=//8".OSPL<5#9^#=M_%IA [O8(FH#
M0URD!MB*"D2U"([H$#'?:DMCI V1&8KJ2"SB5D2DM:V1KPT+2C(I'![PQJ>G
M[.@W?I^LUC;<;H<97)_+?)+-M=0C!BAR>5J]W)W[?#4$D@(JA;MNXB[&L!(2
MM .5%%1$7>.4K\.1I[@FRF+/PG:,HY;1\N39Y3:DID\6M%#-$".1,U73P+6_
MPET)N*0RF>RNZ3GL%=C.'UK3^7UJI)!*6?;4#>KX^6>V7-.U#C!+8+;AEKCH
M%W?9.'7-WP# *\&SQ$X77:.Y%6I,15%YAD9;G39/'H[D#!Y=Q<G6C'/!5',6
MPGPO[6"*M=42_,TU4=JG>95ORB>ZULHR1\*$P$(@6I#;2.38CO@#CW5)SVWK
MID]A,CV_&EGI@XV;5MV/ILH#";JPS/*8K9ODHW[J]=Z1;)2LOH]DKW3M/&<A
MUW>N>==SO+)+>[_<6>RZY3=?%LNF;A"^]U88=S8*GY<V_X:/.??U^K08M]-P
M<H>BSW ]>*G0S*>3\*1CT1@'9%'[&CEM!.)1"J0LU0EU*"6%D*3>B@W?VX1]
MWR_:F[QFO?/DE[1B[R8O5VOU+OY]N0J'KR;FTU2PEDLXFARLG0"1/9I_@:\O
MEZ#!)XDU.YPTX)<S(.1R <RD07>,0@SG%;ZM52TH_0!\7=TJ__/@LB\I;@4_
MYZ,<DY]-+\TX!Y;:A)4D)-)F:&!_ %STHT\Y,C^I)F&^O&)CQFT7IMPIH/OT
MM'J3!NJFVOF[/]):IINIDM'6^CHWDMTV#;7O*@!W<,X9T!C!"U_/.</97X5%
M[K$?\^SFZW;DXS+2'3T6CZ.0#Y"^UZ1D@MTH8RHJ(JY&W*6V!J[6B/GH=-2U
M-_56(ZG[0XA.ROS=^-9A<5V%POZ;&AP%:Z8>92.?FYWT74[*IKYA4POAK$B]
M^8*6+.4_!F2TQ8A9%:(UM5!ZJU+NWINZK=%NWGT)/N_I94Y1V<0[237+,=/U
M/3S]LAW/7;G>ME.U3$[C7X<:9^9S *"3<OU;R'*'R;*E1\?=Z/5W\_75)2C[
MK?JEXHS<:UW-.S>?YA;L\M;BFE4B_6J&;YXHFIU6/<$V)W#^U&;.=5^>5&\G
M[K3Z<?V$[C"X_M1FGTIRQ84^#;QR@.53;X N=[A/'.[]+5U'@NY:_ZMI<_[&
M4^/;!IKN; +K_NFR[;>UGH6\GH*<AD.WB!!X^2KR;(K_>[_=T'>-A]C:/5<L
MRM0^/8VG QKUAW9EP<L8R;+*(W2ACG4:MS[=]4-.JH3[ECDM):QX$Z21&,>
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M <%$ADS0#DEE1322&>FVP,NW."%R:>09&-MAUOSZK\5H?OG;=!Y>CQHWGC:
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M O^(,NZ*%V%S)=OSTT.^2,G7(W?MVK;0JG4ME,3&_8;PNX[?A.Z:=AI'XQS
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M7BWT:P<SYSJ^ZFJUWS[*^HID+I*Y2.8BF8MDOK-D;D7RAGR>]:.#VC_32=T
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ML@S?.XZDVX?4FA9P<[AZ]I XZ&@6_>#!30$%/2C@2E/O":(R]2K&.B!;8XX
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M$\KLUMQ.3V4(CF DJ16(.V:15BI7V@)$(G6L'?^.L$^?"+;7/BA/*>)*J>Q
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M8=:*^K,1H)[998=W$H[*>+%3)0EL@\)PW6')19*/S(ID8_D2AC6;$+(%;B/
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M,KE<YG?K H:?RYH6^0T9V;1N#;<+[.U++!]O):1GA4AL9MH9C12+]AI--]%
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MF+^=B('P<FW\O*%$)VBN/?B\7B(>@\W'B>TX=J1]+A<@;UQ.3J:(@>02%EV
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MK7"]+S6 ^973YPU_SW(,HF'A]/F7GVMYUZDU.TFHE'D68MJET]B(:<Q'6/J
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M&1;B',P.6)ZJ#FZ-3%?U.O@N35D  1  04_BR/:1_%(8 11  11  11  11
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MT.0@+8;=]1Y+#^V.KN8 +2RNIUAZ:''^O@5E,:P.6* L5J @.LQI,2   B#
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M%$ !%$ !%$ !%$ !%$!16RS;P^(G-O]%41 (@  (D 8 "J  "J  "J  "J
M"J  "J  "J! 5@M9[2_(:C]"5HO:H2*>1E$$SRNK37='5ON-UTV5Q<U"4_OW
M(FN@J-W)+ -0  50  50  50  50  50  50H*B%HA;U0"   B!0..(@#0 4
M0 $40 $40 $40 $40 $40 $40(&B=A<4M2URNJ8#42UZL"I'\^T>A+FL=MPT
MD_I@?__R\G)4\WAT5E[L'U;QF/IQO<^3,U;M)ZQA^Z8?^(YA[!N&89JA;5JN
M99B!%[KV?A($CF\$B1#GNL.7YHK#4+4/G82V4^5^G5*3L9IK7W-6]%U5NVOG
M<@)+[[.*$]W</P1;F%Q/L?30Y&S;UBT[M T3@&%W/<720[NCJ[E "XOK*98>
M6IR_;^V+01_PPNJ Y8FJ^M;(=%6OZD-2"01   3*Q9'=FAL&%$ !%$ !%$ !
M%$ !%$ !%$ !%$"!L'CGA<4NA,7HP:K,>.P>A$<(BXW0-4S?L"S#<.CG_>66
MOSL@*[ZV@^_GLM 7$N/W6<7CIJRTH_)\PHM:/I'VM<RS>+:GL5ICYYP>+]'H
MM[\S:F+-]/8TB]H12N1^S8\"2^_3$-/0_P:TL+B>8NFAQ1F&J=NA[4.?!;/K
M*Y8>FAUTR+"X'F/IH<79-%860F0+?&%VP (A,B280  $0*!.'-FMN61  11
M 11  11  11  11  11  10(D7=>B.R]/GP#+3(ZL2J3'KL'X6>UR&)SXTW[
M'/MV:(?7]CGVAB](;O7'Y_0/[4N:\DK[Q!N*IEK$FTO."^V:8)D5B?:537/M
M+ZQNLN*LAO2X7S.BP-+[Q.-$QU:L,+B^8NFAP6$+9-A=[['TT.[$V!IH87$]
MQ=)#B_/VS1![(,/L@ 728P4JIL.<-P,"(  "S!X#"J  "J  "J  "J  "J
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MWJ TAM'!Z)Y?:6SW&"WL34$HL#<HC6%T@ *E,2JD0  $0(!P 2B  BB  BB
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M18:FRJ.%Q2F)I8<6Y^V;H5#N8HT*S Y8H-R%9A$(@  (%(HCNS7Y"BB  BB
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M*31"51XOK$Y)+#VT.GO?<H6(%\M58'; LK4*NLHE/>@4@0 (@$"Y@+%;$ZZ
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M)*(#5;0)B>BGPW<*&*)B+'=S3D<Q"#TTJ'LDHI]8Q'.H0S'+"BS  BS  BS
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MR,';V]GVR#"LWT1[;C+J[IE&ANW=\QG''MF&N84+6>;(LYQK'X(V0$EO!&T
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M_11;=L*R?_P:^RH]^X:NJ#CCR?0V6:3F?P7",\;%Q+_!7,P8AO)+O(';H&G
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M(.7F,$TVZ*7.<FCMEY7N VT]Q..F8Z1[-'3^16"9)NZ9G CP$S$I--&<JBY
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M'=G3-78*8FT(WDMB4SDZ:A(Q1]O.UN"^IG(G<W)N7Z^7Y&?WI"9^3K:5Q7M
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M,D*?E= OQ$S7LN^ZZQ6T-X7N+;E39TG<T-// L"C>M$A=6[N_8Y>6=.'?]7
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M4\>)%Z1K8+L=D-V.3I)6)#.''=1X]FROC4%?,;K[N9,QN?Q-<UQBHSHAJ<,
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MUB)_NX^Q5;"QV"B$@VA5Z'5T,(U*,X:O'L&OB)9S-IVA,81.\185\II^6DE
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M'=^$=7K)#>M\:&_?P8D\CG2;K<UPS$$9:)%NV\F.B2D# 2^PHATS6@;"?MO
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MR;C1%2Z['3F7>Z)O<]9WQN$$8?_Y[S7G=(!DEU:23>FC="[91'^9:SE!G<L
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MD^]H)UW]F?T/JU_UM_\/4$L#!!0    ( $B(<%:=XP=QVLH  /$?"0 5
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MIX -BD/<4/RP3=)@>19MPS3>U;Z4\K%#W$2PQZ^29$O]\VW,%U0<MKAAN/V
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MZK&#PX@V>F%QD,6T\A:*:6TJ\-%D+.9JQ_'N4I077(4^^+VX*</*6^^T>6)
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M6LN'1]/T1EP1_(:XPJSBX 6S-!)1KEI7J7,@I3$@B,[7<)4?CB"Z]UQ?I>N
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M33]L67G+]K5U3TQI;^3!'.$\&J#:L.WL@T >_6TK?0G<.*IQ'-6 0QQ&8Q@
M29&!;$+ZU A4/7X@+].!B'NNH?5D\&Z]IO+- F1ZV;5:/G H8)_GB/G<ZA21
M@H;[L>:!GA2_,_B$:+SQXG0'Z7(E^[5R6+^%//(_UT%(BVD(]6/' UM5?1;4
M/#"E>[!M^^0M?SOC:]IP$'-#G-$:-Z/FELR-&<)0@$65*6MMVDI4CQ]BXV\?
M$_I?6[XY+B#]N=9Y73[V/67;]9U8-XI2D<]Q-51MQ> Q5"K4@G>5#QZV<TA\
M'B2;*/'87A^0=J;C4:2F=)=6-0C 3^D*0&[#)%@ZN2D/F7K *^:@]D4-#]GK
M[A*ED!OD,1&H5<YE7.-%.%\^!U3X+A<K[8$N;_IR%*$Q-9)J"B4V/C=,TF9U
M^];JI,V:9\:6#&F4_A^3 6D^;L_4+[1;?MBL8GYAR;E*;?[Z)T:RZ)"I#G'9
ML+Y_?>.#4[JWZEJ@G@>0-1#Z%?&Y?N>VMGL+#23+MFMQ2%_M5"AL('YE^_3M
MC[2Z6+\X;H#]EB$8*PRWHK9]AC6=5Y"ZMJWT2QY,9@!1/V\]\"?P;_Z1!4\"
MUD%Z3]O@FK=^?)!3(XI3.+R:4Q%+AP[=HZ0Y^ZED['!]<XP:S@;.:QX8MJE8
MFR:7E2#(U<+:(3]HKGHE6W6V?NO'+>(3:)47@9*>8.&C>#??0)J&QS+CI#I7
M[V :$T7.:/A(K4XQ4%H8N R@2PW?>RW;=-0_-(1/4%<[8DZE4>F"1PJX+I,]
M_;.Q K\K57MIM%[R+!*G*%0QUX#HRC8A7E":S704'6M2**.[O!:W^JAI]=SP
MH8?:,[YLZ!!Z+ VYS<K@-O7708BM@J JKMY;TO34$ [%^,D+I3+ ;>Z$:TB^
M)Q6%FYAOF% !@EP&D)G)SRH-!M]TIMNA/24'0&--?Q_)4#UAK%MW,395AS<^
M.:6=TCJG460?#Y92*:?OIVQ$_#[OSRP-$!Q!91"W:#U6P[ 0#7 R+%8/B="X
M%X^I!STDKT*%(,;UF@H_>-4GVH'B,.'OO::9W%Z4(?[XBY<NGQ7XBFZJ&2^K
M3>\.!(?-2X52*0%I07->GOO(3B< )U,-<GN)':V@T1HNK-+!0]Q1$AKPG&Z@
M\JOJ*BF,&DL6<6,SIJ:G!A#D2Q32W1<O_H6FE]O0K]\H%8/'FDTE\8%1;2\"
M@Z$A?]V 0VA[EM&HL8;:I:*7]Y&$5X&K#[(PDM-=0Q:C'=ICZO!7EU;6\)"]
M:KOG(/;GG+!?[R(I'==3Q!+U;FCZ_$+/O=0K+T)H'#Z6<[LV5%GW1$^K?;-]
M9,'RDD5>]1*;8Z9D7+;NP29:ZSCR0[2>?A#3#%H'):IWD,%3[;YM?,QZOZ2O
M +F_9-N$?^9H8'%5&=R(%] (+GRZ]^(G6E'L?1@%B[5+)2E4\#\BYUD5*_G2
MM8!_JK/U.]$;23)460K95_J6WK]2]D(Q0Z829_U8<D,Y/*"FRPB%U"N_=4\,
MH\,L*?43@,T -Y) Q0L@%57<!:H:O5J=:?F\\UONFM-@-\_<N"@]Y$N'V$.!
M2.^?J;!IE,35.E?UX/' ME2\[ZK1@R9/%)';(3:^!',"P-_IH8B8AU&;DI;4
M9*A:(#S <F FQ&)52'IJB6O8\N'A?.DY(.P:*[IR^)0VZ#ZX@5-]?7^>D6A/
MYS19Q@$R>8"29#XU1+W7S:)6\\G^/I)5ON"?1PJ:]&(E-L1]=/'&?U%5"WD8
MC0E^=UCYK O ZKQ8+F8:JKC,2+N#TN1Z?,[J!X;,4JS/',0[[B&,'J%-&1QV
MB,!9Z*C8MH&RS:E&@=K!C6HJX.HV7"S1P#>!5#U@MJK?R,%DAMK<TDDJ<DSK
M,76KA@]QE6"85*=&7<O(2&U4K/Z9*9W&C=@5NM[>C79T\/Q#+6X+@.]1H'KO
M=PR^B3%#MM!(DAN9N-3B\ZO>Y\<0&R$2O[$5DZJ]V*[\H2M]>VX@@915'M+$
M,&YYD.O AZ=TFNWG:#JUZ6P$6ZJRT//I7LD!^5Y! :'X2^1C@S[!\@JM"(WZ
M7IK)WM?<]CX%E6;_IR!]UNG.<*L$Z;82X?^@1YV[E%7[],L@67KLS_RSO.2_
M*;Z@NI$C,77+XB? Y/UKU#$*HZ@,D;U3YJBMRL$I'6NSQU;A4BYT9E2]H3$\
M7+0BR[Z!CA2'*0C+SNO05UE/,D0 ^2Z-95,'D1@BA524ZC4D?^8'C0'GRO18
MT)ILWMJG!H)6+, D9AVH)(QB_A<FH&)#!T0KM*>DB=4!9OP<,4X&SO:>:S#J
M&1@D(H[65*D550^3V^9)RVT'E*T@$7(N*14M(U25K:Q%,_Y<JF\=2\MB;X#U
M)HJ]>"=\#WPEQ5F$'K4;V=0$=6"M@]Q2\+!Y[&$3A2KS %%T^*_3X-%LR5.:
M]^AVQB&\P::B+#PW-?'"JM'67NF#]!$9#4%@X;@BQG:J+"_7QD8:<-5F04>*
M8\H0;DR*;O/D$+9%IA) IZ5#(;!;/SZF=]4ND:#UXT.HK6$:^)"]$KP89U1C
MG4GC8X-%!D!%W:;/$93OU'Q$%8/'H)$?H(8/I'OS#<UMKNO:2@8U8#!33,6K
MVEADQ;$VC7^QS<J1><O'#.J/W]MC>?29 Q/F#J,V9)Q<1JS1=Z5_^8> QJ#W
M[FH/P\-HC"+(I)UW9]XF2#W6\)4<0& 0S6,IK2JC:5I]IG7-$T/6QC?I2'OC
M7%E9M9@"7^DK_JF-\=22T$A\X;<4/E$3?/4 %WC)P\ZC$&<1M#LNWS7[?[<'
M;FVD]M]!!H_/7[C*5_\*J>O*",;89-D^.93$>-+?]7U]P\\-)@T6A1-2CWG4
MA6)/C8#X>_&W2[RH95%R4GKYU8^U!Y&R7:]Q8QBV.WBC8@$V)C#1U4ZI54XZ
MDQO)&545:;ODIIB%@!V2F9+KNC$E291>JH32WC.B"M,/ZYEI9Q35/& 5?; 0
M.2E# MZ+M-2[7*R2[NG$E9TZJWONYOX^6+8H_RQB^LR_#'Y B L+;C/P_5/_
M#Q&#K)K/_.@'HW\19CZA>1PD_$^F\H>W.[_M:K--'4PW#*AT&9:/V(4Y+)^*
MQ3B P!#6\S8.L5$:_Y8N@S=LF59K>-4\,*C7H]R?B:7B?-6Q<3S?D%L%T5A,
M&6F7BFAEDJ$2XZML.#.:HB(ME9?LX80L&K@%6-KDSS1%!"X KH7%!RTI*F[<
MPYZU&"';<AV4+>*K<!4+C%<LHLS @UO<@X<3&=(!A^4@R36DM?Y8?X;4/#'H
M(5+L:\<-BGV=T4@\-G&=RO5/-'U/,7!TH..U3UZ&ZWNPG_!V2./BUA2&\#U
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MX:OS^OKZ/:X0+,ZG#Q]^_ '^_ -TA*'70/:;_Q DB:0Y(T"51#$!NO_^0\;
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MI-WP\CL5Q\GY1UQ">.0*L<DLCH =BV(XOU*Z6*W 5XVYC/ +?AA=>DNI"%N
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M+O&#I1W$BC./!:LH#@-/]/B>C!"&=T; @"%=8A+N(2WFPHL!P2?A^P6WRGG
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M=J#6@U[4G6M6QG /^C:>95$(YPT-E[OY<AEO/387'@7^R\Y%8!EV3DR?P'7
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M0J&E!NI!Q[T=^E@B5EP=79]?TYQ=>B7YI&) G\T32HL=DEN:<)UVV;5'%M+
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MZL67G%"7%_;IPZ??3%<2%3^4R;-UV"6B@ C0$V8$IB,PG]L:ND(!W2WE]ET
M02!98)?_A3%2N)-4N^=S*O[+?Q;'!#\OGL%'=<MWY,5J18_P]A1@P7PY!2#
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M;F,:L#44J H#308ZP7]1N!*769:$;WG&(^DA&<E/IH(%'(_!2DI'A4N!^>#
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MR;'Y_&=O^DO?-^T*=-J$<@[_$149>:XQTS4#&4S('XT1T%<+.F%+(:HOKM6
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M[M!L*D5G!>X\S7+I;NWV!3L',''7:S:>QBEO.VVJ DG!R]AD2WVTF*][BZU
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M,+D2#G:Y\;3Y>>4$_Q2K6J_6UMC$1^S=1"UP8Q/K>S<MYNK0!E?Q\HKDDE-
MJ/3ON^JZ%C1GSP"US]T9AA;?Y:\R9P<NB3CB>QMV[ZV?T(,$8>);N'@JX\6&
MAU*HD3U!7)X*_)OGHRL,*)&JKK>14_@A5H0>NQA+\V*XCLV8=E5JIUVQ.FO!
MN3CA^.E%^.H0;:M4V@B8(9<GF+7FZ.FUCJM8XM'[E_OP@YL9HW=^,G/UYJPX
MHAW,.,<)U R^C*,F9L! <Y\>@JC*PC))9@KCG2O.*IM0!T]ID6\Y[VD%*4&(
M)PB;=43\T2>]TK96\=>IK=\58[3*DZ68,08BZ664A0'@(+,#HA24'_T=&8ZE
MH-/65 ?V#AGY\V&)]N!F E@% >D WK0\V\8)G#(#KSD)$L$]:8KFW.=/[5-W
M?I\U/)HGN#&;(7!-I^R\.=!-^C=-AW)1*.?#I[D,6* T_G2;&S0&8QT>9N#I
M6\'3I7N>V&VQ";/[H<B/,D)QCO.DY13E!_T3D/GY OY)<YY6]A0G8L&S+ G?
M\HQ',&4QAY,#X.N84FC&BXD[+0L\X'74PC#&XM5Y^GK%832&3'M=\7\Y#$,8
M9>;JXJ\ZMIPJ&"J(4-R4)!V<_%]>E"1UG(H^=-J-JWWV,V[&7\+,,Z#G,G6Z
MP$=HW'I,9='4QO'*R;R$[Q'/+N/I\+M]'/$X&78C&F[+L^=<;D0=!\+ )M?>
M=!O$E%B31:"+Q,?D:2?%C[^%) &WY&&X#J>%J114.>>/E]_.E#W:S=DTZEPM
M4KQ(]KGV]R&[UT>Y<'DN*<>K+G-)_7+_:D'?#F]C=[R6=X8I\KU,GY+#3&0<
M7,NHFP>VA3("WB4R0M5<&3^@$7445>& $5KE ;:>SL<4%1AXY9UT%#%6)N,!
MN6EVU-#)TVGG;7+E<R,Y^.=)<),#B+/ SQ<H=(_DDS\Z6K6JFE->?'%;URSD
MEMJ][J#ZIN._/<;F[LA0F1]XH6A]C:2W2/ASQ7">&$]6=I!,>VQ(\?RL^>\(
M99&NI%"L0R#60<  2<P?MC4^Q7.7NHTIO?J9@"BF_@45S@:?W1[4B3@W+HI#
MW)(;7HP@(5I63G@$/(+KF)T@0Y,U@(;[6T@OH_X"B30!V_2J /,CU&)6AR1'
M61OHL=0JJJ=JL.E+R$_!.*WQ#,-XQ3AE5>U'7F*[O(FNSY?EVA':];K-;]OA
MV6FIDUP8N9Z8L$UER((R(<LP_F$A99:ZW1?L I$C<H$_E&.JQ(@?8B6H81'T
MJM(7GN:J?*JLAQI9Y5+\$.NA^SK&6!1G/HXTR># "/(U-QXR\?B#*:?I<(N9
M),JYD51G/GMJG;A#.Q@_L5_RW8Z?T5H,(R1R)!\D6,3)(L_RA*A#>T1SMABV
M$>.JAO;8V)X8O+BYSG\%:)7Y>DQK&_.>,&V[A1>8>CUJ][FV*2K1K(E:%P#D
MVXAU47?ZQ)J0#6AJ$7X,NL)__<NO_W:^G'3I16V863#>#/.8.\N4?..AV:HX
MYKB50478]Y]O5=3Y.%GM%C'=LI;H)/'*#J(YIG$BC<=#X8S0 JPG"^XP &2\
M;.,D VO-'4^YX!NF 9,Q8FBU#2>#ST.44-5F8D++^+'6AI;+TL0"X1/@MK3*
MHEP:($14_+9[*0EIH6H2$V>Z@4*3\@7CNRBL[:(:.(T#Z0GTH@?_.^!D#/>X
M2D(SG"6M3'"RBI'L-DS(EEV(3&H2&CRH^)#B3H+?8@HQC%^9M@AQC<NH#)&_
M3,*4/=*]&=P:Q[3_H88G,;: X 2)O3S!M+WWXR]+U0UJ6AB'B=MS6PSY<2RO
M[RZ\&_*659(U+C_\D(+:^(6I<U_ 80QEA(OUDC/T8(I%@.X;86V)=QG\,Q<[
MZL+S-VR3@?G*W7(R]OF1G<0?84""J\-K"K*M.-[9'"_76?@Q!"P 3//BWI)#
M@%3[$XS"/IZ?O6(@KQSI'+FM1U_S"VNOLYPKEL."97\"EA=Y$H5@3F#7]"+\
M#G\;(<.[H,IO7$7W'+B@;0Q,<,>5T:7F#++;[Q"G3P)P+\$QEPLY:+FI0QJ/
M6K'-DG;FJ=D(SYLV'^C4Q$2>LFP;QO+1VLK%/59N4U^Y&&GEVB(^]+Q^E?/?
MW[1A+(S9-/FH5'Z75A]W3+HKSZ3FDDYAI'&_0I7$D H"30/A0<-VT$$=/.>Q
M8)$?97<[N)]%U/??2;:*G\F:L*\8C@XP\\9#L2W$,%ZHC>,=F&R0Q4Q'Y4.)
MPX'RP5RAM[EB5GX(DDF=OL<&\%:Q)X<0=X<8Y,QXK 8^UM]FF7):?Z_.D%IR
M]CG197(7;1+R'SF;PUU&=NE-F*Z9#L8DF#'M=\MO=S=??OE?[-B* K)S4:UA
M&J:HTE?Y.-XR\<J1/#Z45XXUH7G-.>,-J!VQ ''"[IEB 4*^ $$QIDM$,)5:
M<Q<Q82B]AX*@?QVNB^AI8Z]1_ :.5.Y(%L,P!1L&\O[Z\UEPIO23(F_H0O)Q
MX4D^)E52=-D&XMD6<=)TFVE5BB%C?2U%;K,+CD?%77'P$R>Q%D+B>FM*9LX#
MH,YBU0SR:R&7EC.2Z1M,@(41)TTZM)8R:;KFAN-$3US09@(>Y?MMU*KQM5HU
M)I^DP[A @(^[3;-PQ[3#0;'/KT)5*&C-=<[4/-UIL9?TBM\*$DH'FQKA<S(4
M;]_K@%I$C76.W-$J8P52V*4.IU5)S9ZD>+L;9BT%W,UOLU(@=H(B[F:+!1>.
M1C7I6).T+I0D5L7EO$6S9XW'^W!CC4/FR3MLMV>R!\0:QCL_-4=4<>4 7C'"
MF?%"+6S@@/R=''%7B:N#<TT6)UG%WWB* -]W7$YZ?T^XC?DNRMC'D(9K_B$,
MNK<424@<$30YIAA1$8KBZ%/E4K*8__Q?B^C"#OZM7/!;;<&_<1 JC8,+KWQK
M!1/BB$8 [612WB:G]^%FT#Y40F+@Y9P>NV/91H.SUGT5E]$9DWNC XA4T/=@
M *>0?5#S_AJ S0#LC.TTF QHM\]%VM#0VE4 -K'61O#V;(@SXTF^,TG;TXGS
MUR<L JYDVR (822FG4,T?5''?;AQL*0L\Y4+VF?!"NWBPC4X_+CLU-6,DBW*
MV?(5>6>EC""B2E9-'V%S\?@L518=#FNH@NA\APWF@1JG[WHG#9YV???PZ1]@
M^MEG[+::L$H2$VYI"08\\.:XUE2L"X5_X1>DSX(?6F'E1; B(4TN';(B@!5W
M>S],N %]D-I;DIG?1.D9S+$.4%E2<FD54ID($'P+Q2L&926+I!2>?P'T+CR@
MZ# O&?!-5HD/4< OA]U;3 =%)@A"GJ TP\G2:>;9(1\/#IBTRL;N@_?&9*E+
MTI^"F[=,"\I7P?+@)?7IF!GX6IRF.>WL/'DLWF!GVL$DGEM^?RCL6H6$PQW6
MX_J8"GC< OS&);21(X9HC9<"PXC3G]"?Y(B_FC!@>6<3N9 @!6X59A"2<1<%
MX4<8Y#[]/<RVSX3R":;;<+^*;Z,LS$: ,>9#P6%3#G:6/%$K.Q- %K_D;ZF(
M3;O]8/\9H]):2=+C-+ET-WL.:,ODIZ]"P_/NAKP$3H"CT\U]UO4C6B_1P@DZ
MS&ZLHCE"?=?EYC4E?/C+';CW1*'G$2#5'N/H"T]3$[8WYWAIKGF3KZV)6 DC
M?8DW7R >AP_&)"5M./>!@5<^!;_ZRY:0[%X&^@TX$20YC]/S%$'G1X(AZ?;D
M!&LM$*]"UG$1H1%9H*;9UVKNR'I.C/I%H]K.D^\VZDZ=7M=;/WDGZ8A1$Q;1
M]5Q8J9_NDBI"<-XBAOR19:36<;GA!M01LG,Y86\9E:\(-&"'=>I'985V<N':
M5S$J.S6-2++%$T%+MK@7P*&YM!9Q/$[$IX@PW@N2<Y\[K4U;4IL@ 'JDM=?N
M3"L3[HNUU0Q9-3/7FFWUG$(<R]>$W8$EY@7<B%<<X>*8N]:86%Q,@6,EIF#E
M2C4CF(:S 8,Z#>.?=#&.-OY=>-H4/#Z'^NH4L"-.04; J@SU:X?J\=PZ[;:L
M[Y"ITMHLG4GD1A/0T,7%,UX-6&NCB<JQ'E0 6D.P5;0.:<AO]N)GJ4Y*&.K+
M;$$"II'2%R8 Y%F<',K^[+L<H>JBAH;N^1F3).0X7N(V1P9U'>3[OV4BU#K3
M5"^PU0 ]KSHI6!@YOE=,H-Z'FP5R9P;W(DFT CLL@OL'%\_C,<N-P'U1:>4,
M^*$:*Z):7ATX^NY<6*F+^UUOQZ'0;PWM/3U>HE+D)H[>O]R'']Q$&KWS6D^7
M;DN+.^"(=C S@<M#VW-/?K),X(0B(LE'P16-%VBV]^5^/"M^:(45&6C&B .:
M@2 OSXT"4<E-'(QPJ_U.*/U;%']&+\1/XX@$_*@89+,1A#V@_.4/(.TIVN+H
M<^!T&)T?BL:*VGG?_"0$':BH93CDE2AB4SE(!D^>UN:M56+$25&\YE4 4XYK
M<%U6!"S5UF''FB(N;E9KP4$PM^L7[P^R%O)M]TA;K:Z4-KAF0)C4Z3)Z)F?5
M#7,_M1-IS&Q.DT?IS!(Z.TLH?&4DH#*4B\(2[T#[/"M+#%L6=1Y,5EE"3'<2
MT,*N)4\[TF*K*_L[@9  $ERR<]!_)RIY_BD)UX,$;47WBR\(ESGS>R ]A[V)
MMU!';,^T;\9P?0=>>&K&GIQR =+@\4D[] 4,@Z,5EJ=!_C@=B+9TB+ ]J /1
MKJM M$0!T3*M6IR@/]@*4</BG([2Z\Y"6 @7?KJ]C():V8W"/E5B PXS'$\0
M .^,$R4G0>@:I)0W2\QH9L1RF%9.+Y-UA3<_6:LIL;]VS$JV^%<P.)-]]D5,
M4':'C:6KVI=!P!8NO69_728KIAP7BQJW-N.K]*^33]P06:G%B#^2HCR2SD;O
M3LA,E8!]A1^AXI2H^A"J.1LF?H?00UJ*<L?=?E^QVS3E"=GB-C7OS&8[Y+=H
M.%+2MEW9UAZ9E<:=U\*&K2T2"R*)-%HG8'.ZB_B4[L-=F%W"#-?@$'EG'\8R
MS]*,G=J02\@5MHK'91G=^VDF\P1O?*8K,:DMYEGC^A*X'FLN&UI#D_U%Q)ZU
M[N=F<\R](#3SY>81 KJ9E 7F#!Z*G:[BKR0BMX#]$+VO(/H2$H_68%Q-)61W
MT'C=P\AAWY[L#DBS<'T-PF-RL+]+8T/L6[+%J/E(/OF3U'@=]NF(S-PS2=D'
MOP9)]08^G)A[$V7H@C"VF5CKT0V9,4NIHT48^4P$T4L=M5TRQU/!WJRG&N>*
M4_22;<N=0E44*&0W$%I$H@!D..-&=SWHN2YJI\53NZ)KMJ9G DYWGI<:\8V5
M^Q3P&<PGS9PFB'GI%AOJ@8E&3+ %GB W5,?%%V)"51>!?U(_33F.OK"_/"DG
MFO#C,TU_J]*VBEK7JU@LX.L^CA1Z:,6[5272N-3G/5U$E>R2K40 J[&@_GM=
M#ZL\/->C0<ES=02B43]OVR#8B]9,$!8Q1D;F;8TQSYE:]F:Z?,M\0!.Y ^%\
M"Z]E$2?5A$_- L2DIYS" S#Z,DF0/T\;IX.+09#??&L.K.GMMW9 W0%<LX(#
M^C4*2*($8H@U@:\-I'T0&B'HH/EB^_?%9+&^HV3U6-A/8BNR?]3WJ$F8'DP,
M<Q$:*?4W9)^0M;B'H7"%EDG=8/J8SIA,<AW'#P-VG@@'3WH7"<?07:2))LM-
MXRW:7O=@BL@'%=1+(\1\N![85QNF/ .-!.PH9DT%CZ8#["1",S/#U@)[^EAC
M3;% 2)N[]$I8Y*@"A?4NVL3)CO_(P60 /5RO,M#8Y>.1QC<#94D(:K?9;6G^
MU6['&T(/<Z_4=-RJ_/P:"4C\1HH$Z%/L Z '%6Q1-;1;-H_#L;#E>PA(YUD)
M(..83:-ZBUD)I<7A_,AZBJSB;L'4T F9J6NN(-Q%,E6:RY1AM [WE)0_O8!I
MA^F)Z>L^@(H(.X#@3T*?"O^MB>\QZ,[J?4M]V6A7,[?$/* >_._K0T:D?Z<&
M1]XX8EI;HQ\2+868;W=[&A\(J1BS(.GI&$=+%REL#X4\\(M-)NO8&%FT-D9F
MHFHQE&[FTF9L8J6C"_:Y65ZFU_X^S'PJ9@A*>O)!0*%9Y!E37Y0!U7A('DL$
MT]2:,QF5S2=,=G>-D)?*0^P#PYF3XS&6TE9-)./AM3?LZBKL]-,Z7_K/ZX=]
M-:(FDB4>&_O]'#DYW,@DIHC6BYB !:JUOHDAZ.@4,LB[LXA!E X0!0MKVBRV
MMICOKEQ<)07<^(=T%3^3/?77Y)YD&?QXS:[4L&F).ZHW*IO"3KC\9$HNF,6+
M3=1DR=82>:-9%:!?__++__KE5[NYI%=').8 LN8IB8-\G2V3%R:^,&4"$&9T
M/FQML.V8NNAO7WU#LYE,7)H*FZCD;6Q8.\W0I)ZV&I7;>\SD'6EVMYY;3&\\
M*U.(+<*'/X38GE^ZC23=-+"WH>9KBH0.NHTINT52(>\9-V)''V26F+@B1-#Z
MN6QL@&TQD AS=AFLV@)3)%F1W3Y._.0@7G-;0"_8Y76( W8=[L(TC9/#8YP9
M@CO&(XW\/EO=&)I=IRW,]E@:V#:B$VS@ET&\S\SA70/(H08-Q GLX(PL-QN0
M]R( *(4?V,9<^&MY7EH4R6,ZHZ>&@5(HIAN"58_-6N8G7,=!Q>30L\LL].'"
M!=?V85J:SH*!!O(B-\]<!O_,96YOJW[?WA7;GM:0,)X)'/]"?GS9T]#XMGIT
MPY8WDW<_D@%/[$I+8QH&*ACJB9WU"C=PN9$I%@(O4Z BE/F*K5K#V&-@RTM)
MO"8D2"%23OBP;&XP<TO4'#B2E=I!G(+PS#X]86JZ]I/DL(D3L+2FJYC= RFQ
MF1U/I(.<"FHZ:-1=KR%NWC!)[\.'9.DBBL!@=QU #?LP\WF %&Q(D.J7&YX_
MS6X1QD!+V'=GK_GHD2U&F=E98=KK,CYK".TF=OKWQMYT+?J4-2+@B-B"=D+8
MMZQ^5E;.QW;[3;TU]A?6%CJK@G%N<L*+JF\38O3^'4T$\]+0;_#+;+4E#W[R
M!Q1H$H52>*TF%3+ BPXU+HJC*6!_IZJ,=0'Z:7;AUEMA1\O7(E<;\:[%C#6L
MH:82?"*AN:A?/>+";6U1OS(-(^,E?Z,\.HY]'&*NS4^JM3GZ]W-B<,.#_SW<
MY;OB"LO?TG42<L_$Z&G>'6.A*UC->+3V?,SV'JBY#NR4)^F5-:77HE_UZX;H
M@+[>AJ14UX7-,&DRT]$4^ULMX;'4ER!<Y98/B])897>#VO<>P>X2XB>_NNW1
M]2X&FHU,:_ RWL@L*CA-Y'%]M*?20 ,WOU0DA185'BR?KJ4=^IE:BJ$%TD B
M='J[F[6[%[HKX&7G4WJ5L_N?5#5D2Q-L3U4/";/Z@];2Z*L:0A#;3<ZH+S>:
MO&)UEYL:H@O=2OR'V5VS0^H=Q V_/>ZDNQ=VR!Q/BVXQH%4:X)]JYNH[]^Q;
MO\N(&9RGN]>9>/"9X!"N31P>10#Q" <TV<N$^":WK?X,6TX\5<]J8C;=1>PD
M9MKJ>OSH^*[!4/U.<017#YL083M0X=(M(TW!,4?E].UXYCMD$2<;$D("4@%U
M[V)O&(:9!Q  TV[W?AC(UPON1!X (&\9<>78X8X'$\-V 14^;IX[7KQ8&3C,
M53[^7M^T]]H*DSB,(K:;H731=7CPT,4/\.R"@VEMR=%I;XEX\][(HI#B$+B-
M@IN:C=':"'MS"(=#!>'0[K2VMYX-OD='+H2Q(>:A#06[E4EJY7^7U713A7Z=
MWA#YEPK>&8>R%ON(^QX$7'OSOA^5.K:N'_-,Q;4H0LRTCG>HH&!_U6WML6^H
M.FX6^XOZ3=ZS%8DD"M2;,XLL-K^BBW'PEPXP ODA%+[EO$H!4SS+&[I55^W?
M&Q>83L]99 )YN";B<[PZ%)9_R-MELB>P<$4V<4(NHX@=R>RUAB(JMWX%C4SZ
MS%6$UD)8CA.O3YL"NJ30##1Y9J?%IQ #^L:F:%VP37.UZ*Y:[)> +A3"/1AV
MC.?)L30P3Y5O3&9.PGQG<;14'R/Z0I_A\S%EX!8/,%?Q*_6_QR^[,-O^C<)=
M$66$4L*E864(U2H&\*HE[)N. M[O:Q+G>_F;Y36,3!_;J\GS#KILX,U6L\!8
M[P<Z7H;/--[ER92P[]8J)'6K1&5KBWVX\]UD=[C,!')7,[Z<B+O;CP+VAFH#
M,+ON*IQMW':#**(O!V0X1L%]O/;I_V5S2H-PW>[H[.B"C1500\>]@5*<YM@R
M2U-T^U$6"L1F4 ?!EVSSG9M;8F^HPE@_L AKS_*'8XV">0K_#=Z?10C3GLVE
M5MP)%528*"6=TFDA8UB562<#H8<SR3*K3TS_\NG_"_?VA&93RQDX%!9AR@Y\
M<;DMV&^-F"QK0_0350^2:C?%0PO<M)0>PKD]%^!4&K@Y'DER6(@\J+LH +,H
M4QJIH71AC^;X)F&^\BH)J)$YU-IP)I,O3/1P<!9ARY\V!-8>W?#=-840KN41
M2'F<!$:LI<Y.Z"YJ_2NW7J:&9JC^A'YHVK.$T=9 *U9QB?4(M5?N(AU\^*UN
MB'\F_Y&'*3NF9'* N!ME @ TL+X^UV.B%STJ/3D/<91!3+.Q!'-+6TS[,-G+
MV[78J1Q[AB1[/\D.9NRMHSIB&TW-R;Q&RZFY*3;R>^^JLB:>^O>>$73:,_'7
MXM/G=Y=PHX,OM;S1%L2'4$% .WLA649E@:@C@=1&&PC;9*'R?L%EUF9P,3;$
MQ06C5&!Y"3MKS]NU7S?LMZ* @C3P(!7_TQ8@V:<?=G9,#9"0"Y;"@FSBJ*7Y
MF9J$+(::K^S" V2,LGZ=,M>-:28Z>G!TT]$BI#+3PVPP*I\CRD(O[ SQF8CY
M&J5[L@XW(0G,LH^UX7P.'+CT%TQW;8W$;FN/S,J53T'M?MD2DLG \#*NK)6I
M?CUG&/]C IJYW#"!&E2$1?@Q"+&F0@@7=("U"(JJW,O-D44ECNR/*M6:4.=*
M#="H)?;H@\D2Q+F"D?E*!)]E2R8E%V#=#69:6V,'19D!(;1'\SG,FU"=/4]U
M>T=LYO*W- Q")A%JT'U6I<76&)L)H]6J&;+Z5@]9+=#?$J:V5$IRMN!1N!L-
M\T"QX\EU')1].Z(;[G?[A&P!!.J#"! H#JL&KH:6;[A'-_PJ</<2"*8NTM<>
M8[\!ZJ>I/#3LR5C-5M@2(FSKF*.YDVA]N%ROD]RGET(N8#]:[>V].J+[LS](
ME!,1VR(2X$#OO<[3C.WTI =4W'$4L-^E B*TIPEW-,4\HA^8;LY6-5(E;46%
MB=V>$H4"]9Y3CL5?M"RJEE\S8N':IUJ4=>,D'YG^7 Q*5P==$^7!Y.SK:WWY
M??MBRSW5*.5V$X.E[5S>DF8:Z/=J3!WF@5/PDN_WPCT!26=,&MKI:?6KN%X:
MJR]DP2"ZV-X_#J[0%*;@DE0"U1-$=C-).A-9C'SZ\9.?=%2[&(DT]K=\JE8A
MT^YNOS,=(DR!,ULQKUJ*NS%4!6$:J#%R<<88"'U:O_L,&,W6INC1.[4"$M57
M80-#[>@T(Z8*4$%=9>YBRMAI9LZZ%I#Z1_+)GYB1[DZ@,[> 0',E$(6+:>+Z
M2!*8QXI6$PSTGY"D]Z9LLZZV^-^@&0*O54#K[H7K]=C[1; "DYSZ>3HZ^V";
M5J )W*I<'@S3/\1W 7\S&[6LS;'C(H>EX%P=S 1L!FV'P\TH&K)/%.0,++2%
M9J<E?\IXC&!9"[5H!&94XS*,IZW+<=!/ZDJ:AI\L$^Y\$C* VJ[FT[I/3]S
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M%F55?H+L).3 *9LX 3W&LGM[=T<7#9_).R__&F4F$$A3&VPE7Q02K)4/[(&
MTZLCMDH/DD(I(#PE\7OB[ZJP;I=YMHT3R%5=Q5>D;&Q.?1E"$!OW4R8D*#-:
MJ^7&VAC[C9;A9&:<12W&OZSY4@8<'(/\,L8(V,NE4C=XU)T"S.W*\Z@W1F;B
M]>5K_$&2B+\"93[L66^\;U_T6$1 U;P7]9P*6<VJ3[<TQ]YPO4$W9HFU82T+
M8P%V:&L_AS<Q )@)E&\2 $\J)#&&GS3#5<VX_$S 9LGS7D3!]]RGXP=-CCZ[
M.;RFDVS^_#\0R\Y6 ?8?")-VT[*+<;"7KDC--E4MM+?"/NM+V]Z1=1KZ]<1^
M*Z?&\ISZ90]WJSF=$:)**H6<PR^_OJW"C#;4T?IS5%CKPF"S(A&[3.]V^X1)
M;OQ=J)*-S5B'7KVP->S2:&V74QN-YO 5GW(_EZBR'0 28Q#'M_B#^8,)@8 ?
M%UP=7E. KBC,4Y?K+/P0>#4MI_KQ5+ -"548 +O,86PX%W>G]#]R"W=7C.+1
MG5$]]](:=>,?4NX>H_Z:W/KK;361K>F;[]</6T.K5_)L!^@T*FW'D4"_/BRE
M]=HND]8NZ'DU'R3*">0.*EWL]S#;7N=I%N](<OM]37,0JL#6S_X76()_3B"#
M[AU@XDK")L-5DF7"3_QH;?$2F-MBZRZ&ZB^%!U5]5S<Y 43Y19Q;\FF/HX']
M_;&[N>;D*&N,2B=(]0>MI1!3FJ7:Y=YDFY278(2DM]O-AEA2LR:=P1R2HM@(
M]8]"?X8=+&^N/<]^$#=DJL+63"^S=^<9&=VO)32A++&K[.C'VM][DD$_I5^V
MA-)6\!:]!78P 5-SUQ !:[9RM.0/]>LY%W&])[R<"(9(*A&%K>;!40>86YP%
M%(:7OY70#23Y(*DJ8^'3M!ERV"L(XT3:/\!^Z@YS'4H<6\J#L!H]6:/U"[*W
MGA42%+MF>/Q;Q-0[ICED!Y M95@8!&N8$4\:6O)(=&=@%5:BGRE0R=0&U:;Q
MQS6[<9D2!  U-I1'4R-LY4&+I&C]B(P-L44+]DT'(<TA4:T4TH1B30*A>._V
MN:@!M=S40X9:^1V+-K:9/'R/.,AUE)7 EMP6"%6A6L.,>O4\&P/W,,,VZM%R
M-("^4)[ASUH21_-$&H\VMLU_MZ?Q@;!O-?D(U\2L,CS&O)0$$2$#Z2H6%5:+
MYP"(^AAG?R<\IX?M?W8]"OO$(D[D3]#.&#$R[0RPSY6!X3''Q\'\ZB)*YX1I
MX.))%ZG9C$L% &#RW?5HCBUY]$F][@"$ZD]@5DE \)&;.&JV0O>$**,ME_M>
M(S#_O;RV H[9.^"B;!BMFNQHW?G@^FW(@?U[8>O";=X*B9U[Z(XJ/X$,]A54
MQ,&_@HE"7I;L95V1B&Q@X['C;R'R;HZ)JC^6VDQ ,.UE/"_AX2A@F6.-,9N=
M8Q;23*>8B#05"D&/SVGD(6:^8'K*R7AKU$T57?O\U%3C)([87]<B5KEWQ,ZQ
M-&8@M?5!ENC3'MMZM%XG NE,@SE;;E2E6! JGQ*R"_-=JE4@--J*3J*$+9(R
M/0<\;'PRRXX"+];&V$Q4Y)5TD3,YA3PPO6V7[U2D!I/=2,C1.GKGW/<D-!=7
M$4<A2>_!>/^K_1VV-,?^$GN6L#9^>SW[HE\51E.C. Z&1N*V4$&N?L4V&DG@
M_'N)-QD3;PQ%;#N:SA!61EQDCG!E3B*.'8ICUIA43%=:*<<@ST[!+>")Q<+6
M;/RZQZ$\ YG)8J@ZTJXU T8JPIS8OKWD/M$4U8]",K@@TH>0_2>+(Z+N]:97
MQ-82-?^(PXW+>CL/?AAED%"T)@O2/%M:VB*QD";9OTMQJGD%-![B8D_5\K1*
ML:]I&K&W1;VW3LXGE(4!FYE18]*=E<Y0V#A[E9(S=\&VSHQ9\.0Y3/]8)(0I
M"4P<8Z??E,566L:>A9%=Z(8]C#HMS<]UKU0!?.&$FSK+N>?0V+IL\,]<&GB8
M1MIBW;.!W!Q% !\Q6"0%Z!AG-L:LC;'?V)&HJ/.#/Y7NXAW;%F)O0,F0QNUM
M;(5]'(&"L(UIP%1_X2UJNX;MK1&EVFOX.$FR]Y/L %&H]>UO:X.>12+S]^0?
M]V%$*B$VK0VQ%5$SM)_EX+&WQM[]SJH*L9MC0T*P8:<SJW=TS,RP+X8"5\AV
M5>L-L+4:6&<9P=E9F<G:&/N#R-]2\A\YVS>WD*E@]V48&_ZH$:BF!7 VV-PR
MQ+XF%K!R<TML/;&>:F1'2#2VQ$X<+HME)3=ANH]3GS;*9O70?T^A@WWTC*.=
MEI5M^-=V!Q#F41JNQ[]ICQAW)E=3_\J![3U02YW%&02S^51$""C' '\[R^AR
MO0V)L 0O-X7WP% ![10JV!YLV^MH=5AW=<(/<+97D3<QU-H!^_+IB5MBMUAV
M]T4U<PA_5I'(\+IG#Z-,SJYI[VAM/L-W!>DEX.F/[/B:G;W.]19MJ[U^$T*T
M2Q28_+63#HRY^6NUJ!N[O?8<W;IT36!#,D$D(-__1BPP);5&R)NW!,M7R)QU
M'>.:YYK?09QG;K8/'TL#F>6ON0]6%W:FO-'P72#?2(-V9WV-OGW1CZ0XR>"0
M[ CB-;7#%KGT>EP=<8'-AMC6LT;2>!L']M;X;*@2GGW*9%OQ]BU,CT(;^PLK
M\CBL,[2:0?KVQ45J*01]#F3W#J\L3@Z7>XC[\6FIHEFB6X\E,)>X\@$H06W?
M^ICTL1U1X$Y-V'=+GWRV>_M4I6KM@6U]+?*F><2QEJW&#RFP%Z<-,;H=1F0@
M2=3X=3_=BH ^ N@++0#NLHZ6'S9CYDXA@LFT,G"8L0,L!UR?3MB75-5C9+^0
M#.VPA702,86?@C00[,*(E^:#?-H6,U5'%VR#</+N1U*HN69: Y/X E\*/$\)
MVTN1@E5:A!"WS [+HDA*Z\TR"F'LC3K0(8!8AV3>!4=ZF7!;H2VZNIWKSND=
MBRMB])W;WUK&GFTZF/B]:F-N.GZ.)X%NIV[!JYD-3 V<-<O-:RHTBN5;YD,!
MZ;M(H4,RP<OBVC!^Z:>3PY;?#96SF3HM@T62!S];;Q6D55%9.UE;S!.G4\.V
MV90AU) E*:![2,5(MHI'*(SC8ASL3XF(S:[P+-ON0U-+["M0PL+>D#TD?QIO
MJFJ3.4;0MQ=*[.B"S-!#')'#@Y_\0;)%'@4M&\C<\AR"^"0P/5<DZC"-W*!Q
MWX8L._(0Z >&22S6!#_EF5[%$C<*;D^([TFO#FW!M:,0QJX%9;-I6Z,:VWN@
MYL5NPR2X9%,)6@Q!ID;HKFBN1OAPTY(;/_,-V3U=;>=X2=A]T"W-T=_%4_Y&
MP_6"QK[E!6@-L&4)YU5914$[%Y:8OF.C:Y=0N"]5E?NTZ=EW=U>?.50V?(3J
M-&N:I^P8X=HDTP/ )'L+Q6"C]Y6?O!,3[L11W7$S#@WA@O ?D4Z@L@P#:;7A
MCZQ&D2'$T#=PO[#)1_(]6WT2^D%XG):Y3,F)M-"7@,T3DC(UIU:+U-_2'%]8
M6Q,2I  E!*8X@6\:0IBVN)04BH5%;NO7&?$&OF<:!7W:,K6K>?&8GJ.BW62K
M+1'*H5HYB\AI;3E/4"S3YK$TQ99_BM"<>G$3B,!8@UX&]5'(4>#*1Y'"7H!3
MA;!6]7\X5>1EX?$WRTTM8J\/UFV_GG.XSZZK11]L-@I;VW/=N$VD%7<J2F,0
M]/?>%+]N2+I.0C[?OA*;U@4[F?-I:1?#BH<S7/5;]@5E(/$O-V*OK.+;[^P'
M8R+T403._+OD" E%HJ?5ANA@&.R (3#K:D&B %W0@N5L;3V7P-KV>%=^3;Y&
M\1M4*X7SD0,VU\HQM]VS+L;!_G0:T#^/<48$ONB><7@-4 =)"H&E,&]C@:YC
M:<QATTL#M(B4;L%GM[3%OH*X'[P(L;N7+BV[;[.U _86=(:)4^!T.)"VCAU\
M#HO<551B;I4D%!SU#1%_LJLSX8'<M?K33,_EJR^^4,O^/X$2]COKJ..B[=+4
MMDU[) @-)(YJS1*H@6:7-G?G&YR2Q_7$W@/CA0Z[4SGGXOX2.1/5*,/TB###
ML 9\_Q 'O%*O8'+#U9^BE$EC2TTU,.H'IW)/?@^S;1'K#[=@F.7F4C?']$,T
MXM_$:WZ/+\)T[=._LU-AP7ZIO.669C/4]DTN+ICOZC,>XB63)+##R4SF;F-0
MF*DA<L',FB12J_<,N47B<E+"B'9*-#ZL8>3PLSS+VR8*5 "?]-- J%9[#N0Q
M_;%#IT5*;EO0<Z4%?L![%010-_L06U1[6Q?LK>:GVQI0;5DJ4@+95G_0(6W;
MJB6/0?A<A<PVD)]O,65DX/:8,L6I=73T0 BN<AI5S19H]![=\.OG*$5*@H,M
M"!%%EE12ODP>U1XW9<03">$6M=GMX\1/#L(<Q%Z5. 2Y\?-)5A'CBD$A2ST3
M,(;Z]'4?1RJBA>.,L9^S\$VOM-=8(K?#85OQ=;5 &-5L_F%+4\R=\"JM?5J!
M+EAR)G_2@\K2K92;D[JS16$:1@[]H+,$V[=G)O3HAJUGE2(-%%0\JLA"W[YS
M?7<]XE#Z]L66Q:,L#" N*OS03K_VY+"N/OB6\GA'0/3.LVT,:7BVC\S<<F[J
M1E\= U^Q8'N>Z9KW]K0C^11[S^OB8K<:6FN(;# 1&]8 ^FYL@*U,%8Z5QFZM
M(G(=$]YY%"EL.4ZI93(T@EL.BQ]_"TD"\OW!?M8>10#_X*W9WPH3ZK6_#S.?
MMGUL_7NC"SYKJ7QJ54];DA'LS;$94= :K:):O=&,5,Q6I)-'\LD?=6J._:B@
MOZNF2^*9P$>O8W3W=68T>R)ZFZYCIGZ;MF#C(6I1!BWYY@7"UP*V@50RR"/D
MA2B+ O>8-S;=D?WGF5A2B!=/[!BC4GU3"$HM4'$#R"%6W6.O+,C77+Z0. II
M\Z)N;8B*))7O=GR+:881,"@F B125 51>\XN?PVE-<-ST^;*73!]=J@[&&A@
M"]W.POA$QK<*VA[5?W'DV-B[JE&:M:>U:T:ZI,%99X*G;[CL6FQ?8])%//=E
M.?"F2-]X.(OH;?:A)63+OC5V](@;%:Y;\ Z1X+>80B3:5W87@>%E&97VNLLD
M3-DC7>3E8@B[CDV;V-58^.4/3.!I8J-6P--,B]*_-[8=(D\B7A"5?7:+\#LO
MC6I76>VML:^VP@ADMD%S1 OV(D#(AKV:*RC>>NA3CU#@,4; 7JXVS5;WE"DO
MFOE./YH*KHF@!GZ>_IUD'#D1X-'AM8$X%QM@I7IVQ'6LYDS&ILOD+MHD D&<
M9VN7 /A=M_/1%+ /+F7JY'ECZ3T$IO^UY>2R-\?^%HN#I5X=ERE039E8RSC0
M8?K,\C6W&%QQ5^,QAO0))X+M\;'%@39%<Z,?J']W;+L-1$+<,MECYV=FD:7:
M8@8)*\I1KOO(VU_+\;VQOWWS#<H/JJ'7L)T(-M/D'5[&,]E#=:DC$#QZ=<1F
MS@UVGH97<?G^GI!W]HVZ+^]\\F3PPPW,(3;LC-OD]#[<&)>K1S?\$! 3*#K<
MKB5.KR4FI+LCZID? +Q@'/F46U&[:OZT-T=E9).11.;_V";?:((=]U\:[X7R
M)L.>+)NII3EJ#,QNSX1\,\JC]@S]@I FSQORED'$ICW$P](4T2.[2GRPY+T<
M=F\QU:?<>#C/@])JW6EKC\[*6Z893#_\D,*L0"?S:8M_[I3^N(4N1?26<GU+
MH/E.>;]G/T2WP2K,0*N^BP(HZ9W[%/)[>0E"$+*VX7X5"_AILQ/YR.[8YUNM
MA%U+*+NE*?KW5HLBY X.RZ%A:(GM^JG&\U33[?6"OBU1&<?20,>$I!!>\+(E
MI #ML>TY6UM\":SN/VOSN;4TG\G7<[T%G/"TAU;?W@/S1EK$4!YU&:F;9;GA
M,J]%JF]M/2\S9W^+YCS,9'6AI2;2E(7,.5Q@Z7@&;_,5V<3@=#-^1Z,0QC9V
ML ,-4FRL"6/:\SD)0?7Y6AOA!Z^+6,0J-F'QL[P#9>CB9;8@ 52_!1BY'.JL
ME_W91C*]H%$'0#TOE8^M$@XH+-/-X[*E,?879;,#MJOK/;KA2QEJH9_\9)EP
MJ$/A*%#1"1WV'ELW]-(^OQ-*_Q;%G]$+$UEC )2"G=2H,M#:&/GM?/.3$.ZB
MUJJGC4;8ZEZ+\ZF$-.V1NC\*0?SOJRZ6]W9N]>V+_;Z=Q?%6@9]'=6<=.?;<
ME]@*-6GD9O0Z[.,-CZU6# ODLU<)&X4P]EDF4)EJ =N%U%:&A1D/L[Z=2R;_
M][^6/-ZSO_V?_Z9^8?]Y8UOM__Q_4$L#!!0    ( $B(<%:A:H/X"E4  ">&
M!@ 5    ;FMT>"TR,#(R,3(S,5]P<F4N>&UL[7U;D]PVDN[[_@H=GY?=.$>V
M)<]X1A/KW:B^:7JGI>KHKK9WSHN"3:*JN&*195Y:7?[U!P#)*EYP90$$"3)B
MQI*Z 3#Q(9%(9"8R__T_7W?!FQ<0)WX4_O+=N^]__.X-"-W(\\/-+]\]/;Y=
M/%[>WG[WG__Q+__^O]Z^?7-U<_OYS6?P[<W"3?T7<.4G;A E60S>_.OCIW][
M\]\7#W=O[OSPZ[.3@#=7D9OM0)B^>?MFFZ;[O_WPP[=OW[[WUGZ81$&6P@\F
MW[O1[H<W;]\6PU_&P$$_?W/EI.#-W][_^/ZGMS_^]/;=SZMW/__MW?N_O?OP
M_9]^?/>G__/CCW_[\<=*MVA_B/W--GWSK^Z_O4&]X+?#$ 3!X<V-'SJAZSO!
MF\?RH__WS6WH?O]F$01O'E"OY,T#2$#\ KSO\S$#.(._!>4T7A/_;XF[!3OG
M+G(Q>;]\5YG/ZW,<?!_%FQ_>__CC3S\<>U%;H'^]+9N]13]Z^^[]VY_>??^:
M>-^]@:L1)OC; A\IF[^VVG_[";=^]^'#AQ_P;X]-$Y_4$ [[[H?__G3WB.?Y
M%JY0"E$#W_W'O[QYD\,11P%X .LWZ,^GA]OC(.%7)TZ=]!6O)(3^_;OW/[W[
M(75>HS#:'7Y S7]X@/_Y4G)#^><B]*[#U$\/M^$ZBG<86$@E_M@V!NM?O@N_
MIJ]ORR$1//];>J#TL >_?)?XNWT OOM!X6P>82N OG[A! BIQRT :2)$/[MK
MSQ3?.S'\T1:DONL$9Y!/'$?_7(Y_29;KY1[$>/$3R!&7T6X?@RT($RBF[J)$
M<FGDQ]4Q5R(YCVGD?MU&@0=E]O7O&>1[WM0DA^EWU2Z=9'L31-_.6*#6$-IF
M<#KOKD#BQOX>L<5R?9$E?@@$>4QPC![F<.$D/H3O/H:G7YAB%H<<_NAO0G\-
MMS&4K*X;95"TAIO[*/!='\C.\(PO]##_SR!%._@>Q(];*+XDYT;IW0/=-XX?
M_^H$&5BNC]K-+3RQ8WP<RJZ1X&B]\./I0$%R-@H[3(<]2 ^SN -0,Y.ENMZI
M!RHA-#L_Q2N,3S6\!Z'B+[_'!4;2,9\J 4'@/$=Q*5[N?!<>SV"QB4%^0KSC
MS:C+6#VLT34<.SH < %"L/:E=P*MN][5D%=/1/KV@#:6XO#  EC'@ZLN<2,1
M'*2'6<";;;0#*^=5>A\3>FKFE.PY ;]G<%==OX@(>G[/8>I,_>E.YG6HE?,<
M2,^4.89Y?:K3G*3&-*9;=9J:R%"]Z5F=9D#J:NR$Z30#D:'Z/6TZ38/:W]0-
M?N%Y/OH)VJQ'8^(52!T_4'*[%QE_@*<84 F,GH_W?]:AG9?E],,%AI-RX32N
M_"!+@==HV@TH9=_K'YO';+=S8O\/D"RS%/D2/+R:*5QP>! &!TRV_P(>@9O%
M<&U!<OWJ!ID'O-OPT@G<+"CFJ1'/?FDTK\?D\SW 7S+;=<-6R[?-8Z90["GX
MDGD\D'_0RP+XV\=M%*<K$.]NPQ>0Y/8?/:PC\\DA(72Y=<(-5''@0;<&<0P\
M;-ZXSV)W"Q4W['F^\YUG/_#3@V;DSB#%V-WD1#VD>N_XWO4K4G0!LC(NTRV(
M+[,8^1P720*ZLIZ&+P\"KV@/XO2 '.._9_X>,0,\G'1!)/(Q8Z@HU5N[?F
M/ %UZC@#7H.#RTT/=1L]W"'[V=[L!B=BEVO\DV*/=X-!:LS>YE@Y.;,]_!C:
MFC4V?0!0A07>*BI"',)-WO$<$%1]M#>4%$H(\0$-\, G)RVN,<>0E@+ZLZ6
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MCR"W>4@;85!7;]??0D+M*/'SRQ\'OU93[43F>_3&#\#G;/<,8@)QK28]$?4
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MR"2WB$A/LQ,2W!RL'D.8 '-;T%H/@7#^AA O83FB2!71@V<.]!& K[V'K7<
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MGTD-,AQY1? =G^U\GC>*=A*^&$F$BG6UP@:5NRPXTI_:WG2L3?>0C&,DNW1
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MQ9,>P MB;'S=?-P'?BI"K$Q/990^A5F2.<$RO@W7<;[Q;U.PJWAV!(B6'\0
M STE4(&_3E)_!]5V6@V:1B,C-M30A?CE?H$'/_EZ"66IGZ*_44VF]!Z&C, Q
MV,)KDO]2W ]DMJIP=Y,QCY^ @[@:W?1DYB;>7]G^)CQ/?=Q&<;H"\:Z2LZSU
M2%5@UZL:VDS!2G+R/+%U%.YNXG:XVT,NP^\^X_+Q_')]%X6;.[BAB@SB8M/L
M-)21"G2YQGFY=>(-$)P<IY.Z.HJE/IRG8<UB=UMF^#DFM178;%V&43:'%=CM
MH]B)#[G-7(!<3@\C)=?A?28#*#4;"F%!:NQO?KJ]S)(4'C&Q&--(#F*FLCR
M-T.4=> *$AM$6"X5Z1MR^JASX_<<5LB6L$(A.H"Q6-$\6%)L/JP>)LPD1%]2
MGO@0XGV+=5-X7&!W-I,!NXQDTOPJ>(C2FIM8*[!!^^ ![%%".;DKM%C? ;S_
M$YL.KY>1"K/?*@:*. KA7]T\M%!FH:2',6V>E'MD+&H'LKRHF!AH4L8HRPLK
M2"#6P2AF>7YDN3W:-+59GJM4#ARF@4]'3LP1(R5J2=22>G&LL$E8*2U/@28A
M\I792?O(CC9X2.7MK 5L?YUAZVS#+2#\,$,H8!,NE=WY?M#-0EWB-]\6N-;Q
M$JKY;M#%#E^B-U\>A,W[)63S+4+6@5 B-U\DN+Z)$JIIWQW.\H*4$,YW!;9?
MI<1IOAQ(.'%*T.;K@)"3J+3?3OL^T-T55>*G]3XPD*2N*U199S1QWR-.[?KH
M;H&7!<B9T* *>0%=7 XFR%+@X17A>K [CF9TX@NX!3U$%E0>3O6=KE]1>1S@
MY;>HW3XK4Z;+)L/5\"'3DDXFBVYG!K/<N]P-0W6\VH<K>J IC,=UN%B0R/A8
M7 (C3Y.3]49&PLY*)]0*?F7QZM.>L! :&B?W$J*W@?LXK_KQ">R>02Q$/K&C
MD2C'MB^0.0U&!Y,\#H4'P*$L/#X_-33YSN;B4$W/BVL PA-#^)D-K[N1MPK/
MC#J=0GJLU! F5Z]20+X(1?"6X0.B'!7AQ8%\3V'TG(#X!1%]&T+=H*P-Y^,-
M+[S2*C]E6OF2S4/?/, LUTW)YW7=DM@^*BT'1?RXK5NMZ:?:I "KJE-T3B+#
M:CE0=-6!&'/&/;&G A=5.I$ M3ST6HR'Y%2C&3)MJE8?L>S#JEPS+J/+,.O7
M4-X.G\R#]S'8.[Y7!*N@8 Q<9_P2\BB$.0]J9%Z SA]O2*D&.B<9&(IG(G<0
M)O?. 8$,*80_B3,H#TZR2-(OTV%(TW):O@B1@EUAN0[5O;"3R&:S7'$XHRK6
M65O;9J6AJ&4T*B5A-+6R( 4HAZ[044%KK4%;J=:(NPW74;RK9OU=1<U"5Q**
MRWE##Z2@V?%IP"<G15>V@^ "RH]D6J**E#ZC,+'E!S4=&;6;R?(CNUMM/>X&
MM/E$)L=;C^N$GNL8--1.\J+B5VEY)'VR<%/_1?2L43"P#KV"2,O"\_Q\1Y+$
M8Y52CFIQ[N@#9(#3@VM,Z5/H0X;]YL2>4FZ0_8HZULAV.R<^X.VZ*[@2/?.*
M7X!W$\4W68KJ+"1)AJYU FKF&<,97?SJ8B QA>S^S;(:E:IWR2+ %.%00O*2
M8F%W@8T!DBS2)RT#V7'EK!#+5R4"<B_D0@3RS"[_6><-=\9'3"MIZ@O+J#CX
M++]@J -=^2EL^9VD?W:7/N8M3[FEFO?/43,L3^"ED]E[56LL3Q_6CU Z1Q/J
M(Q'9 &J]C<O0,OJ*;Y5G:NLU0,?A:3$>(.<W(GDD'T/*#VD4@C*S$R0T]XXO
MPC-"#N1&,SKQIS"&B[()_3\PN67U<[A+ WBH(&DE.7?I 4W+?\E*@>=M&\NO
M5IVQE-Q_EM^3.L,HOYMM]N=<@<2-_7VN]EYDB1^")"%>QZ] ZOC!:'2/9;QQ
MPN+%P"54&*/ ]W+^#+UJM<'*8^!CZ"_/UZ-F;!.9[C/T=&*Y/CHTBYPVM%>)
M]/9&*JQ !@R!5SY?7[ANMLOR0"NXA5V?MEP"'766_:KGK475+0FO?T@>A<YC
MF9;-2O=>+3T.G7\MUQJT02JRJY2J$A]R;$.PP=9=BR$^4R#8K';(EOT%5N@D
MZ"WC<ETQ.C*R29#;&CAV:S;2T/L,E^#TDQ7\6P+9'IGDF&D99$=1-=$D3BN3
MA/\Z31#^X\L#(H&P"O7?]4D,$<7F;_LB".R+I-2+30SP4EVB70EB*$W3PV=G
M!ZZB'3P^2.0*]U6F>WT,H,AYW/GI]A\!>KP'/Q8$P$TS)RC?)U1R]][YL"7P
M(#/B?OC%;/$SXAIH^41/"_G)#_U=MJ/R5OWW)HH-!DX"SP-L]2>R%*.AF5K1
M+W"M_>< U).X,V4@KY>RC=#..7E'23_#;6XD9PZ$9!L%4/M)\LSNGZ.T4D4K
MAS%![B=TQ+^CF5MEA]$(/RG#%;.I =@+A</+54LF(Q.;FE!-CNA!13STG-A+
MGO909P?O?WSW\[N?V J)4%]U=H$H@ 1$<:GJWD&=-JR<C?0C1["GR>165:',
M4&GI[4WPCO<_67'5NHEB1MY=QH3DQNCIK&]J613MEMC,Z!ZFY4>F;MQ6A[ZT
M*>>5K4W5?C^($[15BE+XT&SW')B@__#N?6=!?^H[I 0%3PE89\&=OZ8EQ13I
M:2+UY*EZ5K-FUM]!@(+=('VTP ^AOD;R!N:*^G(-_X1,A&.=:&^ B&V-N$J8
MM7[RS,"00 0P_!_R@U)])_(CF7@H&R7)J<+, ;^:=X)%>NG$\0'^$.?JH4Q1
MK*^I"N_/K5CID]WLXM *NL/!<]>O>S_7%^\A'T8>3=@K&U^9FGR]VP?1 8!:
M130DYNZBZ.N% W]&FI!4U]GM*FGKV")VN VKNJT?NOX^ -2C%5\- 8WOSAEQ
M3  @!P7\NVH4RF%' L7M#A6CCGTGR(/!%,+1&MJT"Y'IX*EZ7:6=*I:ZMXD^
M& 14RQ]B,P"R;I:C<UFYQ\-FE-O>M9+1&NX12T'@^UKJU1LY+@Y+41)UH-0S
MR\IZ+*8%7BLE;T/L6XJ&B&>EIA2(N3,L1ZMCO,DIX$K0TV(YC%SG3$W8$XX$
MR_'IY/^I8D;>U9:BQG,L'86ZN"IK*5+B?JVCQ*(>F)9"Q-/&Z^XU2]\QJ=$S
M"7Z]:>'%K_;0/O\L14BENEEQJEJ*5I?])^2QM30[BNS^HYA"IX4.DYL$W>66
MIH"1,160-<]I <-D)4J0@J59:61%D>15;UJH,?FJ4QR)CE0\4,M]C@:*8(OO
M^$CWD:UH.  Q64PP<J= [.<9,95A006J?YDPJG)A1P5@?U4)6# :K,2?X7^8
M,$<I"9PJ;]VVV?YZ!?(8@%6B.1LQ5,5PE8A:F9W@,TB16@*%/CY(T3&;E;D?
M4.8"=Q%Z5WZ0P9W::#JRA 1ETH^2?,[3&VIS$S&U(,U3@"'X.723VQH@^C?@
M;[8H! O>9YP-*,]1#&:RS-($;3MTGV+/1WJ8H4T5I3L&'MY*7:98[6Z:]418
M3EU\/!.6)YP]!E\+RD33.5)/^RB$>S<X7+^"V/434$M&S:AOHO-S!A:N*;]8
M#$AN.[2-5-GLG7=3:XP!K$QQN@JN3=EZ.*M34-0"6&Y]J*.8=C'R](;:99%\
M4%L:VW#N25]%3OP(M1Q,IJY'Y37K89'9A?+\:*G?7\4&U:^*60Z^#.=2E#9+
M PEZ.S_:FJ/EB)[#<T=UU-*8@QZXCJX1]X'I0"R)>2TH_X\: O=1"K_L.T%P
MP"#Y+^ 1N*BRL ^2W,4.O-OPT@E<E)<76R%GZ^-0"L,LX-)YU&7+(R<JYN/F
M)$B9X31]9$[K.):TCN?G2SJ/7RX.Y %8J= T?G$P %(3W@IWF[/T]<K(=Y2T
MI\J''Q\TBQUR]>K!I1A;8?+,Y@V9E2Z3TM9(&JYV9=6'QR?F:<+NHPQ2@H%"
MR#1!!_[,$4U??62NAZJU/\OME'/"":$'H_IUMEI0/%?#L1SO^8&\5GYLJ5Y\
MYI/672:Y HQT4/3CVG*D])ACY)X3VXJM#!<**KZ6>[?T<Z-67<'RU9&6JN=>
ME2SWJPV>V^]:[^ZL#%J_<?P8/Y:KU">\#:$<SO#3G-SU=("_9+8;F0NI54JQ
M46J1_%-! TR'(8TX+78[)(2<X-[9@YCCJB"U-5%L".5Q@YL,97A[!/&+[\(=
M2V9<E$@B(?^*:8M7^@DCZQKO418[< 6>TY/8XZPOJX\)(S5.9W$4.?1:[4T#
M-+>?@<E\BD)P^.3$7T%ZDX5>(E9>@-?+P$2.N%X<CG_]NP]B>.AO#W<H83##
M/R38V>2T/@$'\4J>\:%%(U-JR(UAHM*%[SS[ =[6\MM*L+,R+T/=D%L^K'Y
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M<4%][ & <B*Z/@7!>5.[#^YE)^%)E$3'P5@S9%\^S:GB*<@2;W@(PM9MRW8
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MJ.O"ANIT*'Z!_O,,9<!__']02P,$%     @ 2(AP5L@^EVLR)   7&L! !
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M-MC-H^%01,ZYZ5R,3R3E_-Y/%XAI.)T6&XJ$%J=C'LE_&WUV*M(Q<C*%*09
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M/F>U_<*#.,GHZ[A$$[&SUC/I=?Z))R?ICL\_ 1>)W+Y)$JM=88$6S+%LZ+3
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M.SKIXH9DQUKG>$K5&#V&7F$"8=:.(PP".@Q'CX5RY!22 HO@ OO6#RZ'1<W
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MV7ETPW2F"E?]TQ2\BD0I&^ &LFZ[Q%3@^*]=9(A2W]%Z1^MM6O=5[Z@<4\V
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M$]_DL_-/CVR#;SZWX)'-[&ND"^08@9@9QRI$P2->!&(-V!#=-$]L)S='0ES
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MP"P&9C$PBUZ2:3B0!FXQ<(N!6PS<HI=D_J%, :LJCM/9#(T#,_1'(@L9.,?
M.0;.,7".?IMJ6LC8*B7D!SC_9,1Y[6PJG!-J/3A)!\!R8"4#*QE8R2V$D'-T
M&);Q]_*MX@)O/1_MOWKM_WD!X[[M=/='+V\_VRPUY"4]R%4L$571._^=>X.3
MW.DVK@>CO^V1?:IH]7]]2)3XK91Y ??_QLZSYYL.6\+FRKF.8W$%)QN1K<Y3
MB5^G\-[&SJ98*)D'HIBG8F.W^FV:*_AVS_V.<(-)6D('S_DC^"2!HY0;F6ME
M7).]6@Q,HH2>BZDL?/0+C]!,\:.QHE'6"-R^_A8WZHWE'VVGC.$]3ABRWAX$
MW,#K);8 WR"J.Q$G0!D:/9T?H2L:!Q##Y90;H2E$T/Z_N]C$*M*&N.Z2A__1
M1_MM,2/[MSR%5CQ[>L?PKPLAPU!E1)$U;6^,%R*,=?@9/W;H#@/S=O"!H/J4
M7Z^0@"E(8!I&A;0??D[2>:RB2Z9QH']^F,(4'(UBIW 4,IDLN)'7A\8B7C,$
M$.4J!#[^6:D,QV(6<-9F%K+@PAHBF!UBH'-$02_\%G$XKB.)\ *86P8\9X&G
M=:S@!$_<L;1O; :-TX:<!N=M.K )"N&.>9K@I8&01QZ4-\6:0P#-1,2-U&3"
M&$DZO-J"HUQO=-3;W>!K54L%W&S ; ($VF$H"$@)S,>H"UW ,%0"WX5*,OJ
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M;YZ-TVCQ]H]OGDV+6?SV_P%02P,$%     @ 2(AP5DI]]>U<!   HR<   \
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MM.X!?JWBR2_= _=UC/\'4$L#!!0    ( $B(<%8:YV)<\ @  ')1   /
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M OX3Z^X2%9.+6W GA3PFB_:6A0?"6 U%RK3!+(4$%Y<_*UR]<URUM@)77R#
M&$(G'9/;3(TD9P->\_#RL"%,@=I,68*MJ,@(S<:DR*PN. R<0IR"*L04)2E\
MT@(@&=,(+FFB4JA)K?)R*P(9C[@Q5(]1)*6WG" 0ISH-7&-@#'0IT1?8!PI$
M0D=%"F(9- =+&-<$_!@EQ!3X8]9^Q#4OE>  4F$DI[CO0$;")C! D_/(&8AZ
M<S!-,1CF$)HQ$H[GW5!QP!9R0'N[.8"36&2 ,@3L#%4U(  0A]MZ[K[(8K32
M"M CLD@6#'0"<N<@5 /4"RW'! 9ID#.02Z2<D4*)1[/4-5C*!"JNH40A00"8
M0 %<77?&V1-1DY!8JI&9T,1L(2<4+WJ[P<K:'-K-Q)@5:RO ;R'@#[8"\#<+
MZ/B[*<%<EI"X/*HX%O#1(>:<4,T=-@%K(I0<,40X^#"4PB0HCF(II :8'N!G
M\%@DE2F@'?:JE?0@S;6*.(/+ANP )AD'D'O@G=U%"<T&G/1A/;XJ)$@TV[3>
M[.SP7=>TV6'^D_\H<,LD\^2 ^@DNVG.<X3&,MCRYHWBAHQ@ZPG$N,PE(8"42
M/,X.)7H1E!A@K<\?NQ5AO!O"..JTFD>?#P^.6^VC@Z-6!]ECA^YN WU\Y0:"
M!^#DTNW'L5[#2B"BA7EZ$TS)0PZX+7OR2;XJ-"B A7LHC$L'0(IG3@]N>\T2
MB?ED1'-)'1&46?X,S+4R4<&; I(*L,4H*1BUSM#0"":H%C@ X6L1EQYEJ*DP
M6!\XWC2NF'#)@S(<#+*0K&"C'&)&1(6DF// L)P1LSH#6OBJ9;[8@K]"CH(P
ML=">LR>D(3]#-(<5S[Q!G@FWD&>>O.*OT,W3<X4GLPXPU5 P)!-J5$8Q*:(&
MB BW))!AJ&83M /_"!H**>P8*Y-UW2+W.6)PF/>TM2 ZMZ7A<J^[<D!YH7/@
M'.,JJ2A2FCD#W.;&@&=0($F@'KC#<^0T%"DRZ^D%N$_DD/Z\,,%4F<R;9)AH
M*QCF;$AEX99[A!^/8QY9,03@F#6["% G/2%Q\1_7;RDX*H&&D'08OW$1JL+>
MW_=34BLZE>:X*Q,_OI-)PLE^CV-'[GT ]G11><4&FQ*>&\0&;"O8X*N'VRIL
M\<"CW#5P=Y98X0?R"ZQ25!05&F$Y5Q(LZ$N5L7 %'PL!+28"%=\+F"=0NK,B
M' .GP&J_)%>:&0& W,D,'MJXLU)ORZZW)*%F6C-AGN XB#.70+G1E\G-F$AQ
MRV5Y3+,D7_L)ASR1<2IZ>3?T4NZS=JI]UC7[K.X1!S9AH=ILH<:\89X59FLV
MHOL'*J.5/1 PBA9,6*7-M QQ%T!9F@IK.5^;"84*2AR\PP38Y)KO &M XF$P
ML8'?N ,SH3?^O1!@LB.T(HO<J<UNM86Z,:&Z0:G&=FRA]B44]1 ^ N"/QPIX
M0!$)#G@M2XCI5N:(TUNL"7R1[ZH"MSWAGJZ8'('^$ N4NX[^4&?-"D\9-#1\
MNL"O88QR.P.$ ?Q* U6YDL1 /6**%" $'G/#*!.HM<?$5;FQ44&Y01RP'=N;
M?:@J8@V+;0T0R5UF )AVSRF5X*_Y-%UD0R6'''/UC [*QZUTF4SP-)=JS.'N
M*%$^@Z +U )4\)-ER]X]($WTQ/LYF%4/@4UNZS0&K0&5(SHVRR]V+4&YW5Z$
M<AW"X>#XX^3=L 6YE4EX\:?"7_]-)>OVE=?X#M^EZX; NUP[ _%%ND;7B=<!
M(JH N(D[SKJ^JV;#D639 * @:6YX8/QF\Y3NW(MP7K>;-S!@.L&X]>U)/YBT
M+X5 BDU=YD'=V6MWV@CDWKYE]PBU]XZ/#Q^1.=AK'7<>DSF$SHX6A. /O6Q_
MXA%=3MJJY>OIH]7IU";_@3 F<5F^]-$467<$/O6!'_CPQPOKF66(63_4Z&7(
M^5"<ZO3.+[7"8.Y[/V(2<B_U+LJ[6,H^G'R%N [([U1#HM,\K)%6H]6>0]?:
M@*IBX($8V,1))BNLN2'S"DK>Q*2^06!_&0>;-]\ECLL%=CH#K4X.KL8G2LBB
M$]?&QIJY>JU8^>M>2'SA:-DW^XOOR:V+G2I?>%>9\V9QPEN8KTU$[L:N[:E@
M3/+W.Z\O^HKXQL[J0VC=RH7Y9;]$I%J2JR6YFJ]J2:[F]=6Y^$W.:K4D/_O7
M3R6"Q^3;]/ '#V^_%$:XQU$O_5,J#ZW4\!N/'U[S:Y0V;]U[^B%9;Q^_,_'D
ME]Z^^Z[%_P-02P,$%     @ 2(AP5I4Y$=;E!@  %U    T   !N:W1X+65X
M,S(N:'1M[5QM<]HX$/[>7Z%+)YUD!@.&D 2;RPPE9)KK'>D$.M/[*-LR5NNW
M2G* ^_6WDFU" B&]7D@AT20A8$F[JV?W6<D2<B<047CV!G4"@CWXCSJ"BI"<
M];\8S4:GEG^ XEI1WG$2;X:XF(7D][T(LS&-+80SD?Q&HS1A L?"3K'GT7AL
MH=-T:N\IH6G91)"I,&CLD5A8]6I]W_:36!B<_D,L$SZGPLZ%&B))K?R"JN'C
MB(8S:T0CPM& 3-!U$N&XK.PD0B1145^IP"$=QU9(? $6=*2(TH))0 4Q>(I=
M8J6,&!.&TV4K%I6^^YXEPKZG.K]809PPZML1&#&AG@@LGPK#A<;00=#\[JUY
M7+<[-2GNK%-+?R48C(Z#)30<['X;LR2+/; Z3)C%Q@X^J%?4SZ&]=,T\M!\&
M<$*D"LM)0F]CB/:G 76H0#(ZMP%5'6(+8+B@AK"=C['!Q^[UJ%M!EX->50/[
MA,#V^M>CRXO+7G=T>35 GSY?#S]W!R,TNM(H/R'*YBGZ7!U6>U4T[/<4TF:S
M5:]HC)\0X^X0=<^O/HWZYSJ,-P1Q&;SM^C&ZND"C#WTT[%Z_[P[Z0^/JRY_]
MOU&W-Y(EC7K]AR8#1]56L[D>>[.QB?G )J"/$Q;A<&/@7\8(/L3$%32)T82*
M (F H&X<9SA$UT3.]1&47( 9R*P;'Y&?,%5E1C!#!!#WT#EQ2>00AIIF!;S4
M:*#$1X-O&&X38'"-W2HZD"W>O9TVZJ9K]Y(HQ?$L_^C9APASY-,0!,WU#XF;
M,2HH= C''NI/W0#'8X*@:40YE[;"KZSI84%00!@!E866YI&=&Z[>'E;0A%30
M)YR%Z(\J^H"Y@)L67D&]@!(?1(,J06\(NO)]ZD(G0)"44UA9408,L$<9^@L'
M49)X9=,+&N/8I8"3K/(^XS0FG#\H!ZX)ZL.;-&,\@QLH)!)TF\-5[I908"])
M!8"Q6&U8.$ARI) [Q,S!H-"XFH9DAKJND"62(Q4HQ\*Z1Q6/WMR]GS-D"$NR
M-$[W[:7,Y5&>AGAF^2&9KF#.UXS+SI21I*H97(#+;<4/ \(ZXI:#.0D!EI5L
MNHU)R=B3_1='KSN@SA&EL43$4,"NU7L_(ZW!?!'*DU;#/#D]/FHWFB=')XW6
M/N!X8!Z6X; 0!W<MVGFX]\Y&P(LB9_E9&,X@MT5I*+/(/+,P\CVCC$30@$O"
M\()99O, '\ZY=9M^YJFG()C9AIPB"3^G%P!:O&J:O7::-5X-S6CL2R6*.[($
M0]<\N*KX4W(04P8D!!.YI%M%%N,P1- ,Y,.X"04I\(]75"M_/IZ"0(\JT7)D
MA5I9F+,U20E3.OF]X;7Z !U73A -\-Y1>[]<P)PS]+%9XPM=1!+8"<FJI"77
M>VTG81YARD"YV%NW574# CK)@!QT2CP[5V7654HK&D#@ACCEQ.(DQ>"T>7)2
MZY.Y;+5H# :P4OL-Y=2A(14SJVQ?5():WARRG(*MZE']6-*N4Q/>0Y6J[=;)
M(W6:U7;[43FMZO&1>:<2O&'W[0]R_A5.6[9\-=D;K5:E_ -ZEV%9A)Q)8WL"
MF!H.(_B;I5X->6%U'KB1TTP7AT7(Y:$XEYF#7TB%SCQTZUJ&W',R80<SX3G$
MM07W!<P-D'FL;GZ:"^Q:&5 Z!M;$P#8Z&2UES2WQ*PC9":?N(+'?SZSM\W?!
MXV* G7N@T4H!ZB2D,%6Z ^+*V%CAJU\5*\^W@+GA:*GQVM("TZKPT5,&/5QH
MOVJ_/JU?(^IY(7FY?MWH[M/6>G4=6U_E&+[1,-"C]ZYD@]>:Y;5?M5]WT:]Z
M]-:C]\:_;[CZJQSK!G'X+_<Q]";1B]\D:K9;CV\2'9_J3:*=&(-V<'50;Q)M
MPSSDM<XO]2:1WB32FT1;$"URD^C.]XCU&I,>*[8R=VB_OC"_ZAVBE^A5O<;T
MK(>%]="]"ZG@M:9X[5?MUUWTJQZZ]=#]/-M#ZX_K_J^]HOI6/G[&? ##'HAT
M&)UCAV-N[,ZS9WX"B?;&=\>V"(MG61G[*43SYM)*BPKH@+OF@"'E"'X= MD1
M^1F+*0^()]<O23B3!^*QZ^8'_Q;/&ZX^6"\==F*K\_55I"3G)_$A':LCACR0
M9Q+C1( ZY!$2@:+R407JL03E@PK4HP] 1YIPHLX?EJ?R0=>/'1S.S_='ZJD)
M%032$FC$)I03Q#/G*XB3IDM!(<7Y%F<N&8ORH'(%+&6%S5293&,W 9OD[JF'
MG!EBQ">,Q*XLD4@!1M -">3=(Y,(0H2P^V;?6MM<LO8_]Y!,79+.^P1Q2Z1S
M9&\6[9!G0)4[Y(GMA=YPU<&%#FW)0YJV<X,^F-]TIGA,\FF)@7T8ORT<3O",
MJ]O/3DT^V._L3:>F'@CX+U!+ 0(4 Q0    ( $B(<%;J':MI$<\  !(D 0 2
M              "  0    !I;6<Q.#,V-#@V-#E?,"YJ<&=02P$"% ,4
M" !(B'!6%=ZTS 7G   0( $ $@              @ %!SP  :6UG,3@S-C0X
M-C0Y7S$N:G!G4$L! A0#%     @ 2(AP5D'3T@[H\0  &R4! !(
M     ( !=K8! &EM9S$X,S8T.#8T.5\R+FIP9U!+ 0(4 Q0    ( $B(<%8*
M7?DM0/4  *H) 0 2              "  8ZH @!I;6<Q.#,V-#@V-#E?,RYJ
M<&=02P$"% ,4    " !(B'!61-]\T4'I  #^*@$ $@              @ '^
MG0, :6UG,3@S-C0X-C0Y7S0N:G!G4$L! A0#%     @ 2(AP5LVN;5L['@$
M*#4! !(              ( !;X<$ &EM9S$X,S8T.#8T.5\U+FIP9U!+ 0(4
M Q0    ( $B(<%8J\A)OL',! "?1 0 2              "  =JE!0!I;6<Q
M.#,V-#@V-#E?-BYJ<&=02P$"% ,4    " !(B'!6>>&M3V49 0 N*0$ $@
M            @ &Z&0< :6UG,3@S-C0X-C0Y7S<N:G!G4$L! A0#%     @
M2(AP5@*3"I+@N $ QO(! !(              ( !3S,( &EM9S$X,S8T.#8T
M.5\X+FIP9U!+ 0(4 Q0    ( $B(<%8XE)>JM'P! +>2 0 2
M  "  5_L"0!I;6<Q.#,V-#@V-#E?.2YJ<&=02P$"% ,4    " !(B'!68^0>
M&* %! !/0C@ $0              @ %#:0L ;FMT>"TR,#(R,3(S,2YH=&U0
M2P$"% ,4    " !(B'!6;I(I.447  #P! $ $0              @ $2;P\
M;FMT>"TR,#(R,3(S,2YX<V102P$"% ,4    " !(B'!6WPA3%'@0  "!Y@
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M,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ 2(AP5L@^EVLR)   7&L! !
M             ( !RNH0 &YK='@M97@Q,%\S8RYH=&U02P$"% ,4    " !(
MB'!6R0= '3(>  !/)0$ $               @ $J#Q$ ;FMT>"UE>#$P7S-E
M+FAT;5!+ 0(4 Q0    ( $B(<%8C:BXX"2   +D1 0 0              "
M 8HM$0!N:W1X+65X,3!?,V8N:'1M4$L! A0#%     @ 2(AP5DI]]>U<!
MHR<   \              ( !P4T1 &YK='@M97@R,U\Q+FAT;5!+ 0(4 Q0
M   ( $B(<%;IO[_0T0@  )51   /              "  4I2$0!N:W1X+65X
M,S%?,2YH=&U02P$"% ,4    " !(B'!6&N=B7/ (  !R40  #P
M    @ %(6Q$ ;FMT>"UE>#,Q7S(N:'1M4$L! A0#%     @ 2(AP5I4Y$=;E
M!@  %U    T              ( !9601 &YK='@M97@S,BYH=&U02P4&
/ !< %P"V!0  =6L1

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
